feel well live long august interim update update information corporate responsibility report publish march insert relevant section report highlight blue box similar style text responsibility great west road brentford middlesex tw gs uk tel corporate responsibility report content download corporate responsibility report corporate responsibility gsk research practice message ceo emerge technology corporate responsibility principle clone technology stem cell research genetic research business case corporate responsibility collaborative research emerge technology key issue animal research corporate responsibility governance human tissue research stakeholder engagement medical governance report clinical research benchmarking plan approval assurance internal audit inform consent corporate responsibility datum summary posttrial treatment resource download clinical trial develop world public disclosure clinical research contribution global health patient safety cost disease patient safety governance framework role vaccine collect report safety datum performance treat ill health disease awareness prevention maintain confidentiality research participant invest rd work healthcare professional contribute scientific understanding training auditing prepare pandemic flu case study qas qas access medicine ethical conduct approach contribution code conduct business ethic role market ethic develop country relationship healthcare professional research development directtoconsumer advertising publicprivate partnership train awareness product registration lead example preferential pricing performance plan price middleincome country monitor compliance develop country case study price medicine qas intellectual property future response assurance recommendation case study qas corporate responsibility report content supply chain people responsibility supply chain culture behaviour human right clause restructure choose supplier consultation monitoring engagement communication supplier diversity diversity inclusion fair treatment supplier training development maintain quality reward recognition security supply health safety wellbeing counterfeit health safety management case study hazard assessment communication qas safety programme health wellbeing programme environmental sustainability health business continuity training awareness plan excellence performance target journey sustainability case study manage ehs sustainability qas ehss vision policy training awareness human right audits compliance employee reward recognition supplier management ehss communitie environmental fundamental society wastewater activity sensitive country hazardous nonhazardous waste contaminate land public policy patient advocacy emission air ehss business process approach external affair supplier performance public policy activity sustainability advocacy healthcare material efficiency disease prevention climate change energy advocacy research practice water use advocacy patient safety product stewardship advocacy intellectual property packaging advocacy pricing competitiveness open transparent relation political contribution stakeholder engagement lobbying expenditure ehss report patient advocacy assurance transparency gsk response assurance understand patient qas develop industry standard environmental metric advocacy qas corporate responsibility report content work community community investment prevent disease eliminate lymphatic filariasis p ersonal hygiene sanitation education phase local programme build community capacity combat hivaids positive action combat malaria africa malaria partnership local programme respond disaster world support science education plan corporate responsibility report august corporate responsibility report select report content corporate responsibility gsk contribution health access medicine research practice ethical conduct supply chain environmental sustainability people human right public policy patient advocacy work community find corporate responsibility glaxosmithkline online wwwgskcomresponsibility home responsibility corporate responsibility gsk corporate responsibility report corporate responsibility gsk corporate responsibility cr central business aim operate way reflect value understand respond stakeholder view connect business decision ethical social environmental concern seek minimise negative impact maximise benefit business read message ceo importance cr gsk gsk employee responsible uphold value maintain high ethical standard corporate responsibility principle define approach key responsibility issue provide guidance employee standard company commit communicate people underline commitment corporate responsibility update progress engage external stakeholder include healthcare professional investor patient non governmental organisation local community supplier identify key issue gain feedback approach corporate responsibility business make valuable contribution society medicine vaccine produce improve people live know research development manufacture sale medicine vaccine raise ethical issue consequently pharmaceutical industry subject high level public scrutiny critical medium coverage aim high ethical standard regularly report progress essential maintain good relationship stakeholder achieve goal strategic priority ensure future sustainability business support inclusion key sustainability index ftsegood index dow jones sustainability index score industry investor benchmark corporate responsibility principle define approach key responsibility issue provide guidance employee standard company commit read management structure process advance progress cr principle home responsibility corporate responsibility gsk corporate responsibility report corporate responsibility gsk corporate responsibility cr central business aim operate way reflect value understand respond stakeholder view connect business decision ethical social environmental concern seek minimise negative impact maximise benefit business read message ceo importance cr gsk gsk employee responsible uphold value maintain high ethical standard corporate responsibility principle define approach key responsibility issue provide guidance employee standard company commit communicate people underline commitment corporate responsibility update progress engage external stakeholder include healthcare professional investor patient non governmental organisation local community supplier identify key issue gain feedback approach corporate responsibility business make valuable contribution society medicine vaccine produce improve people live know research development manufacture sale medicine vaccine raise ethical issue consequently pharmaceutical industry subject high level public scrutiny critical medium coverage aim high ethical standard regularly report progress essential maintain good relationship stakeholder achieve goal strategic priority ensure future sustainability business support inclusion key sustainability index ftsegood index dow jones sustainability index score industry investor benchmark corporate responsibility principle define approach key responsibility issue provide guidance employee standard company commit read management structure process advance progress cr principle home responsibility corporate responsibility gsk message ceo corporate responsibility report message ceo new mindset welcome gsk corporate responsibility report provide information activity performance want company forward look innovative willing try new approach partnership company constantly look new sustainable way increase access medicine vaccine especially able pay significant progress help address global healthcare challenge example past year donate billion tablet programme eliminate lymphatic filariasis debilitate tropical disease double manufacturing capacity million tablet year commitment preferential pricing mean offer aids malaria medicine notforprofit price world poor country supply vaccine organisation gavi unicef preferential price typically cent price develop country success story example review performance believe time new mindset industry new contract society difficult economic time challenge think shortterm performance look longterm distract economic problem need develop world remain press begin area go thing differently explore flexible approach intellectual property right incentivise need research medicine neglect tropical disease severe lack research option develop country ldc patent pool relevant small molecule compound process patent knowledge allow access develop produce new product secondly april reduce price patent medicine poor country world ldc high cent develop world price possible reduce price ensure cover manufacturing cost offer sustainable recognise challenge middleincome country wide disparity income ability pay intention work casebycase basis recognise size fit solution improve access medicine country thirdly seek partnership open door develop world research centre spain know partnership achieve example successfully trialle malaria vaccine candidate partnership path malaria vaccine initiative bill melinda gates foundation extend approach benefit huge fourthly work partner ngo reinvest cent profit sell medicine ldc support strengthen healthcare infrastructure country sale ldc relatively low profit limit initially fund million annually action hope send signal multinational company operate ldc join meaningful change country develop country transform gsk local company address local healthcare need brazilian business lead way supply vaccine share technical expertise help build local capacity forget significant healthcare challenge exist develop country work partnership create virtuous circle industry get reward demonstrate genuine innovation healthcare payer valueformoney medicine save highcost healthcare intervention patient medicine need course access medicine issue count want gsk recognise world stakeholder company high ethical standard good progress commit stop corporate political contribution decision report fully fund medical education patient group payment physician increase transparency provide reassurance stakeholder reflect commitment animal welfare take voluntary decision end research great ape highestorder animal human time new mindset industry new contract society support pharmaceutical company partner outside industry believe significant improvement human health achieve andrew witty ceo tophome responsibility corporate responsibility gsk message ceo corporate responsibility report message ceo new mindset welcome gsk corporate responsibility report provide information activity performance want company forward look innovative willing try new approach partnership company constantly look new sustainable way increase access medicine vaccine especially able pay significant progress help address global healthcare challenge example past year donate billion tablet programme eliminate lymphatic filariasis debilitate tropical disease double manufacturing capacity million tablet year commitment preferential pricing mean offer aids malaria medicine notforprofit price world poor country supply vaccine organisation gavi unicef preferential price typically cent price develop country success story example review performance believe time new mindset industry new contract society difficult economic time challenge think shortterm performance look longterm distract economic problem need develop world remain press begin area go thing differently explore flexible approach intellectual property right incentivise need research medicine neglect tropical disease severe lack research option develop country ldc patent pool relevant small molecule compound process patent knowledge allow access develop produce new product secondly april reduce price patent medicine poor country world ldc high cent develop world price possible reduce price ensure cover manufacturing cost offer sustainable recognise challenge middleincome country wide disparity income ability pay intention work casebycase basis recognise size fit solution improve access medicine country thirdly seek partnership open door develop world research centre spain know partnership achieve example successfully trialle malaria vaccine candidate partnership path malaria vaccine initiative bill melinda gates foundation extend approach benefit huge fourthly work partner ngo reinvest cent profit sell medicine ldc support strengthen healthcare infrastructure country sale ldc relatively low profit limit initially fund million annually action hope send signal multinational company operate ldc join meaningful change country develop country transform gsk local company address local healthcare need brazilian business lead way supply vaccine share technical expertise help build local capacity forget significant healthcare challenge exist develop country work partnership create virtuous circle industry get reward demonstrate genuine innovation healthcare payer valueformoney medicine save highcost healthcare intervention patient medicine need course access medicine issue count want gsk recognise world stakeholder company high ethical standard good progress commit stop corporate political contribution decision report fully fund medical education patient group payment physician increase transparency provide reassurance stakeholder reflect commitment animal welfare take voluntary decision end research great ape highestorder animal human time new mindset industry new contract society support pharmaceutical company partner outside industry believe significant improvement human health achieve andrew witty ceo home responsibility corporate responsibility gsk message ceo corporate responsibility report message ceo new mindset welcome gsk corporate responsibility report provide information activity performance want company forward look innovative willing try new approach partnership company constantly look new sustainable way increase access medicine vaccine especially able pay significant progress help address global healthcare challenge example past year donate billion tablet programme eliminate lymphatic filariasis debilitate tropical disease double manufacturing capacity million tablet year commitment preferential pricing mean offer aids malaria medicine notforprofit price world poor country supply vaccine organisation gavi unicef preferential price typically cent price develop country success story example review performance believe time new mindset industry new contract society difficult economic time challenge think shortterm performance look longterm distract economic problem need develop world remain press begin area go thing differently explore flexible approach intellectual property right incentivise need research medicine neglect tropical disease severe lack research option develop country ldc patent pool relevant small molecule compound process patent knowledge allow access develop produce new product secondly april reduce price patent medicine poor country world ldc high cent develop world price possible reduce price ensure cover manufacturing cost offer sustainable recognise challenge middleincome country wide disparity income ability pay intention work casebycase basis recognise size fit solution improve access medicine country thirdly seek partnership open door develop world research centre spain know partnership achieve example successfully trialle malaria vaccine candidate partnership path malaria vaccine initiative bill melinda gates foundation extend approach benefit huge fourthly work partner ngo reinvest cent profit sell medicine ldc support strengthen healthcare infrastructure country sale ldc relatively low profit limit initially fund million annually action hope send signal multinational company operate ldc join meaningful change country develop country transform gsk local company address local healthcare need brazilian business lead way supply vaccine share technical expertise help build local capacity forget significant healthcare challenge exist develop country work partnership create virtuous circle industry get reward demonstrate genuine innovation healthcare payer valueformoney medicine save highcost healthcare intervention patient medicine need course access medicine issue count want gsk recognise world stakeholder company high ethical standard good progress commit stop corporate political contribution decision report fully fund medical education patient group payment physician increase transparency provide reassurance stakeholder reflect commitment animal welfare take voluntary decision end research great ape highestorder animal human time new mindset industry new contract society support pharmaceutical company partner outside industry believe significant improvement human health achieve andrew witty ceo home responsibility corporate responsibility gsk corporate responsibility principle corporate responsibility report corporate responsibility principle corporate responsibility principle identify key responsibility issue provide guidance employee standard gsk committed employment practice treat employee respect dignity encourage diversity ensure fair treatment phase employment provide safe healthy work environment support employee perform potential responsibility performance reputation business read employment practice human right commit uphold un universal declaration human right oecd guideline multinational enterprise core labour standard set international labour organization expect standard supplier contractor business partner work gsk behalf read approach human right access medicine continue research develop medicine treat disease develop world find sustainable way improve access medicine disadvantaged people seek partnership support activity read approach access medicine leadership advocacy establish challenging standard corporate responsibility appropriate complexity specific need business build external guideline experience share good practice seek influence remain competitive order sustain business community investment positive contribution community operate invest health education programme partnership aim bring sustainable improvement underserve people develop develop world read work community engagement stakeholder want understand concern interest corporate responsibility issue engage range stakeholder communicate openly address cr issue way aim meet need different group allow pursue legitimate business goal read stakeholder engagement standard ethical conduct expect employee meet high ethical standard aspect business conduct activity honesty integrity adhere cr principle comply applicable law regulation read ethical conduct research innovation undertaking research innovating explore apply new technology constructively engage stakeholder concern arise ensure product subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulation legal standard applicable research development product read research practice product customer promote product line high ethical medical scientific standard comply applicable law regulation read marketing ethic caring environment operate environmentally responsible manner systematic management environmental impact measurement performance set challenging performance target improve efficiency activity minimise material energy use waste generate aim find opportunity use renewable material recycle waste read environmental sustainability tophome responsibility corporate responsibility gsk corporate responsibility principle corporate responsibility report corporate responsibility principle corporate responsibility principle identify key responsibility issue provide guidance employee standard gsk committed employment practice treat employee respect dignity encourage diversity ensure fair treatment phase employment provide safe healthy work environment support employee perform potential responsibility performance reputation business read employment practice human right commit uphold un universal declaration human right oecd guideline multinational enterprise core labour standard set international labour organization expect standard supplier contractor business partner work gsk behalf read approach human right access medicine continue research develop medicine treat disease develop world find sustainable way improve access medicine disadvantaged people seek partnership support activity read approach access medicine leadership advocacy establish challenging standard corporate responsibility appropriate complexity specific need business build external guideline experience share good practice seek influence remain competitive order sustain business community investment positive contribution community operate invest health education programme partnership aim bring sustainable improvement underserve people develop develop world read work community engagement stakeholder want understand concern interest corporate responsibility issue engage range stakeholder communicate openly address cr issue way aim meet need different group allow pursue legitimate business goal read stakeholder engagement standard ethical conduct expect employee meet high ethical standard aspect business conduct activity honesty integrity adhere cr principle comply applicable law regulation read ethical conduct research innovation undertaking research innovating explore apply new technology constructively engage stakeholder concern arise ensure product subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulation legal standard applicable research development product read research practice product customer promote product line high ethical medical scientific standard comply applicable law regulation read marketing ethic caring environment operate environmentally responsible manner systematic management environmental impact measurement performance set challenging performance target improve efficiency activity minimise material energy use waste generate aim find opportunity use renewable material recycle waste read environmental sustainability home responsibility corporate responsibility gsk corporate responsibility principle corporate responsibility report corporate responsibility principle corporate responsibility principle identify key responsibility issue provide guidance employee standard gsk committed employment practice treat employee respect dignity encourage diversity ensure fair treatment phase employment provide safe healthy work environment support employee perform potential responsibility performance reputation business read employment practice human right commit uphold un universal declaration human right oecd guideline multinational enterprise core labour standard set international labour organization expect standard supplier contractor business partner work gsk behalf read approach human right access medicine continue research develop medicine treat disease develop world find sustainable way improve access medicine disadvantaged people seek partnership support activity read approach access medicine leadership advocacy establish challenging standard corporate responsibility appropriate complexity specific need business build external guideline experience share good practice seek influence remain competitive order sustain business community investment positive contribution community operate invest health education programme partnership aim bring sustainable improvement underserve people develop develop world read work community engagement stakeholder want understand concern interest corporate responsibility issue engage range stakeholder communicate openly address cr issue way aim meet need different group allow pursue legitimate business goal read stakeholder engagement standard ethical conduct expect employee meet high ethical standard aspect business conduct activity honesty integrity adhere cr principle comply applicable law regulation read ethical conduct research innovation undertaking research innovating explore apply new technology constructively engage stakeholder concern arise ensure product subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulation legal standard applicable research development product read research practice product customer promote product line high ethical medical scientific standard comply applicable law regulation read marketing ethic caring environment operate environmentally responsible manner systematic management environmental impact measurement performance set challenging performance target improve efficiency activity minimise material energy use waste generate aim find opportunity use renewable material recycle waste read environmental sustainability home responsibility corporate responsibility gsk business case corporate responsibility corporate responsibility report business case corporate responsibility demonstrate practice responsible ethical benefit business follow way improve reputation great trust gsk product ability attract retain motivate talented people increasingly important few young people major market choose sciencebase career constructive engagement stakeholder help prevent avoidable conflict identify innovative approach benefit gsk wide society great access market ability influence healthcare policy improve relationship regulator healthcare payer help government increase access medicine resolve healthcare challenge particularly important great ability anticipate prepare legislative change maintain competitive advantage helping maintain support intellectual property system find innovative way increase access medicine reduce cost efficient use resource increase environmental efficiency business strategy business performance development drive strategic priority support corporate responsibility activity believe corporate responsibility manage overall business strategy daytoday business operation reason separate corporate responsibility strategy gsk corporate responsibility strategic priority establish strategic priority believe increase growth reduce risk improve longterm financial performance grow diversified global business deliver product value simplify operating model believe priority enable navigate come year successfully retain leadingedge position company able meet patient healthcare provider need future run business responsible way fundamental success inseparable strategic priority want work way reflect value seeks understand respond stakeholder view connect business decision ethical social environmental concern way aim minimise negative impact maximise positive benefit business home responsibility corporate responsibility gsk business case corporate responsibility corporate responsibility report business case corporate responsibility demonstrate practice responsible ethical benefit business follow way improve reputation great trust gsk product ability attract retain motivate talented people increasingly important few young people major market choose sciencebase career constructive engagement stakeholder help prevent avoidable conflict identify innovative approach benefit gsk wide society great access market ability influence healthcare policy improve relationship regulator healthcare payer help government increase access medicine resolve healthcare challenge particularly important great ability anticipate prepare legislative change maintain competitive advantage helping maintain support intellectual property system find innovative way increase access medicine reduce cost efficient use resource increase environmental efficiency business strategy business performance development drive strategic priority support corporate responsibility activity believe corporate responsibility manage overall business strategy daytoday business operation reason separate corporate responsibility strategy gsk corporate responsibility strategic priority establish strategic priority believe increase growth reduce risk improve longterm financial performance grow diversified global business deliver product value simplify operating model believe priority enable navigate come year successfully retain leadingedge position company able meet patient healthcare provider need future run business responsible way fundamental success inseparable strategic priority want work way reflect value seeks understand respond stakeholder view connect business decision ethical social environmental concern way aim minimise negative impact maximise positive benefit business home responsibility corporate responsibility gsk business case corporate responsibility corporate responsibility report business case corporate responsibility demonstrate practice responsible ethical benefit business follow way improve reputation great trust gsk product ability attract retain motivate talented people increasingly important few young people major market choose sciencebase career constructive engagement stakeholder help prevent avoidable conflict identify innovative approach benefit gsk wide society great access market ability influence healthcare policy improve relationship regulator healthcare payer help government increase access medicine resolve healthcare challenge particularly important great ability anticipate prepare legislative change maintain competitive advantage helping maintain support intellectual property system find innovative way increase access medicine reduce cost efficient use resource increase environmental efficiency business strategy business performance development drive strategic priority support corporate responsibility activity believe corporate responsibility manage overall business strategy daytoday business operation reason separate corporate responsibility strategy gsk corporate responsibility strategic priority establish strategic priority believe increase growth reduce risk improve longterm financial performance grow diversified global business deliver product value simplify operating model believe priority enable navigate come year successfully retain leadingedge position company able meet patient healthcare provider need future run business responsible way fundamental success inseparable strategic priority want work way reflect value seeks understand respond stakeholder view connect business decision ethical social environmental concern way aim minimise negative impact maximise positive benefit business home responsibility corporate responsibility gsk key issue corporate responsibility report key issue cr report focused material significant relevant issue business follow factor influence materiality assessment business strategy risk management process stakeholder interest include investor feedback change business operation example type product produce location operate exist propose legislation public opinion press coverage identify follow responsibility issue material gsk contribution core business make health research development manufacture sale medicine vaccine increase access medicine underserved community ethical standard research development sale marketing environmental impact particularly climate change home responsibility corporate responsibility gsk key issue corporate responsibility report key issue cr report focused material significant relevant issue business follow factor influence materiality assessment business strategy risk management process stakeholder interest include investor feedback change business operation example type product produce location operate exist propose legislation public opinion press coverage identify follow responsibility issue material gsk contribution core business make health research development manufacture sale medicine vaccine increase access medicine underserved community ethical standard research development sale marketing environmental impact particularly climate change home responsibility corporate responsibility gsk corporate responsibility governance corporate responsibility report corporate responsibility governance corporate responsibility committee crc nonexecutive director provide highlevel guidance approach cr ceo member corporate executive team cet accountable responsible management business participate crc meeting committee member sir christopher gent chair dr stephanie burn dr daniel podolsky sir ian prosser tom de swaan committee meet time year review policy progress cr principle committee review performance cr principle annually access medicine standard ethical conduct research innovation employment practice community investment principle discuss year committee report finding board management corporate responsibility crc review gsk activity number area include access medicine community partnership humanitarian donation employee volunteer sale marketing practice disclosure fund medical education patient advocacy group product safety communication clinical trial result rd disease develop world use animal research outsource research research emerge market reduction employee number restructure employee consultation requirement employment litigation committee review sign annual performance information publish website annual cr highlight document augment gsk engagement stakeholder opinion march sophia tickell appoint external advisor corporate responsibility committee sophia executive director member leadership team sustainability think tank consultancy seek enhance business engagement social environmental concern sophia extensive experience constructively challenging company increase understand societal expectation develop strategy meet gain experience work journalist latin america work international development advocacy work oxfam recently direction investorle pharma future dialogue aim well align societal shareholder value sophia attend meeting corporate responsibility committee advise company capacity read corporate responsibility committee corporate responsibility risk risk oversight compliance council rocc coordinates management significant business risk rocc consider reputational corporate responsibility risk read risk management compliance gsk management structure cr cover diverse range issue gsk believe manage business function relevant subject expert work crossfunctional team representative key business area oversee development implementation communication policy include responsibility element gsk member senior manager direct access corporate executive team small central cr team coordinate policy development report specifically respect cr communicate socially responsible investor stakeholder measure performance establish metric key performance indicator track performance responsibility issue tophome responsibility corporate responsibility gsk corporate responsibility governance corporate responsibility report corporate responsibility governance corporate responsibility committee crc nonexecutive director provide highlevel guidance approach cr ceo member corporate executive team cet accountable responsible management business participate crc meeting committee member sir christopher gent chair dr stephanie burn dr daniel podolsky sir ian prosser tom de swaan committee meet time year review policy progress cr principle committee review performance cr principle annually access medicine standard ethical conduct research innovation employment practice community investment principle discuss year committee report finding board management corporate responsibility crc review gsk activity number area include access medicine community partnership humanitarian donation employee volunteer sale marketing practice disclosure fund medical education patient advocacy group product safety communication clinical trial result rd disease develop world use animal research outsource research research emerge market reduction employee number restructure employee consultation requirement employment litigation committee review sign annual performance information publish website annual cr highlight document augment gsk engagement stakeholder opinion march sophia tickell appoint external advisor corporate responsibility committee sophia executive director member leadership team sustainability think tank consultancy seek enhance business engagement social environmental concern sophia extensive experience constructively challenging company increase understand societal expectation develop strategy meet gain experience work journalist latin america work international development advocacy work oxfam recently direction investorle pharma future dialogue aim well align societal shareholder value sophia attend meeting corporate responsibility committee advise company capacity read corporate responsibility committee corporate responsibility risk risk oversight compliance council rocc coordinates management significant business risk rocc consider reputational corporate responsibility risk read risk management compliance gsk management structure cr cover diverse range issue gsk believe manage business function relevant subject expert work crossfunctional team representative key business area oversee development implementation communication policy include responsibility element gsk member senior manager direct access corporate executive team small central cr team coordinate policy development report specifically respect cr communicate socially responsible investor stakeholder measure performance establish metric key performance indicator track performance responsibility issue home responsibility corporate responsibility gsk corporate responsibility governance corporate responsibility report corporate responsibility governance corporate responsibility committee crc nonexecutive director provide highlevel guidance approach cr ceo member corporate executive team cet accountable responsible management business participate crc meeting committee member sir christopher gent chair dr stephanie burn dr daniel podolsky sir ian prosser tom de swaan committee meet time year review policy progress cr principle committee review performance cr principle annually access medicine standard ethical conduct research innovation employment practice community investment principle discuss year committee report finding board management corporate responsibility crc review gsk activity number area include access medicine community partnership humanitarian donation employee volunteer sale marketing practice disclosure fund medical education patient advocacy group product safety communication clinical trial result rd disease develop world use animal research outsource research research emerge market reduction employee number restructure employee consultation requirement employment litigation committee review sign annual performance information publish website annual cr highlight document augment gsk engagement stakeholder opinion march sophia tickell appoint external advisor corporate responsibility committee sophia executive director member leadership team sustainability think tank consultancy seek enhance business engagement social environmental concern sophia extensive experience constructively challenging company increase understand societal expectation develop strategy meet gain experience work journalist latin america work international development advocacy work oxfam recently direction investorle pharma future dialogue aim well align societal shareholder value sophia attend meeting corporate responsibility committee advise company capacity read corporate responsibility committee corporate responsibility risk risk oversight compliance council rocc coordinates management significant business risk rocc consider reputational corporate responsibility risk read risk management compliance gsk management structure cr cover diverse range issue gsk believe manage business function relevant subject expert work crossfunctional team representative key business area oversee development implementation communication policy include responsibility element gsk member senior manager direct access corporate executive team small central cr team coordinate policy development report specifically respect cr communicate socially responsible investor stakeholder measure performance establish metric key performance indicator track performance responsibility issue home responsibility corporate responsibility gsk stakeholder engagement corporate responsibility report stakeholder engagement stakeholder engagement dialogue enable connect view opinion society operate help identify important issue shape response interest shareholder wide society regular engagement mean well inform emerge current issue change societal expectation provide opportunity voice approach responsibility issue obtain important feedback build trust discussion take place normal course business example scientist regularly meet academic researcher pharmaceutical company advisory board medical conference describe engage stakeholder example engagement stakeholder group provide information respond feedback receive find example engagement stakeholder website home responsibility corporate responsibility gsk stakeholder engagement corporate responsibility report stakeholder engagement stakeholder engagement dialogue enable connect view opinion society operate help identify important issue shape response interest shareholder wide society regular engagement mean well inform emerge current issue change societal expectation provide opportunity voice approach responsibility issue obtain important feedback build trust discussion take place normal course business example scientist regularly meet academic researcher pharmaceutical company advisory board medical conference describe engage stakeholder example engagement stakeholder group provide information respond feedback receive find example engagement stakeholder website home responsibility corporate responsibility gsk stakeholder engagement engage corporate responsibility report engage healthcare professional engage healthcare professional way include sale representative run clinical trial read research ethic policy govern relationship healthcare professional patient gsk researcher scientist meet patient focus patient initiative engagement influence understand disease research priority read case studywe support work patient advocacy group conduct market research party understand patient need government regulator engage debate legislation seek influence policy decision affect gsk engage government responsibilityrelate issue healthcare provider engage healthcare provider government affair marketing access medicine activity investor meet regularly investor socially responsible investor read investor engagement activity employee seek feedback employee regular survey consult employee change affect discuss business development regional national consultation forum local community interaction local community manage individual gsk site read financial practical support community multilateral agency engage multilateral agency access public health initiative nongovernmental organisation ngo engage international local ngo access education public health programme public policy work engage regularly animal welfare organisation read animal research gsk scientific community academic partnership important gsk scientific debate involve number academic collaboration supplier hold global regional supplier review meeting senior gsk manager address interact supplier key issue read engagement supplier peer company engage peer company membership pharmaceutical industry organisation example efpia phrma ifpma collaboration specific project home responsibility corporate responsibility gsk stakeholder engagement engage corporate responsibility report engage healthcare professional engage healthcare professional way include sale representative run clinical trial read research ethic policy govern relationship healthcare professional patient gsk researcher scientist meet patient focus patient initiative engagement influence understand disease research priority read case studywe support work patient advocacy group conduct market research party understand patient need government regulator engage debate legislation seek influence policy decision affect gsk engage government responsibilityrelate issue healthcare provider engage healthcare provider government affair marketing access medicine activity investor meet regularly investor socially responsible investor read investor engagement activity employee seek feedback employee regular survey consult employee change affect discuss business development regional national consultation forum local community interaction local community manage individual gsk site read financial practical support community multilateral agency engage multilateral agency access public health initiative nongovernmental organisation ngo engage international local ngo access education public health programme public policy work engage regularly animal welfare organisation read animal research gsk scientific community academic partnership important gsk scientific debate involve number academic collaboration supplier hold global regional supplier review meeting senior gsk manager address interact supplier key issue read engagement supplier peer company engage peer company membership pharmaceutical industry organisation example efpia phrma ifpma collaboration specific project home responsibility corporate responsibility gsk stakeholder engagement engage corporate responsibility report engage healthcare professional engage healthcare professional way include sale representative run clinical trial read research ethic policy govern relationship healthcare professional patient gsk researcher scientist meet patient focus patient initiative engagement influence understand disease research priority read case studywe support work patient advocacy group conduct market research party understand patient need government regulator engage debate legislation seek influence policy decision affect gsk engage government responsibilityrelate issue healthcare provider engage healthcare provider government affair marketing access medicine activity investor meet regularly investor socially responsible investor read investor engagement activity employee seek feedback employee regular survey consult employee change affect discuss business development regional national consultation forum local community interaction local community manage individual gsk site read financial practical support community multilateral agency engage multilateral agency access public health initiative nongovernmental organisation ngo engage international local ngo access education public health programme public policy work engage regularly animal welfare organisation read animal research gsk scientific community academic partnership important gsk scientific debate involve number academic collaboration supplier hold global regional supplier review meeting senior gsk manager address interact supplier key issue read engagement supplier peer company engage peer company membership pharmaceutical industry organisation example efpia phrma ifpma collaboration specific project home responsibility corporate responsibility gsk stakeholder engagement engagement employee corporate responsibility report engagement employee important employee know commitment corporate responsibility understand responsibility uptodate progress read approach embed ethical culture gsk employee inform corporate responsibility mygsk intranet site spirit internal quarterly magazine feature article responsibility issue read engage employee environment health safety issue article responsibility issue publish spirit include article environmental sustainability community investment effort combat disease develop world lymphatic filariasis year publish edition spirit distribute copy edition internally additionally year online version magazine introduce intranet offer access employee distribute corporate responsibility review spirit magazine directly corporate executive team gsk board senior manager site director communication staff news article icon intranet site guide user directly review year publish short cr highlight document direct people website raise awareness online cr report publicise website company intranet home responsibility corporate responsibility gsk stakeholder engagement engagement employee corporate responsibility report engagement employee important employee know commitment corporate responsibility understand responsibility uptodate progress read approach embed ethical culture gsk employee inform corporate responsibility mygsk intranet site spirit internal quarterly magazine feature article responsibility issue read engage employee environment health safety issue article responsibility issue publish spirit include article environmental sustainability community investment effort combat disease develop world lymphatic filariasis year publish edition spirit distribute copy edition internally additionally year online version magazine introduce intranet offer access employee distribute corporate responsibility review spirit magazine directly corporate executive team gsk board senior manager site director communication staff news article icon intranet site guide user directly review year publish short cr highlight document direct people website raise awareness online cr report publicise website company intranet home responsibility corporate responsibility gsk stakeholder engagement engagement investor corporate responsibility report engagement investor hold meeting investor discuss responsibility issue comprise onetoone meeting teleconference socially responsible investment sri roadshow investor question question raise investor responsibility issue concern access medicine clinical trial result disclosure clinical trial develop world patient safety operation sensitive country read gsk position human right sale marketing practice read marketing ethic gsk stem cell research animal research include genetic engineering animal environmental issue include climate change water pollution political contribution disclose information greenhouse gas emission carbon disclosure project cdp investor collaboration home responsibility corporate responsibility gsk stakeholder engagement engagement investor corporate responsibility report engagement investor hold meeting investor discuss responsibility issue comprise onetoone meeting teleconference socially responsible investment sri roadshow investor question question raise investor responsibility issue concern access medicine clinical trial result disclosure clinical trial develop world patient safety operation sensitive country read gsk position human right sale marketing practice read marketing ethic gsk stem cell research animal research include genetic engineering animal environmental issue include climate change water pollution political contribution disclose information greenhouse gas emission carbon disclosure project cdp investor collaboration home responsibility corporate responsibility gsk stakeholder engagement engagement opinion leader corporate responsibility report engagement opinion leader ipso mori survey gsk participate ipsos mori survey rate company accord cr expert ngos perception cr performance nearly threequarter people survey thought gsk take responsibility seriously maintain significant improvement compare gsk seventhhighest rate company question company respondent spontaneously mention gsk leader corporate responsibility spontaneous mention gsk year home responsibility corporate responsibility gsk stakeholder engagement engagement opinion leader corporate responsibility report engagement opinion leader ipso mori survey gsk participate ipsos mori survey rate company accord cr expert ngos perception cr performance nearly threequarter people survey thought gsk take responsibility seriously maintain significant improvement compare gsk seventhhighest rate company question company respondent spontaneously mention gsk leader corporate responsibility spontaneous mention gsk year home responsibility corperate responsibility gsk stakeholder engagement engagement access medicine corporate responsibility report engagement access medicine engagement issue relate access medicine describe access medicine section engagement gsk conduct formal stakeholder discussion feedback approach different issue relate access medicine engage influential individual organisation expertise area include ngo government representative journalist academic investor industry organisation topic cover increase access hivaids medicine develop country expand rd disease develop world increase access medicine middleincome country necessarily agree comment participant session provide valuable feedback approach feedback gsk approach develop country participant feel gsk moral responsibility product accessible poor people access medicine important gsk longterm business sustainability feel gsk approach increase access develop country rd preferential pricing voluntary licensing appropriate participant like gsk invest rd disease develop world remove obstacle supply generic medicine country participant urge gsk collaborate pharmaceutical company address access issue develop country feel industrywide approach help address issue quickly effectively feedback gsk approach middleincome country participant emphasise importance increase access medicine middleincome country mic large number poor people encourage gsk treat mic highincome country participant feel gsk clear strategy access mic like gsk clear approach objective particular like know regard mic significant commercial market point chronic disease grow problem mic suggest gsk broad approach access encompass medicine highprofile disease hivaid malaria tb read finding session detail home responsibility corperate responsibility gsk stakeholder engagement engagement access medicine corporate responsibility report engagement access medicine engagement issue relate access medicine describe access medicine section engagement gsk conduct formal stakeholder discussion feedback approach different issue relate access medicine engage influential individual organisation expertise area include ngo government representative journalist academic investor industry organisation topic cover increase access hivaids medicine develop country expand rd disease develop world increase access medicine middleincome country necessarily agree comment participant session provide valuable feedback approach feedback gsk approach develop country participant feel gsk moral responsibility product accessible poor people access medicine important gsk longterm business sustainability feel gsk approach increase access develop country rd preferential pricing voluntary licensing appropriate participant like gsk invest rd disease develop world remove obstacle supply generic medicine country participant urge gsk collaborate pharmaceutical company address access issue develop country feel industrywide approach help address issue quickly effectively feedback gsk approach middleincome country participant emphasise importance increase access medicine middleincome country mic large number poor people encourage gsk treat mic highincome country participant feel gsk clear strategy access mic like gsk clear approach objective particular like know regard mic significant commercial market point chronic disease grow problem mic suggest gsk broad approach access encompass medicine highprofile disease hivaid malaria tb read finding session detail home responsibility cr gsk stakeholder engagement engagement ehs corporate responsibility report engagement ehss environment health safety sustainability stakeholder panel uk provide independent feedback performance panel member represent customer supplier regulator public interest group investor senior ehss representative gsk regularly participate gsk manager attend discussion specific topic panel facilitate environment council independent charity panel meet april october debate range issue include broad issue sustainability gsk position nanotechnology progress climate change process safety green chemistry programme gsk plan comply eus registration evaluation authorisation chemical reach legislation mass efficiency improvement pharmaceutical environment feedback stakeholder panel inform environment health safety sustainability programme panel provide input new gsk sustainability council compose senior manager gsk panel member provide feedback direction panel effectiveness dialogue propose panel broad geographic reach add new european panel member recruit panel find gsk honest open discussion consider participation valuable comment take gsk long time demonstrate change occur result suggestion feedback value feedback receive panel look way speed response recommendation site engage stakeholder locally ehss issue activity open day newsletter community project home responsibility cr gsk stakeholder engagement engagement ehs corporate responsibility report engagement ehss environment health safety sustainability stakeholder panel uk provide independent feedback performance panel member represent customer supplier regulator public interest group investor senior ehss representative gsk regularly participate gsk manager attend discussion specific topic panel facilitate environment council independent charity panel meet april october debate range issue include broad issue sustainability gsk position nanotechnology progress climate change process safety green chemistry programme gsk plan comply eus registration evaluation authorisation chemical reach legislation mass efficiency improvement pharmaceutical environment feedback stakeholder panel inform environment health safety sustainability programme panel provide input new gsk sustainability council compose senior manager gsk panel member provide feedback direction panel effectiveness dialogue propose panel broad geographic reach add new european panel member recruit panel find gsk honest open discussion consider participation valuable comment take gsk long time demonstrate change occur result suggestion feedback value feedback receive panel look way speed response recommendation site engage stakeholder locally ehss issue activity open day newsletter community project home responsibility corporate responsibility gsk report corporate responsibility report report welcome corporate responsibility report year report activity performance online provide easy access information key issue plus ability build custom version report report report corporate responsibility activity performance annually website contain detailed account cr policy performance select performance information download read use website publish corporate responsibility highlight provide overview approach cr available print datum relate worldwide operation calendar year state environmental datum collect pharmaceutical consumer healthcare nutritional manufacturing site vaccine site operation pharmaceutical consumer healthcare rd site include environmental datum include host site small new warrant collection environmental datum uk headquarters building small office distribution centre injury illness datum collect pharmaceutical consumer healthcare nutritional manufacturing site vaccine site operation pharmaceutical consumer healthcare rd site consider new start report uk headquarters site office sale group million hour work small office distribution centre data environment health safety section independently assure sgs use external guideline inform report relevant base report global reporting initiative gri guideline produce gri index element guideline cover report aid comparison company report join un global compact provide index report line global compact expectation brandname appear italic report trademark own andor license gsk associate company contact welcome feedback information contain report contact corporate responsibility glaxosmithkline plc great west road brentford middlesex tw gs united kingdom csrcontactgskcom home responsibility corporate responsibility gsk report corporate responsibility report report welcome corporate responsibility report year report activity performance online provide easy access information key issue plus ability build custom version report report report corporate responsibility activity performance annually website contain detailed account cr policy performance select performance information download read use website publish corporate responsibility highlight provide overview approach cr available print datum relate worldwide operation calendar year state environmental datum collect pharmaceutical consumer healthcare nutritional manufacturing site vaccine site operation pharmaceutical consumer healthcare rd site include environmental datum include host site small new warrant collection environmental datum uk headquarters building small office distribution centre injury illness datum collect pharmaceutical consumer healthcare nutritional manufacturing site vaccine site operation pharmaceutical consumer healthcare rd site consider new start report uk headquarters site office sale group million hour work small office distribution centre data environment health safety section independently assure sgs use external guideline inform report relevant base report global reporting initiative gri guideline produce gri index element guideline cover report aid comparison company report join un global compact provide index report line global compact expectation brandname appear italic report trademark own andor license gsk associate company contact welcome feedback information contain report contact corporate responsibility glaxosmithkline plc great west road brentford middlesex tw gs united kingdom csrcontactgskcom home responsibility corporate responsibility gsk report corporate responsibility report report welcome corporate responsibility report year report activity performance online provide easy access information key issue plus ability build custom version report report report corporate responsibility activity performance annually website contain detailed account cr policy performance select performance information download read use website publish corporate responsibility highlight provide overview approach cr available print datum relate worldwide operation calendar year state environmental datum collect pharmaceutical consumer healthcare nutritional manufacturing site vaccine site operation pharmaceutical consumer healthcare rd site include environmental datum include host site small new warrant collection environmental datum uk headquarters building small office distribution centre injury illness datum collect pharmaceutical consumer healthcare nutritional manufacturing site vaccine site operation pharmaceutical consumer healthcare rd site consider new start report uk headquarters site office sale group million hour work small office distribution centre data environment health safety section independently assure sgs use external guideline inform report relevant base report global reporting initiative gri guideline produce gri index element guideline cover report aid comparison company report join un global compact provide index report line global compact expectation brandname appear italic report trademark own andor license gsk associate company contact welcome feedback information contain report contact corporate responsibility glaxosmithkline plc great west road brentford middlesex tw gs united kingdom csrcontactgskcom home responsibility corporate responsibility gsk benchmarke corporate responsibility report benchmarking gsk receive follow rating benchmarking organisation index organisationaccess medicine index access medicine foundation innov strategic value adviser rating gsk rank high index assess company contribution improve access medicine gsk clear overall leader category assess organisation dow jones sustainability index rating gsk continue member dow jones sustainability index cover cent sustainable company sector gsk award silver class sector mover distinction improve bronze class award class award company relative sector leader organisation ftsegood rating gsk include ftsegood index organisation global sustainable corporation innovest strategic value advisor rating gsk include list global sustainable corporation company select demonstrate capacity address sectorspecific environmental social governance risk opportunity organisation business community communitymark rating gsk company manufacture company award new communitymark follow independent assessment outstanding community investment mark endorse uk government voluntary sector leader give work local national level uk large international programme organisation business community environment index rating gsk maintain position platinum league index assess company investor rating organisation cere rating gsk rank th overall nd pharmaceutical sector ceress climate change governance rank world large company organisation storebrand rating gsk achieve good class status lead environmental social performance storebrand assess indicator include corporate governance marketing ethic standard business partner occupational health safety environmental risk management labour relation reporting organisation association charter certify accountant acca rating gsk corporate responsibility report shortlist acca award recognise transparency credibility report organisation pwc build public trust award rating gsk company shortlist people report award assess extent publicly available information enable stakeholder organisation sustainability global reporter benchmark rating gsk report score cent versus cent report improvement category particularly accessibility assurance tophome responsibility corporate responsibility gsk benchmarke corporate responsibility report benchmarking gsk receive follow rating benchmarking organisation index organisationaccess medicine index access medicine foundation innov strategic value adviser rating gsk rank high index assess company contribution improve access medicine gsk clear overall leader category assess organisation dow jones sustainability index rating gsk continue member dow jones sustainability index cover cent sustainable company sector gsk award silver class sector mover distinction improve bronze class award class award company relative sector leader organisation ftsegood rating gsk include ftsegood index organisation global sustainable corporation innovest strategic value advisor rating gsk include list global sustainable corporation company select demonstrate capacity address sectorspecific environmental social governance risk opportunity organisation business community communitymark rating gsk company manufacture company award new communitymark follow independent assessment outstanding community investment mark endorse uk government voluntary sector leader give work local national level uk large international programme organisation business community environment index rating gsk maintain position platinum league index assess company investor rating organisation cere rating gsk rank th overall nd pharmaceutical sector ceress climate change governance rank world large company organisation storebrand rating gsk achieve good class status lead environmental social performance storebrand assess indicator include corporate governance marketing ethic standard business partner occupational health safety environmental risk management labour relation reporting organisation association charter certify accountant acca rating gsk corporate responsibility report shortlist acca award recognise transparency credibility report organisation pwc build public trust award rating gsk company shortlist people report award assess extent publicly available information enable stakeholder organisation sustainability global reporter benchmark rating gsk report score cent versus cent report improvement category particularly accessibility assurance home responsibility corporate responsibility gsk benchmarke corporate responsibility report benchmarking gsk receive follow rating benchmarking organisation index organisationaccess medicine index access medicine foundation innov strategic value adviser rating gsk rank high index assess company contribution improve access medicine gsk clear overall leader category assess organisation dow jones sustainability index rating gsk continue member dow jones sustainability index cover cent sustainable company sector gsk award silver class sector mover distinction improve bronze class award class award company relative sector leader organisation ftsegood rating gsk include ftsegood index organisation global sustainable corporation innovest strategic value advisor rating gsk include list global sustainable corporation company select demonstrate capacity address sectorspecific environmental social governance risk opportunity organisation business community communitymark rating gsk company manufacture company award new communitymark follow independent assessment outstanding community investment mark endorse uk government voluntary sector leader give work local national level uk large international programme organisation business community environment index rating gsk maintain position platinum league index assess company investor rating organisation cere rating gsk rank th overall nd pharmaceutical sector ceress climate change governance rank world large company organisation storebrand rating gsk achieve good class status lead environmental social performance storebrand assess indicator include corporate governance marketing ethic standard business partner occupational health safety environmental risk management labour relation reporting organisation association charter certify accountant acca rating gsk corporate responsibility report shortlist acca award recognise transparency credibility report organisation pwc build public trust award rating gsk company shortlist people report award assess extent publicly available information enable stakeholder organisation sustainability global reporter benchmark rating gsk report score cent versus cent report improvement category particularly accessibility assurance home responsibility corporate responsibility gsk assurance internal audit corporate responsibility report assurance internal audit external assurance ehs activity information provide environment health safety activity gsk externally assure independent thirdparty assurer report environment health safety performance assure sgs external assurer assurance process include verification key environment health safety datum site visit telephone call ehs professional review system process collect collate analyse interpret datum read ehs assurance statement sgs external assurance access medicine activity cr report information access medicine externally assure read respond recommendation assurer access medicine activity report year conduct assurance cr report describe ehs section plan conduct assurance new section report year section report subject external assurance internal audit assurance gsk develop assurance programme provide holistic assessment internal control process risk management audit company key programme extensive independent internal audit schedule deliver specialist audit group audits assess compliance law regulation company standard evaluate effectiveness risk management process identify managing mitigate significant risk face gsk global internal audit gia responsible evaluate financial operational control ensure financial reporting integrity safeguard asset loss include fraud corporate environment health safety sustainability cehss responsible assess management health safety risk environmental impact global manufacturing supply audit risk management arm assess quality supply risk relate manufacture supply chain process gsk commercial product global quality compliance gqc responsible assess risk relate medicine vaccine medical device product development process include manufacture clinical trial material central assurance function responsible develop assurance programme ensure gsk audit group work efficient effective way deliver audit schedule global internal audit audit audit group alignment institute internal auditor international standard professional practice internal auditing cehss arm gcq audit group additional responsibility audit contract manufacturer key supplier gsk gsk employ approximately fulltime internal auditor audit group audits range duration manweek simple activity scope limit month audit involve complex highly technical process audit team supplement external expert specific technical skill use guest auditor business audits conduct base level risk regularly assess level internal control number responsibility area include animal research business continuity planning community investment conduct clinical trial employment practice environmental factor ethical conduct financial process health safety information technology intellectual property interaction patient group manufacture supply chain standard patient safety sale marketing practice issue control deficiency identify audit group recommend process improvement gsk manager develop corrective action plan eliminate cause noncompliance gap internal control audit group track plan completion report result senior management audit committee audit group report audit committee assurance programme provide assessment adequate control place manage significant risk significant audit result report audit committee early opportunity tophome responsibility corporate responsibility gsk assurance internal audit corporate responsibility report assurance internal audit external assurance ehs activity information provide environment health safety activity gsk externally assure independent thirdparty assurer report environment health safety performance assure sgs external assurer assurance process include verification key environment health safety datum site visit telephone call ehs professional review system process collect collate analyse interpret datum read ehs assurance statement sgs external assurance access medicine activity cr report information access medicine externally assure read respond recommendation assurer access medicine activity report year conduct assurance cr report describe ehs section plan conduct assurance new section report year section report subject external assurance internal audit assurance gsk develop assurance programme provide holistic assessment internal control process risk management audit company key programme extensive independent internal audit schedule deliver specialist audit group audits assess compliance law regulation company standard evaluate effectiveness risk management process identify managing mitigate significant risk face gsk global internal audit gia responsible evaluate financial operational control ensure financial reporting integrity safeguard asset loss include fraud corporate environment health safety sustainability cehss responsible assess management health safety risk environmental impact global manufacturing supply audit risk management arm assess quality supply risk relate manufacture supply chain process gsk commercial product global quality compliance gqc responsible assess risk relate medicine vaccine medical device product development process include manufacture clinical trial material central assurance function responsible develop assurance programme ensure gsk audit group work efficient effective way deliver audit schedule global internal audit audit audit group alignment institute internal auditor international standard professional practice internal auditing cehss arm gcq audit group additional responsibility audit contract manufacturer key supplier gsk gsk employ approximately fulltime internal auditor audit group audits range duration manweek simple activity scope limit month audit involve complex highly technical process audit team supplement external expert specific technical skill use guest auditor business audits conduct base level risk regularly assess level internal control number responsibility area include animal research business continuity planning community investment conduct clinical trial employment practice environmental factor ethical conduct financial process health safety information technology intellectual property interaction patient group manufacture supply chain standard patient safety sale marketing practice issue control deficiency identify audit group recommend process improvement gsk manager develop corrective action plan eliminate cause noncompliance gap internal control audit group track plan completion report result senior management audit committee audit group report audit committee assurance programme provide assessment adequate control place manage significant risk significant audit result report audit committee early opportunity home responsibility corporate responsibility gsk assurance internal audit corporate responsibility report assurance internal audit external assurance ehs activity information provide environment health safety activity gsk externally assure independent thirdparty assurer report environment health safety performance assure sgs external assurer assurance process include verification key environment health safety datum site visit telephone call ehs professional review system process collect collate analyse interpret datum read ehs assurance statement sgs external assurance access medicine activity cr report information access medicine externally assure read respond recommendation assurer access medicine activity report year conduct assurance cr report describe ehs section plan conduct assurance new section report year section report subject external assurance internal audit assurance gsk develop assurance programme provide holistic assessment internal control process risk management audit company key programme extensive independent internal audit schedule deliver specialist audit group audits assess compliance law regulation company standard evaluate effectiveness risk management process identify managing mitigate significant risk face gsk global internal audit gia responsible evaluate financial operational control ensure financial reporting integrity safeguard asset loss include fraud corporate environment health safety sustainability cehss responsible assess management health safety risk environmental impact global manufacturing supply audit risk management arm assess quality supply risk relate manufacture supply chain process gsk commercial product global quality compliance gqc responsible assess risk relate medicine vaccine medical device product development process include manufacture clinical trial material central assurance function responsible develop assurance programme ensure gsk audit group work efficient effective way deliver audit schedule global internal audit audit audit group alignment institute internal auditor international standard professional practice internal auditing cehss arm gcq audit group additional responsibility audit contract manufacturer key supplier gsk gsk employ approximately fulltime internal auditor audit group audits range duration manweek simple activity scope limit month audit involve complex highly technical process audit team supplement external expert specific technical skill use guest auditor business audits conduct base level risk regularly assess level internal control number responsibility area include animal research business continuity planning community investment conduct clinical trial employment practice environmental factor ethical conduct financial process health safety information technology intellectual property interaction patient group manufacture supply chain standard patient safety sale marketing practice issue control deficiency identify audit group recommend process improvement gsk manager develop corrective action plan eliminate cause noncompliance gap internal control audit group track plan completion report result senior management audit committee audit group report audit committee assurance programme provide assessment adequate control place manage significant risk significant audit result report audit committee early opportunity home responsibility corporate responsibility gsk corporate responsibility datum summary corporate responsibility report corporate responsibility datum summary metric access medicine number country supply gsk preferentially price arvs number combivir epivir tablet ship millions number generic arvs supply licence gsk millions gsk combivir notforprofit price day voluntary licence grant generic manufacturer gsk arvs cumulative total value product donate gsk patient assistance program million cost wholesale price wac research development expenditure rd billion gsk animal research facility accredit association assessment accreditation laboratory animal care cumulative total number trial publish gsk clinical study register cumulative total ethical conduct number employee complete certification gsk code conduct number contact ethic compliance channel employment woman management grade ethnic diversity people colour ethnic diversity ethnic minority uk lose time injury illness rate case hour work environment number contract manufacturer audit energy consumption million gigajoule water consumption million cubic metre ozone depletion potential meter dose inhaler tonne cfc equivalent ozone depletion potential production tonne cfc equivalent ozone depletion potential refrigeration ancillary use tonne cfc equivalent volatile organic compound emission thousand tonne global warming potential energy source thousand tonne co equivalent hazardous waste dispose thousand tonne community investment total community investment expenditure million cost wholesale price wac value humanitarian product donation include albendazole million cost wholesale price wac number albendazole tablet donate prevention lymphatic filariasis million include arvs sell notforprofit discount price unable collect datum number patient treat include freight delivery cost mdecin san frontires pricing report list average cost generic equivalent currently force restate figure reflect value cost average cost good wholesale acquisition price wac year value donation way believe accurate reflection true cost gsk transparent figure remain wac cover cent animal house gskowne laboratory include contact line manager compliance officer confidential integrity helpline offsite post office box datum include inhaler asia climate change impact calculate co equivalent greenhouse gas protocol develop world resources institute world business council sustainable development year review co factor update datum year appropriate great change generally update factor electricity tophome responsibility corporate responsibility gsk corporate responsibility datum summary corporate responsibility report corporate responsibility datum summary metric access medicine number country supply gsk preferentially price arvs number combivir epivir tablet ship millions number generic arvs supply licence gsk millions gsk combivir notforprofit price day voluntary licence grant generic manufacturer gsk arvs cumulative total value product donate gsk patient assistance program million cost wholesale price wac research development expenditure rd billion gsk animal research facility accredit association assessment accreditation laboratory animal care cumulative total number trial publish gsk clinical study register cumulative total ethical conduct number employee complete certification gsk code conduct number contact ethic compliance channel employment woman management grade ethnic diversity people colour ethnic diversity ethnic minority uk lose time injury illness rate case hour work environment number contract manufacturer audit energy consumption million gigajoule water consumption million cubic metre ozone depletion potential meter dose inhaler tonne cfc equivalent ozone depletion potential production tonne cfc equivalent ozone depletion potential refrigeration ancillary use tonne cfc equivalent volatile organic compound emission thousand tonne global warming potential energy source thousand tonne co equivalent hazardous waste dispose thousand tonne community investment total community investment expenditure million cost wholesale price wac value humanitarian product donation include albendazole million cost wholesale price wac number albendazole tablet donate prevention lymphatic filariasis million include arvs sell notforprofit discount price unable collect datum number patient treat include freight delivery cost mdecin san frontires pricing report list average cost generic equivalent currently force restate figure reflect value cost average cost good wholesale acquisition price wac year value donation way believe accurate reflection true cost gsk transparent figure remain wac cover cent animal house gskowne laboratory include contact line manager compliance officer confidential integrity helpline offsite post office box datum include inhaler asia climate change impact calculate co equivalent greenhouse gas protocol depvaegleo pe odf world resources institute world business council sustainable development year review co factor update datum year appropriate great change generally update factor electricity tophome responsibility corporate responsibility gsk corporate responsibility datum summary corporate responsibility report corporate responsibility datum summary metric access medicine number country supply gsk preferentially price arvs number combivir epivir tablet ship millions number generic arvs supply licence gsk millions gsk combivir notforprofit price day voluntary licence grant generic manufacturer gsk arvs cumulative total value product donate gsk patient assistance program million cost wholesale price wac research development expenditure rd billion gsk animal research facility accredit association assessment accreditation laboratory animal care cumulative total number trial publish gsk clinical study register cumulative total ethical conduct number employee complete certification gsk code conduct number contact ethic compliance channel employment woman management grade ethnic diversity people colour ethnic diversity ethnic minority uk lose time injury illness rate case hour work environment number contract manufacturer audit energy consumption million gigajoule water consumption million cubic metre ozone depletion potential meter dose inhaler tonne cfc equivalent ozone depletion potential production tonne cfc equivalent ozone depletion potential refrigeration ancillary use tonne cfc equivalent volatile organic compound emission thousand tonne global warming potential energy source thousand tonne co equivalent hazardous waste dispose thousand tonne community investment total community investment expenditure million cost wholesale price wac value humanitarian product donation include albendazole million cost wholesale price wac number albendazole tablet donate prevention lymphatic filariasis million include arvs sell notforprofit discount price unable collect datum number patient treat include freight delivery cost mdecin san frontires pricing report list average cost generic equivalent currently force restate figure reflect value cost average cost good wholesale acquisition price wac year value donation way believe accurate reflection true cost gsk transparent figure remain wac cover cent animal house gskowne laboratory include contact line manager compliance officer confidential integrity helpline offsite post office box datum include inhaler asia climate change impact calculate co equivalent greenhouse gas protocol develop world resources institute world business council sustainable development year review co factor update datum year appropriate great change generally update factor electricity home responsibility corporate responsibility gsk corporate responsibility datum summary corporate responsibility report corporate responsibility datum summary metric access medicine number country supply gsk preferentially price arvs number combivir epivir tablet ship millions number generic arvs supply licence gsk millions gsk combivir notforprofit price day voluntary licence grant generic manufacturer gsk arvs cumulative total value product donate gsk patient assistance program million cost wholesale price wac research development expenditure rd billion gsk animal research facility accredit association assessment accreditation laboratory animal care cumulative total number trial publish gsk clinical study register cumulative total ethical conduct number employee complete certification gsk code conduct number contact ethic compliance channel employment woman management grade ethnic diversity people colour ethnic diversity ethnic minority uk lose time injury illness rate case hour work environment number contract manufacturer audit energy consumption million gigajoule water consumption million cubic metre ozone depletion potential meter dose inhaler tonne cfc equivalent ozone depletion potential production tonne cfc equivalent ozone depletion potential refrigeration ancillary use tonne cfc equivalent volatile organic compound emission thousand tonne global warming potential energy source thousand tonne co equivalent hazardous waste dispose thousand tonne community investment total community investment expenditure million cost wholesale price wac value humanitarian product donation include albendazole million cost wholesale price wac number albendazole tablet donate prevention lymphatic filariasis million include arvs sell notforprofit discount price unable collect datum number patient treat include freight delivery cost mdecin san frontires pricing report list average cost generic equivalent currently force restate figure reflect value cost average cost good wholesale acquisition price wac year value donation way believe accurate reflection true cost gsk transparent figure remain wac cover cent animal house gskowne laboratory include contact line manager compliance officer confidential integrity helpline offsite post office box datum include inhaler asia climate change impact calculate co equivalent greenhouse gas protocol develop world resources institute world business council sustainable development year review co factor update datum year appropriate great change generally update factor electricity home responsibility corporate responsibility gsk resource download corporate responsibility report resource download report corporate responsibility report commitment transparency access corporate responsibility highlight pdf kb gri index pdf kb global compact index pdf kb corporate responsibility datum summary environmental metric archive report additional resource access medicine briefing paper access medicine pdf kb finding stakeholder engagement session gsk access hiv medicine workshop pdf kb gsk ddw workshop findings pdf kb gsk mic workshop finding pdf kb ethical conduct gsk code conduct pdf kb employee guide business conduct pdf mb gsk european promotion medicine code practice pdf kb human right human right statement pdf kb public policy patient advocacy public policy position statement detail relationship patient group home responsibility corporate responsibility gsk resource download corporate responsibility report resource download report corporate responsibility report commitment transparency access corporate responsibility highlight pdf kb gri index pdf kb global compact index pdf kb corporate responsibility datum summary environmental metric archive report additional resource access medicine briefing paper access medicine pdf kb finding stakeholder engagement session gsk access hiv medicine workshop pdf kb gsk ddw workshop findings pdf kb gsk mic workshop finding pdf kb ethical conduct gsk code conduct pdf kb employee guide business conduct pdf mb gsk european promotion medicine code practice pdf kb human right human right statement pdf kb public policy patient advocacy public policy position statement detail relationship patient group home responsibility contribution global health corporate responsibility report contribution global health respond societys healthcare need important responsibility issue gsk central commercial success ill health disease continue place huge burden society aids epidemic africa asia health need age population develop world huge global growth chronic disease diabete emerge disease pandemic flu pose potentially threat ill health expensive increase healthcare cost reduce economic productivity business make significant contribution society bring product market address medical need patient world contribution key area prevent disease world large producer vaccine disease prevalent develop develop country prevent disease community investment disease awareness work overthe counter product treat ill health product treat disease place high burden society invest rd pipeline include new medicine vaccine need develop develop country contribute scientific understanding participate partnership advance scientific knowledge lie ground future medical advance believe business make significant contribution society look way accelerate research neglect disease share research resource finding organisation expand partnership government ngos pharmaceutical company want partner support delivery healthcare service medicine product beneficial accessible affordable healthcare payer patient read effort increase access key product develop develop country support healthcare programme community investment home responsibility contribution global health corporate responsibility report contribution global health respond societys healthcare need important responsibility issue gsk central commercial success ill health disease continue place huge burden society aids epidemic africa asia health need age population develop world huge global growth chronic disease diabete emerge disease pandemic flu pose potentially threat ill health expensive increase healthcare cost reduce economic productivity business make significant contribution society bring product market address medical need patient world contribution key area prevent disease world large producer vaccine disease prevalent develop develop country prevent disease community investment disease awareness work overthe counter product treat ill health product treat disease place high burden society invest rd pipeline include new medicine vaccine need develop develop country contribute scientific understanding participate partnership advance scientific knowledge lie ground future medical advance believe business make significant contribution society look way accelerate research neglect disease share research resource finding organisation expand partnership government ngos pharmaceutical company want partner support delivery healthcare service medicine product beneficial accessible affordable healthcare payer patient read effort increase access key product develop develop country support healthcare programme community investment home responsibility contribution global health cost disease corporate responsibility report cost disease ill health expensive individual society result poverty important cause poverty patient mean loss quality life loss earning shorten life expectancy place great burden family instance need care sick relative reduce attendance school work government employer taxpayer mean increase healthcare cost loss workforce productivity africa parts asia aids effect social economic development undermine progress millennium development goal poverty reduction effort world bank estimate death work age adult hivaid subtract cent year gdp economic growth subsaharan african country south africa hivaids depress gdp cent decade malaria estimate cost african nation billion year lose economic output economic cost tbrelate death include hiv coinfection sub saharan africa estimate billion read research disease develop world effort help people country access essential medicine vaccine accord government center disease control prevention cdc cost chronic disease include billion year direct indirect cost diabete billion annual medical care cost arthritis total cost include medical care lose productivity billion billion project cost heart disease stroke read working partnership combat chronic disease role vaccine prevent disease wwwwhointtradeglossarystoryenindexhtml rollback malaria httprbmwhointglobaladvocacyprhtml httpwwwwhointmediacentrenewsreleasesprenindexhtml wwwcdcgovnccdphpoverviewhtm home responsibility contribution global health cost disease corporate responsibility report cost disease ill health expensive individual society result poverty important cause poverty patient mean loss quality life loss earning shorten life expectancy place great burden family instance need care sick relative reduce attendance school work government employer taxpayer mean increase healthcare cost loss workforce productivity africa parts asia aids effect social economic development undermine progress millennium development goal poverty reduction effort world bank estimate death work age adult hivaid subtract cent year gdp economic growth subsaharan african country south africa hivaids depress gdp cent decade malaria estimate cost african nation billion year lose economic output economic cost tbrelate death include hiv coinfection sub saharan africa estimate billion read research disease develop world effort help people country access essential medicine vaccine accord government center disease control prevention cdc cost chronic disease include billion year direct indirect cost diabete billion annual medical care cost arthritis total cost include medical care lose productivity billion billion project cost heart disease stroke read working partnership combat chronic disease role vaccine prevent disease wwwwhointtradeglossarystoryenindexhtml rollback malaria httprbmwhointglobaladvocacyprhtml httpwwwwhointmediacentrenewsreleasesprenindexhtml wwwcdcgovnccdphpoverviewhtm home responsibility contribution global health role vaccine corporate responsibility report role vaccine vaccine play major role prevent eliminate disease immunisation acknowledge world health organization cost effective health investment immunisation programme substantial contribution aim united nations millennium development goal economic growth estimate million death prevent child save disability vaccine year number death africa measle fall cent well coverage routine immunisation programme target campaign ensure child second chance vaccinate despite progress vaccine underuse estimate life million child save year exist vaccine accessible need require sustained financing development innovative vaccination programme gsk world vaccine provider vaccine approve marketing rd pipeline onethird target disease particularly prevalent develop world gsk vaccine include immunisation campaign country worldwide scientist work vaccine research gsk believe vaccine pipeline large industry remain committed research develop vaccine infectious disease priority tuberculosis hiv malaria path malaria vaccine initiative demonstrate phase trial significant protection malaria infant young child gsk rtss candidate vaccine read malaria vaccine supply billion vaccine dose nearly cent ship use develop country read tiere pricing system vaccine vaccine portfolio address medical need develop develop country portfolio cover leading cause childhood mortality define world health organization vaccine range include product protect follow disease cervical cancer pneumococcal disease chickenpox polio diphtheria rotavirus hepatitis b rubella measle seasonal influenza meningitis tetanus mump typhoid pandemic influenza whooping cough pertussis ehreth j global value vaccination vaccine progress global measle control mortality reduction wwwwhointwerwerpdf home responsibility contribution global health role vaccine corporate responsibility report role vaccine vaccine play major role prevent eliminate disease immunisation acknowledge world health organization cost effective health investment immunisation programme substantial contribution aim united nations millennium development goal economic growth estimate million death prevent child save disability vaccine year number death africa measle fall cent well coverage routine immunisation programme target campaign ensure child second chance vaccinate despite progress vaccine underuse estimate life million child save year exist vaccine accessible need require sustained financing development innovative vaccination programme gsk world vaccine provider vaccine approve marketing rd pipeline onethird target disease particularly prevalent develop world gsk vaccine include immunisation campaign country worldwide scientist work vaccine research gsk believe vaccine pipeline large industry remain committed research develop vaccine infectious disease priority tuberculosis hiv malaria path malaria vaccine initiative demonstrate phase trial significant protection malaria infant young child gsk rtss candidate vaccine read malaria vaccine supply billion vaccine dose nearly cent ship use develop country read tiere pricing system vaccine vaccine portfolio address medical need develop develop country portfolio cover leading cause childhood mortality define world health organization vaccine range include product protect follow disease cervical cancer pneumococcal disease chickenpox polio diphtheria rotavirus hepatitis b rubella measle seasonal influenza meningitis tetanus mump typhoid pandemic influenza whooping cough pertussis ehreth j global value vaccination vaccine progress global measle control mortality reduction wwwwhointwerwerpdf home responsibility contribution global health role vaccine corporate responsibility report role vaccine vaccine play major role prevent eliminate disease immunisation acknowledge world health organization cost effective health investment immunisation programme substantial contribution aim united nations millennium development goal economic growth estimate million death prevent child save disability vaccine year number death africa measle fall cent well coverage routine immunisation programme target campaign ensure child second chance vaccinate despite progress vaccine underuse estimate life million child save year exist vaccine accessible need require sustained financing development innovative vaccination programme gsk world vaccine provider vaccine approve marketing rd pipeline onethird target disease particularly prevalent develop world gsk vaccine include immunisation campaign country worldwide scientist work vaccine research gsk believe vaccine pipeline large industry remain committed research develop vaccine infectious disease priority tuberculosis hiv malaria path malaria vaccine initiative demonstrate phase trial significant protection malaria infant young child gsk rtss candidate vaccine read malaria vaccine supply billion vaccine dose nearly cent ship use develop country read tiere pricing system vaccine vaccine portfolio address medical need develop develop country portfolio cover leading cause childhood mortality define world health organization vaccine range include product protect follow disease cervical cancer pneumococcal disease chickenpox polio diphtheria rotavirus hepatitis b rubella measle seasonal influenza meningitis tetanus mump typhoid pandemic influenza whooping cough pertussis ehreth j global value vaccination vaccine progress global measle control mortality reduction wwwwhointwerwerpdf home responsibility contribution global health treat ill health corporate responsibility report treat ill health help treat ill health develop medicine consumer healthcare product work government employer find innovative way reduce impact chronic disease pharmaceutical product target disease follow area antibacterial antibiotic antimalarial infection malaria antiviral hivaid herpe hepatitis b influenza cardiovascular heart failure hypertension deep vein thrombosis central nervous system migraine epilepsy anxiety depression parkinson disease smoking cessation anaesthesia analgesia antiemetics dermatology eczema dermatitis psoriasis metabolic diabetes osteoporosis obesity oncology breast cervical lung ovarian cancer nonhodgkin lymphoma leukaemia idiopathic thrombocytopaenic purpura respiratory immunoinflammation asthma chronic obstructive pulmonary disease rhinitis post operative ileus urogenital prostatic hypertrophy overactive bladder vaccine prevent disease product help improve health number way prolong life antiretroviral arvs combivir help patient control effect hiv infection year sell arvs develop country country sub saharan africa notforprofit price read effort increase access medicine prevent complication disease diabetes progressive patient receive right treatment suffer severe complication example day diabetes cause estimate low limb amputation case blindness people experience kidney failure avandia diabetes treatment help patient control symptom delay progression disease prevent complication avandia seven million people worldwide improve quality life medicine asthma diabetes help patient chronic disease live productive life gsk preventative treatment asthma seretideadvair control symptom asthma prevent asthma attack cure infection produce antibiotic treat respiratory tract infection donate antibiotic help relief effort disaster area paracetamol paracetamol widely lowcost medicine treat adult child pain fever list world health organization essential medicine gsk produce billion tablet year overthecounter paracetomol product panadol available country include low middleincome country provide affordable lowcost singledose pack medical guideline globe recommend paracetamol medicine panadol firstline oral painkiller chronic disease osteoarthritis efficacy safety profile cost effectiveness firstchoice treatment condition headache backache childrens fever paracetamol recommend treatment symptom dengue fever debilitate life threaten disease transmit mosquito tropical subtropical region billion people risk infection twofifth world population country read effort increase awareness dengue fever correct treatment tophome responsibility contribution global health treat ill health corporate responsibility report treat ill health help treat ill health develop medicine consumer healthcare product work government employer find innovative way reduce impact chronic disease pharmaceutical product target disease follow area antibacterial antibiotic antimalarial infection malaria antiviral hivaid herpe hepatitis b influenza cardiovascular heart failure hypertension deep vein thrombosis central nervous system migraine epilepsy anxiety depression parkinson disease smoking cessation anaesthesia analgesia antiemetics dermatology eczema dermatitis psoriasis metabolic diabetes osteoporosis obesity oncology breast cervical lung ovarian cancer nonhodgkin lymphoma leukaemia idiopathic thrombocytopaenic purpura respiratory immunoinflammation asthma chronic obstructive pulmonary disease rhinitis post operative ileus urogenital prostatic hypertrophy overactive bladder vaccine prevent disease product help improve health number way prolong life antiretroviral arvs combivir help patient control effect hiv infection year sell arvs develop country country sub saharan africa notforprofit price read effort increase access medicine prevent complication disease diabetes progressive patient receive right treatment suffer severe complication example day diabetes cause estimate low limb amputation case blindness people experience kidney failure avandia diabetes treatment help patient control symptom delay progression disease prevent complication avandia seven million people worldwide improve quality life medicine asthma diabetes help patient chronic disease live productive life gsk preventative treatment asthma seretideadvair control symptom asthma prevent asthma attack cure infection produce antibiotic treat respiratory tract infection donate antibiotic help relief effort disaster area paracetamol paracetamol widely lowcost medicine treat adult child pain fever list world health organization essential medicine gsk produce billion tablet year overthecounter paracetomol product panadol available country include low middleincome country provide affordable lowcost singledose pack medical guideline globe recommend paracetamol medicine panadol firstline oral painkiller chronic disease osteoarthritis efficacy safety profile cost effectiveness firstchoice treatment condition headache backache childrens fever paracetamol recommend treatment symptom dengue fever debilitate life threaten disease transmit mosquito tropical subtropical region billion people risk infection twofifth world population country read effort increase awareness dengue fever correct treatment home responsibility contribution global health treat ill health corporate responsibility report treat ill health help treat ill health develop medicine consumer healthcare product work government employer find innovative way reduce impact chronic disease pharmaceutical product target disease follow area antibacterial antibiotic antimalarial infection malaria antiviral hivaid herpe hepatitis b influenza cardiovascular heart failure hypertension deep vein thrombosis central nervous system migraine epilepsy anxiety depression parkinson disease smoking cessation anaesthesia analgesia antiemetics dermatology eczema dermatitis psoriasis metabolic diabetes osteoporosis obesity oncology breast cervical lung ovarian cancer nonhodgkin lymphoma leukaemia idiopathic thrombocytopaenic purpura respiratory immunoinflammation asthma chronic obstructive pulmonary disease rhinitis post operative ileus urogenital prostatic hypertrophy overactive bladder vaccine prevent disease product help improve health number way prolong life antiretroviral arvs combivir help patient control effect hiv infection year sell arvs develop country country sub saharan africa notforprofit price read effort increase access medicine prevent complication disease diabetes progressive patient receive right treatment suffer severe complication example day diabetes cause estimate low limb amputation case blindness people experience kidney failure avandia diabetes treatment help patient control symptom delay progression disease prevent complication avandia seven million people worldwide improve quality life medicine asthma diabetes help patient chronic disease live productive life gsk preventative treatment asthma seretideadvair control symptom asthma prevent asthma attack cure infection produce antibiotic treat respiratory tract infection donate antibiotic help relief effort disaster area paracetamol paracetamol widely lowcost medicine treat adult child pain fever list world health organization essential medicine gsk produce billion tablet year overthecounter paracetomol product panadol available country include low middleincome country provide affordable lowcost singledose pack medical guideline globe recommend paracetamol medicine panadol firstline oral painkiller chronic disease osteoarthritis efficacy safety profile cost effectiveness firstchoice treatment condition headache backache childrens fever paracetamol recommend treatment symptom dengue fever debilitate life threaten disease transmit mosquito tropical subtropical region billion people risk infection twofifth world population country read effort increase awareness dengue fever correct treatment home responsibility contribution global health treat ill health partnering combat chronic disease corporate responsibility report partner combat chronic disease healthcare cost country concern patient healthcare payer pharmaceutical industry alike increase prevalence chronic disease asthma diabete heart disease major contributing factor work government employer find new way address problem chronic disease reduce healthcare cost approach know triple solution focus area prevention addressing cause chronic disease obesity smoke poor diet lack exercise intervention properly manage chronic disease prevent complication avoid hospitalisation cost reduce time away work innovation develop new treatment costly unmet medical need alzheimer disease stroke work employer communitie healthcare major source expenditure government employer consumer expenditure healthcare exceed trillion additionally absence work ill health significant cost go unrecognised work closely state local public health agency large number employer help create health management programme remove barrier healthcare access reduce healthcare cost improve health organisation work state municipality employer help address disease great burden healthcare budget encourage employer provide preventative service worker example regular health screening detect early sign disease awareness campaign initiative help employee adopt healthy lifestyle develop disease management programme help employee control symptom stick treatment regimen initiate comprehensive wellness initiative obesity smoking lead product smoke leading cause death disease united states direct indirect cost associate overweight obese estimate exceed billion year approximately cent annual medical expenditure advise employer create new incentive well health management example reduce copay element prescription medicine charge increase total employer pay pharmaceutical short term improve patient medication adherence rate prevent costly complication time away work long term help lower overall healthcare cost diabete city challenge day diabete cause estimate low limb amputation people lose sight right treatment complication prevent diabete city challenge support gsk partnership city government private employer city american pharmacist association apha foundation pharmacistpsag iet olfp employee diabetes manage condition nutrition medication adopt healthy lifestyle aim prevent sideeffect reduce associate healthcare cost key feature include low copay portion prescription cost pay patient make medicine affordable make likely patient adhere prescribe treatment regimen regular meeting patient pharmacist discuss symptom identify potential complication early possible help participant set achieve nutrition exercise weight loss goal include print material meeting pharmacist coach share challenge finding resource employer outside city dedicated website programme base apha foundation asheville project helped reduce healthcare cost participate employee cent cut absenteeism cent average pilot project base asheville project launch japan run team showa university pilot involve diabete asthma patient twoyear period community health centre donate st cecilias health centre new orleans ninth ward city see great devastation hurricane katrina money fund clinic community diabete outreach program help exceed national average percentage diabetic receive regular test control symptom read effort raise awareness prevent disease tophome responsibility contribution global health treat ill health partnering combat chronic disease corporate responsibility report partner combat chronic disease healthcare cost country concern patient healthcare payer pharmaceutical industry alike increase prevalence chronic disease asthma diabete heart disease major contributing factor work government employer find new way address problem chronic disease reduce healthcare cost approach know triple solution focus area prevention addressing cause chronic disease obesity smoke poor diet lack exercise intervention properly manage chronic disease prevent complication avoid hospitalisation cost reduce time away work innovation develop new treatment costly unmet medical need alzheimer disease stroke work employer communitie healthcare major source expenditure government employer consumer expenditure healthcare exceed trillion additionally absence work ill health significant cost go unrecognised work closely state local public health agency large number employer help create health management programme remove barrier healthcare access reduce healthcare cost improve health organisation work state municipality employer help address disease great burden healthcare budget encourage employer provide preventative service worker example regular health screening detect early sign disease awareness campaign initiative help employee adopt healthy lifestyle develop disease management programme help employee control symptom stick treatment regimen initiate comprehensive wellness initiative obesity smoking lead product smoke leading cause death disease united states direct indirect cost associate overweight obese estimate exceed billion year approximately cent annual medical expenditure advise employer create new incentive well health management example reduce copay element prescription medicine charge increase total employer pay pharmaceutical short term improve patient medication adherence rate prevent costly complication time away work long term help lower overall healthcare cost diabete city challenge day diabete cause estimate low limb amputation people lose sight right treatment complication prevent diabete city challenge support gsk partnership city government private employer city american pharmacist association apha foundation pharmacist help employee diabetes manage condition nutrition medication adopt healthy lifestyle aim prevent sideeffect reduce associate healthcare cost key feature include low copay portion prescription cost pay patient make medicine affordable make likely patient adhere prescribe treatment regimen regular meeting patient pharmacist discuss symptom identify potential complication early possible help participant set achieve nutrition exercise weight loss goal include print material meeting pharmacist coach share challenge finding resource employer outside city dedicated website programme base apha foundation asheville project helped reduce healthcare cost participate employee cent cut absenteeism cent average pilot project base asheville project launch japan run team showa university pilot involve diabete asthma patient twoyear period community health centre donate st cecilias health centre new orleans ninth ward city see great devastation hurricane katrina money fund clinic community diabete outreach program help exceed national average percentage diabetic receive regular test control symptom read effort raise awareness prevent disease home responsibility contribution global health treat ill health partnering combat chronic disease corporate responsibility report partner combat chronic disease healthcare cost country concern patient healthcare payer pharmaceutical industry alike increase prevalence chronic disease asthma diabete heart disease major contributing factor work government employer find new way address problem chronic disease reduce healthcare cost approach know triple solution focus area prevention addressing cause chronic disease obesity smoke poor diet lack exercise intervention properly manage chronic disease prevent complication avoid hospitalisation cost reduce time away work innovation develop new treatment costly unmet medical need alzheimer disease stroke work employer communitie healthcare major source expenditure government employer consumer expenditure healthcare exceed trillion additionally absence work ill health significant cost go unrecognised work closely state local public health agency large number employer help create health management programme remove barrier healthcare access reduce healthcare cost improve health organisation work state municipality employer help address disease great burden healthcare budget encourage employer provide preventative service worker example regular health screening detect early sign disease awareness campaign initiative help employee adopt healthy lifestyle develop disease management programme help employee control symptom stick treatment regimen initiate comprehensive wellness initiative obesity smoking lead product smoke leading cause death disease united states direct indirect cost associate overweight obese estimate exceed billion year approximately cent annual medical expenditure advise employer create new incentive well health management example reduce copay element prescription medicine charge increase total employer pay pharmaceutical short term improve patient medication adherence rate prevent costly complication time away work long term help lower overall healthcare cost diabete city challenge day diabete cause estimate low limb amputation people lose sight right treatment complication prevent diabete city challenge support gsk partnership city government private employer city american pharmacist association apha foundation pharmacist help employee diabetes manage condition nutrition medication adopt healthy lifestyle aim prevent sideeffect reduce associate healthcare cost key feature include low copay portion prescription cost pay patient make medicine affordable make likely patient adhere prescribe treatment regimen regular meeting patient pharmacist discuss symptom identify potential complication early possible help participant set achieve nutrition exercise weight loss goal include print material meeting pharmacist coach share challenge finding resource employer outside city dedicated website programme base apha foundation asheville project helped reduce healthcare cost participate employee cent cut absenteeism cent average pilot project base asheville project launch japan run team showa university pilot involve diabete asthma patient twoyear period community health centre donate st cecilias health centre new orleans ninth ward city see great devastation hurricane katrina money fund clinic community diabete outreach program help exceed national average percentage diabetic receive regular test control symptom read effort raise awareness prevent disease home responsibility contribution global health disease awareness prevention corporate responsibility report disease awareness prevention world large producer vaccine play vital role prevent disease develop overthecounter product help people stop smoke lose weight maintain good oral health help raise awareness healthcare professional public work patient group disease awareness campaign place coincide launch new product market positive impact public health create commercial benefit gsk read effort raise awareness prevent disease home responsibility contribution global health disease awareness prevention corporate responsibility report disease awareness prevention world large producer vaccine play vital role prevent disease develop overthecounter product help people stop smoke lose weight maintain good oral health help raise awareness healthcare professional public work patient group disease awareness campaign place coincide launch new product market positive impact public health create commercial benefit gsk read effort raise awareness prevent disease home responsibility contribution global health disease awareness prevention raise awareness disease corporate responsibility report raise awareness disease run range disease awareness campaign include pandemic flu world health organization consider world close flu pandemic time outbreak hold workshop journalist european influenza congress portugal highlight threat pandemic flu journalist play important role raise government awareness health issue influence health policy workshop participant spend hour talk independent expert discuss key subject learn past pandemic personal economic impact outbreak role vaccine government prepare read gsk flu product effort help prepare pandemic flu cervical cancer vaccine cervarix help prevent infection cancercause type human papillomavirus hpv commonly lead cervical cancer year launch cervarix europe research region show cent woman know link hpv cervical cancer run disease awareness campaign country highlight link educate people importance screen help prevent cervical cancer campaign target healthcare professional medium policy maker woman press article educational event healthcare professional support cervical cancer patient group activitie european cervical cancer prevention week rotavirus rotarix vaccine rotavirus leading cause gastroenteritis infection rotavirus associate million clinic visit million hospitalisation death worldwide child year launch rotarix mexico latin american country precede widespread disease awareness campaign achieve gsk educate journalist gastroenteritis infection cause rotavirus cause prevent detect symptom early rotavirus quickly fatal child dehydrate receive treatment educational material discuss vaccination guidance prompt detection treatment method chronic disease healthy community programme offer free health screening community country aim educate people chronic disease encourage well control health people manage chronic disease develop complication lead great health problem announce finding nationwide health screening people conduct programme approximately cent participant report health excellent test indicate good health example nearly half participant type diabete show poor glucose control nearly asthmatic screen poor control condition individual poorly control diabetes asthma twothird visit primary care physician past year gsk partner national association chronic disease director nacdd webmd health information site help people engaged manage health triple solution approach encourage people assess risk chronic disease health check tool provide advice big health risk dengue fever paracetamol recommend effective symptomatic treatment dengue fever debilitate disease transmit mosquito tropical subtropical region people know correct treatment dengue fever especially child people use feverreducer aspirin exacerbate bleed symptom dengue fever seek medical treatment late increase risk complication death panadol gsk overthecounter paracetamol brand strong presence region dengue fever prevalent notably asia africa middle east central south america gsk position lead drive global awareness healthcare professional public dengue fever threat initiated sponsor dengue fever public awareness campaign highrisk area include caribbean southeast asia work collaboration organisation unicef pan america health organization engage locally respect campaign ambassador campaign increase awareness television radio pr activity roadside banner poster hospital public health centre pharmacy drugstore local medium pick activity help raise awareness health professional target raise awareness provide information help diagnosis treatment free panadol sample distribute hospital campaign run costa rica contribute cent reduction dengue fever case report board health campaign run number case increase cent gsk activate campaign collaboration board health end save life campaign contribute cent reduction dengue case similarly panadol campaign contribute decrease southeast asian dengue case especially indonesia dengue fever fatality rate drop cent previous year gsk planning continue campaign parashar ud et al global illness death cause rotavirus disease child emerg infect dis datum file tophome responsibility contribution global health disease awareness prevention raise awareness disease corporate responsibility report raise awareness disease run range disease awareness campaign include pandemic flu world health organization consider world close flu pandemic time outbreak hold workshop journalist european influenza congress portugal highlight threat pandemic flu journalist play important role raise government awareness health issue influence health policy workshop participant spend hour talk independent expert discuss key subject learn past pandemic personal economic impact outbreak role vaccine government prepare read gsk flu product effort help prepare pandemic flu cervical cancer vaccine cervarix help prevent infection cancercause type human papillomavirus hpv commonly lead cervical cancer year launch cervarix europe research region show cent woman know link hpv cervical cancer run disease awareness campaign country highlight link educate people importance screen help prevent cervical cancer campaign target healthcare professional medium policy maker woman press article educational event healthcare professional support cervical cancer patient group activitie european cervical cancer prevention week rotavirus rotarix vaccine rotavirus leading cause gastroenteritis infection rotavirus associate million clinic visit million hospitalisation death worldwide child year launch rotarix mexico latin american country precede widespread disease awareness campaign achieve gsk educate journalist gastroenteritis infection cause rotavirus cause prevent detect symptom early rotavirus quickly fatal child dehydrate receive treatment educational material discuss vaccination guidance prompt detection treatment method chronic disease healthy community programme offer free health screening community country aim educate people chronic disease encourage well control health people manage chronic disease develop complication lead great health problem announce finding nationwide health screening people conduct programme approximately cent participant report health excellent test indicate good health example nearly half participant type diabete show poor glucose control nearly asthmatic screen poor control condition individual poorly control diabetes asthma twothird visit primary care physician past year gsk partner national association chronic disease director nacdd webmd health information site help people engaged manage health triple solution approach encourage people assess risk chronic disease health check tool provide advice big health risk dengue fever paracetamol recommend effective symptomatic treatment dengue fever debilitate disease transmit mosquito tropical subtropical region people know correct treatment dengue fever especially child people use feverreducer aspirin exacerbate bleed symptom dengue fever seek medical treatment late increase risk complication death panadol gsk overthecounter paracetamol brand strong presence region dengue fever prevalent notably asia africa middle east central south america gsk position lead drive global awareness healthcare professional public dengue fever threat initiated sponsor dengue fever public awareness campaign highrisk area include caribbean southeast asia work collaboration organisation unicef pan america health organization engage locally respect campaign ambassador campaign increase awareness television radio pr activity roadside banner poster hospital public health centre pharmacy drugstore local medium pick activity help raise awareness health professional target raise awareness provide information help diagnosis treatment free panadol sample distribute hospital campaign run costa rica contribute cent reduction dengue fever case report board health campaign run number case increase cent gsk activate campaign collaboration board health end save life campaign contribute cent reduction dengue case similarly panadol campaign contribute decrease southeast asian dengue case especially indonesia dengue fever fatality rate drop cent previous year gsk planning continue campaign parashar ud et al global illness death cause rotavirus disease child emerg infect dis datum file home responsibility contribution global health disease awareness prevention raise awareness disease corporate responsibility report raise awareness disease run range disease awareness campaign include pandemic flu world health organization consider world close flu pandemic time outbreak hold workshop journalist european influenza congress portugal highlight threat pandemic flu journalist play important role raise government awareness health issue influence health policy workshop participant spend hour talk independent expert discuss key subject learn past pandemic personal economic impact outbreak role vaccine government prepare read gsk flu product effort help prepare pandemic flu cervical cancer vaccine cervarix help prevent infection cancercause type human papillomavirus hpv commonly lead cervical cancer year launch cervarix europe research region show cent woman know link hpv cervical cancer run disease awareness campaign country highlight link educate people importance screen help prevent cervical cancer campaign target healthcare professional medium policy maker woman press article educational event healthcare professional support cervical cancer patient group activitie european cervical cancer prevention week rotavirus rotarix vaccine rotavirus leading cause gastroenteritis infection rotavirus associate million clinic visit million hospitalisation death worldwide child year launch rotarix mexico latin american country precede widespread disease awareness campaign achieve gsk educate journalist gastroenteritis infection cause rotavirus cause prevent detect symptom early rotavirus quickly fatal child dehydrate receive treatment educational material discuss vaccination guidance prompt detection treatment method chronic disease healthy community programme offer free health screening community country aim educate people chronic disease encourage well control health people manage chronic disease develop complication lead great health problem announce finding nationwide health screening people conduct programme approximately cent participant report health excellent test indicate good health example nearly half participant type diabete show poor glucose control nearly asthmatic screen poor control condition individual poorly control diabetes asthma twothird visit primary care physician past year gsk partner national association chronic disease director nacdd webmd health information site help people engaged manage health triple solution approach encourage people assess risk chronic disease health check tool provide advice big health risk dengue fever paracetamol recommend effective symptomatic treatment dengue fever debilitate disease transmit mosquito tropical subtropical region people know correct treatment dengue fever especially child people use feverreducer aspirin exacerbate bleed symptom dengue fever seek medical treatment late increase risk complication death panadol gsk overthecounter paracetamol brand strong presence region dengue fever prevalent notably asia africa middle east central south america gsk position lead drive global awareness healthcare professional public dengue fever threat initiated sponsor dengue fever public awareness campaign highrisk area include caribbean southeast asia work collaboration organisation unicef pan america health organization engage locally respect campaign ambassador campaign increase awareness television radio pr activity roadside banner poster hospital public health centre pharmacy drugstore local medium pick activity help raise awareness health professional target raise awareness provide information help diagnosis treatment free panadol sample distribute hospital campaign run costa rica contribute cent reduction dengue fever case report board health campaign run number case increase cent gsk activate campaign collaboration board health end save life campaign contribute cent reduction dengue case similarly panadol campaign contribute decrease southeast asian dengue case especially indonesia dengue fever fatality rate drop cent previous year gsk planning continue campaign parashar ud et al global illness death cause rotavirus disease child emerg infect dis datum file home responsibility contribution global health disease awareness prevention prevent disease corporate responsibility report prevent disease vaccine vaccine significant contribution health recognise successful way prevent disease vaccine second clean drinking water reduce impact infectious disease gsk large supplier vaccine lead supplier childhood vaccine unicef vaccine design eradicate control disease individual level prevent disease limit severity highly cost effective benefit society individual vaccine widespread endorsement supranational organisation include united nations world bank propose government immunisation priority healthcare investment immunisation programme successfully eradicate smallpox worldwide significant progress elimination polio global eradication possible disease reduce low level vaccination maintain high level example haemophilus influenzae type b vaccine bacterial meningitis cause virus dramatically reduce majority cervical cancer preventable vaccination human papillomavirus hpv combine cervical screening gsk vaccine hpv cervarix available high middle lowincome country world commit work accelerate global access vaccine cervarix choose vaccine national immunisation programme nip uk large human papillomavirus immunisation programme world date nip launch september cent girl age vaccinate consumer healthcare product smoking cessation smoke major public health problem contribute million premature death worldwide year nicotine replacement therapy nrt significantly increase smoker chance stop gsk create overthecounter nrt market range nicotine replacement brand include niquitin cqnicoderm commit lozenge nicorette help million people stop smoke estimate cent smoker currently access nrt aim increase figure cent launch nicotine replacement brand new market poverty major barrier nrt purchase especially emerge market provide smoking cessation education counselling support brazilian government effort help low income smoker try stop smoke support petition submit new york commissioner health ask food drug administration fda allow overthecounter nrt product sell cigarette sell permit sale small pack few dose low price fda currently allow sale small oneday affordable pack size uk support national health service stop smoke clinic provide clinic educational material run online telephone support smoker help train nhs nurse pharmacist stop smoke adviser prevent obesity obesity major cause ill health disease diabete alli overthecounter weightloss treatment help people lose weight combine lowfat reduce calorie diet alli market receive positive opinion nonprescription product european medicine agency emea committee medicinal product human use january european commission grant nonprescription licence product launch million starter pack alli sell help million people lose weight read case study ensure alli market responsibly oral healthcare important people maintain good oral health prevent gum disease tooth decay oral healthcare product include toothpaste mouth wash denture cleaner facility weybridge uk make global brand aquafresh sensodyne large oral healthcare research centre europe employee facility regularly visit oral healthcare conference publish article journal promote importance oral healthcare product cosponsor innovation oral care awards international association dental research run award scheme recognise innovative research prevent mouth infection improve oral healthcare diagnostic community investment invest community activity focus disease prevention example participate global alliance eliminate lymphatic filariasis leading cause disability tropical country phase handwash programme helps prevent spread diarrhoearelate disease child develop country tophome responsibility contribution global health disease awareness prevention prevent disease corporate responsibility report prevent disease vaccine vaccine significant contribution health recognise successful way prevent disease vaccine second clean drinking water reduce impact infectious disease gsk large supplier vaccine lead supplier childhood vaccine unicef vaccine design eradicate control disease individual level prevent disease limit severity highly cost effective benefit society individual vaccine widespread endorsement supranational organisation include united nations world bank propose government immunisation priority healthcare investment immunisation programme successfully eradicate smallpox worldwide significant progress elimination polio global eradication possible disease reduce low level vaccination maintain high level example haemophilus influenzae type b vaccine bacterial meningitis cause virus dramatically reduce majority cervical cancer preventable vaccination human papillomavirus hpv combine cervical screening gsk vaccine hpv cervarix available high middle lowincome country world commit work accelerate global access vaccine cervarix choose vaccine national immunisation programme nip uk large human papillomavirus immunisation programme world date nip launch september cent girl age vaccinate consumer healthcare product smoking cessation smoke major public health problem contribute million premature death worldwide year nicotine replacement therapy nrt significantly increase smoker chance stop gsk create overthecounter nrt market range nicotine replacement brand include niquitin cqnicoderm commit lozenge nicorette help million people stop smoke estimate cent smoker currently access nrt aim increase figure cent launch nicotine replacement brand new market poverty major barrier nrt purchase especially emerge market provide smoking cessation education counselling support brazilian government effort help low income smoker try stop smoke support petition submit new york commissioner health ask food drug administration fda allow overthecounter nrt product sell cigarette sell permit sale small pack few dose low price fda currently allow sale small oneday affordable pack size uk support national health service stop smoke clinic provide clinic educational material run online telephone support smoker help train nhs nurse pharmacist stop smoke adviser prevent obesity obesity major cause ill health disease diabete alli overthecounter weightloss treatment help people lose weight combine lowfat reduce calorie diet alli market receive positive opinion nonprescription product european medicine agency emea committee medicinal product human use january european commission grant nonprescription licence product launch million starter pack alli sell help million people lose weight read case study ensure alli market responsibly oral healthcare important people maintain good oral health prevent gum disease tooth decay oral healthcare product include toothpaste mouth wash denture cleaner facility weybridge uk make global brand aquafresh sensodyne large oral healthcare research centre europe employee facility regularly visit oral healthcare conference publish article journal promote importance oral healthcare product cosponsor innovation oral care awards international association dental research run award scheme recognise innovative research prevent mouth infection improve oral healthcare diagnostic community investment invest community activity focus disease prevention example participate global alliance eliminate lymphatic filariasis leading cause disability tropical country phase handwash programme helps prevent spread diarrhoearelate disease child develop country home responsibility contribution global health disease awareness prevention prevent disease corporate responsibility report prevent disease vaccine vaccine significant contribution health recognise successful way prevent disease vaccine second clean drinking water reduce impact infectious disease gsk large supplier vaccine lead supplier childhood vaccine unicef vaccine design eradicate control disease individual level prevent disease limit severity highly cost effective benefit society individual vaccine widespread endorsement supranational organisation include united nations world bank propose government immunisation priority healthcare investment immunisation programme successfully eradicate smallpox worldwide significant progress elimination polio global eradication possible disease reduce low level vaccination maintain high level example haemophilus influenzae type b vaccine bacterial meningitis cause virus dramatically reduce majority cervical cancer preventable vaccination human papillomavirus hpv combine cervical screening gsk vaccine hpv cervarix available high middle lowincome country world commit work accelerate global access vaccine cervarix choose vaccine national immunisation programme nip uk large human papillomavirus immunisation programme world date nip launch september cent girl age vaccinate consumer healthcare product smoking cessation smoke major public health problem contribute million premature death worldwide year nicotine replacement therapy nrt significantly increase smoker chance stop gsk create overthecounter nrt market range nicotine replacement brand include niquitin cqnicoderm commit lozenge nicorette help million people stop smoke estimate cent smoker currently access nrt aim increase figure cent launch nicotine replacement brand new market poverty major barrier nrt purchase especially emerge market provide smoking cessation education counselling support brazilian government effort help low income smoker try stop smoke support petition submit new york commissioner health ask food drug administration fda allow overthecounter nrt product sell cigarette sell permit sale small pack few dose low price fda currently allow sale small oneday affordable pack size uk support national health service stop smoke clinic provide clinic educational material run online telephone support smoker help train nhs nurse pharmacist stop smoke adviser prevent obesity obesity major cause ill health disease diabete alli overthecounter weightloss treatment help people lose weight combine lowfat reduce calorie diet alli market receive positive opinion nonprescription product european medicine agency emea committee medicinal product human use january european commission grant nonprescription licence product launch million starter pack alli sell help million people lose weight read case study ensure alli market responsibly oral healthcare important people maintain good oral health prevent gum disease tooth decay oral healthcare product include toothpaste mouth wash denture cleaner facility weybridge uk make global brand aquafresh sensodyne large oral healthcare research centre europe employee facility regularly visit oral healthcare conference publish article journal promote importance oral healthcare product cosponsor innovation oral care awards international association dental research run award scheme recognise innovative research prevent mouth infection improve oral healthcare diagnostic community investment invest community activity focus disease prevention example participate global alliance eliminate lymphatic filariasis leading cause disability tropical country phase handwash programme helps prevent spread diarrhoearelate disease child develop country home responsibility contribution global health investing rd corporate responsibility report invest rd despite advance healthcare disease cure treatment improve continued research innovation essential investment rd new medicine vaccine core business spend billion rd cent expenditure pharmaceutical rd remainder vaccine consumer healthcare rd nearly prescription medicine vaccine clinical development detail rd annual report current latestage pipeline include product target disease include form cancer infection respiratory disease autoimmune disorder metabolic cardiovascular disease psychiatric disorder neurological disease new product approve time submission new product product line extension example reflect strong focus oncology december file licence pazopanib treatment advanced renal cell carcinoma read ensure high ethical standard rd activity expand research capability improve productivity strategic priority improve rd productivity rd organisation restructure support change describe rd section annual report early conduct review involve external expert identify therapy area recent advance science mean probability find new treatment base outcomes review refocus earlystage research activity follow area biopharmaceutical immunoinflammatory disease infectious disease metabolic pathway neuroscience oncology ophthalmology respiratory disease rd china chinese rd centre open employee move stateof theart facility shanghai centre investigate neurodegenerative disorder alzheimer disease parkinson disease multiple sclerosis centre progress early pipeline target validation candidate selection intend develop centre lead facility global discovery development activity neurodegenerative disorder cost conduct research china low market low cost primary reason opening facility china offer huge pool scientific talent recruitment roadshow reach phd graduate university rd china conduct gsk global quality ethical standard rd policy monitor procedure global apply operation china invest new area science invest technology provide new opportunity medical intervention include stem cell technology believe stem cell science great potential aid discovery new medicine improve screening identification development new compound stem cell help develop medicine safe effective read collaboration harvard stem cell institute participation stem cell safe medicine publicprivate partnership external collaboration gsk monopoly good science expand collaboration external partner business development activity access innovation outside organisation external collaboration underway complement internal discovery performance unit immunoinflammation centre excellence drug discovery announce fiveyear research partnership immune disease institute idi boston partnership combine idis world class immunological expertise gsk pharmaceutical capability sign agreement university cambridge develop compound potential treating obesity addictive disorder university contribute knowhow expertise bear financial risk compensate programme successful gsk provide operational support access inhouse clinical research imaging facility background preclinical datum drug cambridge university dedicate team academic expert neuroscience metabolic disorder importantly agreement allow academic scientist freedom publish result work incubator project acquire pharmaceutical company sirtris leader research sirtuin recently discover class enzyme believe involved ageing process combination specialist knowledge sirtris gsk development capability provide good possible chance validate new approach disease metabolism age read investment new technology annual report tophome responsibility contribution global health investing rd corporate responsibility report invest rd despite advance healthcare disease cure treatment improve continued research innovation essential investment rd new medicine vaccine core business spend billion rd cent expenditure pharmaceutical rd remainder vaccine consumer healthcare rd nearly prescription medicine vaccine clinical development detail rd annual report current latestage pipeline include product target disease include form cancer infection respiratory disease autoimmune disorder metabolic cardiovascular disease psychiatric disorder neurological disease new product approve time submission new product product line extension example reflect strong focus oncology december file licence pazopanib treatment advanced renal cell carcinoma read ensure high ethical standard rd activity expand research capability improve productivity strategic priority improve rd productivity rd organisation restructure support change describe rd section annual report early conduct review involve external expert identify therapy area recent advance science mean probability find new treatment base outcomes review refocus earlystage research activity follow area biopharmaceutical immunoinflammatory disease infectious disease metabolic pathway neuroscience oncology ophthalmology respiratory disease rd china chinese rd centre open employee move stateof theart facility shanghai centre investigate neurodegenerative disorder alzheimer disease parkinson disease multiple sclerosis centre progress early pipeline target validation candidate selection intend develop centre lead facility global discovery development activity neurodegenerative disorder cost conduct research china low market low cost primary reason opening facility china offer huge pool scientific talent recruitment roadshow reach phd graduate university rd china conduct gsk global quality ethical standard rd policy monitor procedure global apply operation china invest new area science invest technology provide new opportunity medical intervention include stem cell technology believe stem cell science great potential aid discovery new medicine improve screening identification development new compound stem cell help develop medicine safe effective read collaboration harvard stem cell institute participation stem cell safe medicine publicprivate partnership external collaboration gsk monopoly good science expand collaboration external partner business development activity access innovation outside organisation external collaboration underway complement internal discovery performance unit immunoinflammation centre excellence drug discovery announce fiveyear research partnership immune disease institute idi boston partnership combine idis world class immunological expertise gsk pharmaceutical capability sign agreement university cambridge develop compound potential treating obesity addictive disorder university contribute knowhow expertise bear financial risk compensate programme successful gsk provide operational support access inhouse clinical research imaging facility background preclinical datum drug cambridge university dedicate team academic expert neuroscience metabolic disorder importantly agreement allow academic scientist freedom publish result work incubator project acquire pharmaceutical company sirtris leader research sirtuin recently discover class enzyme believe involved ageing process combination specialist knowledge sirtris gsk development capability provide good possible chance validate new approach disease metabolism age read investment new technology annual report home responsibility contribution global health investing rd corporate responsibility report invest rd despite advance healthcare disease cure treatment improve continued research innovation essential investment rd new medicine vaccine core business spend billion rd cent expenditure pharmaceutical rd remainder vaccine consumer healthcare rd nearly prescription medicine vaccine clinical development detail rd annual report current latestage pipeline include product target disease include form cancer infection respiratory disease autoimmune disorder metabolic cardiovascular disease psychiatric disorder neurological disease new product approve time submission new product product line extension example reflect strong focus oncology december file licence pazopanib treatment advanced renal cell carcinoma read ensure high ethical standard rd activity expand research capability improve productivity strategic priority improve rd productivity rd organisation restructure support change describe rd section annual report early conduct review involve external expert identify therapy area recent advance science mean probability find new treatment base outcomes review refocus earlystage research activity follow area biopharmaceutical immunoinflammatory disease infectious disease metabolic pathway neuroscience oncology ophthalmology respiratory disease rd china chinese rd centre open employee move stateof theart facility shanghai centre investigate neurodegenerative disorder alzheimer disease parkinson disease multiple sclerosis centre progress early pipeline target validation candidate selection intend develop centre lead facility global discovery development activity neurodegenerative disorder cost conduct research china low market low cost primary reason opening facility china offer huge pool scientific talent recruitment roadshow reach phd graduate university rd china conduct gsk global quality ethical standard rd policy monitor procedure global apply operation china invest new area science invest technology provide new opportunity medical intervention include stem cell technology believe stem cell science great potential aid discovery new medicine improve screening identification development new compound stem cell help develop medicine safe effective read collaboration harvard stem cell institute participation stem cell safe medicine publicprivate partnership external collaboration gsk monopoly good science expand collaboration external partner business development activity access innovation outside organisation external collaboration underway complement internal discovery performance unit immunoinflammation centre excellence drug discovery announce fiveyear research partnership immune disease institute idi boston partnership combine idis world class immunological expertise gsk pharmaceutical capability sign agreement university cambridge develop compound potential treating obesity addictive disorder university contribute knowhow expertise bear financial risk compensate programme successful gsk provide operational support access inhouse clinical research imaging facility background preclinical datum drug cambridge university dedicate team academic expert neuroscience metabolic disorder importantly agreement allow academic scientist freedom publish result work incubator project acquire pharmaceutical company sirtris leader research sirtuin recently discover class enzyme believe involved ageing process combination specialist knowledge sirtris gsk development capability provide good possible chance validate new approach disease metabolism age read investment new technology annual report home responsibility contribution global health contribute scientific understanding corporate responsibility report contribute scientific understanding fund basic medical research conduct outside gsk increase understand human body impact disease foundation future advance diagnosis treatment prevention disease research conduct partnership new technology example include open innovation december announce joint million investment wellcome trust generate chemical probe protein involve epigenetic signal available researcher restriction partnership new commitment promote openness research collaboration gsk pharmaceutical company traditionally keep research datum confidential publicprivate partnership lead structural genomics consortium involve national institutes health chemical genomics centre washington university oxford initiative offer new model future interaction academia industry collaborate accelerate drug development renew support university dundee division signal transduction therapy dstt collaboration medical research council consortium pharmaceutical company aim dstt accelerate development drug treat disease cancer diabete rheumatoid arthritis target kinase phosphatase enzyme collaboration provide million dstt gsk work path malaria vaccine initiative mvi develop paediatric vaccine malaria rtssas december partnership announce study result show rtssa provide infant young child significant protection malaria pende national regulatory approval phase lll study start seven country africa early patient safety gsk team wall street journal technology innovation award healthcare team develop new software system help screen novel drug candidate potential safety issue system know molecular clinical safety intelligence mcsi help gsk researcher screen prioritise novel drug candidate potential adverse medical reaction early stage prior clinical trial software enable direct translation safety knowledge human clinical experience earlystage drug discovery time read patient safety gsk home responsibility contribution global health contribute scientific understanding corporate responsibility report contribute scientific understanding fund basic medical research conduct outside gsk increase understand human body impact disease foundation future advance diagnosis treatment prevention disease research conduct partnership new technology example include open innovation december announce joint million investment wellcome trust generate chemical probe protein involve epigenetic signal available researcher restriction partnership new commitment promote openness research collaboration gsk pharmaceutical company traditionally keep research datum confidential publicprivate partnership lead structural genomics consortium involve national institutes health chemical genomics centre washington university oxford initiative offer new model future interaction academia industry collaborate accelerate drug development renew support university dundee division signal transduction therapy dstt collaboration medical research council consortium pharmaceutical company aim dstt accelerate development drug treat disease cancer diabete rheumatoid arthritis target kinase phosphatase enzyme collaboration provide million dstt gsk work path malaria vaccine initiative mvi develop paediatric vaccine malaria rtssas december partnership announce study result show rtssa provide infant young child significant protection malaria pende national regulatory approval phase lll study start seven country africa early patient safety gsk team wall street journal technology innovation award healthcare team develop new software system help screen novel drug candidate potential safety issue system know molecular clinical safety intelligence mcsi help gsk researcher screen prioritise novel drug candidate potential adverse medical reaction early stage prior clinical trial software enable direct translation safety knowledge human clinical experience earlystage drug discovery time read patient safety gsk home responsibility contribution global health contribute scientific understanding academic collaboration corporate responsibility report academic collaboration invest research capability university fund leadingedge academic research project support science student academic collaboration ukbased company provide support million support benefit academic institution increase funding technology transfer access research facility expertise contribute well scientific understanding capability country operate benefit gsk enable tap rd expertise activity outside company expand potential recruitment pool well train scientist support include academic discovery performance unit new initiative combine good academic thinking gsk industry expertise new agreement university cambridge develop novel agent therapeutic potential treating obesity addictive disorder alliance lead university help accelerate drug discovery example establish research agreement trinity college dublin university manchester collaboration agency include uk engineering physical sciences research council epsrc wellcome trust fund project mutual interest training gsk laboratory undergraduate intellectual property right relate academic collaboration typically hold gsk partner institution free use outcome collaboration future research university receive percentage financial return derive new intellectual property home responsibility contribution global health contribute scientific understanding academic collaboration corporate responsibility report academic collaboration invest research capability university fund leadingedge academic research project support science student academic collaboration ukbased company provide support million support benefit academic institution increase funding technology transfer access research facility expertise contribute well scientific understanding capability country operate benefit gsk enable tap rd expertise activity outside company expand potential recruitment pool well train scientist support include academic discovery performance unit new initiative combine good academic thinking gsk industry expertise new agreement university cambridge develop novel agent therapeutic potential treating obesity addictive disorder alliance lead university help accelerate drug discovery example establish research agreement trinity college dublin university manchester collaboration agency include uk engineering physical sciences research council epsrc wellcome trust fund project mutual interest training gsk laboratory undergraduate intellectual property right relate academic collaboration typically hold gsk partner institution free use outcome collaboration future research university receive percentage financial return derive new intellectual property home responsibility contribution global health pandemic flu respond hn outbreak corporate responsibility report pandemic flu respond hn outbreak update august prepare influenza pandemic flu year research develop pre pandemic pandemic vaccine antiviral face mask exist antibiotic portfolio preparation mean able respond rapidly new influenza hn strain emerge mexico late april world health organization decision june pandemic alert level send particularly strong message government stakeholder involve pandemic preparedness ensure adequate robust plan place respond new strain hn know swine flu collaborative global response involve government international organisation business need reduce impact hn gsk commit support government health authority world respond challenge gsk contribution offer key product combat pandemic flu hn pandemic vaccine actiprotect face mask relenza antiviral invest billion expand capacity manufacture product believe global community step protect population include resource protect read effort help facilitate access relenza pandemic flu vaccine develop country prevention treatment product prevention vaccine immediately receive hn swine flu virus strain late begin production vaccine help protect people hn unable begin production vaccine need base strain act scale production manufacturing facility canada germany working vaccine available quickly possible expect produce million dose hn vaccine deliver september onwards date gsk receive order million dose vaccine antigen stimulate immune response virus adjuvant helps boost immune response use adjuvant help increase effectiveness vaccine mean antigen need produce vaccine addition clinical study hn avian influenza strain adjuvante vaccine demonstrate potential provide protection influenza strain drift change slightly delivery vaccine depend gain approval regulator discussion authority world ensure regulatory process proceed quickly possible gsk receive european licence pandemic vaccine base mockup dossier contain datum hn avian flu anticipate provisional licence speed registration hn vaccine quickly supplement datum dossier datum actual hn pandemic strain currently discussion regulatory authority develop appropriate clinical development plan vaccine number people study initial trial limit need provide government vaccine quickly possible additional study ongoing monitoring conduct vaccine launch gsk rapidly share result immunogenicity post marketing safety effectiveness study international community face mask gsk develop actiprotect face mask coat antiviral agent provide physical barrier prevent wearer inhale virus particle kill flu virus minute contact actiprotect test pandemic hn strain mask show inactivate influenza virus strain test include previous strain hn hn hn hn hn influenza b strain currently limited manufacturing capacity actiprotect invest increase exist manufacturing capacity seek additional manufacturing capability discussion company treatment relenza zanamivir antiviral shorten duration flu help sufferer feel well soon gsk work government supply relenza use pandemic global spread avian flu hn begin clinical test hn sensitive relenza follow outbreak hn strain contact government world establish demand relenza ensure equitable distribution exist supply place series measure raise production level result expect increase annual production capacity relenza million treatment course end threefold increase previous maximum annual capacity million treatment course relenza register country currently contract place supply government support access pandemic flu product develop country government lack resource protect population hn concern ability mount effective rapid response gsk commit facilitate access relenza pandemic flu vaccine country strongly endorse principle set gate foundation help guide global allocation pandemic vaccine support message global community step necessary protect population include resource protect committed donate million dose hn vaccine million treatment course relenza use develop country ensure vaccine available develop country subject yield exist contractual commitment allocate cent hn vaccine production capacity canadian manufacturing site develop country cent new increase relenza production capacity allocate develop country commitment include donation operate tieredprice policy pandemic vaccine relenza base world bank classification country gavi eligibility vaccine line commitment set march brand medicine affordable world poor people relenza continue available notforprofit price develop country remain committed engage voluntary licence discussion company willing manufacture supply zanamivircontaining product active ingredient relenza use develop country example grant voluntary licence chinese manufacturer simcere manufacture sell product contain zanamivir china number country include world develop country ensure business continuity take step ensure flu pandemic continue supply essential pharmaceutical vaccine influenza disease patient need read business continuity plan lerouxroel et al antigen spare crossreactive immunity adjuvante rhn prototype pandemic influenza vaccine randomise control trial lancet lerouxroel et al broad clade crossreactive immunity induce adjuvant systemed clade rhn pandemic influenza vaccine plo e doijounalpone bara et al crossprotection lethal hn challenge ferret adjuvante pandemic influenza vaccine plo e tophome responsibility contribution global health pandemic flu respond hn outbreak corporate responsibility report pandemic flu respond hn outbreak update august prepare influenza pandemic flu year research develop pre pandemic pandemic vaccine antiviral face mask exist antibiotic portfolio preparation mean able respond rapidly new influenza hn strain emerge mexico late april world health organization decision june pandemic alert level send particularly strong message government stakeholder involve pandemic preparedness ensure adequate robust plan place respond new strain hn know swine flu collaborative global response involve government international organisation business need reduce impact hn gsk commit support government health authority world respond challenge gsk contribution offer key product combat pandemic flu hn pandemic vaccine actiprotect face mask relenza antiviral invest billion expand capacity manufacture product believe global community step protect population include resource protect read effort help facilitate access relenza pandemic flu vaccine develop country prevention treatment product prevention vaccine immediately receive hn swine flu virus strain late begin production vaccine help protect people hn unable begin production vaccine need base strain act scale production manufacturing facility canada germany working vaccine available quickly possible expect produce million dose hn vaccine deliver september onwards date gsk receive order million dose vaccine antigen stimulate immune response virus adjuvant helps boost immune response use adjuvant help increase effectiveness vaccine mean antigen need produce vaccine addition clinical study hn avian influenza strain adjuvante vaccine demonstrate potential provide protection influenza strain drift change slightly delivery vaccine depend gain approval regulator discussion authority world ensure regulatory process proceed quickly possible gsk receive european licence pandemic vaccine base mockup dossier contain datum hn avian flu anticipate provisional licence speed registration hn vaccine quickly supplement datum dossier datum actual hn pandemic strain currently discussion regulatory authority develop appropriate clinical development plan vaccine number people study initial trial limit need provide government vaccine quickly possible additional study ongoing monitoring conduct vaccine launch gsk rapidly share result immunogenicity post marketing safety effectiveness study international community face mask gsk develop actiprotect face mask coat antiviral agent provide physical barrier prevent wearer inhale virus particle kill flu virus minute contact actiprotect test pandemic hn strain mask show inactivate influenza virus strain test include previous strain hn hn hn hn hn influenza b strain currently limited manufacturing capacity actiprotect invest increase exist manufacturing capacity seek additional manufacturing capability discussion company treatment relenza zanamivir antiviral shorten duration flu help sufferer feel well soon gsk work government supply relenza use pandemic global spread avian flu hn begin clinical test hn sensitive relenza follow outbreak hn strain contact government world establish demand relenza ensure equitable distribution exist supply place series measure raise production level result expect increase annual production capacity relenza million treatment course end threefold increase previous maximum annual capacity million treatment course relenza register country currently contract place supply government support access pandemic flu product develop country government lack resource protect population hn concern ability mount effective rapid response gsk commit facilitate access relenza pandemic flu vaccine country strongly endorse principle set gate foundation help guide global allocation pandemic vaccine support message global community step necessary protect population include resource protect committed donate million dose hn vaccine million treatment course relenza use develop country ensure vaccine available develop country subject yield exist contractual commitment allocate cent hn vaccine production capacity canadian manufacturing site develop country cent new increase relenza production capacity allocate develop country commitment include donation operate tieredprice policy pandemic vaccine relenza base world bank classification country gavi eligibility vaccine line commitment set march brand medicine affordable world poor people relenza continue available notforprofit price develop country remain committed engage voluntary licence discussion company willing manufacture supply zanamivircontaining product active ingredient relenza use develop country example grant voluntary licence chinese manufacturer simcere manufacture sell product contain zanamivir china number country include world develop country ensure business continuity take step ensure flu pandemic continue supply essential pharmaceutical vaccine influenza disease patient need read business continuity plan lerouxroel et al antigen spare crossreactive immunity adjuvante rhn prototype pandemic influenza vaccine randomise control trial lancet lerouxroel et al broad clade crossreactive immunity induce adjuvant systemed clade rhn pandemic influenza vaccine plo e doijounalpone bara et al crossprotection lethal hn challenge ferret adjuvante pandemic influenza vaccine plo e tophome responsibility contribution global health pandemic flu respond hn outbreak corporate responsibility report pandemic flu respond hn outbreak update august prepare influenza pandemic flu year research develop pre pandemic pandemic vaccine antiviral face mask exist antibiotic portfolio preparation mean able respond rapidly new influenza hn strain emerge mexico late april world health organization decision june pandemic alert level send particularly strong message government stakeholder involve pandemic preparedness ensure adequate robust plan place respond new strain hn know swine flu collaborative global response involve government international organisation business need reduce impact hn gsk commit support government health authority world respond challenge gsk contribution offer key product combat pandemic flu hn pandemic vaccine actiprotect face mask relenza antiviral invest billion expand capacity manufacture product believe global community step protect population include resource protect read effort help facilitate access relenza pandemic flu vaccine develop country prevention treatment product prevention vaccine immediately receive hn swine flu virus strain late begin production vaccine help protect people hn unable begin production vaccine need base strain act scale production manufacturing facility canada germany working vaccine available quickly possible expect produce million dose hn vaccine deliver september onwards date gsk receive order million dose vaccine antigen stimulate immune response virus adjuvant helps boost immune response use adjuvant help increase effectiveness vaccine mean antigen need produce vaccine addition clinical study hn avian influenza strain adjuvante vaccine demonstrate potential provide protection influenza strain drift change slightly delivery vaccine depend gain approval regulator discussion authority world ensure regulatory process proceed quickly possible gsk receive european licence pandemic vaccine base mockup dossier contain datum hn avian flu anticipate provisional licence speed registration hn vaccine quickly supplement datum dossier datum actual hn pandemic strain currently discussion regulatory authority develop appropriate clinical development plan vaccine number people study initial trial limit need provide government vaccine quickly possible additional study ongoing monitoring conduct vaccine launch gsk rapidly share result immunogenicity post marketing safety effectiveness study international community face mask gsk develop actiprotect face mask coat antiviral agent provide physical barrier prevent wearer inhale virus particle kill flu virus minute contact actiprotect test pandemic hn strain mask show inactivate influenza virus strain test include previous strain hn hn hn hn hn influenza b strain currently limited manufacturing capacity actiprotect invest increase exist manufacturing capacity seek additional manufacturing capability discussion company treatment relenza zanamivir antiviral shorten duration flu help sufferer feel well soon gsk work government supply relenza use pandemic global spread avian flu hn begin clinical test hn sensitive relenza follow outbreak hn strain contact government world establish demand relenza ensure equitable distribution exist supply place series measure raise production level result expect increase annual production capacity relenza million treatment course end threefold increase previous maximum annual capacity million treatment course relenza register country currently contract place supply government support access pandemic flu product develop country government lack resource protect population hn concern ability mount effective rapid response gsk commit facilitate access relenza pandemic flu vaccine country strongly endorse principle set gate foundation help guide global allocation pandemic vaccine support message global community step necessary protect population include resource protect committed donate million dose hn vaccine million treatment course relenza use develop country ensure vaccine available develop country subject yield exist contractual commitment allocate cent hn vaccine production capacity canadian manufacturing site develop country cent new increase relenza production capacity allocate develop country commitment include donation operate tieredprice policy pandemic vaccine relenza base world bank classification country gavi eligibility vaccine line commitment set march brand medicine affordable world poor people relenza continue available notforprofit price develop country remain committed engage voluntary licence discussion company willing manufacture supply zanamivircontaining product active ingredient relenza use develop country example grant voluntary licence chinese manufacturer simcere manufacture sell product contain zanamivir china number country include world develop country ensure business continuity take step ensure flu pandemic continue supply essential pharmaceutical vaccine influenza disease patient need read business continuity plan lerouxroel et al antigen spare crossreactive immunity adjuvante rhn prototype pandemic influenza vaccine randomise control trial lancet lerouxroel et al broad clade crossreactive immunity induce adjuvant systemed clade rhn pandemic influenza vaccine plo e doijounalpone bara et al crossprotection lethal hn challenge ferret adjuvante pandemic influenza vaccine plo e home responsibility contribution global health pandemic flu respond hn outbreak corporate responsibility report pandemic flu respond hn outbreak update august prepare influenza pandemic flu year research develop pre pandemic pandemic vaccine antiviral face mask exist antibiotic portfolio preparation mean able respond rapidly new influenza hn strain emerge mexico late april world health organization decision june pandemic alert level send particularly strong message government stakeholder involve pandemic preparedness ensure adequate robust plan place respond new strain hn know swine flu collaborative global response involve government international organisation business need reduce impact hn gsk commit support government health authority world respond challenge gsk contribution offer key product combat pandemic flu hn pandemic vaccine actiprotect face mask relenza antiviral invest billion expand capacity manufacture product believe global community step protect population include resource protect read effort help facilitate access relenza pandemic flu vaccine develop country prevention treatment product prevention vaccine immediately receive hn swine flu virus strain late begin production vaccine help protect people hn unable begin production vaccine need base strain act scale production manufacturing facility canada germany working vaccine available quickly possible expect produce million dose hn vaccine deliver september onwards date gsk receive order million dose vaccine antigen stimulate immune response virus adjuvant helps boost immune response use adjuvant help increase effectiveness vaccine mean antigen need produce vaccine addition clinical study hn avian influenza strain adjuvante vaccine demonstrate potential provide protection influenza strain drift change slightly delivery vaccine depend gain approval regulator discussion authority world ensure regulatory process proceed quickly possible gsk receive european licence pandemic vaccine base mockup dossier contain datum hn avian flu anticipate provisional licence speed registration hn vaccine quickly supplement datum dossier datum actual hn pandemic strain currently discussion regulatory authority develop appropriate clinical development plan vaccine number people study initial trial limit need provide government vaccine quickly possible additional study ongoing monitoring conduct vaccine launch gsk rapidly share result immunogenicity post marketing safety effectiveness study international community face mask gsk develop actiprotect face mask coat antiviral agent provide physical barrier prevent wearer inhale virus particle kill flu virus minute contact actiprotect test pandemic hn strain mask show inactivate influenza virus strain test include previous strain hn hn hn hn hn influenza b strain currently limited manufacturing capacity actiprotect invest increase exist manufacturing capacity seek additional manufacturing capability discussion company treatment relenza zanamivir antiviral shorten duration flu help sufferer feel well soon gsk work government supply relenza use pandemic global spread avian flu hn begin clinical test hn sensitive relenza follow outbreak hn strain contact government world establish demand relenza ensure equitable distribution exist supply place series measure raise production level result expect increase annual production capacity relenza million treatment course end threefold increase previous maximum annual capacity million treatment course relenza register country currently contract place supply government support access pandemic flu product develop country government lack resource protect population hn concern ability mount effective rapid response gsk commit facilitate access relenza pandemic flu vaccine country strongly endorse principle set gate foundation help guide global allocation pandemic vaccine support message global community step necessary protect population include resource protect committed donate million dose hn vaccine million treatment course relenza use develop country ensure vaccine available develop country subject yield exist contractual commitment allocate cent hn vaccine production capacity canadian manufacturing site develop country cent new increase relenza production capacity allocate develop country commitment include donation operate tieredprice policy pandemic vaccine relenza base world bank classification country gavi eligibility vaccine line commitment set march brand medicine affordable world poor people relenza continue available notforprofit price develop country remain committed engage voluntary licence discussion company willing manufacture supply zanamivircontaining product active ingredient relenza use develop country example grant voluntary licence chinese manufacturer simcere manufacture sell product contain zanamivir china number country include world develop country ensure business continuity take step ensure flu pandemic continue supply essential pharmaceutical vaccine influenza disease patient need read business continuity plan lerouxroel et al antigen spare crossreactive immunity adjuvante rhn prototype pandemic influenza vaccine randomise control trial lancet lerouxroel et al broad clade crossreactive immunity induce adjuvant systemed clade rhn pandemic influenza vaccine plo e doijounalpone bara et al crossprotection lethal hn challenge ferret adjuvante pandemic influenza vaccine plo e home responsibility contribution global health qas corporate responsibility report qas respond question raise stakeholder goal cure disease find treatment ongoing chronic use ideally want cure disease antibiotic help treat disease cause bacterial infection antiparasitic medicine help prevent treat prevalent disease lymphatic filariasis malaria unfortunately know cure disease medicine help reduce symptom need take long period medicine valuable enable patient normal lifestyle example remain work look family case continue research find cure ideally want prevent disease occur place vaccine important role factor consider prioritise rd effort main interrelated factor science patient need commercial potential assess scientific opportunity determine advance scientific disease understanding lead innovative new way treat prevent disease outcome systematic therapy area review look scientific understanding therapy area refocus research effort continually evaluate scientific information obtain compound help predict develop effective welltolerate medicine assess patient need fundamental rd gsk range look medicine treat disease current effective treatment development medicine improve exist treatment term safety efficacy ease use assessment commercial potential possible new treatment include product differentiate competitor size potential market new treatment range condition suitable treat well able meet patient need likely product commercially successful possible achieve return investment example develop treatment disease prevalent develop world case commercial potential limited patient need high seek way share cost risk associate drug development research drug treat disease pipeline product range include product major cause mortality morbidity disease product launch include promacta treatment idiopathic thrombocytopenic purpura volibris pulmonary arterial hypertension topselle product treat asthma chronic obstructive pulmonary disease epilepsy bipolar disorder diabete herpe migraine vaccine portfolio include vaccine prevent influenza hepatitis rotavirus human papillomavirus infection cause cervical cancer vaccine prevent childhood illness measle rubella measure rd productivity ultimate measure productivity delivery new medicine meet patient need gsk launch product base new chemical biological entity new vaccine number product line extension benefit patient target sustain latestage pipeline key asset give research development long year measure productivity number way rd process include number compound pipeline emerge risk benefit compound success progress compound pipeline clinical trial phase l lll market registration speed progress pipeline indication efficiency rd process true research productivity fall large pharmaceutical company gsk manage investment pharmaceutical rd risen number new medicine gain regulatory approval remain relatively constant decrease believe reason include increase focus rd chronic degenerative disease alzheimer scientifically challenging require long clinical trial increase failure rate significant investment industry new technology help deliver innovative medicine long term example system biology tool genomewide association scan new vitro vivo model sophisticated imaging equipment extensive requirement regulator healthcare payer include need conduct large clinical study evaluate longterm outcome treatment medicine high hurdle approval effectiveness exist treatment condition demonstrate improved safety efficacy new treatment increasingly difficult approach focus meet patient need increase effectiveness efficiency rd example establish discovery performance unit dpu establish centre excellence drug discovery dpus small group scientist focus specific disease molecular pathway structure efficient possible organisation combine entrepreneurial approach small company resource reach large organisation tophome responsibility contribution global health qas corporate responsibility report qas respond question raise stakeholder goal cure disease find treatment ongoing chronic use ideally want cure disease antibiotic help treat disease cause bacterial infection antiparasitic medicine help prevent treat prevalent disease lymphatic filariasis malaria unfortunately know cure disease medicine help reduce symptom need take long period medicine valuable enable patient normal lifestyle example remain work look family case continue research find cure ideally want prevent disease occur place vaccine important role factor consider prioritise rd effort main interrelated factor science patient need commercial potential assess scientific opportunity determine advance scientific disease understanding lead innovative new way treat prevent disease outcome systematic therapy area review look scientific understanding therapy area refocus research effort continually evaluate scientific information obtain compound help predict develop effective welltolerate medicine assess patient need fundamental rd gsk range look medicine treat disease current effective treatment development medicine improve exist treatment term safety efficacy ease use assessment commercial potential possible new treatment include product differentiate competitor size potential market new treatment range condition suitable treat well able meet patient need likely product commercially successful possible achieve return investment example develop treatment disease prevalent develop world case commercial potential limited patient need high seek way share cost risk associate drug development research drug treat disease pipeline product range include product major cause mortality morbidity disease product launch include promacta treatment idiopathic thrombocytopenic purpura volibris pulmonary arterial hypertension topselle product treat asthma chronic obstructive pulmonary disease epilepsy bipolar disorder diabete herpe migraine vaccine portfolio include vaccine prevent influenza hepatitis rotavirus human papillomavirus infection cause cervical cancer vaccine prevent childhood illness measle rubella measure rd productivity ultimate measure productivity delivery new medicine meet patient need gsk launch product base new chemical biological entity new vaccine number product line extension benefit patient target sustain latestage pipeline key asset give research development long year measure productivity number way rd process include number compound pipeline emerge risk benefit compound success progress compound pipeline clinical trial phase l lll market registration speed progress pipeline indication efficiency rd process true research productivity fall large pharmaceutical company gsk manage investment pharmaceutical rd risen number new medicine gain regulatory approval remain relatively constant decrease believe reason include increase focus rd chronic degenerative disease alzheimer scientifically challenging require long clinical trial increase failure rate significant investment industry new technology help deliver innovative medicine long term example system biology tool genomewide association scan new vitro vivo model sophisticated imaging equipment extensive requirement regulator healthcare payer include need conduct large clinical study evaluate longterm outcome treatment medicine high hurdle approval effectiveness exist treatment condition demonstrate improved safety efficacy new treatment increasingly difficult approach focus meet patient need increase effectiveness efficiency rd example establish discovery performance unit dpu establish centre excellence drug discovery dpus small group scientist focus specific disease molecular pathway structure efficient possible organisation combine entrepreneurial approach small company resource reach large organisation home responsibility contribution global health qas corporate responsibility report qas respond question raise stakeholder goal cure disease find treatment ongoing chronic use ideally want cure disease antibiotic help treat disease cause bacterial infection antiparasitic medicine help prevent treat prevalent disease lymphatic filariasis malaria unfortunately know cure disease medicine help reduce symptom need take long period medicine valuable enable patient normal lifestyle example remain work look family case continue research find cure ideally want prevent disease occur place vaccine important role factor consider prioritise rd effort main interrelated factor science patient need commercial potential assess scientific opportunity determine advance scientific disease understanding lead innovative new way treat prevent disease outcome systematic therapy area review look scientific understanding therapy area refocus research effort continually evaluate scientific information obtain compound help predict develop effective welltolerate medicine assess patient need fundamental rd gsk range look medicine treat disease current effective treatment development medicine improve exist treatment term safety efficacy ease use assessment commercial potential possible new treatment include product differentiate competitor size potential market new treatment range condition suitable treat well able meet patient need likely product commercially successful possible achieve return investment example develop treatment disease prevalent develop world case commercial potential limited patient need high seek way share cost risk associate drug development research drug treat disease pipeline product range include product major cause mortality morbidity disease product launch include promacta treatment idiopathic thrombocytopenic purpura volibris pulmonary arterial hypertension topselle product treat asthma chronic obstructive pulmonary disease epilepsy bipolar disorder diabete herpe migraine vaccine portfolio include vaccine prevent influenza hepatitis rotavirus human papillomavirus infection cause cervical cancer vaccine prevent childhood illness measle rubella measure rd productivity ultimate measure productivity delivery new medicine meet patient need gsk launch product base new chemical biological entity new vaccine number product line extension benefit patient target sustain latestage pipeline key asset give research development long year measure productivity number way rd process include number compound pipeline emerge risk benefit compound success progress compound pipeline clinical trial phase l lll market registration speed progress pipeline indication efficiency rd process true research productivity fall large pharmaceutical company gsk manage investment pharmaceutical rd risen number new medicine gain regulatory approval remain relatively constant decrease believe reason include increase focus rd chronic degenerative disease alzheimer scientifically challenging require long clinical trial increase failure rate significant investment industry new technology help deliver innovative medicine long term example system biology tool genomewide association scan new vitro vivo model sophisticated imaging equipment extensive requirement regulator healthcare payer include need conduct large clinical study evaluate longterm outcome treatment medicine high hurdle approval effectiveness exist treatment condition demonstrate improved safety efficacy new treatment increasingly difficult approach focus meet patient need increase effectiveness efficiency rd example establish discovery performance unit dpu establish centre excellence drug discovery dpus small group scientist focus specific disease molecular pathway structure efficient possible organisation combine entrepreneurial approach small company resource reach large organisation home responsibility access medicine corporate responsibility report access medicine access healthcare world press social challenge year million people develop country die curable infectious disease access basic healthcare service include essential medicine million unnecessarily expose threat ill health inadequate ineffective disease prevention strategy number complex factor prevent access medicine limit prospect commercial return rd neglect disease unify registration system medicine make registration process costly complex time consume develop country distribution network medicine healthcare infrastructure treat patient prescribe medicine problem excuse inaction indicate action need decade pharmaceutical industry help address healthcare challenge develop world research new medicine make available affordable despite progress scale healthcare crisis mean industry proactive approach identify key area strengthen approach flexible intellectual property flexible pricing recognise achieve partnership look supplier medicine partner deliver solution read plan area abbas hussain president emerge market gsk lead access effort review corporate executive team gsk senior team corporate responsibility committee board increase access medicine important business ethical reputational commercial reason morally right thing value shareholder employee stakeholder align corporate mission contribute gsk reputation ability attract retain talented employee business objective increase proportion world population access medicine currently cent successful pharmaceutical company future serve big proportion world population business rely intellectual property ip right system encourage medical innovation progress take measure counter claim ip major barrier access look way improve availability affordability help increase access maintain support intellectual property right key business area access problem confine develop world example people suffer unnecessary ill health healthcare insurance community investment programme provide additional resource address healthcare challenge world support underserved community fund education practical support donation look refine improve contribution improve access medicine anpdag ien ceo andrew witty announce number new approach pursue believe pharmaceutical industry huge role play need leadership role historically react problem future want proactive genuinely find new way increase research increase access eradicate disease andrew witty ceo speech carter center atlanta december highlight announce new approach increase flexibility pricing develop country intellectual property relate neglect disease identify industry leader access medicine index successful result report phase clinical trial rtss malaria vaccine candidate african child enter new rd partnership drug neglect disease initiative notforprofit price antiretroviral reduce positive opinion receive european medicine agency pneumococcal vaccine million antiretroviral tablet supply develop country include million tablet supply generic manufacturer license gsk billion vaccine ship cent go develop world restructure commercial operation reflect need patient business opportunity emerge market enter new partnership acquisition develop relevant product portfoliohome responsibility access medicine corporate responsibility report access medicine access healthcare world press social challenge year million people develop country die curable infectious disease access basic healthcare service include essential medicine million unnecessarily expose threat ill health inadequate ineffective disease prevention strategy number complex factor prevent access medicine limit prospect commercial return rd neglect disease unify registration system medicine make registration process costly complex time consume develop country distribution network medicine healthcare infrastructure treat patient prescribe medicine problem excuse inaction indicate action need decade pharmaceutical industry help address healthcare challenge develop world research new medicine make available affordable despite progress scale healthcare crisis mean industry proactive approach identify key area strengthen approach flexible intellectual property flexible pricing recognise achieve partnership look supplier medicine partner deliver solution read plan area abbas hussain president emerge market gsk lead access effort review corporate executive team gsk senior team corporate responsibility committee board increase access medicine important business ethical reputational commercial reason morally right thing value shareholder employee stakeholder align corporate mission contribute gsk reputation ability attract retain talented employee business objective increase proportion world population access medicine currently cent successful pharmaceutical company future serve big proportion world population business rely intellectual property ip right system encourage medical innovation progress take measure counter claim ip major barrier access look way improve availability affordability help increase access maintain support intellectual property right key business area access problem confine develop world example people suffer unnecessary ill health healthcare insurance community investment programme provide additional resource address healthcare challenge world support underserved community fund education practical support donation look refine improve contribution improve access medicine ceo andrew witty announce number new approach pursue believe pharmaceutical industry huge role play need leadership role historically react problem future want proactive genuinely find new way increase research increase access eradicate disease andrew witty ceo speech carter center atlanta december highlight announce new approach increase flexibility pricing develop country intellectual property relate neglect disease identify industry leader access medicine index successful result report phase clinical trial rtss malaria vaccine candidate african child enter new rd partnership drug neglect disease initiative notforprofit price antiretroviral reduce positive opinion receive european medicine agency pneumococcal vaccine million antiretroviral tablet supply develop country include million tablet supply generic manufacturer license gsk billion vaccine ship cent go develop world restructure commercial operation reflect need patient business opportunity emerge market enter new partnership acquisition develop relevant product portfolio home responsibility access medicine corporate responsibility report access medicine access healthcare world press social challenge year million people develop country die curable infectious disease access basic healthcare service include essential medicine million unnecessarily expose threat ill health inadequate ineffective disease prevention strategy number complex factor prevent access medicine limit prospect commercial return rd neglect disease unify registration system medicine make registration process costly complex time consume develop country distribution network medicine healthcare infrastructure treat patient prescribe medicine problem excuse inaction indicate action need decade pharmaceutical industry help address healthcare challenge develop world research new medicine make available affordable despite progress scale healthcare crisis mean industry proactive approach identify key area strengthen approach flexible intellectual property flexible pricing recognise achieve partnership look supplier medicine partner deliver solution read plan area abbas hussain president emerge market gsk lead access effort review corporate executive team gsk senior team corporate responsibility committee board increase access medicine important business ethical reputational commercial reason morally right thing value shareholder employee stakeholder align corporate mission contribute gsk reputation ability attract retain talented employee business objective increase proportion world population access medicine currently cent successful pharmaceutical company future serve big proportion world population business rely intellectual property ip right system encourage medical innovation progress take measure counter claim ip major barrier access look way improve availability affordability help increase access maintain support intellectual property right key business area access problem confine develop world example people suffer unnecessary ill health healthcare insurance community investment programme provide additional resource address healthcare challenge world support underserved community fund education practical support donation look refine improve contribution improve access medicine ceo andrew witty announce number new approach pursue believe pharmaceutical industry huge role play need leadership role historically react problem future want proactive genuinely find new way increase research increase access eradicate disease andrew witty ceo speech carter center atlanta december highlight announce new approach increase flexibility pricing develop country intellectual property relate neglect disease identify industry leader access medicine index successful result report phase clinical trial rtss malaria vaccine candidate african child enter new rd partnership drug neglect disease initiative notforprofit price antiretroviral reduce positive opinion receive european medicine agency pneumococcal vaccine million antiretroviral tablet supply develop country include million tablet supply generic manufacturer license gsk billion vaccine ship cent go develop world restructure commercial operation reflect need patient business opportunity emerge market enter new partnership acquisition develop relevant product portfolio home responsibility access medicine approach contribution corporate responsibility report approach contribution gsk commit play address healthcare challenge world core business activity develop launch new medicine vaccine make significant contribution recognise scale challenge require coordinated approach look expand research partnership government ngos company support intellectual property right essential encourage innovation want find way use intellectual property flexibly speed development medicine neglect disease compromise sustainability business difference activity rd pricing work partnership significant barrier access remain develop country key barrier lack healthcare infrastructure physical human health service provider want work deliver healthcare include invest infrastructure seek new opportunity area make contribution strengthen infrastructure example donate equipment stateoftheart laboratory lago state university college medicine professor clement adebamowo chairman national health research ethic committee nigeria say new laboratory help nigeria regain lose ground health research reclaim position reputable partner education health research play address global healthcare challenge individually partnership right thing make good business sense work address global healthcare challenge action area improve affordability preferential pricing medicine tiere pricing vaccine world poor country explore new business model middleincome country provide discount card develop country invest research development target disease affect develop world work partnership research new medicine help deliver healthcare service undertake community investment activity partnership foster effective healthcare recognise develop world particular pose healthcare challenge require longterm commitment fundamental approach need ensure contribution sustainable build way business duty try ensure product clinically appropriate way country available particularly important case communicable disease inappropriate use product speed development resistance treatment activity undertake partnership organisation relevant specialist knowledge government international agency charity private sector organisation academic institution gsk rank access medicine index publish june index rate company performance accord criterion management influence research development patenting capacity pricing drug donation philanthropy retain concern methodology report please multifaceted effort medicine available recognise index testament innovative sustainable approach gsk employee contribute effort help address healthcare challenge develop world home responsibility access medicine approach contribution corporate responsibility report approach contribution gsk commit play address healthcare challenge world core business activity develop launch new medicine vaccine make significant contribution recognise scale challenge require coordinated approach look expand research partnership government ngos company support intellectual property right essential encourage innovation want find way use intellectual property flexibly speed development medicine neglect disease compromise sustainability business difference activity rd pricing work partnership significant barrier access remain develop country key barrier lack healthcare infrastructure physical human health service provider want work deliver healthcare include invest infrastructure seek new opportunity area make contribution strengthen infrastructure example donate equipment stateoftheart laboratory lago state university college medicine professor clement adebamowo chairman national health research ethic committee nigeria say new laboratory help nigeria regain lose ground health research reclaim position reputable partner education health research play address global healthcare challenge individually partnership right thing make good business sense work address global healthcare challenge action area improve affordability preferential pricing medicine tiere pricing vaccine world poor country explore new business model middleincome country provide discount card develop country invest research development target disease affect develop world work partnership research new medicine help deliver healthcare service undertake community investment activity partnership foster effective healthcare recognise develop world particular pose healthcare challenge require longterm commitment fundamental approach need ensure contribution sustainable build way business duty try ensure product clinically appropriate way country available particularly important case communicable disease inappropriate use product speed development resistance treatment activity undertake partnership organisation relevant specialist knowledge government international agency charity private sector organisation academic institution gsk rank access medicine index publish june index rate company performance accord criterion management influence research development patenting capacity pricing drug donation philanthropy retain concern methodology report please multifaceted effort medicine available recognise index testament innovative sustainable approach gsk employee contribute effort help address healthcare challenge develop world home responsibility access medicine approach contribution corporate responsibility report approach contribution gsk commit play address healthcare challenge world core business activity develop launch new medicine vaccine make significant contribution recognise scale challenge require coordinated approach look expand research partnership government ngos company support intellectual property right essential encourage innovation want find way use intellectual property flexibly speed development medicine neglect disease compromise sustainability business difference activity rd pricing work partnership significant barrier access remain develop country key barrier lack healthcare infrastructure physical human health service provider want work deliver healthcare include invest infrastructure seek new opportunity area make contribution strengthen infrastructure example donate equipment stateoftheart laboratory lago state university college medicine professor clement adebamowo chairman national health research ethic committee nigeria say new laboratory help nigeria regain lose ground health research reclaim position reputable partner education health research play address global healthcare challenge individually partnership right thing make good business sense work address global healthcare challenge action area improve affordability preferential pricing medicine tiere pricing vaccine world poor country explore new business model middleincome country provide discount card develop country invest research development target disease affect develop world work partnership research new medicine help deliver healthcare service undertake community investment activity partnership foster effective healthcare recognise develop world particular pose healthcare challenge require longterm commitment fundamental approach need ensure contribution sustainable build way business duty try ensure product clinically appropriate way country available particularly important case communicable disease inappropriate use product speed development resistance treatment activity undertake partnership organisation relevant specialist knowledge government international agency charity private sector organisation academic institution gsk rank access medicine index publish june index rate company performance accord criterion management influence research development patenting capacity pricing drug donation philanthropy retain concern methodology report please multifaceted effort medicine available recognise index testament innovative sustainable approach gsk employee contribute effort help address healthcare challenge develop world home responsibility access medicine role corporate responsibility report role improve access healthcare develop country complex challenge believe holistic approach embrace prevention treatment fundamentally strengthen health system work require stakeholder include pharmaceutical industry work increase resource dedicate improve healthcare system pharmaceutical company include gsk medicine affordable possible people world poor country sustainable manner invest research disease develop world new prevention tool treatment urgently need company look way use intellectual property right flexibly maximise rd resource neglect disease supplier medicine support government effort strengthen health system develop innovative way deliver medicine people need wealthy nation new funding come global fund fight aids tb malaria bill melinda gates foundation pepfar president emergency plan aid relief unitaid fund inadequate need predictable sustainable resource need fund research strengthen health system purchase medicine support disease prevention discourage migration train healthcare worker develop country current global financial crisis divert resource away assist develop country develop country genuine political commitment prioritise healthcare national budget address stigma improve affordability remove import tariff medicine approach middleincome country accept responsibility seek low price offer world poor country country provide environment encourage innovation support intellectual property ip right avoid measure widespread compulsory licensing negatively impact investment rd innovation supportive environment ip generally encourage company flexible ip defensive country address risk product diversion patient poor country wealthy one lobby government policy maker advocate sustainable approach improve healthcare develop world approach support innovation critical improve access long term work area include urge g continue make healthcare develop world major agenda item support development pilot advance market commitment pneumococcal vaccine engage work s intergovernmental working group igwg public health innovation intellectual property work uk government global health issue development department international development dfid medicine transparency alliance meta review good practice framework pharmaceutical company play lead role pharma future industry dialogue explore link sustainable pharmaceutical business model improve health outcome middleincome market include china india brazil discuss ip innovation funding ngo foundation stakeholder attend executive board meeting world health assembly meeting un secretary general ban ki moon discuss priority address hivaid contribute design affordable medicine facility malaria playing lead role major global health initiative example gsk sit board gavi alliance roll malaria participate board meeting global fund fight aid tb malaria support development quality assurance standard contribute development un human right guideline pharmaceutical company relation access medicine engage negotiation wto doha round seek sustainable proinnovation outcome address hivaids eu neighbouring country european commission breman process engage intergovernmental meeting pandemic influenza preparedness contribute report prepare paul hunt un special rapporteur right health report gsk approach access medicine number senior executive include ceo dr jp garni chairman sir christopher gent interview expect report publish half read malaria advocacyhome responsibility access medicine role corporate responsibility report role improve access healthcare develop country complex challenge believe holistic approach embrace prevention treatment fundamentally strengthen health system work require stakeholder include pharmaceutical industry work increase resource dedicate improve healthcare system pharmaceutical company include gsk medicine affordable possible people world poor country sustainable manner invest research disease develop world new prevention tool treatment urgently need company look way use intellectual property right flexibly maximise rd resource neglect disease supplier medicine support government effort strengthen health system develop innovative way deliver medicine people need wealthy nation new funding come global fund fight aids tb malaria bill melinda gates foundation pepfar president emergency plan aid relief unitaid fund inadequate need predictable sustainable resource need fund research strengthen health system purchase medicine support disease prevention discourage migration train healthcare worker develop country current global financial crisis divert resource away assist develop country develop country genuine political commitment prioritise healthcare national budget address stigma improve affordability remove import tariff medicine approach middleincome country accept responsibility seek low price offer world poor country country provide environment encourage innovation support intellectual property ip right avoid measure widespread compulsory licensing negatively impact investment rd innovation supportive environment ip generally encourage company flexible ip defensive country address risk product diversion patient poor country wealthy one lobby government policy maker advocate sustainable approach improve healthcare develop world approach support innovation critical improve access long term work area include urge g continue make healthcare develop world major agenda item support development pilot advance market commitment pneumococcal vaccine engage work s intergovernmental working group igwg public health innovation intellectual property work uk government global health issue development department international development dfid medicine transparency alliance meta review good practice framework pharmaceutical company play lead role pharma future industry dialogue explore link sustainable pharmaceutical business model improve health outcome middleincome market include china india brazil discuss ip innovation funding ngo foundation stakeholder attend executive board meeting world health assembly meeting un secretary general ban ki moon discuss priority address hivaid contribute design affordable medicine facility malaria playing lead role major global health initiative example gsk sit board gavi alliance roll malaria participate board meeting global fund fight aid tb malaria support development quality assurance standard contribute development un human right guideline pharmaceutical company relation access medicine engage negotiation wto doha round seek sustainable proinnovation outcome address hivaids eu neighbouring country european commission breman process engage intergovernmental meeting pandemic influenza preparedness contribute report prepare paul hunt un special rapporteur right health report gsk approach access medicine number senior executive include ceo dr jp garni chairman sir christopher gent interview expect report publish half read malaria advocacy home responsibility access medicine role corporate responsibility report role improve access healthcare develop country complex challenge believe holistic approach embrace prevention treatment fundamentally strengthen health system work require stakeholder include pharmaceutical industry work increase resource dedicate improve healthcare system pharmaceutical company include gsk medicine affordable possible people world poor country sustainable manner invest research disease develop world new prevention tool treatment urgently need company look way use intellectual property right flexibly maximise rd resource neglect disease supplier medicine support government effort strengthen health system develop innovative way deliver medicine people need wealthy nation new funding come global fund fight aids tb malaria bill melinda gates foundation pepfar president emergency plan aid relief unitaid fund inadequate need predictable sustainable resource need fund research strengthen health system purchase medicine support disease prevention discourage migration train healthcare worker develop country current global financial crisis divert resource away assist develop country develop country genuine political commitment prioritise healthcare national budget address stigma improve affordability remove import tariff medicine approach middleincome country accept responsibility seek low price offer world poor country country provide environment encourage innovation support intellectual property ip right avoid measure widespread compulsory licensing negatively impact investment rd innovation supportive environment ip generally encourage company flexible ip defensive country address risk product diversion patient poor country wealthy one lobby government policy maker advocate sustainable approach improve healthcare develop world approach support innovation critical improve access long term work area include urge g continue make healthcare develop world major agenda item support development pilot advance market commitment pneumococcal vaccine engage work s intergovernmental working group igwg public health innovation intellectual property work uk government global health issue development department international development dfid medicine transparency alliance meta review good practice framework pharmaceutical company play lead role pharma future industry dialogue explore link sustainable pharmaceutical business model improve health outcome middleincome market include china india brazil discuss ip innovation funding ngo foundation stakeholder attend executive board meeting world health assembly meeting un secretary general ban ki moon discuss priority address hivaid contribute design affordable medicine facility malaria playing lead role major global health initiative example gsk sit board gavi alliance roll malaria participate board meeting global fund fight aid tb malaria support development quality assurance standard contribute development un human right guideline pharmaceutical company relation access medicine engage negotiation wto doha round seek sustainable proinnovation outcome address hivaids eu neighbouring country european commission breman process engage intergovernmental meeting pandemic influenza preparedness contribute report prepare paul hunt un special rapporteur right health report gsk approach access medicine number senior executive include ceo dr jp garni chairman sir christopher gent interview expect report publish half read malaria advocacy home responsibility access medicine develop country corporate responsibility report develop country poverty underlie cause healthcare crisis part develop world world poor country million people reliable access food clean water mind adequate healthcare service healthcare crisis develop world complex holistic approach work improve situation involve comprehensive programme prevention health education screen diagnosis treatment community care support increase access medicine play vital area gsk seek opportunity contribution significant additional funding national international source mobilise difference recommend minimum spend health person year provide basic health service average spend subsaharan africa accord uks department international development african region suffer cent global burden disease cent world health worker pharmaceutical industry look form partnership help deliver healthcare service political need aid development build healthcare infrastructure gsk important contribution research new treatment vaccine disease affect develop country register product country need offer preferential pricing arrangement medicine tiere pricing vaccine need seek innovative partnership help improve healthcare develop world grant voluntary licence allow company manufacture medicine investing project support healthcare delivery underserve community disease disproportionately affect develop country malaria kill million people year children year old billion people worldwide infect tb million people die disease year new treatment tb develop year unaid estimate hivaidsrelate illness kill million people million people worldwide live hiv worldwide woman die cervical cancer minute cent develop world rotavirus infection cause death year children year age cent death occur lowincome country home responsibility access medicine develop country corporate responsibility report develop country poverty underlie cause healthcare crisis part develop world world poor country million people reliable access food clean water mind adequate healthcare service healthcare crisis develop world complex holistic approach work improve situation involve comprehensive programme prevention health education screen diagnosis treatment community care support increase access medicine play vital area gsk seek opportunity contribution significant additional funding national international source mobilise difference recommend minimum spend health person year provide basic health service average spend subsaharan africa accord uks department international development african region suffer cent global burden disease cent world health worker pharmaceutical industry look form partnership help deliver healthcare service political need aid development build healthcare infrastructure gsk important contribution research new treatment vaccine disease affect develop country register product country need offer preferential pricing arrangement medicine tiere pricing vaccine need seek innovative partnership help improve healthcare develop world grant voluntary licence allow company manufacture medicine investing project support healthcare delivery underserve community disease disproportionately affect develop country malaria kill million people year children year old billion people worldwide infect tb million people die disease year new treatment tb develop year unaid estimate hivaidsrelate illness kill million people million people worldwide live hiv worldwide woman die cervical cancer minute cent develop world rotavirus infection cause death year children year age cent death occur lowincome country home responsibility access medicine develop country research development corporate responsibility report research development disease affect develop country effective treatment case treatment exist effective drug resistance treatment suitable example difficult administer area poor healthcare infrastructure expensive researchbase company aim major contribution health develop country research develop affordable new vaccine treatment infectious disease currently conduct rd disease particular relevance develop world bacterial meningitis chlamydia dengue fever hepatitis e hivaid leishmaniasis malaria pandemic flu pneumococcal disease chagas disease human african trypanosomiasis tb information rd pipeline annual report biomedical rd costly risky time consume activity develop successful medicine vaccine typically year average include cost failure cost billion compound test estimate reach clinical trial reach market s different rd medicine develop world gsk scientist work treatment project disease develop world ddw access medicine priority right start rd process research new ddw treatment emphasise factor heat humidity resistance product able survive hot climate refrigeration facility ease use easy use setting limit healthcare facility example onceaday tablet take home preferable injectable medicine administer hospital clinic affordability price important factor look molecule formulation straightforward manufacture inexpensive produce disease disproportionately affect develop world market exist develop country hivaid pursue business model accept rd cost risk involve expectation market wealthy country subsidise poor one disease develop world market exist pursue new way work solution publicprivate partnership ppp model business public sector work model enable collaborator achieve explore way share knowledge organisation help facilitate speed discovery development new medicine flexible intellectual property aim encourage pharmaceutical company follow suit believe gsk currently company research new vaccine treatment s priority infectious disease malaria tb hivaids extensive portfolio rd project disease develop world industry leader research hivaid treatment currently evaluate multiple secondgeneration integrase inhibitor clinical development look new treatment neglect disease typically collaboration external partner example engage ongoing rd programme leishmaniasis chagas disease human african trypanosomiasis african sleeping sickness create dedicated group focus disease develop world fully integrate pharmaceutical rd organisation group prioritise project base socioeconomic public health benefit commercial return addition scientist base uk include drug discovery centre tre canto rd site spain scientist focus primarily malaria tb half scientist fund ppps medicine malaria venture tb alliance group focus develop world disease active vaccine organisation belgium look way expand tre cantos site global centre excellence encourage investment collaboration government ngos company override objective ensure gsk make good possible contribution improve health affect neglect disease develop world achieve pursue approach lead extensive effective sustainable pipeline disease develop world ddw increase partnership external ddw community cover neglect disease diverse expertise research tool novel target developable drug candidate worldwide talent pool include strong link good academic group spread ddw remit learn develop country emerge market share training activity science forum researcher upcoming scientist country avoid brain drain downside strengthen current rd partnership organisation medicine malaria venture mmv tb alliance drug neglect disease initiative dndi international aids vaccine initiative iavi path malaria vaccine initiative mvi aeras global tb vaccine foundation seek new partnership read position statement clinical trial develop world paediatric medicine briefing treatment child live hiv develop country tuft center study drug development pharmaceutical industry profile washington dc phrma march home responsibility access medicine develop country research development corporate responsibility report research development disease affect develop country effective treatment case treatment exist effective drug resistance treatment suitable example difficult administer area poor healthcare infrastructure expensive researchbase company aim major contribution health develop country research develop affordable new vaccine treatment infectious disease currently conduct rd disease particular relevance develop world bacterial meningitis chlamydia dengue fever hepatitis e hivaid leishmaniasis malaria pandemic flu pneumococcal disease chagas disease human african trypanosomiasis tb information rd pipeline annual report biomedical rd costly risky time consume activity develop successful medicine vaccine typically year average include cost failure cost billion compound test estimate reach clinical trial reach market s different rd medicine develop world gsk scientist work treatment project disease develop world ddw access medicine priority right start rd process research new ddw treatment emphasise factor heat humidity resistance product able survive hot climate refrigeration facility ease use easy use setting limit healthcare facility example onceaday tablet take home preferable injectable medicine administer hospital clinic affordability price important factor look molecule formulation straightforward manufacture inexpensive produce disease disproportionately affect develop world market exist develop country hivaid pursue business model accept rd cost risk involve expectation market wealthy country subsidise poor one disease develop world market exist pursue new way work solution publicprivate partnership ppp model business public sector work model enable collaborator achieve explore way share knowledge organisation help facilitate speed discovery development new medicine flexible intellectual property aim encourage pharmaceutical company follow suit believe gsk currently company research new vaccine treatment s priority infectious disease malaria tb hivaids extensive portfolio rd project disease develop world industry leader research hivaid treatment currently evaluate multiple secondgeneration integrase inhibitor clinical development look new treatment neglect disease typically collaboration external partner example engage ongoing rd programme leishmaniasis chagas disease human african trypanosomiasis african sleeping sickness create dedicated group focus disease develop world fully integrate pharmaceutical rd organisation group prioritise project base socioeconomic public health benefit commercial return addition scientist base uk include drug discovery centre tre canto rd site spain scientist focus primarily malaria tb half scientist fund ppps medicine malaria venture tb alliance group focus develop world disease active vaccine organisation belgium look way expand tre cantos site global centre excellence encourage investment collaboration government ngos company override objective ensure gsk make good possible contribution improve health affect neglect disease develop world achieve pursue approach lead extensive effective sustainable pipeline disease develop world ddw increase partnership external ddw community cover neglect disease diverse expertise research tool novel target developable drug candidate worldwide talent pool include strong link good academic group spread ddw remit learn develop country emerge market share training activity science forum researcher upcoming scientist country avoid brain drain downside strengthen current rd partnership organisation medicine malaria venture mmv tb alliance drug neglect disease initiative dndi international aids vaccine initiative iavi path malaria vaccine initiative mvi aeras global tb vaccine foundation seek new partnership read position statement clinical trial develop world paediatric medicine briefing treatment child live hiv develop country tuft center study drug development pharmaceutical industry profile washington dc phrma march home responsibility access medicine develop country research development corporate responsibility report research development disease affect develop country effective treatment case treatment exist effective drug resistance treatment suitable example difficult administer area poor healthcare infrastructure expensive researchbase company aim major contribution health develop country research develop affordable new vaccine treatment infectious disease currently conduct rd disease particular relevance develop world bacterial meningitis chlamydia dengue fever hepatitis e hivaid leishmaniasis malaria pandemic flu pneumococcal disease chagas disease human african trypanosomiasis tb information rd pipeline annual report biomedical rd costly risky time consume activity develop successful medicine vaccine typically year average include cost failure cost billion compound test estimate reach clinical trial reach market s different rd medicine develop world gsk scientist work treatment project disease develop world ddw access medicine priority right start rd process research new ddw treatment emphasise factor heat humidity resistance product able survive hot climate refrigeration facility ease use easy use setting limit healthcare facility example onceaday tablet take home preferable injectable medicine administer hospital clinic affordability price important factor look molecule formulation straightforward manufacture inexpensive produce disease disproportionately affect develop world market exist develop country hivaid pursue business model accept rd cost risk involve expectation market wealthy country subsidise poor one disease develop world market exist pursue new way work solution publicprivate partnership ppp model business public sector work model enable collaborator achieve explore way share knowledge organisation help facilitate speed discovery development new medicine flexible intellectual property aim encourage pharmaceutical company follow suit believe gsk currently company research new vaccine treatment s priority infectious disease malaria tb hivaids extensive portfolio rd project disease develop world industry leader research hivaid treatment currently evaluate multiple secondgeneration integrase inhibitor clinical development look new treatment neglect disease typically collaboration external partner example engage ongoing rd programme leishmaniasis chagas disease human african trypanosomiasis african sleeping sickness create dedicated group focus disease develop world fully integrate pharmaceutical rd organisation group prioritise project base socioeconomic public health benefit commercial return addition scientist base uk include drug discovery centre tre canto rd site spain scientist focus primarily malaria tb half scientist fund ppps medicine malaria venture tb alliance group focus develop world disease active vaccine organisation belgium look way expand tre cantos site global centre excellence encourage investment collaboration government ngos company override objective ensure gsk make good possible contribution improve health affect neglect disease develop world achieve pursue approach lead extensive effective sustainable pipeline disease develop world ddw increase partnership external ddw community cover neglect disease diverse expertise research tool novel target developable drug candidate worldwide talent pool include strong link good academic group spread ddw remit learn develop country emerge market share training activity science forum researcher upcoming scientist country avoid brain drain downside strengthen current rd partnership organisation medicine malaria venture mmv tb alliance drug neglect disease initiative dndi international aids vaccine initiative iavi path malaria vaccine initiative mvi aeras global tb vaccine foundation seek new partnership read position statement clinical trial develop world paediatric medicine briefing treatment child live hiv develop country tuft center study drug development pharmaceutical industry profile washington dc phrma march home responsibility access medicine develop country research development malaria corporate responsibility report malaria working malaria vaccine year invest million resource date currently develop candidate malaria vaccine rtss partnership path malaria vaccine initiative mvi contribute million result separate phase trial confirm finding early study candidate vaccine provide infant young child vulnerable group significant protection malaria child age month rtssa vaccine reduce risk clinical episode malaria cent eightmonth period trial infant month receive dose modify rtssa vaccine risk infection malaria reduce cent month period trial show rtssas vaccine interfere efficacy vaccine administer exist african national immunisation programme mean country malaria prevalent vaccine deliver current immunisation schedule infant call expand program immunization epi christian loucq mvi director comment significance trial result say close develop malaria vaccine children africa commence largescale phase lll vaccine efficacy trial seven african country site trial confirm safety efficacy candidate vaccine file registration introduce early child month age long establish efficacy infant epi age week old complexity enrolment trial early vaccine fully available follow approval use infant read malaria vaccine case study update august phase iii trial rtss malaria vaccine candidate start bagamoyo tanzania work malaria treatment include tafenoquine potential new treatment radical cure p vivax malaria develop partnership medicine malaria venture mmv cause acute infection red blood cell p vivax cause dormant infection liver cell parasite reactivate result reappearance parasite blood recurrence malaria radical cure imply complete elimination malaria parasite body include dormant liver stage tafenoquine offer potential day treatment course replace primaquine standard care p vivax radical cure initial study commencing focus understand safety tafenoquine subject inherit glucosephosphate dehydrogenase gpd deficiency tafenoquine novel inclusion mmvs portfolio give activity liver stage malaria hypnozoite essential fight p vivax infections malaria elimination agenda move forwards need increase array tool parasite say dr timothy wells chief scientific officer medicine malaria venture mmv gsk work successfully number malaria project past hope develop radical cure p vivax malaria pyridone new class compound potential highly effective drugsensitive drugresistant strain p falciparum p vivax malaria pyridone gsk pdaegvee lo opf ed partnership mmv enter time human clinical trial early backup programme include gskmmv agreement advanced candidate development expect mid isoquine new aminoquinoline compound time human clinical trial complete base advice mmv expert scientific advisory committee follow discussion partner gsk university liverpool mmv isoquine project terminate time evidence provide demonstrate adequate therapeutic blood exposure achieve acceptable oral dosage bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old child n engl j me abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infant n engl j med gsk press release issue february dacart lapdap report corporate responsibility report early gsk medicine malaria venture mmv receive datum phase lll clinical trial assess use artemisininbase combination therapy dacart develop trial primarily design establish efficacy dacart versus coartem currently line antimalarial therapy endemic country second trial design establish efficacy dacart versus lapdap chlorproguanil dapsone antimalarial product gsk develop partnership include world health organization uks department international development key safety finding trial patient glucosephosphate dehydrogenase gpd deficiency find risk anaemia take dacart lapdap consequently give haematological profile dacart fact cent population sub saharan africa gpd deficient gsk mmv decide terminate development dacart reason gsk decide withdraw lapdap market disappointment highlight highly risky complex nature pharmaceutical research development gsk remain committed work partner mmv seek solution patient suffer devastating diseasehome responsibility access medicine develop country research development malaria corporate responsibility report malaria working malaria vaccine year invest million resource date currently develop candidate malaria vaccine rtss partnership path malaria vaccine initiative mvi contribute million result separate phase trial confirm finding early study candidate vaccine provide infant young child vulnerable group significant protection malaria child age month rtssa vaccine reduce risk clinical episode malaria cent eightmonth period trial infant month receive dose modify rtssa vaccine risk infection malaria reduce cent month period trial show rtssas vaccine interfere efficacy vaccine administer exist african national immunisation programme mean country malaria prevalent vaccine deliver current immunisation schedule infant call expand program immunization epi christian loucq mvi director comment significance trial result say close develop malaria vaccine children africa commence largescale phase lll vaccine efficacy trial seven african country site trial confirm safety efficacy candidate vaccine file registration introduce early child month age long establish efficacy infant epi age week old complexity enrolment trial early vaccine fully available follow approval use infant read malaria vaccine case study update august phase iii trial rtss malaria vaccine candidate start bagamoyo tanzania work malaria treatment include tafenoquine potential new treatment radical cure p vivax malaria develop partnership medicine malaria venture mmv cause acute infection red blood cell p vivax cause dormant infection liver cell parasite reactivate result reappearance parasite blood recurrence malaria radical cure imply complete elimination malaria parasite body include dormant liver stage tafenoquine offer potential day treatment course replace primaquine standard care p vivax radical cure initial study commencing focus understand safety tafenoquine subject inherit glucosephosphate dehydrogenase gpd deficiency tafenoquine novel inclusion mmvs portfolio give activity liver stage malaria hypnozoite essential fight p vivax infections malaria elimination agenda move forwards need increase array tool parasite say dr timothy wells chief scientific officer medicine malaria venture mmv gsk work successfully number malaria project past hope develop radical cure p vivax malaria pyridone new class compound potential highly effective drugsensitive drugresistant strain p falciparum p vivax malaria pyridone gsk develop partnership mmv enter time human clinical trial early backup programme include gskmmv agreement advanced candidate development expect mid isoquine new aminoquinoline compound time human clinical trial complete base advice mmv expert scientific advisory committee follow discussion partner gsk university liverpool mmv isoquine project terminate time evidence provide demonstrate adequate therapeutic blood exposure achieve acceptable oral dosage bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old child n engl j me abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infant n engl j med gsk press release issue february dacart lapdap report corporate responsibility report early gsk medicine malaria venture mmv receive datum phase lll clinical trial assess use artemisininbase combination therapy dacart develop trial primarily design establish efficacy dacart versus coartem currently line antimalarial therapy endemic country second trial design establish efficacy dacart versus lapdap chlorproguanil dapsone antimalarial product gsk develop partnership include world health organization uks department international development key safety finding trial patient glucosephosphate dehydrogenase gpd deficiency find risk anaemia take dacart lapdap consequently give haematological profile dacart fact cent population sub saharan africa gpd deficient gsk mmv decide terminate development dacart reason gsk decide withdraw lapdap market disappointment highlight highly risky complex nature pharmaceutical research development gsk remain committed work partner mmv seek solution patient suffer devastating disease home responsibility access medicine develop country research development tuberculosis corporate responsibility report tuberculosis tuberculosis medicine research conduct partnership global alliance tb drug development tb alliance january announce renewal year joint research programme tb alliance speak time announcement dr mel spigelman tb alliance director research development say encouraged success pioneer work gsk nearly double number tb drug discovery project pipeline collaboration advance tb alliance mission develop revolutionary fast well tb treatment regimen explore npaegwe w aofy attack disease lead tb project mycobacterium gyrase inhibitor expect select candidate development mid tb partnership project way include research biomarker currently effectiveness new tb drug determine month completion treatment biomarker enable predict early stage patient respond significantly speed tb research mtbf tb candidate vaccine develop aeras global tb vaccine foundation early result positive suggesting vaccine safe produce strong immune reaction adult tb endemic region trial plan infant tb endemic regionshome responsibility access medicine develop country research development tuberculosis corporate responsibility report tuberculosis tuberculosis medicine research conduct partnership global alliance tb drug development tb alliance january announce renewal year joint research programme tb alliance speak time announcement dr mel spigelman tb alliance director research development say encouraged success pioneer work gsk nearly double number tb drug discovery project pipeline collaboration advance tb alliance mission develop revolutionary fast well tb treatment regimen explore new way attack disease lead tb project mycobacterium gyrase inhibitor expect select candidate development mid tb partnership project way include research biomarker currently effectiveness new tb drug determine month completion treatment biomarker enable predict early stage patient respond significantly speed tb research mtbf tb candidate vaccine develop aeras global tb vaccine foundation early result positive suggesting vaccine safe produce strong immune reaction adult tb endemic region trial plan infant tb endemic region home responsibility access medicine develop country research development tuberculosis corporate responsibility report tuberculosis tuberculosis medicine research conduct partnership global alliance tb drug development tb alliance january announce renewal year joint research programme tb alliance speak time announcement dr mel spigelman tb alliance director research development say encouraged success pioneer work gsk nearly double number tb drug discovery project pipeline collaboration advance tb alliance mission develop revolutionary fast well tb treatment regimen explore new way attack disease lead tb project mycobacterium gyrase inhibitor expect select candidate development mid tb partnership project way include research biomarker currently effectiveness new tb drug determine month completion treatment biomarker enable predict early stage patient respond significantly speed tb research mtbf tb candidate vaccine develop aeras global tb vaccine foundation early result positive suggesting vaccine safe produce strong immune reaction adult tb endemic region trial plan infant tb endemic region home responsibility access medicine develop country research development hivaid corporate responsibility report hivaids involve aids vaccine research decade gsk commit development new molecule target unmet medical need hiv press need variety new antihiv drug novel mechanism action vaccine pursue separate vaccine strategy successful aid vaccine combine approach recombinant measle vector measle vaccine powerful provide lifelong protection disease working pasteur institute paris develop aids vaccine fusing gene hiv virus measles vaccine fco candidate vaccine advance phase lll trial hivinfecte subject extramural collaborative discovery rd programme aim identify hiv envelopebase protein vaccine capable produce broadly neutralise antibodie hiv infection addition continue collaborate international aids vaccine initiative iavi evaluate modification joint programme treatment gsk commit development new molecule target unmet medical need hiv press need variety new antihiv drug novel mechanism action integrase inhibitor represent important new class compound treatment hiv increasingly clear secondgeneration integrase inhibitor need address issue drug resistance dose complexity currently number secondgeneration integrase inhibitor early stage clinical development february announce licence agreement idenix pharmaceuticals inc grant gsk exclusive worldwide right idx novel nonnucleoside reverse transcriptase inhibitor nnrti phase clinical development develop idenix treatment hivaid new nnrtis need address increase prevalence viral resistance effect associate drug class date idx demonstrate high potency low milligram dose high barrier drug resistance favourable riskbenefit profile convenience onceaday administration million child live hiv worldwide nearly cent subsaharan africa commit improve treatment child live hivaids develop product design use child develop score tablet simplify treatment score tablet enable antiretroviral arvs break small dose simplify treatment child unicef state access tablet form arvs improve treatment option child able swallow tablet tablet easy store distribute complicated administer liquid formulation currently available particularly medicine combine pill gain approval european commission new score tablet epivir combivir ziagen enable child kilogram weight benefit solid dosage form receive approval epivir ziagen score tablet food drug administration february fda approve score version combivir new tablet treatment easy child example child weigh kilogram half tablet combivir morning second half evening combination arv instead require ml epivir solution twice day plus ml retrovir solution timpaege da oifl commit support paediatric clinical study resourcepoor country determine good way expand access hivaids treatment international hiv collaborative research trial crt programme resourcepoor setting support clinical trial sponsor external organisation uks medical research council national institutes health nih end trial way plan involve approximately patient nineteen trial conduct site africa crt focus predominantly public healthrelated issue develop world prevention mothertochild hiv transmission paediatric treatment strategy hivtb coinfection gsk donate study antiretroviral andor financial support provide scientific input country hiv crt study conduct include african country asia latin america countries south africa india uganda thailand zimbabwe cambodia kenya vietnam botswana brazil zambia haiti tanzania peru malawi argentina ethiopia mali nigeriahome responsibility access medicine develop country research development hivaid corporate responsibility report hivaids involve aids vaccine research decade gsk commit development new molecule target unmet medical need hiv press need variety new antihiv drug novel mechanism action vaccine pursue separate vaccine strategy successful aid vaccine combine approach recombinant measle vector measle vaccine powerful provide lifelong protection disease working pasteur institute paris develop aids vaccine fusing gene hiv virus measles vaccine fco candidate vaccine advance phase lll trial hivinfecte subject extramural collaborative discovery rd programme aim identify hiv envelopebase protein vaccine capable produce broadly neutralise antibodie hiv infection addition continue collaborate international aids vaccine initiative iavi evaluate modification joint programme treatment gsk commit development new molecule target unmet medical need hiv press need variety new antihiv drug novel mechanism action integrase inhibitor represent important new class compound treatment hiv increasingly clear secondgeneration integrase inhibitor need address issue drug resistance dose complexity currently number secondgeneration integrase inhibitor early stage clinical development february announce licence agreement idenix pharmaceuticals inc grant gsk exclusive worldwide right idx novel nonnucleoside reverse transcriptase inhibitor nnrti phase clinical development develop idenix treatment hivaid new nnrtis need address increase prevalence viral resistance effect associate drug class date idx demonstrate high potency low milligram dose high barrier drug resistance favourable riskbenefit profile convenience onceaday administration million child live hiv worldwide nearly cent subsaharan africa commit improve treatment child live hivaids develop product design use child develop score tablet simplify treatment score tablet enable antiretroviral arvs break small dose simplify treatment child unicef state access tablet form arvs improve treatment option child able swallow tablet tablet easy store distribute complicated administer liquid formulation currently available particularly medicine combine pill gain approval european commission new score tablet epivir combivir ziagen enable child kilogram weight benefit solid dosage form receive approval epivir ziagen score tablet food drug administration february fda approve score version combivir new tablet treatment easy child example child weigh kilogram half tablet combivir morning second half evening combination arv instead require ml epivir solution twice day plus ml retrovir solution time daily commit support paediatric clinical study resourcepoor country determine good way expand access hivaids treatment international hiv collaborative research trial crt programme resourcepoor setting support clinical trial sponsor external organisation uks medical research council national institutes health nih end trial way plan involve approximately patient nineteen trial conduct site africa crt focus predominantly public healthrelated issue develop world prevention mothertochild hiv transmission paediatric treatment strategy hivtb coinfection gsk donate study antiretroviral andor financial support provide scientific input country hiv crt study conduct include african country asia latin america countries south africa india uganda thailand zimbabwe cambodia kenya vietnam botswana brazil zambia haiti tanzania peru malawi argentina ethiopia mali nigeria home responsibility access medicine develop country research development hivaid corporate responsibility report hivaids involve aids vaccine research decade gsk commit development new molecule target unmet medical need hiv press need variety new antihiv drug novel mechanism action vaccine pursue separate vaccine strategy successful aid vaccine combine approach recombinant measle vector measle vaccine powerful provide lifelong protection disease working pasteur institute paris develop aids vaccine fusing gene hiv virus measles vaccine fco candidate vaccine advance phase lll trial hivinfecte subject extramural collaborative discovery rd programme aim identify hiv envelopebase protein vaccine capable produce broadly neutralise antibodie hiv infection addition continue collaborate international aids vaccine initiative iavi evaluate modification joint programme treatment gsk commit development new molecule target unmet medical need hiv press need variety new antihiv drug novel mechanism action integrase inhibitor represent important new class compound treatment hiv increasingly clear secondgeneration integrase inhibitor need address issue drug resistance dose complexity currently number secondgeneration integrase inhibitor early stage clinical development february announce licence agreement idenix pharmaceuticals inc grant gsk exclusive worldwide right idx novel nonnucleoside reverse transcriptase inhibitor nnrti phase clinical development develop idenix treatment hivaid new nnrtis need address increase prevalence viral resistance effect associate drug class date idx demonstrate high potency low milligram dose high barrier drug resistance favourable riskbenefit profile convenience onceaday administration million child live hiv worldwide nearly cent subsaharan africa commit improve treatment child live hivaids develop product design use child develop score tablet simplify treatment score tablet enable antiretroviral arvs break small dose simplify treatment child unicef state access tablet form arvs improve treatment option child able swallow tablet tablet easy store distribute complicated administer liquid formulation currently available particularly medicine combine pill gain approval european commission new score tablet epivir combivir ziagen enable child kilogram weight benefit solid dosage form receive approval epivir ziagen score tablet food drug administration february fda approve score version combivir new tablet treatment easy child example child weigh kilogram half tablet combivir morning second half evening combination arv instead require ml epivir solution twice day plus ml retrovir solution time daily commit support paediatric clinical study resourcepoor country determine good way expand access hivaids treatment international hiv collaborative research trial crt programme resourcepoor setting support clinical trial sponsor external organisation uks medical research council national institutes health nih end trial way plan involve approximately patient nineteen trial conduct site africa crt focus predominantly public healthrelated issue develop world prevention mothertochild hiv transmission paediatric treatment strategy hivtb coinfection gsk donate study antiretroviral andor financial support provide scientific input country hiv crt study conduct include african country asia latin america countries south africa india uganda thailand zimbabwe cambodia kenya vietnam botswana brazil zambia haiti tanzania peru malawi argentina ethiopia mali nigeria home responsibility access medicine develop country research development visceral leishmaniasis corporate responsibility report visceral leishmaniasis vl sitamaquine oral onceaday candidate treatment visceral leishmaniasis vl potentially fatal disease spread parasite datum phase proofofconcept study kenya india encourage overall day course cent patient remained cure month sitamaquine generally tolerate patient study concern renal adverse event see subject appear treatment relate interpretation datum complicate particular vl associate renal impairment proceeding phase lll trial set phase llb study compare safety tolerability day course sitamaquine intravenous amphotericin b early result show comparable efficacy previous study despite short course sitamaquine well tolerate amphotericin small number patient mild reversible renal effect currently review utility sitamaquine potential treatment vl regulatory authority external stakeholder wasunna rashid jr mbui j et al phase ii doseincreasing study sitamaquine treatment visceral leishmaniasis kenya j trop me hyg jha tk sundar thakur cp et al phase ii doseranging study sitamaquine treatment visceral leishmaniasis india j trop me hyg prasad ls sen ganguly renal involvement kalaazar indian j med res jan dutra martinelli r de carvalho em et al renal involvement visceral leishmaniasis j kidney dis home responsibility access medicine develop country research development visceral leishmaniasis corporate responsibility report visceral leishmaniasis vl sitamaquine oral onceaday candidate treatment visceral leishmaniasis vl potentially fatal disease spread parasite datum phase proofofconcept study kenya india encourage overall day course cent patient remained cure month sitamaquine generally tolerate patient study concern renal adverse event see subject appear treatment relate interpretation datum complicate particular vl associate renal impairment proceeding phase lll trial set phase llb study compare safety tolerability day course sitamaquine intravenous amphotericin b early result show comparable efficacy previous study despite short course sitamaquine well tolerate amphotericin small number patient mild reversible renal effect currently review utility sitamaquine potential treatment vl regulatory authority external stakeholder wasunna rashid jr mbui j et al phase ii doseincreasing study sitamaquine treatment visceral leishmaniasis kenya j trop me hyg jha tk sundar thakur cp et al phase ii doseranging study sitamaquine treatment visceral leishmaniasis india j trop me hyg prasad ls sen ganguly renal involvement kalaazar indian j med res jan dutra martinelli r de carvalho em et al renal involvement visceral leishmaniasis j kidney dis home responsibility access medicine develop country research development pneumococcal disease corporate responsibility report pneumococcal disease pneumococcal disease global health issue year streptococcus pneumoniae infection estimate kill million child year age worldwide distinct strain serotype pneumococcus cause vast majority invasive disease young child january european medicines agencys committee medicinal product human use issue positive opinion recommend approval gsk paediatric pneumococcal candidate vaccine synflorix paediatric vaccine propose indicate active immunisation invasive pneumococcal disease middle ear infection acute otitis medium cause spneumoniae infant child week year european marketing authorisation vaccine expected grant half submit file potentially lifesave candidate vaccine world health organization prequalification early prequalification service provide facilitate access medicine affluent country discussion global alliance vaccine immunization accelerate availability fund pneumococcal vaccination pilot advance market commitment amc mechanism amcs new approach public health funding design stimulate development manufacture vaccine develop country donor commit money guarantee price vaccine develop create potential viable future market home responsibility access medicine develop country research development pneumococcal disease corporate responsibility report pneumococcal disease pneumococcal disease global health issue year streptococcus pneumoniae infection estimate kill million child year age worldwide distinct strain serotype pneumococcus cause vast majority invasive disease young child january european medicines agencys committee medicinal product human use issue positive opinion recommend approval gsk paediatric pneumococcal candidate vaccine synflorix paediatric vaccine propose indicate active immunisation invasive pneumococcal disease middle ear infection acute otitis medium cause spneumoniae infant child week year european marketing authorisation vaccine expected grant half submit file potentially lifesave candidate vaccine world health organization prequalification early prequalification service provide facilitate access medicine affluent country discussion global alliance vaccine immunization accelerate availability fund pneumococcal vaccination pilot advance market commitment amc mechanism amcs new approach public health funding design stimulate development manufacture vaccine develop country donor commit money guarantee price vaccine develop create potential viable future market home responsibility access medicine develop country research development neglect disease corporate responsibility report neglect disease march announce collaborative research effort notforprofit organisation drug neglect disease initiative dndi target neglect tropical disease disproportionately affect develop world research focus compound activity neglect disease include visceral leishmaniasis kala azar human african trypanosomiasis sleep sickness chaga disease collaboration establish initial period year extend focus identify develop compound exist gsk programme leverage expertise researcher gsk tre canto facility lead academic centre like london school hygiene tropical medicine collaboration form specifically address unmet patient need current treatment disease significant drawback difficulty administration severe effect length treatment cost emerge parasitic resistance home responsibility access medicine develop country research development neglect disease corporate responsibility report neglect disease march announce collaborative research effort notforprofit organisation drug neglect disease initiative dndi target neglect tropical disease disproportionately affect develop world research focus compound activity neglect disease include visceral leishmaniasis kala azar human african trypanosomiasis sleep sickness chaga disease collaboration establish initial period year extend focus identify develop compound exist gsk programme leverage expertise researcher gsk tre canto facility lead academic centre like london school hygiene tropical medicine collaboration form specifically address unmet patient need current treatment disease significant drawback difficulty administration severe effect length treatment cost emerge parasitic resistance home responsibility access medicine develop country research development plan corporate responsibility report plan plan conduct largescale phase lll malaria vaccine efficacy trial seven african country commence study focus understand safety tafenoquine subject inherit glucosephosphate dehydrogenase gpd deficiency select candidate lead tb project mycobacterium gyrase inhibitor development mid initiate trail candidate tb vaccine infant continue clinical development multiple secondgeneration integrase inhibitor hivaid enter time human clinical trial pyridone antimalarial develop partnership mmv achieve january select candidate development mid review utility sitamaquine potential treatment vl regulatory authority external stakeholder pandemic flu happen influenza pandemic devastating effect particularly poor country resource capacity prepare gsk active global preparation relate pandemic flu read help country prepare pandemic flu home responsibility access medicine develop country research development plan corporate responsibility report plan plan conduct largescale phase lll malaria vaccine efficacy trial seven african country commence study focus understand safety tafenoquine subject inherit glucosephosphate dehydrogenase gpd deficiency select candidate lead tb project mycobacterium gyrase inhibitor development mid initiate trail candidate tb vaccine infant continue clinical development multiple secondgeneration integrase inhibitor hivaid enter time human clinical trial pyridone antimalarial develop partnership mmv achieve january select candidate development mid review utility sitamaquine potential treatment vl regulatory authority external stakeholder pandemic flu happen influenza pandemic devastating effect particularly poor country resource capacity prepare gsk active global preparation relate pandemic flu read help country prepare pandemic flu home responsibility access medicine develop country publicprivate partnership corporate responsibility report publicprivate partnership gsk remain profitable sustain business provide fund enable continue develop new medicine vaccine limit prospect commercial return rd disease develop world publicprivate partnership ppp enable rd disease make work commercially viable sharing risk cost involve ppps speed rd process enable partner ppp company gsk provide rd technology manufacturing distribution expertise academic institution provide research disease area knowledge public sector partner government organisation bill melinda gates foundation help fund development delivery cost ensure medicine vaccine people need fund usually channel organisation medicine malaria venture mmv help coordinate global rd activity ppps work different way example partnership centre dedicated disease develop world discovery centre tre canto global vaccine business headquartered belgium gsk provide facility medicinal drug discovery meet run cost scientist tre canto half subsidise partner organisation mmv global alliance tb drug development compound clinical development gsk provide clinical regulatory manufacturing expertise resource global rd supply network partner help fund cost run clinical trial address issue access distribution reduce cost development get new product patient fast research programme oversee joint steering committee representative gsk partner term agreement new treatment result ppps available disease endemic country affordable price accelerate access initiative accelerate access initiative aai publicprivate partnership accelerate access care treatment hivaid gsk founder member aai form aai partnership unaid world bank unicef unfpa researchbase pharmaceutical company abbott laboratories boehringer ingelheim bristolmyers squibb gilead sciences glaxosmithkline johnson johnson merck co inc pfizer roche objective aai accelerate sustained access increase use appropriate good quality intervention preventiontreatment hivaid ensure care treatment reach significantly great number people need new alliance involve committed government private industry un development assistance agency nongovernmental organisation people live hivaid report accelerate access initiative suggest december patient develop country receive arv treatment supply rd base pharmaceutical company aai year december total number patient develop country receive treatment aai company increase cent africa patient treat arv supply aai company increase cent year result fold increase number people treat medicine supply aai company africa establishment aai home responsibility access medicine develop country publicprivate partnership corporate responsibility report publicprivate partnership gsk remain profitable sustain business provide fund enable continue develop new medicine vaccine limit prospect commercial return rd disease develop world publicprivate partnership ppp enable rd disease make work commercially viable sharing risk cost involve ppps speed rd process enable partner ppp company gsk provide rd technology manufacturing distribution expertise academic institution provide research disease area knowledge public sector partner government organisation bill melinda gates foundation help fund development delivery cost ensure medicine vaccine people need fund usually channel organisation medicine malaria venture mmv help coordinate global rd activity ppps work different way example partnership centre dedicated disease develop world discovery centre tre canto global vaccine business headquartered belgium gsk provide facility medicinal drug discovery meet run cost scientist tre canto half subsidise partner organisation mmv global alliance tb drug development compound clinical development gsk provide clinical regulatory manufacturing expertise resource global rd supply network partner help fund cost run clinical trial address issue access distribution reduce cost development get new product patient fast research programme oversee joint steering committee representative gsk partner term agreement new treatment result ppps available disease endemic country affordable price accelerate access initiative accelerate access initiative aai publicprivate partnership accelerate access care treatment hivaid gsk founder member aai form aai partnership unaid world bank unicef unfpa researchbase pharmaceutical company abbott laboratories boehringer ingelheim bristolmyers squibb gilead sciences glaxosmithkline johnson johnson merck co inc pfizer roche objective aai accelerate sustained access increase use appropriate good quality intervention preventiontreatment hivaid ensure care treatment reach significantly great number people need new alliance involve committed government private industry un development assistance agency nongovernmental organisation people live hivaid report accelerate access initiative suggest december patient develop country receive arv treatment supply rd base pharmaceutical company aai year december total number patient develop country receive treatment aai company increase cent africa patient treat arv supply aai company increase cent year result fold increase number people treat medicine supply aai company africa establishment aai home responsibility access medicine develop country publicprivate partnership corporate responsibility report publicprivate partnership gsk remain profitable sustain business provide fund enable continue develop new medicine vaccine limit prospect commercial return rd disease develop world publicprivate partnership ppp enable rd disease make work commercially viable sharing risk cost involve ppps speed rd process enable partner ppp company gsk provide rd technology manufacturing distribution expertise academic institution provide research disease area knowledge public sector partner government organisation bill melinda gates foundation help fund development delivery cost ensure medicine vaccine people need fund usually channel organisation medicine malaria venture mmv help coordinate global rd activity ppps work different way example partnership centre dedicated disease develop world discovery centre tre canto global vaccine business headquartered belgium gsk provide facility medicinal drug discovery meet run cost scientist tre canto half subsidise partner organisation mmv global alliance tb drug development compound clinical development gsk provide clinical regulatory manufacturing expertise resource global rd supply network partner help fund cost run clinical trial address issue access distribution reduce cost development get new product patient fast research programme oversee joint steering committee representative gsk partner term agreement new treatment result ppps available disease endemic country affordable price accelerate access initiative accelerate access initiative aai publicprivate partnership accelerate access care treatment hivaid gsk founder member aai form aai partnership unaid world bank unicef unfpa researchbase pharmaceutical company abbott laboratories boehringer ingelheim bristolmyers squibb gilead sciences glaxosmithkline johnson johnson merck co inc pfizer roche objective aai accelerate sustained access increase use appropriate good quality intervention preventiontreatment hivaid ensure care treatment reach significantly great number people need new alliance involve committed government private industry un development assistance agency nongovernmental organisation people live hivaid report accelerate access initiative suggest december patient develop country receive arv treatment supply rd base pharmaceutical company aai year december total number patient develop country receive treatment aai company increase cent africa patient treat arv supply aai company increase cent year result fold increase number people treat medicine supply aai company africa establishment aai home responsibility access medicine develop country product registration corporate responsibility report product registration approach performance plan rapid product registration important ensure new medicine reach patient quickly possible regulatory process complex costly time consume little regulatory harmonisation world distinct submission require virtually country company prioritise regulatory resource lead concern pharmaceutical company register essential medicine develop country prevent country take advantage preferential pricing offer prioritise registration medicine base commercial consideration prevalence disease use mechanism european medicine agency emea article help facilitate product registration develop country article allow agency committee medicinal product human use chmp opinion cooperation world health organization medicinal product human use intend exclusively market outside eu medicine treat malaria leishmaniasis positive opinion obtain article support registration process develop country conduct regulatory review regularly review registration status key antiretroviral arvs prioritise registration base need arvs help epivir retrovir combivir ziagen available widely necessary possible screening vaccination prevent thousand woman get cervical cancer working register vaccine human papillomavirus hpv cervarix widely possible woman well protect disease available high middle low income country world gsk commit accelerate global access vaccine read position cervical cancer prevention home responsibility access medicine develop country product registration corporate responsibility report product registration approach performance plan rapid product registration important ensure new medicine reach patient quickly possible regulatory process complex costly time consume little regulatory harmonisation world distinct submission require virtually country company prioritise regulatory resource lead concern pharmaceutical company register essential medicine develop country prevent country take advantage preferential pricing offer prioritise registration medicine base commercial consideration prevalence disease use mechanism european medicine agency emea article help facilitate product registration develop country article allow agency committee medicinal product human use chmp opinion cooperation world health organization medicinal product human use intend exclusively market outside eu medicine treat malaria leishmaniasis positive opinion obtain article support registration process develop country conduct regulatory review regularly review registration status key antiretroviral arvs prioritise registration base need arvs help epivir retrovir combivir ziagen available widely necessary possible screening vaccination prevent thousand woman get cervical cancer working register vaccine human papillomavirus hpv cervarix widely possible woman well protect disease available high middle low income country world gsk commit accelerate global access vaccine read position cervical cancer prevention home responsibility access medicine develop country product registration corporate responsibility report product registration approach performance plan cervical cancer rotavirus october submit cervarix vaccine help prevent infection hpv world health organization prequalification product prequalification status un agencies gavi alliance mass vaccination programme develop world submit cervarix prequalification early possible working eliminate historical year delay new vaccine available develop country anticipate prequalification half early receive prequalification status rotavirus vaccine rotarix conclude deal brazilian government institute fiocruz supply rotarix protect baby brazil rotavirus year include technology transfer agreement fiocruz produce rotarix domestic market manufacture rotarix gsk contract export develop country similar exist arrangement brazil oral polio vaccine haemophilus influenzae type b hib vaccine measle mumps rubella vaccine result approach rotarix brazil impressive hivaid gsk produce pack arvs specifically design distribute develop country access pack combivir epivir tablet epivir solution trizivir register country mean product available sale target country include country formal regulatory approval process secondline arv ziagen formally register tablet form country oral solution target country ziagen access pack register country process seek registration flu support government preparation global flu pandemic register relenza country relenza antiviral medicine help treat influenza home responsibility access medicine develop country product registration corporate responsibility report product registration approach performance plan cervical cancer rotavirus october submit cervarix vaccine help prevent infection hpv world health organization prequalification product prequalification status un agencies gavi alliance mass vaccination programme develop world submit cervarix prequalification early possible working eliminate historical year delay new vaccine available develop country anticipate prequalification half early receive prequalification status rotavirus vaccine rotarix conclude deal brazilian government institute fiocruz supply rotarix protect baby brazil rotavirus year include technology transfer agreement fiocruz produce rotarix domestic market manufacture rotarix gsk contract export develop country similar exist arrangement brazil oral polio vaccine haemophilus influenzae type b hib vaccine measle mumps rubella vaccine result approach rotarix brazil impressive hivaid gsk produce pack arvs specifically design distribute develop country access pack combivir epivir tablet epivir solution trizivir register country mean product available sale target country include country formal regulatory approval process secondline arv ziagen formally register tablet form country oral solution target country ziagen access pack register country process seek registration flu support government preparation global flu pandemic register relenza country relenza antiviral medicine help treat influenza home responsibility access medicine develop country preferential pricing corporate responsibility report preferential pricing approach performance plan price factor impact access medicine vaccine develop country price medicine preferentially develop country use tiere pricing system wealthy middle income market people ability pay medicine vary significantly price aspect affordability ability pay provision allocation resource primarily government poverty reduction billion people live day virtually affordable early announce new strategic approach pricing develop country ldc april reduce price patent medicine ldc high cent price develop world maximum price possible reduce price aggressively ensure cover manufacturing cost offer sustainable price reduction april product formulation develop country average price reduction cent reinvest cent profit ldc project partner organisation ngo widen access strengthen healthcare infrastructure ldc sale ldc relatively low cent profit limit initially million year action hope send signal multinational company operate ldc join contribute make difference develop country healthcare crisis dominate social economic impact hivaid tb malaria gsk antiretroviral arvs treat hivaid antimalarial treatment portfolio commit increase access provide medicine develop country subsaharan africa notforprofit price key fact box negotiate preferential price hivaid medicine middleincome country casebycase basis read extend product portfolio develop world vaccine tiere pricing model vaccine significant contribution public health helping prevent potentially fatal infectious disease immunisation acknowledge world health organization costeffective health investment vaccine portfolio available preferential price develop country tiered pricing system price link gross national income define world bank size order length particular supply contract develop world price little tenth develop country work multinational organisation gavi unicef pan american health organization government nongovernmental organisation provide appropriate affordable vaccine develop country typically supply vaccine gavi unicef cent develop world price organisation sell vaccine large volume longerterm contract able significantly reduce price individual dose include basic polio vaccine specially develop combination vaccine target disease billion vaccine dose ship cent go develop world vaccine include government vaccination programme middleincome country example rotarix rotavirus vaccine include government vaccination programme new bear baby brazil el salvador mexico panama venezuela supply millionp adgoe se sof vaccine vast majority go develop middleincome country addition tiere pricing look innovative way increase access vaccine poor country option explore cervarix vaccine human papillomavirus partner major international nongovernmental organisation partnership able use organisation distribution network increase supply vaccine develop country death cervical cancer occur prevent product diversion product diversion notforprofit medicine illegally ship sale wealthy country deny treatment patient poor country antidiversion measure include specially design access pack arvs red white tablet epivir combivir enter voluntary licence know manufacturer ensure product diversion occur define un httpwwwunorgspecialrepohrllsldclisthtm notforprofit nfp price medicine key fact gsk offer preferential pricing antiretroviral formal notforprofit nfp pricing nfp price sustainable profit cover cost mean sustain supply highquality product long need notforprofit price apply gsk antiretroviral malaria treatment nfp price available develop country subsaharan africa total country addition pepfar project eligible global fund project bring number country eligible customer include public sector customer nfp organisation private employer subsaharan africa provide treatment uninsured staff combivir lead combination arv available day nfp price include insurance freight cost unlike price quote generic company applicable order size dependent large order quantitieshome responsibility access medicine develop country preferential pricing corporate responsibility report preferential pricing approach performance plan price factor impact access medicine vaccine develop country price medicine preferentially develop country use tiere pricing system wealthy middle income market people ability pay medicine vary significantly price aspect affordability ability pay provision allocation resource primarily government poverty reduction billion people live day virtually affordable early announce new strategic approach pricing develop country ldc april reduce price patent medicine ldc high cent price develop world maximum price possible reduce price aggressively ensure cover manufacturing cost offer sustainable price reduction april product formulation develop country average price reduction cent reinvest cent profit ldc project partner organisation ngo widen access strengthen healthcare infrastructure ldc sale ldc relatively low cent profit limit initially million year action hope send signal multinational company operate ldc join contribute make difference develop country healthcare crisis dominate social economic impact hivaid tb malaria gsk antiretroviral arvs treat hivaid antimalarial treatment portfolio commit increase access provide medicine develop country subsaharan africa notforprofit price key fact box negotiate preferential price hivaid medicine middleincome country casebycase basis read extend product portfolio develop world vaccine tiere pricing model vaccine significant contribution public health helping prevent potentially fatal infectious disease immunisation acknowledge world health organization costeffective health investment vaccine portfolio available preferential price develop country tiered pricing system price link gross national income define world bank size order length particular supply contract develop world price little tenth develop country work multinational organisation gavi unicef pan american health organization government nongovernmental organisation provide appropriate affordable vaccine develop country typically supply vaccine gavi unicef cent develop world price organisation sell vaccine large volume longerterm contract able significantly reduce price individual dose include basic polio vaccine specially develop combination vaccine target disease billion vaccine dose ship cent go develop world vaccine include government vaccination programme middleincome country example rotarix rotavirus vaccine include government vaccination programme new bear baby brazil el salvador mexico panama venezuela supply million dose vaccine vast majority go develop middleincome country addition tiere pricing look innovative way increase access vaccine poor country option explore cervarix vaccine human papillomavirus partner major international nongovernmental organisation partnership able use organisation distribution network increase supply vaccine develop country death cervical cancer occur prevent product diversion product diversion notforprofit medicine illegally ship sale wealthy country deny treatment patient poor country antidiversion measure include specially design access pack arvs red white tablet epivir combivir enter voluntary licence know manufacturer ensure product diversion occur define un httpwwwunorgspecialrepohrllsldclisthtm notforprofit nfp price medicine key fact gsk offer preferential pricing antiretroviral formal notforprofit nfp pricing nfp price sustainable profit cover cost mean sustain supply highquality product long need notforprofit price apply gsk antiretroviral malaria treatment nfp price available develop country subsaharan africa total country addition pepfar project eligible global fund project bring number country eligible customer include public sector customer nfp organisation private employer subsaharan africa provide treatment uninsured staff combivir lead combination arv available day nfp price include insurance freight cost unlike price quote generic company applicable order size dependent large order quantitie home responsibility access medicine develop country preferential pricing corporate responsibility report preferential pricing approach performance plan price factor impact access medicine vaccine develop country price medicine preferentially develop country use tiere pricing system wealthy middle income market people ability pay medicine vary significantly price aspect affordability ability pay provision allocation resource primarily government poverty reduction billion people live day virtually affordable early announce new strategic approach pricing develop country ldc april reduce price patent medicine ldc high cent price develop world maximum price possible reduce price aggressively ensure cover manufacturing cost offer sustainable price reduction april product formulation develop country average price reduction cent reinvest cent profit ldc project partner organisation ngo widen access strengthen healthcare infrastructure ldc sale ldc relatively low cent profit limit initially million year action hope send signal multinational company operate ldc join contribute make difference develop country healthcare crisis dominate social economic impact hivaid tb malaria gsk antiretroviral arvs treat hivaid antimalarial treatment portfolio commit increase access provide medicine develop country subsaharan africa notforprofit price key fact box negotiate preferential price hivaid medicine middleincome country casebycase basis read extend product portfolio develop world vaccine tiere pricing model vaccine significant contribution public health helping prevent potentially fatal infectious disease immunisation acknowledge world health organization costeffective health investment vaccine portfolio available preferential price develop country tiered pricing system price link gross national income define world bank size order length particular supply contract develop world price little tenth develop country work multinational organisation gavi unicef pan american health organization government nongovernmental organisation provide appropriate affordable vaccine develop country typically supply vaccine gavi unicef cent develop world price organisation sell vaccine large volume longerterm contract able significantly reduce price individual dose include basic polio vaccine specially develop combination vaccine target disease billion vaccine dose ship cent go develop world vaccine include government vaccination programme middleincome country example rotarix rotavirus vaccine include government vaccination programme new bear baby brazil el salvador mexico panama venezuela supply million dose vaccine vast majority go develop middleincome country addition tiere pricing look innovative way increase access vaccine poor country option explore cervarix vaccine human papillomavirus partner major international nongovernmental organisation partnership able use organisation distribution network increase supply vaccine develop country death cervical cancer occur prevent product diversion product diversion notforprofit medicine illegally ship sale wealthy country deny treatment patient poor country antidiversion measure include specially design access pack arvs red white tablet epivir combivir enter voluntary licence know manufacturer ensure product diversion occur define un httpwwwunorgspecialrepohrllsldclisthtm notforprofit nfp price medicine key fact gsk offer preferential pricing antiretroviral formal notforprofit nfp pricing nfp price sustainable profit cover cost mean sustain supply highquality product long need notforprofit price apply gsk antiretroviral malaria treatment nfp price available develop country subsaharan africa total country addition pepfar project eligible global fund project bring number country eligible customer include public sector customer nfp organisation private employer subsaharan africa provide treatment uninsured staff combivir lead combination arv available day nfp price include insurance freight cost unlike price quote generic company applicable order size dependent large order quantitie home responsibility access medicine develop country preferential pricing corporate responsibility report preferential pricing approach performance plan offer antiretroviral arvs antimalarial notforprofit nfp price public sector customer notforprofit organisation country develop country subsaharan africa february announce significant new price reduction arvs offer nfp basis country reduction fifth time reduce price pioneer preferential pricing policy originally introduce combivir lead arv sell patient year develop country compare significant reduction cent ziagen oral solution abacavir recommend world health organization use firstline secondline regimen resourcelimite setting particularly child number factor enable implement price change include improvement efficiency manufacturing supply reduction cost active ingredient number tablet ship ship million tablet nfp combivir million tablet nfp epivir develop world compare million million respectively decline supply arvs outweigh growth volume licensee licensee supply million tablet version epivir combivir african country supply combivir epivir tablet gsk include preferentially price tablet supply gsk tablet supply licensees gsk supply arvs nfp price country compare continue look new customer nfp arvs country regularly review nfp price license able produce firstline arvs low cost continue increase share business patient receive treatment difficult estimate number patient treat result preferential pricing agreement control healthcare provision estimate million people develop world treat arvs end increase million year report accelerate access initiative aai suggest december page patient develop country receive arv treatment supply rdbased pharmaceutical company aai year december total number patient develop country receive treatment aai company increase cent africa patient treat arv supply aai company increase cent year result fold increase number people treat medicine supply aai company africa establishment aai read gsk vaccine contribute elimination hib mengingitishome responsibility access medicine develop country preferential pricing corporate responsibility report preferential pricing approach performance plan offer antiretroviral arvs antimalarial notforprofit nfp price public sector customer notforprofit organisation country develop country subsaharan africa february announce significant new price reduction arvs offer nfp basis country reduction fifth time reduce price pioneer preferential pricing policy originally introduce combivir lead arv sell patient year develop country compare significant reduction cent ziagen oral solution abacavir recommend world health organization use firstline secondline regimen resourcelimite setting particularly child number factor enable implement price change include improvement efficiency manufacturing supply reduction cost active ingredient number tablet ship ship million tablet nfp combivir million tablet nfp epivir develop world compare million million respectively decline supply arvs outweigh growth volume licensee licensee supply million tablet version epivir combivir african country supply combivir epivir tablet gsk include preferentially price tablet supply gsk tablet supply licensees gsk supply arvs nfp price country compare continue look new customer nfp arvs country regularly review nfp price license able produce firstline arvs low cost continue increase share business patient receive treatment difficult estimate number patient treat result preferential pricing agreement control healthcare provision estimate million people develop world treat arvs end increase million year report accelerate access initiative aai suggest december patient develop country receive arv treatment supply rdbased pharmaceutical company aai year december total number patient develop country receive treatment aai company increase cent africa patient treat arv supply aai company increase cent year result fold increase number people treat medicine supply aai company africa establishment aai read gsk vaccine contribute elimination hib mengingitis home responsibility access medicine develop country preferential pricing corporate responsibility report preferential pricing approach performance plan offer antiretroviral arvs antimalarial notforprofit nfp price public sector customer notforprofit organisation country develop country subsaharan africa february announce significant new price reduction arvs offer nfp basis country reduction fifth time reduce price pioneer preferential pricing policy originally introduce combivir lead arv sell patient year develop country compare significant reduction cent ziagen oral solution abacavir recommend world health organization use firstline secondline regimen resourcelimite setting particularly child number factor enable implement price change include improvement efficiency manufacturing supply reduction cost active ingredient number tablet ship ship million tablet nfp combivir million tablet nfp epivir develop world compare million million respectively decline supply arvs outweigh growth volume licensee licensee supply million tablet version epivir combivir african country supply combivir epivir tablet gsk include preferentially price tablet supply gsk tablet supply licensees gsk supply arvs nfp price country compare continue look new customer nfp arvs country regularly review nfp price license able produce firstline arvs low cost continue increase share business patient receive treatment difficult estimate number patient treat result preferential pricing agreement control healthcare provision estimate million people develop world treat arvs end increase million year report accelerate access initiative aai suggest december patient develop country receive arv treatment supply rdbased pharmaceutical company aai year december total number patient develop country receive treatment aai company increase cent africa patient treat arv supply aai company increase cent year result fold increase number people treat medicine supply aai company africa establishment aai read gsk vaccine contribute elimination hib mengingitis home responsibility access medicine develop country price middleincome country corporate responsibility report pricing middleincome country approach performance plan middleincome country mic brazil china thailand indonesia lowincome country india economically develop world poor country large affluent middle class provide great commercial opportunity world poor country accord report accounting firm pricewaterhousecooper grow wealth brazil china india indonesia mexico russia turkey mean account cent global pharmaceutical market middle income country large number people live extreme poverty healthcare demand outstrip available resource challenge bad increase incidence chronic disease asthma diabete reflect situation restructure commercial organisation split old international division create new region emerge market asia pacific enable respond commercial opportunity reflect healthcare environment individual need increase access medicine middleincome country responsible commercial framework complex clear universal size fit solution complexity key aspect pharma future dialogue explore link sustainable pharmaceutical business model improve health outcome middleincome market include china india brazil vital identify good approach gsk address complex challenge challenge include low government healthcare spend relative gross domestic product gdp low cent gdp compare average cent eu poor healthcare infrastructure include hospital clinic doctor nurse high level income inequality country complicate pricing consideration affordability medicine vaccine taxis markup medicine vaccine stigma discrimination associate certain disease use traditional medicine remote rural population recognise middleincome country need assistance believe different approach need world poor country offer supply medicine notforprofit price vaccine highly preferential price world poor country sustainable continue adequate return wealthy market middleincome country grow commercial market gsk represent important source future business industry response market balance commercial objective global commitment work government stakeholder support effort deliver medicine vaccine needy people possible approach combine longestablished practice voluntary licence tiere pricing vaccine preferential pricing hivaid malaria medicine innovative strategy focus different socioeconomic group individual micshome responsibility access medicine develop country price middleincome country corporate responsibility report pricing middleincome country approach performance plan middleincome country mic brazil china thailand indonesia lowincome country india economically develop world poor country large affluent middle class provide great commercial opportunity world poor country accord report accounting firm pricewaterhousecooper grow wealth brazil china india indonesia mexico russia turkey mean account cent global pharmaceutical market middle income country large number people live extreme poverty healthcare demand outstrip available resource challenge bad increase incidence chronic disease asthma diabete reflect situation restructure commercial organisation split old international division create new region emerge market asia pacific enable respond commercial opportunity reflect healthcare environment individual need increase access medicine middleincome country responsible commercial framework complex clear universal size fit solution complexity key aspect pharma future dialogue explore link sustainable pharmaceutical business model improve health outcome middleincome market include china india brazil vital identify good approach gsk address complex challenge challenge include low government healthcare spend relative gross domestic product gdp low cent gdp compare average cent eu poor healthcare infrastructure include hospital clinic doctor nurse high level income inequality country complicate pricing consideration affordability medicine vaccine taxis markup medicine vaccine stigma discrimination associate certain disease use traditional medicine remote rural population recognise middleincome country need assistance believe different approach need world poor country offer supply medicine notforprofit price vaccine highly preferential price world poor country sustainable continue adequate return wealthy market middleincome country grow commercial market gsk represent important source future business industry response market balance commercial objective global commitment work government stakeholder support effort deliver medicine vaccine needy people possible approach combine longestablished practice voluntary licence tiere pricing vaccine preferential pricing hivaid malaria medicine innovative strategy focus different socioeconomic group individual mic home responsibility access medicine develop country price middleincome country corporate responsibility report pricing middleincome country approach performance plan middleincome country mic brazil china thailand indonesia lowincome country india economically develop world poor country large affluent middle class provide great commercial opportunity world poor country accord report accounting firm pricewaterhousecooper grow wealth brazil china india indonesia mexico russia turkey mean account cent global pharmaceutical market middle income country large number people live extreme poverty healthcare demand outstrip available resource challenge bad increase incidence chronic disease asthma diabete reflect situation restructure commercial organisation split old international division create new region emerge market asia pacific enable respond commercial opportunity reflect healthcare environment individual need increase access medicine middleincome country responsible commercial framework complex clear universal size fit solution complexity key aspect pharma future dialogue explore link sustainable pharmaceutical business model improve health outcome middleincome market include china india brazil vital identify good approach gsk address complex challenge challenge include low government healthcare spend relative gross domestic product gdp low cent gdp compare average cent eu poor healthcare infrastructure include hospital clinic doctor nurse high level income inequality country complicate pricing consideration affordability medicine vaccine taxis markup medicine vaccine stigma discrimination associate certain disease use traditional medicine remote rural population recognise middleincome country need assistance believe different approach need world poor country offer supply medicine notforprofit price vaccine highly preferential price world poor country sustainable continue adequate return wealthy market middleincome country grow commercial market gsk represent important source future business industry response market balance commercial objective global commitment work government stakeholder support effort deliver medicine vaccine needy people possible approach combine longestablished practice voluntary licence tiere pricing vaccine preferential pricing hivaid malaria medicine innovative strategy focus different socioeconomic group individual mic home responsibility access medicine develop country price middleincome country corporate responsibility report pricing middleincome country approach performance plan approach price middleincome market constantly evolve ongoing pricing pilot programme inform evolution comprise mixture longestablished practice new approach intend formalise communicate pricing policy middleincome country longestablished practice tiere pricing vaccine vaccine available gavieligible middleincome country mic include indonesia sri lanka cuba highly discount price vaccine include government vaccination programme middleincome country preferential pricing hivaid malaria medicine negotiate preferential pricing arrangement hivaid medicine antimalarial middle income country casebycase basis bilaterally dialogue government believe approach appropriate burden disease resource available address burden vary significantly country country country arrangement combine viable sustainable commercial return gsk improve affordability healthcare system concern novel approach develop flexible responsive approach access private public sector market mic strategy focus different socioeconomic group individual mic use standard classification socioeconomic group group wealthy section society e poor typically company gsk make disproportionate share sale people ab group sale tail sharply cd group usually unable compete lowcost generic medicine sale e group believe productive way align commercial accessibility goal product readily available cd segment market free government fund poor segment population explore option project include tiere pricing model country include enable product price differently private public health sector gauge relationship price volume select product target mic example able reduce price product order sufficiently high volume product local source manufacturing arrangement design address cost issue early draw definitive conclusion pilot project result pilot commercially sensitive pilot investigate relationship price volume volume target achieve analysis confound unexpected factor reduce demand diabete medicine avandia clear simple universal solution learn project continue investigate approach establish pilot initial pilot prove inconclusive example explore option withincountry tiere pricing vaccine clear pricing decision assess vacuum factor market dynamic include new product introduction competitor react price change take account evident programme suitable middleincome country pilot help inform approach middleincome country confident successful element incorporate longterm commercial strategy plan report cervarix price reduction philippine vietnam indonesia south africa gsk work partnership stakeholder optimise availability vaccine human papillonnaviru improve access treatment require stakeholder work develop well infrastructure distribution channel adequate fund well disease awareness education appropriate market dynamic gsk commit ensure pricing barrier access develop world reduce price philippine vietnam indonesia south africa example philippine reduce price cervarix cent south africa price reduction order cent gsk long track record tiere pricing vaccine available governmentled programme charge reduced price country low level income reduction price cervarix number country demonstration commitment increase access vaccineshome responsibility access medicine develop country price middleincome country corporate responsibility report pricing middleincome country approach performance plan approach price middleincome market constantly evolve ongoing pricing pilot programme inform evolution comprise mixture longestablished practice new approach intend formalise communicate pricing policy middleincome country longestablished practice tiere pricing vaccine vaccine available gavieligible middleincome country mic include indonesia sri lanka cuba highly discount price vaccine include government vaccination programme middleincome country preferential pricing hivaid malaria medicine negotiate preferential pricing arrangement hivaid medicine antimalarial middle income country casebycase basis bilaterally dialogue government believe approach appropriate burden disease resource available address burden vary significantly country country country arrangement combine viable sustainable commercial return gsk improve affordability healthcare system concern novel approach develop flexible responsive approach access private public sector market mic strategy focus different socioeconomic group individual mic use standard classification socioeconomic group group wealthy section society e poor typically company gsk make disproportionate share sale people ab group sale tail sharply cd group usually unable compete lowcost generic medicine sale e group believe productive way align commercial accessibility goal product readily available cd segment market free government fund poor segment population explore option project include tiere pricing model country include enable product price differently private public health sector gauge relationship price volume select product target mic example able reduce price product order sufficiently high volume product local source manufacturing arrangement design address cost issue early draw definitive conclusion pilot project result pilot commercially sensitive pilot investigate relationship price volume volume target achieve analysis confound unexpected factor reduce demand diabete medicine avandia clear simple universal solution learn project continue investigate approach establish pilot initial pilot prove inconclusive example explore option withincountry tiere pricing vaccine clear pricing decision assess vacuum factor market dynamic include new product introduction competitor react price change take account evident programme suitable middleincome country pilot help inform approach middleincome country confident successful element incorporate longterm commercial strategy plan report cervarix price reduction philippine vietnam indonesia south africa gsk work partnership stakeholder optimise availability vaccine human papillonnaviru improve access treatment require stakeholder work develop well infrastructure distribution channel adequate fund well disease awareness education appropriate market dynamic gsk commit ensure pricing barrier access develop world reduce price philippine vietnam indonesia south africa example philippine reduce price cervarix cent south africa price reduction order cent gsk long track record tiere pricing vaccine available governmentled programme charge reduced price country low level income reduction price cervarix number country demonstration commitment increase access vaccine home responsibility access medicine develop country price middleincome country corporate responsibility report pricing middleincome country approach performance plan approach price middleincome market constantly evolve ongoing pricing pilot programme inform evolution comprise mixture longestablished practice new approach intend formalise communicate pricing policy middleincome country longestablished practice tiere pricing vaccine vaccine available gavieligible middleincome country mic include indonesia sri lanka cuba highly discount price vaccine include government vaccination programme middleincome country preferential pricing hivaid malaria medicine negotiate preferential pricing arrangement hivaid medicine antimalarial middle income country casebycase basis bilaterally dialogue government believe approach appropriate burden disease resource available address burden vary significantly country country country arrangement combine viable sustainable commercial return gsk improve affordability healthcare system concern novel approach develop flexible responsive approach access private public sector market mic strategy focus different socioeconomic group individual mic use standard classification socioeconomic group group wealthy section society e poor typically company gsk make disproportionate share sale people ab group sale tail sharply cd group usually unable compete lowcost generic medicine sale e group believe productive way align commercial accessibility goal product readily available cd segment market free government fund poor segment population explore option project include tiere pricing model country include enable product price differently private public health sector gauge relationship price volume select product target mic example able reduce price product order sufficiently high volume product local source manufacturing arrangement design address cost issue early draw definitive conclusion pilot project result pilot commercially sensitive pilot investigate relationship price volume volume target achieve analysis confound unexpected factor reduce demand diabete medicine avandia clear simple universal solution learn project continue investigate approach establish pilot initial pilot prove inconclusive example explore option withincountry tiere pricing vaccine clear pricing decision assess vacuum factor market dynamic include new product introduction competitor react price change take account evident programme suitable middleincome country pilot help inform approach middleincome country confident successful element incorporate longterm commercial strategy plan report cervarix price reduction philippine vietnam indonesia south africa gsk work partnership stakeholder optimise availability vaccine human papillonnaviru improve access treatment require stakeholder work develop well infrastructure distribution channel adequate fund well disease awareness education appropriate market dynamic gsk commit ensure pricing barrier access develop world reduce price philippine vietnam indonesia south africa example philippine reduce price cervarix cent south africa price reduction order cent gsk long track record tiere pricing vaccine available governmentled programme charge reduced price country low level income reduction price cervarix number country demonstration commitment increase access vaccine home responsibility access medicine develop country voluntary licensing corporate responsibility report voluntary licensing approach performance voluntary licence grant patent holder allow generic company manufacture sell product people assume generic cheap brand product see key solution access crisis develop world pharmaceutical company increase pressure grant licence generic cheap success voluntary licence depend right licensee choose particularly true treatment chronic disease like hivaids sustainable supply goodquality antiretroviral arvs key believe voluntary licence universal solution tackle hivaid disease general case local manufacture arvs little difference affordability access patient point endorse real barrier access lack healthcare infrastructure resource pay medicine regardless come fund world bank international donor mean voluntary licence role play effort tackle hivaid epidemic subsaharan africa help increase availability medicine contribute well security supply decision grant voluntary licence depend number factor include case hivaid severity epidemic country local healthcare provision economic manufacturing environment discuss voluntary licence potential partner casebycase basis need sure manufacturer provide longterm supply goodquality medicine implement safeguard prevent diversion medicine wealthy market continue consider role voluntary licensing help increase access medicine middle income country undermine commercial business compulsory licence compulsory licence issue government involve intellectual property right take away right holder compulsory licence flexibility world trade organization trip agreement intellectual property humanitarian purpose widespread use compulsory licence undermine intellectual property framework counter productive long term rd new treatment especially commercial market exist hivaid depend protection intellectual property home responsibility access medicine develop country voluntary licensing corporate responsibility report voluntary licensing approach performance voluntary licence grant patent holder allow generic company manufacture sell product people assume generic cheap brand product see key solution access crisis develop world pharmaceutical company increase pressure grant licence generic cheap success voluntary licence depend right licensee choose particularly true treatment chronic disease like hivaids sustainable supply goodquality antiretroviral arvs key believe voluntary licence universal solution tackle hivaid disease general case local manufacture arvs little difference affordability access patient point endorse real barrier access lack healthcare infrastructure resource pay medicine regardless come fund world bank international donor mean voluntary licence role play effort tackle hivaid epidemic subsaharan africa help increase availability medicine contribute well security supply decision grant voluntary licence depend number factor include case hivaid severity epidemic country local healthcare provision economic manufacturing environment discuss voluntary licence potential partner casebycase basis need sure manufacturer provide longterm supply goodquality medicine implement safeguard prevent diversion medicine wealthy market continue consider role voluntary licensing help increase access medicine middle income country undermine commercial business compulsory licence compulsory licence issue government involve intellectual property right take away right holder compulsory licence flexibility world trade organization trip agreement intellectual property humanitarian purpose widespread use compulsory licence undermine intellectual property framework counter productive long term rd new treatment especially commercial market exist hivaid depends protection intellectual property home responsibility access medicine develop country voluntary licensing corporate responsibility report voluntary licensing approach performance grant voluntary licence vl negotiate licensing agreement arvs africa vls cover individual country trade blocs cover sub saharan africa update august july agree royalty free voluntary licence enable aspen produce arv abacavir take total number license agreement arvs africa offer grant licence abacavir open licensee august give consent enable canadian company apotex manufacture generic fix dose combination arv contain molecule gsk patent right treatment hivaid rwanda consent grant canadas access medicine regime reflect wto f agreement enable government authorise production certain patent medicine export gsk agree waive royalty basis apotexs triple combination generic arv supply notforprofit basis licensee supply million tablet version epivir combivir africa represent cent growth cent welcome trend give customer subsaharan africa great choice contribute well security supply grant vl simcere chinese manufacturer grant right manufacture sell zanamivir relenza contain product china sell number country include develop country zanamivir antiviral help treat influenza vl drive specific concern help ensure sufficient supply event global flu pandemic collaboration local manufacture significantly reduce disease burden rotavirus brazil pursue initiative high public health impact commercially viable example see implementation universal mss vaccination umv programme brazil rotavirus gsk brazilian vaccine manufacturer fiocruz longstanding partnership production vaccine disease cause high mortality morbidity polio haemophilus influenzae type b hib measle mumps rubella recently rotavirus partnership gsk fiocruz support brazil requirement universal mass vaccination rotavirus rotarix vaccine despite incomplete coverage vaccination programme significantly improve public health cent reduction hospitalisation acute diarrhoea aetiology cent reduction rotavirusrelate hospitalisation reduction diarrhoea outbreak rotavirus paulo cent cent reduction proportion case gastroenteritis cause rotavirus cent cent rotavirus vaccine expect lead avoid death cent reduction pmagileli f avoid case cent reduction brazilian ministry health statisticshome responsibility access medicine develop country voluntary licensing corporate responsibility report voluntary licensing approach performance grant voluntary licence vl negotiate licensing agreement arvs africa vls cover individual country trade blocs cover sub saharan africa update august july agree royalty free voluntary licence enable aspen produce arv abacavir take total number license agreement arvs africa offer grant licence abacavir open licensee august give consent enable canadian company apotex manufacture generic fix dose combination arv contain molecule gsk patent right treatment hivaid rwanda consent grant canadas access medicine regime reflect wto f agreement enable government authorise production certain patent medicine export gsk agree waive royalty basis apotexs triple combination generic arv supply notforprofit basis licensee supply million tablet version epivir combivir africa represent cent growth cent welcome trend give customer subsaharan africa great choice contribute well security supply grant vl simcere chinese manufacturer grant right manufacture sell zanamivir relenza contain product china sell number country include develop country zanamivir antiviral help treat influenza vl drive specific concern help ensure sufficient supply event global flu pandemic collaboration local manufacture significantly reduce disease burden rotavirus brazil pursue initiative high public health impact commercially viable example see implementation universal mss vaccination umv programme brazil rotavirus gsk brazilian vaccine manufacturer fiocruz longstanding partnership production vaccine disease cause high mortality morbidity polio haemophilus influenzae type b hib measle mumps rubella recently rotavirus partnership gsk fiocruz support brazil requirement universal mass vaccination rotavirus rotarix vaccine despite incomplete coverage vaccination programme significantly improve public health cent reduction hospitalisation acute diarrhoea aetiology cent reduction rotavirusrelate hospitalisation reduction diarrhoea outbreak rotavirus paulo cent cent reduction proportion case gastroenteritis cause rotavirus cent cent rotavirus vaccine expect lead avoid death cent reduction million avoid case cent reduction brazilian ministry health statistic home responsibility access medicine develop country voluntary licensing corporate responsibility report voluntary licensing approach performance grant voluntary licence vl negotiate licensing agreement arvs africa vls cover individual country trade blocs cover sub saharan africa update august july agree royalty free voluntary licence enable aspen produce arv abacavir take total number license agreement arvs africa offer grant licence abacavir open licensee august give consent enable canadian company apotex manufacture generic fix dose combination arv contain molecule gsk patent right treatment hivaid rwanda consent grant canadas access medicine regime reflect wto f agreement enable government authorise production certain patent medicine export gsk agree waive royalty basis apotexs triple combination generic arv supply notforprofit basis licensee supply million tablet version epivir combivir africa represent cent growth cent welcome trend give customer subsaharan africa great choice contribute well security supply grant vl simcere chinese manufacturer grant right manufacture sell zanamivir relenza contain product china sell number country include develop country zanamivir antiviral help treat influenza vl drive specific concern help ensure sufficient supply event global flu pandemic collaboration local manufacture significantly reduce disease burden rotavirus brazil pursue initiative high public health impact commercially viable example see implementation universal mss vaccination umv programme brazil rotavirus gsk brazilian vaccine manufacturer fiocruz longstanding partnership production vaccine disease cause high mortality morbidity polio haemophilus influenzae type b hib measle mumps rubella recently rotavirus partnership gsk fiocruz support brazil requirement universal mass vaccination rotavirus rotarix vaccine despite incomplete coverage vaccination programme significantly improve public health cent reduction hospitalisation acute diarrhoea aetiology cent reduction rotavirusrelate hospitalisation reduction diarrhoea outbreak rotavirus paulo cent cent reduction proportion case gastroenteritis cause rotavirus cent cent rotavirus vaccine expect lead avoid death cent reduction million avoid case cent reduction brazilian ministry health statistic home responsibility access medicine develop country corporate responsibility report develop country approach performance access medicine issue develop world develop country patient afford medicine need particular problem people health insurance limited public health provision develop patient assistance program pap discount saving card introduce discount card middleincome country program patient assistance program pap discount saving card provide prescription medicine uninsured patient free minimal cost gsk operate programme include commitment access cover cancer treatment bridge access cover medicine outpatient patient register trough phone patient advocate receive medicine local pharmacy mail order gsk access provide extra help lowincome senior disabled patient enrol medicare programme provide free medicine eligible patient spend prescription medicine current year income cent cent federal poverty level federal poverty level single person couple family member rx access industry programme gives uninsure citizen cent discount medicine gsk seven pharmaceutical company programme open people earn time federal poverty level nearly million americans enrol rx access work government employer find new way address problem chronic disease reduce healthcare cost discount card country gsk introduce discount card lithuania ukraine enable lowincome patient chronic disease asthma obtain prescription medicine discount price home responsibility access medicine develop country corporate responsibility report develop country approach performance access medicine issue develop world develop country patient afford medicine need particular problem people health insurance limited public health provision develop patient assistance program pap discount saving card introduce discount card middleincome country program patient assistance program pap discount saving card provide prescription medicine uninsured patient free minimal cost gsk operate programme include commitment access cover cancer treatment bridge access cover medicine outpatient patient register trough phone patient advocate receive medicine local pharmacy mail order gsk access provide extra help lowincome senior disabled patient enrol medicare programme provide free medicine eligible patient spend prescription medicine current year income cent cent federal poverty level federal poverty level single person couple family member rx access industry programme gives uninsure citizen cent discount medicine gsk seven pharmaceutical company programme open people earn time federal poverty level nearly million americans enrol rx access work government employer find new way address problem chronic disease reduce healthcare cost discount card country gsk introduce discount card lithuania ukraine enable lowincome patient chronic disease asthma obtain prescription medicine discount price home responsibility access medicine develop country corporate responsibility report develop country approach performance programme patient receive gsk medicine worth million programme value medicine calculate average cost good wholesale acquisition cost wac previous year new approach value medicine accurately reflect true cost gsk transparent believe pharmaceutical company adopt practice number patient large patient assistance programme decline cent compare decline sale avandia generic substitution coreg paxil increase number people insurance delaying visit doctor year patient receive day prescription gsk medicine rx access programme give patient discount million inception rx access give nearly million patient saving totalling million wide range product discount card country lithuania orange card give senior citizen disable discount cent patient copayment gsk prescription medicine far patient apply orange card pharmacy cent pharmacy lithuania register participate total discount give orange card ukraine give significant discount asthma chronic obstructive pulmonary disease patient need financial support purchase seretide inhale treatment asthma chronic obstructive pulmonary disease patient receive eorange card pharmacy register participate programme total discount give gsk product home responsibility access medicine develop country corporate responsibility report develop country approach performance programme patient receive gsk medicine worth million programme value medicine calculate average cost good wholesale acquisition cost wac previous year new approach value medicine accurately reflect true cost gsk transparent believe pharmaceutical company adopt practice number patient large patient assistance programme decline cent compare decline sale avandia generic substitution coreg paxil increase number people insurance delaying visit doctor year patient receive day prescription gsk medicine rx access programme give patient discount million inception rx access give nearly million patient saving totalling million wide range product discount card country lithuania orange card give senior citizen disable discount cent patient copayment gsk prescription medicine far patient apply orange card pharmacy cent pharmacy lithuania register participate total discount give orange card ukraine give significant discount asthma chronic obstructive pulmonary disease patient need financial support purchase seretide inhale treatment asthma chronic obstructive pulmonary disease patient receive eorange card pharmacy register participate programme total discount give gsk product home responsibility access medicine pricing medicine corporate responsibility report pricing medicine price newly approve medicine determine countrybycountry basis country price negotiate directly government payer example sickness fund private health insurer manufacturer free set price subject kind government control pharmaceutical rd lengthy expensive process develop successful medicine vaccine average year typically cost billion product reach market thousand research process seek ensure price new product reflect clinical value patient term improve therapy well safety few effect high risk associate rd need fair return investment affordability customer ultimately national price regulation balance act manage public healthcare budget enable patient access reward innovation rd investment sell medicine wholesaler pharmacy directly patient intermediary add price markups pharmaceutical product addition dutie tariff impose import product affect price pay end customer example national health service hospitals patient tufts center study drug development home responsibility access medicine pricing medicine corporate responsibility report pricing medicine price newly approve medicine determine countrybycountry basis country price negotiate directly government payer example sickness fund private health insurer manufacturer free set price subject kind government control pharmaceutical rd lengthy expensive process develop successful medicine vaccine average year typically cost billion product reach market thousand research process seek ensure price new product reflect clinical value patient term improve therapy well safety few effect high risk associate rd need fair return investment affordability customer ultimately national price regulation balance act manage public healthcare budget enable patient access reward innovation rd investment sell medicine wholesaler pharmacy directly patient intermediary add price markups pharmaceutical product addition dutie tariff impose import product affect price pay end customer example national health service hospital patient tufts center study drug development home responsibility access medicine intellectual property corporate responsibility report intellectual property intellectual property ip refer creation human mind law country stop creation include patent copyright trademark international level ip protect world trade organization wto trade relate aspect intellectual property right agreement commonly know trip patent ip right play vital role encourage innovation need develop new treatment lifethreatening disease invest considerable time money develop new pharmaceutical product average billion year product compound test estimate reach clinical trial reach market new product immediately copy sell able continue fund new research discourage innovation limit research new well medicine vaccine relation healthcare crisis develop world intellectual property specifically patent criticise broad reason opponent claim marketdriven ipbase rd system lead misprioritisation rd resource mean rd prioritisation base developed world market opportunity unmet medical need lead rd deficit disease develop world ip act barrier access facet firstly patent lead monopoly pricing prevent generic competition able drive price secondly patent act barrier followon innovation development fixeddose combination believe concern overstate recognise need seek new approach ip help tackle healthcare crisis believe ip system compatible rd disease develop world gsk industry expand research neglect disease recent year november international trade association ifpma publish datum show number medicine vaccine project undertake company product development partnership increase november believe patent minor issue prevent people develop world get access medicine little patent protection vital medicine treatment malaria tuberculosis diarrhoeal disease kill million people year cent medicine world health organization essential medicine list patent protect world say onethird worlds population regular access drug africa parts asia figure rise twothird population poverty big barrier effective healthcare develop world usually associate poorly develop healthcare infrastructure little access doctor hospital significant barrier stand way access medicine develop world tackle share responsibility sector global society traditionally allow access intellectual property control situation explore way flexible intellectual property relate neglect disease ips primary objective incentivise reward research number neglect tropical disease leprose cholera lack research variety complex reason need explore address gap include use ip approach patent pool encourage research neglect tropical disease gsk place grant patent pende application relate approximately patent family pool help develop potential medicine neglect disease addition provide access patent filing gsk set mechanism enable party request access intellectual property knowhow medicine help researcher develop new medicine neglect tropical disease aim pool encourage research happen hope new come research benefit directly ldc pool voluntary foster atmosphere cooperation encourage join pool mechanism explore achieve aim consider new way stimulate research continue defend ip robustly outside pool business sustain reward discovery development innovative medicine poor country plan flexible develop work area intellectual property law help prevent distribution counterfeit product present health risk patient tufts center study drug development pharmaceutical industry profile washington dc phrma march wwwifpmaorgnewsnewsreleasedetailaspxnidhome responsibility access medicine intellectual property corporate responsibility report intellectual property intellectual property ip refer creation human mind law country stop creation include patent copyright trademark international level ip protect world trade organization wto trade relate aspect intellectual property right agreement commonly know trip patent ip right play vital role encourage innovation need develop new treatment lifethreatening disease invest considerable time money develop new pharmaceutical product average billion year product compound test estimate reach clinical trial reach market new product immediately copy sell able continue fund new research discourage innovation limit research new well medicine vaccine relation healthcare crisis develop world intellectual property specifically patent criticise broad reason opponent claim marketdriven ipbase rd system lead misprioritisation rd resource mean rd prioritisation base developed world market opportunity unmet medical need lead rd deficit disease develop world ip act barrier access facet firstly patent lead monopoly pricing prevent generic competition able drive price secondly patent act barrier followon innovation development fixeddose combination believe concern overstate recognise need seek new approach ip help tackle healthcare crisis believe ip system compatible rd disease develop world gsk industry expand research neglect disease recent year november international trade association ifpma publish datum show number medicine vaccine project undertake company product development partnership increase november believe patent minor issue prevent people develop world get access medicine little patent protection vital medicine treatment malaria tuberculosis diarrhoeal disease kill million people year cent medicine world health organization essential medicine list patent protect world say onethird worlds population regular access drug africa parts asia figure rise twothird population poverty big barrier effective healthcare develop world usually associate poorly develop healthcare infrastructure little access doctor hospital significant barrier stand way access medicine develop world tackle share responsibility sector global society traditionally allow access intellectual property control situation explore way flexible intellectual property relate neglect disease ips primary objective incentivise reward research number neglect tropical disease leprose cholera lack research variety complex reason need explore address gap include use ip approach patent pool encourage research neglect tropical disease gsk place grant patent pende application relate approximately patent family pool help develop potential medicine neglect disease addition provide access patent filing gsk set mechanism enable party request access intellectual property knowhow medicine help researcher develop new medicine neglect tropical disease aim pool encourage research happen hope new come research benefit directly ldc pool voluntary foster atmosphere cooperation encourage join pool mechanism explore achieve aim consider new way stimulate research continue defend ip robustly outside pool business sustain reward discovery development innovative medicine poor country plan flexible develop work area intellectual property law help prevent distribution counterfeit product present health risk patient tufts center study drug development pharmaceutical industry profile washington dc phrma march wwwifpmaorgnewsnewsreleasedetailaspxnid home responsibility access medicine intellectual property corporate responsibility report intellectual property intellectual property ip refer creation human mind law country stop creation include patent copyright trademark international level ip protect world trade organization wto trade relate aspect intellectual property right agreement commonly know trip patent ip right play vital role encourage innovation need develop new treatment lifethreatening disease invest considerable time money develop new pharmaceutical product average billion year product compound test estimate reach clinical trial reach market new product immediately copy sell able continue fund new research discourage innovation limit research new well medicine vaccine relation healthcare crisis develop world intellectual property specifically patent criticise broad reason opponent claim marketdriven ipbase rd system lead misprioritisation rd resource mean rd prioritisation base developed world market opportunity unmet medical need lead rd deficit disease develop world ip act barrier access facet firstly patent lead monopoly pricing prevent generic competition able drive price secondly patent act barrier followon innovation development fixeddose combination believe concern overstate recognise need seek new approach ip help tackle healthcare crisis believe ip system compatible rd disease develop world gsk industry expand research neglect disease recent year november international trade association ifpma publish datum show number medicine vaccine project undertake company product development partnership increase november believe patent minor issue prevent people develop world get access medicine little patent protection vital medicine treatment malaria tuberculosis diarrhoeal disease kill million people year cent medicine world health organization essential medicine list patent protect world say onethird worlds population regular access drug africa parts asia figure rise twothird population poverty big barrier effective healthcare develop world usually associate poorly develop healthcare infrastructure little access doctor hospital significant barrier stand way access medicine develop world tackle share responsibility sector global society traditionally allow access intellectual property control situation explore way flexible intellectual property relate neglect disease ips primary objective incentivise reward research number neglect tropical disease leprose cholera lack research variety complex reason need explore address gap include use ip approach patent pool encourage research neglect tropical disease gsk place grant patent pende application relate approximately patent family pool help develop potential medicine neglect disease addition provide access patent filing gsk set mechanism enable party request access intellectual property knowhow medicine help researcher develop new medicine neglect tropical disease aim pool encourage research happen hope new come research benefit directly ldc pool voluntary foster atmosphere cooperation encourage join pool mechanism explore achieve aim consider new way stimulate research continue defend ip robustly outside pool business sustain reward discovery development innovative medicine poor country plan flexible develop work area intellectual property law help prevent distribution counterfeit product present health risk patient tufts center study drug development pharmaceutical industry profile washington dc phrma march wwwifpmaorgnewsnewsreleasedetailaspxnid home responsibility access medicine intellectual property wto trip agreement corporate responsibility report wto trip agreement intellectual property ip right protect globally world trade organization wto trade relate aspect intellectual property right agreement trip trip agreement sign wto member country cover type ip include patent copyright trademark set minimum standard ip right wto member country agreement cover area business society include software music art design encourage innovation business sector develop country give extra time comply trip country example india introduce patent pharmaceutical develop country world example rwanda gambia comply agreement pharmaceutical sector patent trip access medicine concern patent trip agreement restrict access medicine people develop country make difficult obtain cheap generic version important drug treat hivaid trip agreement contain number public health safeguard clarify wto concern trip access medicine address wto ministerial conference doha wto minister confirm ip protection important development new medicine restrict member right protect public health agree trip agreement implement interpret way support public health promote access medicine understanding capture doha declaration trip public health doha declaration confirm right member country use flexibility trip compulsory licence protect public health priority compulsory licensing allow government issue licence patent product manufacture consent patent owner wto member agree modify trip provision relate compulsory licensing august country unable produce pharmaceutical domestically import patent product compulsory licence abroad provision confirm amendment trip agreement wto december gsk support doha declaration agreement compulsory licensing commit play key role access crisis home responsibility access medicine intellectual property wto trip agreement corporate responsibility report wto trip agreement intellectual property ip right protect globally world trade organization wto trade relate aspect intellectual property right agreement trip trip agreement sign wto member country cover type ip include patent copyright trademark set minimum standard ip right wto member country agreement cover area business society include software music art design encourage innovation business sector develop country give extra time comply trip country example india introduce patent pharmaceutical develop country world example rwanda gambia comply agreement pharmaceutical sector patent trip access medicine concern patent trip agreement restrict access medicine people develop country make difficult obtain cheap generic version important drug treat hivaid trip agreement contain number public health safeguard clarify wto concern trip access medicine address wto ministerial conference doha wto minister confirm ip protection important development new medicine restrict member right protect public health agree trip agreement implement interpret way support public health promote access medicine understanding capture doha declaration trip public health doha declaration confirm right member country use flexibility trip compulsory licence protect public health priority compulsory licensing allow government issue licence patent product manufacture consent patent owner wto member agree modify trip provision relate compulsory licensing august country unable produce pharmaceutical domestically import patent product compulsory licence abroad provision confirm amendment trip agreement wto december gsk support doha declaration agreement compulsory licensing commit play key role access crisis home responsibility access medicine intellectual property intellectual property right brief corporate responsibility report intellectual property right brief patent patent give inventor new product exclusive right manufacture use sell import product process right grant set period generally year term patent run lengthy research development rd period year patent remain product market country extend patent term compensate long rd process patent grant condition inventor publish description invention allow manufacture product help build scientific understanding encourage research innovation trademark trademark brand word phrase symbol design combination identify distinguish product company owner trademark prevent use party trademark enable customer tell product competitor provide reassurance quality origin product vital marketing datum exclusivity sell new product prove effective safe use product rigorously test clinical trial medical research result research submit government confidential basis datum exclusivity mean government use disclose datum fix period ensure company benefit research free example demonstrate safety efficacy generic copy product interest facilitate timely market access need avoid repetitive animal testing human clinical trial competitor refer datum expiration period exclusivity home responsibility access medicine intellectual property intellectual property right brief corporate responsibility report intellectual property right brief patent patent give inventor new product exclusive right manufacture use sell import product process right grant set period generally year term patent run lengthy research development rd period year patent remain product market country extend patent term compensate long rd process patent grant condition inventor publish description invention allow manufacture product help build scientific understanding encourage research innovation trademark trademark brand word phrase symbol design combination identify distinguish product company owner trademark prevent use party trademark enable customer tell product competitor provide reassurance quality origin product vital marketing datum exclusivity sell new product prove effective safe use product rigorously test clinical trial medical research result research submit government confidential basis datum exclusivity mean government use disclose datum fix period ensure company benefit research free example demonstrate safety efficacy generic copy product interest facilitate timely market access need avoid repetitive animal testing human clinical trial competitor refer datum expiration period exclusivity home responsibility access medicine future corporate responsibility report future increase access medicine global challenge encourage progress area significant problem remain new issue likely emerge example continue need significant scaleup treatment hivaids subsaharan africa resource poor setting potential global flu pandemic healthcare need poor people middleincome country grow impact noncommunicable disease diabete poor rich country death million child year vaccinepreventable disease implement programme number area help address challenge intellectual property explore way flexible intellectual property right relate neglect disease include explore idea patent pool believe speed development new medicine encourage pharmaceutical company adopt similar approach update august march launch ldc neglect tropical disease patent pool website enable interested stakeholder access list gsk patent filing small molecule pharmaceutical treatment neglect tropical disease ntd organisation apply licence area develop treatment request licence research develop treatment ntd gsk patent technology small molecule currently develop help problem arise research development small molecule therapeutic treat ntds develop country july biotechnology group alnylam company follow gsk contribute patent pool pricing improve transparency pricing policy implement new pricing policy develop country continue evolve new approach increase affordability middle income country update august april implement price reduction patent product develop country ldc commitment gsk patent product country cost cent price reference develop country reduce price seven patent brand individual product line formulation average cent country price reduce immediately regulatory process need obtain government authorisation price reduction process initiated cut price nonldc markets east africa francophone west africa reduce risk product divert ldc sell wealthy country reduce availability ldc research evaluate opportunity expand tre canto disease develop world research centre worldclass global centre excellence encourage partnership government ngos pharmaceutical company update august appoint leadership team work partner extend capacity scope tre cantos facility create open collaborative way work provide facility support network need visit scientist form drug discovery project team gsk scientist healthcare service seek partner government stakeholder help strengthen healthcare infrastructure service update august reinvestment initiative gsk support government ldc address priority healthcare challenge remove barrier quality healthcare strengthen health infrastructure achieve targeted partnership increase access essential medicine basic healthcare service work begin end ldc gsk region east africa southern africa anglophone west africa francophone west central africa expand maternal child health activity specific focus child integrate management childhood illness programme additional ldc pilot new child family wellness cfw model cfw micro franchising model involve build network micro pharmacy clinic improve access essential medicine basic healthcare prevention service child family work use business model maintain standard readily scalable achieve economy scale gsk currently work ngo healthstore foundation implement model kenya run viability study ldc east africa select country implement initiative july announce new commitment fight hivaids subsaharan africa special focus care treatment child include million seed funding support public private partnership research development new hivaids medicine child commitment seek collaboration company develop fixeddose antiretroviral combination creation positive action child fund work main industry association new initiative increase rd improve access outcome activity announcement january grant million international federation pharmaceutical manufacturer association ifpma special programme research train tropical disease tdr cosponsor unicef undp world bank grant support tdrs development new medicine combat disease disproportionately affect poor people live develop country activity include plan establish pilot industry consortium focus develop new target molecule prevent interrupt disease progression disease develop world update august april announce intention combine gsk pfizer hiv business create new company dedicate discovery delivery hiv treatment combine business create specialist unit sustainable broad scope company individual business new company particularly look improve treatment formulation child live hiv continue offer hiv medicine notforprofit price world poor country issue new voluntary licence diversify production expand capacity market new company responsible delivering commitment announce gsk july home responsibility access medicine future corporate responsibility report future increase access medicine global challenge encourage progress area significant problem remain new issue likely emerge example continue need significant scaleup treatment hivaids subsaharan africa resource poor setting potential global flu pandemic healthcare need poor people middleincome country grow impact noncommunicable disease diabete poor rich country death million child year vaccinepreventable disease implement programme number area help address challenge intellectual property explore way flexible intellectual property right relate neglect disease include explore idea patent pool believe speed development new medicine encourage pharmaceutical company adopt similar approach update august march launch ldc neglect tropical disease patent pool website enable interested stakeholder access list gsk patent filing small molecule pharmaceutical treatment neglect tropical disease ntd organisation apply licence area develop treatment request licence research develop treatment ntd gsk patent technology small molecule currently develop help problem arise research development small molecule therapeutic treat ntds develop country july biotechnology group alnylam company follow gsk contribute patent pool pricing improve transparency pricing policy implement new pricing policy develop country continue evolve new approach increase affordability middle income country update august april implement price reduction patent product develop country ldc commitment gsk patent product country cost cent price reference develop country reduce price seven patent brand individual product line formulation average cent country price reduce immediately regulatory process need obtain government authorisation price reduction process initiated cut price nonldc markets east africa francophone west africa reduce risk product divert ldc sell wealthy country reduce availability ldc research evaluate opportunity expand tre canto disease develop world research centre worldclass global centre excellence encourage partnership government ngos pharmaceutical company update august appoint leadership team work partner extend capacity scope tre cantos facility create open collaborative way work provide facility support network need visit scientist form drug discovery project team gsk scientist healthcare service seek partner government stakeholder help strengthen healthcare infrastructure service update august reinvestment initiative gsk support government ldc address priority healthcare challenge remove barrier quality healthcare strengthen health infrastructure achieve targeted partnership increase access essential medicine basic healthcare service work begin end ldc gsk region east africa southern africa anglophone west africa francophone west central africa expand maternal child health activity specific focus child integrate management childhood illness programme additional ldc pilot new child family wellness cfw model cfw micro franchising model involve build network micro pharmacy clinic improve access essential medicine basic healthcare prevention service child family work use business model maintain standard readily scalable achieve economy scale gsk currently work ngo healthstore foundation implement model kenya run viability study ldc east africa select country implement initiative july announce new commitment fight hivaids subsaharan africa special focus care treatment child include million seed funding support public private partnership research development new hivaids medicine child commitment seek collaboration company develop fixeddose antiretroviral combination creation positive action child fund work main industry association new initiative increase rd improve access outcome activity announcement january grant million international federation pharmaceutical manufacturer association ifpma special programme research train tropical disease tdr cosponsor unicef undp world bank grant support tdrs development new medicine combat disease disproportionately affect poor people live develop country activity include plan establish pilot industry consortium focus develop new target molecule prevent interrupt disease progression disease develop world update august april announce intention combine gsk pfizer hiv business create new company dedicate discovery delivery hiv treatment combine business create specialist unit sustainable broad scope company individual business new company particularly look improve treatment formulation child live hiv continue offer hiv medicine notforprofit price world poor country issue new voluntary licence diversify production expand capacity market new company responsible delivering commitment announce gsk july home responsibility access medicine future corporate responsibility report future increase access medicine global challenge encourage progress area significant problem remain new issue likely emerge example continue need significant scaleup treatment hivaids subsaharan africa resource poor setting potential global flu pandemic healthcare need poor people middleincome country grow impact noncommunicable disease diabete poor rich country death million child year vaccinepreventable disease implement programme number area help address challenge intellectual property explore way flexible intellectual property right relate neglect disease include explore idea patent pool believe speed development new medicine encourage pharmaceutical company adopt similar approach update august march launch ldc neglect tropical disease patent pool website enable interested stakeholder access list gsk patent filing small molecule pharmaceutical treatment neglect tropical disease ntd organisation apply licence area develop treatment request licence research develop treatment ntd gsk patent technology small molecule currently develop help problem arise research development small molecule therapeutic treat ntds develop country july biotechnology group alnylam company follow gsk contribute patent pool pricing improve transparency pricing policy implement new pricing policy develop country continue evolve new approach increase affordability middle income country update august april implement price reduction patent product develop country ldc commitment gsk patent product country cost cent price reference develop country reduce price seven patent brand individual product line formulation average cent country price reduce immediately regulatory process need obtain government authorisation price reduction process initiated cut price nonldc markets east africa francophone west africa reduce risk product divert ldc sell wealthy country reduce availability ldc research evaluate opportunity expand tre canto disease develop world research centre worldclass global centre excellence encourage partnership government ngos pharmaceutical company update august appoint leadership team work partner extend capacity scope tre cantos facility create open collaborative way work provide facility support network need visit scientist form drug discovery project team gsk scientist healthcare service seek partner government stakeholder help strengthen healthcare infrastructure service update august reinvestment initiative gsk support government ldc address priority healthcare challenge remove barrier quality healthcare strengthen health infrastructure achieve targeted partnership increase access essential medicine basic healthcare service work begin end ldc gsk region east africa southern africa anglophone west africa francophone west central africa expand maternal child health activity specific focus child integrate management childhood illness programme additional ldc pilot new child family wellness cfw model cfw micro franchising model involve build network micro pharmacy clinic improve access essential medicine basic healthcare prevention service child family work use business model maintain standard readily scalable achieve economy scale gsk currently work ngo healthstore foundation implement model kenya run viability study ldc east africa select country implement initiative july announce new commitment fight hivaids subsaharan africa special focus care treatment child include million seed funding support public private partnership research development new hivaids medicine child commitment seek collaboration company develop fixeddose antiretroviral combination creation positive action child fund work main industry association new initiative increase rd improve access outcome activity announcement january grant million international federation pharmaceutical manufacturer association ifpma special programme research train tropical disease tdr cosponsor unicef undp world bank grant support tdrs development new medicine combat disease disproportionately affect poor people live develop country activity include plan establish pilot industry consortium focus develop new target molecule prevent interrupt disease progression disease develop world update august april announce intention combine gsk pfizer hiv business create new company dedicate discovery delivery hiv treatment combine business create specialist unit sustainable broad scope company individual business new company particularly look improve treatment formulation child live hiv continue offer hiv medicine notforprofit price world poor country issue new voluntary licence diversify production expand capacity market new company responsible delivering commitment announce gsk july home responsibility access medicine future corporate responsibility report future increase access medicine global challenge encourage progress area significant problem remain new issue likely emerge example continue need significant scaleup treatment hivaids subsaharan africa resource poor setting potential global flu pandemic healthcare need poor people middleincome country grow impact noncommunicable disease diabete poor rich country death million child year vaccinepreventable disease implement programme number area help address challenge intellectual property explore way flexible intellectual property right relate neglect disease include explore idea patent pool believe speed development new medicine encourage pharmaceutical company adopt similar approach update august march launch ldc neglect tropical disease patent pool website enable interested stakeholder access list gsk patent filing small molecule pharmaceutical treatment neglect tropical disease ntd organisation apply licence area develop treatment request licence research develop treatment ntd gsk patent technology small molecule currently develop help problem arise research development small molecule therapeutic treat ntds develop country july biotechnology group alnylam company follow gsk contribute patent pool pricing improve transparency pricing policy implement new pricing policy develop country continue evolve new approach increase affordability middle income country update august april implement price reduction patent product develop country ldc commitment gsk patent product country cost cent price reference develop country reduce price seven patent brand individual product line formulation average cent country price reduce immediately regulatory process need obtain government authorisation price reduction process initiated cut price nonldc markets east africa francophone west africa reduce risk product divert ldc sell wealthy country reduce availability ldc research evaluate opportunity expand tre canto disease develop world research centre worldclass global centre excellence encourage partnership government ngos pharmaceutical company update august appoint leadership team work partner extend capacity scope tre cantos facility create open collaborative way work provide facility support network need visit scientist form drug discovery project team gsk scientist healthcare service seek partner government stakeholder help strengthen healthcare infrastructure service update august reinvestment initiative gsk support government ldc address priority healthcare challenge remove barrier quality healthcare strengthen health infrastructure achieve targeted partnership increase access essential medicine basic healthcare service work begin end ldc gsk region east africa southern africa anglophone west africa francophone west central africa expand maternal child health activity specific focus child integrate management childhood illness programme additional ldc pilot new child family wellness cfw model cfw micro franchising model involve build network micro pharmacy clinic improve access essential medicine basic healthcare prevention service child family work use business model maintain standard readily scalable achieve economy scale gsk currently work ngo healthstore foundation implement model kenya run viability study ldc east africa select country implement initiative july announce new commitment fight hivaids subsaharan africa special focus care treatment child include million seed funding support public private partnership research development new hivaids medicine child commitment seek collaboration company develop fixeddose antiretroviral combination creation positive action child fund work main industry association new initiative increase rd improve access outcome activity announcement january grant million international federation pharmaceutical manufacturer association ifpma special programme research train tropical disease tdr cosponsor unicef undp world bank grant support tdrs development new medicine combat disease disproportionately affect poor people live develop country activity include plan establish pilot industry consortium focus develop new target molecule prevent interrupt disease progression disease develop world update august april announce intention combine gsk pfizer hiv business create new company dedicate discovery delivery hiv treatment combine business create specialist unit sustainable broad scope company individual business new company particularly look improve treatment formulation child live hiv continue offer hiv medicine notforprofit price world poor country issue new voluntary licence diversify production expand capacity market new company responsible delivering commitment announce gsk july home responsibility access medicine response assurance recommendation corporate responsibility report response assurance recommendation bureau verita assure access medicine section cr report detail page recommendation improve report access medicine key area report challenge respond vision gsk enhance communicate overall vision strategy access medicine demonstrate holistic longterm approach articulate business case provide context explain integrate overall business strategy gsk response june gsk publish face challenge summarise approach contribution improve access medicine principle underlie approach andrew witty assumed position ceo gsk instigate review approach access medicine major speech harvard university february andrew witty set approach improve access medicine develop world initiative implement governance gsk provide great detail governance accountability management structure access medicine relationship external stakeholder gsk response abbas hussain president emerge market gsk lead access effort review corporate executive team gsk senior management team corporate responsibility committee board continue engage stakeholder access issue include atm index participate development report gsk approach paul hunt un special rapporteur right health transparency gsk provide significant information case study consider provide great transparency impact access medicine initiative context relation overall operating model gsk response assess impact access medicine programme challenge report datum number tablet ship preferential pricing programme voluntary licence agreement difficult translate figure number patient receive treatment involve healthcare delivery medicine combination medicine supply pharmaceutical company simply convert shipment patient number mislead accelerate access initiative aai publicprivate partnership work combat hivaid calculate treatment rate medicine supply rdbased pharmaceutical company involve partnership estimate december patient develop country receive arv treatment supply company able generate robust data impact programme seek example october significant datum lymphatic filariasis lf elimination programme publish public library science plos journal neglect tropical disease study find year gsk commitment lf elimination programme prevent million child acquire lf stop million infected people progress debilitate stage result fastestgrowe drug administration programme public health history deliver study call good buy public health measuring performance link transparency gsk consider provide relevant indicator demonstrate implementation longterm strategy promote comparison industry gsk response welcome comparison industry performance access mpeadgiec ine osf approach differ significantly company make meaningful comparison challenge right company right method rank company approach access medicine develop access medicine index gsk rank access medicine index publish index rate company accord performance criterion management influence research development patenting capacity pricing drug donation philanthropy pleased effort medicine available recognise index additionally ask paul hunt un special rapporteur right health contribute report prepare gsk approach access medicine cooperate fully number senior executive include ceo dr jp garni chairman sir christopher gent interviewed expect report publish half wwwplosntdsorgarticleinfodoijournalpntdhome responsibility access medicine response assurance recommendation corporate responsibility report response assurance recommendation bureau verita assure access medicine section cr report detail page recommendation improve report access medicine key area report challenge respond vision gsk enhance communicate overall vision strategy access medicine demonstrate holistic longterm approach articulate business case provide context explain integrate overall business strategy gsk response june gsk publish face challenge summarise approach contribution improve access medicine principle underlie approach andrew witty assumed position ceo gsk instigate review approach access medicine major speech harvard university february andrew witty set approach improve access medicine develop world initiative implement governance gsk provide great detail governance accountability management structure access medicine relationship external stakeholder gsk response abbas hussain president emerge market gsk lead access effort review corporate executive team gsk senior management team corporate responsibility committee board continue engage stakeholder access issue include atm index participate development report gsk approach paul hunt un special rapporteur right health transparency gsk provide significant information case study consider provide great transparency impact access medicine initiative context relation overall operating model gsk response assess impact access medicine programme challenge report datum number tablet ship preferential pricing programme voluntary licence agreement difficult translate figure number patient receive treatment involve healthcare delivery medicine combination medicine supply pharmaceutical company simply convert shipment patient number mislead accelerate access initiative aai publicprivate partnership work combat hivaid calculate treatment rate medicine supply rdbased pharmaceutical company involve partnership estimate december patient develop country receive arv treatment supply company able generate robust data impact programme seek example october significant datum lymphatic filariasis lf elimination programme publish public library science plos journal neglect tropical disease study find year gsk commitment lf elimination programme prevent million child acquire lf stop million infected people progress debilitate stage result fastestgrowe drug administration programme public health history deliver study call good buy public health measuring performance link transparency gsk consider provide relevant indicator demonstrate implementation longterm strategy promote comparison industry gsk response welcome comparison industry performance access medicine approach differ significantly company make meaningful comparison challenge right company right method rank company approach access medicine develop access medicine index gsk rank access medicine index publish index rate company accord performance criterion management influence research development patenting capacity pricing drug donation philanthropy pleased effort medicine available recognise index additionally ask paul hunt un special rapporteur right health contribute report prepare gsk approach access medicine cooperate fully number senior executive include ceo dr jp garni chairman sir christopher gent interviewed expect report publish half wwwplosntdsorgarticleinfodoijournalpntd home responsibility access medicine response assurance recommendation corporate responsibility report response assurance recommendation bureau verita assure access medicine section cr report detail page recommendation improve report access medicine key area report challenge respond vision gsk enhance communicate overall vision strategy access medicine demonstrate holistic longterm approach articulate business case provide context explain integrate overall business strategy gsk response june gsk publish face challenge summarise approach contribution improve access medicine principle underlie approach andrew witty assumed position ceo gsk instigate review approach access medicine major speech harvard university february andrew witty set approach improve access medicine develop world initiative implement governance gsk provide great detail governance accountability management structure access medicine relationship external stakeholder gsk response abbas hussain president emerge market gsk lead access effort review corporate executive team gsk senior management team corporate responsibility committee board continue engage stakeholder access issue include atm index participate development report gsk approach paul hunt un special rapporteur right health transparency gsk provide significant information case study consider provide great transparency impact access medicine initiative context relation overall operating model gsk response assess impact access medicine programme challenge report datum number tablet ship preferential pricing programme voluntary licence agreement difficult translate figure number patient receive treatment involve healthcare delivery medicine combination medicine supply pharmaceutical company simply convert shipment patient number mislead accelerate access initiative aai publicprivate partnership work combat hivaid calculate treatment rate medicine supply rdbased pharmaceutical company involve partnership estimate december patient develop country receive arv treatment supply company able generate robust data impact programme seek example october significant datum lymphatic filariasis lf elimination programme publish public library science plos journal neglect tropical disease study find year gsk commitment lf elimination programme prevent million child acquire lf stop million infected people progress debilitate stage result fastestgrowe drug administration programme public health history deliver study call good buy public health measuring performance link transparency gsk consider provide relevant indicator demonstrate implementation longterm strategy promote comparison industry gsk response welcome comparison industry performance access medicine approach differ significantly company make meaningful comparison challenge right company right method rank company approach access medicine develop access medicine index gsk rank access medicine index publish index rate company accord performance criterion management influence research development patenting capacity pricing drug donation philanthropy pleased effort medicine available recognise index additionally ask paul hunt un special rapporteur right health contribute report prepare gsk approach access medicine cooperate fully number senior executive include ceo dr jp garni chairman sir christopher gent interviewed expect report publish half wwwplosntdsorgarticleinfodoijournalpntd home responsibility access medicine case study corporate responsibility report case study potential malaria vaccine malaria kill million people year worldwide make million sick child live subsaharan africa international community urgently need safe effective vaccine control disease vaccine partially effective profile necessary component comprehensive malaria control programme potentially save hundred thousand life year malaria vaccine candidate rtss clinically advanced malaria vaccine candidate world discovery gsk scientist gsk invest million resource progress rtss phase lll trial set clinical trial successful vaccine candidate year involve volunteer cost million vaccine candidate survive rigorous process reason pharmaceutical research development expensive create malaria vaccine young child pregnant woman important vaccinedevelopment challenge today exception january gsk mvi path malaria vaccine initiative support bill melinda gates foundation enter publicprivate partnership develop rtssbase vaccine infant child live malaria endemic region subsaharan africa clinical development rtss conduct clinical trial partnership committee collaboration lead african research institutes northern academic partner mvi gsk support malaria clinical trial alliance date gsk invest million resource develop vaccine december new england journal medicine publish result separate study demonstrate malaria vaccine candidate provide infant child significant protection malaria infant datum show time vaccine candidate administer exist african immunisation programme child age seventeen month candidate rtssa reduce risk clinical episode cent eightmonth followup period rtss enter pivotal phase lll study world large malaria vaccine trial date involve participant centre africa place trials limited healthcare infrastructure partner help set clinic seven african country train doctor nurse laboratory staff hope infrastructure remain long trial complete update august phase iii trial rtss malaria vaccine candidate start bagamoyo tanzania child need vaccine poor world price barrier access work supply organisation gavi unicef ensure price set right level commit work international community mobilise resource fund vaccine infrastructure need deliver abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infant n engl j med bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old child n engl j me extend product portfolio develop world low middle income country july gsk enter partnership south african pharmaceutical company aspen line aim grow diversified business operate way adapt patient need low middleincome market aspen product portfolio cover broad range therapy area relevant disease profile develop country include analgesic pain relief antihypertensive high blood pressure bronchodilator treatment asthma antibacterial antigout agent antiinflammatory agent antidepressant antifungal agent antihistamine treatment allergy decongestant gastrointestinal agent dermatological treat skin condition gain access aspen current portfolio future pipeline gsk distribute product medicine need low middleincome country longterm nature collaboration initially tenyear period underline gsk philosophy invest meaningful sustainable manner develop world january announce agreement ucb sa acquire current market product portfolio certain territory africa middle east asia pacific latin america result agreement gsk acquire lead pharmaceutical brand number disease area include keppra treatment epilepsy xyzal zyrtec treatment allergic rhinitis aspen partnership ucb deal sit alongside recent acquisition bristol myers squibb mature pharmaceutical business egypt pakistan associated manufacturing facility deal provide gsk access renewable highquality competitively price pipeline brand pharmaceutical product complement exist portfolio product help drive patient access low middleincome market gsk vaccine eliminate hib meningitis public concern uganda national fouryear immunisation programme gsk tritanrixhb hib vaccine eliminate hib meningitis public health concern uganda accord global alliance vaccine immunisations gavi hib meningitis dangerous inflammation lining brain spinal cord gavi publicprivate partnership include world health organization world bank support bill melinda gates foundation say use tritanrixhb hib reduce number incidence disease ugandan child zero news follow similar result bangladesh kenya chile gambia britain vaccine show cut number case hib meningitis cent tofive year period julian loblevyt executive director gavi say result extremely positive applaud true success control deadly disease claim life say develop country largely eliminate disease hib vaccine distribution slow poor part world financial logistical problem limited awareness disease uganda government obtain gavi support use million dose vaccine give protection hib diphtheria pertussis tetanus hepatitis b accord study publish bulletin world health organization vaccination programme uganda prevent case severe hib disease child death year introduction hib vaccine completely change epidemiology bacterial meningitis uganda say adeodata kekitiinwa paediatrician kampala mulago hospital coauthored study hib kill child age year link million case illness result longterm effect deafness paralysis mental retardation learning disability gavi say child hib meningitis develop country think hibrelate pneumonia preventable vaccination gsk press release march home responsibility access medicine case study corporate responsibility report case study potential malaria vaccine malaria kill million people year worldwide make million sick child live subsaharan africa international community urgently need safe effective vaccine control disease vaccine partially effective profile necessary component comprehensive malaria control programme potentially save hundred thousand life year malaria vaccine candidate rtss clinically advanced malaria vaccine candidate world discovery gsk scientist gsk invest million resource progress rtss phase lll trial set clinical trial successful vaccine candidate year involve volunteer cost million vaccine candidate survive rigorous process reason pharmaceutical research development expensive create malaria vaccine young child pregnant woman important vaccinedevelopment challenge today exception january gsk mvi path malaria vaccine initiative support bill melinda gates foundation enter publicprivate partnership develop rtssbase vaccine infant child live malaria endemic region subsaharan africa clinical development rtss conduct clinical trial partnership committee collaboration lead african research institutes northern academic partner mvi gsk support malaria clinical trial alliance date gsk invest million resource develop vaccine december new england journal medicine publish result separate study demonstrate malaria vaccine candidate provide infant child significant protection malaria infant datum show time vaccine candidate administer exist african immunisation programme child age seventeen month candidate rtssa reduce risk clinical episode cent eightmonth followup period rtss enter pivotal phase lll study world large malaria vaccine trial date involve participant centre africa place trials limited healthcare infrastructure partner help set clinic seven african country train doctor nurse laboratory staff hope infrastructure remain long trial complete update august phase iii trial rtss malaria vaccine candidate start bagamoyo tanzania child need vaccine poor world price barrier access work supply organisation gavi unicef ensure price set right level commit work international community mobilise resource fund vaccine infrastructure need deliver abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infant n engl j med bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old child n engl j me extend product portfolio develop world low middle income country july gsk enter partnership south african pharmaceutical company aspen line aim grow diversified business operate way adapt patient need low middleincome market aspen product portfolio cover broad range therapy area relevant disease profile develop country include analgesic pain relief antihypertensive high blood pressure bronchodilator treatment asthma antibacterial antigout agent antiinflammatory agent antidepressant antifungal agent antihistamine treatment allergy decongestant gastrointestinal agent dermatological treat skin condition gain access aspen current portfolio future pipeline gsk distribute product medicine need low middleincome country longterm nature collaboration initially tenyear period underline gsk philosophy invest meaningful sustainable manner develop world january announce agreement ucb sa acquire current market product portfolio certain territory africa middle east asia pacific latin america result agreement gsk acquire lead pharmaceutical brand number disease area include keppra treatment epilepsy xyzal zyrtec treatment allergic rhinitis aspen partnership ucb deal sit alongside recent acquisition bristol myers squibb mature pharmaceutical business egypt pakistan associated manufacturing facility deal provide gsk access renewable highquality competitively price pipeline brand pharmaceutical product complement exist portfolio product help drive patient access low middleincome market gsk vaccine eliminate hib meningitis public concern uganda national fouryear immunisation programme gsk tritanrixhb hib vaccine eliminate hib meningitis public health concern uganda accord global alliance vaccine immunisations gavi hib meningitis dangerous inflammation lining brain spinal cord gavi publicprivate partnership include world health organization world bank support bill melinda gates foundation say use tritanrixhb hib reduce number incidence disease ugandan child zero news follow similar result bangladesh kenya chile gambia britain vaccine show cut number case hib meningitis cent tofive year period julian loblevyt executive director gavi say result extremely positive applaud true success control deadly disease claim life say develop country largely eliminate disease hib vaccine distribution slow poor part world financial logistical problem limited awareness disease uganda government obtain gavi support use million dose vaccine give protection hib diphtheria pertussis tetanus hepatitis b accord study publish bulletin world health organization vaccination programme uganda prevent case severe hib disease child death year introduction hib vaccine completely change epidemiology bacterial meningitis uganda say adeodata kekitiinwa paediatrician kampala mulago hospital coauthored study hib kill child age year link million case illness result longterm effect deafness paralysis mental retardation learning disability gavi say child hib meningitis develop country think hibrelate pneumonia preventable vaccination gsk press release march home responsibility access medicine case study corporate responsibility report case study potential malaria vaccine malaria kill million people year worldwide make million sick child live subsaharan africa international community urgently need safe effective vaccine control disease vaccine partially effective profile necessary component comprehensive malaria control programme potentially save hundred thousand life year malaria vaccine candidate rtss clinically advanced malaria vaccine candidate world discovery gsk scientist gsk invest million resource progress rtss phase lll trial set clinical trial successful vaccine candidate year involve volunteer cost million vaccine candidate survive rigorous process reason pharmaceutical research development expensive create malaria vaccine young child pregnant woman important vaccinedevelopment challenge today exception january gsk mvi path malaria vaccine initiative support bill melinda gates foundation enter publicprivate partnership develop rtssbase vaccine infant child live malaria endemic region subsaharan africa clinical development rtss conduct clinical trial partnership committee collaboration lead african research institutes northern academic partner mvi gsk support malaria clinical trial alliance date gsk invest million resource develop vaccine december new england journal medicine publish result separate study demonstrate malaria vaccine candidate provide infant child significant protection malaria infant datum show time vaccine candidate administer exist african immunisation programme child age seventeen month candidate rtssa reduce risk clinical episode cent eightmonth followup period rtss enter pivotal phase lll study world large malaria vaccine trial date involve participant centre africa place trials limited healthcare infrastructure partner help set clinic seven african country train doctor nurse laboratory staff hope infrastructure remain long trial complete update august phase iii trial rtss malaria vaccine candidate start bagamoyo tanzania child need vaccine poor world price barrier access work supply organisation gavi unicef ensure price set right level commit work international community mobilise resource fund vaccine infrastructure need deliver abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infant n engl j med bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old child n engl j me extend product portfolio develop world low middle income country july gsk enter partnership south african pharmaceutical company aspen line aim grow diversified business operate way adapt patient need low middleincome market aspen product portfolio cover broad range therapy area relevant disease profile develop country include analgesic pain relief antihypertensive high blood pressure bronchodilator treatment asthma antibacterial antigout agent antiinflammatory agent antidepressant antifungal agent antihistamine treatment allergy decongestant gastrointestinal agent dermatological treat skin condition gain access aspen current portfolio future pipeline gsk distribute product medicine need low middleincome country longterm nature collaboration initially tenyear period underline gsk philosophy invest meaningful sustainable manner develop world january announce agreement ucb sa acquire current market product portfolio certain territory africa middle east asia pacific latin america result agreement gsk acquire lead pharmaceutical brand number disease area include keppra treatment epilepsy xyzal zyrtec treatment allergic rhinitis aspen partnership ucb deal sit alongside recent acquisition bristol myers squibb mature pharmaceutical business egypt pakistan associated manufacturing facility deal provide gsk access renewable highquality competitively price pipeline brand pharmaceutical product complement exist portfolio product help drive patient access low middleincome market gsk vaccine eliminate hib meningitis public concern uganda national fouryear immunisation programme gsk tritanrixhb hib vaccine eliminate hib meningitis public health concern uganda accord global alliance vaccine immunisations gavi hib meningitis dangerous inflammation lining brain spinal cord gavi publicprivate partnership include world health organization world bank support bill melinda gates foundation say use tritanrixhb hib reduce number incidence disease ugandan child zero news follow similar result bangladesh kenya chile gambia britain vaccine show cut number case hib meningitis cent tofive year period julian loblevyt executive director gavi say result extremely positive applaud true success control deadly disease claim life say develop country largely eliminate disease hib vaccine distribution slow poor part world financial logistical problem limited awareness disease uganda government obtain gavi support use million dose vaccine give protection hib diphtheria pertussis tetanus hepatitis b accord study publish bulletin world health organization vaccination programme uganda prevent case severe hib disease child death year introduction hib vaccine completely change epidemiology bacterial meningitis uganda say adeodata kekitiinwa paediatrician kampala mulago hospital coauthored study hib kill child age year link million case illness result longterm effect deafness paralysis mental retardation learning disability gavi say child hib meningitis develop country think hibrelate pneumonia preventable vaccination gsk press release march home responsibility access medicine case study corporate responsibility report case study potential malaria vaccine malaria kill million people year worldwide make million sick child live subsaharan africa international community urgently need safe effective vaccine control disease vaccine partially effective profile necessary component comprehensive malaria control programme potentially save hundred thousand life year malaria vaccine candidate rtss clinically advanced malaria vaccine candidate world discovery gsk scientist gsk invest million resource progress rtss phase lll trial set clinical trial successful vaccine candidate year involve volunteer cost million vaccine candidate survive rigorous process reason pharmaceutical research development expensive create malaria vaccine young child pregnant woman important vaccinedevelopment challenge today exception january gsk mvi path malaria vaccine initiative support bill melinda gates foundation enter publicprivate partnership develop rtssbase vaccine infant child live malaria endemic region subsaharan africa clinical development rtss conduct clinical trial partnership committee collaboration lead african research institutes northern academic partner mvi gsk support malaria clinical trial alliance date gsk invest million resource develop vaccine december new england journal medicine publish result separate study demonstrate malaria vaccine candidate provide infant child significant protection malaria infant datum show time vaccine candidate administer exist african immunisation programme child age seventeen month candidate rtssa reduce risk clinical episode cent eightmonth followup period rtss enter pivotal phase lll study world large malaria vaccine trial date involve participant centre africa place trials limited healthcare infrastructure partner help set clinic seven african country train doctor nurse laboratory staff hope infrastructure remain long trial complete update august phase iii trial rtss malaria vaccine candidate start bagamoyo tanzania child need vaccine poor world price barrier access work supply organisation gavi unicef ensure price set right level commit work international community mobilise resource fund vaccine infrastructure need deliver abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infant n engl j med bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old child n engl j me extend product portfolio develop world low middle income country july gsk enter partnership south african pharmaceutical company aspen line aim grow diversified business operate way adapt patient need low middleincome market aspen product portfolio cover broad range therapy area relevant disease profile develop country include analgesic pain relief antihypertensive high blood pressure bronchodilator treatment asthma antibacterial antigout agent antiinflammatory agent antidepressant antifungal agent antihistamine treatment allergy decongestant gastrointestinal agent dermatological treat skin condition gain access aspen current portfolio future pipeline gsk distribute product medicine need low middleincome country longterm nature collaboration initially tenyear period underline gsk philosophy invest meaningful sustainable manner develop world january announce agreement ucb sa acquire current market product portfolio certain territory africa middle east asia pacific latin america result agreement gsk acquire lead pharmaceutical brand number disease area include keppra treatment epilepsy xyzal zyrtec treatment allergic rhinitis aspen partnership ucb deal sit alongside recent acquisition bristol myers squibb mature pharmaceutical business egypt pakistan associated manufacturing facility deal provide gsk access renewable highquality competitively price pipeline brand pharmaceutical product complement exist portfolio product help drive patient access low middleincome market gsk vaccine eliminate hib meningitis public concern uganda national fouryear immunisation programme gsk tritanrixhb hib vaccine eliminate hib meningitis public health concern uganda accord global alliance vaccine immunisations gavi hib meningitis dangerous inflammation lining brain spinal cord gavi publicprivate partnership include world health organization world bank support bill melinda gates foundation say use tritanrixhb hib reduce number incidence disease ugandan child zero news follow similar result bangladesh kenya chile gambia britain vaccine show cut number case hib meningitis cent tofive year period julian loblevyt executive director gavi say result extremely positive applaud true success control deadly disease claim life say develop country largely eliminate disease hib vaccine distribution slow poor part world financial logistical problem limited awareness disease uganda government obtain gavi support use million dose vaccine give protection hib diphtheria pertussis tetanus hepatitis b accord study publish bulletin world health organization vaccination programme uganda prevent case severe hib disease child death year introduction hib vaccine completely change epidemiology bacterial meningitis uganda say adeodata kekitiinwa paediatrician kampala mulago hospital coauthored study hib kill child age year link million case illness result longterm effect deafness paralysis mental retardation learning disability gavi say child hib meningitis develop country think hibrelate pneumonia preventable vaccination gsk press release march home responsibility access medicine qas corporate responsibility report qas respond question raise stakeholder not access programme drop ocean give scale healthcare crisis develop world global healthcare crisis extensive complex programme single organisation insufficient political effective investment extra resource require support healthcare development build infrastructure gsk wide pharmaceutical industry mandate expertise resource address problem global partnership address issue effort individual stakeholder inadequate primary responsibility deal crisis lie government international agency ngo support gsk commit play partnership organisation seek new way contribution focus access programme specific area think real difference example research develop medicine vaccine particularly need develop country available low price preferential pricing arrangement voluntary licence work identify way support strengthen healthcare system expand pricing policy flexible intellectual property investing healthcare infrastructure medicine expensive not responsible thing cut price medicine improve affordability medicine important take step area kevin de cock head hivaids say work country obvious quickly elephant room current price drug real obstacle fragility health system particularly africa action take address underlie problem poverty healthcare infrastructure reduce price solve problem price product level enable continue fund rd discover medicine vaccine future need profit gsk remain attractive prospect investor want difference cut price far mean undermine long term profitability sustainability business get balance right not easy pricing pilot conduct recent year teach easy solution believe new pricing policy announce help improve affordability world poor continue learn refine approach roll policy people hivaid receive treatment develop world important progress area million people develop world receive treatment lifesaving antiretroviral lead decline death cause aid despite increase number people live hiv core issue people develop country access effective healthcare service unable access medicine poverty clinic patient unable pay cheap basic generic medicine access issue complex multifacete pricing medicine important believe significant barrier factor play inadequate healthcare resource lack clinic hospital poor distribution network low number train healthcare provider high level patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budget announce cent profit sell medicine develop country reinveste project strengthen infrastructure widen access not donate aid product world poorest common stakeholder include oxfam believe donation arvs offer solution aids pandemic healthcare problem develop world generally widespread crisis require longterm commitment treatment commitment assure donation director general margaret chan say health system tap root well health donate drug world will not good infrastructure delivery limit circumstance donation appropriate example disease elimination effort global alliance eliminate lf past donate arvs support unicef prevention mothertochild transmission programme continue support collaborative clinical trial assess appropriate use arvs resource poor setting not gsk extend notforprofit price middleincome country middleincome country automatically eligible notforprofit price offer develop country ldc subsaharan africa access medicine reduce price middle income country secure preferential price bilateral discussion gsk look way process easy focus preferential price country need great resource limit widely accept term support improve healthcare service ldc define un subsaharan africa conduct pricing pilot middleincome country recent year teach easy solution continue develop policy middleincome country flexible price closely reflect countrys ability pay not allow middleincome country buy arvs generic manufacturer grant voluntary licence arvs african generic company arrangement supply number middleincome country africa middleincome country generally economically develop develop country large affluent middleclass country large number people live extreme poverty healthcare demand outstrip available resource recognise middleincome country need assistance believe different approach need world poor country continue refine approach offer supply product notforprofit price world poor country sustainable continue adequate return wealthy market middleincome country grow commercial market gsk represent important source future business industry response market balance commercial objective global commitment work government stakeholder ensure medicine vaccine reach possible need believe government middleincome country improve access increase investment disease prevention healthcare eliminate taxation tariff medicine create environment allow strong private healthcare sector coexist public healthcare provision work government find creative way meet goal not pharmaceutical company work increase access medicine work main industry association new initiative increase rd improve access continue seek new opportunity work collaboration stakeholder include companieshome responsibility access medicine qas corporate responsibility report qas respond question raise stakeholder not access programme drop ocean give scale healthcare crisis develop world global healthcare crisis extensive complex programme single organisation insufficient political effective investment extra resource require support healthcare development build infrastructure gsk wide pharmaceutical industry mandate expertise resource address problem global partnership address issue effort individual stakeholder inadequate primary responsibility deal crisis lie government international agency ngo support gsk commit play partnership organisation seek new way contribution focus access programme specific area think real difference example research develop medicine vaccine particularly need develop country available low price preferential pricing arrangement voluntary licence work identify way support strengthen healthcare system expand pricing policy flexible intellectual property investing healthcare infrastructure medicine expensive not responsible thing cut price medicine improve affordability medicine important take step area kevin de cock head hivaids say work country obvious quickly elephant room current price drug real obstacle fragility health system particularly africa action take address underlie problem poverty healthcare infrastructure reduce price solve problem price product level enable continue fund rd discover medicine vaccine future need profit gsk remain attractive prospect investor want difference cut price far mean undermine long term profitability sustainability business get balance right not easy pricing pilot conduct recent year teach easy solution believe new pricing policy announce help improve affordability world poor continue learn refine approach roll policy people hivaid receive treatment develop world important progress area million people develop world receive treatment lifesaving antiretroviral lead decline death cause aid despite increase number people live hiv core issue people develop country access effective healthcare service unable access medicine poverty clinic patient unable pay cheap basic generic medicine access issue complex multifacete pricing medicine important believe significant barrier factor play inadequate healthcare resource lack clinic hospital poor distribution network low number train healthcare provider high level patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budget announce cent profit sell medicine develop country reinveste project strengthen infrastructure widen access not donate aid product world poorest common stakeholder include oxfam believe donation arvs offer solution aids pandemic healthcare problem develop world generally widespread crisis require longterm commitment treatment commitment assure donation director general margaret chan say health system tap root well health donate drug world will not good infrastructure delivery limit circumstance donation appropriate example disease elimination effort global alliance eliminate lf past donate arvs support unicef prevention mothertochild transmission programme continue support collaborative clinical trial assess appropriate use arvs resource poor setting not gsk extend notforprofit price middleincome country middleincome country automatically eligible notforprofit price offer develop country ldc subsaharan africa access medicine reduce price middle income country secure preferential price bilateral discussion gsk look way process easy focus preferential price country need great resource limit widely accept term support improve healthcare service ldc define un subsaharan africa conduct pricing pilot middleincome country recent year teach easy solution continue develop policy middleincome country flexible price closely reflect countrys ability pay not allow middleincome country buy arvs generic manufacturer grant voluntary licence arvs african generic company arrangement supply number middleincome country africa middleincome country generally economically develop develop country large affluent middleclass country large number people live extreme poverty healthcare demand outstrip available resource recognise middleincome country need assistance believe different approach need world poor country continue refine approach offer supply product notforprofit price world poor country sustainable continue adequate return wealthy market middleincome country grow commercial market gsk represent important source future business industry response market balance commercial objective global commitment work government stakeholder ensure medicine vaccine reach possible need believe government middleincome country improve access increase investment disease prevention healthcare eliminate taxation tariff medicine create environment allow strong private healthcare sector coexist public healthcare provision work government find creative way meet goal not pharmaceutical company work increase access medicine work main industry association new initiative increase rd improve access continue seek new opportunity work collaboration stakeholder include company home responsibility access medicine qas corporate responsibility report qas respond question raise stakeholder not access programme drop ocean give scale healthcare crisis develop world global healthcare crisis extensive complex programme single organisation insufficient political effective investment extra resource require support healthcare development build infrastructure gsk wide pharmaceutical industry mandate expertise resource address problem global partnership address issue effort individual stakeholder inadequate primary responsibility deal crisis lie government international agency ngo support gsk commit play partnership organisation seek new way contribution focus access programme specific area think real difference example research develop medicine vaccine particularly need develop country available low price preferential pricing arrangement voluntary licence work identify way support strengthen healthcare system expand pricing policy flexible intellectual property investing healthcare infrastructure medicine expensive not responsible thing cut price medicine improve affordability medicine important take step area kevin de cock head hivaids say work country obvious quickly elephant room current price drug real obstacle fragility health system particularly africa action take address underlie problem poverty healthcare infrastructure reduce price solve problem price product level enable continue fund rd discover medicine vaccine future need profit gsk remain attractive prospect investor want difference cut price far mean undermine long term profitability sustainability business get balance right not easy pricing pilot conduct recent year teach easy solution believe new pricing policy announce help improve affordability world poor continue learn refine approach roll policy people hivaid receive treatment develop world important progress area million people develop world receive treatment lifesaving antiretroviral lead decline death cause aid despite increase number people live hiv core issue people develop country access effective healthcare service unable access medicine poverty clinic patient unable pay cheap basic generic medicine access issue complex multifacete pricing medicine important believe significant barrier factor play inadequate healthcare resource lack clinic hospital poor distribution network low number train healthcare provider high level patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budget announce cent profit sell medicine develop country reinveste project strengthen infrastructure widen access not donate aid product world poorest common stakeholder include oxfam believe donation arvs offer solution aids pandemic healthcare problem develop world generally widespread crisis require longterm commitment treatment commitment assure donation director general margaret chan say health system tap root well health donate drug world will not good infrastructure delivery limit circumstance donation appropriate example disease elimination effort global alliance eliminate lf past donate arvs support unicef prevention mothertochild transmission programme continue support collaborative clinical trial assess appropriate use arvs resource poor setting not gsk extend notforprofit price middleincome country middleincome country automatically eligible notforprofit price offer develop country ldc subsaharan africa access medicine reduce price middle income country secure preferential price bilateral discussion gsk look way process easy focus preferential price country need great resource limit widely accept term support improve healthcare service ldc define un subsaharan africa conduct pricing pilot middleincome country recent year teach easy solution continue develop policy middleincome country flexible price closely reflect countrys ability pay not allow middleincome country buy arvs generic manufacturer grant voluntary licence arvs african generic company arrangement supply number middleincome country africa middleincome country generally economically develop develop country large affluent middleclass country large number people live extreme poverty healthcare demand outstrip available resource recognise middleincome country need assistance believe different approach need world poor country continue refine approach offer supply product notforprofit price world poor country sustainable continue adequate return wealthy market middleincome country grow commercial market gsk represent important source future business industry response market balance commercial objective global commitment work government stakeholder ensure medicine vaccine reach possible need believe government middleincome country improve access increase investment disease prevention healthcare eliminate taxation tariff medicine create environment allow strong private healthcare sector coexist public healthcare provision work government find creative way meet goal not pharmaceutical company work increase access medicine work main industry association new initiative increase rd improve access continue seek new opportunity work collaboration stakeholder include company home responsibility access medicine qas corporate responsibility report qas respond question raise stakeholder not access programme drop ocean give scale healthcare crisis develop world global healthcare crisis extensive complex programme single organisation insufficient political effective investment extra resource require support healthcare development build infrastructure gsk wide pharmaceutical industry mandate expertise resource address problem global partnership address issue effort individual stakeholder inadequate primary responsibility deal crisis lie government international agency ngo support gsk commit play partnership organisation seek new way contribution focus access programme specific area think real difference example research develop medicine vaccine particularly need develop country available low price preferential pricing arrangement voluntary licence work identify way support strengthen healthcare system expand pricing policy flexible intellectual property investing healthcare infrastructure medicine expensive not responsible thing cut price medicine improve affordability medicine important take step area kevin de cock head hivaids say work country obvious quickly elephant room current price drug real obstacle fragility health system particularly africa action take address underlie problem poverty healthcare infrastructure reduce price solve problem price product level enable continue fund rd discover medicine vaccine future need profit gsk remain attractive prospect investor want difference cut price far mean undermine long term profitability sustainability business get balance right not easy pricing pilot conduct recent year teach easy solution believe new pricing policy announce help improve affordability world poor continue learn refine approach roll policy people hivaid receive treatment develop world important progress area million people develop world receive treatment lifesaving antiretroviral lead decline death cause aid despite increase number people live hiv core issue people develop country access effective healthcare service unable access medicine poverty clinic patient unable pay cheap basic generic medicine access issue complex multifacete pricing medicine important believe significant barrier factor play inadequate healthcare resource lack clinic hospital poor distribution network low number train healthcare provider high level patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budget announce cent profit sell medicine develop country reinveste project strengthen infrastructure widen access not donate aid product world poorest common stakeholder include oxfam believe donation arvs offer solution aids pandemic healthcare problem develop world generally widespread crisis require longterm commitment treatment commitment assure donation director general margaret chan say health system tap root well health donate drug world will not good infrastructure delivery limit circumstance donation appropriate example disease elimination effort global alliance eliminate lf past donate arvs support unicef prevention mothertochild transmission programme continue support collaborative clinical trial assess appropriate use arvs resource poor setting not gsk extend notforprofit price middleincome country middleincome country automatically eligible notforprofit price offer develop country ldc subsaharan africa access medicine reduce price middle income country secure preferential price bilateral discussion gsk look way process easy focus preferential price country need great resource limit widely accept term support improve healthcare service ldc define un subsaharan africa conduct pricing pilot middleincome country recent year teach easy solution continue develop policy middleincome country flexible price closely reflect countrys ability pay not allow middleincome country buy arvs generic manufacturer grant voluntary licence arvs african generic company arrangement supply number middleincome country africa middleincome country generally economically develop develop country large affluent middleclass country large number people live extreme poverty healthcare demand outstrip available resource recognise middleincome country need assistance believe different approach need world poor country continue refine approach offer supply product notforprofit price world poor country sustainable continue adequate return wealthy market middleincome country grow commercial market gsk represent important source future business industry response market balance commercial objective global commitment work government stakeholder ensure medicine vaccine reach possible need believe government middleincome country improve access increase investment disease prevention healthcare eliminate taxation tariff medicine create environment allow strong private healthcare sector coexist public healthcare provision work government find creative way meet goal not pharmaceutical company work increase access medicine work main industry association new initiative increase rd improve access continue seek new opportunity work collaboration stakeholder include company home responsibility research practice corporate responsibility report research practice commit focus patient rd pipeline central ability meet patient need high ethical standard rd key protect participant clinical research ensure quality research maximise benefit minimise risk product high ethical standard essential obtain regulatory approval new medicine patient doctor trust research programme product aim medicine safe possible evaluate risk benefit stage initial research clinical trial new product approve sale commit high level transparency result clinical research use number reporting channel evaluate efficacy safety medicine use medicine informed decision use recognise biomedical research raise ethical concern include use emerge technology cloning use stem cell animal research storage use human tissue protection personal information research participant participate discussion research practice regularly engage academic scientist regulator policy maker stakeholder relate issue home responsibility research practice corporate responsibility report research practice commit focus patient rd pipeline central ability meet patient need high ethical standard rd key protect participant clinical research ensure quality research maximise benefit minimise risk product high ethical standard essential obtain regulatory approval new medicine patient doctor trust research programme product aim medicine safe possible evaluate risk benefit stage initial research clinical trial new product approve sale commit high level transparency result clinical research use number reporting channel evaluate efficacy safety medicine use medicine informed decision use recognise biomedical research raise ethical concern include use emerge technology cloning use stem cell animal research storage use human tissue protection personal information research participant participate discussion research practice regularly engage academic scientist regulator policy maker stakeholder relate issue home responsibility research practice emerge technology corporate responsibility report emerge technology research capability expand development technology relate area research stem cell genetic research advance help expand boundary scientific understanding technology hold hope new way treat disease well way evaluate risk benefit medicine develop example advance genetic research beginning enable identification patient likely experience effect medicine use emerge technology research involve collaborative research technology recognise research emerge technology rise ethical concern outline involvement approach use cloning technology use stem cell genetic research collaborative research emerge technology use transgenic animal home responsibility research practice emerge technology corporate responsibility report emerge technology research capability expand development technology relate area research stem cell genetic research advance help expand boundary scientific understanding technology hold hope new way treat disease well way evaluate risk benefit medicine develop example advance genetic research begin enable identification patient likely experience effect medicine use emerge technology research involve collaborative research technology recognise research emerge technology rise ethical concern outline involvement approach use cloning technology use stem cell genetic research collaborative research emerge technology use transgenic animal home responsibility research practice emerge technology clone technology stem cell research corporate responsibility report clone technology stem cell research cloning technology gsk use cloning technology replicate molecule cell research technology provide well way evaluate compound enable great insight risk benefit potential medicine helping create well medicine patient technology fundamental component medicine discovery development gsk clone animal use cloning technology intention reproduce entire human being medical research case read position statement cloning technology stem cell research stem cell research recognise importance clear approach stem cell research standard apply area research update publish approach stem cell research set standard apply stem cell include embryonic foetal stem cell begin fiveyear collaboration harvard stem cell institute hsci include million investment support research harvard university number affiliate hospital area neuroscience heart disease cancer diabete musculoskeletal disease obesity collaboration oversee joint steering committee hsci gsk scientist manager found member stem cell safe medicine scsm initiative uk scsm aim develop bank human cell line early medicine discovery provide early identification elimination potential toxicity issue clinical testing number public sector organisation contribute initiative include department health department innovation university skill scottish government medical research council biotechnology biological sciences research council independent ethic review board establish review scsm ethic policy read collaborate research emerge technology home responsibility research practice emerge technology clone technology stem cell research corporate responsibility report clone technology stem cell research cloning technology gsk use cloning technology replicate molecule cell research technology provide well way evaluate compound enable great insight risk benefit potential medicine helping create well medicine patient technology fundamental component medicine discovery development gsk clone animal use cloning technology intention reproduce entire human being medical research case read position statement cloning technology stem cell research stem cell research recognise importance clear approach stem cell research standard apply area research update publish approach stem cell research set standard apply stem cell include embryonic foetal stem cell begin fiveyear collaboration harvard stem cell institute hsci include million investment support research harvard university number affiliate hospital area neuroscience heart disease cancer diabete musculoskeletal disease obesity collaboration oversee joint steering committee hsci gsk scientist manager found member stem cell safe medicine scsm initiative uk scsm aim develop bank human cell line early medicine discovery provide early identification elimination potential toxicity issue clinical testing number public sector organisation contribute initiative include department health department innovation university skill scottish government medical research council biotechnology biological sciences research council independent ethic review board establish review scsm ethic policy read collaborate research emerge technology home responsibility research practice emerge technology genetic research corporate responsibility report genetic research genetic variation underpin aspect human health people certain disease age disease manifest fast progress year gene identify common human disease cumulative history genetic research disease genetic risk factor identify include diabete heart disease obesity cancer asthma number autoimmune disorder gsk researcher lead contribute substantially finding discovery come offer promise development innovative new medicine individual difference gene affect people respond medicine difference gene explain patient experience adverse response certain medicine enjoy benefit effect individual require great dose medicine achieve level efficacy group individual respond treatment gsk scientist emerge genetic information study medicine differentiate suit group patient different genetic characteristic successful genetic research require close collaboration organisation different area expertise engage number research project involve academic partner regulatory agency pharmaceutical company read involvement adverse event consortium saec collaboration recognise people concern application standard genetic research aim address concern transparent conduct genetic research genetic analysis gsk clinical trial undertake seek obtain informed consent patient procedure include provide information purpose scope research access genetic research datum believe pharmaceutical industry share responsibility government helping identify develop policy genetic research refer guidance national international group inform genetic research activity european medicine evaluation agency food drug administration council international organisation medical sciences home responsibility research practice emerge technology genetic research corporate responsibility report genetic research genetic variation underpin aspect human health people certain disease age disease manifest fast progress year gene identify common human disease cumulative history genetic research disease genetic risk factor identify include diabete heart disease obesity cancer asthma number autoimmune disorder gsk researcher led contribute substantially finding discovery come offer promise development innovative new medicine individual difference gene affect people respond medicine difference gene explain patient experience adverse response certain medicine enjoy benefit effect individual require great dose medicine achieve level efficacy group individual respond treatment gsk scientist emerge genetic information study medicine differentiate suit group patient different genetic characteristic successful genetic research require close collaboration organisation different area expertise engage number research project involve academic partner regulatory agency pharmaceutical company read involvement adverse event consortium saec collaboration recognise people concern application standard genetic research aim address concern transparent conduct genetic research genetic analysis gsk clinical trial undertake seek obtain informed consent patient procedure include provide information purpose scope research access genetic research datum believe pharmaceutical industry share responsibility government helping identify develop policy genetic research refer guidance national international group inform genetic research activity european medicine evaluation agency food drug administration council international organisation medical sciences home responsibility research practice emerge technology collaborative research emerge technology corporate responsibility report collaborative research emerge technology new scientific knowledge technology develop application medicine discovery development collaborative research combine resource expertise knowhow partner benefit research realise make result widely available research community example active participant innovative medicine initiative imi publicprivate partnership set european commission pharmaceutical industry european federation pharmaceutical industry association efpia imi support stimulate collaborative research europe involve pharmaceutical company small bioscience company academia regulator patient group aim remove barrier discovery development new medicine read investment rd new technology partnership academic collaboration home responsibility research practice emerge technology collaborative research emerge technology corporate responsibility report collaborative research emerge technology new scientific knowledge technology develop application medicine discovery development collaborative research combine resource expertise knowhow partner benefit research realise make result widely available research community example active participant innovative medicine initiative imi publicprivate partnership set european commission pharmaceutical industry european federation pharmaceutical industry association efpia imi support stimulate collaborative research europe involve pharmaceutical company small bioscience company academia regulator patient group aim remove barrier discovery development new medicine read investment rd new technology partnership academic collaboration home responsibility research practice animal research corporate responsibility report animal research approach performance plan animal study remain small vital researchthey method demonstrate effect potential new medicine living body human addition research animal provide vital information cause disease disease develop safety regulation require test new medicine animal test clinical trial human vaccine test animal time new batch produce nonmedicinal consumer health product ingredient example dietary supplement test animal specific demand regulatory authority determine study need support safe use gsk conduct animal testing nutritional healthcare product product classify cosmetic example toothpaste market european union animal necessary research commit act ethically provide animal health wellbee practise good animal welfare approach gsk animal research laboratory europe asia animal research conduct external contractor behalf represent cent total animal use estimate animal research account cent gsk research expenditure animal gsk rodent mainly rat mouse use rabbit dog non human primate fish ferret chicken pig cat sheep goat account cent list order magnitude use ultimately gsk like important benefit research achieve applied human need animal research believe achieve foreseeable future goal use animal scientifically necessary use scientifically feasible minimise pain distress gsk remain committed rs rs key aspect animal welfare cover biomedical community refer rs rs rs replace research animal nonanimal alternative specie low possible order phylogenetically reduce number animal experiment obtain information large study refining technique minimise pain distress maximise welfare animal scientist try devise experiment require animal possible researcher work design experiment obtain necessary information small number animal possible effect individual animal implement rs advanced scientific method training raise awareness share encourage good practice example use ultrasound imaging heart disease rat forum discussion global principle animal housing read recent gsk advance replace reduce refining animal use addition encourage rs culture gsk regular training staff involve care use animal review study design ethical panel consider rs alternative animal study possible prior approval study refine technique minimise pain distress maximise welfare animal internal rs website champion advance refinement reduction replacement animal use medicine discovery development promote application rd news bulletin advance rs update rolling basis easily accessible rs website internal animal welfare award employee outstanding advance implement rs nonhuman primate policy require study involve animal use low possible order phylogenetically animal appropriate research study occasionally nonhuman primate animal anatomy andor physiology disease similar human human nonhuman primate affect respond potential medicine vaccine instance new medicine base molecule produce primate include human destroy immune system specie use nonhuman primate specie low neurophysiological sensitivity appropriate common nonhuman primate specie research macaque marmoset animal research carry cent involve nonhuman primate transgenic genetically modify animal genetically modify animal know transgenic animal genetically adapt scientist create new characteristic transgenic animal cent biomedical research mice transgenic strain animal develop answer specific compound diseaserelate question medicine discovery process example transgenic mice model alzheimer disease fundamental biological research new compound development target validation use transgenic model mouse replace need study high order animal gsk worldwide standard recognise difference countryspecific regulation gsk achieve worldwide standard core principle care laboratory animal principle establish basis animal work conduct onbehalf gsk addition gsk facility external laboratory conduct research behalf follow legal regulatory requirement uk regulations responsibility home office europe animal research come directive eec cover animal welfare act continue seek voluntary accreditation recognise agency association assessment accreditation laboratory animal care international aaalaci communicating approach people hold strong view animal research testing believe important explain need animal research testing transparent laboratory host visit school college animal welfare organisation engage regularly animal welfare organisation investor contribute debate media protest accept right lawful protest animal research free society condemn use violence intimidation oppose animal use welcome shift away extremism inform debatehome responsibility research practice animal research corporate responsibility report animal research approach performance plan animal study remain small vital researchthey method demonstrate effect potential new medicine living body human addition research animal provide vital information cause disease disease develop safety regulation require test new medicine animal test clinical trial human vaccine test animal time new batch produce nonmedicinal consumer health product ingredient example dietary supplement test animal specific demand regulatory authority determine study need support safe use gsk conduct animal testing nutritional healthcare product product classify cosmetic example toothpaste market european union animal necessary research commit act ethically provide animal health wellbee practise good animal welfare approach gsk animal research laboratory europe asia animal research conduct external contractor behalf represent cent total animal use estimate animal research account cent gsk research expenditure animal gsk rodent mainly rat mouse use rabbit dog non human primate fish ferret chicken pig cat sheep goat account cent list order magnitude use ultimately gsk like important benefit research achieve applied human need animal research believe achieve foreseeable future goal use animal scientifically necessary use scientifically feasible minimise pain distress gsk remain committed rs rs key aspect animal welfare cover biomedical community refer rs rs rs replace research animal nonanimal alternative specie low possible order phylogenetically reduce number animal experiment obtain information large study refining technique minimise pain distress maximise welfare animal scientist try devise experiment require animal possible researcher work design experiment obtain necessary information small number animal possible effect individual animal implement rs advanced scientific method training raise awareness share encourage good practice example use ultrasound imaging heart disease rat forum discussion global principle animal housing read recent gsk advance replace reduce refining animal use addition encourage rs culture gsk regular training staff involve care use animal review study design ethical panel consider rs alternative animal study possible prior approval study refine technique minimise pain distress maximise welfare animal internal rs website champion advance refinement reduction replacement animal use medicine discovery development promote application rd news bulletin advance rs update rolling basis easily accessible rs website internal animal welfare award employee outstanding advance implement rs nonhuman primate policy require study involve animal use low possible order phylogenetically animal appropriate research study occasionally nonhuman primate animal anatomy andor physiology disease similar human human nonhuman primate affect respond potential medicine vaccine instance new medicine base molecule produce primate include human destroy immune system specie use nonhuman primate specie low neurophysiological sensitivity appropriate common nonhuman primate specie research macaque marmoset animal research carry cent involve nonhuman primate transgenic genetically modify animal genetically modify animal know transgenic animal genetically adapt scientist create new characteristic transgenic animal cent biomedical research mice transgenic strain animal develop answer specific compound diseaserelate question medicine discovery process example transgenic mice model alzheimer disease fundamental biological research new compound development target validation use transgenic model mouse replace need study high order animal gsk worldwide standard recognise difference countryspecific regulation gsk achieve worldwide standard core principle care laboratory animal principle establish basis animal work conduct onbehalf gsk addition gsk facility external laboratory conduct research behalf follow legal regulatory requirement uk regulations responsibility home office europe animal research come directive eec cover animal welfare act continue seek voluntary accreditation recognise agency association assessment accreditation laboratory animal care international aaalaci communicating approach people hold strong view animal research testing believe important explain need animal research testing transparent laboratory host visit school college animal welfare organisation engage regularly animal welfare organisation investor contribute debate media protest accept right lawful protest animal research free society condemn use violence intimidation oppose animal use welcome shift away extremism inform debate home responsibility research practice animal research corporate responsibility report animal research approach performance plan animal study remain small vital researchthey method demonstrate effect potential new medicine living body human addition research animal provide vital information cause disease disease develop safety regulation require test new medicine animal test clinical trial human vaccine test animal time new batch produce nonmedicinal consumer health product ingredient example dietary supplement test animal specific demand regulatory authority determine study need support safe use gsk conduct animal testing nutritional healthcare product product classify cosmetic example toothpaste market european union animal necessary research commit act ethically provide animal health wellbee practise good animal welfare approach gsk animal research laboratory europe asia animal research conduct external contractor behalf represent cent total animal use estimate animal research account cent gsk research expenditure animal gsk rodent mainly rat mouse use rabbit dog non human primate fish ferret chicken pig cat sheep goat account cent list order magnitude use ultimately gsk like important benefit research achieve applied human need animal research believe achieve foreseeable future goal use animal scientifically necessary use scientifically feasible minimise pain distress gsk remain committed rs rs key aspect animal welfare cover biomedical community refer rs rs rs replace research animal nonanimal alternative specie low possible order phylogenetically reduce number animal experiment obtain information large study refining technique minimise pain distress maximise welfare animal scientist try devise experiment require animal possible researcher work design experiment obtain necessary information small number animal possible effect individual animal implement rs advanced scientific method training raise awareness share encourage good practice example use ultrasound imaging heart disease rat forum discussion global principle animal housing read recent gsk advance replace reduce refining animal use addition encourage rs culture gsk regular training staff involve care use animal review study design ethical panel consider rs alternative animal study possible prior approval study refine technique minimise pain distress maximise welfare animal internal rs website champion advance refinement reduction replacement animal use medicine discovery development promote application rd news bulletin advance rs update rolling basis easily accessible rs website internal animal welfare award employee outstanding advance implement rs nonhuman primate policy require study involve animal use low possible order phylogenetically animal appropriate research study occasionally nonhuman primate animal anatomy andor physiology disease similar human human nonhuman primate affect respond potential medicine vaccine instance new medicine base molecule produce primate include human destroy immune system specie use nonhuman primate specie low neurophysiological sensitivity appropriate common nonhuman primate specie research macaque marmoset animal research carry cent involve nonhuman primate transgenic genetically modify animal genetically modify animal know transgenic animal genetically adapt scientist create new characteristic transgenic animal cent biomedical research mice transgenic strain animal develop answer specific compound diseaserelate question medicine discovery process example transgenic mice model alzheimer disease fundamental biological research new compound development target validation use transgenic model mouse replace need study high order animal gsk worldwide standard recognise difference countryspecific regulation gsk achieve worldwide standard core principle care laboratory animal principle establish basis animal work conduct onbehalf gsk addition gsk facility external laboratory conduct research behalf follow legal regulatory requirement uk regulations responsibility home office europe animal research come directive eec cover animal welfare act continue seek voluntary accreditation recognise agency association assessment accreditation laboratory animal care international aaalaci communicating approach people hold strong view animal research testing believe important explain need animal research testing transparent laboratory host visit school college animal welfare organisation engage regularly animal welfare organisation investor contribute debate media protest accept right lawful protest animal research free society condemn use violence intimidation oppose animal use welcome shift away extremism inform debate home responsibility research practice animal research corporate responsibility report animal research approach performance plan animal study remain small vital researchthey method demonstrate effect potential new medicine living body human addition research animal provide vital information cause disease disease develop safety regulation require test new medicine animal test clinical trial human vaccine test animal time new batch produce nonmedicinal consumer health product ingredient example dietary supplement test animal specific demand regulatory authority determine study need support safe use gsk conduct animal testing nutritional healthcare product product classify cosmetic example toothpaste market european union animal necessary research commit act ethically provide animal health wellbee practise good animal welfare approach gsk animal research laboratory europe asia animal research conduct external contractor behalf represent cent total animal use estimate animal research account cent gsk research expenditure animal gsk rodent mainly rat mouse use rabbit dog non human primate fish ferret chicken pig cat sheep goat account cent list order magnitude use ultimately gsk like important benefit research achieve applied human need animal research believe achieve foreseeable future goal use animal scientifically necessary use scientifically feasible minimise pain distress gsk remain committed rs rs key aspect animal welfare cover biomedical community refer rs rs rs replace research animal nonanimal alternative specie low possible order phylogenetically reduce number animal experiment obtain information large study refining technique minimise pain distress maximise welfare animal scientist try devise experiment require animal possible researcher work design experiment obtain necessary information small number animal possible effect individual animal implement rs advanced scientific method training raise awareness share encourage good practice example use ultrasound imaging heart disease rat forum discussion global principle animal housing read recent gsk advance replace reduce refining animal use addition encourage rs culture gsk regular training staff involve care use animal review study design ethical panel consider rs alternative animal study possible prior approval study refine technique minimise pain distress maximise welfare animal internal rs website champion advance refinement reduction replacement animal use medicine discovery development promote application rd news bulletin advance rs update rolling basis easily accessible rs website internal animal welfare award employee outstanding advance implement rs nonhuman primate policy require study involve animal use low possible order phylogenetically animal appropriate research study occasionally nonhuman primate animal anatomy andor physiology disease similar human human nonhuman primate affect respond potential medicine vaccine instance new medicine base molecule produce primate include human destroy immune system specie use nonhuman primate specie low neurophysiological sensitivity appropriate common nonhuman primate specie research macaque marmoset animal research carry cent involve nonhuman primate transgenic genetically modify animal genetically modify animal know transgenic animal genetically adapt scientist create new characteristic transgenic animal cent biomedical research mice transgenic strain animal develop answer specific compound diseaserelate question medicine discovery process example transgenic mice model alzheimer disease fundamental biological research new compound development target validation use transgenic model mouse replace need study high order animal gsk worldwide standard recognise difference countryspecific regulation gsk achieve worldwide standard core principle care laboratory animal principle establish basis animal work conduct onbehalf gsk addition gsk facility external laboratory conduct research behalf follow legal regulatory requirement uk regulations responsibility home office europe animal research come directive eec cover animal welfare act continue seek voluntary accreditation recognise agency association assessment accreditation laboratory animal care international aaalaci communicating approach people hold strong view animal research testing believe important explain need animal research testing transparent laboratory host visit school college animal welfare organisation engage regularly animal welfare organisation investor contribute debate media protest accept right lawful protest animal research free society condemn use violence intimidation oppose animal use welcome shift away extremism inform debate home responsibility research practice animal research corporate responsibility report animal research approach performance plan rs great ape family comprise gorilla chimpanzee orangutan bonobo specie ape pan troglodyte know common chimpanzee biomedical research decade great ape biomedical research take voluntary decision long carry research great ape read position statement use nonhuman primate great ape research ban use great ape recent gsk advance replace reduce refining animal use include implement polio vaccine test bulk manufacturing stage use transgenic mouse instead nonhuman primate mice genetically alter susceptible polio virus decrease number animal need vaccine testing example include vitro non animal test regulatory submission new vaccine human papillomavirus cervarix mean market new batch cervarix need test animal develop transgenic mouse model mimic accelerate form alzheimer disease replace primate primary model disorder fundamental biological research compound development target validation carry mouse model facilitate great understand disorder potential future therapy implement new technology collect blood sample animal study approach enable analysis carry small blood sample traditional technique enable quality datum obtain few animal work government change regulatory requirement few animal require routine testing proposal reduce animal testing originate gsk vaccine business submit european vaccine manufacturers association later present european directorate quality medicine develop vitro alternative safety test check potential impact pharmaceutical process material worker skin eye animal evaluation dermal eye irritation worker safety purpose donate collection information commonly blood collection method uk national centre rs ncrs donation found ncrs blood sampling website uk site laboratory staff choose appropriate technique humane efficient sample blood internal animal welfare award recognise work demonstrably high standard care experimental design implementation expect gsk employee involve animal experimentation receive award contribution tangible benefit term rs difference animal experimentation conduct gsk animal routinely care recent recipient internal animal welfare award team uk implement bloodspot technology preclinical toxicokinetic tk study technology mean researcher need significantly small volume blood mean few animal need tk study member neuroscience department develop assess alternative method administer medicine rat replace previous method require restraint dosing allow train rat drink test substance directly syringe team italy develop innovative nicotine selfadministration animal model pharmacological treatment aim smoking cessation result cent reduction number animal need study number animal absolute number animal laboratory cent low rd activity triple period estimate proportion total gsk animal research conduct external contractor low cent compare cent animal gsk cent mice rat guinea pig rodent rabbit include animal external contractor behalf animal external contractor behalf rodent rabbit change rd activity compare change number animal gsk datum include animal research conduct external contractor behalf rd activity combine rd budget vaccine sale main driver animal use start separately estimate external animal use record external animal use represent total animal use range external interaction involve gsk directly indirectly animal use diverse report regulator party refer datum estimate aaalaci accreditation animal laboratory belgium italy spain uk vast majority accredit association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promote humane treatment animal science voluntary accreditation assessment programme achieve aaalaci accreditation organisation rigorous assessment association review facility worker animal care maintain accreditation annual update onsite review triannual basis require site visit conduct member aaalac council train professional staff accreditation cover cent animal house gskowne laboratory work extend accreditation animal facility plan gsk commit rs current initiative include review animal model business look type study perform ensure suitable model appropriate number animal involve rd leadership team review outcome analysis recommendation initiative beyondhome responsibility research practice animal research corporate responsibility report animal research approach performance plan rs great ape family comprise gorilla chimpanzee orangutan bonobo specie ape pan troglodyte know common chimpanzee biomedical research decade great ape biomedical research take voluntary decision long carry research great ape read position statement use nonhuman primate great ape research ban use great ape recent gsk advance replace reduce refining animal use include implement polio vaccine test bulk manufacturing stage use transgenic mouse instead nonhuman primate mice genetically alter susceptible polio virus decrease number animal need vaccine testing example include vitro non animal test regulatory submission new vaccine human papillomavirus cervarix mean market new batch cervarix need test animal develop transgenic mouse model mimic accelerate form alzheimer disease replace primate primary model disorder fundamental biological research compound development target validation carry mouse model facilitate great understand disorder potential future therapy implement new technology collect blood sample animal study approach enable analysis carry small blood sample traditional technique enable quality datum obtain few animal work government change regulatory requirement few animal require routine testing proposal reduce animal testing originate gsk vaccine business submit european vaccine manufacturers association later present european directorate quality medicine develop vitro alternative safety test check potential impact pharmaceutical process material worker skin eye animal evaluation dermal eye irritation worker safety purpose donate collection information commonly blood collection method uk national centre rs ncrs donation found ncrs blood sampling website uk site laboratory staff choose appropriate technique humane efficient sample blood internal animal welfare award recognise work demonstrably high standard care experimental design implementation expect gsk employee involve animal experimentation receive award contribution tangible benefit term rs difference animal experimentation conduct gsk animal routinely care recent recipient internal animal welfare award team uk implement bloodspot technology preclinical toxicokinetic tk study technology mean researcher need significantly small volume blood mean few animal need tk study member neuroscience department develop assess alternative method administer medicine rat replace previous method require restraint dosing allow train rat drink test substance directly syringe team italy develop innovative nicotine selfadministration animal model pharmacological treatment aim smoking cessation result cent reduction number animal need study number animal absolute number animal laboratory cent low rd activity triple period estimate proportion total gsk animal research conduct external contractor low cent compare cent animal gsk cent mice rat guinea pig rodent rabbit include animal external contractor behalf animal external contractor behalf rodent rabbit change rd activity compare change number animal gsk datum include animal research conduct external contractor behalf rd activity combine rd budget vaccine sale main driver animal use start separately estimate external animal use record external animal use represent total animal use range external interaction involve gsk directly indirectly animal use diverse report regulator party refer datum estimate aaalaci accreditation animal laboratory belgium italy spain uk vast majority accredit association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promote humane treatment animal scpiaegnec e voluntary accreditation assessment programme achieve aaalaci accreditation organisation rigorous assessment association review facility worker animal care maintain accreditation annual update onsite review triannual basis require site visit conduct member aaalac council train professional staff accreditation cover cent animal house gskowne laboratory work extend accreditation animal facility plan gsk commit rs current initiative include review animal model business look type study perform ensure suitable model appropriate number animal involve rd leadership team review outcome analysis recommendation initiative beyondhome responsibility research practice animal research corporate responsibility report animal research approach performance plan rs great ape family comprise gorilla chimpanzee orangutan bonobo specie ape pan troglodyte know common chimpanzee biomedical research decade great ape biomedical research take voluntary decision long carry research great ape read position statement use nonhuman primate great ape research ban use great ape recent gsk advance replace reduce refining animal use include implement polio vaccine test bulk manufacturing stage use transgenic mouse instead nonhuman primate mice genetically alter susceptible polio virus decrease number animal need vaccine testing example include vitro non animal test regulatory submission new vaccine human papillomavirus cervarix mean market new batch cervarix need test animal develop transgenic mouse model mimic accelerate form alzheimer disease replace primate primary model disorder fundamental biological research compound development target validation carry mouse model facilitate great understand disorder potential future therapy implement new technology collect blood sample animal study approach enable analysis carry small blood sample traditional technique enable quality datum obtain few animal work government change regulatory requirement few animal require routine testing proposal reduce animal testing originate gsk vaccine business submit european vaccine manufacturers association later present european directorate quality medicine develop vitro alternative safety test check potential impact pharmaceutical process material worker skin eye animal evaluation dermal eye irritation worker safety purpose donate collection information commonly blood collection method uk national centre rs ncrs donation found ncrs blood sampling website uk site laboratory staff choose appropriate technique humane efficient sample blood internal animal welfare award recognise work demonstrably high standard care experimental design implementation expect gsk employee involve animal experimentation receive award contribution tangible benefit term rs difference animal experimentation conduct gsk animal routinely care recent recipient internal animal welfare award team uk implement bloodspot technology preclinical toxicokinetic tk study technology mean researcher need significantly small volume blood mean few animal need tk study member neuroscience department develop assess alternative method administer medicine rat replace previous method require restraint dosing allow train rat drink test substance directly syringe team italy develop innovative nicotine selfadministration animal model pharmacological treatment aim smoking cessation result cent reduction number animal need study number animal absolute number animal laboratory cent low rd activity triple period estimate proportion total gsk animal research conduct external contractor low cent compare cent animal gsk cent mice rat guinea pig rodent rabbit include animal external contractor behalf animal external contractor behalf rodent rabbit change rd activity compare change number animal gsk datum include animal research conduct external contractor behalf rd activity combine rd budget vaccine sale main driver animal use start separately estimate external animal use record external animal use represent total animal use range external interaction involve gsk directly indirectly animal use diverse report regulator party refer datum estimate aaalaci accreditation animal laboratory belgium italy spain uk vast majority accredit association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promote humane treatment animal science voluntary accreditation assessment programme achieve aaalaci accreditation organisation rigorous assessment association review facility worker animal care maintain accreditation annual update onsite review triannual basis require site visit conduct member aaalac council train professional staff accreditation cover cent animal house gskowne laboratory work extend accreditation animal facility plan gsk commit rs current initiative include review animal model business look type study perform ensure suitable model appropriate number animal involve rd leadership team review outcome analysis recommendation initiative home responsibility research practice animal research corporate responsibility report animal research approach performance plan rs great ape family comprise gorilla chimpanzee orangutan bonobo specie ape pan troglodyte know common chimpanzee biomedical research decade great ape biomedical research take voluntary decision long carry research great ape read position statement use nonhuman primate great ape research ban use great ape recent gsk advance replace reduce refining animal use include implement polio vaccine test bulk manufacturing stage use transgenic mouse instead nonhuman primate mice genetically alter susceptible polio virus decrease number animal need vaccine testing example include vitro non animal test regulatory submission new vaccine human papillomavirus cervarix mean market new batch cervarix need test animal develop transgenic mouse model mimic accelerate form alzheimer disease replace primate primary model disorder fundamental biological research compound development target validation carry mouse model facilitate great understand disorder potential future therapy implement new technology collect blood sample animal study approach enable analysis carry small blood sample traditional technique enable quality datum obtain few animal work government change regulatory requirement few animal require routine testing proposal reduce animal testing originate gsk vaccine business submit european vaccine manufacturers association later present european directorate quality medicine develop vitro alternative safety test check potential impact pharmaceutical process material worker skin eye animal evaluation dermal eye irritation worker safety purpose donate collection information commonly blood collection method uk national centre rs ncrs donation found ncrs blood sampling website uk site laboratory staff choose appropriate technique humane efficient sample blood internal animal welfare award recognise work demonstrably high standard care experimental design implementation expect gsk employee involve animal experimentation receive award contribution tangible benefit term rs difference animal experimentation conduct gsk animal routinely care recent recipient internal animal welfare award team uk implement bloodspot technology preclinical toxicokinetic tk study technology mean researcher need significantly small volume blood mean few animal need tk study member neuroscience department develop assess alternative method administer medicine rat replace previous method require restraint dosing allow train rat drink test substance directly syringe team italy develop innovative nicotine selfadministration animal model pharmacological treatment aim smoking cessation result cent reduction number animal need study number animal absolute number animal laboratory cent low rd activity triple period estimate proportion total gsk animal research conduct external contractor low cent compare cent animal gsk cent mice rat guinea pig rodent rabbit include animal external contractor behalf animal external contractor behalf rodent rabbit change rd activity compare change number animal gsk datum include animal research conduct external contractor behalf rd activity combine rd budget vaccine sale main driver animal use start separately estimate external animal use record external animal use represent total animal use range external interaction involve gsk directly indirectly animal use diverse report regulator party refer datum estimate aaalaci accreditation animal laboratory belgium italy spain uk vast majority accredit association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promote humane treatment animal science voluntary accreditation assessment programme achieve aaalaci accreditation organisation rigorous assessment association review facility worker animal care maintain accreditation annual update onsite review triannual basis require site visit conduct member aaalac council train professional staff accreditation cover cent animal house gskowne laboratory work extend accreditation animal facility plan gsk commit rs current initiative include review animal model business look type study perform ensure suitable model appropriate number animal involve rd leadership team review outcome analysis recommendation initiative home responsibility research practice human tissue research corporate responsibility report human tissue research research human tissue human biological sample fundamental discovery development safety monitor gsk medicine vital research conduct manner respect right research participant meet legal ethical obligation uk human tissue act make consent fundamental legal requirement collection use storage human tissue uk introduce follow event alder hey hospital bristol royal infirmary human tissue take store consent introduce policy apply principle uk human tissue act global basis research conduct sponsor support fund gsk ensure stringent ethical requirement uk law apply research conduct human biological sample home responsibility research practice human tissue research corporate responsibility report human tissue research research human tissue human biological sample fundamental discovery development safety monitor gsk medicine vital research conduct manner respect right research participant meet legal ethical obligation uk human tissue act make consent fundamental legal requirement collection use storage human tissue uk introduce follow event alder hey hospital bristol royal infirmary human tissue take store consent introduce policy apply principle uk human tissue act global basis research conduct sponsor support fund gsk ensure stringent ethical requirement uk law apply research conduct human biological sample home responsibility research practice medical governance corporate responsibility report medical governance gsk commit high standard ethical medical practice support mission improve quality human life enable people feel well live long medical governance gsk system principle policy accountability ensure apply generally recognise principle good medical science medical integrity ethic standard provide framework embed follow principle patient safety fundamental operating principle gsk ahead commercial interest clinical research conduct objective scientific ethical manner protect inform patient promotional practice information provide product ethical accurate balanced medicine appropriately benefit minimise risk patientss medical governance gsk encompass principle policy accountabilitie area framework medical governance business chief medical officer senior physician gsk responsibility authority establish effective medical governance system corporate executive team member responsible performance compliance system area responsibility medical governance executive committee establishes policy medical governance subject approval corporate executive team ensure medical governance system operate effectively regional medical director regional president countryterritory medical director ensure policy system medical governance understand complied country responsibility read patient safety governance framework home responsibility research practice medical governance corporate responsibility report medical governance gsk commit high standard ethical medical practice support mission improve quality human life enable people feel well live long medical governance gsk system principle policy accountability ensure apply generally recognise principle good medical science medical integrity ethic standard provide framework embed follow principle patient safety fundamental operating principle gsk ahead commercial interest clinical research conduct objective scientific ethical manner protect inform patient promotional practice information provide product ethical accurate balanced medicine appropriately benefit minimise risk patientss medical governance gsk encompass principle policy accountabilitie area framework medical governance business chief medical officer senior physician gsk responsibility authority establish effective medical governance system corporate executive team member responsible performance compliance system area responsibility medical governance executive committee establish policy medical governance subject approval corporate executive team ensure medical governance system operate effectively regional medical director regional president countryterritory medical director ensure policy system medical governance understand complied country responsibility read patient safety governance framework home responsibility research practice clinical research corporate responsibility report clinical research carry series clinical trial evaluate investigational medicine potential new medicine effect potential medicine compare marketed medicine case inactive substance placebo successful clinical trial programme usually phase safety evaluate clinical trial process rigorous procedure assurance process ensure clinical trial medicine conduct accord good clinical practice gcp guideline develop international conference harmonisation ich principle contain world medical association declaration helsinki ethical principle medical research involve human subject gsksponsore clinical trial conduct ethical standard irrespective place develop develop country safety participate clinical trial paramount importance inform consent procedure ensure volunteer inform aspect trial relevant decision participate gsk employee involve conduct trial receive train regulatory requirement gsk policy trial subject audit internal audit department regulator home responsibility research practice clinical research corporate responsibility report clinical research carry series clinical trial evaluate investigational medicine potential new medicine effect potential medicine compare marketed medicine case inactive substance placebo successful clinical trial programme usually phase safety evaluate clinical trial process rigorous procedure assurance process ensure clinical trial medicine conduct accord good clinical practice gcp guideline develop international conference harmonisation ich principle contain world medical association declaration helsinki ethical principle medical research involve human subject gsksponsore clinical trial conduct ethical standard irrespective place develop develop country safety participate clinical trial paramount importance inform consent procedure ensure volunteer inform aspect trial relevant decision participate gsk employee involve conduct trial receive train regulatory requirement gsk policy trial subject audit internal audit department regulator home responsibility research practice clinical research planning approval corporate responsibility report plan approval protocol develop clinical trial protocol set purpose research explain trial conduct result analyse include detail dosage duration treatment number participant require protocol define measurement evaluate safety efficacy medicine appropriate procedure participant wish withdraw study trial protocol review government regulatory agency relevant country require protocol review independent ethical review committee lie people medical professional scientist committee review approve information provide process seek informed consent ethic committee power reject stop clinical trial home responsibility research practice clinical research planning approval corporate responsibility report plan approval protocol develop clinical trial protocol set purpose research explain trial conduct result analyse include detail dosage duration treatment number participant require protocol define measurement evaluate safety efficacy medicine appropriate procedure participant wish withdraw study trial protocol review government regulatory agency relevant country require protocol review independent ethical review committee lie people medical professional scientist committee review approve information provide process seek informed consent ethic committee power reject stop clinical trial home responsibility research practice clinical research inform consent corporate responsibility report inform consent inform consent mean potential clinical trial participant voluntarily confirm willingness participate informed aspect trial relevant decision participate document mean write sign date informed consent form inform consent clinical trial involve read sign consent form essential element process communicate information answer question sign documentation inform consent information write communicate nontechnical style lie person understand include summary clinical trial include purpose treatment procedure schedule potential risk benefit alternative participation provision datum protection explain participant right include voluntary participation right end participation researcher health professional know write document ensure understand participation mean research team discuss person trial purpose procedure risk potential benefit participant right person decide participate team continue update new information affect willingness continue trial trial person give opportunity ask question raise concern inform consent ongoing interactive process special case obtain someone inform consent possible emergency research scenario child age legal consent circumstance consent seek allow provide local law regulation situation read able speak understand local language impartial witness present inform consent process confirm write information inform consent form accurately explain potential participant able ask question give consent voluntarily home responsibility research practice clinical research inform consent corporate responsibility report inform consent inform consent mean potential clinical trial participant voluntarily confirm willingness participate informed aspect trial relevant decision participate document mean write sign date informed consent form inform consent clinical trial involve read sign consent form essential element process communicate information answer question sign documentation inform consent information write communicate nontechnical style lie person understand include summary clinical trial include purpose treatment procedure schedule potential risk benefit alternative participation provision datum protection explain participant right include voluntary participation right end participation researcher health professional know write document ensure understand participation mean research team discuss person trial purpose procedure risk potential benefit participant right person decide participate team continue update new information affect willingness continue trial trial person give opportunity ask question raise concern inform consent ongoing interactive process special case obtain someone inform consent possible emergency research scenario child age legal consent circumstance consent seek allow provide local law regulation situation read able speak understand local language impartial witness present inform consent process confirm write information inform consent form accurately explain potential participant able ask question give consent voluntarily home responsibility research practice clinical research posttrial treatment corporate responsibility report posttrial treatment general responsible funding nationally license medicine trial responsibility government provider national healthcare system begin trial disease condition continue completion trial assure healthcare system able provide responsibility continue care patient exceptional circumstance nationally license medicine fund gsk trial available trial participant derive measurable medical benefit continue fund medicine fund normal healthcare infrastructure patient long derive medical benefit circumstance compelling medical rationale patient continue receive investigational medicine clinical trial case posttrial treatment provide clinical trial expand access programme enable appropriate oversight report adverse event circumstance gsk fund investigational medicine long patient benefit compound approve license country read public policy clinical trial develop world home responsibility research practice clinical research posttrial treatment corporate responsibility report posttrial treatment general responsible funding nationally license medicine trial responsibility government provider national healthcare system begin trial disease condition continue completion trial assure healthcare system able provide responsibility continue care patient exceptional circumstance nationally license medicine fund gsk trial available trial participant derive measurable medical benefit continue fund medicine fund normal healthcare infrastructure patient long derive medical benefit circumstance compelling medical rationale patient continue receive investigational medicine clinical trial case posttrial treatment provide clinical trial expand access programme enable appropriate oversight report adverse event circumstance gsk fund investigational medicine long patient benefit compound approve license country read public policy clinical trial develop world home responsibility research practice clinical research clinical trial develop world corporate responsibility report clinical trial develop world gsk clinical trial carry conduct high standard gsk conduct clinical trial country know outset intent pursue registration product available use country additional step need ensure trial develop country conduct accord good clinical practice gcp guideline example matching objective inform consent local culture necessary instance involve local leader andor family member circumstance capacity provide help develop certain skill competence general upgrading performance ability facilitate prospective conduct clinical research activity gsk broad community read posttrial treatment read position statement clinical trial develop world home responsibility research practice clinical research clinical trial develop world corporate responsibility report clinical trial develop world gsk clinical trial carry conduct high standard gsk conduct clinical trial country know outset intent pursue registration product available use country additional step need ensure trial develop country conduct accord good clinical practice gcp guideline example matching objective inform consent local culture necessary instance involve local leader andor family member circumstance capacity provide help develop certain skill competence general upgrading performance ability facilitate prospective conduct clinical research activity gsk broad community read posttrial treatment read position statement clinical trial develop world home responsibility research practice public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plan pharmaceutical company legally require disclose relevant data clinical trial appropriate regulatory authority seek approval new medicine approval sponsor continue obligation provide regulatory authority update safety information clinical trial read patient safety safety efficacy information provide doctor prescribe information approve regulator public disclosure research fundamental advance medical science inform prescriber patient scientific finding relate medicine clinical trial register launch design supplement prescribing information publication scientific literature contain datum relate market medicine serve resource researcher medical professional public use alongside locally approve prescribing information improve clinical study register launch replace previous register include protocol summary enhance search capability read case study new register help improve access clinical trial information read position statement disclosure clinical trial information home responsibility research practice public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plan pharmaceutical company legally require disclose relevant data clinical trial appropriate regulatory authority seek approval new medicine approval sponsor continue obligation provide regulatory authority update safety information clinical trial read patient safety safety efficacy information provide doctor prescribe information approve regulator public disclosure research fundamental advance medical science inform prescriber patient scientific finding relate medicine clinical trial register launch design supplement prescribing information publication scientific literature contain datum relate market medicine serve resource researcher medical professional public use alongside locally approve prescribing information improve clinical study register launch replace previous register include protocol summary enhance search capability read case study new register help improve access clinical trial information read position statement disclosure clinical trial information home responsibility research practice public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plan end protocol summary gsk actively recruit clinical trial clinicaltrialsgov total registry clinical trial conduct world provide information trial purpose participate location contact detail information end clinical trial summary clinical study register include clinical trial major market product complete formation gsk complete likely inform medical judgement objective disclose trial result summarie new product register month product reach market aim disclose result trial complete product approve marketing year trial completion meet objective update august internal audit subsequently show result small number trial post register month product reach market follow audit result study post register july improve procedure collect post trial result expect meet objective new clinical study register replace previous register provide protocol summary enhance search capability user number summary gsk clinical trial gsk clinical study register cumulative total important step build gsk commitment transparency clinical research take commit january post information type gsk clinical research evaluate medicine gsk clinical study register add gsk observational research metaanalyse study terminate compound current commitment post information relate clinical trial phase llv market medicine addition add name investigator participate clinical research ensure clinical research publish manuscript peer review journal study publish provide context interpretation gsk clinical study register supplement result summary post ensure study publicly available irrespective result perceive positive negative medicine progress meeting commitment monitor external audience gsk clinical study register include protocol plan research study initiate summary result reference publication follow completionhome responsibility research practice public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plan end protocol summary gsk actively recruit clinical trial clinicaltrialsgov total registry clinical trial conduct world provide information trial purpose participate location contact detail information end clinical trial summary clinical study register include clinical trial major market product complete formation gsk complete likely inform medical judgement objective disclose trial result summarie new product register month product reach market aim disclose result trial complete product approve marketing year trial completion meet objective update august internal audit subsequently show result small number trial post register month product reach market follow audit result study post register july improve procedure collect post trial result expect meet objective new clinical study register replace previous register provide protocol summary enhance search capability user number summary gsk clinical trial gsk clinical study register cumulative total important step build gsk commitment transparency clinical research take commit january post information type gsk clinical research evaluate medicine gsk clinical study register add gsk observational research metaanalyse study terminate compound current commitment post information relate clinical trial phase llv market medicine addition add name investigator participate clinical research ensure clinical research publish manuscript peer review journal study publish provide context interpretation gsk clinical study register supplement result summary post ensure study publicly available irrespective result perceive positive negative medicine progress meeting commitment monitor external audience gsk clinical study register include protocol plan research study initiate summary result reference publication follow completion home responsibility research practice public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plan end protocol summary gsk actively recruit clinical trial clinicaltrialsgov total registry clinical trial conduct world provide information trial purpose participate location contact detail information end clinical trial summary clinical study register include clinical trial major market product complete formation gsk complete likely inform medical judgement objective disclose trial result summarie new product register month product reach market aim disclose result trial complete product approve marketing year trial completion meet objective update august internal audit subsequently show result small number trial post register month product reach market follow audit result study post register july improve procedure collect post trial result expect meet objective new clinical study register replace previous register provide protocol summary enhance search capability user number summary gsk clinical trial gsk clinical study register cumulative total important step build gsk commitment transparency clinical research take commit january post information type gsk clinical research evaluate medicine gsk clinical study register add gsk observational research metaanalyse study terminate compound current commitment post information relate clinical trial phase llv market medicine addition add name investigator participate clinical research ensure clinical research publish manuscript peer review journal study publish provide context interpretation gsk clinical study register supplement result summary post ensure study publicly available irrespective result perceive positive negative medicine progress meeting commitment monitor external audience gsk clinical study register include protocol plan research study initiate summary result reference publication follow completion home responsibility research practice patient safety corporate responsibility report patient safety ensure safety medicine medical device critically important health wellbeing patient success business medicine potential risk benefit take medicine experience effect important identify evaluate minimise safety concern ensure overall benefit medicine outweigh risk strive serve patient interest promptly detect potential safety issue product communicate regulator appropriate decision action take product safety assess clinical trial product approve marketing adverse event potential safety issue occur approval product large number patient policy governance framework place help detect act adverse event dedicated team scientist healthcare professional world monitor communicate safety issue regulatory authority invest genetic research help predict individual patient respond medicine future help healthcare provider prescribe safe effective medicine read patient safety governance framework collect report safety datum home responsibility research practice patient safety corporate responsibility report patient safety ensure safety medicine medical device critically important health wellbeing patient success business medicine potential risk benefit take medicine experience effect important identify evaluate minimise safety concern ensure overall benefit medicine outweigh risk strive serve patient interest promptly detect potential safety issue product communicate regulator appropriate decision action take product safety assess clinical trial product approve marketing adverse event potential safety issue occur approval product large number patient policy governance framework place help detect act adverse event dedicated team scientist healthcare professional world monitor communicate safety issue regulatory authority invest genetic research help predict individual patient respond medicine future help healthcare provider prescribe safe effective medicine read patient safety governance framework collect report safety datum home responsibility research practice patient safety patient safety governance framework corporate responsibility report patient safety governance framework global safety board gsb make decision product safety issue board lead chief medical officer compose senior physician scientist role oversee safety investigational market medicine approve administration investigational medicine human define dose duration treatment consider safe approve progression investigational medicine pivotal trial trial provide primary datum regulatory approval base assess issue relate patient safety arise product development marketing central department responsible recording investigate evaluate adverse event report relevant regulatory authority example food drug administration fda european medicine evaluation agency emea global clinical safety pharmacovigilance team gcsp gsk research development responsible safety evaluation pharmaceutical device gsk biological clinical safety pharmacovigilance department vaccine business responsible safety evaluation gsk vaccine consumer healthcare product safety group consumer healthcare business responsible safety evaluation consumer healthcare product require gsk staff immediately report issue relate safety quality medicine read expectation employee guide business conduct read medical governance benefitrisk management assess balance benefit risk particular medicine lifecycle early development clinical trial product market evaluate document available safety information build detailed benefitrisk profile product use information develop benefitrisk management plan identify way improve product benefit minimise risk review update plan regularly clinical development period product approve marketing home responsibility research practice patient safety patient safety governance framework corporate responsibility report patient safety governance framework global safety board gsb make decision product safety issue board lead chief medical officer compose senior physician scientist role oversee safety investigational market medicine approve administration investigational medicine human define dose duration treatment consider safe approve progression investigational medicine pivotal trial trial provide primary datum regulatory approval base assess issue relate patient safety arise product development marketing central department responsible recording investigate evaluate adverse event report relevant regulatory authority example food drug administration fda european medicine evaluation agency emea global clinical safety pharmacovigilance team gcsp gsk research development responsible safety evaluation pharmaceutical device gsk biological clinical safety pharmacovigilance department vaccine business responsible safety evaluation gsk vaccine consumer healthcare product safety group consumer healthcare business responsible safety evaluation consumer healthcare product require gsk staff immediately report issue relate safety quality medicine read expectation employee guide business conduct read medical governance benefitrisk management assess balance benefit risk particular medicine lifecycle early development clinical trial product market evaluate document available safety information build detailed benefitrisk profile product use information develop benefitrisk management plan identify way improve product benefit minimise risk review update plan regularly clinical development period product approve marketing home responsibility research practice patient safety collecting report safety datum corporate responsibility report collect report safety datum receive information adverse event source include unsolicited report health professional patient postmarkete trial observational study investigator submit clinical study report regulatory authority medical scientific literature newspaper medium gsk employee responsible reporting adverse event aware adverse event occur record global safety database clinical trial database investigate clinical pharmacovigilance team report potential safety issue regulatory authority regular basis country manager responsible ensure collection safety information report relevant central safety department local regulatory authority management certification process manager acknowledge compliance policy adverse event report specifie gsk employee responsible reporting adverse event aware conduct work add adverse event report button mygsk intranet site easy employee report adverse event learn regulator country publish information adverse event internet example data product market uk available medicine healthcare product regulatory agency safety datum available canada food drug administration information database accessible public publish quarterly report potential safety issue investigate research diabetes product avandia continue new fda require cardiovascular outcome study design initiate combine fda advisory committee review respiratory product contain longacte beta agonist read question raise avandia read question safety product contain longacte beta agonist read medical governance read position statement pharmacovigilance respond adverse event adverse event affect benefitrisk profile product corrective action need minimise risk include carry clinical trial modify prescribing information communication physicians healthcare provider establish specific method minimise risk product subject limited distribution programme prescription specialist doctor certain case appropriate stop clinical trial withdraw product market global labelling committee review approve prescribe information product ensure update appropriate home responsibility research practice patient safety collecting report safety datum corporate responsibility report collect report safety datum receive information adverse event source include unsolicited report health professional patient postmarkete trial observational study investigator submit clinical study report regulatory authority medical scientific literature newspaper medium gsk employee responsible reporting adverse event aware adverse event occur record global safety database clinical trial database investigate clinical pharmacovigilance team report potential safety issue regulatory authority regular basis country manager responsible ensure collection safety information report relevant central safety department local regulatory authority management certification process manager acknowledge compliance policy adverse event report specifie gsk employee responsible reporting adverse event aware conduct work add adverse event report button mygsk intranet site easy employee report adverse event learn regulator country publish information adverse event internet example data product market uk available medicine healthcare product regulatory agency safety datum available canada food drug administration information database accessible public publish quarterly report potential safety issue investigate research diabetes product avandia continue new fda require cardiovascular outcome study design initiate combine fda advisory committee review respiratory product contain longacte beta agonist read question raise avandia read question safety product contain longacte beta agonist read medical governance read position statement pharmacovigilance respond adverse event adverse event affect benefitrisk profile product corrective action need minimise risk include carry clinical trial modify prescribing information communication physicians healthcare provider establish specific method minimise risk product subject limited distribution programme prescription specialist doctor certain case appropriate stop clinical trial withdraw product market global labelling committee review approve prescribe information product ensure update appropriate home responsibility research practice patient safety collecting report safety datum corporate responsibility report collect report safety datum receive information adverse event source include unsolicited report health professional patient postmarkete trial observational study investigator submit clinical study report regulatory authority medical scientific literature newspaper medium gsk employee responsible reporting adverse event aware adverse event occur record global safety database clinical trial database investigate clinical pharmacovigilance team report potential safety issue regulatory authority regular basis country manager responsible ensure collection safety information report relevant central safety department local regulatory authority management certification process manager acknowledge compliance policy adverse event report specifie gsk employee responsible reporting adverse event aware conduct work add adverse event report button mygsk intranet site easy employee report adverse event learn regulator country publish information adverse event internet example data product market uk available medicine healthcare product regulatory agency safety datum available canada food drug administration information database accessible public publish quarterly report potential safety issue investigate research diabetes product avandia continue new fda require cardiovascular outcome study design initiate combine fda advisory committee review respiratory product contain longacte beta agonist read question raise avandia read question safety product contain longacte beta agonist read medical governance read position statement pharmacovigilance respond adverse event adverse event affect benefitrisk profile product corrective action need minimise risk include carry clinical trial modify prescribing information communication physicians healthcare provider establish specific method minimise risk product subject limited distribution programme prescription specialist doctor certain case appropriate stop clinical trial withdraw product market global labelling committee review approve prescribe information product ensure update appropriate home responsibility research practice patient safety collecting report safety datum respond question avandia corporate responsibility report respond question avandia avandia lead treatment type diabete metaanalysis publish new england journal medicine gsk metaanalysis submit fda regulator centre debate avandia associate increase risk myocardial infarction death cardiovascular cause follow fda advisory committee meeting fda approve update prescribe information avandia include new text exist box warning november update prescribe information summarise datum fda metaanalysis myocardial ischemic event suggest risk associated avandia longterm clinical trial compare avandia placebo oral antidiabete medicine confirm exclude risk revise prescribing information include entirety available datum risk myocardial ischemia inconclusive research involve avandia continue include cardiovascular outcome study call record result available addition gsk work design fdarequire cardiovascular outcome study avandia call tide study begin update august result cardiovascular outcome study record publish june record large prospective randomize control study initiate design compare cardiovascular outcome patient avandia add metformin sulfonylurea metformin sulfonylurea study show combined endpoint cardiovascular hospitalization cardiovascular death include heart attack congestive heart failure stroke statistically different group average year therapy tide study start plan medicine avandia include carry risk benefit type diabetes chronic relentlessly progressive lifethreatening disease physician need prescribe medicine help patient maintain blood sugar level array treatment option important gsk believe important avandia available support effective treatment type diabete nissen k wolski effect rosiglitazone risk myocardial infarction death cardiovascular cause n engl j med cobitz et al retrospective evaluation congestive heart failure myocardial ischemia event patient type diabete mellitus enrol shortterm doubleblind randomize clinical study rosiglitazone pharmacoepidemiology drug safety p home et al rosiglitazone evaluate cardiovascular outcome interim analysis n engl j med ii kahn et al glycemic durability rosiglitazone metformin glyburide monotherapy n engl j med iii dream diabete reduction assessment ramipril rosiglitazone medication trial investigator effect rosiglitazone frequency diabete patient impair glucose tolerance impaired fasting glucose randomise control trial lancet p home et al rosiglitazone evaluate cardiovascular outcome oral agent combination therapy type diabete record multicentre randomise openlabel trial lancet home responsibility research practice patient safety collecting report safety datum respond question avandia corporate responsibility report respond question avandia avandia lead treatment type diabete metaanalysis publish new england journal medicine gsk metaanalysis submit fda regulator centre debate avandia associate increase risk myocardial infarction death cardiovascular cause follow fda advisory committee meeting fda approve update prescribe information avandia include new text exist box warning november update prescribe information summarise datum fda metaanalysis myocardial ischemic event suggest risk associated avandia longterm clinical trial compare avandia placebo oral antidiabete medicine confirm exclude risk revise prescribing information include entirety available datum risk myocardial ischemia inconclusive research involve avandia continue include cardiovascular outcome study call record result available addition gsk work design fdarequire cardiovascular outcome study avandia call tide study begin update august result cardiovascular outcome study record publish june record large prospective randomize control study initiate design compare cardiovascular outcome patient avandia add metformin sulfonylurea metformin sulfonylurea study show combined endpoint cardiovascular hospitalization cardiovascular death include heart attack congestive heart failure stroke statistically different group average year therapy tide study start plan medicine avandia include carry risk benefit type diabetes chronic relentlessly progressive lifethreatening disease physician need prescribe medicine help patient maintain blood sugar level array treatment option important gsk believe important avandia available support effective treatment type diabete nissen k wolski effect rosiglitazone risk myocardial infarction death cardiovascular cause n engl j med cobitz et al retrospective evaluation congestive heart failure myocardial ischemia event patient type diabete mellitus enrol shortterm doubleblind randomize clinical study rosiglitazone pharmacoepidemiology drug safety p home et al rosiglitazone evaluate cardiovascular outcome interim analysis n engl j med ii kahn et al glycemic durability rosiglitazone metformin glyburide monotherapy n engl j med iii dream diabete reduction assessment ramipril rosiglitazone medication trial investigator effect rosiglitazone frequency diabete patient impair glucose tolerance impaired fasting glucose randomise control trial lancet p home et al rosiglitazone evaluate cardiovascular outcome oral agent combination therapy type diabete record multicentre randomise openlabel trial lancet home responsibility research practice patient safety collecting report safety datum respond question avandia corporate responsibility report respond question avandia avandia lead treatment type diabete metaanalysis publish new england journal medicine gsk metaanalysis submit fda regulator centre debate avandia associate increase risk myocardial infarction death cardiovascular cause follow fda advisory committee meeting fda approve update prescribe information avandia include new text exist box warning november update prescribe information summarise datum fda metaanalysis myocardial ischemic event suggest risk associated avandia longterm clinical trial compare avandia placebo oral antidiabete medicine confirm exclude risk revise prescribing information include entirety available datum risk myocardial ischemia inconclusive research involve avandia continue include cardiovascular outcome study call record result available addition gsk work design fdarequire cardiovascular outcome study avandia call tide study begin update august result cardiovascular outcome study record publish june record large prospective randomize control study initiate design compare cardiovascular outcome patient avandia add metformin sulfonylurea metformin sulfonylurea study show combined endpoint cardiovascular hospitalization cardiovascular death include heart attack congestive heart failure stroke statistically different group average year therapy tide study start plan medicine avandia include carry risk benefit type diabetes chronic relentlessly progressive lifethreatening disease physician need prescribe medicine help patient maintain blood sugar level array treatment option important gsk believe important avandia available support effective treatment type diabete nissen k wolski effect rosiglitazone risk myocardial infarction death cardiovascular cause n engl j med cobitz et al retrospective evaluation congestive heart failure myocardial ischemia event patient type diabete mellitus enrol shortterm doubleblind randomize clinical study rosiglitazone pharmacoepidemiology drug safety p home et al rosiglitazone evaluate cardiovascular outcome interim analysis n engl j med ii kahn et al glycemic durability rosiglitazone metformin glyburide monotherapy n engl j med iii dream diabete reduction assessment ramipril rosiglitazone medication trial investigator effect rosiglitazone frequency diabete patient impair glucose tolerance impaired fasting glucose randomise control trial lancet p home et al rosiglitazone evaluate cardiovascular outcome oral agent combination therapy type diabete record multicentre randomise openlabel trial lancet home responsibility research practice patient safety collecting report safety datum question safety product contain long act beta agonist corporate responsibility report question safety product contain longacte beta agonist longacte beta agonist know labas daily controller medicine relieve help prevent airway constriction airway constriction main component asthma labas treat main component asthma inflammation treat type daily controller medicine call inhale corticosteroid ics labas include gsk product serevent treatment persistent asthma lead treatment guideline recommend labas appropriate patient asthma combination ics gsk make product contain laba salmeterol seretideadvair combination salmeterol ics fluticasone serevent contain salmeterol december combine advisory committee food drug administration review benefitrisk profile medicine contain labas child adult asthma review include labacontaine product indicate use treat asthma gsk product address linger concern labas increase risk asthmarelate death current product label prominently warn advisory committee make recommendation fda make final decision action require seretideadvair committee unanimously vote benefit seretideadvair outweigh risk patient year old committee vote favour positive benefitrisk profile young patient individual vote mixed serevent committee find benefit outweigh risk treatment asthma concern express potential serevent treatment asthma contrary current prescribing information way benefitrisk profile unfavourable contrast seretideadvair combination therapy laba ics combination use assure gsk acknowledge concern use serevent ics good interest asthma patient favour option allow dual therapy separate inhaler use separate inhaler important treatment option asthma patient need alternative ic fluticasone ic contain seretideadvair flexibility ics dose available combination product important asthma patient receive favourable reimbursement separate inhaler gsk believe appropriate labelling proactive communication risk laba potential misuse serevent monotherapy acceptably reduce dual therapy separate inhaler remain available asthma patient need september advisory committee meeting gsk submit propose label change fda serevent clarify use asthma patient combination ics line prescribe information country serevent market await outcome fda consideration gsk propose label change advisory committee review actively cooperate agency reach appropriate resolution good interest asthma patient home responsibility research practice patient safety collecting report safety datum question safety product contain long act beta agonist corporate responsibility report question safety product contain longacte beta agonist longacte beta agonist know labas daily controller medicine relieve help prevent airway constriction airway constriction main component asthma labas treat main component asthma inflammation treat type daily controller medicine call inhale corticosteroid ics labas include gsk product serevent treatment persistent asthma lead treatment guideline recommend labas appropriate patient asthma combination ics gsk make product contain laba salmeterol seretideadvair combination salmeterol ics fluticasone serevent contain salmeterol december combine advisory committee food drug administration review benefitrisk profile medicine contain labas child adult asthma review include labacontaine product indicate use treat asthma gsk product address linger concern labas increase risk asthmarelate death current product label prominently warn advisory committee make recommendation fda make final decision action require seretideadvair committee unanimously vote benefit seretideadvair outweigh risk patient year old committee vote favour positive benefitrisk profile young patient individual vote mixed serevent committee find benefit outweigh risk treatment asthma concern express potential serevent treatment asthma contrary current prescribing information way benefitrisk profile unfavourable contrast seretideadvair combination therapy laba ics combination use assure gsk acknowledge concern use serevent ics good interest asthma patient favour option allow dual therapy separate inhaler use separate inhaler important treatment option asthma patient need alternative ic fluticasone ic contain seretideadvair flexibility ics dose available combination product important asthma patient receive favourable reimbursement separate inhaler gsk believe appropriate labelling proactive communication risk laba potential misuse serevent monotherapy acceptably reduce dual therapy separate inhaler remain available asthma patient need september advisory committee meeting gsk submit propose label change fda serevent clarify use asthma patient combination ics line prescribe information country serevent market await outcome fda consideration gsk propose label change advisory committee review actively cooperate agency reach appropriate resolution good interest asthma patient home responsibility research practice patient safety performance corporate responsibility report performance continue improve patient safety system safety database monitoring process example include establish clinical toxicity strategy panel comprise internal external expert provide expert safety input medicine development process expert panel area cardiovascular hepatic renal haematological implement clinical trial signal detection ctsd tool review complete study datum partnership lincoln technologies enhance ability identify explore safety signal clinical trial system bio award launch prototype molecular clinical safety programme mcsp mcsp tool seek well inform decisionmake medicine development integrate chemistry preclinical human safety datum enable look pattern different type safety information october gsk team wall street journal technology innovation award healthcare develop system entry select independent panel judge review application award work work government official industry partner policy maker effort build enhanced safety system example gsk industry lead benefitrisk project consortium european commission publicprivate partnership innovative medicine initiative aim develop methodology enhance assessment benefitrisk profile new medicine gsk key partner food drug administration pharmaceutical company academia explore development new system detection adverse event benefit medicine large healthcare system database read collaborative research emerge technology adverse event consortium cofounde adverse event consortium saec collaboration involve partner saec work improve patient safety identify genetic variant predict adverse event druginduce liver injury rare severe skin rash call stevens johnson syndrome gsk scientist cochair saec scientific management committee seat board director home responsibility research practice patient safety performance corporate responsibility report performance continue improve patient safety system safety database monitoring process example include establish clinical toxicity strategy panel comprise internal external expert provide expert safety input medicine development process expert panel area cardiovascular hepatic renal haematological implement clinical trial signal detection ctsd tool review complete study datum partnership lincoln technologies enhance ability identify explore safety signal clinical trial system bio award launch prototype molecular clinical safety programme mcsp mcsp tool seek well inform decisionmake medicine development integrate chemistry preclinical human safety datum enable look pattern different type safety information october gsk team wall street journal technology innovation award healthcare develop system entry select independent panel judge review application award work work government official industry partner policy maker effort build enhanced safety system example gsk industry lead benefitrisk project consortium european commission publicprivate partnership innovative medicine initiative aim develop methodology enhance assessment benefitrisk profile new medicine gsk key partner food drug administration pharmaceutical company academia explore development new system detection adverse event benefit medicine large healthcare system database read collaborative research emerge technology adverse event consortium cofounde adverse event consortium saec collaboration involve partner saec work improve patient safety identify genetic variant predict adverse event druginduce liver injury rare severe skin rash call stevens johnson syndrome gsk scientist cochair saec scientific management committee seat board director home responsibility research practice maintain confidentiality research participant corporate responsibility report maintain confidentiality research participant vital medical information collect research protect maintain confidentiality participant rigorous procedure control use research datum research activity conduct accord fundamental ethical legal principle include consent ethic committee approval use variety procedure protect confidentiality research participant datum include datum code datum encryption restrict access research database party handle research datum behalf require comply relevant data protection legislation standard collect information individual relevant research study include medical information health status medical condition include occasion genetic datum treatment condition ethnic origin mean vast majority instance collect store information directly identify individual initial name address personal d number information identify individual specific instance require law regulation safety monitor pharmacovigilance retain medical research datum minimum identify information duration reasonably necessary meet regulatory legal research need home responsibility research practice maintain confidentiality research participant corporate responsibility report maintain confidentiality research participant vital medical information collect research protect maintain confidentiality participant rigorous procedure control use research datum research activity conduct accord fundamental ethical legal principle include consent ethic committee approval use variety procedure protect confidentiality research participant datum include datum code datum encryption restrict access research database party handle research datum behalf require comply relevant data protection legislation standard collect information individual relevant research study include medical information health status medical condition include occasion genetic datum treatment condition ethnic origin mean vast majority instance collect store information directly identify individual initial name address personal d number information identify individual specific instance require law regulation safety monitor pharmacovigilance retain medical research datum minimum identify information duration reasonably necessary meet regulatory legal research need home responsibility research practice work healthcare professional corporate responsibility report work healthcare professional policy govern interaction gsk rd staff healthcare practitioner require clinical trial investigator select solely qualification conduct good quality clinical n research history gsk product take account decide include exclude particular trial payment practitioner govern contract compensation reflect fair market value n work perform payment offer influence judgement enrol maintain participant n clinical study gift healthcare professional involve research project gsk permit n phrma code interaction healthcare professional prohibit noneducational gift healthcare professional involve research gsk policy prohibit gift healthcare professional involve research commit disclose research payment healthcare professional institution start payment healthcare professional institution conduct clinical trial start extend payment type research healthcare professional institution outside read policy monitor system govern relationship healthcare professional home responsibility research practice work healthcare professional corporate responsibility report work healthcare professional policy govern interaction gsk rd staff healthcare practitioner require clinical trial investigator select solely qualification conduct good quality clinical n research history gsk product take account decide include exclude particular trial payment practitioner govern contract compensation reflect fair market value n work perform payment offer influence judgement enrol maintain participant n clinical study gift healthcare professional involve research project gsk permit n phrma code interaction healthcare professional prohibit noneducational gift healthcare professional involve research gsk policy prohibit gift healthcare professional involve research commit disclose research payment healthcare professional institution start payment healthcare professional institution conduct clinical trial start extend payment type research healthcare professional institution outside read policy monitor system govern relationship healthcare professional home responsibility research practice training auditing corporate responsibility report training auditing approach performance train clinical trial employee involve design conduct recording reporting gsksponsore clinical research study train good clinical practice gcp guideline develop international conference harmonisation ich employee complete required training undertaking role detailed training record routinely request regulatory authority undertake inspection gsk clinical research trial audit clinical trial gsk internal audit department audits conduct clinical trial audits cover gsk system process external clinical research organisation investigator perform clinical research behalf trial select audit base risk risk factor include complexity study patient population location study previous audit history unusual finding conduct study result report quarterly rd compliance board annually risk oversight compliance council audit committee gsk board director read corporate governance section annual report member global safety board gsb receive individual audit report safetyrelate finding concern issue identify fully investigate appropriate corrective action take gsk staff corrective action include development new training programme retrain individual concern severe case appropriate disciplinary action take include dismissal external investigator gsk retrain investigator stop work investigator trial datum noncompliant investigative site exclude analysis regulatory authority carry inspection gsk investigator use conduct clinical trial home responsibility research practice training auditing corporate responsibility report training auditing approach performance train clinical trial employee involve design conduct recording reporting gsksponsore clinical research study train good clinical practice gcp guideline develop international conference harmonisation ich employee complete required training undertaking role detailed training record routinely request regulatory authority undertake inspection gsk clinical research trial audit clinical trial gsk internal audit department audits conduct clinical trial audits cover gsk system process external clinical research organisation investigator perform clinical research behalf trial select audit base risk risk factor include complexity study patient population location study previous audit history unusual finding conduct study result report quarterly rd compliance board annually risk oversight compliance council audit committee gsk board director read corporate governance section annual report member global safety board gsb receive individual audit report safetyrelate finding concern issue identify fully investigate appropriate corrective action take gsk staff corrective action include development new training programme retrain individual concern severe case appropriate disciplinary action take include dismissal external investigator gsk retrain investigator stop work investigator trial datum noncompliant investigative site exclude analysis regulatory authority carry inspection gsk investigator use conduct clinical trial home responsibility research practice training auditing corporate responsibility report training auditing approach performance train clinical trial training activity relate good clinical practice gcp training activity represent successful completion elearning module instructorle course relate gcp employee contractor audit clinical trial conduct audits include audits investigator site conduct gsksponsore trial represent approximately cent investigator site participate pivotal clinical trial audits internal gsk system process manage clinical trial data audits clinical research organisation carry clinical trial gsk behalf audits gsk local operating company involve clinical research activity win addition investigation conduct response suspect irregularity investigator site issue identify investigator site include insufficient oversight clinical trial activity investigator oversight cover area investigator responsibility include knowledge protocol design appropriate document delegation task skilled personnel availability meet sponsor representative regular interval study additional training investigator implementation internal control help reduce frequency significance issue inspection investigator clinical research organisation independent ethic committeesinstitutional review board sponsor clinical trial carry regulatory authority ensure safety trial participant quality datum trial conduct accord good clinical practice inspection gsk investigator gsk conduct clinical trial food drug administration fda conduct routine post marketing adverse drug experience inspection inspection involve review gsk process receive capture track adverse drug experience information gsk product report datum fda course inspection inspector focus gsk compliance regulatory requirement new drug application nda annual report periodic adverse drug experience report result inspection gsk receive warning letter agency march fda determine product certain require report submit gsk include require information clinical study timely basis fda letter acknowledge information capture periodic report case submit agency report communication addition information start clinical trial omit report available wwwclinicaltrialsgov clinical trial result post publicly gsk clinical study register acknowledge seriousness issue raise warning letter corrective step take underway sure periodic report file completely promptly inspection gsk initiate review applicable process report system continue progress update procedure improve compliance area report include additional training ensure procedure follow product line gsk work continuously monitor necessary enhance compliance system procedure home responsibility research practice training auditing corporate responsibility report training auditing approach performance train clinical trial training activity relate good clinical practice gcp training activity represent successful completion elearning module instructorle course relate gcp employee contractor audit clinical trial conduct audits include audits investigator site conduct gsksponsore trial represent approximately cent investigator site participate pivotal clinical trial audits internal gsk system process manage clinical trial data audits clinical research organisation carry clinical trial gsk behalf audits gsk local operating company involve clinical research activity win addition investigation conduct response suspect irregularity investigator site issue identify investigator site include insufficient oversight clinical trial activity investigator oversight cover area investigator responsibility include knowledge protocol design appropriate document delegation task skilled personnel availability meet sponsor representative regular interval study additional training investigator implementation internal control help reduce frequency significance issue inspection investigator clinical research organisation independent ethic committeesinstitutional review board sponsor clinical trial carry regulatory authority ensure safety trial participant quality datum trial conduct accord good clinical practice inspection gsk investigator gsk conduct clinical trial food drug administration fda conduct routine post marketing adverse drug experience inspection inspection involve review gsk process receive capture track adverse drug experience information gsk product report datum fda course inspection inspector focus gsk compliance regulatory requirement new drug application nda annual report periodic adverse drug experience report result inspection gsk receive warning letter agency march fda determine product certain require report submit gsk include require information clinical study timely basis fda letter acknowledge information capture periodic report case submit agency report communication addition information start clinical trial omit report available wwwclinicaltrialsgov clinical trial result post publicly gsk clinical study register acknowledge seriousness issue raise warning letter corrective step take underway sure periodic report file completely promptly inspection gsk initiate review applicable process report system continue progress update procedure improve compliance area report include additional training ensure procedure follow product line gsk work continuously monitor necessary enhance compliance system procedure home responsibility research practice training auditing corporate responsibility report training auditing approach performance train clinical trial training activity relate good clinical practice gcp training activity represent successful completion elearning module instructorle course relate gcp employee contractor audit clinical trial conduct audits include audits investigator site conduct gsksponsore trial represent approximately cent investigator site participate pivotal clinical trial audits internal gsk system process manage clinical trial data audits clinical research organisation carry clinical trial gsk behalf audits gsk local operating company involve clinical research activity win addition investigation conduct response suspect irregularity investigator site issue identify investigator site include insufficient oversight clinical trial activity investigator oversight cover area investigator responsibility include knowledge protocol design appropriate document delegation task skilled personnel availability meet sponsor representative regular interval study additional training investigator implementation internal control help reduce frequency significance issue inspection investigator clinical research organisation independent ethic committeesinstitutional review board sponsor clinical trial carry regulatory authority ensure safety trial participant quality datum trial conduct accord good clinical practice inspection gsk investigator gsk conduct clinical trial food drug administration fda conduct routine post marketing adverse drug experience inspection inspection involve review gsk process receive capture track adverse drug experience information gsk product report datum fda course inspection inspector focus gsk compliance regulatory requirement new drug application nda annual report periodic adverse drug experience report result inspection gsk receive warning letter agency march fda determine product certain require report submit gsk include require information clinical study timely basis fda letter acknowledge information capture periodic report case submit agency report communication addition information start clinical trial omit report available wwwclinicaltrialsgov clinical trial result post publicly gsk clinical study register acknowledge seriousness issue raise warning letter corrective step take underway sure periodic report file completely promptly inspection gsk initiate review applicable process report system continue progress update procedure improve compliance area report include additional training ensure procedure follow product line gsk work continuously monitor necessary enhance compliance system procedure home responsibility research practice case study corporate responsibility report case study focus patient programme focus patient programme help rd employee understand patient need inspire help improve life patient hold seminar patient visit gsk site help rd employee understand reality live illness seminar include discussion breast cancer cystic fibrosis hivaid inflammatory bowel disease schizophrenia epilepsy meningitis hepatitis c pulmonary hypertension idiopathic pulmonary fibrosis migraine headache attendee seminar hold lunchtime session develop idea action session prompt organisation seminar site verona italy provide insight local scientist develop medicine sleep disorder depression idea lead patient empower project improve patient experience gsk clinical trial patientfocuse study design simplify patientdirecte communication inform employee patient help work rd regular monthly bulletin highlight key medicine pipeline meet need patient help motivate employee remind importance work survey rd employee show respondent feel increase patient focus business great application patient focus work process development medicine clinical study register important result study evaluate medicine public domain enable information help inform medical judgement advance medical science traditionally publication scientific medical journal seek recognise limitation study publish researcher possible publish study peer review journal post summary study internet initiate enable study track publication study publicly disclose identify researcher call account posting result study complete mean result public domain study accept publication gsk provide online clinical study register contain result trial cover gsk product date company form launch pleased site success late figure site receive visitor month take step build commitment transparency clinical research help people quickly find information need launch revise version clinical study register include improved user interface make easy user find information disease area medicine add observational research metaanalyse evaluate medicine study terminate compound register add current commitment postprotocol summary summary result gsk clinical trial phase llv market medicine disclosure research protocol result online see supplement replacement need publish study peer review journal believe level ppaugeb lic disclosure achieve posting result register achieve paper publish peer review journal fully explain study place result context gsk aim publish clinical research medicine comprehensive paper peer review journal study publish provide context interpretation registerhome responsibility research practice case study corporate responsibility report case study focus patient programme focus patient programme help rd employee understand patient need inspire help improve life patient hold seminar patient visit gsk site help rd employee understand reality live illness seminar include discussion breast cancer cystic fibrosis hivaid inflammatory bowel disease schizophrenia epilepsy meningitis hepatitis c pulmonary hypertension idiopathic pulmonary fibrosis migraine headache attendee seminar hold lunchtime session develop idea action session prompt organisation seminar site verona italy provide insight local scientist develop medicine sleep disorder depression idea lead patient empower project improve patient experience gsk clinical trial patientfocuse study design simplify patientdirecte communication inform employee patient help work rd regular monthly bulletin highlight key medicine pipeline meet need patient help motivate employee remind importance work survey rd employee show respondent feel increase patient focus business great application patient focus work process development medicine clinical study register important result study evaluate medicine public domain enable information help inform medical judgement advance medical science traditionally publication scientific medical journal seek recognise limitation study publish researcher possible publish study peer review journal post summary study internet initiate enable study track publication study publicly disclose identify researcher call account posting result study complete mean result public domain study accept publication gsk provide online clinical study register contain result trial cover gsk product date company form launch pleased site success late figure site receive visitor month take step build commitment transparency clinical research help people quickly find information need launch revise version clinical study register include improved user interface make easy user find information disease area medicine add observational research metaanalyse evaluate medicine study terminate compound register add current commitment postprotocol summary summary result gsk clinical trial phase llv market medicine disclosure research protocol result online see supplement replacement need publish study peer review journal believe level public disclosure achieve posting result register achieve paper publish peer review journal fully explain study place result context gsk aim publish clinical research medicine comprehensive paper peer review journal study publish provide context interpretation register home responsibility research practice case study corporate responsibility report case study focus patient programme focus patient programme help rd employee understand patient need inspire help improve life patient hold seminar patient visit gsk site help rd employee understand reality live illness seminar include discussion breast cancer cystic fibrosis hivaid inflammatory bowel disease schizophrenia epilepsy meningitis hepatitis c pulmonary hypertension idiopathic pulmonary fibrosis migraine headache attendee seminar hold lunchtime session develop idea action session prompt organisation seminar site verona italy provide insight local scientist develop medicine sleep disorder depression idea lead patient empower project improve patient experience gsk clinical trial patientfocuse study design simplify patientdirecte communication inform employee patient help work rd regular monthly bulletin highlight key medicine pipeline meet need patient help motivate employee remind importance work survey rd employee show respondent feel increase patient focus business great application patient focus work process development medicine clinical study register important result study evaluate medicine public domain enable information help inform medical judgement advance medical science traditionally publication scientific medical journal seek recognise limitation study publish researcher possible publish study peer review journal post summary study internet initiate enable study track publication study publicly disclose identify researcher call account posting result study complete mean result public domain study accept publication gsk provide online clinical study register contain result trial cover gsk product date company form launch pleased site success late figure site receive visitor month take step build commitment transparency clinical research help people quickly find information need launch revise version clinical study register include improved user interface make easy user find information disease area medicine add observational research metaanalyse evaluate medicine study terminate compound register add current commitment postprotocol summary summary result gsk clinical trial phase llv market medicine disclosure research protocol result online see supplement replacement need publish study peer review journal believe level public disclosure achieve posting result register achieve paper publish peer review journal fully explain study place result context gsk aim publish clinical research medicine comprehensive paper peer review journal study publish provide context interpretation register home responsibility research practice qas corporate responsibility report qas respond question raise stakeholder assure risk healthy volunteer experimental medicine time minimise clinical trial place new compound undergo series stringent laboratory test test involve use animal human tissue predict effect investigational medicine human body include potential effect basis prediction establish dose level sufficient margin safety andor appropriate monitoring procedure preclinical datum laboratory test proposal design time human clinical trial review gsk committee know global safety board experience senior physician expert independent project team regulatory authority independent ethic committee approve trial ahead clinical trial design minimise risk example initially volunteer low dose investigational medicine increase dose gradually carefully sequence subgroup cautious approach trial investigational medicine test human time conduct clinical unit rapid access hospital emergency care clinical trial volunteer provide information study include potential risk opportunity discuss risk researcher decide participate know informed consent plan enter research collaboration ensure organisation partner meet research animal welfare standard recognise work collaboration organisation bring certain risk develop routine safeguard ensure partner work accord core principle gsk include govern use animal research check apply evaluate enter collaboration subsequently ongoing basis framework establish govern collaboration typically joint steering committee gsk willingness enter continue collaboration depend adequate assurance share commitment core principle gsk open rd facility china affect research standard cost reduction exercise open new rd facility china focus rd neurodegenerative disorder well therapy desperately need alzheimer disease parkinson disease multiple sclerosis cost conduct research china currently relativity low market low cost reason decision set new facility new centre enable benefit access vast talent pool knowledge life sciences china increase focus depth important disease area rd china conduct accordance gsk global quality ethical standard rd policy monitor procedure apply operation china commit significant regional local resource ensure operation china comply chinese government requirement gsk global standard home responsibility research practice qas corporate responsibility report qas respond question raise stakeholder assure risk healthy volunteer experimental medicine time minimise clinical trial place new compound undergo series stringent laboratory test test involve use animal human tissue predict effect investigational medicine human body include potential effect basis prediction establish dose level sufficient margin safety andor appropriate monitoring procedure preclinical datum laboratory test proposal design time human clinical trial review gsk committee know global safety board experience senior physician expert independent project team regulatory authority independent ethic committee approve trial ahead clinical trial design minimise risk example initially volunteer low dose investigational medicine increase dose gradually carefully sequence subgroup cautious approach trial investigational medicine test human time conduct clinical unit rapid access hospital emergency care clinical trial volunteer provide information study include potential risk opportunity discuss risk researcher decide participate know informed consent plan enter research collaboration ensure organisation partner meet research animal welfare standard recognise work collaboration organisation bring certain risk develop routine safeguard ensure partner work accord core principle gsk include govern use animal research check apply evaluate enter collaboration subsequently ongoing basis framework establish govern collaboration typically joint steering committee gsk willingness enter continue collaboration depend adequate assurance share commitment core principle gsk open rd facility china affect research standard cost reduction exercise open new rd facility china focus rd neurodegenerative disorder well therapy desperately need alzheimer disease parkinson disease multiple sclerosis cost conduct research china currently relativity low market low cost reason decision set new facility new centre enable benefit access vast talent pool knowledge life sciences china increase focus depth important disease area rd china conduct accordance gsk global quality ethical standard rd policy monitor procedure apply operation china commit significant regional local resource ensure operation china comply chinese government requirement gsk global standard home responsibility research practice qas corporate responsibility report qas respond question raise stakeholder assure risk healthy volunteer experimental medicine time minimise clinical trial place new compound undergo series stringent laboratory test test involve use animal human tissue predict effect investigational medicine human body include potential effect basis prediction establish dose level sufficient margin safety andor appropriate monitoring procedure preclinical datum laboratory test proposal design time human clinical trial review gsk committee know global safety board experience senior physician expert independent project team regulatory authority independent ethic committee approve trial ahead clinical trial design minimise risk example initially volunteer low dose investigational medicine increase dose gradually carefully sequence subgroup cautious approach trial investigational medicine test human time conduct clinical unit rapid access hospital emergency care clinical trial volunteer provide information study include potential risk opportunity discuss risk researcher decide participate know informed consent plan enter research collaboration ensure organisation partner meet research animal welfare standard recognise work collaboration organisation bring certain risk develop routine safeguard ensure partner work accord core principle gsk include govern use animal research check apply evaluate enter collaboration subsequently ongoing basis framework establish govern collaboration typically joint steering committee gsk willingness enter continue collaboration depend adequate assurance share commitment core principle gsk open rd facility china affect research standard cost reduction exercise open new rd facility china focus rd neurodegenerative disorder well therapy desperately need alzheimer disease parkinson disease multiple sclerosis cost conduct research china currently relativity low market low cost reason decision set new facility new centre enable benefit access vast talent pool knowledge life sciences china increase focus depth important disease area rd china conduct accordance gsk global quality ethical standard rd policy monitor procedure apply operation china commit significant regional local resource ensure operation china comply chinese government requirement gsk global standard home responsibility ethical conduct corporate responsibility report ethical conduct commit create strong ethical culture gsk put appropriate policy place recruit right people equip tool ethical decision put patient core principle ethical pharmaceutical company profit principle short live failure uphold high standard ethical conduct carry significant business risk erosion trust gsk product include regulator doctor patient fine litigation result financial legal consequence damage gsk reputation code conduct set fundamental standard employee employee guide business conduct build code explain employee meet requirement provide guidance include specific example constitute unethical behaviour strong policy code practice good training essential element approach guarantee employee meet standard internal compliance system design identify address breach code fully investigate suspect breach appropriate disciplinary action include dismissal appropriate clear policy procedure prevent corrupt anticompetitive behaviour maintain high ethical standard marketing vital relevant patient safety essential marketing practice help doctor prescribe medicine patient good interest policy prohibit kickback bribery inducement doctor promotion unapproved use medicine maintain high ethical standard stage rd product approve marketing key commitment patient ethical compass employee guide business conduct include ethical compass help employee deal ethical issue difficult resolve faced situation encourage people ask question legal ethical consistent gsk policy code conduct consistent gsk mission spirit explain family friend comfortable appeared newspaper encourage employee seek additional guidance ask question certain making right choice home responsibility ethical conduct corporate responsibility report ethical conduct commit create strong ethical culture gsk put appropriate policy place recruit right people equip tool ethical decision put patient core principle ethical pharmaceutical company profit principle short live failure uphold high standard ethical conduct carry significant business risk erosion trust gsk product include regulator doctor patient fine litigation result financial legal consequence damage gsk reputation code conduct set fundamental standard employee employee guide business conduct build code explain employee meet requirement provide guidance include specific example constitute unethical behaviour strong policy code practice good training essential element approach guarantee employee meet standard internal compliance system design identify address breach code fully investigate suspect breach appropriate disciplinary action include dismissal appropriate clear policy procedure prevent corrupt anticompetitive behaviour maintain high ethical standard marketing vital relevant patient safety essential marketing practice help doctor prescribe medicine patient good interest policy prohibit kickback bribery inducement doctor promotion unapproved use medicine maintain high ethical standard stage rd product approve marketing key commitment patient ethical compass employee guide business conduct include ethical compass help employee deal ethical issue difficult resolve faced situation encourage people ask question legal ethical consistent gsk policy code conduct consistent gsk mission spirit explain family friend comfortable appeared newspaper encourage employee seek additional guidance ask question certain making right choice home responsibility ethical conduct code conduct business ethic corporate responsibility report code conduct business ethic code conduct gsk code conduct set standard expect employee contractor contain follow key requirement conduct business honesty integrity professional manner protect gsk good public image reputation build relationship customer vendor supplier fellow employee base trust treat individual respect dignity conduct business familiar comply legal requirement gsk policy procedure avoid activity involve lead involvement unlawful practice harm gsk reputation image avoid actual potential conflict interest gsk appearance thereof transaction read code conduct employee guide business conduct build code explain employee meet requirement business ethic corrupt anticompetitive behaviour undermine fair competition inhibit economic development bad economy business people employee guide business conduct contain policy guidance ensure operate letter spirit law maintain high standard ethical business behaviour anticompetitive behaviour commit free open competition succeed company high quality competitiveness product talent commitment employee policy anticompetitive behaviour cover issue merger abuse monopoly power resale price maintenance predatory pricing restrictive agreement practice set standard behaviour expect employee agent prevent corruption policy anticorruption forbid payment inducement political candidate legislator political party party official government official employee local national include official employee governmentowne enterprise public international organisation separate policy political contribution donation acceptance gift entertainment employee sample question employee guide business conduct question receive order unusual volume combination pharmaceutical new customer location note political instability shipment location country customer say bother include usual consumer use information problem answer red flag need advice gsk legal department information indicate material ship prohibit country improper terrorist activity need know customer advice question vendor offer sell gsk product manager mailing list name individual treat depression concern purchase list answer yes country include eu establish strict law protect healthcare information identifie individual write authorisation individual usually require gsk receive information tophome responsibility ethical conduct code conduct business ethic corporate responsibility report code conduct business ethic code conduct gsk code conduct set standard expect employee contractor contain follow key requirement conduct business honesty integrity professional manner protect gsk good public image reputation build relationship customer vendor supplier fellow employee base trust treat individual respect dignity conduct business familiar comply legal requirement gsk policy procedure avoid activity involve lead involvement unlawful practice harm gsk reputation image avoid actual potential conflict interest gsk appearance thereof transaction read code conduct employee guide business conduct build code explain employee meet requirement business ethic corrupt anticompetitive behaviour undermine fair competition inhibit economic development bad economy business people employee guide business conduct contain policy guidance ensure operate letter spirit law maintain high standard ethical business behaviour anticompetitive behaviour commit free open competition succeed company high quality competitiveness product talent commitment employee policy anticompetitive behaviour cover issue merger abuse monopoly power resale price maintenance predatory pricing restrictive agreement practice set standard behaviour expect employee agent prevent corruption policy anticorruption forbid payment inducement political candidate legislator political party party official government official employee local national include official employee governmentowne enterprise public international organisation separate policy political contribution donation acceptance gift entertainment employee sample question employee guide business conduct question receive order unusual volume combination pharmaceutical new customer location note political instability shipment location country customer say bother include usual consumer use information problem answer red flag need advice gsk legal department information indicate material ship prohibit country improper terrorist activity need know customer advice question vendor offer sell gsk product manager mailing list name individual treat depression concern purchase list answer yes country include eu establish strict law protect healthcare information identifie individual write authorisation individual usually require gsk receive information home responsibility ethical conduct code conduct business ethic corporate responsibility report code conduct business ethic code conduct gsk code conduct set standard expect employee contractor contain follow key requirement conduct business honesty integrity professional manner protect gsk good public image reputation build relationship customer vendor supplier fellow employee base trust treat individual respect dignity conduct business familiar comply legal requirement gsk policy procedure avoid activity involve lead involvement unlawful practice harm gsk reputation image avoid actual potential conflict interest gsk appearance thereof transaction read code conduct employee guide business conduct build code explain employee meet requirement business ethic corrupt anticompetitive behaviour undermine fair competition inhibit economic development bad economy business people employee guide business conduct contain policy guidance ensure operate letter spirit law maintain high standard ethical business behaviour anticompetitive behaviour commit free open competition succeed company high quality competitiveness product talent commitment employee policy anticompetitive behaviour cover issue merger abuse monopoly power resale price maintenance predatory pricing restrictive agreement practice set standard behaviour expect employee agent prevent corruption policy anticorruption forbid payment inducement political candidate legislator political party party official government official employee local national include official employee governmentowne enterprise public international organisation separate policy political contribution donation acceptance gift entertainment employee sample question employee guide business conduct question receive order unusual volume combination pharmaceutical new customer location note political instability shipment location country customer say bother include usual consumer use information problem answer red flag need advice gsk legal department information indicate material ship prohibit country improper terrorist activity need know customer advice question vendor offer sell gsk product manager mailing list name individual treat depression concern purchase list answer yes country include eu establish strict law protect healthcare information identifie individual write authorisation individual usually require gsk receive information home responsibility ethical conduct marketing ethic corporate responsibility report marketing ethic market prescription medicine vaccine doctor hospital government country advertise medicine directly consumer specialist sale representative meet regularly doctor pharmacist inform medicine approve use believe sale representative play important role provide uptodate information doctor product benefit risk patient recognise marketing pharmaceutical product raise challenge issue particular people concern marketing pharmaceutical company exert undue influence doctor sale representative doctor information potential sideeffect promotion unapproved use medicine occur regional marketing code forbid practice unethical conduct provide regular training sale team understand code conduct monitor assess compliance marketing code practice sale promotion pharmaceutical product highly regulate government medical agency develop marketing code policy provide training sale representative ensure understand behave ethically comply law country code policy legal requirement product sell country world priority product country patient safety system process collect analyse report safety concern product marketing code practice apply employee agent commit promotional practice ethical responsible principled patientcentred prohibit kickback bribery inducement doctor promotion unapproved use medicine company policy support regional marketing practice code apply standard reflect difference market structure national healthcare system regulation new phrma code interaction healthcare professional hcp come effect january fully align sale marketing practice requirement code case gsk go requirement code include phase prohibition give non educational item reinforce cap payment individual usbased hcp work consultant company example participate advisory board speak gsksponsore meeting update commercial practice policy cpp available quarter gsk initiate review internal regional code relate sale promotion pharmaceutical product review intend align legally culturally appropriate gsk regional code alignment lead gsk develop detailed global principle guide sale marketing gsk pharmaceutical product world help strengthen industry code gsk support effort strengthen marketing standard pharmaceutical industry benefit create level playing field country operate help improve reputation pharmaceutical industry take active role work pharmaceutical industry association phrma develop change code interaction healthcare professional gsk certify compliance code quarter code guide sale marketing gsk pharmaceutical product marketing code practice summary accurate information information provide approve use medicine base valid scientific evidence accurate balanced fair objective unambiguous date promotional item healthcare professional brand promotional item give occasionally relevant practice medicine nominal value uk long distribute noneducational item line phrma code item give inducement prescribe medicine medical professional retain consultant gsk appropriate hospitality meeting entertainment permit hospitality travel cost food provide meeting educational professional purpose level hospitality appropriate occasion provide relevant healthcare professional spouse child office personnel guest decision grant medical education review qualified medical scientific personnel tophome responsibility ethical conduct marketing ethic corporate responsibility report marketing ethic market prescription medicine vaccine doctor hospital government country advertise medicine directly consumer specialist sale representative meet regularly doctor pharmacist inform medicine approve use believe sale representative play important role provide uptodate information doctor product benefit risk patient recognise marketing pharmaceutical product raise challenge issue particular people concern marketing pharmaceutical company exert undue influence doctor sale representative doctor information potential sideeffect promotion unapproved use medicine occur regional marketing code forbid practice unethical conduct provide regular training sale team understand code conduct monitor assess compliance marketing code practice sale promotion pharmaceutical product highly regulate government medical agency develop marketing code policy provide training sale representative ensure understand behave ethically comply law country code policy legal requirement product sell country world priority product country patient safety system process collect analyse report safety concern product marketing code practice apply employee agent commit promotional practice ethical responsible principled patientcentred prohibit kickback bribery inducement doctor promotion unapproved use medicine company policy support regional marketing practice code apply standard reflect difference market structure national healthcare system regulation new phrma code interaction healthcare professional hcp come effect january fully align sale marketing practice requirement code case gsk go requirement code include phase prohibition give non educational item reinforce cap payment individual usbased hcp work consultant company example participate advisory board speak gsksponsore meeting update commercial practice policy cpp available quarter gsk initiate review internal regional code relate sale promotion pharmaceutical product review intend align legally culturally appropriate gsk regional code alignment lead gsk develop detailed global principle guide sale marketing gsk pharmaceutical product world help strengthen industry code gsk support effort strengthen marketing standard pharmaceutical industry benefit create level playing field country operate help improve reputation pharmaceutical industry take active role work pharmaceutical industry association phrma develop change code interaction healthcare professional gsk certify compliance code quarter code guide sale marketing gsk pharmaceutical product marketing code practice summary accurate information information provide approve use medicine base valid scientific evidence accurate balanced fair objective unambiguous date promotional item healthcare professional brand promotional item give occasionally relevant practice medicine nominal value uk long distribute noneducational item line phrma code item give inducement prescribe medicine medical professional retain consultant gsk appropriate hospitality meeting entertainment permit hospitality travel cost food provide meeting educational professional purpose level hospitality appropriate occasion provide relevant healthcare professional spouse child office personnel guest decision grant medical education review qualified medical scientific personnel home responsibility ethical conduct marketing ethic corporate responsibility report marketing ethic market prescription medicine vaccine doctor hospital government country advertise medicine directly consumer specialist sale representative meet regularly doctor pharmacist inform medicine approve use believe sale representative play important role provide uptodate information doctor product benefit risk patient recognise marketing pharmaceutical product raise challenge issue particular people concern marketing pharmaceutical company exert undue influence doctor sale representative doctor information potential sideeffect promotion unapproved use medicine occur regional marketing code forbid practice unethical conduct provide regular training sale team understand code conduct monitor assess compliance marketing code practice sale promotion pharmaceutical product highly regulate government medical agency develop marketing code policy provide training sale representative ensure understand behave ethically comply law country code policy legal requirement product sell country world priority product country patient safety system process collect analyse report safety concern product marketing code practice apply employee agent commit promotional practice ethical responsible principled patientcentred prohibit kickback bribery inducement doctor promotion unapproved use medicine company policy support regional marketing practice code apply standard reflect difference market structure national healthcare system regulation new phrma code interaction healthcare professional hcp come effect january fully align sale marketing practice requirement code case gsk go requirement code include phase prohibition give non educational item reinforce cap payment individual usbased hcp work consultant company example participate advisory board speak gsksponsore meeting update commercial practice policy cpp available quarter gsk initiate review internal regional code relate sale promotion pharmaceutical product review intend align legally culturally appropriate gsk regional code alignment lead gsk develop detailed global principle guide sale marketing gsk pharmaceutical product world help strengthen industry code gsk support effort strengthen marketing standard pharmaceutical industry benefit create level playing field country operate help improve reputation pharmaceutical industry take active role work pharmaceutical industry association phrma develop change code interaction healthcare professional gsk certify compliance code quarter code guide sale marketing gsk pharmaceutical product marketing code practice summary accurate information information provide approve use medicine base valid scientific evidence accurate balanced fair objective unambiguous date promotional item healthcare professional brand promotional item give occasionally relevant practice medicine nominal value uk long distribute noneducational item line phrma code item give inducement prescribe medicine medical professional retain consultant gsk appropriate hospitality meeting entertainment permit hospitality travel cost food provide meeting educational professional purpose level hospitality appropriate occasion provide relevant healthcare professional spouse child office personnel guest decision grant medical education review qualified medical scientific personnel home responsibility ethical conduct marketing ethic relationship healthcare professional corporate responsibility report relationship healthcare professional approach performance plan marketing code detailed policy monitor system govern relationship healthcare professional follow area medical education programme provide funding enable physician pharmacist nurse healthcare professional attend education course conference therapeutic area relevant gsk consider marketing policy state content education programme choice faculty independently approve sponsor speaker provide sponsorship healthcare professional attend conference present research result speak healthcare issue speaker declare speech fund gsk advisory service engage healthcare professional understand unmet medical need development science treatment help understand current future market product engagement form convene advisory panel conduct broad market research read engage healthcare professional conduct medical research behalf policy process vary region comply local law industry practice meet exceed code relationship healthcare professional follow industry organisation pharmaceutical research manufacturers america phrma european federation pharmaceutical industry association efpia international federation pharmaceutical manufacturer association ifpma japan pharmaceuticals manufacturers association jpma policy process restrict include limit payment healthcare professional speaker advisory fee year individual physician majority healthcare professional consultant receive fee total year state reporting system expenditure healthcare professional line legislation state system help investigate situation excessive meal gift provide gsk requirement gsk funding grant healthcarerelate group include patient advocacy group physician association exceed cent group annual income speaker evaluation process cover healthcare professional sponsor gsk require regional medical scientist evaluate highfrequency speaker provide feedback healthcare professional effectiveness compliance gsk speaker programme policy process monitor question pose doctor medical information department offlabel use product number type referral individual representative help ensure representative promote offlabel use question doctor offlabel use product refer medical information department home responsibility ethical conduct marketing ethic relationship healthcare professional corporate responsibility report relationship healthcare professional approach performance plan marketing code detailed policy monitor system govern relationship healthcare professional follow area medical education programme provide funding enable physician pharmacist nurse healthcare professional attend education course conference therapeutic area relevant gsk consider marketing policy state content education programme choice faculty independently approve sponsor speaker provide sponsorship healthcare professional attend conference present research result speak healthcare issue speaker declare speech fund gsk advisory service engage healthcare professional understand unmet medical need development science treatment help understand current future market product engagement form convene advisory panel conduct broad market research read engage healthcare professional conduct medical research behalf policy process vary region comply local law industry practice meet exceed code relationship healthcare professional follow industry organisation pharmaceutical research manufacturers america phrma european federation pharmaceutical industry association efpia international federation pharmaceutical manufacturer association ifpma japan pharmaceuticals manufacturers association jpma policy process restrict include limit payment healthcare professional speaker advisory fee year individual physician majority healthcare professional consultant receive fee total year state reporting system expenditure healthcare professional line legislation state system help investigate situation excessive meal gift provide gsk requirement gsk funding grant healthcarerelate group include patient advocacy group physician association exceed cent group annual income speaker evaluation process cover healthcare professional sponsor gsk require regional medical scientist evaluate highfrequency speaker provide feedback healthcare professional effectiveness compliance gsk speaker programme policy process monitor question pose doctor medical information department offlabel use product number type referral individual representative help ensure representative promote offlabel use question doctor offlabel use product refer medical information department home responsibility ethical conduct marketing ethic relationship healthcare professional corporate responsibility report relationship healthcare professional approach performance plan marketing code detailed policy monitor system govern relationship healthcare professional follow area medical education programme provide funding enable physician pharmacist nurse healthcare professional attend education course conference therapeutic area relevant gsk consider marketing policy state content education programme choice faculty independently approve sponsor speaker provide sponsorship healthcare professional attend conference present research result speak healthcare issue speaker declare speech fund gsk advisory service engage healthcare professional understand unmet medical need development science treatment help understand current future market product engagement form convene advisory panel conduct broad market research read engage healthcare professional conduct medical research behalf policy process vary region comply local law industry practice meet exceed code relationship healthcare professional follow industry organisation pharmaceutical research manufacturers america phrma european federation pharmaceutical industry association efpia international federation pharmaceutical manufacturer association ifpma japan pharmaceuticals manufacturers association jpma policy process restrict include limit payment healthcare professional speaker advisory fee year individual physician majority healthcare professional consultant receive fee total year state reporting system expenditure healthcare professional line legislation state system help investigate situation excessive meal gift provide gsk requirement gsk funding grant healthcarerelate group include patient advocacy group physician association exceed cent group annual income speaker evaluation process cover healthcare professional sponsor gsk require regional medical scientist evaluate highfrequency speaker provide feedback healthcare professional effectiveness compliance gsk speaker programme policy process monitor question pose doctor medical information department offlabel use product number type referral individual representative help ensure representative promote offlabel use question doctor offlabel use product refer medical information department home responsibility ethical conduct marketing ethic relationship healthcare professional corporate responsibility report relationship healthcare professional approach performance plan united states payment healthcare professional consultancy work participate advisory board speak gsksponsore meeting majority hcp consultant receive fee total year reinforce cap payment hcp year individual physician interest physicians work receive excessive funding gsk ensure work gsk detract time spend patient conduct research reduce professional credibility value gsk source current medical expertise europe change european code practice interaction healthcare professional response new code promotion publish european federation pharmaceutical industry association follow change refinement code use consultant gsk employee responsible select consultant expertise evaluate consultant suitable meet identify business need real value gsk consultant require declare consultancy arrangement speak publicly relate issue sample product sample give limit number limit time reference local standard purpose familiarisation replace previous limit restrictive specify quantity timeframe grant donation introduce new policy grant financial donation health organisation involve grant donation receive service return new policy state grant donation give health organisation response unsolicite request purpose healthcare research offer give understand recipient prescribe recommend product document publish externally meet requirement grant recipient publish gsk website permit health organisation individual phase lv clinical study study conduct medicine approve marketing clarify principle study clearly set term gsk collaborative study study commission inducement prescribe supply recommend medicine clear scientific andor educational purpose contract institution undertake research trial protocol review approve ethical committee available gsk rd medical personnel approve supervise study result distribute investigator asia pacific japan emerge market gsk continue active ifpma code compliance network senior country manager supportive lead industry change strengthen local code nigeria gsk receive good compliant company award issue nafdac regulatory authority award kind aim encourage compliance company nigeria encourage nigerians buy company deem compliant nafdac australia january gsk australia stop distribute brand reminder healthcare professional include pen notepad exception new brand launch align behaviour community expectation interact customer plan publish grant donation europe australia initiative state victoria operating model effect august deliver improve control sample accountability security support aim achieve high level professional standard field sale force long distribute sample directly healthcare professional instead order take medical representative sample deliver direct surgery central warehouse gsk international promotion marketing code applicable emerge market asia pacific region subject regular twoyear review revision incorporate major structural change align structure content ifpma code go case tophome responsibility ethical conduct marketing ethic relationship healthcare professional corporate responsibility report relationship healthcare professional approach performance plan united states payment healthcare professional consultancy work participate advisory board speak gsksponsore meeting majority hcp consultant receive fee total year reinforce cap payment hcp year individual physician interest physicians work receive excessive funding gsk ensure work gsk detract time spend patient conduct research reduce professional credibility value gsk source current medical expertise europe change european code practice interaction healthcare professional response new code promotion publish european federation pharmaceutical industry association follow change refinement code use consultant gsk employee responsible select consultant expertise evaluate consultant suitable meet identify business need real value gsk consultant require declare consultancy arrangement speak publicly relate issue sample product sample give limit number limit time reference local standard purpose familiarisation replace previous limit restrictive specify quantity timeframe grant donation introduce new policy grant financial donation health organisation involve grant donation receive service return new policy state grant donation give health organisation response unsolicite request purpose healthcare research offer give understand recipient prescribe recommend product document publish externally meet requirement grant recipient publish gsk website permit health organisation individual phase lv clinical study study conduct medicine approve marketing clarify principle study clearly set term gsk collaborative study study commission inducement prescribe supply recommend medicine clear scientific andor educational purpose contract institution undertake research trial protocol review approve ethical committee available gsk rd medical personnel approve supervise study result distribute investigator asia pacific japan emerge market gsk continue active ifpma code compliance network senior country manager supportive lead industry change strengthen local code nigeria gsk receive good compliant company award issue nafdac regulatory authority award kind aim encourage compliance company nigeria encourage nigerians buy company deem compliant nafdac australia january gsk australia stop distribute brand reminder healthcare professional include pen notepad exception new brand launch align behaviour community expectation interact customer plan publish grant donation europe australia initiative state victoria operating model effect august deliver improve control sample accountability security support aim achieve high level professional standard field sale force long distribute sample directly healthcare professional instead order take medical representative sample deliver direct surgery central warehouse gsk international promotion marketing code applicable emerge market asia pacific region subject regular twoyear review revision incorporate major structural change align structure content ifpma code go case home responsibility ethical conduct marketing ethic relationship healthcare professional corporate responsibility report relationship healthcare professional approach performance plan united states payment healthcare professional consultancy work participate advisory board speak gsksponsore meeting majority hcp consultant receive fee total year reinforce cap payment hcp year individual physician interest physicians work receive excessive funding gsk ensure work gsk detract time spend patient conduct research reduce professional credibility value gsk source current medical expertise europe change european code practice interaction healthcare professional response new code promotion publish european federation pharmaceutical industry association follow change refinement code use consultant gsk employee responsible select consultant expertise evaluate consultant suitable meet identify business need real value gsk consultant require declare consultancy arrangement speak publicly relate issue sample product sample give limit number limit time reference local standard purpose familiarisation replace previous limit restrictive specify quantity timeframe grant donation introduce new policy grant financial donation health organisation involve grant donation receive service return new policy state grant donation give health organisation response unsolicite request purpose healthcare research offer give understand recipient prescribe recommend product document publish externally meet requirement grant recipient publish gsk website permit health organisation individual phase lv clinical study study conduct medicine approve marketing clarify principle study clearly set term gsk collaborative study study commission inducement prescribe supply recommend medicine clear scientific andor educational purpose contract institution undertake research trial protocol review approve ethical committee available gsk rd medical personnel approve supervise study result distribute investigator asia pacific japan emerge market gsk continue active ifpma code compliance network senior country manager supportive lead industry change strengthen local code nigeria gsk receive good compliant company award issue nafdac regulatory authority award kind aim encourage compliance company nigeria encourage nigerians buy company deem compliant nafdac australia january gsk australia stop distribute brand reminder healthcare professional include pen notepad exception new brand launch align behaviour community expectation interact customer plan publish grant donation europe australia initiative state victoria operating model effect august deliver improve control sample accountability security support aim achieve high level professional standard field sale force long distribute sample directly healthcare professional instead order take medical representative sample deliver direct surgery central warehouse gsk international promotion marketing code applicable emerge market asia pacific region subject regular twoyear review revision incorporate major structural change align structure content ifpma code go case home responsibility ethical conduct marketing ethic directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance legal advertise prescription medicine consumer tv print advertisement know directtoconsumer dtc advertise new zealand bangladesh korea allow limited dtc advertising dtc advertising prescription medicine permit market promote use prescription medicine directly consumer raise concern critic believe encourage people request unnecessary treatment add burden healthcare system believe responsible pharmaceutical advertising useful source health information patient help increase knowledge condition educate patient treatment option country dtc advertise common industry practice competitive disadvantage promote product way patient consult physician condition appropriateness prescription medicine obtain consent receive medicine prescription medicine dtc communication policy base phrma guiding principle direct consumer advertisement prescription medicine detailed approval process dtc advertising include review legal regulatory medical specialist appropriate marketing employee receive training dtc policy dtc television advertisement include audio visual component submit food drug administration fda review day advance broadcast member public healthcare professional send comment complaint dtc advertise phrmas office accountability report comment response company fda fda amendment act impose restriction dtc advertising give fda ability require submission dtc television advertisement day prior dissemination impose new standard presentation safety information broadcast advertisement company responsible false misleading dtc advertisement fine implement provision dtc advertising line act requirement fund diseaseawareness campaign design increase understand specific disease link promotion gsk product govern dtc policy disease awareness campaign include television print advertisement direct mail mention specific gsk product people aware treatment available condition encourage doctor campaign material brand indicate produce gsk overthecounter medicine consumer healthcare product advertising overthecounter medicine oral healthcare nutritional product govern national regulation code practice advertising overthecounter medicine promote pharmacist doctor dentist sale team belong consumer healthcare product association comply code advertising practice nonprescription medicine gsk consumer healthcare advertising review copy review committee large market medical legal personnel small market publication ensure meet standard advertising child guideline advertising child prohibit advertising design appeal target child legally mandate minimum age example comply guideline uk buy advertising space children medium supply vend machine primary school sport star sponsorship important brand lucozade sport guideline state people set appropriate example sponsorship appeal solely child age principle dtc advertise policy require dtc advertising dedicate appropriate time educate healthcare professional prior initiate dtc promotion new medicine new therapeutic indication approve medicine design educate consumer medicine condition prescribe accurate support evidence include information risk benefit treatment provide information treatment option diet lifestyle change reference prescribe information product target audience cent adult tophome responsibility ethical conduct marketing ethic directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance legal advertise prescription medicine consumer tv print advertisement know directtoconsumer dtc advertise new zealand bangladesh korea allow limited dtc advertising dtc advertising prescription medicine permit market promote use prescription medicine directly consumer raise concern critic believe encourage people request unnecessary treatment add burden healthcare system believe responsible pharmaceutical advertising useful source health information patient help increase knowledge condition educate patient treatment option country dtc advertise common industry practice competitive disadvantage promote product way patient consult physician condition appropriateness prescription medicine obtain consent receive medicine prescription medicine dtc communication policy base phrma guiding principle direct consumer advertisement prescription medicine detailed approval process dtc advertising include review legal regulatory medical specialist appropriate marketing employee receive training dtc policy dtc television advertisement include audio visual component submit food drug administration fda review day advance broadcast member public healthcare professional send comment complaint dtc advertise phrmas office accountability report comment response company fda fda amendment act impose restriction dtc advertising give fda ability require submission dtc television advertisement day prior dissemination impose new standard presentation safety information broadcast advertisement company responsible false misleading dtc advertisement fine implement provision dtc advertising line act requirement fund diseaseawareness campaign design increase understand specific disease link promotion gsk product govern dtc policy disease awareness campaign include television print advertisement direct mail mention specific gsk product people aware treatment available condition encourage doctor campaign material brand indicate produce gsk overthecounter medicine consumer healthcare product advertising overthecounter medicine oral healthcare nutritional product govern national regulation code practice advertising overthecounter medicine promote pharmacist doctor dentist sale team belong consumer healthcare product association comply code advertising practice nonprescription medicine gsk consumer healthcare advertising review copy review committee large market medical legal personnel small market publication ensure meet standard advertising child guideline advertising child prohibit advertising design appeal target child legally mandate minimum age example comply guideline uk buy advertising space children medium supply vend machine primary school sport star sponsorship important brand lucozade sport guideline state people set appropriate example sponsorship appeal solely child age principle dtc advertise policy require dtc advertising dedicate appropriate time educate healthcare professional prior initiate dtc promotion new medicine new therapeutic indication approve medicine design educate consumer medicine condition prescribe accurate support evidence include information risk benefit treatment provide information treatment option diet lifestyle change reference prescribe information product target audience cent adult home responsibility ethical conduct marketing ethic directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance legal advertise prescription medicine consumer tv print advertisement know directtoconsumer dtc advertise new zealand bangladesh korea allow limited dtc advertising dtc advertising prescription medicine permit market promote use prescription medicine directly consumer raise concern critic believe encourage people request unnecessary treatment add burden healthcare system believe responsible pharmaceutical advertising useful source health information patient help increase knowledge condition educate patient treatment option country dtc advertise common industry practice competitive disadvantage promote product way patient consult physician condition appropriateness prescription medicine obtain consent receive medicine prescription medicine dtc communication policy base phrma guiding principle direct consumer advertisement prescription medicine detailed approval process dtc advertising include review legal regulatory medical specialist appropriate marketing employee receive training dtc policy dtc television advertisement include audio visual component submit food drug administration fda review day advance broadcast member public healthcare professional send comment complaint dtc advertise phrmas office accountability report comment response company fda fda amendment act impose restriction dtc advertising give fda ability require submission dtc television advertisement day prior dissemination impose new standard presentation safety information broadcast advertisement company responsible false misleading dtc advertisement fine implement provision dtc advertising line act requirement fund diseaseawareness campaign design increase understand specific disease link promotion gsk product govern dtc policy disease awareness campaign include television print advertisement direct mail mention specific gsk product people aware treatment available condition encourage doctor campaign material brand indicate produce gsk overthecounter medicine consumer healthcare product advertising overthecounter medicine oral healthcare nutritional product govern national regulation code practice advertising overthecounter medicine promote pharmacist doctor dentist sale team belong consumer healthcare product association comply code advertising practice nonprescription medicine gsk consumer healthcare advertising review copy review committee large market medical legal personnel small market publication ensure meet standard advertising child guideline advertising child prohibit advertising design appeal target child legally mandate minimum age example comply guideline uk buy advertising space children medium supply vend machine primary school sport star sponsorship important brand lucozade sport guideline state people set appropriate example sponsorship appeal solely child age principle dtc advertise policy require dtc advertising dedicate appropriate time educate healthcare professional prior initiate dtc promotion new medicine new therapeutic indication approve medicine design educate consumer medicine condition prescribe accurate support evidence include information risk benefit treatment provide information treatment option diet lifestyle change reference prescribe information product target audience cent adult home responsibility ethical conduct marketing ethic directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance problem gsk dtc advertising identify fda receive comment phrma office accountability relate gsk dtc print advertisement february gsk receive letter food drug administration division drug marketing advertising communication say television advertisement present mislead suggestion superiority drug therapy overstate efficacy gsk product avodart advertisement air march september long use time letter receive continue effort ensure future advertisement incorporate direction provide fda home responsibility ethical conduct marketing ethic directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance problem gsk dtc advertising identify fda receive comment phrma office accountability relate gsk dtc print advertisement february gsk receive letter food drug administration division drug marketing advertising communication say television advertisement present mislead suggestion superiority drug therapy overstate efficacy gsk product avodart advertisement air march september long use time letter receive continue effort ensure future advertisement incorporate direction provide fda home responsibility ethical conduct training awareness corporate responsibility report train awareness train awareness programme help employee understand importance ethical conduct apply policy practice new employee uk complete induction training code conduct available intranet site annual management certification programme require manager confirm comply ethic policy programme cover manager worldwide manager access elearning module ethical leadership specialised training provide employee work rd manufacturing sale market additional regulatory requirement corporate ethic compliance intranet contain link company policy ethic compliance train new recruit ethical decisionmake model ethic quiz contact detail compliance officer free phone number global confidential reporting line phone line available language report concern employee relate compliance policy code conduct integrity helpline base provide advice caller outside company code conduct issue report channel training employee work sale marketing include induction training testing marketing code practice detailed training sale representative medicine promote disease design treat regular refresher course hold year regular management update europe emerge market asia pacific type unethical conduct detect disciplinary action take ethic training practice ethic training help employee right decision apply policy practice example new employee encourage ask follow question make decision legal ethical consistent gsk policy code conduct consistent gsk mission spirit explain family friend comfortable appeared newspaper run ethical decisionmake training establish employee leader train employee explore ethical dilemma face work receive guidance help understand appropriate response example ethical dilemma arrive office large gift basket fill expensive chocolate gourmet treat desk estimate value enclose note consultant thank choose consulting partner look forward work gift choose consultant gift not consider influence decision b owner explain gift certainly thoughtful accept gsk policy accept item tell return gift basket look forward work firm c goody office coffee station enjoy good solution return gift answer b tophome responsibility ethical conduct training awareness corporate responsibility report train awareness train awareness programme help employee understand importance ethical conduct apply policy practice new employee uk complete induction training code conduct available intranet site annual management certification programme require manager confirm comply ethic policy programme cover manager worldwide manager access elearning module ethical leadership specialised training provide employee work rd manufacturing sale market additional regulatory requirement corporate ethic compliance intranet contain link company policy ethic compliance train new recruit ethical decisionmake model ethic quiz contact detail compliance officer free phone number global confidential reporting line phone line available language report concern employee relate compliance policy code conduct integrity helpline base provide advice caller outside company code conduct issue report channel training employee work sale marketing include induction training testing marketing code practice detailed training sale representative medicine promote disease design treat regular refresher course hold year regular management update europe emerge market asia pacific type unethical conduct detect disciplinary action take ethic training practice ethic training help employee right decision apply policy practice example new employee encourage ask follow question make decision legal ethical consistent gsk policy code conduct consistent gsk mission spirit explain family friend comfortable appeared newspaper run ethical decisionmake training establish employee leader train employee explore ethical dilemma face work receive guidance help understand appropriate response example ethical dilemma arrive office large gift basket fill expensive chocolate gourmet treat desk estimate value enclose note consultant thank choose consulting partner look forward work gift choose consultant gift not consider influence decision b owner explain gift certainly thoughtful accept gsk policy accept item tell return gift basket look forward work firm c goody office coffee station enjoy good solution return gift answer b home responsibility ethical conduct training awareness corporate responsibility report train awareness train awareness programme help employee understand importance ethical conduct apply policy practice new employee uk complete induction training code conduct available intranet site annual management certification programme require manager confirm comply ethic policy programme cover manager worldwide manager access elearning module ethical leadership specialised training provide employee work rd manufacturing sale market additional regulatory requirement corporate ethic compliance intranet contain link company policy ethic compliance train new recruit ethical decisionmake model ethic quiz contact detail compliance officer free phone number global confidential reporting line phone line available language report concern employee relate compliance policy code conduct integrity helpline base provide advice caller outside company code conduct issue report channel training employee work sale marketing include induction training testing marketing code practice detailed training sale representative medicine promote disease design treat regular refresher course hold year regular management update europe emerge market asia pacific type unethical conduct detect disciplinary action take ethic training practice ethic training help employee right decision apply policy practice example new employee encourage ask follow question make decision legal ethical consistent gsk policy code conduct consistent gsk mission spirit explain family friend comfortable appeared newspaper run ethical decisionmake training establish employee leader train employee explore ethical dilemma face work receive guidance help understand appropriate response example ethical dilemma arrive office large gift basket fill expensive chocolate gourmet treat desk estimate value enclose note consultant thank choose consulting partner look forward work gift choose consultant gift not consider influence decision b owner explain gift certainly thoughtful accept gsk policy accept item tell return gift basket look forward work firm c goody office coffee station enjoy good solution return gift answer b home responsibility ethical conduct training awareness lead example corporate responsibility report lead example senior manager expect lead example comply company policy support staff reinforce annually formal management certification business ethic manager confirm understand compliance company policy contain employee guide business conduct management certification promote awareness gsk ethical standard company policy emphasise importance company policy thousand gsk employee course daily activity comply law company policy conduct company transaction certification statement understand gsk commit principle performance integrity particular ensuring activity comply applicable law receive copy access gsk code conduct polgsk gsk corporate policy corporate policy index accessible corporate ethic compliance community read understand employee guide business conduct accessible corporate ethic compliance community comply applicable law regulation gsk corporate local policy procedure understand responsibility promptly report actual suspect violation law regulation gsk corporate local policy procedure report actual potential compliance issue aware concern legal requirement company policy follow statement applicable supervisor personnel management responsibility people supervision receive copy access gsk code conduct applicable gsk policy inform responsibility place appropriate measure ensure people supervision comply applicable law regulation gsk corporate local policy procedure work behalf gsk new hire employee supervision complete schedule complete gsk corporate ethic compliance new hire training program gsk induction corporate ethic compliance community read understand shall comply fully policy procedure specify learn activity home responsibility ethical conduct training awareness lead example corporate responsibility report lead example senior manager expect lead example comply company policy support staff reinforce annually formal management certification business ethic manager confirm understand compliance company policy contain employee guide business conduct management certification promote awareness gsk ethical standard company policy emphasise importance company policy thousand gsk employee course daily activity comply law company policy conduct company transaction certification statement understand gsk commit principle performance integrity particular ensuring activity comply applicable law receive copy access gsk code conduct polgsk gsk corporate policy corporate policy index accessible corporate ethic compliance community read understand employee guide business conduct accessible corporate ethic compliance community comply applicable law regulation gsk corporate local policy procedure understand responsibility promptly report actual suspect violation law regulation gsk corporate local policy procedure report actual potential compliance issue aware concern legal requirement company policy follow statement applicable supervisor personnel management responsibility people supervision receive copy access gsk code conduct applicable gsk policy inform responsibility place appropriate measure ensure people supervision comply applicable law regulation gsk corporate local policy procedure work behalf gsk new hire employee supervision complete schedule complete gsk corporate ethic compliance new hire training program gsk induction corporate ethic compliance community read understand shall comply fully policy procedure specify learn activity home responsibility ethical conduct training awareness performance corporate responsibility report performance plan global gsk intend ethic integrity follow key ethic integrity principle message provide business training group company integration regular training course gsk unwavere commitment conduct business integrity compliance law gsk employee personally professionally responsible help gsk maintain organisational integrity good reputation profit principle short live face difficult ethical situation reference ethical decisionmake model legal consistent company policy consistent gsk value code conduct explain family friend comfortable print newspaper benefit people involve training describe gsk employee obtain assistance manager corporate ethic compliance web community human resource legal compliance officer champion integrity helpline base training awareness activity include manager complete selfcertification process launch train new general manager site director compliance responsibility wider monitor compliance arrangement gsk add perform lead integrity training induction programme focus ethical decision make code conduct raise awareness global confidential reporting line extensive poster campaign awareness programme intranet confidential reporting phone line available country language target set ethical leadership objective manager hold transition new ceo planning implement track assess ethical measure executive level company united states employee contractor complete compliance refresher training new hire training complete people launch redesign training curriculum new pharmaceutical field sale employee curriculum integrate train ethical commercial practice sale training provide standalone module integrate compliance training range sale training programme add ethic section employee manual commercial policy expand policy provide information help people right decision commercial interaction japan promotion compliance team train employee gsk promotional code include entire sale force marketing employee clinical trial monitor employee interact healthcare professional employee take course submit letter pledge compliance standard law tophome responsibility ethical conduct training awareness performance corporate responsibility report performance plan global gsk intend ethic integrity follow key ethic integrity principle message provide business training group company integration regular training course gsk unwavere commitment conduct business integrity compliance law gsk employee personally professionally responsible help gsk maintain organisational integrity good reputation profit principle short live face difficult ethical situation reference ethical decisionmake model legal consistent company policy consistent gsk value code conduct explain family friend comfortable print newspaper benefit people involve training describe gsk employee obtain assistance manager corporate ethic compliance web community human resource legal compliance officer champion integrity helpline base training awareness activity include manager complete selfcertification process launch train new general manager site director compliance responsibility wider monitor compliance arrangement gsk add perform lead integrity training induction programme focus ethical decision make code conduct raise awareness global confidential reporting line extensive poster campaign awareness programme intranet confidential reporting phone line available country language target set ethical leadership objective manager hold transition new ceo planning implement track assess ethical measure executive level company united states employee contractor complete compliance refresher training new hire training complete people launch redesign training curriculum new pharmaceutical field sale employee curriculum integrate train ethical commercial practice sale training provide standalone module integrate compliance training range sale training programme add ethic section employee manual commercial policy expand policy provide information help people right decision commercial interaction japan promotion compliance team train employee gsk promotional code include entire sale force marketing employee clinical trial monitor employee interact healthcare professional employee take course submit letter pledge compliance standard law home responsibility ethical conduct training awareness performance corporate responsibility report performance plan global gsk intend ethic integrity follow key ethic integrity principle message provide business training group company integration regular training course gsk unwavere commitment conduct business integrity compliance law gsk employee personally professionally responsible help gsk maintain organisational integrity good reputation profit principle short live face difficult ethical situation reference ethical decisionmake model legal consistent company policy consistent gsk value code conduct explain family friend comfortable print newspaper benefit people involve training describe gsk employee obtain assistance manager corporate ethic compliance web community human resource legal compliance officer champion integrity helpline base training awareness activity include manager complete selfcertification process launch train new general manager site director compliance responsibility wider monitor compliance arrangement gsk add perform lead integrity training induction programme focus ethical decision make code conduct raise awareness global confidential reporting line extensive poster campaign awareness programme intranet confidential reporting phone line available country language target set ethical leadership objective manager hold transition new ceo planning implement track assess ethical measure executive level company united states employee contractor complete compliance refresher training new hire training complete people launch redesign training curriculum new pharmaceutical field sale employee curriculum integrate train ethical commercial practice sale training provide standalone module integrate compliance training range sale training programme add ethic section employee manual commercial policy expand policy provide information help people right decision commercial interaction japan promotion compliance team train employee gsk promotional code include entire sale force marketing employee clinical trial monitor employee interact healthcare professional employee take course submit letter pledge compliance standard law home responsibility ethical conduct monitor compliance corporate responsibility report monitor compliance approach performance plan manager accountable managing risk noncompliance policy area responsibility oversee seek advice corporate ethic compliance department promote effective compliance programme address compliance issue report problem progress senior management board dedicated compliance officer business unit rd manufacture vaccine pharma europe pharmaceutical emerge market pharmaceutical asia pacific japan consumer healthcare corporate pharmaceutical additional compliance representative market compliance officer senior manager direct access leadership team gsk function source expertise question ethic gsk policy corporate compliance officer report directly ceo develop gsk internal infrastructure new fulltime compliance director position establish latin america middle eastnorth africa asia pacific china demonstrate ongoing commitment provide dedicated focused support senior management team globally previously support champion role fulfil individual additional functional responsibility ethic compliance risk management risk oversight compliance council rocc include corporate executive team cet member oversee risk management internal control activity rocc support gsk corporate assurance department corporate ethic compliance department gsk corporate compliance officer chair rocc regularly report significant risk cet audit committee board information risk management corporate governance section annual report monitor sale marketing sale representative supervise manager regularly monitor educational event visit doctor expense use riskbase approach determine frequency check different district individual sale representative sale representative receive inquiry physician offlabel use gsk product notify medical information department respond inquiry medical information letter sale representative solicit offlabel question physician frequent medical information letter request sale representative indicate employee prompt question promote offlabel use gsk product monitor request medical information letter internal audit department regularly audit sale marketing practice globally monitor payment healthcare professional organisation payment record monitor different way different country example introduce state reporting system expenditure healthcare professional line legislation state japan payments individual healthcare professional medical institution monitor quarterly basis result report promotion compliance officer internal audit department system help identify situation excessive meal gift provide gsk reporting channel employee encourage seek help ethical issue report concern suspect case misconduct line manager corporate ethic compliance department compliance officer compliance champion gsk human resource legal department global confidential reporting line integrity helpline employee report concern offsite post office box email reporting channel promote employee guide business conduct gsk intranet training address misconduct corporate ethic compliance department monitor track allegation suspect legal ethical policy infraction ensure allegation appropriately investigate disciplinary action include dismissal take necessary violation policy report audit committee board tophome responsibility ethical conduct monitor compliance corporate responsibility report monitor compliance approach performance plan manager accountable managing risk noncompliance policy area responsibility oversee seek advice corporate ethic compliance department promote effective compliance programme address compliance issue report problem progress senior management board dedicated compliance officer business unit rd manufacture vaccine pharma europe pharmaceutical emerge market pharmaceutical asia pacific japan consumer healthcare corporate pharmaceutical additional compliance representative market compliance officer senior manager direct access leadership team gsk function source expertise question ethic gsk policy corporate compliance officer report directly ceo develop gsk internal infrastructure new fulltime compliance director position establish latin america middle eastnorth africa asia pacific china demonstrate ongoing commitment provide dedicated focused support senior management team globally previously support champion role fulfil individual additional functional responsibility ethic compliance risk management risk oversight compliance council rocc include corporate executive team cet member oversee risk management internal control activity rocc support gsk corporate assurance department corporate ethic compliance department gsk corporate compliance officer chair rocc regularly report significant risk cet audit committee board information risk management corporate governance section annual report monitor sale marketing sale representative supervise manager regularly monitor educational event visit doctor expense use riskbase approach determine frequency check different district individual sale representative sale representative receive inquiry physician offlabel use gsk product notify medical information department respond inquiry medical information letter sale representative solicit offlabel question physician frequent medical information letter request sale representative indicate employee prompt question promote offlabel use gsk product monitor request medical information letter internal audit department regularly audit sale marketing practice globally monitor payment healthcare professional organisation payment record monitor different way different country example introduce state reporting system expenditure healthcare professional line legislation state japan payments individual healthcare professional medical institution monitor quarterly basis result report promotion compliance officer internal audit department system help identify situation excessive meal gift provide gsk reporting channel employee encourage seek help ethical issue report concern suspect case misconduct line manager corporate ethic compliance department compliance officer compliance champion gsk human resource legal department global confidential reporting line integrity helpline employee report concern offsite post office box email reporting channel promote employee guide business conduct gsk intranet training address misconduct corporate ethic compliance department monitor track allegation suspect legal ethical policy infraction ensure allegation appropriately investigate disciplinary action include dismissal take necessary violation policy report audit committee board home responsibility ethical conduct monitor compliance corporate responsibility report monitor compliance approach performance plan manager accountable managing risk noncompliance policy area responsibility oversee seek advice corporate ethic compliance department promote effective compliance programme address compliance issue report problem progress senior management board dedicated compliance officer business unit rd manufacture vaccine pharma europe pharmaceutical emerge market pharmaceutical asia pacific japan consumer healthcare corporate pharmaceutical additional compliance representative market compliance officer senior manager direct access leadership team gsk function source expertise question ethic gsk policy corporate compliance officer report directly ceo develop gsk internal infrastructure new fulltime compliance director position establish latin america middle eastnorth africa asia pacific china demonstrate ongoing commitment provide dedicated focused support senior management team globally previously support champion role fulfil individual additional functional responsibility ethic compliance risk management risk oversight compliance council rocc include corporate executive team cet member oversee risk management internal control activity rocc support gsk corporate assurance department corporate ethic compliance department gsk corporate compliance officer chair rocc regularly report significant risk cet audit committee board information risk management corporate governance section annual report monitor sale marketing sale representative supervise manager regularly monitor educational event visit doctor expense use riskbase approach determine frequency check different district individual sale representative sale representative receive inquiry physician offlabel use gsk product notify medical information department respond inquiry medical information letter sale representative solicit offlabel question physician frequent medical information letter request sale representative indicate employee prompt question promote offlabel use gsk product monitor request medical information letter internal audit department regularly audit sale marketing practice globally monitor payment healthcare professional organisation payment record monitor different way different country example introduce state reporting system expenditure healthcare professional line legislation state japan payments individual healthcare professional medical institution monitor quarterly basis result report promotion compliance officer internal audit department system help identify situation excessive meal gift provide gsk reporting channel employee encourage seek help ethical issue report concern suspect case misconduct line manager corporate ethic compliance department compliance officer compliance champion gsk human resource legal department global confidential reporting line integrity helpline employee report concern offsite post office box email reporting channel promote employee guide business conduct gsk intranet training address misconduct corporate ethic compliance department monitor track allegation suspect legal ethical policy infraction ensure allegation appropriately investigate disciplinary action include dismissal take necessary violation policy report audit committee board home responsibility ethical conduct monitor compliance corporate responsibility report monitor compliance approach performance plan review compliance risk management strategy conduct review corporate ethic strategy base result review take step follow area embed ethical culture gsk recruitment include question ethic integrity recruitment process gsk manager interview guide carry extensive preemployment check ensure recruit people share gsk value train extended ethic compliance induction train new employee worldwide provide extra training guidance employee commit minor breach prevent commit breach future global confidential reporting line extend independently manage reporting line country operate country employee native language undertake extensive intranet poster campaign raise awareness service senior management develop new training awareness programme site director general manager key representative gsk country location work include individual briefing executive team new appointee compliance responsibility policy streamline administration corporate policy procedure involve reduce number policy procedure half require employee need detailed awareness policy procedure specific role financial fraud establish new fraud risk assessment tool help prevent financial fraud finance leadership team regularly review financial fraud case progress meeting strategy review objective review twice year gsk audit committee board plan enhance global confidential reporting phone line facility internet reporting introduce select country language supplier evolve technology number language available address misconduct employee discipline policy violation dismiss agree leave company voluntarily know separation disciplinary action include document warning instance financial penalty disciplinary action include case employee breach sale marketing code case result dismissal separation company case result document warning addition appropriate discipline employee stay company receive retrain increase monitoring case retrain extend employee colleague prevent make similar mistake main type violation year include market promotional activity good manufacturinggood distribution practice falsification document travel expense claim code conduct issue tophome responsibility ethical conduct monitor compliance corporate responsibility report monitor compliance approach performance plan review compliance risk management strategy conduct review corporate ethic strategy base result review take step follow area embed ethical culture gsk recruitment include question ethic integrity recruitment process gsk manager interview guide carry extensive preemployment check ensure recruit people share gsk value train extended ethic compliance induction train new employee worldwide provide extra training guidance employee commit minor breach prevent commit breach future global confidential reporting line extend independently manage reporting line country operate country employee native language undertake extensive intranet poster campaign raise awareness service senior management develop new training awareness programme site director general manager key representative gsk country location work include individual briefing executive team new appointee compliance responsibility policy streamline administration corporate policy procedure involve reduce number policy procedure half require employee need detailed awareness policy procedure specific role financial fraud establish new fraud risk assessment tool help prevent financial fraud finance leadership team regularly review financial fraud case progress meeting strategy review objective review twice year gsk audit committee board plan enhance global confidential reporting phone line facility internet reporting introduce select country language supplier evolve technology number language available address misconduct employee discipline policy violation dismiss agree leave company voluntarily know separation disciplinary action include document warning instance financial penalty disciplinary action include case employee breach sale marketing code case result dismissal separation company case result document warning addition appropriate discipline employee stay company receive retrain increase monitoring case retrain extend employee colleague prevent make similar mistake main type violation year include market promotional activity good manufacturinggood distribution practice falsification document travel expense claim code conduct issue home responsibility ethical conduct monitor compliance corporate responsibility report monitor compliance approach performance plan review compliance risk management strategy conduct review corporate ethic strategy base result review take step follow area embed ethical culture gsk recruitment include question ethic integrity recruitment process gsk manager interview guide carry extensive preemployment check ensure recruit people share gsk value train extended ethic compliance induction train new employee worldwide provide extra training guidance employee commit minor breach prevent commit breach future global confidential reporting line extend independently manage reporting line country operate country employee native language undertake extensive intranet poster campaign raise awareness service senior management develop new training awareness programme site director general manager key representative gsk country location work include individual briefing executive team new appointee compliance responsibility policy streamline administration corporate policy procedure involve reduce number policy procedure half require employee need detailed awareness policy procedure specific role financial fraud establish new fraud risk assessment tool help prevent financial fraud finance leadership team regularly review financial fraud case progress meeting strategy review objective review twice year gsk audit committee board plan enhance global confidential reporting phone line facility internet reporting introduce select country language supplier evolve technology number language available address misconduct employee discipline policy violation dismiss agree leave company voluntarily know separation disciplinary action include document warning instance financial penalty disciplinary action include case employee breach sale marketing code case result dismissal separation company case result document warning addition appropriate discipline employee stay company receive retrain increase monitoring case retrain extend employee colleague prevent make similar mistake main type violation year include market promotional activity good manufacturinggood distribution practice falsification document travel expense claim code conduct issue home responsibility ethical conduct case study corporate responsibility report case study suitability gsk approve speaker list ensure employee comply policy vital people work behalf meet high ethical standard pharmaceuticals compliance department receive information gsk integrity helpline healthcare professional hcp engage speak gsk behalf allegedly fail comply company policy promotional programme consecutive day gsk review material programme question identify number issue policy violation person suspend gsk speaker pende completion followup investigation investigation remove hcp approve speaker list responsible marketing weight loss treatment nearly twothird adult clinically obese seriously overweight cause dramatic increase lifethreatene medical condition heart disease diabetes add strain healthcare system small weight loss greatly reduce risk develop associate medical problem gsk overthecounter weight loss product alli orlistat mg help overweight adult lose weight prevent cent dietary fat absorb gut help people lose cent weight diet exercise alli launch june sell million starter pack alli receive positive opinion european medicine agency emea committee medicinal product human use january european commission grant nonprescription licence product vital alli market responsibly right way need educate physician dieticians pharmacist ensure alli sell appropriately patient receive right information treatment marketing emphasise alli require lifestyle change include exercise lowfat diet produce right result unwanted effect safety efficacy profile orlistat document establish datum clinical study set website wwwmyallicom provide support alli user enable people set target track weight loss post success story include ready alli quiz ask potential user confirm commitment moderate diet take exercise read label carefully site include alli circles online moderated forum user share experience help stay focused weight loss target forum give valuable feedback patient effectiveness product monitor site report adverse effect report fda inappropriate content donate dress success dfs mark oneyear anniversary launch alli dfs international nonprofit organisation provide business clothing career support disadvantaged woman encourage alli user volunteer dfs donate clothing big lose weight dfs far receive piece clothing alli users anderson j orlistat management overweight individual obesity review potential mg overthecounter dosage expert opin pharmacother alli summary product characteristic spc jacob togerson j orlistat treatment beneficial primary care tertiary setting obesity review home responsibility ethical conduct case study corporate responsibility report case study suitability gsk approve speaker list ensure employee comply policy vital people work behalf meet high ethical standard pharmaceuticals compliance department receive information gsk integrity helpline healthcare professional hcp engage speak gsk behalf allegedly fail comply company policy promotional programme consecutive day gsk review material programme question identify number issue policy violation person suspend gsk speaker pende completion followup investigation investigation remove hcp approve speaker list responsible marketing weight loss treatment nearly twothird adult clinically obese seriously overweight cause dramatic increase lifethreatene medical condition heart disease diabetes add strain healthcare system small weight loss greatly reduce risk develop associate medical problem gsk overthecounter weight loss product alli orlistat mg help overweight adult lose weight prevent cent dietary fat absorb gut help people lose cent weight diet exercise alli launch june sell million starter pack alli receive positive opinion european medicine agency emea committee medicinal product human use january european commission grant nonprescription licence product vital alli market responsibly right way need educate physician dieticians pharmacist ensure alli sell appropriately patient receive right information treatment marketing emphasise alli require lifestyle change include exercise lowfat diet produce right result unwanted effect safety efficacy profile orlistat document establish datum clinical study set website wwwmyallicom provide support alli user enable people set target track weight loss post success story include ready alli quiz ask potential user confirm commitment moderate diet take exercise read label carefully site include alli circles online moderated forum user share experience help stay focused weight loss target forum give valuable feedback patient effectiveness product monitor site report adverse effect report fda inappropriate content donate dress success dfs mark oneyear anniversary launch alli dfs international nonprofit organisation provide business clothing career support disadvantaged woman encourage alli user volunteer dfs donate clothing big lose weight dfs far receive piece clothing alli users anderson j orlistat management overweight individual obesity review potential mg overthecounter dosage expert opin pharmacother alli summary product characteristic spc jacob togerson j orlistat treatment beneficial primary care tertiary setting obesity review home responsibility ethical conduct case study corporate responsibility report case study suitability gsk approve speaker list ensure employee comply policy vital people work behalf meet high ethical standard pharmaceuticals compliance department receive information gsk integrity helpline healthcare professional hcp engage speak gsk behalf allegedly fail comply company policy promotional programme consecutive day gsk review material programme question identify number issue policy violation person suspend gsk speaker pende completion followup investigation investigation remove hcp approve speaker list responsible marketing weight loss treatment nearly twothird adult clinically obese seriously overweight cause dramatic increase lifethreatene medical condition heart disease diabetes add strain healthcare system small weight loss greatly reduce risk develop associate medical problem gsk overthecounter weight loss product alli orlistat mg help overweight adult lose weight prevent cent dietary fat absorb gut help people lose cent weight diet exercise alli launch june sell million starter pack alli receive positive opinion european medicine agency emea committee medicinal product human use january european commission grant nonprescription licence product vital alli market responsibly right way need educate physician dieticians pharmacist ensure alli sell appropriately patient receive right information treatment marketing emphasise alli require lifestyle change include exercise lowfat diet produce right result unwanted effect safety efficacy profile orlistat document establish datum clinical study set website wwwmyallicom provide support alli user enable people set target track weight loss post success story include ready alli quiz ask potential user confirm commitment moderate diet take exercise read label carefully site include alli circles online moderated forum user share experience help stay focused weight loss target forum give valuable feedback patient effectiveness product monitor site report adverse effect report fda inappropriate content donate dress success dfs mark oneyear anniversary launch alli dfs international nonprofit organisation provide business clothing career support disadvantaged woman encourage alli user volunteer dfs donate clothing big lose weight dfs far receive piece clothing alli users anderson j orlistat management overweight individual obesity review potential mg overthecounter dosage expert opin pharmacother alli summary product characteristic spc jacob togerson j orlistat treatment beneficial primary care tertiary setting obesity review home responsibility ethical conduct qas corporate responsibility report qas respond question raise stakeholder company establish high standard ethical conduct industry approach require set high standard ethical conduct hope establish benchmark company judge work company trade association develop high ethical standard believe good interest patient pharmaceutical industry adopt common high standard ethical conduct help improve trust industry stakeholder lot gsk employee dismiss unethical conduct policy work employee dismiss agree leave company voluntarily result policy violation unethical conduct occur company believe figure demonstrate effectiveness monitor compliance programme further ethical culture recruit right people provide right training tool improve check encourage people speak enable identify address unethical conduct consistent responsive manner gsk unduly influence doctor approach protect inappropriate influence doctor include regional marketing code practice regular training monitoring policy apply employee agent commit promotional practice ethical responsible principle patient centre prohibit kickback bribery inducement doctor promotion unapproved use medicine sale force regularly train supervise manager monitor educational event visit doctor expense prevent offlabel promotion gsk employee deal healthcare professional undergo extensive training monitoring instruct accurate information provide approve use medicine base valid scientific evidence accurate balanced fair objective unambiguous date question doctor offlabel use product refer medical information department additional process place monitor referral help ensure representative promote offlabel use monitor volume letter respond question type referral individual representative example number referral relate particular product particular offlabel use additionally internal audit department regularly audit sale marketing practice globally advertising standard authority rule health claim horlick advert show uk unsubstantiated gsk involve false advertising gsk involve false advertising nepali tv bengalilanguage satellite channel aim viewers indian subcontinent briefly air advert home uk advert intend approve use india knowledge health claim advert appropriate uk claim advert relate specifically indian market indian diet advertising standard authority uk uphold complaint nepali tv broadcasting advert uk reprimand gsk uk office fair trading oft investigate supermarket supplier wrongly share information price gsk consumer product involve uk office fair trading oft begin investigation potential breach comppaegteit ion olaf w company include gsk oft look claim data pricing pass rival company supplier ask gsk cooperation accuse break law tolerate unethical behaviour corrupt anticompetitive behaviour undermine fair competition inhibit economic development bad economy business people code conduct set expectation employee conduct training ensure operate letter spirit law maintain high standard ethical business behaviour cooperate fully oft disciplinary action dismissal gsk employee find breach policy law tophome responsibility ethical conduct qas corporate responsibility report qas respond question raise stakeholder company establish high standard ethical conduct industry approach require set high standard ethical conduct hope establish benchmark company judge work company trade association develop high ethical standard believe good interest patient pharmaceutical industry adopt common high standard ethical conduct help improve trust industry stakeholder lot gsk employee dismiss unethical conduct policy work employee dismiss agree leave company voluntarily result policy violation unethical conduct occur company believe figure demonstrate effectiveness monitor compliance programme further ethical culture recruit right people provide right training tool improve check encourage people speak enable identify address unethical conduct consistent responsive manner gsk unduly influence doctor approach protect inappropriate influence doctor include regional marketing code practice regular training monitoring policy apply employee agent commit promotional practice ethical responsible principle patient centre prohibit kickback bribery inducement doctor promotion unapproved use medicine sale force regularly train supervise manager monitor educational event visit doctor expense prevent offlabel promotion gsk employee deal healthcare professional undergo extensive training monitoring instruct accurate information provide approve use medicine base valid scientific evidence accurate balanced fair objective unambiguous date question doctor offlabel use product refer medical information department additional process place monitor referral help ensure representative promote offlabel use monitor volume letter respond question type referral individual representative example number referral relate particular product particular offlabel use additionally internal audit department regularly audit sale marketing practice globally advertising standard authority rule health claim horlick advert show uk unsubstantiated gsk involve false advertising gsk involve false advertising nepali tv bengalilanguage satellite channel aim viewers indian subcontinent briefly air advert home uk advert intend approve use india knowledge health claim advert appropriate uk claim advert relate specifically indian market indian diet advertising standard authority uk uphold complaint nepali tv broadcasting advert uk reprimand gsk uk office fair trading oft investigate supermarket supplier wrongly share information price gsk consumer product involve uk office fair trading oft begin investigation potential breach competition law company include gsk oft look claim data pricing pass rival company supplier ask gsk cooperation accuse break law tolerate unethical behaviour corrupt anticompetitive behaviour undermine fair competition inhibit economic development bad economy business people code conduct set expectation employee conduct training ensure operate letter spirit law maintain high standard ethical business behaviour cooperate fully oft disciplinary action dismissal gsk employee find breach policy law home responsibility ethical conduct qas corporate responsibility report qas respond question raise stakeholder company establish high standard ethical conduct industry approach require set high standard ethical conduct hope establish benchmark company judge work company trade association develop high ethical standard believe good interest patient pharmaceutical industry adopt common high standard ethical conduct help improve trust industry stakeholder lot gsk employee dismiss unethical conduct policy work employee dismiss agree leave company voluntarily result policy violation unethical conduct occur company believe figure demonstrate effectiveness monitor compliance programme further ethical culture recruit right people provide right training tool improve check encourage people speak enable identify address unethical conduct consistent responsive manner gsk unduly influence doctor approach protect inappropriate influence doctor include regional marketing code practice regular training monitoring policy apply employee agent commit promotional practice ethical responsible principle patient centre prohibit kickback bribery inducement doctor promotion unapproved use medicine sale force regularly train supervise manager monitor educational event visit doctor expense prevent offlabel promotion gsk employee deal healthcare professional undergo extensive training monitoring instruct accurate information provide approve use medicine base valid scientific evidence accurate balanced fair objective unambiguous date question doctor offlabel use product refer medical information department additional process place monitor referral help ensure representative promote offlabel use monitor volume letter respond question type referral individual representative example number referral relate particular product particular offlabel use additionally internal audit department regularly audit sale marketing practice globally advertising standard authority rule health claim horlick advert show uk unsubstantiated gsk involve false advertising gsk involve false advertising nepali tv bengalilanguage satellite channel aim viewers indian subcontinent briefly air advert home uk advert intend approve use india knowledge health claim advert appropriate uk claim advert relate specifically indian market indian diet advertising standard authority uk uphold complaint nepali tv broadcasting advert uk reprimand gsk uk office fair trading oft investigate supermarket supplier wrongly share information price gsk consumer product involve uk office fair trading oft begin investigation potential breach competition law company include gsk oft look claim data pricing pass rival company supplier ask gsk cooperation accuse break law tolerate unethical behaviour corrupt anticompetitive behaviour undermine fair competition inhibit economic development bad economy business people code conduct set expectation employee conduct training ensure operate letter spirit law maintain high standard ethical business behaviour cooperate fully oft disciplinary action dismissal gsk employee find breach policy law home responsibility supply chain corporate responsibility report supply chain want source company maintain high labour environmental standard inadequate environment health safety eh human right standard indicator poor management impact quality compromise patient safety impede continuity supply essential medicine association poorly perform supplier damage reputation conduct detailed assessment new exist supplier monitor performance eh human right issue work closely supplier prevent disruption supply key medicine counterfeit drug pose threat patient build anticounterfeite feature product packaging step prevent criminal make distribute fake gsk product work assess environment health safety impact manufacture supplier supply chain number supplier spend bn buy good service supplier supply chain complex range strategic relationship supplier manufacture active pharmaceutical ingredient intermediate raw material packaging gsk medicine contract good service office equipment clean security home responsibility supply chain corporate responsibility report supply chain want source company maintain high labour environmental standard inadequate environment health safety eh human right standard indicator poor management impact quality compromise patient safety impede continuity supply essential medicine association poorly perform supplier damage reputation conduct detailed assessment new exist supplier monitor performance eh human right issue work closely supplier prevent disruption supply key medicine counterfeit drug pose threat patient build anticounterfeite feature product packaging step prevent criminal make distribute fake gsk product work assess environment health safety impact manufacture supplier supply chain number supplier spend bn buy good service supplier supply chain complex range strategic relationship supplier manufacture active pharmaceutical ingredient intermediate raw material packaging gsk medicine contract good service office equipment clean security home responsibility supply chain responsibility supply chain corporate responsibility report responsibility supply chain approach ensure high standard global supplier include preassessment potential supplier gather information help evaluation inclusion human right clause supplier contract environment health safety ehs requirement contract critical supplier review ehs human right routine supplier engagement example business performance meeting eh audits potential exist supplier regular progress monitor additional advice technical support supplier contract supplier contract contain ehs requirement base global ehs standard human right clause base international labour organization convention un universal declaration human right company agree ehs human right requirement include selection riskbase approach supply chain large complex use riskbase approach target effort focus critical supplier base europe north america asia account approximately cent supplier spend critical supplier include contract manufacturer supplier present great risk gsk follow issue relevance supply essential medicine threat continuity supply value affect product gsk regulatory requirement hazards associate manufacturing process material environmental impact develop longterm relationship critical supplier conduct regular monitoring support uninterrupted supply high quality material service gsk training gsk procurement team train new procurement employee standard requirement ehs human right emphasise role promote compliance standard key procurement employee include procurement manager receive ongoing training topic develop new sustainable procurement guideline support training plan focus source material sustainable source product recycle content energyefficient equipmenthome responsibility supply chain responsibility supply chain corporate responsibility report responsibility supply chain approach ensure high standard global supplier include preassessment potential supplier gather information help evaluation inclusion human right clause supplier contract environment health safety ehs requirement contract critical supplier review ehs human right routine supplier engagement example business performance meeting eh audits potential exist supplier regular progress monitor additional advice technical support supplier contract supplier contract contain ehs requirement base global ehs standard human right clause base international labour organization convention un universal declaration human right company agree ehs human right requirement include selection riskbase approach supply chain large complex use riskbase approach target effort focus critical supplier base europe north america asia account approximately cent supplier spend critical supplier include contract manufacturer supplier present great risk gsk follow issue relevance supply essential medicine threat continuity supply value affect product gsk regulatory requirement hazards associate manufacturing process material environmental impact develop longterm relationship critical supplier conduct regular monitoring support uninterrupted supply high quality material service gsk training gsk procurement team train new procurement employee standard requirement ehs human right emphasise role promote compliance standard key procurement employee include procurement manager receive ongoing training topic develop new sustainable procurement guideline support training plan focus source material sustainable source product recycle content energyefficient equipment home responsibility supply chain responsibility supply chain corporate responsibility report responsibility supply chain approach ensure high standard global supplier include preassessment potential supplier gather information help evaluation inclusion human right clause supplier contract environment health safety ehs requirement contract critical supplier review ehs human right routine supplier engagement example business performance meeting eh audits potential exist supplier regular progress monitor additional advice technical support supplier contract supplier contract contain ehs requirement base global ehs standard human right clause base international labour organization convention un universal declaration human right company agree ehs human right requirement include selection riskbase approach supply chain large complex use riskbase approach target effort focus critical supplier base europe north america asia account approximately cent supplier spend critical supplier include contract manufacturer supplier present great risk gsk follow issue relevance supply essential medicine threat continuity supply value affect product gsk regulatory requirement hazards associate manufacturing process material environmental impact develop longterm relationship critical supplier conduct regular monitoring support uninterrupted supply high quality material service gsk training gsk procurement team train new procurement employee standard requirement ehs human right emphasise role promote compliance standard key procurement employee include procurement manager receive ongoing training topic develop new sustainable procurement guideline support training plan focus source material sustainable source product recycle content energyefficient equipment home responsibility supply chain responsibility supply chain human right clause corporate responsibility report human right clause supplier contract contain human right clause base international labour organization convention un universal declaration human right amend exact wording clause negotiation supplier translation suit local law change reduce contractual impact intent clause gsk standard contract clause ethical standard human right require prohibit law supplier warrant good knowledge relation supply good service term agreement employ engage use child labour circumstance task perform child labour reasonably foresee cause physical emotional impairment development child use force labour form prison indenture bond employee require lodge paper deposit start work provide safe healthy workplace present immediate hazard employee housing provide supplier employee safe habitation supplier provide access clean water food emergency healthcare employee event accident incident supplier workplace discriminate employee ground include race religion disability gender engage support use corporal punishment mental physical sexual verbal abuse use cruel abusive disciplinary practice workplace pay employee minimum wage fair representation prevail industry wage whichever higher provide employee legally mandate benefit comply law work hour employment right country operate respectful employee right join form independent trade union freedom association supplier agree responsible control supply chain shall encourage compliance ethical standard human right subsequent supplier good service supplier perform obligation agreement supplier shall ensure ethical human right policy appropriate complaint procedure deal breach policy gsk reserve right reasonable notice inspection cause case notice shall necessary enter supplier premise monitor compliance supplier warranty set clause supplier shall subject compliance law furnish gsk relevant document request gsk relation thereto subsection require general right audit agreement home responsibility supply chain responsibility supply chain human right clause corporate responsibility report human right clause supplier contract contain human right clause base international labour organization convention un universal declaration human right amend exact wording clause negotiation supplier translation suit local law change reduce contractual impact intent clause gsk standard contract clause ethical standard human right require prohibit law supplier warrant good knowledge relation supply good service term agreement employ engage use child labour circumstance task perform child labour reasonably foresee cause physical emotional impairment development child use force labour form prison indenture bond employee require lodge paper deposit start work provide safe healthy workplace present immediate hazard employee housing provide supplier employee safe habitation supplier provide access clean water food emergency healthcare employee event accident incident supplier workplace discriminate employee ground include race religion disability gender engage support use corporal punishment mental physical sexual verbal abuse use cruel abusive disciplinary practice workplace pay employee minimum wage fair representation prevail industry wage whichever higher provide employee legally mandate benefit comply law work hour employment right country operate respectful employee right join form independent trade union freedom association supplier agree responsible control supply chain shall encourage compliance ethical standard human right subsequent supplier good service supplier perform obligation agreement supplier shall ensure ethical human right policy appropriate complaint procedure deal breach policy gsk reserve right reasonable notice inspection cause case notice shall necessary enter supplier premise monitor compliance supplier warranty set clause supplier shall subject compliance law furnish gsk relevant document request gsk relation thereto subsection require general right audit agreement home responsibility supply chain responsibility supply chain choose supplier corporate responsibility report choose supplier conduct detailed assessment critical supplier select critical supplier include contract manufacturer supplier present great risk gsk key risk area use questionnaire onsite review ehs audits assess performance health safety environmental human right issue assess potential new critical supplier ehs standard achieve minimum audit score cent standard join supply chain follow audit supplier meet requirement implement plan improve ehs performance monitor progress case provide opportunity train technical support enable supplier achieve require standard expect supplier establish supply arrangement improvement monitor progress review followup visit audits include question help identify potential breach human right clause include supplier contract supplier ask information policy practice relate age limit employee discrimination employee local population prevention abuse individual wage benefit work hour meet legal minimum right worker organise recognition worker organisation question contribute ehs audit score reason progress business supplier read audit programme ensure compliance quality standard home responsibility supply chain responsibility supply chain choose supplier corporate responsibility report choose supplier conduct detailed assessment critical supplier select critical supplier include contract manufacturer supplier present great risk gsk key risk area use questionnaire onsite review ehs audits assess performance health safety environmental human right issue assess potential new critical supplier ehs standard achieve minimum audit score cent standard join supply chain follow audit supplier meet requirement implement plan improve ehs performance monitor progress case provide opportunity train technical support enable supplier achieve require standard expect supplier establish supply arrangement improvement monitor progress review followup visit audits include question help identify potential breach human right clause include supplier contract supplier ask information policy practice relate age limit employee discrimination employee local population prevention abuse individual wage benefit work hour meet legal minimum right worker organise recognition worker organisation question contribute ehs audit score reason progress business supplier read audit programme ensure compliance quality standard home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance order maintain gsk standard supply chain routinely interact supplier reviews followup visit procurement quality ehs staff consider ehs human right issue interaction hold global regional supplier review meeting senior gsk manager interact supplier key issue provide contract manufacturer information eh risk associate gsk material produce handle supplier booklet work gsk include ethic policy requirement conduct regular ehs audits critical supplier pharmaceutical consumer healthcare product focus higherrisk supplier supplier facility evaluate ehs standard achieve score cent standard demonstrate acceptable performance support continue supply arrangement supplier develop improvement plan base audit finding follow monitor progress plan read case study help supplier improve ehs performance provide feedback supplier identify issue question relate human right require corrective action issue present potential breach human right clause include supplier contract supplier promotional item gift item indian business source india industry high risk use child labour conduct unannounced spot check supplier night focus maintain quality standard check supplier child labour spot check conduct gsk procurement regional sale staff finding programme india inform promotional supplier qualification process region begin conduct detailed inspection assembly site possible add extra check region child labour common home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance order maintain gsk standard supply chain routinely interact supplier reviews followup visit procurement quality ehs staff consider ehs human right issue interaction hold global regional supplier review meeting senior gsk manager interact supplier key issue provide contract manufacturer information eh risk associate gsk material produce handle supplier booklet work gsk include ethic policy requirement conduct regular ehs audits critical supplier pharmaceutical consumer healthcare product focus higherrisk supplier supplier facility evaluate ehs standard achieve score cent standard demonstrate acceptable performance support continue supply arrangement supplier develop improvement plan base audit finding follow monitor progress plan read case study help supplier improve ehs performance provide feedback supplier identify issue question relate human right require corrective action issue present potential breach human right clause include supplier contract supplier promotional item gift item indian business source india industry high risk use child labour conduct unannounced spot check supplier night focus maintain quality standard check supplier child labour spot check conduct gsk procurement regional sale staff finding programme india inform promotional supplier qualification process region begin conduct detailed inspection assembly site possible add extra check region child labour common home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance conduct supplier audits reviewsthe average audit score gsk ehs standard cent high score achieve percent low percent ehs audit score key supplier americas canada north america south america region high average score north america europe contrast low average score asia largely related maturity ehs management support legislative framework enforcement region broad range score asia region reflect high perform supplier long term intervention gsk low score relate supplier undertake initial audits find significant deficiency ehs management risk control supplier fail meet minimum requirement percent gsk ehs standard potential new supplier score minimum level progress work underway improve performance acceptable level work exist supplier ensure necessary improvement agree timeframe gsk standard apply supply chain significant audit finding occur mainly emerge economy include infrastructure fire protection poor emergency response capability absence fundamental risk control process safety poor control exposure hazardous substance poor waste management environmental control frequent regulatory finding significant issue identify relate human right question ask audits continue work number key supplier help improve ehs performance include develop close relationship fulltime position china india support work audit supplier improve ehs performance work include help supppaligeer f develop improvement plan provide coaching opportunity read case study help supplier improve ehs performance attend supplier forum rdbase pharmaceutical association committee rdpac industry consortium china forum provide opportunity gsk engage supplier supplier company advantage training network make progress pilot project strategic supplier achieve highly protect risk hpr status achieve hpr status good class insurance industry designation company adopt engineering approach minimise property supply chain risk plan extend strategic supplier number type audits americas europe asia africa total type supplier primary raw material intermediate active pharmaceutical ingredient pharmaceutical formulation consumer healthcare excipient active raw material type engagement audit review average audit score cent number supplier audit total cumulative total number america europe asia africa number visit visit americas canada north america south america region supplier promotional item conduct unannounced spot check promotional good supplier india visit company supply promotional good indian business uncover evidence child labourhome responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance conduct supplier audits reviewsthe average audit score gsk ehs standard cent high score achieve percent low percent ehs audit score key supplier americas canada north america south america region high average score north america europe contrast low average score asia largely related maturity ehs management support legislative framework enforcement region broad range score asia region reflect high perform supplier long term intervention gsk low score relate supplier undertake initial audits find significant deficiency ehs management risk control supplier fail meet minimum requirement percent gsk ehs standard potential new supplier score minimum level progress work underway improve performance acceptable level work exist supplier ensure necessary improvement agree timeframe gsk standard apply supply chain significant audit finding occur mainly emerge economy include infrastructure fire protection poor emergency response capability absence fundamental risk control process safety poor control exposure hazardous substance poor waste management environmental control frequent regulatory finding significant issue identify relate human right question ask audits continue work number key supplier help improve ehs performance include develop close relationship fulltime position china india support work audit supplier improve ehs performance work include help supplier develop improvement plan provide coaching opportunity read case study help supplier improve ehs performance attend supplier forum rdbase pharmaceutical association committee rdpac industry consortium china forum provide opportunity gsk engage supplier supplier company advantage training network make progress pilot project strategic supplier achieve highly protect risk hpr status achieve hpr status good class insurance industry designation company adopt engineering approach minimise property supply chain risk plan extend strategic supplier number type audits americas europe asia africa total type supplier primary raw material intermediate active pharmaceutical ingredient pharmaceutical formulation consumer healthcare excipient active raw material type engagement audit review average audit score cent number supplier audit total cumulative total number america europe asia africa number visit visit americas canada north america south america region supplier promotional item conduct unannounced spot check promotional good supplier india visit company supply promotional good indian business uncover evidence child labour home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance conduct supplier audits reviewsthe average audit score gsk ehs standard cent high score achieve percent low percent ehs audit score key supplier americas canada north america south america region high average score north america europe contrast low average score asia largely related maturity ehs management support legislative framework enforcement region broad range score asia region reflect high perform supplier long term intervention gsk low score relate supplier undertake initial audits find significant deficiency ehs management risk control supplier fail meet minimum requirement percent gsk ehs standard potential new supplier score minimum level progress work underway improve performance acceptable level work exist supplier ensure necessary improvement agree timeframe gsk standard apply supply chain significant audit finding occur mainly emerge economy include infrastructure fire protection poor emergency response capability absence fundamental risk control process safety poor control exposure hazardous substance poor waste management environmental control frequent regulatory finding significant issue identify relate human right question ask audits continue work number key supplier help improve ehs performance include develop close relationship fulltime position china india support work audit supplier improve ehs performance work include help supplier develop improvement plan provide coaching opportunity read case study help supplier improve ehs performance attend supplier forum rdbase pharmaceutical association committee rdpac industry consortium china forum provide opportunity gsk engage supplier supplier company advantage training network make progress pilot project strategic supplier achieve highly protect risk hpr status achieve hpr status good class insurance industry designation company adopt engineering approach minimise property supply chain risk plan extend strategic supplier number type audits americas europe asia africa total type supplier primary raw material intermediate active pharmaceutical ingredient pharmaceutical formulation consumer healthcare excipient active raw material type engagement audit review average audit score cent number supplier audit total cumulative total number america europe asia africa number visit visit americas canada north america south america region supplier promotional item conduct unannounced spot check promotional good supplier india visit company supply promotional good indian business uncover evidence child labour home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance conduct supplier audits reviewsthe average audit score gsk ehs standard cent high score achieve percent low percent ehs audit score key supplier americas canada north america south america region high average score north america europe contrast low average score asia largely related maturity ehs management support legislative framework enforcement region broad range score asia region reflect high perform supplier long term intervention gsk low score relate supplier undertake initial audits find significant deficiency ehs management risk control supplier fail meet minimum requirement percent gsk ehs standard potential new supplier score minimum level progress work underway improve performance acceptable level work exist supplier ensure necessary improvement agree timeframe gsk standard apply supply chain significant audit finding occur mainly emerge economy include infrastructure fire protection poor emergency response capability absence fundamental risk control process safety poor control exposure hazardous substance poor waste management environmental control frequent regulatory finding significant issue identify relate human right question ask audits continue work number key supplier help improve ehs performance include develop close relationship fulltime position china india support work audit supplier improve ehs performance work include help supplier develop improvement plan provide coaching opportunity read case study help supplier improve ehs performance attend supplier forum rdbase pharmaceutical association committee rdpac industry consortium china forum provide opportunity gsk engage supplier supplier company advantage training network make progress pilot project strategic supplier achieve highly protect risk hpr status achieve hpr status good class insurance industry designation company adopt engineering approach minimise property supply chain risk plan extend strategic supplier number type audits americas europe asia africa total type supplier primary raw material intermediate active pharmaceutical ingredient pharmaceutical formulation consumer healthcare excipient active raw material type engagement audit review average audit score cent number supplier audit total cumulative total number america europe asia africa number visit visit americas canada north america south america region supplier promotional item conduct unannounced spot check promotional good supplier india visit company supply promotional good indian business uncover evidence child labour home responsibility supply chain responsibility supply chain supplier diversity corporate responsibility report supplier diversity small minorityowne company underrepresented supply chain large company response government large company require supplier source diverse company broadbase black economic empowerment bill south africa include similar requirement work increase diversity supply chain provide opportunity small diverse business provide good service help diverse supplier sustain business create job boost local economy business benefit comply regulation supplier diversity encourage innovation expose new perspective fresh idea programme dedicate team work create opportunity diverse supplier work gsk channel procurement spend woman minorityowned company activity include participate national local diversity council mentor highpotential diverse supplier provide improvement grant help expand business gsk corporation read case study sponsor diverse business leader attend executive programme tuck school business kellogg school management sponsor attend outreach network conference cosponsor congressional black caucus foundation cbcf nonprofit organisation support african americans underserve community donate foundation provide training help diverse business competitive support initiative run cbcf help change federal policy restrict longterm relationship minority womenowne business major corporation sponsor roanoke online technology company host online database electronic source system diverse supplier give large company include gsk well access diverse supplier corporation gain access large diverse pool contractor ultimately help low cost small diverse supplier chance grow business increase opportunity supply company traditionally reach adopt neighbourhood development initiative procurement community relation team work local community durham north carolina philadelphia pennsylvania area historically deprive overlook company choose locate business gsk provide annual grant support selfdevelopment community area attractive business location outside gsk dedicated supplier diversity team base procurement employee worldwide responsible support diverse supplier possible sponsor global link programme role international advisory board national minority supplier development council programme help diverse supplier develop partnership local business world collaboration pharmaceutical company pay usbased minorityowned company visit south africa late company meet diverse south african business get chance form partnership help compete globally participate similar trip australia brazil china initiative enable gsk invest local economy community serve help ensure supplier base reflect diversity community gsk member new uk minority supplier development council council form link corporation certify minority business enterprise aim increase procurement business development opportunitieshome responsibility supply chain responsibility supply chain supplier diversity corporate responsibility report supplier diversity small minorityowne company underrepresented supply chain large company response government large company require supplier source diverse company broadbase black economic empowerment bill south africa include similar requirement work increase diversity supply chain provide opportunity small diverse business provide good service help diverse supplier sustain business create job boost local economy business benefit comply regulation supplier diversity encourage innovation expose new perspective fresh idea programme dedicate team work create opportunity diverse supplier work gsk channel procurement spend woman minorityowned company activity include participate national local diversity council mentor highpotential diverse supplier provide improvement grant help expand business gsk corporation read case study sponsor diverse business leader attend executive programme tuck school business kellogg school management sponsor attend outreach network conference cosponsor congressional black caucus foundation cbcf nonprofit organisation support african americans underserve community donate foundation provide training help diverse business competitive support initiative run cbcf help change federal policy restrict longterm relationship minority womenowne business major corporation sponsor roanoke online technology company host online database electronic source system diverse supplier give large company include gsk well access diverse supplier corporation gain access large diverse pool contractor ultimately help low cost small diverse supplier chance grow business increase opportunity supply company traditionally reach adopt neighbourhood development initiative procurement community relation team work local community durham north carolina philadelphia pennsylvania area historically deprive overlook company choose locate business gsk provide annual grant support selfdevelopment community area attractive business location outside gsk dedicated supplier diversity team base procurement employee worldwide responsible support diverse supplier possible sponsor global link programme role international advisory board national minority supplier development council programme help diverse supplier develop partnership local business world collaboration pharmaceutical company pay usbased minorityowned company visit south africa late company meet diverse south african business get chance form partnership help compete globally participate similar trip australia brazil china initiative enable gsk invest local economy community serve help ensure supplier base reflect diversity community gsk member new uk minority supplier development council council form link corporation certify minority business enterprise aim increase procurement business development opportunitie home responsibility supply chain responsibility supply chain supplier diversity corporate responsibility report supplier diversity small minorityowne company underrepresented supply chain large company response government large company require supplier source diverse company broadbase black economic empowerment bill south africa include similar requirement work increase diversity supply chain provide opportunity small diverse business provide good service help diverse supplier sustain business create job boost local economy business benefit comply regulation supplier diversity encourage innovation expose new perspective fresh idea programme dedicate team work create opportunity diverse supplier work gsk channel procurement spend woman minorityowned company activity include participate national local diversity council mentor highpotential diverse supplier provide improvement grant help expand business gsk corporation read case study sponsor diverse business leader attend executive programme tuck school business kellogg school management sponsor attend outreach network conference cosponsor congressional black caucus foundation cbcf nonprofit organisation support african americans underserve community donate foundation provide training help diverse business competitive support initiative run cbcf help change federal policy restrict longterm relationship minority womenowne business major corporation sponsor roanoke online technology company host online database electronic source system diverse supplier give large company include gsk well access diverse supplier corporation gain access large diverse pool contractor ultimately help low cost small diverse supplier chance grow business increase opportunity supply company traditionally reach adopt neighbourhood development initiative procurement community relation team work local community durham north carolina philadelphia pennsylvania area historically deprive overlook company choose locate business gsk provide annual grant support selfdevelopment community area attractive business location outside gsk dedicated supplier diversity team base procurement employee worldwide responsible support diverse supplier possible sponsor global link programme role international advisory board national minority supplier development council programme help diverse supplier develop partnership local business world collaboration pharmaceutical company pay usbased minorityowned company visit south africa late company meet diverse south african business get chance form partnership help compete globally participate similar trip australia brazil china initiative enable gsk invest local economy community serve help ensure supplier base reflect diversity community gsk member new uk minority supplier development council council form link corporation certify minority business enterprise aim increase procurement business development opportunitie home responsibility supply chain responsibility supply chain fair treatment supplier corporate responsibility report fair treatment supplier important foster relationship supplier characterise mutual trust respect gsk establish procurement policy require high standard ethical conduct integrity general term condition website supplier review process way dialogue identify area mutual improvement provide environment supplier discuss issue present new idea support impartiality phase procurement cycle global electronic bid system ensure supplier treat fairly equally vast majority supplier provide good service gsk register system company invite bid supply gsk receive information time example invitation compete specification supply require system manage bidding negotiationrelate event country highly competitive good service allow supplier transparency seeing bid rank competition payment supplier september gsk change standard payment term uncontracte supplier uk day receipt invoice day review term condition contract supplier contract renewal early step take project reduce work capital recognise impact cash flow supplier new day term bring line practice industry fast term set company realise cause genuine financial difficulty organisation evaluate implication casebycase basis home responsibility supply chain responsibility supply chain fair treatment supplier corporate responsibility report fair treatment supplier important foster relationship supplier characterise mutual trust respect gsk establish procurement policy require high standard ethical conduct integrity general term condition website supplier review process way dialogue identify area mutual improvement provide environment supplier discuss issue present new idea support impartiality phase procurement cycle global electronic bid system ensure supplier treat fairly equally vast majority supplier provide good service gsk register system company invite bid supply gsk receive information time example invitation compete specification supply require system manage bidding negotiationrelate event country highly competitive good service allow supplier transparency seeing bid rank competition payment supplier september gsk change standard payment term uncontracte supplier uk day receipt invoice day review term condition contract supplier contract renewal early step take project reduce work capital recognise impact cash flow supplier new day term bring line practice industry fast term set company realise cause genuine financial difficulty organisation evaluate implication casebycase basis home responsibility supply chain maintain quality corporate responsibility report maintain quality maintain quality product material buy essential safety patient success business conduct quality assessment supplier ingredient packaging material product agree specification ingredient packaging material supplier apply set global auditing standard type ingredient packaging material buy use riskbase approach determine frequency audit conduct audits ingredient packaging material supplier compare receipt gks site sample take testing perform accord test protocol sample test identity batch test quality specification example additional measure place maintain quality supply chain prevent contamination include use dedicated transport use tamper evident seal use sophisticated analytical tool check authenticity material receive help supplier meet quality standard conduct quality assessment potential supplier enable identify company meet require standard work necessary improvement example identify exist chemical supplier asia expertise supply final active ingredient gsk product work closely supplier help develop technical process quality standard begin trial manufacturing include site visit advise configuration plan building modification assistance prepare documentation require regulator food drug administration conduct day quality compliance inspection site result adverse finding approve site supply market raise employee awareness commitment quality andrew witty gsk ceo endorse new internal quality statement stress importance quality business activity include critical aspect product quality raise awareness statement discussion internal quality council business unit new article global intranet site mygsk poster display facility quality statement quality heart activity support discovery supply marketing product patient customer quality critical building trust society future business success andrew witty chief executive officer home responsibility supply chain maintain quality corporate responsibility report maintain quality maintain quality product material buy essential safety patient success business conduct quality assessment supplier ingredient packaging material product agree specification ingredient packaging material supplier apply set global auditing standard type ingredient packaging material buy use riskbase approach determine frequency audit conduct audits ingredient packaging material supplier compare receipt gks site sample take testing perform accord test protocol sample test identity batch test quality specification example additional measure place maintain quality supply chain prevent contamination include use dedicated transport use tamper evident seal use sophisticated analytical tool check authenticity material receive help supplier meet quality standard conduct quality assessment potential supplier enable identify company meet require standard work necessary improvement example identify exist chemical supplier asia expertise supply final active ingredient gsk product work closely supplier help develop technical process quality standard begin trial manufacturing include site visit advise configuration plan building modification assistance prepare documentation require regulator food drug administration conduct day quality compliance inspection site result adverse finding approve site supply market raise employee awareness commitment quality andrew witty gsk ceo endorse new internal quality statement stress importance quality business activity include critical aspect product quality raise awareness statement discussion internal quality council business unit new article global intranet site mygsk poster display facility quality statement quality heart activity support discovery supply marketing product patient customer quality critical building trust society future business success andrew witty chief executive officer home responsibility supply chain security supply corporate responsibility report security supply ensure continuous supply high quality medicine essential patient depend product success business vital security supply compromise stage distribution chain prepare major incident disrupt supply range largescale theft product natural manmade disaster near facility strategy director therapy area overall responsibility security supply divisional head meet procurement team month discuss potential issue gms manufacture business implement contingency plan medically critical product define product medically critical lifesaving available patient likelihood detriment health know alternative plan define productbyproduct basis include hold sufficient stock product active pharmaceutical ingredient work critical supplier encourage implement contingency plan highrisk country set joint venture ensure maintain control distribution chain global contract supplier deliver good gsk facility distribute product market conduct regular highlevel operational review supplier include security element read measure take protect employee event pandemic flu outbreak ensure supply critical medicine disrupt home responsibility supply chain security supply corporate responsibility report security supply ensure continuous supply high quality medicine essential patient depend product success business vital security supply compromise stage distribution chain prepare major incident disrupt supply range largescale theft product natural manmade disaster near facility strategy director therapy area overall responsibility security supply divisional head meet procurement team month discuss potential issue gms manufacture business implement contingency plan medically critical product define product medically critical lifesaving available patient likelihood detriment health know alternative plan define productbyproduct basis include hold sufficient stock product active pharmaceutical ingredient work critical supplier encourage implement contingency plan highrisk country set joint venture ensure maintain control distribution chain global contract supplier deliver good gsk facility distribute product market conduct regular highlevel operational review supplier include security element read measure take protect employee event pandemic flu outbreak ensure supply critical medicine disrupt home responsibility supply chain counterfeit corporate responsibility report counterfeit approach performance accord world health organization cent pharmaceutical product sell develop country counterfeit develop world figure high cent cent country counterfeit drug come variation contain legitimate active ingredient active ingredient reduce subtherapeutic amount completely different andor inappropriate active ingredient impuritie unapproved colourant microorganism packaging falsify product description expiry date counterfeit drug subject quality control hygiene standard test ingredient monitor product specification equipment counterfeiting threat public health potentially cause harm patient death add anticounterfeite feature product packaging include hologram security seal complicated background pattern difficult photocopy scan wide variety covert identifier add print technology sophisticated marker help identify counterfeit gather evidence offender pack design technology security team uk carry forensic examination suspect counterfeit gsk product sale representative worldwide play important role helping discover counterfeit product continual observation local market corporate security department investigate potential case counterfeiting use internal external investigator collect information assess report relevant government authority set motion official law enforcement action remove fake product market primary aim trace product source shut manufacturer partner example packaging printer distributor provide training regulatory authority state food drug administration sfda china law enforcement agency custom officer part world gsk work closely wide pharmaceutical industry investigate case counterfeit raise awareness government internationally press strict law severe penalty gsk found member pharmaceutical security institute psi coordinates information collection investigation industry internationally psi influential help shape anti counterfeiting policy national government international organisation psi gsk major contributor s internationally represent anticounterfeite work group internet pharmacy evidence large number internet pharmacy involve sale counterfeit divert medicine illegal generic substitution switch time delivery request brand product internet pharmacy provide substandard product engage fraud customer credit card information fraudulent activity ignore local law regulation relate licence prescription patient information seemingly operate immunity prosecution internet pharmacy flourish past year likely rise continue provide lucrative lowrisk opportunity direct selling patient global largely unrestricted market uk medicine healthcare product regulatory agency estimate british patient purchase prescription medicine internet fda report pill purchase internet pharmacy month state kentucky alonehome responsibility supply chain counterfeit corporate responsibility report counterfeit approach performance accord world health organization cent pharmaceutical product sell develop country counterfeit develop world figure high cent cent country counterfeit drug come variation contain legitimate active ingredient active ingredient reduce subtherapeutic amount completely different andor inappropriate active ingredient impuritie unapproved colourant microorganism packaging falsify product description expiry date counterfeit drug subject quality control hygiene standard test ingredient monitor product specification equipment counterfeiting threat public health potentially cause harm patient death add anticounterfeite feature product packaging include hologram security seal complicated background pattern difficult photocopy scan wide variety covert identifier add print technology sophisticated marker help identify counterfeit gather evidence offender pack design technology security team uk carry forensic examination suspect counterfeit gsk product sale representative worldwide play important role helping discover counterfeit product continual observation local market corporate security department investigate potential case counterfeiting use internal external investigator collect information assess report relevant government authority set motion official law enforcement action remove fake product market primary aim trace product source shut manufacturer partner example packaging printer distributor provide training regulatory authority state food drug administration sfda china law enforcement agency custom officer part world gsk work closely wide pharmaceutical industry investigate case counterfeit raise awareness government internationally press strict law severe penalty gsk found member pharmaceutical security institute psi coordinates information collection investigation industry internationally psi influential help shape anti counterfeiting policy national government international organisation psi gsk major contributor s internationally represent anticounterfeite work group internet pharmacy evidence large number internet pharmacy involve sale counterfeit divert medicine illegal generic substitution switch time delivery request brand product internet pharmacy provide substandard product engage fraud customer credit card information fraudulent activity ignore local law regulation relate licence prescription patient information seemingly operate immunity prosecution internet pharmacy flourish past year likely rise continue provide lucrative lowrisk opportunity direct selling patient global largely unrestricted market uk medicine healthcare product regulatory agency estimate british patient purchase prescription medicine internet fda report pill purchase internet pharmacy month state kentucky home responsibility supply chain counterfeit corporate responsibility report counterfeit approach performance accord world health organization cent pharmaceutical product sell develop country counterfeit develop world figure high cent cent country counterfeit drug come variation contain legitimate active ingredient active ingredient reduce subtherapeutic amount completely different andor inappropriate active ingredient impuritie unapproved colourant microorganism packaging falsify product description expiry date counterfeit drug subject quality control hygiene standard test ingredient monitor product specification equipment counterfeiting threat public health potentially cause harm patient death add anticounterfeite feature product packaging include hologram security seal complicated background pattern difficult photocopy scan wide variety covert identifier add print technology sophisticated marker help identify counterfeit gather evidence offender pack design technology security team uk carry forensic examination suspect counterfeit gsk product sale representative worldwide play important role helping discover counterfeit product continual observation local market corporate security department investigate potential case counterfeiting use internal external investigator collect information assess report relevant government authority set motion official law enforcement action remove fake product market primary aim trace product source shut manufacturer partner example packaging printer distributor provide training regulatory authority state food drug administration sfda china law enforcement agency custom officer part world gsk work closely wide pharmaceutical industry investigate case counterfeit raise awareness government internationally press strict law severe penalty gsk found member pharmaceutical security institute psi coordinates information collection investigation industry internationally psi influential help shape anti counterfeiting policy national government international organisation psi gsk major contributor s internationally represent anticounterfeite work group internet pharmacy evidence large number internet pharmacy involve sale counterfeit divert medicine illegal generic substitution switch time delivery request brand product internet pharmacy provide substandard product engage fraud customer credit card information fraudulent activity ignore local law regulation relate licence prescription patient information seemingly operate immunity prosecution internet pharmacy flourish past year likely rise continue provide lucrative lowrisk opportunity direct selling patient global largely unrestricted market uk medicine healthcare product regulatory agency estimate british patient purchase prescription medicine internet fda report pill purchase internet pharmacy month state kentucky home responsibility supply chain counterfeiting performance corporate responsibility report counterfeit approach performance report case counterfeit gsk product result raid suspect counterfeiter arrest million worth counterfeit product find raid take place criminal manufacturing facility wholesaledistribution outlet factory represent criminal operation capable mass production counterfeit medicine healthcare product raid facility undoubtedly prevent huge amount counterfeit product enter legitimate market world million worth product find time raid reduction number report case counterfeit positive sign anticounterfeite measure work number raid gsk rise cent result proactive security investigation activity number raid directly relate number report case counterfeit base intelligence security investigation activity gsk recognise leader industry combat counterfeit medicine currently chair pharmaceutical security institute anticounterfeite number value number report number counterfeit case raid product find arrest counterfeit raid million million million million home responsibility supply chain counterfeiting performance corporate responsibility report counterfeit approach performance report case counterfeit gsk product result raid suspect counterfeiter arrest million worth counterfeit product find raid take place criminal manufacturing facility wholesaledistribution outlet factory represent criminal operation capable mass production counterfeit medicine healthcare product raid facility undoubtedly prevent huge amount counterfeit product enter legitimate market world million worth product find time raid reduction number report case counterfeit positive sign anticounterfeite measure work number raid gsk rise cent result proactive security investigation activity number raid directly relate number report case counterfeit base intelligence security investigation activity gsk recognise leader industry combat counterfeit medicine currently chair pharmaceutical security institute anticounterfeite number value number report number counterfeit case raid product find arrest counterfeit raid million million million million home responsibility supply chain case study corporate responsibility report case study mentor diverse supplier callis construction services ccs minorityowne contracting company durham north carolina companys president jesse callis take diverse supplier mentor programme beginning help supplier form partnership gsk large corporation programme assess ccss business process identify issue prevent company gsk prefer supplier concern range management accessibility ability scale supply need gsk company implement improvement base recommendation enable preferred supplier win business worth million success partnership enable ccs contribute local community pay employee attend local university mr callis develop training programme durham technical college prepare minority construction worker management position major project area ask relationship gsk mr callis say gsk wonderful mentor real leader commitment action help diverse minority supplier case provide assistance lead significant growth business turn provide job durham surround area ensure monie pay gsk stay local community win involve helping improve supplier performance case provide assistance supplier fail meet minimum ehs quality standard improve performance enable company improve work practice win business help develop supply chain need provide secure supply high quality medicine example provide support potential supplier active pharmaceutical ingredient india supplier receive audit score cent cent minimum standard follow audit recommendation improvement provide coach facilitate meeting supplier expert consultant supplier achieve audit score cent accept gsk supplier audit find company manage key risk effectively establish detailed improvement programme continue monitor progress improvement plan success collaboration rely effort gsk staff willingness supplier recognise improvement need result secure supply chain gsk safe working environment worker facility home responsibility supply chain case study corporate responsibility report case study mentor diverse supplier callis construction services ccs minorityowne contracting company durham north carolina companys president jesse callis take diverse supplier mentor programme beginning help supplier form partnership gsk large corporation programme assess ccss business process identify issue prevent company gsk prefer supplier concern range management accessibility ability scale supply need gsk company implement improvement base recommendation enable preferred supplier win business worth million success partnership enable ccs contribute local community pay employee attend local university mr callis develop training programme durham technical college prepare minority construction worker management position major project area ask relationship gsk mr callis say gsk wonderful mentor real leader commitment action help diverse minority supplier case provide assistance lead significant growth business turn provide job durham surround area ensure monie pay gsk stay local community win involve helping improve supplier performance case provide assistance supplier fail meet minimum ehs quality standard improve performance enable company improve work practice win business help develop supply chain need provide secure supply high quality medicine example provide support potential supplier active pharmaceutical ingredient india supplier receive audit score cent cent minimum standard follow audit recommendation improvement provide coach facilitate meeting supplier expert consultant supplier achieve audit score cent accept gsk supplier audit find company manage key risk effectively establish detailed improvement programme continue monitor progress improvement plan success collaboration rely effort gsk staff willingness supplier recognise improvement need result secure supply chain gsk safe working environment worker facility home responsibility supply chain qas corporate responsibility report qas respond question raise stakeholder raise standard supply chain longterm relationship critical supplier offer training support help raise standard monitoring process key raise awareness expectation identify area supplier need improve work supplier help necessary change identify human right risk supply chain gsk supply chain large complex like similar supply chain contain risk human right violation risk vary considerably base type supplier good service source manufacture ranpd supplier employ skilled worker low risk human right violation ehs audits aim ensure good working condition supplier facility considerably high human right risk supplier employ lowskilled worker example promotional good supplier conduct spot check supplier india supplier selection process aim ensure enter relationship supplier respect human right include clause contract supplier specify uphold human right condition business gsk supply chain plan flu pandemic implement contingency plan ensure operation supply medically critical product compromise flu pandemic encourage critical supplier implement contingency plan outsource manufacturing mean control product increase risk patient manufacture medicine vaccine closely control subject quality standard regardless produce outsource process contract manufacturer outsource stage manufacturing process confirm contractor carry require process high standard contract manufacturer approve relevant regulatory authority subject inspection gsk regulator home responsibility supply chain qas corporate responsibility report qas respond question raise stakeholder raise standard supply chain longterm relationship critical supplier offer training support help raise standard monitoring process key raise awareness expectation identify area supplier need improve work supplier help necessary change identify human right risk supply chain gsk supply chain large complex like similar supply chain contain risk human right violation risk vary considerably base type supplier good service source manufacture ranpd supplier employ skilled worker low risk human right violation ehs audits aim ensure good working condition supplier facility considerably high human right risk supplier employ lowskilled worker example promotional good supplier conduct spot check supplier india supplier selection process aim ensure enter relationship supplier respect human right include clause contract supplier specify uphold human right condition business gsk supply chain plan flu pandemic implement contingency plan ensure operation supply medically critical product compromise flu pandemic encourage critical supplier implement contingency plan outsource manufacturing mean control product increase risk patient manufacture medicine vaccine closely control subject quality standard regardless produce outsource process contract manufacturer outsource stage manufacturing process confirm contractor carry require process high standard contract manufacturer approve relevant regulatory authority subject inspection gsk regulator home responsibility environmental sustainability corporate responsibility report environmental sustainability sustainability define meeting need today compromise ability future generation meet need gsk embark journey sustainability expect continue year benefit environment sustainability effort encourage innovation provide well outcome society help reduce cost early environmental management programme focus control emission waste operation treatment disposal system approach sustainability change fundamental process reduce resource consume avoid waste source simply treat waste emission arise begin change business develop innovative new manufacturing process set initial sustainability goal double average efficiency convert raw material finish product new product end baseline reduce energy climate change impact unit sale level cent eliminate cfc product equipment end example sustainability initiative include reduce material resource use raw material fossil fuel minimise waste recycling unavoidable waste redesigning production process eliminate production toxic material reduce energy consumption associate carbon emission manage environment health safety sustainability ehss programme accord framework set consistent standard employee health safety environmental protection sustainability framework act internal regulatory system reflect understand risk ensure operation comply law regulation provide information tool training help gsk meet standard include target set plan excellence address fundamental environmental sustainability impact work supplier help sustainable openness transparency fundamental sustainability performance continue engage stakeholder share view dilemma home responsibility environmental sustainability corporate responsibility report environmental sustainability sustainability define meeting need today compromise ability future generation meet need gsk embark journey sustainability expect continue year benefit environment sustainability effort encourage innovation provide well outcome society help reduce cost early environmental management programme focus control emission waste operation treatment disposal system approach sustainability change fundamental process reduce resource consume avoid waste source simply treat waste emission arise begin change business develop innovative new manufacturing process set initial sustainability goal double average efficiency convert raw material finish product new product end baseline reduce energy climate change impact unit sale level cent eliminate cfc product equipment end example sustainability initiative include reduce material resource use raw material fossil fuel minimise waste recycling unavoidable waste redesigning production process eliminate production toxic material reduce energy consumption associate carbon emission manage environment health safety sustainability ehss programme accord framework set consistent standard employee health safety environmental protection sustainability framework act internal regulatory system reflect understand risk ensure operation comply law regulation provide information tool training help gsk meet standard include target set plan excellence address fundamental environmental sustainability impact work supplier help sustainable openness transparency fundamental sustainability performance continue engage stakeholder share view dilemma home responsibility environmental sustainability plan excellence corporate responsibility report plan excellence ehss plan excellence set tenyear strategy improve environment health safety sustainability performance detail develop concert business plan integrate business plan specific action identify business plan review year new target set design support gsk business plan consist strategic priority environment health safety fundamental embed business produce sustain high ehs performance need combine structured system attitude value create positive ehs culture achieve need embed awareness environment health safety concern system gsk activity environmental sustainability embrace environmental sustainability driver competitive advantage need define principle environmental sustainability progressively integrate business translate practical action open transparent external relation external stakeholder legitimate interest company environment health safety sustainability affair ready access relevant information opportunity dialogue issue concern build open relationship partnership lead business opportunity failure engage damage reputation strategic priority support plan performance target key area gsk work external stakeholder panel help set plan review annual performance target ehss plan excellence include company target improve environment health safety sustainability performance base site base practical improvement plan forecast manufacture operation read target set view detail company target home responsibility environmental sustainability plan excellence corporate responsibility report plan excellence ehss plan excellence set tenyear strategy improve environment health safety sustainability performance detail develop concert business plan integrate business plan specific action identify business plan review year new target set design support gsk business plan consist strategic priority environment health safety fundamental embed business produce sustain high ehs performance need combine structured system attitude value create positive ehs culture achieve need embed awareness environment health safety concern system gsk activity environmental sustainability embrace environmental sustainability driver competitive advantage need define principle environmental sustainability progressively integrate business translate practical action open transparent external relation external stakeholder legitimate interest company environment health safety sustainability affair ready access relevant information opportunity dialogue issue concern build open relationship partnership lead business opportunity failure engage damage reputation strategic priority support plan performance target key area gsk work external stakeholder panel help set plan review annual performance target ehss plan excellence include company target improve environment health safety sustainability performance base site base practical improvement plan forecast manufacture operation read target set view detail company target home responsibility environmental sustainability plan excellence target corporate responsibility report target set companywide target drive continuous improvement manage significant environment health safety sustainability impact table compare proposal company target forward operation benchmarke information environment health safety professional senior manager management team business closely review agree final target number believe important set achieve target low resource consumption waste benefit environment gsk track meet target recognise difficult meet time set explain progress target discussion individual metric read health safety target target progress progress target sustainability target material efficiency new process average period material efficiency active achieve reduction unit sale increase energy operation transport baseline sale cer climate change impact energy reduction unit sale increase sale operation transport baseline cer annual reduction reduce sale water baseline unit sale cer fundamental target wastewater chemical oxygen annual reduction reduce sale demand baseline unit sale cer annual reduction reduce sale solid waste baseline unit sale cer elimination ozone depletion eliminate air emission volatile organic annual reduction reduce sale emission baseline unit sale cer average minimum average minimum eh audit score climate change impact measure co equivalent emission include ozone depletion potential production refrigeration loss target performance normalise sale base constant exchange rate cer sgs verify tophome responsibility environmental sustainability plan excellence target corporate responsibility report target set companywide target drive continuous improvement manage significant environment health safety sustainability impact table compare proposal company target forward operation benchmarke information environment health safety professional senior manager management team business closely review agree final target number believe important set achieve target low resource consumption waste benefit environment gsk track meet target recognise difficult meet time set explain progress target discussion individual metric read health safety target target progress progress target sustainability target material efficiency new process average period material efficiency active achieve reduction unit sale increase energy operation transport baseline sale cer climate change impact energy reduction unit sale increase sale operation transport baseline cer annual reduction reduce sale water baseline unit sale cer fundamental target wastewater chemical oxygen annual reduction reduce sale demand baseline unit sale cer annual reduction reduce sale solid waste baseline unit sale cer elimination ozone depletion eliminate air emission volatile organic annual reduction reduce sale emission baseline unit sale cer average minimum average minimum eh audit score climate change impact measure co equivalent emission include ozone depletion potential production refrigeration loss target performance normalise sale base constant exchange rate cer sgs verify home responsibility environmental sustainability plan excellence target corporate responsibility report target set companywide target drive continuous improvement manage significant environment health safety sustainability impact table compare proposal company target forward operation benchmarke information environment health safety professional senior manager management team business closely review agree final target number believe important set achieve target low resource consumption waste benefit environment gsk track meet target recognise difficult meet time set explain progress target discussion individual metric read health safety target target progress progress target sustainability target material efficiency new process average period material efficiency active achieve reduction unit sale increase energy operation transport baseline sale cer climate change impact energy reduction unit sale increase sale operation transport baseline cer annual reduction reduce sale water baseline unit sale cer fundamental target wastewater chemical oxygen annual reduction reduce sale demand baseline unit sale cer annual reduction reduce sale solid waste baseline unit sale cer elimination ozone depletion eliminate air emission volatile organic annual reduction reduce sale emission baseline unit sale cer average minimum average minimum eh audit score climate change impact measure co equivalent emission include ozone depletion potential production refrigeration loss target performance normalise sale base constant exchange rate cer sgs verify home responsibility environmental sustainability plan excellence journey sustainability corporate responsibility report journey sustainability james hagan vice president corporate environment health safety sustainability chart gsk history environmental management describe company make shift sustainability sustainability define meeting need today compromise ability future generation meet need gsk sustainable need efficient use resource include energy water raw material need use renewable resource resource scarce expensive sustainability cost closely link ultimately mean ability continue manufacture affordable medicine require address sustainability work sustainability gsk form similar industry time company form gsk start manage emission waste treatment disposal method consider management waste necessary cost soon recognise bolton control measure essential incrementally improve impact waste achieve stepchange sustainability need process efficient prevent waste emission produce place fundamental change require investment innovative solution innovation create efficient process use resource reduce cost virtuous circle complete portion sale reinvest innovation sustainability reflect builtin approach begin guide business sustainability develop management framework set policy consistent standard gsk follow produce plan outline timetable achieve goal set framework set fiveyear improvement target plan refresh period plan identify manufacturing efficiency area significant progress sustainability material balance calculation look produce compare amount raw material measure material efficiency set improvement target double efficiency new product ecodesign toolkit support development efficient manufacturing process read process design success new medicine think improve process exist product climate change great challenge face mankind key sustainability strategy set target halve energy use co produce unit sale sustainability focus extend manufacture aspect business include rd sale activity include environmental product stewardship responsibility environmental impact medicine gsk sustainability start root example nutritional healthcare business comprehensive sustainability programme read casestudy detail work supplier examine lifecycle biodiversity impact raw material develop zero waste landfill manufacturing approach recycled material packaging develop innovative way recover bottle reverse vend consumer healthcare business develop sustainability strategy call bright green include packaging climate change water use product stewardship total supply chain goal progress nutritional business certain area achieve fundamental environmental improvement target make progress sustainability continue challenge assess achieve target course learn success failure year explain succeed fail continpuagee broaden view sustainability mean gsk far focus attention sustainability rd manufacturing go forward know need broaden focus include sale force office realise begin journey need commitment innovation succeed internal sustainability council compose senior manager lead effort external stakeholder panel give feedback approach performance suggest improvement alternative recognise value stakeholder bring welcome view approach feel free let know thought email csrcontactgskcom tophome responsibility environmental sustainability plan excellence journey sustainability corporate responsibility report journey sustainability james hagan vice president corporate environment health safety sustainability chart gsk history environmental management describe company make shift sustainability sustainability define meeting need today compromise ability future generation meet need gsk sustainable need efficient use resource include energy water raw material need use renewable resource resource scarce expensive sustainability cost closely link ultimately mean ability continue manufacture affordable medicine require address sustainability work sustainability gsk form similar industry time company form gsk start manage emission waste treatment disposal method consider management waste necessary cost soon recognise bolton control measure essential incrementally improve impact waste achieve stepchange sustainability need process efficient prevent waste emission produce place fundamental change require investment innovative solution innovation create efficient process use resource reduce cost virtuous circle complete portion sale reinvest innovation sustainability reflect builtin approach begin guide business sustainability develop management framework set policy consistent standard gsk follow produce plan outline timetable achieve goal set framework set fiveyear improvement target plan refresh period plan identify manufacturing efficiency area significant progress sustainability material balance calculation look produce compare amount raw material measure material efficiency set improvement target double efficiency new product ecodesign toolkit support development efficient manufacturing process read process design success new medicine think improve process exist product climate change great challenge face mankind key sustainability strategy set target halve energy use co produce unit sale sustainability focus extend manufacture aspect business include rd sale activity include environmental product stewardship responsibility environmental impact medicine gsk sustainability start root example nutritional healthcare business comprehensive sustainability programme read casestudy detail work supplier examine lifecycle biodiversity impact raw material develop zero waste landfill manufacturing approach recycled material packaging develop innovative way recover bottle reverse vend consumer healthcare business develop sustainability strategy call bright green include packaging climate change water use product stewardship total supply chain goal progress nutritional business certain area achieve fundamental environmental improvement target make progress sustainability continue challenge assess achieve target course learn success failure year explain succeed fail continue broaden view sustainability mean gsk far focus attention sustainability rd manufacturing go forward know need broaden focus include sale force office realise begin journey need commitment innovation succeed internal sustainability council compose senior manager lead effort external stakeholder panel give feedback approach performance suggest improvement alternative recognise value stakeholder bring welcome view approach feel free let know thought email csrcontactgskcom home responsibility environmental sustainability plan excellence journey sustainability corporate responsibility report journey sustainability james hagan vice president corporate environment health safety sustainability chart gsk history environmental management describe company make shift sustainability sustainability define meeting need today compromise ability future generation meet need gsk sustainable need efficient use resource include energy water raw material need use renewable resource resource scarce expensive sustainability cost closely link ultimately mean ability continue manufacture affordable medicine require address sustainability work sustainability gsk form similar industry time company form gsk start manage emission waste treatment disposal method consider management waste necessary cost soon recognise bolton control measure essential incrementally improve impact waste achieve stepchange sustainability need process efficient prevent waste emission produce place fundamental change require investment innovative solution innovation create efficient process use resource reduce cost virtuous circle complete portion sale reinvest innovation sustainability reflect builtin approach begin guide business sustainability develop management framework set policy consistent standard gsk follow produce plan outline timetable achieve goal set framework set fiveyear improvement target plan refresh period plan identify manufacturing efficiency area significant progress sustainability material balance calculation look produce compare amount raw material measure material efficiency set improvement target double efficiency new product ecodesign toolkit support development efficient manufacturing process read process design success new medicine think improve process exist product climate change great challenge face mankind key sustainability strategy set target halve energy use co produce unit sale sustainability focus extend manufacture aspect business include rd sale activity include environmental product stewardship responsibility environmental impact medicine gsk sustainability start root example nutritional healthcare business comprehensive sustainability programme read casestudy detail work supplier examine lifecycle biodiversity impact raw material develop zero waste landfill manufacturing approach recycled material packaging develop innovative way recover bottle reverse vend consumer healthcare business develop sustainability strategy call bright green include packaging climate change water use product stewardship total supply chain goal progress nutritional business certain area achieve fundamental environmental improvement target make progress sustainability continue challenge assess achieve target course learn success failure year explain succeed fail continue broaden view sustainability mean gsk far focus attention sustainability rd manufacturing go forward know need broaden focus include sale force office realise begin journey need commitment innovation succeed internal sustainability council compose senior manager lead effort external stakeholder panel give feedback approach performance suggest improvement alternative recognise value stakeholder bring welcome view approach feel free let know thought email csrcontactgskcom home responsibility environmental sustainability manage ehs sustainability corporate responsibility report manage environment health safety sustainability manage environment health safety sustainability issue management system align recognise management system standard iso ohsa management system base structured framework start vision policy policy support standard guidance material tool train recognition audits assist business manage environment health safety sustainability site key business operation systematic audits assess site adoption management system approach manage risk framework define ehss vision policy set broad principle expect operation meet ehss standard outline specific requirement company base ehss risk meet exceed applicable law regulation consistent international standard iso ohsa base management system approach ehss guidelines support ehss standard provide information requirement standard set approve approach achieve compliance incorporate good practice outside gsk wide range information supplement ehss guideline include technical information training material help employee understand implement ehss management system audits assess implementation management system reward recognition recognise team outstanding progress achieve goal framework include plan excellence set strategy improve ehss performance improve efficiency great integration horlick manufacturing facility near delhi india certify international quality standard iso environmental standard iso safety standard iso ohsa site introduce integrate management system reduce burden comply separate standard new system improve efficiency cut cost plant reduce documentation require number audits employee use instruction manual separate document standard project place ceo ehs excellence awards initiativehealth safety category home responsibility environmental sustainability manage ehs sustainability corporate responsibility report manage environment health safety sustainability manage environment health safety sustainability issue management system align recognise management system standard iso ohsa management system base structured framework start vision policy policy support standard guidance material tool train recognition audits assist business manage environment health safety sustainability site key business operation systematic audits assess site adoption management system approach manage risk framework define ehss vision policy set broad principle expect operation meet ehss standard outline specific requirement company base ehss risk meet exceed applicable law regulation consistent international standard iso ohsa base management system approach ehss guidelines support ehss standard provide information requirement standard set approve approach achieve compliance incorporate good practice outside gsk wide range information supplement ehss guideline include technical information training material help employee understand implement ehss management system audits assess implementation management system reward recognition recognise team outstanding progress achieve goal framework include plan excellence set strategy improve ehss performance improve efficiency great integration horlick manufacturing facility near delhi india certify international quality standard iso environmental standard iso safety standard iso ohsa site introduce integrate management system reduce burden comply separate standard new system improve efficiency cut cost plant reduce documentation require number audits employee use instruction manual separate document standard project place ceo ehs excellence awards initiativehealth safety category home responsibility environmental sustainability manage ehs sustainability ehss vision policy corporate responsibility report ehss vision policy vision gsk environment health safety sustainability ehss vision achieve sustainable competitive business advantage environmental sustainability leadership excellence ehss vision support mission help people feel well live long policy ehss policy describe employee external stakeholder want accomplish environment health safety sustainability set aspiration global leadership excellence outline broad scope plan achieve revise policy approve corporate executive team cet leadership continuous improvement culture leader ehss performance protect environment community work enable healthy motivated employee fully engage success maintain culture continuous improvement ehs fundamental risk impact embe ehs fundamental fabric business implement management system ehs governance risk management practice address risk impact facility process contract research manufacturing organisation supplier sustainability integrate sustainability principle aspect healthcare business working stakeholder operate environmentally sustainable limit lower ecological footprint enhance social equity address future issue open ehss communication open transparent stakeholder effort address ehss responsibilitie ehss performance corporate executive team cet ensure risk track mitigated communication significant risk escalate business management structure commensurate risk impact involve cet ensure effective management involvement staff clearly assign accountability responsibility home responsibility environmental sustainability manage ehs sustainability ehss vision policy corporate responsibility report ehss vision policy vision gsk environment health safety sustainability ehss vision achieve sustainable competitive business advantage environmental sustainability leadership excellence ehss vision support mission help people feel well live long policy ehss policy describe employee external stakeholder want accomplish environment health safety sustainability set aspiration global leadership excellence outline broad scope plan achieve revise policy approve corporate executive team cet leadership continuous improvement culture leader ehss performance protect environment community work enable healthy motivated employee fully engage success maintain culture continuous improvement ehs fundamental risk impact embe ehs fundamental fabric business implement management system ehs governance risk management practice address risk impact facility process contract research manufacturing organisation supplier sustainability integrate sustainability principle aspect healthcare business working stakeholder operate environmentally sustainable limit lower ecological footprint enhance social equity address future issue open ehss communication open transparent stakeholder effort address ehss responsibilitie ehss performance corporate executive team cet ensure risk track mitigated communication significant risk escalate business management structure commensurate risk impact involve cet ensure effective management involvement staff clearly assign accountability responsibility home responsibility environmental sustainability manage ehs sustainability training awareness corporate responsibility report training awareness provide detailed guideline technical information framework manage environment health safety sustainability ehss training awareness programme base guideline inform employee level risk create culture ehss consideration integral way business help employee understand ehss issue specific job ehss training manage site specific job role ehss professional receive induction training undertake regular training ensure aware late technical information field business leader receive training understand responsibility review training programme find opportunity improve standardise ehss training gsk include ehss competency job grade programme employee ehss responsibility read health safety training raise employee awareness environment health safety sustainability provide training support material intranet regular internal publication event myehss intranet intranet primary mechanism communicate company area gsk intranet support ehss include main site know myehss myehss way news ehss programme share source support material framework manage ehss policy standard guideline training material document ehss myehss basis information system collect datum measure ehss performance report result gsk external stakeholder gsk site use datum manage ehss programme risk measure progress publication ehss publication available electronically print publish articles environment health safety sustainability spirit internal magazine brief news story internal web page event site participate earthweek annual voluntary programme raise awareness strategic environmental issue encourage integrate environmental concern culture hold june coincide world environment day earthweek encourage employee think impact environment employee site country take earthweek send information kit site help develop activity include tree planting clearing litter local forest involve local school child draw competition environmental theme operation encourage continue voluntary environmental activity long organise centrally award ceos ehs excellence award website vehicle sharing innovative ehs practice site team annual award replace website support ceo award sustainability home responsibility environmental sustainability manage ehs sustainability training awareness corporate responsibility report training awareness provide detailed guideline technical information framework manage environment health safety sustainability ehss training awareness programme base guideline inform employee level risk create culture ehss consideration integral way business help employee understand ehss issue specific job ehss training manage site specific job role ehss professional receive induction training undertake regular training ensure aware late technical information field business leader receive training understand responsibility review training programme find opportunity improve standardise ehss training gsk include ehss competency job grade programme employee ehss responsibility read health safety training raise employee awareness environment health safety sustainability provide training support material intranet regular internal publication event myehss intranet intranet primary mechanism communicate company area gsk intranet support ehss include main site know myehss myehss way news ehss programme share source support material framework manage ehss policy standard guideline training material document ehss myehss basis information system collect datum measure ehss performance report result gsk external stakeholder gsk site use datum manage ehss programme risk measure progress publication ehss publication available electronically print publish articles environment health safety sustainability spirit internal magazine brief news story internal web page event site participate earthweek annual voluntary programme raise awareness strategic environmental issue encourage integrate environmental concern culture hold june coincide world environment day earthweek encourage employee think impact environment employee site country take earthweek send information kit site help develop activity include tree planting clearing litter local forest involve local school child draw competition environmental theme operation encourage continue voluntary environmental activity long organise centrally award ceos ehs excellence award website vehicle sharing innovative ehs practice site team annual award replace website support ceo award sustainability home responsibility environmental sustainability manage ehs sustainability training awareness corporate responsibility report training awareness provide detailed guideline technical information framework manage environment health safety sustainability ehss training awareness programme base guideline inform employee level risk create culture ehss consideration integral way business help employee understand ehss issue specific job ehss training manage site specific job role ehss professional receive induction training undertake regular training ensure aware late technical information field business leader receive training understand responsibility review training programme find opportunity improve standardise ehss training gsk include ehss competency job grade programme employee ehss responsibility read health safety training raise employee awareness environment health safety sustainability provide training support material intranet regular internal publication event myehss intranet intranet primary mechanism communicate company area gsk intranet support ehss include main site know myehss myehss way news ehss programme share source support material framework manage ehss policy standard guideline training material document ehss myehss basis information system collect datum measure ehss performance report result gsk external stakeholder gsk site use datum manage ehss programme risk measure progress publication ehss publication available electronically print publish articles environment health safety sustainability spirit internal magazine brief news story internal web page event site participate earthweek annual voluntary programme raise awareness strategic environmental issue encourage integrate environmental concern culture hold june coincide world environment day earthweek encourage employee think impact environment employee site country take earthweek send information kit site help develop activity include tree planting clearing litter local forest involve local school child draw competition environmental theme operation encourage continue voluntary environmental activity long organise centrally award ceos ehs excellence award website vehicle sharing innovative ehs practice site team annual award replace website support ceo award sustainability home responsibility environmental sustainability manage ehs sustainability audits compliance corporate responsibility report audits compliance approach performance regularly audit operation contract manufacturer key supplier assess system manage risk impact compliance legislation implementation environment health safety sustainability standard audits assess appropriate management system place improve performance maintain compliance internal auditor certify lead auditor iso ohsa standard gsk manufacturing rd site audit year actual frequency determine level risk impact site performance manage risk audit site begin fouryear programme certify gsk pharmaceutical consumer healthcare manufacturing site international environmental standard iso health safety standard ohsa certify site bring total cent pharmaceutical consumer healthcare manufacturing site certify iso home responsibility environmental sustainability manage ehs sustainability audits compliance corporate responsibility report audits compliance approach performance regularly audit operation contract manufacturer key supplier assess system manage risk impact compliance legislation implementation environment health safety sustainability standard audits assess appropriate management system place improve performance maintain compliance internal auditor certify lead auditor iso ohsa standard gsk manufacturing rd site audit year actual frequency determine level risk impact site performance manage risk audit site begin fouryear programme certify gsk pharmaceutical consumer healthcare manufacturing site international environmental standard iso health safety standard ohsa certify site bring total cent pharmaceutical consumer healthcare manufacturing site certify iso home responsibility environmental sustainability manage ehs sustainability audits compliance performance corporate responsibility report audits compliance approach performance audit gsk site implementation ehs standard conduct follow visit average score cent low score consider acceptable cent site score level low score cent site achieve leadership score cent achieve score cent high audit score indicate good management system work practice site achieve audit score cent higher consider leadership category receive certificate sign chief executive officer site achieve cent receive certificate achievement sign business head critical finding relate environment finding indicate high probability incident potentially consequence critical finding relate health safety read performance health safety issue good performance environmental issue waste water management site generally weak assessment risk environment health safety twentysix pharmaceutical consumer healthcare manufacturing site certify iso ohsa standard certify iso consumer healthcare rd site certify standard gsk vaccine site pharmaceutical rd site certify iso site confirm certification audits early certify site argentina australia brazil china egypt france germany india italy japan kenya mexico panama philippine poland saudi arabia spain turkey uk iso certification important indicate good management system place site successfully certify find experience beneficial order achieve target certify pharmaceutical consumer healthcare manufacturing facility upgrade level management system implementation time embark plan expansion iso certification rd vaccine facility compliance environmental fine penalty continue compliance record remain vigilant stay compliance environmental law regulation home responsibility environmental sustainability manage ehs sustainability audits compliance performance corporate responsibility report audits compliance approach performance audit gsk site implementation ehs standard conduct follow visit average score cent low score consider acceptable cent site score level low score cent site achieve leadership score cent achieve score cent high audit score indicate good management system work practice site achieve audit score cent higher consider leadership category receive certificate sign chief executive officer site achieve cent receive certificate achievement sign business head critical finding relate environment finding indicate high probability incident potentially consequence critical finding relate health safety read performance health safety issue good performance environmental issue waste water management site generally weak assessment risk environment health safety twentysix pharmaceutical consumer healthcare manufacturing site certify iso ohsa standard certify iso consumer healthcare rd site certify standard gsk vaccine site pharmaceutical rd site certify iso site confirm certification audits early certify site argentina australia brazil china egypt france germany india italy japan kenya mexico panama philippine poland saudi arabia spain turkey uk iso certification important indicate good management system place site successfully certify find experience beneficial order achieve target certify pharmaceutical consumer healthcare manufacturing facility upgrade level management system implementation time embark plan expansion iso certification rd vaccine facility compliance environmental fine penalty continue compliance record remain vigilant stay compliance environmental law regulation home responsibility environmental sustainability manage ehs sustainability reward recognition corporate responsibility report reward recognition ceo ehs excellence awards recognise reward gsk site leadership ehs sustainability highlight innovation example good practice ehss management share site winner receive trophy select charity receive donation gsk individual team enter competition shortlist draw internal review committee winner choose panel include expert academia government public interest group award divide category green chemistrygreen technology project benefit environment health safety new efficient chemistry technology environmental initiative programme demonstrate improvement environmental management performance occupational health safety initiative programme demonstrate improvement health safety management performance seventh year award entry country gsk business honour go project australia belgium india uk read win environmental project section win health safety project people section award upgrade ceo award sustainability new category new judging criterion support increase focus sustainability home responsibility environmental sustainability manage ehs sustainability reward recognition corporate responsibility report reward recognition ceo ehs excellence awards recognise reward gsk site leadership ehs sustainability highlight innovation example good practice ehss management share site winner receive trophy select charity receive donation gsk individual team enter competition shortlist draw internal review committee winner choose panel include expert academia government public interest group award divide category green chemistrygreen technology project benefit environment health safety new efficient chemistry technology environmental initiative programme demonstrate improvement environmental management performance occupational health safety initiative programme demonstrate improvement health safety management performance seventh year award entry country gsk business honour go project australia belgium india uk read win environmental project section win health safety project people section award upgrade ceo award sustainability new category new judging criterion support increase focus sustainability home responsibility environmental sustainability manage ehs sustainability management ehss corporate responsibility report management ehss overall responsibility environment health safety sustainability issue rest corporate executive team board chief executive officer represent issue board board chairman champion gsk climate change programme chief staff operational management responsibility ehss corporate executive team vice president corporate environment health safety sustainability cehss operational responsibility ehss report directly chief staff dot line report relationship president global manufacturing supply environment health safety sustainability activity oversee risk oversight compliance council corporate executive team audit corporate responsibility committee board director committee regularly review ehss performance progress meeting ehss target result ehss audits gsk operation supplier consider issue sustainability social implication home responsibility environmental sustainability manage ehs sustainability management ehss corporate responsibility report management ehss overall responsibility environment health safety sustainability issue rest corporate executive team board chief executive officer represent issue board board chairman champion gsk climate change programme chief staff operational management responsibility ehss corporate executive team vice president corporate environment health safety sustainability cehss operational responsibility ehss report directly chief staff dot line report relationship president global manufacturing supply environment health safety sustainability activity oversee risk oversight compliance council corporate executive team audit corporate responsibility committee board director committee regularly review ehss performance progress meeting ehss target result ehss audits gsk operation supplier consider issue sustainability social implication home responsibility environmental sustainability environmental fundamental corporate responsibility report environmental fundamental work reduce fundamental environmental impact operation year involve treatment disposal system control emission waste manufacture facility research laboratory numerous office warehouse large fleet vehicle fundamental emission include wastewater general solid hazardous waste ozone deplete substance release equipment production process patient use inhaler product volatile organic compound primarily solvent aim create culture fundamental environmental consideration everyday business decision continue manage fundamental emission move sustainability change production business process avoid waste source simply treat waste emission arise home responsibility environmental sustainability environmental fundamental corporate responsibility report environmental fundamental work reduce fundamental environmental impact operation year involve treatment disposal system control emission waste manufacture facility research laboratory numerous office warehouse large fleet vehicle fundamental emission include wastewater general solid hazardous waste ozone deplete substance release equipment production process patient use inhaler product volatile organic compound primarily solvent aim create culture fundamental environmental consideration everyday business decision continue manage fundamental emission move sustainability change production business process avoid waste source simply treat waste emission arise home responsibility environmental sustainability environmental fundamental wastewater corporate responsibility report wastewater approach performance gsk site discharge wastewater municipal treatment facility large site especially site manufacture active pharmaceutical ingredient api onsite wastewater treatment system site permit discharge wastewater direct sea assess quality wastewater measure chemical oxygen demand cod oxygen require chemically oxidise compound water low cod clean water target improve cod level cent year unit sale reduction cent end vast majority cod come manufacture api wastewater domestic activity washroom canteen include separated manufacturing activity sgs verify home responsibility environmental sustainability environmental fundamental wastewater corporate responsibility report wastewater approach performance gsk site discharge wastewater municipal treatment facility large site especially site manufacture active pharmaceutical ingredient api onsite wastewater treatment system site permit discharge wastewater direct sea assess quality wastewater measure chemical oxygen demand cod oxygen require chemically oxidise compound water low cod clean water target improve cod level cent year unit sale reduction cent end vast majority cod come manufacture api wastewater domestic activity washroom canteen include separated manufacturing activity sgs verify home responsibility environmental sustainability environmental fundamental wastewater corporate responsibility report wastewater approach performance chemical oxygen demand wastewater target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report chemical oxygen demand million sale correct constant exchange rate cer decrease cent baseline absolute chemical oxygen demand decrease cent baseline million kilogram decrease line target decrease cent year explanation trend quality wastewater discharge closely relate type material produce manufacture active pharmaceutical ingredient chemical oxygen demand wastewater decrease significantly decrease production antibiotic ingredient year production product increase chemical oxygen demand increase site increase antibiotic production account cent wastewater volume cent wastewater cod concern level pollution wastewater cause burden local municipal wastewater treatment facility local receive water body change level wastewater pollution year year change production waste minimisation continue improvement wastewater treatment example evaluate wastewater treatment technology pharmaceutical ingredient manufacture plant singapore planning reverse osmosis system pharmaceutical ingredient manufacture plant india addition work improve manufacture efficiency decrease wastewater pollution future generate million cubic metre wastewater compare million cubic metre volume wastewater cent low cent low baseline sgs verify tophome responsibility environmental sustainability environmental fundamental wastewater corporate responsibility report wastewater approach performance chemical oxygen demand wastewater target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report chemical oxygen demand million sale correct constant exchange rate cer decrease cent baseline absolute chemical oxygen demand decrease cent baseline million kilogram decrease line target decrease cent year explanation trend quality wastewater discharge closely relate type material produce manufacture active pharmaceutical ingredient chemical oxygen demand wastewater decrease significantly decrease production antibiotic ingredient year production product increase chemical oxygen demand increase site increase antibiotic production account cent wastewater volume cent wastewater cod concern level pollution wastewater cause burden local municipal wastewater treatment facility local receive water body change level wastewater pollution year year change production waste minimisation continue improvement wastewater treatment example evaluate wastewater treatment technology pharmaceutical ingredient manufacture plant singapore planning reverse osmosis system pharmaceutical ingredient manufacture plant india addition work improve manufacture efficiency decrease wastewater pollution future generate million cubic metre wastewater compare million cubic metre volume wastewater cent low cent low baseline sgs verify home responsibility environmental sustainability environmental fundamental wastewater corporate responsibility report wastewater approach performance chemical oxygen demand wastewater target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report chemical oxygen demand million sale correct constant exchange rate cer decrease cent baseline absolute chemical oxygen demand decrease cent baseline million kilogram decrease line target decrease cent year explanation trend quality wastewater discharge closely relate type material produce manufacture active pharmaceutical ingredient chemical oxygen demand wastewater decrease significantly decrease production antibiotic ingredient year production product increase chemical oxygen demand increase site increase antibiotic production account cent wastewater volume cent wastewater cod concern level pollution wastewater cause burden local municipal wastewater treatment facility local receive water body change level wastewater pollution year year change production waste minimisation continue improvement wastewater treatment example evaluate wastewater treatment technology pharmaceutical ingredient manufacture plant singapore planning reverse osmosis system pharmaceutical ingredient manufacture plant india addition work improve manufacture efficiency decrease wastewater pollution future generate million cubic metre wastewater compare million cubic metre volume wastewater cent low cent low baseline sgs verify home responsibility environmental sustainability environmental fundamental waste corporate responsibility report hazardous nonhazardous waste approach performance production research sale activity produce waste production hazardous waste solvent chemical rd quality control laboratory small amount chemical include product intermediate break glassware plastic office paper standard commercial waste building renovation produce nonroutine waste obsolete equipment office furniture structural material classify waste hazardous nonhazardous nonroutine waste construction demolition rubble significant proportion waste classify hazardous contain solvent chemical manufacture active pharmaceutical ingredient hazardous waste produce include lubricant fluorescent light carcass animal research non hazardous waste general material office waste paper kitchen waste nonhazardous substance manufacturing approach aim eliminate waste reduce eliminate reuse material possible recycle waste dispose remain material sensitively separate hazardous waste different category efficient appropriate treatment regulation vary widely world choice solvent account hazardous waste reuse recycle solvent recover purify site reuse original manufacturing process sell commercial reprocess company include recycling statistic reuse recycle possible solvent incinerate energy recover possible require disposal contractor comply ehs requirement local regulation site audit waste contractor hire consultant carry audits target reduce nonhazardous waste dispose unit sale cent annum reduction cent end set target reduction hazardous waste target improve material efficiency efficiency convert raw material finish product design reduce hazardous waste nonhazardous waste dispose affect factor amount type product year affect waste ability recycle addition production change site actively aggressively work recycle waste possible decrease disposal waste minimum level focus eliminate waste send landfill disposal hazardous waste affect way solvent manage mix product year hazardous waste come manufacture active pharmaceutical ingredient concentrate effort collect hazardous waste datum consumer manufacturing plant laboratory office estimate site generate additional cent hazardous waste report sgs verified building trust environmental commitment manufacturing site boronia australia step environmental effort ceo andrew witty recognise site achievement award prize environment initiative category environment health safety excellence award achievement include establish green team employee volunteer helped increase involvement sustainability activity result site reduce water use cent level energy use cent level waste tonne divert landfill cent reduction co emission product transport result switch air freight sea freight import raw material export finish good save facility estimate million million gbp anticipate saving increase million million gbp annually onwards introduction wastesaving measure cold chain distribution system include reusable cool box datum logger ice brick new cold chain system manage temperature well extreme condition prevent polystyrene cool box temperature alert tag disposable ice brick send landfill save customer trouble waste disposal repack equipment collect project place ceo ehs excellence awards initiativeenvironment category tophome responsibility environmental sustainability environmental fundamental waste corporate responsibility report hazardous nonhazardous waste approach performance production research sale activity produce waste production hazardous waste solvent chemical rd quality control laboratory small amount chemical include product intermediate break glassware plastic office paper standard commercial waste building renovation produce nonroutine waste obsolete equipment office furniture structural material classify waste hazardous nonhazardous nonroutine waste construction demolition rubble significant proportion waste classify hazardous contain solvent chemical manufacture active pharmaceutical ingredient hazardous waste produce include lubricant fluorescent light carcass animal research non hazardous waste general material office waste paper kitchen waste nonhazardous substance manufacturing approach aim eliminate waste reduce eliminate reuse material possible recycle waste dispose remain material sensitively separate hazardous waste different category efficient appropriate treatment regulation vary widely world choice solvent account hazardous waste reuse recycle solvent recover purify site reuse original manufacturing process sell commercial reprocess company include recycling statistic reuse recycle possible solvent incinerate energy recover possible require disposal contractor comply ehs requirement local regulation site audit waste contractor hire consultant carry audits target reduce nonhazardous waste dispose unit sale cent annum reduction cent end set target reduction hazardous waste target improve material efficiency efficiency convert raw material finish product design reduce hazardous waste nonhazardous waste dispose affect factor amount type product year affect waste ability recycle addition production change site actively aggressively work recycle waste possible decrease disposal waste minimum level focus eliminate waste send landfill disposal hazardous waste affect way solvent manage mix product year hazardous waste come manufacture active pharmaceutical ingredient concentrate effort collect hazardous waste datum consumer manufacturing plant laboratory office estimate site generate additional cent hazardous waste report sgs verified building trust environmental commitment manufacturing site boronia australia step environmental effort ceo andrew witty recognise site achievement award prize environment initiative category environment health safety excellence award achievement include establish green team employee volunteer helped increase involvement sustainability activity result site reduce water use cent level energy use cent level waste tonne divert landfill cent reduction co emission product transport result switch air freight sea freight import raw material export finish good save facility estimate million million gbp anticipate saving increase million million gbp annually onwards introduction wastesaving measure cold chain distribution system include reusable cool box datum logger ice brick new cold chain system manage temperature well extreme condition prevent polystyrene cool box temperature alert tag disposable ice brick send landfill save customer trouble waste disposal repack equipment collect project place ceo ehs excellence awards initiativeenvironment category home responsibility environmental sustainability environmental fundamental waste corporate responsibility report hazardous nonhazardous waste approach performance production research sale activity produce waste production hazardous waste solvent chemical rd quality control laboratory small amount chemical include product intermediate break glassware plastic office paper standard commercial waste building renovation produce nonroutine waste obsolete equipment office furniture structural material classify waste hazardous nonhazardous nonroutine waste construction demolition rubble significant proportion waste classify hazardous contain solvent chemical manufacture active pharmaceutical ingredient hazardous waste produce include lubricant fluorescent light carcass animal research non hazardous waste general material office waste paper kitchen waste nonhazardous substance manufacturing approach aim eliminate waste reduce eliminate reuse material possible recycle waste dispose remain material sensitively separate hazardous waste different category efficient appropriate treatment regulation vary widely world choice solvent account hazardous waste reuse recycle solvent recover purify site reuse original manufacturing process sell commercial reprocess company include recycling statistic reuse recycle possible solvent incinerate energy recover possible require disposal contractor comply ehs requirement local regulation site audit waste contractor hire consultant carry audits target reduce nonhazardous waste dispose unit sale cent annum reduction cent end set target reduction hazardous waste target improve material efficiency efficiency convert raw material finish product design reduce hazardous waste nonhazardous waste dispose affect factor amount type product year affect waste ability recycle addition production change site actively aggressively work recycle waste possible decrease disposal waste minimum level focus eliminate waste send landfill disposal hazardous waste affect way solvent manage mix product year hazardous waste come manufacture active pharmaceutical ingredient concentrate effort collect hazardous waste datum consumer manufacturing plant laboratory office estimate site generate additional cent hazardous waste report sgs verified building trust environmental commitment manufacturing site boronia australia step environmental effort ceo andrew witty recognise site achievement award prize environment initiative category environment health safety excellence award achievement include establish green team employee volunteer helped increase involvement sustainability activity result site reduce water use cent level energy use cent level waste tonne divert landfill cent reduction co emission product transport result switch air freight sea freight import raw material export finish good save facility estimate million million gbp anticipate saving increase million million gbp annually onwards introduction wastesaving measure cold chain distribution system include reusable cool box datum logger ice brick new cold chain system manage temperature well extreme condition prevent polystyrene cool box temperature alert tag disposable ice brick send landfill save customer trouble waste disposal repack equipment collect project place ceo ehs excellence awards initiativeenvironment category home responsibility environmental sustainability environmental fundamental waste corporate responsibility report hazardous nonhazardous waste approach performance nonhazardous waste nonhazardous waste dispose target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report destination nonhazardous waste target performance normalise sale base constant exchange rate nonhazardous waste dispose million sale correct constant exchange rate cer decrease cent baseline absolute nonhazardous waste decrease cent baseline million kilogram significantly well cent year improvement target explanation trend decrease nonhazardous waste dispose partially continue effort manage recycle waste especially pharmaceutical consumer manufacturing operation decrease production product partially balance increase waste vaccine business continue grow target specific nonhazardous waste dispose measure total nonhazardous waste generate include nonhazardous waste dispose nonhazardous waste recycle generate million kilogram nonhazardous waste compare million kilogram million kilogram cent recycle cent dispose landfill incineration reduce disposal nonhazardous waste pharmaceutical manufacturing site cent cent pharmaceutical rd site cent increase nonhazardous waste disposal vaccine business continue expansion result overall cent decrease nonhazardous waste dispose gsk compare baseline meet nonhazardous waste improvement target ensure maintain improvement time production increase review improvement project sure continue reduce waste dispose particularly committed reduce waste send landfill want minimise burden environment society landfill space hard find cost send waste landfill increase datum include nonroutine waste construction demolition rubble similar material relate daytoday operation continue look way reduce waste undertaken waste management review site recycle nonhazardous waste paper cardboard glass plastic aluminium usually mean send reprocess reuse new product addition waste reduction measure reduction likely decrease volume production certain pharmaceutical consumer healthcare product example project reduce nonhazardous waste disposal site india stop put coal ash generate landfill instead sell raw material production construction material addition nutritional drink manufacturing site send process waste barley husk use animal food recycle canteen waste effluent treatment plant sludge converting biocompost sgs verify hazardous waste hazardous waste dispose target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report destination hazardous waste error find datum prior year correct datum vary slightly early report hazardous waste dispose million sale correct constant exchange rate cer decrease cent baseline absolute hazardous waste decrease cent baseline million kilogram explanation trend decrease hazardous waste dispose continue effort manage recycle hazardous waste especially solvent decrease production product significant quantity solvent outsource production hazardous waste dispose related type quantitie product solvent factory manufacture active pharmaceutical ingredient solvent waste cent hazardous waste generate cent hazardous waste recycle large site manufacture active pharmaceutical ingredient account cent solvent waste dispose set target reduce hazardous waste dispose instead focus attention improve manufacturing efficiency efficiency improvement mean material manufacturing process waste efficiency improvement time achieve meantime important minimise hazardous waste monitor improve way handle example recycling solvent sgs verify tophome responsibility environmental sustainability environmental fundamental waste corporate responsibility report hazardous nonhazardous waste approach performance nonhazardous waste nonhazardous waste dispose target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report destination nonhazardous waste target performance normalise sale base constant exchange rate nonhazardous waste dispose million sale correct constant exchange rate cer decrease cent baseline absolute nonhazardous waste decrease cent baseline million kilogram significantly well cent year improvement target explanation trend decrease nonhazardous waste dispose partially continue effort manage recycle waste especially pharmaceutical consumer manufacturing operation decrease production product partially balance increase waste vaccine business continue grow target specific nonhazardous waste dispose measure total nonhazardous waste generate include nonhazardous waste dispose nonhazardous waste recycle generate million kilogram nonhazardous waste compare million kilogram million kilogram cent recycle cent dispose landfill incineration reduce disposal nonhazardous waste pharmaceutical manufacturing site cent cent pharmaceutical rd site cent increase nonhazardous waste disposal vaccine business continue expansion result overall cent decrease nonhazardous waste dispose gsk compare baseline meet nonhazardous waste improvement target ensure maintain improvement time production increase review improvement project sure continue reduce waste dispose particularly committed reduce waste send landfill want minimise burden environment society landfill space hard find cost send waste landfill increase datum include nonroutine waste construction demolition rubble similar material relate daytoday operation continue look way reduce waste undertaken waste management review site recycle nonhazardous waste paper cardboard glass plastic aluminium usually mean send reprocess reuse new product addition waste reduction measure reduction likely decrease volume production certain pharmaceutical consumer healthcare product example project reduce nonhazardous waste disposal site india stop put coal ash generate landfill instead sell raw material production construction material addition nutritional drink manufacturing site send process waste barley husk use animal food recycle canteen waste effluent treatment plant sludge converting biocompost sgs verify hazardous waste hazardous waste dispose target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early repoprtasge destination hazardous waste error find datum prior year correct datum vary slightly early report hazardous waste dispose million sale correct constant exchange rate cer decrease cent baseline absolute hazardous waste decrease cent baseline million kilogram explanation trend decrease hazardous waste dispose continue effort manage recycle hazardous waste especially solvent decrease production product significant quantity solvent outsource production hazardous waste dispose related type quantitie product solvent factory manufacture active pharmaceutical ingredient solvent waste cent hazardous waste generate cent hazardous waste recycle large site manufacture active pharmaceutical ingredient account cent solvent waste dispose set target reduce hazardous waste dispose instead focus attention improve manufacturing efficiency efficiency improvement mean material manufacturing process waste efficiency improvement time achieve meantime important minimise hazardous waste monitor improve way handle example recycling solvent sgs verify tophome responsibility environmental sustainability environmental fundamental waste corporate responsibility report hazardous nonhazardous waste approach performance nonhazardous waste nonhazardous waste dispose target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report destination nonhazardous waste target performance normalise sale base constant exchange rate nonhazardous waste dispose million sale correct constant exchange rate cer decrease cent baseline absolute nonhazardous waste decrease cent baseline million kilogram significantly well cent year improvement target explanation trend decrease nonhazardous waste dispose partially continue effort manage recycle waste especially pharmaceutical consumer manufacturing operation decrease production product partially balance increase waste vaccine business continue grow target specific nonhazardous waste dispose measure total nonhazardous waste generate include nonhazardous waste dispose nonhazardous waste recycle generate million kilogram nonhazardous waste compare million kilogram million kilogram cent recycle cent dispose landfill incineration reduce disposal nonhazardous waste pharmaceutical manufacturing site cent cent pharmaceutical rd site cent increase nonhazardous waste disposal vaccine business continue expansion result overall cent decrease nonhazardous waste dispose gsk compare baseline meet nonhazardous waste improvement target ensure maintain improvement time production increase review improvement project sure continue reduce waste dispose particularly committed reduce waste send landfill want minimise burden environment society landfill space hard find cost send waste landfill increase datum include nonroutine waste construction demolition rubble similar material relate daytoday operation continue look way reduce waste undertaken waste management review site recycle nonhazardous waste paper cardboard glass plastic aluminium usually mean send reprocess reuse new product addition waste reduction measure reduction likely decrease volume production certain pharmaceutical consumer healthcare product example project reduce nonhazardous waste disposal site india stop put coal ash generate landfill instead sell raw material production construction material addition nutritional drink manufacturing site send process waste barley husk use animal food recycle canteen waste effluent treatment plant sludge converting biocompost sgs verify hazardous waste hazardous waste dispose target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report destination hazardous waste error find datum prior year correct datum vary slightly early report hazardous waste dispose million sale correct constant exchange rate cer decrease cent baseline absolute hazardous waste decrease cent baseline million kilogram explanation trend decrease hazardous waste dispose continue effort manage recycle hazardous waste especially solvent decrease production product significant quantity solvent outsource production hazardous waste dispose related type quantitie product solvent factory manufacture active pharmaceutical ingredient solvent waste cent hazardous waste generate cent hazardous waste recycle large site manufacture active pharmaceutical ingredient account cent solvent waste dispose set target reduce hazardous waste dispose instead focus attention improve manufacturing efficiency efficiency improvement mean material manufacturing process waste efficiency improvement time achieve meantime important minimise hazardous waste monitor improve way handle example recycling solvent sgs verify tophome responsibility environmental sustainability environmental fundamental waste corporate responsibility report hazardous nonhazardous waste approach performance nonhazardous waste nonhazardous waste dispose target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report destination nonhazardous waste target performance normalise sale base constant exchange rate nonhazardous waste dispose million sale correct constant exchange rate cer decrease cent baseline absolute nonhazardous waste decrease cent baseline million kilogram significantly well cent year improvement target explanation trend decrease nonhazardous waste dispose partially continue effort manage recycle waste especially pharmaceutical consumer manufacturing operation decrease production product partially balance increase waste vaccine business continue grow target specific nonhazardous waste dispose measure total nonhazardous waste generate include nonhazardous waste dispose nonhazardous waste recycle generate million kilogram nonhazardous waste compare million kilogram million kilogram cent recycle cent dispose landfill incineration reduce disposal nonhazardous waste pharmaceutical manufacturing site cent cent pharmaceutical rd site cent increase nonhazardous waste disposal vaccine business continue expansion result overall cent decrease nonhazardous waste dispose gsk compare baseline meet nonhazardous waste improvement target ensure maintain improvement time production increase review improvement project sure continue reduce waste dispose particularly committed reduce waste send landfill want minimise burden environment society landfill space hard find cost send waste landfill increase datum include nonroutine waste construction demolition rubble similar material relate daytoday operation continue look way reduce waste undertaken waste management review site recycle nonhazardous waste paper cardboard glass plastic aluminium usually mean send reprocess reuse new product addition waste reduction measure reduction likely decrease volume production certain pharmaceutical consumer healthcare product example project reduce nonhazardous waste disposal site india stop put coal ash generate landfill instead sell raw material production construction material addition nutritional drink manufacturing site send process waste barley husk use animal food recycle canteen waste effluent treatment plant sludge converting biocompost sgs verify hazardous waste hazardous waste dispose target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report destination hazardous waste error find datum prior year correct datum vary slightly early report hazardous waste dispose million sale correct constant exchange rate cer decrease cent baseline absolute hazardous waste decrease cent baseline million kilogram explanation trend decrease hazardous waste dispose continue effort manage recycle hazardous waste especially solvent decrease production product significant quantity solvent outsource production hazardous waste dispose related type quantitie product solvent factory manufacture active pharmaceutical ingredient solvent waste cent hazardous waste generate cent hazardous waste recycle large site manufacture active pharmaceutical ingredient account cent solvent waste dispose set target reduce hazardous waste dispose instead focus attention improve manufacturing efficiency efficiency improvement mean material manufacturing process waste efficiency improvement time achieve meantime important minimise hazardous waste monitor improve way handle example recycling solvent sgs verify home responsibility environmental sustainability environmental fundamental waste corporate responsibility report hazardous nonhazardous waste approach performance nonhazardous waste nonhazardous waste dispose target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report destination nonhazardous waste target performance normalise sale base constant exchange rate nonhazardous waste dispose million sale correct constant exchange rate cer decrease cent baseline absolute nonhazardous waste decrease cent baseline million kilogram significantly well cent year improvement target explanation trend decrease nonhazardous waste dispose partially continue effort manage recycle waste especially pharmaceutical consumer manufacturing operation decrease production product partially balance increase waste vaccine business continue grow target specific nonhazardous waste dispose measure total nonhazardous waste generate include nonhazardous waste dispose nonhazardous waste recycle generate million kilogram nonhazardous waste compare million kilogram million kilogram cent recycle cent dispose landfill incineration reduce disposal nonhazardous waste pharmaceutical manufacturing site cent cent pharmaceutical rd site cent increase nonhazardous waste disposal vaccine business continue expansion result overall cent decrease nonhazardous waste dispose gsk compare baseline meet nonhazardous waste improvement target ensure maintain improvement time production increase review improvement project sure continue reduce waste dispose particularly committed reduce waste send landfill want minimise burden environment society landfill space hard find cost send waste landfill increase datum include nonroutine waste construction demolition rubble similar material relate daytoday operation continue look way reduce waste undertaken waste management review site recycle nonhazardous waste paper cardboard glass plastic aluminium usually mean send reprocess reuse new product addition waste reduction measure reduction likely decrease volume production certain pharmaceutical consumer healthcare product example project reduce nonhazardous waste disposal site india stop put coal ash generate landfill instead sell raw material production construction material addition nutritional drink manufacturing site send process waste barley husk use animal food recycle canteen waste effluent treatment plant sludge converting biocompost sgs verify hazardous waste hazardous waste dispose target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report destination hazardous waste error find datum prior year correct datum vary slightly early report hazardous waste dispose million sale correct constant exchange rate cer decrease cent baseline absolute hazardous waste decrease cent baseline million kilogram explanation trend decrease hazardous waste dispose continue effort manage recycle hazardous waste especially solvent decrease production product significant quantity solvent outsource production hazardous waste dispose related type quantitie product solvent factory manufacture active pharmaceutical ingredient solvent waste cent hazardous waste generate cent hazardous waste recycle large site manufacture active pharmaceutical ingredient account cent solvent waste dispose set target reduce hazardous waste dispose instead focus attention improve manufacturing efficiency efficiency improvement mean material manufacturing process waste efficiency improvement time achieve meantime important minimise hazardous waste monitor improve way handle example recycling solvent sgs verify home responsibility environmental sustainability environmental fundamental contaminate land corporate responsibility report contaminate land handling practice chemical industry past long follow cause contamination land groundwater land contaminate accidental release material involve number project uk remediate site contaminate land identify site uk require remediation site work government party effect necessary remediation cost remediation share party involve uk site undergo remediation partially fully decommission gsk heritage company spend million cleaning site year continue clean site waste disposal site gsk responsible party figure include datum verification explanation trend heritage company form gsk confront number contaminate land site undertake action avoid similar problem occur future action audit commercial hazardous waste treatment disposal site level performance financial solvency avoid inappropriate disposal second action minimise solvent use possible change solvent coat aqueous coating tablet action initiate project improve material efficiency minimise eliminate hazardous persistent bioaccumulative toxic compound review production operation determine past practice contaminate soil ground water problem discover initiate site remediation home responsibility environmental sustainability environmental fundamental contaminate land corporate responsibility report contaminate land handling practice chemical industry past long follow cause contamination land groundwater land contaminate accidental release material involve number project uk remediate site contaminate land identify site uk require remediation site work government party effect necessary remediation cost remediation share party involve uk site undergo remediation partially fully decommission gsk heritage company spend million cleaning site year continue clean site waste disposal site gsk responsible party figure include datum verification explanation trend heritage company form gsk confront number contaminate land site undertake action avoid similar problem occur future action audit commercial hazardous waste treatment disposal site level performance financial solvency avoid inappropriate disposal second action minimise solvent use possible change solvent coat aqueous coating tablet action initiate project improve material efficiency minimise eliminate hazardous persistent bioaccumulative toxic compound review production operation determine past practice contaminate soil ground water problem discover initiate site remediation home responsibility environmental sustainability environmental fundamental emission air corporate responsibility report emission air approach performance plan ozone depletion ozone layer upper atmosphere essential human survival filter harmful ultra violet ray sun damage ozone deplete substance odss mainly chlorofluorocarbon cfcs hydrochlorofluorocarbon hcfc halon loss ozone upper atmosphere mean ultravioletb radiation reach earth surface affect health example cause skin cancer skin age eye disorder suppression immune system industrial use odss common negative effect realise past cfcs propellant gas meter dose inhaler mdi deliver precise dose medication treat asthma sufferer people chronic obstructive pulmonary disease gas release patient use inhaler small escape production montreal protocol ban production cfc exempt number essential use include mdi support principle plan eliminate use cfc product end cent inhaler contain cfc stop cfcs propellant inhaler european union offer selection alternative country eliminate cfc product worldwide end main alternative propellant hfa hydrofluoroalkane affect ozone layer global warming potential significantly low cfc contribute climate change invest heavily dry powder delivery system use propellant cfc hfa suitable patient particularly child elderly contain propellant rely person lung power active ingredient administer equipment production use odss cool system ancillary use gsk facility contain inside system release event leak maintenance switch hydrofluorocarbon hfcs ammonia hydrocarbon ammonia contribute ozone depletion climate change hydrocarbon small climate change impact aim eliminate cfc hcfc cool system way completely eliminate emission equipment focus remove large piece equipment service end intend replace equipment contain kilogram cfc hcfc prior plan replacement type equipment tends hermetically seal likely leak volatile organic compound volatile organic compound voc react nitrogen oxide presence sunlight create ozone low atmosphere result smog factor human respiratory illness workplace exposure certain voc pose health risk emit vocs atmosphere mainly solvent primary manufacturing operation rd pilot plant solvent coat tablet clean sterile operation use small quantity solvent laboratory measure emission use target reduce volatile organic compound emission air cent year unit sale reduction cent end sgs verifiedhome responsibility environmental sustainability environmental fundamental emission air corporate responsibility report emission air approach performance plan ozone depletion ozone layer upper atmosphere essential human survival filter harmful ultra violet ray sun damage ozone deplete substance odss mainly chlorofluorocarbon cfcs hydrochlorofluorocarbon hcfc halon loss ozone upper atmosphere mean ultravioletb radiation reach earth surface affect health example cause skin cancer skin age eye disorder suppression immune system industrial use odss common negative effect realise past cfcs propellant gas meter dose inhaler mdi deliver precise dose medication treat asthma sufferer people chronic obstructive pulmonary disease gas release patient use inhaler small escape production montreal protocol ban production cfc exempt number essential use include mdi support principle plan eliminate use cfc product end cent inhaler contain cfc stop cfcs propellant inhaler european union offer selection alternative country eliminate cfc product worldwide end main alternative propellant hfa hydrofluoroalkane affect ozone layer global warming potential significantly low cfc contribute climate change invest heavily dry powder delivery system use propellant cfc hfa suitable patient particularly child elderly contain propellant rely person lung power active ingredient administer equipment production use odss cool system ancillary use gsk facility contain inside system release event leak maintenance switch hydrofluorocarbon hfcs ammonia hydrocarbon ammonia contribute ozone depletion climate change hydrocarbon small climate change impact aim eliminate cfc hcfc cool system way completely eliminate emission equipment focus remove large piece equipment service end intend replace equipment contain kilogram cfc hcfc prior plan replacement type equipment tends hermetically seal likely leak volatile organic compound volatile organic compound voc react nitrogen oxide presence sunlight create ozone low atmosphere result smog factor human respiratory illness workplace exposure certain voc pose health risk emit vocs atmosphere mainly solvent primary manufacturing operation rd pilot plant solvent coat tablet clean sterile operation use small quantity solvent laboratory measure emission use target reduce volatile organic compound emission air cent year unit sale reduction cent end sgs verify home responsibility environmental sustainability environmental fundamental emission air corporate responsibility report emission air approach performance plan ozone depletion ozone layer upper atmosphere essential human survival filter harmful ultra violet ray sun damage ozone deplete substance odss mainly chlorofluorocarbon cfcs hydrochlorofluorocarbon hcfc halon loss ozone upper atmosphere mean ultravioletb radiation reach earth surface affect health example cause skin cancer skin age eye disorder suppression immune system industrial use odss common negative effect realise past cfcs propellant gas meter dose inhaler mdi deliver precise dose medication treat asthma sufferer people chronic obstructive pulmonary disease gas release patient use inhaler small escape production montreal protocol ban production cfc exempt number essential use include mdi support principle plan eliminate use cfc product end cent inhaler contain cfc stop cfcs propellant inhaler european union offer selection alternative country eliminate cfc product worldwide end main alternative propellant hfa hydrofluoroalkane affect ozone layer global warming potential significantly low cfc contribute climate change invest heavily dry powder delivery system use propellant cfc hfa suitable patient particularly child elderly contain propellant rely person lung power active ingredient administer equipment production use odss cool system ancillary use gsk facility contain inside system release event leak maintenance switch hydrofluorocarbon hfcs ammonia hydrocarbon ammonia contribute ozone depletion climate change hydrocarbon small climate change impact aim eliminate cfc hcfc cool system way completely eliminate emission equipment focus remove large piece equipment service end intend replace equipment contain kilogram cfc hcfc prior plan replacement type equipment tends hermetically seal likely leak volatile organic compound volatile organic compound voc react nitrogen oxide presence sunlight create ozone low atmosphere result smog factor human respiratory illness workplace exposure certain voc pose health risk emit vocs atmosphere mainly solvent primary manufacturing operation rd pilot plant solvent coat tablet clean sterile operation use small quantity solvent laboratory measure emission use target reduce volatile organic compound emission air cent year unit sale reduction cent end sgs verify home responsibility environmental sustainability environmental fundamental emission air corporate responsibility report emission air approach performance plan ozone depletion ozone depletion potential cfc equivalent target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report cfc ozone depletion potential review refrigeration equipment inventory inventory incomplete estimate base inventory year update factor ozone depletion potential climate change emission wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter estimate ozone depletion potential odp equipment production loss million sale correct constant exchange rate cer decrease cent baseline absolute odp equipment production loss decrease cent thousand kilogram indicate significant progress target eliminate loss cfcs hcfc production equipment explanation trend thousand kilogram ozone deplete substance release production inhaler estimate thousand kilogram cfc equivalent emitted equipment thousand kilogram cfc propellant release patient product ozone depletion potential patient use meter dose inhaler cent low production cfccontaine mdi decrease cfc lose production decline maintain register significant piece equipment contain refrigerant use register track progress target eliminate cfc hcfc refrigeration equipment piece equipment contain cfc amount kilogram total item equipment contain odss odp kilogram cfc equivalent estimate estimation factor cent british refrigeration association kilogram cfc equivalent release equipment make progress target expect achieve sgs verify volatile organic compound volatile organic compound emission target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report volatile organic compound release air million sale correct constant exchange rate cer decrease cent baseline absolute volatile organic compound emission decrease cent baseline million kilogram well cent year target explanation trend emission voc air affect management solvent mix product year decrease production product significant quantity solvent outsource step product important reduce emission voc benefit environment society gsk want reduce emission high production year continue identify project reduce emission site instal carbon absorption unit reduce emission solvent site emission reduction project plan anticipate achieve target plan material efficiency project expect reduce solvent effect work reduce solvent emission future meantime continue look way reduce solvent use increase recycling achieve target cent annual reduction emission result cent improvement end site manufacture active pharmaceutical ingredient project plan control emission sgs verifiedhome responsibility environmental sustainability environmental fundamental emission air corporate responsibility report emission air approach performance plan ozone depletion ozone depletion potential cfc equivalent target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report cfc ozone depletion potential review refrigeration equipment inventory inventory incomplete estimate base inventory year update factor ozone depletion potential climate change emission wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter estimate ozone depletion potential odp equipment production loss million sale correct constant exchange rate cer decrease cent baseline absolute odp equipment production loss decrease cent thousand kilogram indicate significant progress target eliminate loss cfcs hcfc production equipment explanation trend thousand kilogram ozone deplete substance release production inhaler estimate thousand kilogram cfc equivalent emitted equipment thousand kilogram cfc propellant release patient product ozone depletion potential patient use meter dose inhaler cent low production cfccontaine mdi decrease cfc lose production decline maintain register significant piece equipment contain refrigerant use register track progress target eliminate cfc hcfc refrigeration equipment piece equipment contain cfc amount kilogram total item equipment contain odss odp kilogram cfc equivalent estimate estimation factor cent british refrigeration association kilogram cfc equivalent release equipment make progress target expect achieve sgs verify volatile organic compound volatile organic compound emission target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report volatile organic compound release air million sale correct constant exchange rate cer decrease cent baseline absolute volatile organic compound emission decrease cent baseline million kilogram well cent year target explanation trend emission voc air affect management solvent mix product year decrease production product significant quantity solvent outsource step product important reduce emission voc benefit environment society gsk want reduce emission high production year continue identify project reduce emission site instal carbon absorption unit reduce emission solvent site emission reduction project plan anticipate achieve target plan material efficiency project expect reduce solvent effect work reduce solvent emission future meantime continue look way reduce solvent use increase recycling achieve target cent annual reduction emission result cent improvement end site manufacture active pharmaceutical ingredient project plan control emission sgs verify home responsibility environmental sustainability environmental fundamental emission air corporate responsibility report emission air approach performance plan ozone depletion ozone depletion potential cfc equivalent target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report cfc ozone depletion potential review refrigeration equipment inventory inventory incomplete estimate base inventory year update factor ozone depletion potential climate change emission wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter estimate ozone depletion potential odp equipment production loss million sale correct constant exchange rate cer decrease cent baseline absolute odp equipment production loss decrease cent thousand kilogram indicate significant progress target eliminate loss cfcs hcfc production equipment explanation trend thousand kilogram ozone deplete substance release production inhaler estimate thousand kilogram cfc equivalent emitted equipment thousand kilogram cfc propellant release patient product ozone depletion potential patient use meter dose inhaler cent low production cfccontaine mdi decrease cfc lose production decline maintain register significant piece equipment contain refrigerant use register track progress target eliminate cfc hcfc refrigeration equipment piece equipment contain cfc amount kilogram total item equipment contain odss odp kilogram cfc equivalent estimate estimation factor cent british refrigeration association kilogram cfc equivalent release equipment make progress target expect achieve sgs verify volatile organic compound volatile organic compound emission target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report volatile organic compound release air million sale correct constant exchange rate cer decrease cent baseline absolute volatile organic compound emission decrease cent baseline million kilogram well cent year target explanation trend emission voc air affect management solvent mix product year decrease production product significant quantity solvent outsource step product important reduce emission voc benefit environment society gsk want reduce emission high production year continue identify project reduce emission site instal carbon absorption unit reduce emission solvent site emission reduction project plan anticipate achieve target plan material efficiency project expect reduce solvent effect work reduce solvent emission future meantime continue look way reduce solvent use increase recycling achieve target cent annual reduction emission result cent improvement end site manufacture active pharmaceutical ingredient project plan control emission sgs verify home responsibility environmental sustainability environmental fundamental emission air corporate responsibility report emission air approach performance plan ozone depletion ozone depletion potential cfc equivalent target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report cfc ozone depletion potential review refrigeration equipment inventory inventory incomplete estimate base inventory year update factor ozone depletion potential climate change emission wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter estimate ozone depletion potential odp equipment production loss million sale correct constant exchange rate cer decrease cent baseline absolute odp equipment production loss decrease cent thousand kilogram indicate significant progress target eliminate loss cfcs hcfc production equipment explanation trend thousand kilogram ozone deplete substance release production inhaler estimate thousand kilogram cfc equivalent emitted equipment thousand kilogram cfc propellant release patient product ozone depletion potential patient use meter dose inhaler cent low production cfccontaine mdi decrease cfc lose production decline maintain register significant piece equipment contain refrigerant use register track progress target eliminate cfc hcfc refrigeration equipment piece equipment contain cfc amount kilogram total item equipment contain odss odp kilogram cfc equivalent estimate estimation factor cent british refrigeration association kilogram cfc equivalent release equipment make progress target expect achieve sgs verify volatile organic compound volatile organic compound emission target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report volatile organic compound release air million sale correct constant exchange rate cer decrease cent baseline absolute volatile organic compound emission decrease cent baseline million kilogram well cent year target explanation trend emission voc air affect management solvent mix product year decrease production product significant quantity solvent outsource step product important reduce emission voc benefit environment society gsk want reduce emission high production year continue identify project reduce emission site instal carbon absorption unit reduce emission solvent site emission reduction project plan anticipate achieve target plan material efficiency project expect reduce solvent effect work reduce solvent emission future meantime continue look way reduce solvent use increase recycling achieve target cent annual reduction emission result cent improvement end site manufacture active pharmaceutical ingredient project plan control emission sgs verify home responsibility environmental sustainability environmental fundamental ehss business process corporate responsibility report ehss business process describe embed environment health safety sustainability ehss principle business process new product development supply ehss milestone align process help scientist identify address environment health safety sustainability issue new product development supply activity ensure scientist understand environment health safety sustainability impact manage product lifecycle new product process develop harm people property environment opportunity identify process efficiency elimination waste reduce environment health safety sustainability impact improve product development supply acquisition divestiture diligence process acquire divest business ensure environment health safety sustainability issue consider contract negotiation adequate management system place work acquire company develop action plan align ehss practice gsk emergency response crisis management discovery development manufacture pharmaceutical consumer product involve use hazardous material process site incorporate emergency response crisis management programme management plan programme ensure accident effectively manage occur impact business local community environment minimise site conduct annual review internal emergency response programme technical capability develop action plan address area need improvement procurement procurement activity support environment health safety sustainability ehss goal follow area source renewable recycle material appropriate choose safe energyefficient equipment manage ehss risk supply chain capital project technical review process ensure consider environment health safety security loss prevention design new facility process identify ehss issue early project engineer facility process efficient safe worker environment cost effective read ehs procurement home responsibility environmental sustainability environmental fundamental ehss business process corporate responsibility report ehss business process describe embed environment health safety sustainability ehss principle business process new product development supply ehss milestone align process help scientist identify address environment health safety sustainability issue new product development supply activity ensure scientist understand environment health safety sustainability impact manage product lifecycle new product process develop harm people property environment opportunity identify process efficiency elimination waste reduce environment health safety sustainability impact improve product development supply acquisition divestiture diligence process acquire divest business ensure environment health safety sustainability issue consider contract negotiation adequate management system place work acquire company develop action plan align ehss practice gsk emergency response crisis management discovery development manufacture pharmaceutical consumer product involve use hazardous material process site incorporate emergency response crisis management programme management plan programme ensure accident effectively manage occur impact business local community environment minimise site conduct annual review internal emergency response programme technical capability develop action plan address area need improvement procurement procurement activity support environment health safety sustainability ehss goal follow area source renewable recycle material appropriate choose safe energyefficient equipment manage ehss risk supply chain capital project technical review process ensure consider environment health safety security loss prevention design new facility process identify ehss issue early project engineer facility process efficient safe worker environment cost effective read ehs procurement home responsibility environmental sustainability environmental fundamental supplier performance corporate responsibility report supplier performance want understand total environmental footprint process product mean measure impact supplier active pharmaceutical ingredient package product operation improvement hazardous waste air emission outsource production process collect data supplier know impact production product future hope report combine environmental impact manufacture gsk facility contract manufacturer gsk select supplier appropriate level ehs management system control past year prove difficult obtain environment health safety performance datum supplier product manufacture gsk survey supplier receive response cent indicate preferred provide datum quarter year time review input supplier change process energy datum join carbon disclosure project cdp supplier initiative request energy climate change datum large supplier cdp collect water waste injury illness datum supplier second quarter electronic system publish datum corporate responsibility report publish datum report read gsk supply chain home responsibility environmental sustainability environmental fundamental supplier performance corporate responsibility report supplier performance want understand total environmental footprint process product mean measure impact supplier active pharmaceutical ingredient package product operation improvement hazardous waste air emission outsource production process collect data supplier know impact production product future hope report combine environmental impact manufacture gsk facility contract manufacturer gsk select supplier appropriate level ehs management system control past year prove difficult obtain environment health safety performance datum supplier product manufacture gsk survey supplier receive response cent indicate preferred provide datum quarter year time review input supplier change process energy datum join carbon disclosure project cdp supplier initiative request energy climate change datum large supplier cdp collect water waste injury illness datum supplier second quarter electronic system publish datum corporate responsibility report publish datum report read gsk supply chain home responsibility environmental sustainability sustainability corporate responsibility report sustainability traditional environmental programme focus manage waste generate business process sustainable practice change business process consume natural resource switch renewable material protect biodiversity generate waste eliminate waste persistent toxic bioaccumulative low cost approach benefit environment society gsk future generation high priority sustainability issue manufacture efficiency reduce raw material need produce finished product climate change reduce climate impact building equipment transport product water reduce water use product stewardship reduce use material concern environmental impact product use patient packaging reduce packaging use recyclable recycle material home responsibility environmental sustainability sustainability corporate responsibility report sustainability traditional environmental programme focus manage waste generate business process sustainable practice change business process consume natural resource switch renewable material protect biodiversity generate waste eliminate waste persistent toxic bioaccumulative low cost approach benefit environment society gsk future generation high priority sustainability issue manufacture efficiency reduce raw material need produce finished product climate change reduce climate impact building equipment transport product water reduce water use product stewardship reduce use material concern environmental impact product use patient packaging reduce packaging use recyclable recycle material home responsibility environmental sustainability sustainability material efficiency corporate responsibility report material efficiency approach performance aim increase efficiency convert raw material finish product know material efficiency help reduce resource use waste generate cost production pharmaceutical process complex usually require large amount solvent raw material typically industry use tonne material tonne active pharmaceutical ingredient api produce set target double average material efficiency manufacturing process new product introduce process design process design essential minimise environmental impact determine chemical process manufacturing impact production waste ehs team work process development team incorporate ehs consideration process design material source identify potential ehs risk manufacture new manufacturing technique cut energy waste rd facility north carolina develop novel way manufacture diabete drug currently phase clinical trial cut environmental impact cost replace production method resourceintensive use large scale chemical development department find way synthesise molecule efficiently produce yield cent great new process use few raw material half energy cent solvent produce cent wastewater new process save million year raw material waste disposal cost project place ceo ehs excellence awards green chemistry technology category home responsibility environmental sustainability sustainability material efficiency corporate responsibility report material efficiency approach performance aim increase efficiency convert raw material finish product know material efficiency help reduce resource use waste generate cost production pharmaceutical process complex usually require large amount solvent raw material typically industry use tonne material tonne active pharmaceutical ingredient api produce set target double average material efficiency manufacturing process new product introduce process design process design essential minimise environmental impact determine chemical process manufacturing impact production waste ehs team work process development team incorporate ehs consideration process design material source identify potential ehs risk manufacture new manufacturing technique cut energy waste rd facility north carolina develop novel way manufacture diabete drug currently phase clinical trial cut environmental impact cost replace production method resourceintensive use large scale chemical development department find way synthesise molecule efficiently produce yield cent great new process use few raw material half energy cent solvent produce cent wastewater new process save million year raw material waste disposal cost project place ceo ehs excellence awards green chemistry technology category home responsibility environmental sustainability sustainability material efficiency corporate responsibility report material efficiency approach performance mass productivity chart show improve material efficiency compound development stage early stage compound cent material efficient stage achieve cent cent process achieve productivity cent explanation trend improve manufacturing efficiency important way address sustainability meet fundamental environmental target reduce disposal waste emission air easy chemical process medicine complex spite difficulty remain committed improve efficiency new product review production process transfer manufacturing determine additional improvement possible achieve target home responsibility environmental sustainability sustainability material efficiency corporate responsibility report material efficiency approach performance mass productivity chart show improve material efficiency compound development stage early stage compound cent material efficient stage achieve cent cent process achieve productivity cent explanation trend improve manufacturing efficiency important way address sustainability meet fundamental environmental target reduce disposal waste emission air easy chemical process medicine complex spite difficulty remain committed improve efficiency new product review production process transfer manufacturing determine additional improvement possible achieve target home responsibility environmental sustainability sustainability climate change energy corporate responsibility report climate change energy approach performance plan widely acknowledge human activity primarily burn fossil fuel produce energy contribute climate change intergovernmental panel climate change ipcc world lead climate authority state urgent action need avoid effect dangerous climate change include frequent extreme weather event drought flood hurricane want solution climate change commit reduce impact benefit environment take action climate change help cut cost improve reputation stakeholder help prepare future legislation emission read energy climate change position climate change programme follow fourth assessment report intergovernmental panel climate change launch new climate change programme commit new target include commitment reduce climate change impact co equivalent emission energy use operation transport level cent unit sale base constant exchange rate cent replace target reduce energy use cent year normalise sale achieve new target make building equipment energy efficient instal onsite renewable technology wind turbine photovoltaic panel buy electricity produce renewable source reduce climate impact travel transport switch air sea freight transport load reduce number journey need corporate executive team approve central fund help finance energy saving project climate change energy reduction team consult gsk business identify potential energy saving project project complete expect result save kwh gj energy year thousand tonne climate change emission product climate impact research way minimise greenhouse gas release propellant inhaler product patient asthma chronic obstructive pulmonary disease account twothird climate impact propellant inhaler contain hydrofluoroalkane hfas chlorofluorocarbon cfcs ensure consistent dose hfas time damage climate co cfc time damage climate co cfc deplete ozone layer sgs assurance logo tophome responsibility environmental sustainability sustainability climate change energy corporate responsibility report climate change energy approach performance plan widely acknowledge human activity primarily burn fossil fuel produce energy contribute climate change intergovernmental panel climate change ipcc world lead climate authority state urgent action need avoid effect dangerous climate change include frequent extreme weather event drought flood hurricane want solution climate change commit reduce impact benefit environment take action climate change help cut cost improve reputation stakeholder help prepare future legislation emission read energy climate change position climate change programme follow fourth assessment report intergovernmental panel climate change launch new climate change programme commit new target include commitment reduce climate change impact co equivalent emission energy use operation transport level cent unit sale base constant exchange rate cent replace target reduce energy use cent year normalise sale achieve new target make building equipment energy efficient instal onsite renewable technology wind turbine photovoltaic panel buy electricity produce renewable source reduce climate impact travel transport switch air sea freight transport load reduce number journey need corporate executive team approve central fund help finance energy saving project climate change energy reduction team consult gsk business identify potential energy saving project project complete expect result save kwh gj energy year thousand tonne climate change emission product climate impact research way minimise greenhouse gas release propellant inhaler product patient asthma chronic obstructive pulmonary disease account twothird climate impact propellant inhaler contain hydrofluoroalkane hfas chlorofluorocarbon cfcs ensure consistent dose hfas time damage climate co cfc time damage climate co cfc deplete ozone layer sgs assurance logo home responsibility environmental sustainability sustainability climate change energy corporate responsibility report climate change energy approach performance plan widely acknowledge human activity primarily burn fossil fuel produce energy contribute climate change intergovernmental panel climate change ipcc world lead climate authority state urgent action need avoid effect dangerous climate change include frequent extreme weather event drought flood hurricane want solution climate change commit reduce impact benefit environment take action climate change help cut cost improve reputation stakeholder help prepare future legislation emission read energy climate change position climate change programme follow fourth assessment report intergovernmental panel climate change launch new climate change programme commit new target include commitment reduce climate change impact co equivalent emission energy use operation transport level cent unit sale base constant exchange rate cent replace target reduce energy use cent year normalise sale achieve new target make building equipment energy efficient instal onsite renewable technology wind turbine photovoltaic panel buy electricity produce renewable source reduce climate impact travel transport switch air sea freight transport load reduce number journey need corporate executive team approve central fund help finance energy saving project climate change energy reduction team consult gsk business identify potential energy saving project project complete expect result save kwh gj energy year thousand tonne climate change emission product climate impact research way minimise greenhouse gas release propellant inhaler product patient asthma chronic obstructive pulmonary disease account twothird climate impact propellant inhaler contain hydrofluoroalkane hfas chlorofluorocarbon cfcs ensure consistent dose hfas time damage climate co cfc time damage climate co cfc deplete ozone layer sgs assurance logo home responsibility environmental sustainability sustainability climate change energy performance plan corporate responsibility report climate change energy approach performance plan gsk carbon footprint include climate change impact greenhouse gas release cool system production inhaler product wastewater treatment process error find datum prior year correct datum vary slightly early report climate change impact operation energy transport target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report use greenhouse gas protocol calculation co emission energy use update factor climate change emission propellant refrigerant wmo world meteorological organisation scientific assessment ozone depletion global ozone repsaegae rch oaf nd monitor projectreport pp geneva switzerland chapter carbon footprint equivalent million tonne co compare million tonne majority emission come use inhaler patient respiratory disease decrease use cfc inhaler simultaneous increase use hfa inhaler mean climate change emission patient use inhaler change significantly remain million metric tonne co exclude use inhaler carbon footprint reduce million tonne co million tonne reflect emission greenhouse gas inhaler manufacturing decrease million tonne million tonne explanation trend recognise product climate change impact energy consumption rd scientist work develop alternative hfa propellant candidate inhale product emission operation energy transport co emission operation energy transport million sale correct constant exchange rate increase cent baseline absolute climate change emission increase cent baseline million tonne increase energy use grow vaccine business overshadow energy saving pharmaceutical consumer manufacturing operation increase use coal india energy use operation transport co emission base decrease cent million gigajoule sgs verify energy performance energy consumption facility process target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report seventynine cent energy use attribute energy operation facility process energy use million sale correct constant exchange rate cer increase cent baseline absolute energy use decrease cent baseline million gigajoule equivalent energy uk households explanation trend set aggressive target reduce energy use related climate change emission move progress slow expect continue present course expect achieve improvement cent unit sale take step accelerate implementation energy reduction project divert engineering resource support expect project initiate begin deliver energy carbon saving sustain addition business change site closure result efficient use exist facility help achieve target remain committed target cent improvement energy use decrease cent pharmaceutical consumer manufacturing organisation pharmaceutical rd organisation increase cent vaccine organisation continue growth additional enlarged building new product pharmaceutical consumer manufacturing vaccine manufacture research group pharmaceuticals rd group account cent cent cent energy use respectively energy efficiency programme achieve incremental gain energy efficiency focus operational change include optimisation equipment use reset thermostat change energy efficient lighting part business continue incremental gain energy efficiency growth vaccine business associate increase energy use partially offset efficiency gain mid revise climate change programme include challenge target cover energy operation facility process transport product employee fund set encourage energy project potential project identify support fund project complete million spend project expect save million kilowatt hour energy thousand metric tonne climate change emission majority project complete end benefit project realise currently work project significant proportion complete project identify support abandon follow detailed investigation determine business benefit plan gsk identify potential project support climate change fund pharmaceutical consumer healthcare manufacturing business create centre excellence support implementation project particular emphasis give implement combine heat power chp project chp simultaneous generation usable heat power usually electricity single process typically chp use gas turbine engine steam turbine drive alternator produce electricity heat produce recover usually heat recovery boiler provide steam hot water cool right equipment chp system use heat produce electricity generation process achieve overall efficiency excess cent point use conventional power plant efficiency cent excess heat generate normally waste additional loss occur transmission distribution key area focus identify energy saving opportunity associate heating ventilation cool hvac equipment need maintain correct environmental condition production area manufacture product responsible cent operational energy consume energy reduction identify key objective business remuneration senior manager link achievement energy reduction target energy consumption identify key business metric track corporate executive team canal water sustainable cool december gsk unveil energysaving scheme partnership british waterways organisation charge uks canal network initiative gsk house brentford use water nearby canal energyintensive air conditioning cool computer datum centre reduce carbon dioxide emission tonne year low energy bill annually recover cost project year tophome responsibility environmental sustainability sustainability climate change energy performance plan corporate responsibility report climate change energy approach performance plan gsk carbon footprint include climate change impact greenhouse gas release cool system production inhaler product wastewater treatment process error find datum prior year correct datum vary slightly early report climate change impact operation energy transport target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report use greenhouse gas protocol calculation co emission energy use update factor climate change emission propellant refrigerant wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter carbon footprint equivalent million tonne co compare million tonne majority emission come use inhaler patient respiratory disease decrease use cfc inhaler simultaneous increase use hfa inhaler mean climate change emission patient use inhaler change significantly remain million metric tonne co exclude use inhaler carbon footprint reduce million tonne co million tonne reflect emission greenhouse gas inhaler manufacturing decrease million tonne million tonne explanation trend recognise product climate change impact energy consumption rd scientist work develop alternative hfa propellant candidate inhale product emission operation energy transport co emission operation energy transport million sale correct constant exchange rate increase cent baseline absolute climate change emission increase cent baseline million tonne increase energy use grow vaccine business overshadow energy saving pharmaceutical consumer manufacturing operation increase use coal india energy use operation transport co emission base decrease cent million gigajoule sgs verify energy performance energy consumption facility process target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report seventynine cent energy use attribute energy operation facility process energy use million sale correct constant exchange rate cer increase cent baseline absolute energy use decrease cent baseline million gigajoule equivalent energy uk houspeahgoe lds explanation trend set aggressive target reduce energy use related climate change emission move progress slow expect continue present course expect achieve improvement cent unit sale take step accelerate implementation energy reduction project divert engineering resource support expect project initiate begin deliver energy carbon saving sustain addition business change site closure result efficient use exist facility help achieve target remain committed target cent improvement energy use decrease cent pharmaceutical consumer manufacturing organisation pharmaceutical rd organisation increase cent vaccine organisation continue growth additional enlarged building new product pharmaceutical consumer manufacturing vaccine manufacture research group pharmaceuticals rd group account cent cent cent energy use respectively energy efficiency programme achieve incremental gain energy efficiency focus operational change include optimisation equipment use reset thermostat change energy efficient lighting part business continue incremental gain energy efficiency growth vaccine business associate increase energy use partially offset efficiency gain mid revise climate change programme include challenge target cover energy operation facility process transport product employee fund set encourage energy project potential project identify support fund project complete million spend project expect save million kilowatt hour energy thousand metric tonne climate change emission majority project complete end benefit project realise currently work project significant proportion complete project identify support abandon follow detailed investigation determine business benefit plan gsk identify potential project support climate change fund pharmaceutical consumer healthcare manufacturing business create centre excellence support implementation project particular emphasis give implement combine heat power chp project chp simultaneous generation usable heat power usually electricity single process typically chp use gas turbine engine steam turbine drive alternator produce electricity heat produce recover usually heat recovery boiler provide steam hot water cool right equipment chp system use heat produce electricity generation process achieve overall efficiency excess cent point use conventional power plant efficiency cent excess heat generate normally waste additional loss occur transmission distribution key area focus identify energy saving opportunity associate heating ventilation cool hvac equipment need maintain correct environmental condition production area manufacture product responsible cent operational energy consume energy reduction identify key objective business remuneration senior manager link achievement energy reduction target energy consumption identify key business metric track corporate executive team canal water sustainable cool december gsk unveil energysaving scheme partnership british waterways organisation charge uks canal network initiative gsk house brentford use water nearby canal energyintensive air conditioning cool computer datum centre reduce carbon dioxide emission tonne year low energy bill annually recover cost project year tophome responsibility environmental sustainability sustainability climate change energy performance plan corporate responsibility report climate change energy approach performance plan gsk carbon footprint include climate change impact greenhouse gas release cool system production inhaler product wastewater treatment process error find datum prior year correct datum vary slightly early report climate change impact operation energy transport target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report use greenhouse gas protocol calculation co emission energy use update factor climate change emission propellant refrigerant wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter carbon footprint equivalent million tonne co compare million tonne majority emission come use inhaler patient respiratory disease decrease use cfc inhaler simultaneous increase use hfa inhaler mean climate change emission patient use inhaler change significantly remain million metric tonne co exclude use inhaler carbon footprint reduce million tonne co million tonne reflect emission greenhouse gas inhaler manufacturing decrease million tonne million tonne explanation trend recognise product climate change impact energy consumption rd scientist work develop alternative hfa propellant candidate inhale product emission operation energy transport co emission operation energy transport million sale correct constant exchange rate increase cent baseline absolute climate change emission increase cent baseline million tonne increase energy use grow vaccine business overshadow energy saving pharmaceutical consumer manufacturing operation increase use coal india energy use operation transport co emission base decrease cent million gigajoule sgs verify energy performance energy consumption facility process target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report seventynine cent energy use attribute energy operation facility process energy use million sale correct constant exchange rate cer increase cent baseline absolute energy use decrease cent baseline million gigajoule equivalent energy uk households explanation trend set aggressive target reduce energy use related climate change emission move progress slow expect continue present course expect achieve improvement cent unit sale take step accelerate implementation energy reduction project divert engineering resource support expect project initiate begin deliver energy carbon saving sustain addition business change site closure result efficient use exist facility help achieve target remain committed target cent improvement energy use decrease cent pharmaceutical consumer manufacturing organisation pharmaceutical rd organisation increase cent vaccine organisation continue growth additional enlarged building new product pharmaceutical consumer manufacturing vaccine manufacture research group pharmaceuticals rd group account cent cent cent energy use respectively energy efficiency programme achieve incremental gain energy efficiency focus operational change include optimisation equipment use reset thermostat change energy efficient lighting part business continue incremental gain energy efficiency growth vaccine business associate increase energy use partially offset efficiency gain mid revise climate change programme include challenge target cover energy operation facility process transport product employee fund set encourage energy project potential project identify support fund project complete million spend project expect save million kilowatt hour energy thousand metric tonne climate change emission majority project complete end benefit project realise currently work project significant proportion complete project identify support abandon follow detailed investigation determine business benefit plan gsk identify potential project support climate change fund pharmaceutical consumer healthcare manufacturing business create centre excellence support implementation project particular emphasis give implement combine heat power chp project chp simultaneous generation usable heat power usually electricity single process typically chp use gas turbine engine steam turbine drive alternator produce electricity heat produce recover usually heat recovery boiler provide steam hot water cool right equipment chp system use heat produce electricity generation process achieve overall efficiency excess cent point use conventional power plant efficiency cent excess heat generate normally waste additional loss occur transmission distribution key area focus identify energy saving opportunity associate heating ventilation cool hvac equipment need maintain correct environmental condition production area manufacture product responsible cent operational energy consume energy reduction identify key objective business remuneration senior manager link achievement energy reduction target energy consumption identify key business metric track corporate executive team canal water sustainable cool december gsk unveil energysaving scheme partnership british waterwapyasge organisation charge uks canal network initiative gsk house brentford use water nearby canal energyintensive air conditioning cool computer datum centre reduce carbon dioxide emission tonne year low energy bill annually recover cost project year tophome responsibility environmental sustainability sustainability climate change energy performance plan corporate responsibility report climate change energy approach performance plan gsk carbon footprint include climate change impact greenhouse gas release cool system production inhaler product wastewater treatment process error find datum prior year correct datum vary slightly early report climate change impact operation energy transport target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report use greenhouse gas protocol calculation co emission energy use update factor climate change emission propellant refrigerant wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter carbon footprint equivalent million tonne co compare million tonne majority emission come use inhaler patient respiratory disease decrease use cfc inhaler simultaneous increase use hfa inhaler mean climate change emission patient use inhaler change significantly remain million metric tonne co exclude use inhaler carbon footprint reduce million tonne co million tonne reflect emission greenhouse gas inhaler manufacturing decrease million tonne million tonne explanation trend recognise product climate change impact energy consumption rd scientist work develop alternative hfa propellant candidate inhale product emission operation energy transport co emission operation energy transport million sale correct constant exchange rate increase cent baseline absolute climate change emission increase cent baseline million tonne increase energy use grow vaccine business overshadow energy saving pharmaceutical consumer manufacturing operation increase use coal india energy use operation transport co emission base decrease cent million gigajoule sgs verify energy performance energy consumption facility process target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report seventynine cent energy use attribute energy operation facility process energy use million sale correct constant exchange rate cer increase cent baseline absolute energy use decrease cent baseline million gigajoule equivalent energy uk households explanation trend set aggressive target reduce energy use related climate change emission move progress slow expect continue present course expect achieve improvement cent unit sale take step accelerate implementation energy reduction project divert engineering resource support expect project initiate begin deliver energy carbon saving sustain addition business change site closure result efficient use exist facility help achieve target remain committed target cent improvement energy use decrease cent pharmaceutical consumer manufacturing organisation pharmaceutical rd organisation increase cent vaccine organisation continue growth additional enlarged building new product pharmaceutical consumer manufacturing vaccine manufacture research group pharmaceuticals rd group account cent cent cent energy use respectively energy efficiency programme achieve incremental gain energy efficiency focus operational change include optimisation equipment use reset thermostat change energy efficient lighting part business continue incremental gain energy efficiency growth vaccine business associate increase energy use partially offset efficiency gain mid revise climate change programme include challenge target cover energy operation facility process transport product employee fund set encourage energy project potential project identify support fund project complete million spend project expect save million kilowatt hour energy thousand metric tonne climate change emission majority project complete end benefit project realise currently work project significant proportion complete project identify support abandon follow detailed investigation determine business benefit plan gsk identify potential project support climate change fund pharmaceutical consumer healthcare manufacturing business create centre excellence support implementation project particular emphasis give implement combine heat power chp project chp simultaneous generation usable heat power usually electricity single process typically chp use gas turbine engine steam turbine drive alternator produce electricity heat produce recover usually heat recovery boiler provide steam hot water cool right equipment chp system use heat produce electricity generation process achieve overall efficiency excess cent point use conventional power plant efficiency cent excess heat generate normally waste additional loss occur transmission distribution key area focus identify energy saving opportunity associate heating ventilation cool hvac equipment need maintain correct environmental condition production area manufacture product responsible cent operational energy consume energy reduction identify key objective business remuneration senior manager link achievement energy reduction target energy consumption identify key business metric track corporate executive team canal water sustainable cool december gsk unveil energysaving scheme partnership british waterways organisation charge uks canal network initiative gsk house brentford use water nearby canal energyintensive air conditioning cool computer datum centre reduce carbon dioxide emission tonne year low energy bill annually recover cost project year home responsibility environmental sustainability sustainability climate change energy performance plan corporate responsibility report climate change energy approach performance plan gsk carbon footprint include climate change impact greenhouse gas release cool system production inhaler product wastewater treatment process error find datum prior year correct datum vary slightly early report climate change impact operation energy transport target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report use greenhouse gas protocol calculation co emission energy use update factor climate change emission propellant refrigerant wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter carbon footprint equivalent million tonne co compare million tonne majority emission come use inhaler patient respiratory disease decrease use cfc inhaler simultaneous increase use hfa inhaler mean climate change emission patient use inhaler change significantly remain million metric tonne co exclude use inhaler carbon footprint reduce million tonne co million tonne reflect emission greenhouse gas inhaler manufacturing decrease million tonne million tonne explanation trend recognise product climate change impact energy consumption rd scientist work develop alternative hfa propellant candidate inhale product emission operation energy transport co emission operation energy transport million sale correct constant exchange rate increase cent baseline absolute climate change emission increase cent baseline million tonne increase energy use grow vaccine business overshadow energy saving pharmaceutical consumer manufacturing operation increase use coal india energy use operation transport co emission base decrease cent million gigajoule sgs verify energy performance energy consumption facility process target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report seventynine cent energy use attribute energy operation facility process energy use million sale correct constant exchange rate cer increase cent baseline absolute energy use decrease cent baseline million gigajoule equivalent energy uk households explanation trend set aggressive target reduce energy use related climate change emission move progress slow expect continue present course expect achieve improvement cent unit sale take step accelerate implementation energy reduction project divert engineering resource support expect project initiate begin deliver energy carbon saving sustain addition business change site closure result efficient use exist facility help achieve target remain committed target cent improvement energy use decrease cent pharmaceutical consumer manufacturing organisation pharmaceutical rd organisation increase cent vaccine organisation continue growth additional enlarged building new product pharmaceutical consumer manufacturing vaccine manufacture research group pharmaceuticals rd group account cent cent cent energy use respectively energy efficiency programme achieve incremental gain energy efficiency focus operational change include optimisation equipment use reset thermostat change energy efficient lighting part business continue incremental gain energy efficiency growth vaccine business associate increase energy use partially offset efficiency gain mid revise climate change programme include challenge target cover energy operation facility process transport product employee fund set encourage energy project potential project identify support fund project complete million spend project expect save million kilowatt hour energy thousand metric tonne climate change emission majority project complete end benefit project realise currently work project significant proportion complete project identify support abandon follow detailed investigation determine business benefit plan gsk identify potential project support climate change fund pharmaceutical consumer healthcare manufacturing business create centre excellence support implementation project particular emphasis give implement combine heat power chp project chp simultaneous generation usable heat power usually electricity single process typically chp use gas turbine engine steam turbine drive alternator produce electricity heat produce recover usually heat recovery boiler provide steam hot water cool right equipment chp system use heat produce electricity generation process achieve overall efficiency excess cent point use conventional power plant efficiency cent excess heat generate normally waste additional loss occur transmission distribution key area focus identify energy saving opportunity associate heating ventilation cool hvac equipment need maintain correct environmental condition production area manufacture product responsible cent operational energy consume energy reduction identify key objective business remuneration senior manager link achievement energy reduction target energy consumption identify key business metric track corporate executive team canal water sustainable cool december gsk unveil energysaving scheme partnership british waterways organisation charge uks canal network initiative gsk house brentford use water nearby canal energyintensive air conditioning cool computer datum centre reduce carbon dioxide emission tonne year low energy bill annually recover cost project year home responsibility environmental sustainability sustainability climate change energy climate change emission corporate responsibility report climate change emission gsk climate change emission inhaler product significantly great climate change emission operational energy transport climate change emission increase cent sale inhaler chlorofluorocarbon cfc propellant increase phase cfc propellant begin result montreal protocol aim eliminate ozone deplete compound cfc impact ozone depletion climate change replace inhaler hydrofluoroalkane hfa propellant dry powder inhaler use propellant climate change emission improve dramatically hfas low climate change impact cfc currently cent inhaler hfa propellant dry power propellantfree inhaler climate change emission cent low level emission expect grow come year sale inhaler hfa propellant continue grow emission inhaler energy estimate base energy cfc datum public report heritage smithkline beecham heritage glaxowellcome actual data inhaler energy available sale datum factor apply estimate climate change emission climate change emission factor cfc hfc revise year current factor world meteorological organisation publish global warming potential energy transport inhaler use httpwwwepagovozonescienceodsclassonehtml wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter explanation trend montreal protocol call elimination cfc effect ozone layer invest billion develop alternative include device use hfa replacement propellant hfa ozone deplete potential low effect climate change cfc cfc propellant phase hfa phase significant decline climate change impact product estimate climate change emission calculate improvement cent compare cent reduction kyoto protocol require uk kyoto protocol include climate change emission cfc include hfa home responsibility environmental sustainability sustainability climate change energy climate change emission corporate responsibility report climate change emission gsk climate change emission inhaler product significantly great climate change emission operational energy transport climate change emission increase cent sale inhaler chlorofluorocarbon cfc propellant increase phase cfc propellant begin result montreal protocol aim eliminate ozone deplete compound cfc impact ozone depletion climate change replace inhaler hydrofluoroalkane hfa propellant dry powder inhaler use propellant climate change emission improve dramatically hfas low climate change impact cfc currently cent inhaler hfa propellant dry power propellantfree inhaler climate change emission cent low level emission expect grow come year sale inhaler hfa propellant continue grow emission inhaler energy estimate base energy cfc datum public report heritage smithkline beecham heritage glaxowellcome actual data inhaler energy available sale datum factor apply estimate climate change emission climate change emission factor cfc hfc revise year current factor world meteorological organisation publish global warming potential energy transport inhaler use httpwwwepagovozonescienceodsclassonehtml wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter explanation trend montreal protocol call elimination cfc effect ozone layer invest billion develop alternative include device use hfa replacement propellant hfa ozone deplete potential low effect climate change cfc cfc propellant phase hfa phase significant decline climate change impact product estimate climate change emission calculate improvement cent compare cent reduction kyoto protocol require uk kyoto protocol include climate change emission cfc include hfa home responsibility environmental sustainability sustainability climate change energy emission trading corporate responsibility report emission trading number uk site participate uk government voluntary climate change agreement programme provide company energy tax rebate meet agree energyefficiency target gsk report compliance agreement participate gsk site find comply climate change agreement gsk site participate european union emission trading scheme eu ets collectively site emit specify co allowance generate surplus carbon credit proceed sale carbon credit invest energysaving project home responsibility environmental sustainability sustainability climate change energy emission trading corporate responsibility report emission trading number uk site participate uk government voluntary climate change agreement programme provide company energy tax rebate meet agree energyefficiency target gsk report compliance agreement participate gsk site find comply climate change agreement gsk site participate european union emission trading scheme eu ets collectively site emit specify co allowance generate surplus carbon credit proceed sale carbon credit invest energysaving project home responsibility environmental sustainability sustainability climate change energy transport impact corporate responsibility report transport impact estimate transport product employee account million kilogram co compare million kilogram equivalent cent climate change impact energy travelrelate co emission consist business air travel cent global sale fleet cent transport product manufacturing plant distributor cent air freight cent option reduce impact transport product include consolidate freight shipment reduce number shipping point make use round tripping manage inbound freight truck return switch air sea transport possible travel work green travel plan number site encourage employee reduce environmental impact travel work example gsk house brentford uk reserve parking space give carsharer driver fuelefficient car provide change room shower cyclist discount bicycle equipment repair philadelphia office cost public transportation subsidise home responsibility environmental sustainability sustainability climate change energy transport impact corporate responsibility report transport impact estimate transport product employee account million kilogram co compare million kilogram equivalent cent climate change impact energy travelrelate co emission consist business air travel cent global sale fleet cent transport product manufacturing plant distributor cent air freight cent option reduce impact transport product include consolidate freight shipment reduce number shipping point make use round tripping manage inbound freight truck return switch air sea transport possible travel work green travel plan number site encourage employee reduce environmental impact travel work example gsk house brentford uk reserve parking space give carsharer driver fuelefficient car provide change room shower cyclist discount bicycle equipment repair philadelphia office cost public transportation subsidise home responsibility environmental sustainability sustainability water use corporate responsibility report water use approach performance plan clean water valuable resource need conserve protect pollution aim minimise water use environmental impact water discharge gsk use water manufacturing process product cool clean general site use include drink food service sanitation site manufacture active pharmaceutical ingredient use large amount water rd site office use water standard require site minimise water use reuse water feasible ensure wastewater treat discharge way minimise adverse environmental impact target reduce water consumption cent annum unit sale cent water saving end sgs verify home responsibility environmental sustainability sustainability water use corporate responsibility report water use approach performance plan clean water valuable resource need conserve protect pollution aim minimise water use environmental impact water discharge gsk use water manufacturing process product cool clean general site use include drink food service sanitation site manufacture active pharmaceutical ingredient use large amount water rd site office use water standard require site minimise water use reuse water feasible ensure wastewater treat discharge way minimise adverse environmental impact target reduce water consumption cent annum unit sale cent water saving end sgs verify home responsibility environmental sustainability sustainability water use corporate responsibility report water use approach performance plan water consumption target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report water million sale correct constant exchange rate cer decrease cent baseline absolute water use decrease cent baseline million cubic metre significantly well cent year target explanation trend reduction achieve maintenance facility process change small improvement achieve ongoing conservation measure particularly waterstresse location example pharmaceutical manufacturing plant boronia australia locate water stress area ongoing campaign save water reduce water usage cent increase production cent staff cent save average million litre water year water saving accomplish recover wastewater cool tower amenity maintenance capture storm water communicate employee save water believe achieve target plan gsk endorse un global compacts ceo water mandate un estimate billion people access clean water billion people lack basic sanitation necessary health wellbeing water stress expect worsen part world result factor include urbanization population growth increase food production change consumption pattern industrialization water pollution climate change join mandate recognise water important valuable resource need manage responsibly commit take action develop comprehensive approach area identify mandate direct operation supply chain watershed management collective action public policy community engagement transparency area take action example target water conservation report water usage operation plan place collect report water usage sample key supplier work local community conserve pwaagete r onfd preserve wetland educate employee water conservation understand connection water public health philanthropic project know phase educate people develop country importance hand washing meet requirement mandate build exist effort manage single programme team representative business form determine key priority objective sgs verify tophome responsibility environmental sustainability sustainability water use corporate responsibility report water use approach performance plan water consumption target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report water million sale correct constant exchange rate cer decrease cent baseline absolute water use decrease cent baseline million cubic metre significantly well cent year target explanation trend reduction achieve maintenance facility process change small improvement achieve ongoing conservation measure particularly waterstresse location example pharmaceutical manufacturing plant boronia australia locate water stress area ongoing campaign save water reduce water usage cent increase production cent staff cent save average million litre water year water saving accomplish recover wastewater cool tower amenity maintenance capture storm water communicate employee save water believe achieve target plan gsk endorse un global compacts ceo water mandate un estimate billion people access clean water billion people lack basic sanitation necessary health wellbeing water stress expect worsen part world result factor include urbanization population growth increase food production change consumption pattern industrialization water pollution climate change join mandate recognise water important valuable resource need manage responsibly commit take action develop comprehensive approach area identify mandate direct operation supply chain watershed management collective action public policy community engagement transparency area take action example target water conservation report water usage operation plan place collect report water usage sample key supplier work local community conserve water preserve wetland educate employee water conservation understand connection water public health philanthropic project know phase educate people develop country importance hand washing meet requirement mandate build exist effort manage single programme team representative business form determine key priority objective sgs verify home responsibility environmental sustainability sustainability water use corporate responsibility report water use approach performance plan water consumption target performance normalise sale base constant exchange rate error find datum prior year correct datum vary slightly early report water million sale correct constant exchange rate cer decrease cent baseline absolute water use decrease cent baseline million cubic metre significantly well cent year target explanation trend reduction achieve maintenance facility process change small improvement achieve ongoing conservation measure particularly waterstresse location example pharmaceutical manufacturing plant boronia australia locate water stress area ongoing campaign save water reduce water usage cent increase production cent staff cent save average million litre water year water saving accomplish recover wastewater cool tower amenity maintenance capture storm water communicate employee save water believe achieve target plan gsk endorse un global compacts ceo water mandate un estimate billion people access clean water billion people lack basic sanitation necessary health wellbeing water stress expect worsen part world result factor include urbanization population growth increase food production change consumption pattern industrialization water pollution climate change join mandate recognise water important valuable resource need manage responsibly commit take action develop comprehensive approach area identify mandate direct operation supply chain watershed management collective action public policy community engagement transparency area take action example target water conservation report water usage operation plan place collect report water usage sample key supplier work local community conserve water preserve wetland educate employee water conservation understand connection water public health philanthropic project know phase educate people develop country importance hand washing meet requirement mandate build exist effort manage single programme team representative business form determine key priority objective sgs verify home responsibility environmental sustainability sustainability product stewardship corporate responsibility report product stewardship environment account entire lifecycle product begin process design continue manufacturing use patient eventual disposal waste solvent reuse raw material industry paint strip cradle cradle section focus aspect product stewardship pharmaceutical environment portion active pharmaceutical ingredient substance medicine work eventually excrete human enter environment conduct test risk assessment evaluate potential effect pharmaceutical product environment material concern material concern chemical scientific evidence show probable longterm effect human environment exist potential future legislation restrict use process development team develop strategy eliminate substitute use material genetically modify organism use genetically modify organism gmos research development new therapeutic agent manufacture certain medical product vaccine work gmos control strict national international regulation apply good practice facility reach continue work reduce risk continuity supply chemical present introduction eus registration evaluation authorisation restriction chemical reach legislation global harmonisation continue prepare impend change classification labelling hazard un globally harmonise system classification labelling chemical regulation home responsibility environmental sustainability sustainability product stewardship corporate responsibility report product stewardship environment account entire lifecycle product begin process design continue manufacturing use patient eventual disposal waste solvent reuse raw material industry paint strip cradle cradle section focus aspect product stewardship pharmaceutical environment portion active pharmaceutical ingredient substance medicine work eventually excrete human enter environment conduct test risk assessment evaluate potential effect pharmaceutical product environment material concern material concern chemical scientific evidence show probable longterm effect human environment exist potential future legislation restrict use process development team develop strategy eliminate substitute use material genetically modify organism use genetically modify organism gmos research development new therapeutic agent manufacture certain medical product vaccine work gmos control strict national international regulation apply good practice facility reach continue work reduce risk continuity supply chemical present introduction eus registration evaluation authorisation restriction chemical reach legislation global harmonisation continue prepare impend change classification labelling hazard un globally harmonise system classification labelling chemical regulation home responsibility environmental sustainability sustainability product stewardship pharmaceutical environment corporate responsibility report pharmaceutical environment portion active pharmaceutical ingredient apis substance medicine work eventually excrete human enter environment wastewater treatment remove pharmaceutical residue small concentration end river sea low concentration pharmaceutical occasionally find drinking water country wastewater treat high concentration enter environment conduct test risk assessment evaluate potential effect pharmaceutical product environment date indicate product appear pose risk human environment base current risk assessment methodologie information conduct retrospective analysis environmental datum refine testing methodology assessment model recently revise material testing strategy include chronic testing determine impact product environment long term mode action analysis identify sensitive specie meet new regulatory guideline improve understand possible environmental effect commit transparency datum collect environmental datum publicly available assessment environmental datum individual apis provide online safety data sheet datum available swedish doctor prescribe guide information pharmaceutical environment available public publishing result risk assessment scientific journal read public position statement pharmaceutical environment eu environmental risk assessment approval process produce market new medicine allow regulatory agency assess potential environmental impact drug pende approval work regulatory agency ensure potential environmental impact pharmaceutical understand minimised continue monitor late scientific study finding improve risk assessment methodology addition conduct contribute environmental research area recently complete study submit scientific paper assess potential impact human health environmental exposure apis include gsk pharmaceutical begin study possible impact mixture compound household wastewater extremely low concentration include pharmaceutical pharmaceutical household product main source pharmaceutical environment patient excrete medicine take gsk establish limit active pharmaceutical ingredient wastewater manufacture site base study establish safe level api base demonstration risk assess process waste concentration establish level treat wastewater require ensure safe level achieve subsequent environmental risk industry collaboration work pharmaceutical company university research group activity pharmaceutical environment collaborate joint project industry group sponsor academic study example submit environmental datum product swedish classification system pharmaceutical collaboration swedish pharmaceutical association swedish government voluntary transparency initiative make information environmental risk available public doctor scientist participate technical working group pharmaceutical environment sponsor industry group pharmaceutical research manufacturers america phrma phrma association british pharmaceutical industry continually engage regulatory scientistpsa gfreo tohf e environmental protection agency food drug administration uk environment agency tophome responsibility environmental sustainability sustainability product stewardship pharmaceutical environment corporate responsibility report pharmaceutical environment portion active pharmaceutical ingredient apis substance medicine work eventually excrete human enter environment wastewater treatment remove pharmaceutical residue small concentration end river sea low concentration pharmaceutical occasionally find drinking water country wastewater treat high concentration enter environment conduct test risk assessment evaluate potential effect pharmaceutical product environment date indicate product appear pose risk human environment base current risk assessment methodologie information conduct retrospective analysis environmental datum refine testing methodology assessment model recently revise material testing strategy include chronic testing determine impact product environment long term mode action analysis identify sensitive specie meet new regulatory guideline improve understand possible environmental effect commit transparency datum collect environmental datum publicly available assessment environmental datum individual apis provide online safety data sheet datum available swedish doctor prescribe guide information pharmaceutical environment available public publishing result risk assessment scientific journal read public position statement pharmaceutical environment eu environmental risk assessment approval process produce market new medicine allow regulatory agency assess potential environmental impact drug pende approval work regulatory agency ensure potential environmental impact pharmaceutical understand minimised continue monitor late scientific study finding improve risk assessment methodology addition conduct contribute environmental research area recently complete study submit scientific paper assess potential impact human health environmental exposure apis include gsk pharmaceutical begin study possible impact mixture compound household wastewater extremely low concentration include pharmaceutical pharmaceutical household product main source pharmaceutical environment patient excrete medicine take gsk establish limit active pharmaceutical ingredient wastewater manufacture site base study establish safe level api base demonstration risk assess process waste concentration establish level treat wastewater require ensure safe level achieve subsequent environmental risk industry collaboration work pharmaceutical company university research group activity pharmaceutical environment collaborate joint project industry group sponsor academic study example submit environmental datum product swedish classification system pharmaceutical collaboration swedish pharmaceutical association swedish government voluntary transparency initiative make information environmental risk available public doctor scientist participate technical working group pharmaceutical environment sponsor industry group pharmaceutical research manufacturers america phrma phrma association british pharmaceutical industry continually engage regulatory scientist environmental protection agency food drug administration uk environment agency home responsibility environmental sustainability sustainability product stewardship pharmaceutical environment corporate responsibility report pharmaceutical environment portion active pharmaceutical ingredient apis substance medicine work eventually excrete human enter environment wastewater treatment remove pharmaceutical residue small concentration end river sea low concentration pharmaceutical occasionally find drinking water country wastewater treat high concentration enter environment conduct test risk assessment evaluate potential effect pharmaceutical product environment date indicate product appear pose risk human environment base current risk assessment methodologie information conduct retrospective analysis environmental datum refine testing methodology assessment model recently revise material testing strategy include chronic testing determine impact product environment long term mode action analysis identify sensitive specie meet new regulatory guideline improve understand possible environmental effect commit transparency datum collect environmental datum publicly available assessment environmental datum individual apis provide online safety data sheet datum available swedish doctor prescribe guide information pharmaceutical environment available public publishing result risk assessment scientific journal read public position statement pharmaceutical environment eu environmental risk assessment approval process produce market new medicine allow regulatory agency assess potential environmental impact drug pende approval work regulatory agency ensure potential environmental impact pharmaceutical understand minimised continue monitor late scientific study finding improve risk assessment methodology addition conduct contribute environmental research area recently complete study submit scientific paper assess potential impact human health environmental exposure apis include gsk pharmaceutical begin study possible impact mixture compound household wastewater extremely low concentration include pharmaceutical pharmaceutical household product main source pharmaceutical environment patient excrete medicine take gsk establish limit active pharmaceutical ingredient wastewater manufacture site base study establish safe level api base demonstration risk assess process waste concentration establish level treat wastewater require ensure safe level achieve subsequent environmental risk industry collaboration work pharmaceutical company university research group activity pharmaceutical environment collaborate joint project industry group sponsor academic study example submit environmental datum product swedish classification system pharmaceutical collaboration swedish pharmaceutical association swedish government voluntary transparency initiative make information environmental risk available public doctor scientist participate technical working group pharmaceutical environment sponsor industry group pharmaceutical research manufacturers america phrma phrma association british pharmaceutical industry continually engage regulatory scientist environmental protection agency food drug administration uk environment agency home responsibility environmental sustainability sustainability product stewardship material concern gmos nanomaterials corporate responsibility report material concern gmos nanomaterials material concern material concern chemical scientific evidence show probable longterm effect human environment exist potential future legislation restrict use compound include call pbt substance persist environment bioaccumulate animal plant toxic life carcinogen mutagen reproductive toxin substance know cause asthma endocrine disrupt chemical ozone deplete substance ehs team work process development team help develop strategy eliminate substitute use thesematerial read position paper hazardous chemical management performance metric tonne material concern cent account solvent solvent waste production destroy incineration recycle work pilot plant examine use material concern phase development determine substance identify replace development genetically modify organism use genetically modify organism gmos research development new therapeutic agent manufacture certain medical product vaccine use gmos identify genetic target cause disease develop new antibiotic drug condition heart disease diabete depression use number different gmos predominantly harmless organism disabled strain bacterium ecoli eukaryotic cell culture manufacture number product derive genetically modify material hepatitis b vaccine produce plan produce product contain viable organism work gmos control strict national international regulation apply good practice facility work gmos subject risk assessment ensure safe use storage disposal process perform closed vessel minimise risk release largescale fermentation propagation gmos undertake fully contain system research perform containment laboratory appropriate risk material handle work control write procedure carry regular maintenance check treat waste gmo operation ensure release viable gmos contain process environment gmos deactivate prior disposal chemical heat treatment routinely undertake research development involve cultivation genetically modify plant specie nanomaterial nanotechnology area science involve control nanomaterial material atomic molecular scale nanotechnology future develop new medicine participate responsible nano code consultation development code conduct business use nanotechnology responsible nano code collaboration royal society insight investment nanotechnology industry association estimate begin nanotechnology tophome responsibility environmental sustainability sustainability product stewardship material concern gmos nanomaterials corporate responsibility report material concern gmos nanomaterials material concern material concern chemical scientific evidence show probable longterm effect human environment exist potential future legislation restrict use compound include call pbt substance persist environment bioaccumulate animal plant toxic life carcinogen mutagen reproductive toxin substance know cause asthma endocrine disrupt chemical ozone deplete substance ehs team work process development team help develop strategy eliminate substitute use thesematerial read position paper hazardous chemical management performance metric tonne material concern cent account solvent solvent waste production destroy incineration recycle work pilot plant examine use material concern phase development determine substance identify replace development genetically modify organism use genetically modify organism gmos research development new therapeutic agent manufacture certain medical product vaccine use gmos identify genetic target cause disease develop new antibiotic drug condition heart disease diabete depression use number different gmos predominantly harmless organism disabled strain bacterium ecoli eukaryotic cell culture manufacture number product derive genetically modify material hepatitis b vaccine produce plan produce product contain viable organism work gmos control strict national international regulation apply good practice facility work gmos subject risk assessment ensure safe use storage disposal process perform closed vessel minimise risk release largescale fermentation propagation gmos undertake fully contain system research perform containment laboratory appropriate risk material handle work control write procedure carry regular maintenance check treat waste gmo operation ensure release viable gmos contain process environment gmos deactivate prior disposal chemical heat treatment routinely undertake research development involve cultivation genetically modify plant specie nanomaterial nanotechnology area science involve control nanomaterial material atomic molecular scale nanotechnology future develop new medicine participate responsible nano code consultation development code conduct business use nanotechnology responsible nano code collaboration royal society insight investment nanotechnology industry association estimate begin nanotechnology home responsibility environmental sustainability sustainability product stewardship material concern gmos nanomaterials corporate responsibility report material concern gmos nanomaterials material concern material concern chemical scientific evidence show probable longterm effect human environment exist potential future legislation restrict use compound include call pbt substance persist environment bioaccumulate animal plant toxic life carcinogen mutagen reproductive toxin substance know cause asthma endocrine disrupt chemical ozone deplete substance ehs team work process development team help develop strategy eliminate substitute use thesematerial read position paper hazardous chemical management performance metric tonne material concern cent account solvent solvent waste production destroy incineration recycle work pilot plant examine use material concern phase development determine substance identify replace development genetically modify organism use genetically modify organism gmos research development new therapeutic agent manufacture certain medical product vaccine use gmos identify genetic target cause disease develop new antibiotic drug condition heart disease diabete depression use number different gmos predominantly harmless organism disabled strain bacterium ecoli eukaryotic cell culture manufacture number product derive genetically modify material hepatitis b vaccine produce plan produce product contain viable organism work gmos control strict national international regulation apply good practice facility work gmos subject risk assessment ensure safe use storage disposal process perform closed vessel minimise risk release largescale fermentation propagation gmos undertake fully contain system research perform containment laboratory appropriate risk material handle work control write procedure carry regular maintenance check treat waste gmo operation ensure release viable gmos contain process environment gmos deactivate prior disposal chemical heat treatment routinely undertake research development involve cultivation genetically modify plant specie nanomaterial nanotechnology area science involve control nanomaterial material atomic molecular scale nanotechnology future develop new medicine participate responsible nano code consultation development code conduct business use nanotechnology responsible nano code collaboration royal society insight investment nanotechnology industry association estimate begin nanotechnology home responsibility environmental sustainability sustainability product stewardship reach corporate responsibility report reach continue work reduce risk continuity supply chemical present introduction eus registration evaluation authorisation restriction chemical reach legislation involve site inventory eu international site identify chemical source eu supplier import manufacture gsk contact company supply gsk chemical cover reach assess plan management potential risk continuity supply gsk involve evaluation supplier preregistere phasein material manufacture import gsk volume tonne year register new substance manufacture import volume tonne year read position reach gskcom plan start gather information use material ehs hazard datum require meet reach registration milestone november phasein substance continue work supplier ensure meet reach obligation collaborate company substance information exchange forum sief share hazard datum substance mutual interest require reach registration home responsibility environmental sustainability sustainability product stewardship reach corporate responsibility report reach continue work reduce risk continuity supply chemical present introduction eus registration evaluation authorisation restriction chemical reach legislation involve site inventory eu international site identify chemical source eu supplier import manufacture gsk contact company supply gsk chemical cover reach assess plan management potential risk continuity supply gsk involve evaluation supplier preregistere phasein material manufacture import gsk volume tonne year register new substance manufacture import volume tonne year read position reach gskcom plan start gather information use material ehs hazard datum require meet reach registration milestone november phasein substance continue work supplier ensure meet reach obligation collaborate company substance information exchange forum sief share hazard datum substance mutual interest require reach registration home responsibility environmental sustainability sustainability product stewardship global harmonisation corporate responsibility report global harmonisation continue prepare impend change classification labelling hazard un globally harmonise system classification labelling chemical ghs regulation include change way produce safety datum sheet ensure compliance initiate process reclassify substance manufacture import follow ghs rule develop training employee new hazard warning symbol label introduce ghs read position paper hazardous chemical management plan work gsk operation evaluate hazard labelling solution facilitate production ghs compliant label base revise classification develop home responsibility environmental sustainability sustainability product stewardship global harmonisation corporate responsibility report global harmonisation continue prepare impend change classification labelling hazard un globally harmonise system classification labelling chemical ghs regulation include change way produce safety datum sheet ensure compliance initiate process reclassify substance manufacture import follow ghs rule develop training employee new hazard warning symbol label introduce ghs read position paper hazardous chemical management plan work gsk operation evaluate hazard labelling solution facilitate production ghs compliant label base revise classification develop home responsibility environmental sustainability sustainability packaging corporate responsibility report packaging work reduce environmental impact packaging pharmaceutical consumer healthcare product green packaging guide provide guidance evaluate select packaging allow designer manager benchmark new exist packaging design metric manufacturing impact mass material biodegradability pvc content resource depletion petrochemical feedstock example reduce impact packaging use cent recycle plastic ribena bottle achieve despite challenge source sufficient quantity recycle plastic ribena packaging nutritional business embed sustainability aspect business evidence work ribena work biodiversity farmer grow berry work goal zero waste landfill manufacturing ribena use cent recycle material bottle action realise benefit sustainability benefit environment customer business work bottle example approach produce hundred million bottle ribena lucozade year bottle type plastic know pet estimate packaging form cent nutritional healthcare product environmental impact launch uk europe cent recycle recyclable drink bottle ribena squash readytodrink product previously package ribena bottle cent recycle material fill million new bottle ribena cent recycle material avoid emission tonne co prevent total tonne waste send landfill bottle recycle consumer use try understand people recycle away home trialling reverse vend machine major shopping centre people drink bottle machine crush compact ready collection recycle new bottle contribute target gsk nutritional healthcare product use cent packaging use packaging average cent recycle material project vanguard award ceos eh excellence award home responsibility environmental sustainability sustainability packaging corporate responsibility report packaging work reduce environmental impact packaging pharmaceutical consumer healthcare product green packaging guide provide guidance evaluate select packaging allow designer manager benchmark new exist packaging design metric manufacturing impact mass material biodegradability pvc content resource depletion petrochemical feedstock example reduce impact packaging use cent recycle plastic ribena bottle achieve despite challenge source sufficient quantity recycle plastic ribena packaging nutritional business embed sustainability aspect business evidence work ribena work biodiversity farmer grow berry work goal zero waste landfill manufacturing ribena use cent recycle material bottle action realise benefit sustainability benefit environment customer business work bottle example approach produce hundred million bottle ribena lucozade year bottle type plastic know pet estimate packaging form cent nutritional healthcare product environmental impact launch uk europe cent recycle recyclable drink bottle ribena squash readytodrink product previously package ribena bottle cent recycle material fill million new bottle ribena cent recycle material avoid emission tonne co prevent total tonne waste send landfill bottle recycle consumer use try understand people recycle away home trialling reverse vend machine major shopping centre people drink bottle machine crush compact ready collection recycle new bottle contribute target gsk nutritional healthcare product use cent packaging use packaging average cent recycle material project vanguard award ceos eh excellence award home responsibility environmental sustainability open transparent relation corporate responsibility report open transparent relation aim transparent open environmental impact product process help build trust stakeholder provide assurance manage environment health safety sustainability ehss risk report progress ehss objective annual corporate responsibility report respond specific request information year engage formally stakeholder gather feedback approach performance address concern home responsibility environmental sustainability open transparent relation corporate responsibility report open transparent relation aim transparent open environmental impact product process help build trust stakeholder provide assurance manage environment health safety sustainability ehss risk report progress ehss objective annual corporate responsibility report respond specific request information year engage formally stakeholder gather feedback approach performance address concern home responsibility environmental sustainability open transparent relation stakeholder engagement corporate responsibility report stakeholder engagement engage stakeholder corporate local level inform plan approach manage ehss help identify emerge issue include ad hoc meeting formalise feedback stakeholder panel uk create ehs stakeholder workshop hold time expand role uk panel provide input sustainability council council compose senior gsk manager form consider sustainability issue important gsk recommend action component gsk large effort address public concern conduct business engage regulator help develop control protect environment safeguard development launch new medicine read engage stakeholder feedback receive fare benchmark home responsibility environmental sustainability open transparent relation stakeholder engagement corporate responsibility report stakeholder engagement engage stakeholder corporate local level inform plan approach manage ehss help identify emerge issue include ad hoc meeting formalise feedback stakeholder panel uk create ehs stakeholder workshop hold time expand role uk panel provide input sustainability council council compose senior gsk manager form consider sustainability issue important gsk recommend action component gsk large effort address public concern conduct business engage regulator help develop control protect environment safeguard development launch new medicine read engage stakeholder feedback receive fare benchmark home responsibility environmental sustainability open transparent relation ehss report corporate responsibility report ehss report primary objective collect ehss performance datum help operation manage ehss issue ehs manager webbase information management system focus external reporting environmental issue relevant gsk interest stakeholder read overall approach corporate responsibility report read approach health safety health safety performance home responsibility environmental sustainability open transparent relation ehss report corporate responsibility report ehss report primary objective collect ehss performance datum help operation manage ehss issue ehs manager webbase information management system focus external reporting environmental issue relevant gsk interest stakeholder read overall approach corporate responsibility report read approach health safety health safety performance home responsibility environmental sustainability open transparent relation assurance corporate responsibility report assurance sgs assurance statement sgs united kingdom ltds report environment health safety datum glaxosmithkline corporate responsibility report nature scope assurance sgs united kingdom ltd commission glaxosmithkline gsk conduct independent assurance environmental health safety datum corporate responsibility cr report scope assurance base sgs sustainability report assurance methodology include datum contain follow section report waste water injury illness rate waste injury illness cause emission air fatality injury climate change ergonomic energy driver safety transport impact health safety datum table water use environment datum table information gsk cr report presentation responsibility director management gsk sgs united kingdom ltd involve preparation material include cr report responsibility express opinion datum graphs statement scope verification financial datum draw directly independently audit financial account check source assurance process sgs group develop set protocol assurance sustainability report base good practice guidance provide global reporting initiative sustainability report guideline aa assurance standard protocol follow differ level assurance depend report history capability report organisation report assure content veracity assurance comprise combination interview relevant employee documentation record review nineteen gsk location end reporting year follow interim site visit october france evreux notre dame de bondeville saintamandles eaux india nabha italy verona gms rd nigeria agbara uk slough stevenage rd ware gms worthe usa clifton memphis research triangle park rd end year site visit january february india nashik thane ireland cork uk irvine ulverston corporate csr function london site select include submit high proportion key datum include part gsk business statement independence competence sgs group company world leader inspection testing verification operating country provide service include management system service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflict interest organisation subsidiarie stakeholder assurance team assemble base knowledge experience qualification assignment comprise auditor assuror register irca iema emas verifiers assurance opinion basis methodology describe verification work perform satisfied environmental health safety datum contain gsk corporate responsibility report reliable provide fair balanced representation gsk environmental health safety activity believe gsk choose appropriate level assurance stage report key area improvement datum collection submission manipulation identify assurance process far possible address incorporate improvement report improvement opportunity outline enable review establish need system process change future reporting cycle datum point collate centrally year end fully review identify anomaly lead inconsistent approach estimate miss datum datum point calculate new emission factor previous year datum restate calculation allow yearonyear comparison important ensure restate information fully explain reference factor remain current significant contributor select data point fail submit require information calculation methodology ozone deplete substance patient use inhaler update production site remain site note report datum previous year change slightly obtain additional data submission update estimate publication date anomaly identify datum submit review site level datum compare previous year submission include example datum enter twice follow change database improvement opportunity identify site visit mainly site specific common observation focusse follow area manual transfer datum opportunity mistake variation rounding transfer utilise benefit improvement regular review internal check datum accuracy formalise secondary review manual transfer end year check extension monthly report quarterly annual improvement identify previous reporting period start implement follow specific report ehs manager begin implement energy module reduce need additional data transfer spreadsheet site level additional opportunity extend area waste datum provide key subcontractor site visit conduct note staff prepare able provide require evidence auditor majority case particularly site undergone previous visit addition require change generally promptly possible datum ancillary service site activity started include explanation provide comment section ehs manager site visit identify remain miss item review data submission indicate increase monthly reporting annual quarterly allow regular review update data entry indicate discrepancy clearly majority site visit conduct quarter enable issue concern identify deal early assurance process key area improvement datum verification process identify follow site select visit identify early opportunity order enable visit complete alongside isoohsas certification audit possible recommend site visit complete quarter enable followup require complete end year verification perform recommend selection key indicator review calculation methodology major contributor example voc cod emission hazardous waste disposal primary site recommend site visit include detailed review source evidence ozone deplete substance equipment recommend site select visit include sample site manufacture inhaler order verify datum source sample site significant contribution fail submit datum sample site significant change occur reflect datum submit sign behalf sgs united kingdom ltd pauline earl manage director february wwwsgscom tophome responsibility environmental sustainability open transparent relation assurance corporate responsibility report assurance sgs assurance statement sgs united kingdom ltds report environment health safety datum glaxosmithkline corporate responsibility report nature scope assurance sgs united kingdom ltd commission glaxosmithkline gsk conduct independent assurance environmental health safety datum corporate responsibility cr report scope assurance base sgs sustainability report assurance methodology include datum contain follow section report waste water injury illness rate waste injury illness cause emission air fatality injury climate change ergonomic energy driver safety transport impact health safety datum table water use environment datum table information gsk cr report presentation responsibility director management gsk sgs united kingdom ltd involve preparation material include cr report responsibility express opinion datum graphs statement scope verification financial datum draw directly independently audit financial account check source assurance process sgs group develop set protocol assurance sustainability report base good practice guidance provide global reporting initiative sustainability report guideline aa assurance standard protocol follow differ level assurance depend report history capability report organisation report assure content veracity assurance comprise combination interview relevant employee documentation record review nineteen gsk location end reporting year follow interim site visit october france evreux notre dame de bondeville saintamandles eaux india nabha italy verona gms rd nigeria agbara uk slough stevenage rd ware gms worthe usa clifton memphis research triangle park rd end year site visit january february india nashik thane ireland cork uk irvine ulverston corporate csr function london site select include submit high proportion key datum include part gsk business statement independence competence sgs group company world leader inspection testing verification operating country provide service include management system service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflict interest organisation subsidiarie stakeholder assurance team assemble base knowledge experience qualification assignment comprise auditor assuror register irca iema emas verifiers assurance opinion basis methodology describe verification work perform satisfied environmental health safety datum contain gsk corporate responsibility report reliable provide fair balanced representation gsk environmental health safety activity believe gsk choose appropriate level assurance stage report key area improvement datum collection submission manipulation identify assurance process far possible address incorporate improvement report improvement opportunity outline enable review establish need system process change future reporting cycle datum point collate centrally year end fully review identify anomaly lead inconsistent approach estimate miss datum datum point calculate new emission factor previous year datum restate calculation allow yearonyear comparison important ensure restate information fully explain reference factor remain current significant contributor select data point fail submit require information calculation methodology ozone deplete substance patient use inhaler update production site remain site note report datum previous year change slightly obtain additional data submission update estimate publication date anomaly identify datum submit review site level datum compare previous year submission include example datum enter twice follow change database improvement opportunity identify site visit mainly site specific common observation focusse follow area manual transfer datum opportunity mistake variation rounding transfer utilise benefit improvement regular review internal check datum accuracy formalise secondary review manual transfer end year check extension monthly report quarterly annual improvement identify previous reporting period start implement follow specific report ehs manager begin implement energy module reduce need additional data transfer spreadsheet site level additional opportunity extend area waste datum provide key subcontractor site visit conduct note staff prepare able provide require evidence auditor majority case particularly site undergone previous visit addition require change generally promptly possible datum ancillary service site activity started include explanation provide comment section ehs manager site visit identify remain missinpagg eit em sof review data submission indicate increase monthly reporting annual quarterly allow regular review update data entry indicate discrepancy clearly majority site visit conduct quarter enable issue concern identify deal early assurance process key area improvement datum verification process identify follow site select visit identify early opportunity order enable visit complete alongside isoohsas certification audit possible recommend site visit complete quarter enable followup require complete end year verification perform recommend selection key indicator review calculation methodology major contributor example voc cod emission hazardous waste disposal primary site recommend site visit include detailed review source evidence ozone deplete substance equipment recommend site select visit include sample site manufacture inhaler order verify datum source sample site significant contribution fail submit datum sample site significant change occur reflect datum submit sign behalf sgs united kingdom ltd pauline earl manage director february wwwsgscom tophome responsibility environmental sustainability open transparent relation assurance corporate responsibility report assurance sgs assurance statement sgs united kingdom ltds report environment health safety datum glaxosmithkline corporate responsibility report nature scope assurance sgs united kingdom ltd commission glaxosmithkline gsk conduct independent assurance environmental health safety datum corporate responsibility cr report scope assurance base sgs sustainability report assurance methodology include datum contain follow section report waste water injury illness rate waste injury illness cause emission air fatality injury climate change ergonomic energy driver safety transport impact health safety datum table water use environment datum table information gsk cr report presentation responsibility director management gsk sgs united kingdom ltd involve preparation material include cr report responsibility express opinion datum graphs statement scope verification financial datum draw directly independently audit financial account check source assurance process sgs group develop set protocol assurance sustainability report base good practice guidance provide global reporting initiative sustainability report guideline aa assurance standard protocol follow differ level assurance depend report history capability report organisation report assure content veracity assurance comprise combination interview relevant employee documentation record review nineteen gsk location end reporting year follow interim site visit october france evreux notre dame de bondeville saintamandles eaux india nabha italy verona gms rd nigeria agbara uk slough stevenage rd ware gms worthe usa clifton memphis research triangle park rd end year site visit january february india nashik thane ireland cork uk irvine ulverston corporate csr function london site select include submit high proportion key datum include part gsk business statement independence competence sgs group company world leader inspection testing verification operating country provide service include management system service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflict interest organisation subsidiarie stakeholder assurance team assemble base knowledge experience qualification assignment comprise auditor assuror register irca iema emas verifiers assurance opinion basis methodology describe verification work perform satisfied environmental health safety datum contain gsk corporate responsibility report reliable provide fair balanced representation gsk environmental health safety activity believe gsk choose appropriate level assurance stage report key area improvement datum collection submission manipulation identify assurance process far possible address incorporate improvement report improvement opportunity outline enable review establish need system process change future reporting cycle datum point collate centrally year end fully review identify anomaly lead inconsistent approach estimate miss datum datum point calculate new emission factor previous year datum restate calculation allow yearonyear comparison important ensure restate information fully explain reference factor remain current significant contributor select data point fail submit require information calculation methodology ozone deplete substance patient use inhaler update production site remain site note report datum previous year change slightly obtain additional data submission update estimate publication date anomaly identify datum submit review site level datum compare previous year submission include example datum enter twice follow change database improvement opportunity identify site visit mainly site specific common observation focusse follow area manual transfer datum opportunity mistake variation rounding transfer utilise benefit improvement regular review internal check datum accuracy formalise secondary review manual transfer end year check extension monthly report quarterly annual improvement identify previous reporting period start implement follow specific report ehs manager begin implement energy module reduce need additional data transfer spreadsheet site level additional opportunity extend area waste datum provide key subcontractor site visit conduct note staff prepare able provide require evidence auditor majority case particularly site undergone previous visit addition require change generally promptly possible datum ancillary service site activity started include explanation provide comment section ehs manager site visit identify remain miss item review data submission indicate increase monthly reporting annual quarterly allow regular review update data entry indicate discrepancy clearly majority site visit conduct quarter enable issue concern identify deal early assurance process key area improvement datum verification process identify follow site select visit identify early opportunity order enable visit complete alongside isoohsas certification audit possible recommend site visit complete quarter enable followup require complete end year verification perform recommend selection key indicator review calculation methodology major contributor example voc cod emission hazardous waste disposal primary site recommend site visit include detailed review source evidence ozone deplete substance equipment recommend site select visit include sample site manufacture inhaler order verify datum source sample site significant contribution fail submit datum sample site significant change occur reflect datum submit sign behalf sgs united kingdom ltd pauline earl manage director february wwwsgscom home responsibility environmental sustainability open transparent relation assurance corporate responsibility report assurance sgs assurance statement sgs united kingdom ltds report environment health safety datum glaxosmithkline corporate responsibility report nature scope assurance sgs united kingdom ltd commission glaxosmithkline gsk conduct independent assurance environmental health safety datum corporate responsibility cr report scope assurance base sgs sustainability report assurance methodology include datum contain follow section report waste water injury illness rate waste injury illness cause emission air fatality injury climate change ergonomic energy driver safety transport impact health safety datum table water use environment datum table information gsk cr report presentation responsibility director management gsk sgs united kingdom ltd involve preparation material include cr report responsibility express opinion datum graphs statement scope verification financial datum draw directly independently audit financial account check source assurance process sgs group develop set protocol assurance sustainability report base good practice guidance provide global reporting initiative sustainability report guideline aa assurance standard protocol follow differ level assurance depend report history capability report organisation report assure content veracity assurance comprise combination interview relevant employee documentation record review nineteen gsk location end reporting year follow interim site visit october france evreux notre dame de bondeville saintamandles eaux india nabha italy verona gms rd nigeria agbara uk slough stevenage rd ware gms worthe usa clifton memphis research triangle park rd end year site visit january february india nashik thane ireland cork uk irvine ulverston corporate csr function london site select include submit high proportion key datum include part gsk business statement independence competence sgs group company world leader inspection testing verification operating country provide service include management system service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflict interest organisation subsidiarie stakeholder assurance team assemble base knowledge experience qualification assignment comprise auditor assuror register irca iema emas verifiers assurance opinion basis methodology describe verification work perform satisfied environmental health safety datum contain gsk corporate responsibility report reliable provide fair balanced representation gsk environmental health safety activity believe gsk choose appropriate level assurance stage report key area improvement datum collection submission manipulation identify assurance process far possible address incorporate improvement report improvement opportunity outline enable review establish need system process change future reporting cycle datum point collate centrally year end fully review identify anomaly lead inconsistent approach estimate miss datum datum point calculate new emission factor previous year datum restate calculation allow yearonyear comparison important ensure restate information fully explain reference factor remain current significant contributor select data point fail submit require information calculation methodology ozone deplete substance patient use inhaler update production site remain site note report datum previous year change slightly obtain additional data submission update estimate publication date anomaly identify datum submit review site level datum compare previous year submission include example datum enter twice follow change database improvement opportunity identify site visit mainly site specific common observation focusse follow area manual transfer datum opportunity mistake variation rounding transfer utilise benefit improvement regular review internal check datum accuracy formalise secondary review manual transfer end year check extension monthly report quarterly annual improvement identify previous reporting period start implement follow specific report ehs manager begin implement energy module reduce need additional data transfer spreadsheet site level additional opportunity extend area waste datum provide key subcontractor site visit conduct note staff prepare able provide require evidence auditor majority case particularly site undergone previous visit addition require change generally promptly possible datum ancillary service site activity started include explanation provide comment section ehs manager site visit identify remain miss item review data submission indicate increase monthly reporting annual quarterly allow regular review update data entry indicate discrepancy clearly majority site visit conduct quarter enable issue concern identify deal early assurance process key area improvement datum verification process identify follow site select visit identify early opportunity order enable visit complete alongside isoohsas certification audit possible recommend site visit complete quarter enable followup require complete end year verification perform recommend selection key indicator review calculation methodology major contributor example voc cod emission hazardous waste disposal primary site recommend site visit include detailed review source evidence ozone deplete substance equipment recommend site select visit include sample site manufacture inhaler order verify datum source sample site significant contribution fail submit datum sample site significant change occur reflect datum submit sign behalf sgs united kingdom ltd pauline earl manage director february wwwsgscom home responsibility environmental sustainability open transparent relation gsk response assurance corporate responsibility report gsk response assurance gsk response sgs march year sgs review datum environment injury illness datum people section corporate responsibility report verification complex large datum cover year sgs auditor suggest improvement base finding unbiased view data process valuable adopt suggestion result quality system datum continue improve year sgs select site review base magnitude contribution site overall gsk performance type operation degree difficulty site report believe site evaluation valuable learning experience site personnel datum include corporate responsibility report individual site monitor improve environmental programme health safety programme sgs datum verification assure veracity datum corporate responsibility report improve accuracy usefulness data site find challenge collect complete accurate datum timely fashion commit continue improve record reach goal able provide accurate datum public website real time response specific key area improvement year select site review iso certification site select review verify combination iso certification place year site visit complete quarter site notify selection verification visit quarter visit place quarter conjunction iso certification visit early year selection key indicator review calculation methodology work site manufacture active pharmaceutical ingredient principal contributor voc cod emission hazardous waste review calculation method course site visit include detailed review source evidence ozone deplete substance equipment prepare report refrigeration equipment register sgs include site review site select visit include manufacturer inhaler site fail submit data site significant change datum submit site select review fully represent group include large sale group submit incomplete late datum injury illnesse site business region significant datum error look forward improvement attention area bring james hagan vice president corporate environment health safety sustainability home responsibility environmental sustainability open transparent relation gsk response assurance corporate responsibility report gsk response assurance gsk response sgs march year sgs review datum environment injury illness datum people section corporate responsibility report verification complex large datum cover year sgs auditor suggest improvement base finding unbiased view data process valuable adopt suggestion result quality system datum continue improve year sgs select site review base magnitude contribution site overall gsk performance type operation degree difficulty site report believe site evaluation valuable learning experience site personnel datum include corporate responsibility report individual site monitor improve environmental programme health safety programme sgs datum verification assure veracity datum corporate responsibility report improve accuracy usefulness data site find challenge collect complete accurate datum timely fashion commit continue improve record reach goal able provide accurate datum public website real time response specific key area improvement year select site review iso certification site select review verify combination iso certification place year site visit complete quarter site notify selection verification visit quarter visit place quarter conjunction iso certification visit early year selection key indicator review calculation methodology work site manufacture active pharmaceutical ingredient principal contributor voc cod emission hazardous waste review calculation method course site visit include detailed review source evidence ozone deplete substance equipment prepare report refrigeration equipment register sgs include site review site select visit include manufacturer inhaler site fail submit data site significant change datum submit site select review fully represent group include large sale group submit incomplete late datum injury illnesse site business region significant datum error look forward improvement attention area bring james hagan vice president corporate environment health safety sustainability home responsibility environmental sustainability open transparent relation gsk response assurance corporate responsibility report gsk response assurance gsk response sgs march year sgs review datum environment injury illness datum people section corporate responsibility report verification complex large datum cover year sgs auditor suggest improvement base finding unbiased view data process valuable adopt suggestion result quality system datum continue improve year sgs select site review base magnitude contribution site overall gsk performance type operation degree difficulty site report believe site evaluation valuable learning experience site personnel datum include corporate responsibility report individual site monitor improve environmental programme health safety programme sgs datum verification assure veracity datum corporate responsibility report improve accuracy usefulness data site find challenge collect complete accurate datum timely fashion commit continue improve record reach goal able provide accurate datum public website real time response specific key area improvement year select site review iso certification site select review verify combination iso certification place year site visit complete quarter site notify selection verification visit quarter visit place quarter conjunction iso certification visit early year selection key indicator review calculation methodology work site manufacture active pharmaceutical ingredient principal contributor voc cod emission hazardous waste review calculation method course site visit include detailed review source evidence ozone deplete substance equipment prepare report refrigeration equipment register sgs include site review site select visit include manufacturer inhaler site fail submit data site significant change datum submit site select review fully represent group include large sale group submit incomplete late datum injury illnesse site business region significant datum error look forward improvement attention area bring james hagan vice president corporate environment health safety sustainability home responsibility environmental sustainability qas corporate responsibility report qas respond question raise stakeholder inhaler product large environmental impact phase cfc inhaler product year replace gas hfas low climate change impact cent cfc cent inhaler contain cfc commit complete phaseout new climate strategy explore way reduce hfas release inhaler product look alternative propellant offer dry powder inhaler asthma sufferer contain greenhouse gas suitable patient particularly child elderly contain propellant rely person lung power active ingredient administer pharmaceutical manufacturing process efficient make medicine highly regulate complicated number process step require know need improve efficiency set target double average material efficiency manufacturing process new product introduce pharmaceutical residue present drinking water risk human study show gsk pharmaceutical product present watercourse present low concentration risk assessment demonstrate concentration pose risk human health environment complacent continually monitor late scientific study finding improve risk assessment methodology home responsibility environmental sustainability qas corporate responsibility report qas respond question raise stakeholder inhaler product large environmental impact phase cfc inhaler product year replace gas hfas low climate change impact cent cfc cent inhaler contain cfc commit complete phaseout new climate strategy explore way reduce hfas release inhaler product look alternative propellant offer dry powder inhaler asthma sufferer contain greenhouse gas suitable patient particularly child elderly contain propellant rely person lung power active ingredient administer pharmaceutical manufacturing process efficient make medicine highly regulate complicated number process step require know need improve efficiency set target double average material efficiency manufacturing process new product introduce pharmaceutical residue present drinking water risk human study show gsk pharmaceutical product present watercourse present low concentration risk assessment demonstrate concentration pose risk human health environment complacent continually monitor late scientific study finding improve risk assessment methodology home responsibility environmental sustainability environmental metric corporate responsibility report environmental metric metric energy use energy operation million gigajoule natural gas fuel coal steam import electricity import energy transport million gigajoule sale force air travel product logistic electricity sustainable source climate change impact co equivalent total climate change impact million kilogram co equivalent co equivalent operation energy million kilogram natural gas fuel coal steam import electricity import co equivalent transport million page kilogram sale force air travel product logistic co equivalent production activity million kilogram inhaler production loss equipment contain great kg refrigerant co methane nitrous oxide production waste treatment source co equivalent use inhaler patient million kilogram cfc inhaler cfc inhaler hfaa inhaler water use discharge water million cubic metre municipal well borehole water wastewater volume million cubic metre wastewater recycling wastewater municipal sewer wastewater water body cod onsite treatment million kilogram cod recycle water cod municipal sewer cod water body waste generate disposed hazardous waste generate million kilogram hazardous waste recycle hazardous waste dispose hazardous waste incinerate energy recovery hazardous waste incinerate energy recovery hazardous waste landfill nonhazardous waste generate million kilogram nonhazardous waste recycle nonhazardous waste dispose nonhazardous waste incinerate energy recovery nonhazardous waste incinerate energy recovery nonhazardous waste landfill nonroutine waste generate million kilogram nonroutine waste recycle nonroutine waste dispose nonroutine waste incinerate energy recovery nonroutine waste incinerate energy recovery nonroutine waste landfill volatile organic compound emission volatile organic compound emission million kilogram solvent release air million kilogram acetone dichloromethane methanol ethanol isopropanol toluene ozone deplete substance od release production thousand kilogram cfc release production cfc release production ozone depletion potential refrigerant release eqauipment thousand kilogram cfc equivalent cfc releases equipment cfc release equipment od equipment od release patient use inhaler cfc patient use cfc patient use odp refrigerant contine equipment thousand kilogram cfc equivalent estimate cost investment operation maintenance cost million capital investment million footnote energy climate change impact travel transport air land sea calculate greenhouse gas protocol starting distance travel directly fuel use year collect category freight transport employee business travel transport datum estimate capture route employee air travel climate change impact calculate co equivalent greenhouse gas protocol develop world resources institute world business council sustainable development year review co factor update datum year appropriate great change generally update factor electricity review refrigeration equipment inventory inventory incomplete estimate base inventory year update factor ozone depletion potential climate change emission wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable release factor british refrigeration association information calculate climate change impact inhaler use water source include recycle source focus collection wastewater chemical oxygen demand datum primarily major contributor primary manufacturing operation pilot plant coating activity sterile operation sanitary wastewater stream include separate production wastewater stream significant chemical oxygen demand cod measure water pollution measure wastewater leave site follow onsite treatment consider waste hazardous property define basel convention radioactive bioengineere biohazardous basel convention property include flammability explosivity water air reactivity corrosivity oxidise potential acute chronic toxicity ecotoxicity infection biological waste render nonhazardous treatment consider nonhazardous waste focus collection hazardous waste major contributor primary manufacturing operation pilot plant coating activity sterile operation incineration energy recovery mean burn material result energy nonroutine waste include construction demolition rubble include hazardous non hazardous waste calculation focus collection volatile organic compound emission major contributor primary manufacturing operation pilot plant coating activity sterile operation wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emission factor information inhaler produce asia include odp gwp calculation information amount refrigerant contain equipment tophome responsibility environmental sustainability environmental metric corporate responsibility report environmental metric metric energy use energy operation million gigajoule natural gas fuel coal steam import electricity import energy transport million gigajoule sale force air travel product logistic electricity sustainable source climate change impact co equivalent total climate change impact million kilogram co equivalent co equivalent operation energy million kilogram natural gas fuel coal steam import electricity import co equivalent transport million kilogram sale force air travel product logistic co equivalent production activity million kilogram inhaler production loss equipment contain great kg refrigerant co methane nitrous oxide production waste treatment source co equivalent use inhaler patient million kilogram cfc inhaler cfc inhaler hfaa inhaler water use discharge water million cubic metre municipal well borehole water wastewater volume million cubic metre wastewater recycling wastewater municipal sewer wastewater water body cod onsite treatment million kilogram cod recycle water cod municipal sewer page cod water body waste generate disposed hazardous waste generate million kilogram hazardous waste recycle hazardous waste dispose hazardous waste incinerate energy recovery hazardous waste incinerate energy recovery hazardous waste landfill nonhazardous waste generate million kilogram nonhazardous waste recycle nonhazardous waste dispose nonhazardous waste incinerate energy recovery nonhazardous waste incinerate energy recovery nonhazardous waste landfill nonroutine waste generate million kilogram nonroutine waste recycle nonroutine waste dispose nonroutine waste incinerate energy recovery nonroutine waste incinerate energy recovery nonroutine waste landfill volatile organic compound emission volatile organic compound emission million kilogram solvent release air million kilogram acetone dichloromethane methanol ethanol isopropanol toluene ozone deplete substance od release production thousand kilogram cfc release production cfc release production ozone depletion potential refrigerant release eqauipment thousand kilogram cfc equivalent cfc releases equipment cfc release equipment od equipment od release patient use inhaler cfc patient use cfc patient use odp refrigerant contine equipment thousand kilogram cfc equivalent estimate cost investment operation maintenance cost million capital investment million footnote energy climate change impact travel transport air land sea calculate greenhouse gas protocol starting distance travel directly fuel use year collect category freight transport employee business travel transport datum estimate capture route employee air travel climate change impact calculate co equivalent greenhouse gas protocol develop world resources institute world business council sustainable development year review co factor update datum year appropriate great change generally update factor electricity review refrigeration equipment inventory inventory incomplete estimate base inventory year update factor ozone depletion potential climate change emission wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable release factor british refrigeration association information calculate climate change impact inhaler use water source include recycle source focus collection wastewater chemical oxygen demand datum primarily major contributor primary manufacturing operation pilot plant coating activity sterile operation sanitary wastewater stream include separate production wastewater stream significant chemical oxygen demand cod measure water pollution measure wastewater leave site follow onsite treatment consider waste hazardous property define basel convention radioactive bioengineere biohazardous basel convention property include flammability explosivity water air reactivity corrosivity oxidise potential acute chronic toxicity ecotoxicity infection biological waste render nonhazardous treatment consider nonhazardous waste focus collection hazardous waste major contributor primary manufacturing operation pilot plant coating activity sterile operation incineration energy recovery mean burn material result energy nonroutine waste include construction demolition rubble include hazardous non hazardous waste calculation focus collection volatile organic compound emission major contributor primary manufacturing operation pilot plant coating activity sterile operation wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emission factor information inhaler produce asia include odp gwp calculation information amount refrigerant contain equipment tophome responsibility environmental sustainability environmental metric corporate responsibility report environmental metric metric energy use energy operation million gigajoule natural gas fuel coal steam import electricity import energy transport million gigajoule sale force air travel product logistic electricity sustainable source climate change impact co equivalent total climate change impact million kilogram co equivalent co equivalent operation energy million kilogram natural gas fuel coal steam import electricity import co equivalent transport million kilogram sale force air travel product logistic co equivalent production activity million kilogram inhaler production loss equipment contain great kg refrigerant co methane nitrous oxide production waste treatment source co equivalent use inhaler patient million kilogram cfc inhaler cfc inhaler hfaa inhaler water use discharge water million cubic metre municipal well borehole water wastewater volume million cubic metre wastewater recycling wastewater municipal sewer wastewater water body cod onsite treatment million kilogram cod recycle water cod municipal sewer cod water body waste generate disposed hazardous waste generate million kilogram hazardous waste recycle hazardous waste dispose hazardous waste incinerate energy recovery hazardous waste incinerate energy recovery hazardous waste landfill nonhazardous waste generate million kilogram nonhazardous waste recycle nonhazardous waste dispose nonhazardous waste incinerate energy recovery nonhazardous waste incinerate energy recovery nonhazardous waste landfill nonroutine waste generate million kilogram nonroutine waste recycle nonroutine waste dispose nonroutine waste incinerate energy recovery nonroutine waste incinerate energy recovery nonroutine waste landfill volatile organic compound emission volatile organic compound emission million kilogram solvent release air million kilogram acetone dichloromethane methanol ethanol isopropanol toluene ozone deplete substance od release production thousand kilogram cfc release production cfc release production ozone depletion potential refrigerant release eqauipment thousand kilogram cfc equivalent cfc releases equipment cfc release equipment od equipment od release patient use inhaler cfc patient use cfc patient use odp refrigerant contine equipment thousand kilogram cfc equivalent estimate cost investment operation maintenance cost million capital investment million footnote energy climate change impact travel transport air land sea calculate greenhouse gas protocol starting distance travel directly fuel use year collect category freight transport employee business travel transport datum estimate capture route employee air travel climate change impact calculate co equivalent greenhouse gas protocol develop world resources institute world business council sustainable development year review co factor update datum year appropriate great change generally update factor electricity review refrigeration equipment inventory inventory incomplete estimate base inventory year update factor ozone depletion potential climate change emission wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable release factor british refrigeration association information calculate climate change impact inhaler use water source include recycle source focus collection wastewater chemical oxygen demand datum primarily major contributor primary manufacturing operation pilot plant coating activity sterile operation sanitary wastewater stream include separate production wastewater stream significant chemical oxygen demand cod measure water pollution measure wastewater leave site follow onsite treatment consider waste hazardous property define basel convention radioactive bioengineere biohazardous basel convention property include flammability explosivity water air reactivity corrosivity oxidise potential acute chronic toxicity ecotoxicity infection biological waste render nonhazardous treatment consider nonhazardous waste focus collection hazardous waste major contributor primary manufacturing operation pilot plant coating activity sterile operation incineration energy recovery mean burn material result energy nonroutine waste include construction demolition rubble include hazardous non hazardous waste calculation focus collection volatile organic compound emission major contributor primary manufacturing operation pilot plant coating activity sterile operation wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emission factor information inhaler produce asia include odp gwp calculation information amount refrigerant contain equipment tophome responsibility environmental sustainability environmental metric corporate responsibility report environmental metric metric energy use energy operation million gigajoule natural gas fuel coal steam import electricity import energy transport million gigajoule sale force air travel product logistic electricity sustainable source climate change impact co equivalent total climate change impact million kilogram co equivalent co equivalent operation energy million kilogram natural gas fuel coal steam import electricity import co equivalent transport million kilogram sale force air travel product logistic co equivalent production activity million kilogram inhaler production loss equipment contain great kg refrigerant co methane nitrous oxide production waste treatment source co equivalent use inhaler patient million kilogram cfc inhaler cfc inhaler hfaa inhaler water use discharge water million cubic metre municipal well borehole water wastewater volume million cubic metre wastewater recycling wastewater municipal sewer wastewater water body cod onsite treatment million kilogram cod recycle water cod municipal sewer cod water body waste generate disposed hazardous waste generate million kilogram hazardous waste recycle hazardous waste dispose hazardous waste incinerate energy recovery hazardous waste incinerate energy recovery hazardous waste landfill nonhazardous waste generate million kilogram nonhazardous waste recycle nonhazardous waste dispose nonhazardous waste incinerate energy recovery nonhazardous waste incinerate energy recovery nonhazardous waste landfill nonroutine waste generate million kilogram nonroutine waste recycle nonroutine waste dispose nonroutine waste incinerate energy recovery nonroutine waste incinerate energy recovery nonroutine waste landfill volatile organic compound emission volatile organic compound emission million kilogram solvent release air million kilogram acetone dichloromethane methanol ethanol isopropanol toluene ozone deplete substance od release production thousand kilogram cfc release production cfc release production ozone depletion potential refrigerant release eqauipment thousand kilogram cfc equivalent cfc releases equipment cfc release equipment od equipment od release patient use inhaler cfc patient use cfc patient use odp refrigerant contine equipment thousand kilogram cfc equivalent estimate cost investment operation maintenance cost million capital investment million footnote energy climate change impact travel transport air land sea calculate greenhouse gas protocol starting distance travel directly fuel use year collect category freight transport employee business travel transport datum estimate capture route employee air travel climate change impact calculate co equivalent greenhouse gas protocol develop world resources institute world business council sustainable development year review co factor update datum year appropriate great change generally update factor electricity review refrigeration equipment inventory inventory incomplete estimate base inventory year update factor ozone depletion potential climate change emission wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable release factor british refrigeration association information calculate climate change impact inhaler use water source include recycle source focus collection wastewater chemical oxygen demand datum primarily major contributor primary manufacturing operation pilot plant coating activity sterile operation sanitary wastewater stream include separate production wastewater stream significant chemical oxygen demand cod measure water pollution measure wastewater leave site follow onsite treatment consider waste hazardous property define basel convention radioactive bioengineere biohazardous basel convention property include flammability explosivity water air reactivity corrosivity oxidise potential acute chronic toxicity ecotoxicity infection biological waste render nonhazardous treatment consider nonhazardous waste focus collection hazardous waste major contributor primary manufacturing operation pilot plant coating activity sterile operation incineration energy recovery mean burn material result energy nonroutine waste include construction demolition rubble include hazardous non hazardous waste calculation focus collection volatile organic compound emission major contributor primary manufacturing operation pilot plant coating activity sterile operation wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emission factor information inhaler produce asia include odp gwp calculation information amount refrigerant contain equipment tophome responsibility environmental sustainability environmental metric corporate responsibility report environmental metric metric energy use energy operation million gigajoule natural gas fuel coal steam import electricity import energy transport million gigajoule sale force air travel product logistic electricity sustainable source climate change impact co equivalent total climate change impact million kilogram co equivalent co equivalent operation energy million kilogram natural gas fuel coal steam import electricity import co equivalent transport million kilogram sale force air travel product logistic co equivalent production activity million kilogram inhaler production loss equipment contain great kg refrigerant co methane nitrous oxide production waste treatment source co equivalent use inhaler patient million kilogram cfc inhaler cfc inhaler hfaa inhaler water use discharge water million cubic metre municipal well borehole water wastewater volume million cubic metre wastewater recycling wastewater municipal sewer wastewater water body cod onsite treatment million kilogram cod recycle water cod municipal sewer cod water body waste generate disposed hazardous waste generate million kilogram hazardous waste recycle hazardous waste dispose hazardous waste incinerate energy recovery hazardous waste incinerate energy recovery hazardous waste landfill nonhazardous waste generate million kilogram nonhazardous waste recycle nonhazardous waste dispose nonhazardous waste incinerate energy recovery nonhazardous waste incinerate energy recovery nonhazardous waste landfill nonroutine waste generate million kilogram nonroutine waste recycle nonroutine waste dispose nonroutine waste incinerate energy recovery nonroutine waste incinerate energy recovery nonroutine waste landfill volatile organic compound emission volatile organic compound emission million kilogram solvent release air million kilogram acetone dichloromethane methanol ethanol isopropanol toluene ozone deplete substance od release production thousand kilogram cfc release production cfc release production ozone depletion potential refrigerant release eqauipment thousand kilogram cfc equivalent cfc releases equipment cfc release equipment od equipment od release patient use inhaler cfc patient use cfc patient use odp refrigerant contine equipment thousand kilogram cfc equivalent estimate cost investment operation maintenance cost million capital investment million footnote energy climate change impact travel transport air land sea calculate greenhouse gas protocol starting distance travel directly fuel use year collect category freight transport employee business travel transport datum estimate capture route employee air travel climate change impact calculate co equivalent greenhouse gas protocol develop world resources institute world business council sustainable development year review co factor update datum year appropriate great change generally update factor electricity review refrigeration equipment inventory inventory incomplete estimate base inventory year update factor ozone depletion potential climate change emission wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable release factor british refrigeration association information calculate climate change impact inhaler use water source include recycle source focus collection wastewater chemical oxygen demand datum primarily major contributor primary manufacturing operation pilot plant coating activity sterile operation sanitary wastewater stream include separate production wastewater stream significant chemical oxygen demand cod measure water pollution measure wastewater leave site follow onsite treatment consider waste hazardous property define basel convention radioactive bioengineere biohazardous basel convention property include flammability explosivity water air reactivity corrosivity oxidise potential acute chronic toxicity ecotoxicity infection biological waste render nonhazardous treatment consider nonhazardous waste focus collection hazardous waste major contributor primary manufacturing operation pilot plant coating activity sterile operation incineration energy recovery mean burn material result energy nonroutine waste include construction demolition rubble include hazardous non hazardous waste calculation focus collection volatile organic compound emission major contributor primary manufacturing operation pilot plant coating activity sterile operation wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emission factor information inhaler produce asia include odp gwp calculation information amount refrigerant contain equipment home responsibility environmental sustainability environmental metric corporate responsibility report environmental metric metric energy use energy operation million gigajoule natural gas fuel coal steam import electricity import energy transport million gigajoule sale force air travel product logistic electricity sustainable source climate change impact co equivalent total climate change impact million kilogram co equivalent co equivalent operation energy million kilogram natural gas fuel coal steam import electricity import co equivalent transport million kilogram sale force air travel product logistic co equivalent production activity million kilogram inhaler production loss equipment contain great kg refrigerant co methane nitrous oxide production waste treatment source co equivalent use inhaler patient million kilogram cfc inhaler cfc inhaler hfaa inhaler water use discharge water million cubic metre municipal well borehole water wastewater volume million cubic metre wastewater recycling wastewater municipal sewer wastewater water body cod onsite treatment million kilogram cod recycle water cod municipal sewer cod water body waste generate disposed hazardous waste generate million kilogram hazardous waste recycle hazardous waste dispose hazardous waste incinerate energy recovery hazardous waste incinerate energy recovery hazardous waste landfill nonhazardous waste generate million kilogram nonhazardous waste recycle nonhazardous waste dispose nonhazardous waste incinerate energy recovery nonhazardous waste incinerate energy recovery nonhazardous waste landfill nonroutine waste generate million kilogram nonroutine waste recycle nonroutine waste dispose nonroutine waste incinerate energy recovery nonroutine waste incinerate energy recovery nonroutine waste landfill volatile organic compound emission volatile organic compound emission million kilogram solvent release air million kilogram acetone dichloromethane methanol ethanol isopropanol toluene ozone deplete substance od release production thousand kilogram cfc release production cfc release production ozone depletion potential refrigerant release eqauipment thousand kilogram cfc equivalent cfc releases equipment cfc release equipment od equipment od release patient use inhaler cfc patient use cfc patient use odp refrigerant contine equipment thousand kilogram cfc equivalent estimate cost investment operation maintenance cost million capital investment million footnote energy climate change impact travel transport air land sea calculate greenhouse gas protocol starting distance travel directly fuel use year collect category freight transport employee business travel transport datum estimate capture route employee air travel climate change impact calculate co equivalent greenhouse gas protocol develop world resources institute world business council sustainable development year review co factor update datum year appropriate great change generally update factor electricity review refrigeration equipment inventory inventory incomplete estimate base inventory year update factor ozone depletion potential climate change emission wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable release factor british refrigeration association information calculate climate change impact inhaler use water source include recycle source focus collection wastewater chemical oxygen demand datum primarily major contributor primary manufacturing operation pilot plant coating activity sterile operation sanitary wastewater stream include separate production wastewater stream significant chemical oxygen demand cod measure water pollution measure wastewater leave site follow onsite treatment consider waste hazardous property define basel convention radioactive bioengineere biohazardous basel convention property include flammability explosivity water air reactivity corrosivity oxidise potential acute chronic toxicity ecotoxicity infection biological waste render nonhazardous treatment consider nonhazardous waste focus collection hazardous waste major contributor primary manufacturing operation pilot plant coating activity sterile operation incineration energy recovery mean burn material result energy nonroutine waste include construction demolition rubble include hazardous non hazardous waste calculation focus collection volatile organic compound emission major contributor primary manufacturing operation pilot plant coating activity sterile operation wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emission factor information inhaler produce asia include odp gwp calculation information amount refrigerant contain equipment home responsibility people corporate responsibility report people good employment practice essential achieve business strategy goal good place good people good work employ people country world essential characteristic good workplace integrity diversity inclusion development creativity integrity critical gsk spirit define culture behaviour expect employee failure integrity risk damage longterm success diversity inclusion workforce demonstrate commitment equal opportunity enhance business diversity inclusion help attract good people country operate wide range perspective draw enhance understand local market need development employee mean likely stay gsk contribute good success encourage employee achieve potential training programme thejob development offer supportive safe work environment competitive reward package creativity foster good work environment aim gsk workplace empower people creative innovative work benefit company shareholder customer patient employment award selection employment awards gsk uk rank fourth britain employer survey crf international publish guardian book good class engineering science shortlist good graduate employer target award vote graduate postgraduate receive time employer choice research development award base result undergraduate interview rank th time graduate employer survey list organisation new graduate want work employee benefit award effective use employee financial education workplace award employee benefit magazine highly commend pricewaterhousecooper build public trust award people report category base disclosure strength human capital management employee practice award perfect score cent corporate equality human right campaign foundation list good place work gay lesbian bisexual transgender equality name good company work mother magazine th consecutive year award platinum honour workplace lifestyle programme national business group health identify leader provide healthy workplace promote healthy lifestyle employee family home responsibility people corporate responsibility report people good employment practice essential achieve business strategy goal good place good people good work employ people country world essential characteristic good workplace integrity diversity inclusion development creativity integrity critical gsk spirit define culture behaviour expect employee failure integrity risk damage longterm success diversity inclusion workforce demonstrate commitment equal opportunity enhance business diversity inclusion help attract good people country operate wide range perspective draw enhance understand local market need development employee mean likely stay gsk contribute good success encourage employee achieve potential training programme thejob development offer supportive safe work environment competitive reward package creativity foster good work environment aim gsk workplace empower people creative innovative work benefit company shareholder customer patient employment award selection employment awards gsk uk rank fourth britain employer survey crf international publish guardian book good class engineering science shortlist good graduate employer target award vote graduate postgraduate receive time employer choice research development award base result undergraduate interview rank th time graduate employer survey list organisation new graduate want work employee benefit award effective use employee financial education workplace award employee benefit magazine highly commend pricewaterhousecooper build public trust award people report category base disclosure strength human capital management employee practice award perfect score cent corporate equality human right campaign foundation list good place work gay lesbian bisexual transgender equality name good company work mother magazine th consecutive year award platinum honour workplace lifestyle programme national business group health identify leader provide healthy workplace promote healthy lifestyle employee family home responsibility people corporate responsibility report people good employment practice essential achieve business strategy goal good place good people good work employ people country world essential characteristic good workplace integrity diversity inclusion development creativity integrity critical gsk spirit define culture behaviour expect employee failure integrity risk damage longterm success diversity inclusion workforce demonstrate commitment equal opportunity enhance business diversity inclusion help attract good people country operate wide range perspective draw enhance understand local market need development employee mean likely stay gsk contribute good success encourage employee achieve potential training programme thejob development offer supportive safe work environment competitive reward package creativity foster good work environment aim gsk workplace empower people creative innovative work benefit company shareholder customer patient employment award selection employment awards gsk uk rank fourth britain employer survey crf international publish guardian book good class engineering science shortlist good graduate employer target award vote graduate postgraduate receive time employer choice research development award base result undergraduate interview rank th time graduate employer survey list organisation new graduate want work employee benefit award effective use employee financial education workplace award employee benefit magazine highly commend pricewaterhousecooper build public trust award people report category base disclosure strength human capital management employee practice award perfect score cent corporate equality human right campaign foundation list good place work gay lesbian bisexual transgender equality name good company work mother magazine th consecutive year award platinum honour workplace lifestyle programme national business group health identify leader provide healthy workplace promote healthy lifestyle employee family home responsibility people culture behaviour corporate responsibility report culture behaviour mission improve quality human life enable people feel well live long place great emphasis achieve deliver achievement integrity critical gsk spirit define culture behaviour expect employee culture passionate people patientfocuse performance integrity behaviour innovative thinking engage develop lead people achieve excellence mission spirit help employee deal new challenge maintain clear focus raise awareness gsk spirit help employee understand adopt principle workshop team meeting presentation award work individually empower employee empowerment mean trust employee recognise rewarding achieve objective helps encourage innovation entrepreneurship good employee morale empower employee responsibility task able prioritise well decision quickly effectively achieve culture individual empowerment gsk motivate staff effective improve ability deal challenge home responsibility people culture behaviour corporate responsibility report culture behaviour mission improve quality human life enable people feel well live long place great emphasis achieve deliver achievement integrity critical gsk spirit define culture behaviour expect employee culture passionate people patientfocuse performance integrity behaviour innovative thinking engage develop lead people achieve excellence mission spirit help employee deal new challenge maintain clear focus raise awareness gsk spirit help employee understand adopt principle workshop team meeting presentation award work individually empower employee empowerment mean trust employee recognise rewarding achieve objective helps encourage innovation entrepreneurship good employee morale empower employee responsibility task able prioritise well decision quickly effectively achieve culture individual empowerment gsk motivate staff effective improve ability deal challenge home responsibility people restructure corporate responsibility report restructuring october announce threeyear operational excellence programme improve effectiveness productivity operation launch programme response challenge business environment forecast deliver annual pretax saving million february announce expansion restructure programme realise increase pretax annual saving billion saving restructuring mitigate decline expect gross margin product mix change high percentage sale generate vaccine consumer healthcare emerge market support investment strategic priority programme include initiative streamline manufacturing adapt selling model improve efficiency rd conscious effect programme inevitably employee option exist achieve financial goal preserve job consult employee representative implement measure affect outsource site closure staff reduction speak affect employee local regulation allow work council trade union employee representative appropriate aim treat employee dignity respect offer wide range support affect employee include competitive severance package outplacement support assistance find alternative employment career counselling retraining work hard maintain morale employee gsk home responsibility people restructure corporate responsibility report restructuring october announce threeyear operational excellence programme improve effectiveness productivity operation launch programme response challenge business environment forecast deliver annual pretax saving million february announce expansion restructure programme realise increase pretax annual saving billion saving restructuring mitigate decline expect gross margin product mix change high percentage sale generate vaccine consumer healthcare emerge market support investment strategic priority programme include initiative streamline manufacturing adapt selling model improve efficiency rd conscious effect programme inevitably employee option exist achieve financial goal preserve job consult employee representative implement measure affect outsource site closure staff reduction speak affect employee local regulation allow work council trade union employee representative appropriate aim treat employee dignity respect offer wide range support affect employee include competitive severance package outplacement support assistance find alternative employment career counselling retraining work hard maintain morale employee gsk home responsibility people consultation corporate responsibility report consultation europe staff work council european employee consultation forum meet regularly provide opportunity employee company management discuss key issue development business recognise trade union consultation collective bargaining country worldwide european employee consultation forum include employee representative eu country work alongside national consultation process govern uk law operating subcommittee employee representative meet time year management representative receive update review proposal affect structure business extraordinary operating subcommittee meeting call need arise forum meet year annual meeting receive business update senior gsk executive eddie gray president gsk pharmaceuticals europe business leader speak opportunity present new product rd pipeline challenge growth europe gsk vision develop consumer healthcare business discuss issue national consultation forum example uk information consultation ic forum consist gsk elect employee representative seven manager meet time year ic forum review amend number gsk uk policy include drive company business education special leave forum continue review ukwide redeployment selection guideline redundancy proposal handle pension legislation change take effect april forum receive presentation strategy senior manager global manufacturing supply rd home responsibility people consultation corporate responsibility report consultation europe staff work council european employee consultation forum meet regularly provide opportunity employee company management discuss key issue development business recognise trade union consultation collective bargaining country worldwide european employee consultation forum include employee representative eu country work alongside national consultation process govern uk law operating subcommittee employee representative meet time year management representative receive update review proposal affect structure business extraordinary operating subcommittee meeting call need arise forum meet year annual meeting receive business update senior gsk executive eddie gray president gsk pharmaceuticals europe business leader speak opportunity present new product rd pipeline challenge growth europe gsk vision develop consumer healthcare business discuss issue national consultation forum example uk information consultation ic forum consist gsk elect employee representative seven manager meet time year ic forum review amend number gsk uk policy include drive company business education special leave forum continue review ukwide redeployment selection guideline redundancy proposal handle pension legislation change take effect april forum receive presentation strategy senior manager global manufacturing supply rd home responsibility people communication corporate responsibility report communication approach performance plan good twoway communication employee vital aim inform involved company activity provide opportunity feedback internal communication channel include facetoface communication example town hall style meeting lunch corporate executive team conference team meeting gsk experience programme new starter mandatory twoday induction programme teach new employee uk gsk feedback indicate programme help feel value involved country arrange induction programme locally spirit internal magazine print distribute copy company time year spirit publish intranet mygsk reach broad audience print allow employee easily feedback article read global intranet site mygsk provide update company industry news large range information resource employee mygsk feature employee include myceo dedicated intranet staff pose question chief executive officer ceo member corporate executive team employee ask approximately question month ceo answer post regularly site ambassador intranet community provide reference material information tool employee use reference include presentation fact figure interactive intranet feature story allow employee share story inspire impact work company email cascade system message send business leader share employee example detail late financial result survey enable monitor employee engagement help track impact internal communication home responsibility people communication corporate responsibility report communication approach performance plan good twoway communication employee vital aim inform involved company activity provide opportunity feedback internal communication channel include facetoface communication example town hall style meeting lunch corporate executive team conference team meeting gsk experience programme new starter mandatory twoday induction programme teach new employee uk gsk feedback indicate programme help feel value involved country arrange induction programme locally spirit internal magazine print distribute copy company time year spirit publish intranet mygsk reach broad audience print allow employee easily feedback article read global intranet site mygsk provide update company industry news large range information resource employee mygsk feature employee include myceo dedicated intranet staff pose question chief executive officer ceo member corporate executive team employee ask approximately question month ceo answer post regularly site ambassador intranet community provide reference material information tool employee use reference include presentation fact figure interactive intranet feature story allow employee share story inspire impact work company email cascade system message send business leader share employee example detail late financial result survey enable monitor employee engagement help track impact internal communication home responsibility people communication corporate responsibility report communication approach performance plan internal communication way communicate employee ceo communication ceo designate andrew witty hold employee forum employee world help inform strategic priority gsk ceo andrew witty host global employee broadcast record live employee audience broadcast available employee view year video demand online video library gsktv ceo advisory board establish act informal sounding board idea board fill employee company communicate senior leader hold meeting senior leader april september support alignment different part business new strategic priority attend leader respectively online communication launch new feature company intranet mygsk include new myceo discussion forum call let talk design support transition new ceo receive comment employee december employee send question myceo qa facility online version employee magazine spirit september redesign magazine print cent recycle chlorinefree paper gsktv online multimedia library allow employee view download range video organisation new internal website provide employee information event flu pandemic read gsk flu pandemic preparedness business communication business unit communicate directly employee intranet town hall meeting facetoface meeting broadcast video message member corporate executive team run live web chat host qa session intranet community ensure aware area concern region business unit functional area employee survey conduct global leadership survey year track management view range issue survey run measure manager perception progress achieve new strategic priority introduce plan continually review effectiveness communication improve employee encourage ask question comment information provide thep age communication channel use technology update easy encourage direct communication discussion employee expand use technology social medium tool encourage great collaboration communication gsk break traditional communication barriershome responsibility people communication corporate responsibility report communication approach performance plan internal communication way communicate employee ceo communication ceo designate andrew witty hold employee forum employee world help inform strategic priority gsk ceo andrew witty host global employee broadcast record live employee audience broadcast available employee view year video demand online video library gsktv ceo advisory board establish act informal sounding board idea board fill employee company communicate senior leader hold meeting senior leader april september support alignment different part business new strategic priority attend leader respectively online communication launch new feature company intranet mygsk include new myceo discussion forum call let talk design support transition new ceo receive comment employee december employee send question myceo qa facility online version employee magazine spirit september redesign magazine print cent recycle chlorinefree paper gsktv online multimedia library allow employee view download range video organisation new internal website provide employee information event flu pandemic read gsk flu pandemic preparedness business communication business unit communicate directly employee intranet town hall meeting facetoface meeting broadcast video message member corporate executive team run live web chat host qa session intranet community ensure aware area concern region business unit functional area employee survey conduct global leadership survey year track management view range issue survey run measure manager perception progress achieve new strategic priority introduce plan continually review effectiveness communication improve employee encourage ask question comment information provide communication channel use technology update easy encourage direct communication discussion employee expand use technology social medium tool encourage great collaboration communication gsk break traditional communication barrier home responsibility people communication corporate responsibility report communication approach performance plan internal communication way communicate employee ceo communication ceo designate andrew witty hold employee forum employee world help inform strategic priority gsk ceo andrew witty host global employee broadcast record live employee audience broadcast available employee view year video demand online video library gsktv ceo advisory board establish act informal sounding board idea board fill employee company communicate senior leader hold meeting senior leader april september support alignment different part business new strategic priority attend leader respectively online communication launch new feature company intranet mygsk include new myceo discussion forum call let talk design support transition new ceo receive comment employee december employee send question myceo qa facility online version employee magazine spirit september redesign magazine print cent recycle chlorinefree paper gsktv online multimedia library allow employee view download range video organisation new internal website provide employee information event flu pandemic read gsk flu pandemic preparedness business communication business unit communicate directly employee intranet town hall meeting facetoface meeting broadcast video message member corporate executive team run live web chat host qa session intranet community ensure aware area concern region business unit functional area employee survey conduct global leadership survey year track management view range issue survey run measure manager perception progress achieve new strategic priority introduce plan continually review effectiveness communication improve employee encourage ask question comment information provide communication channel use technology update easy encourage direct communication discussion employee expand use technology social medium tool encourage great collaboration communication gsk break traditional communication barrier home responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plan gsk recognise value different perspective experience bring gsk aim recruit diverse range employee global workforce respect employee include talented people workforce regardless race gender sexuality age religion belief disability require medical testing prerequisite employment aim adopt inclusive work practice create environment employee feel individually collectively empower develop contribute business potential diverse inclusive business help gsk recruit retain good people job enable understand meet need diverse patient customer consumer global diversity policy commitment set global diversity policy corporate executive team endorse policy relate activity annual multicultural marketing diversity award employee expect comply policy allegation discrimination take extremely seriously fully investigate finding act business diversity champion employee promote diversity issue uk diversity inclusion di steering committee human resource manager line manager specific responsibility diversity inclusion committee run diversity awareness campaign train session gsk monitor report gender diversity management uk employee network employee network important element diversity inclusion programme support professional growth provide forum people similar interest background meet discuss share experience address problem area help engage empower employee network important source expertise diversity issue gsk manager engage network improve understand employee different background network help media marketing team understand diverse customer stakeholder gsk network asian african american hispanic gay lesbian bisexual transgender employee network mature employee employee early career woman leadership veteran network executive sponsor help set achieve goal obtain resource promote network objective senior management disability work ensure people disability access range recruitment career opportunity gsk uk partner employer forum disability strive disability confident organisation disability confidence concept develop employer forum describe company create culture inclusion remove barrier access adjustment enable individual disability contribute employee customer partner hold tick symbol jobcentreplus demonstrate gsk commitment employ disabled people read information approach diversity inclusion positively manage hiv workplace discriminate prospective current employee base hiv status require testing prerequisite employment maintain medical confidentiality time provide information training staff hivaid prevention addressing problem stigma relate disease provide hivaid test voluntary counselling treatment programme employee family country easily available government healthcare programme offer preferentially price antiretroviral equivalent notforprofit arrangement employers subsahara africa workplace clinicshome responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plan gsk recognise value different perspective experience bring gsk aim recruit diverse range employee global workforce respect employee include talented people workforce regardless race gender sexuality age religion belief disability require medical testing prerequisite employment aim adopt inclusive work practice create environment employee feel individually collectively empower develop contribute business potential diverse inclusive business help gsk recruit retain good people job enable understand meet need diverse patient customer consumer global diversity policy commitment set global diversity policy corporate executive team endorse policy relate activity annual multicultural marketing diversity award employee expect comply policy allegation discrimination take extremely seriously fully investigate finding act business diversity champion employee promote diversity issue uk diversity inclusion di steering committee human resource manager line manager specific responsibility diversity inclusion committee run diversity awareness campaign train session gsk monitor report gender diversity management uk employee network employee network important element diversity inclusion programme support professional growth provide forum people similar interest background meet discuss share experience address problem area help engage empower employee network important source expertise diversity issue gsk manager engage network improve understand employee different background network help media marketing team understand diverse customer stakeholder gsk network asian african american hispanic gay lesbian bisexual transgender employee network mature employee employee early career woman leadership veteran network executive sponsor help set achieve goal obtain resource promote network objective senior management disability work ensure people disability access range recruitment career opportunity gsk uk partner employer forum disability strive disability confident organisation disability confidence concept develop employer forum describe company create culture inclusion remove barrier access adjustment enable individual disability contribute employee customer partner hold tick symbol jobcentreplus demonstrate gsk commitment employ disabled people read information approach diversity inclusion positively manage hiv workplace discriminate prospective current employee base hiv status require testing prerequisite employment maintain medical confidentiality time provide information training staff hivaid prevention addressing problem stigma relate disease provide hivaid test voluntary counselling treatment programme employee family country easily available government healthcare programme offer preferentially price antiretroviral equivalent notforprofit arrangement employers subsahara africa workplace clinics home responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plan gsk recognise value different perspective experience bring gsk aim recruit diverse range employee global workforce respect employee include talented people workforce regardless race gender sexuality age religion belief disability require medical testing prerequisite employment aim adopt inclusive work practice create environment employee feel individually collectively empower develop contribute business potential diverse inclusive business help gsk recruit retain good people job enable understand meet need diverse patient customer consumer global diversity policy commitment set global diversity policy corporate executive team endorse policy relate activity annual multicultural marketing diversity award employee expect comply policy allegation discrimination take extremely seriously fully investigate finding act business diversity champion employee promote diversity issue uk diversity inclusion di steering committee human resource manager line manager specific responsibility diversity inclusion committee run diversity awareness campaign train session gsk monitor report gender diversity management uk employee network employee network important element diversity inclusion programme support professional growth provide forum people similar interest background meet discuss share experience address problem area help engage empower employee network important source expertise diversity issue gsk manager engage network improve understand employee different background network help media marketing team understand diverse customer stakeholder gsk network asian african american hispanic gay lesbian bisexual transgender employee network mature employee employee early career woman leadership veteran network executive sponsor help set achieve goal obtain resource promote network objective senior management disability work ensure people disability access range recruitment career opportunity gsk uk partner employer forum disability strive disability confident organisation disability confidence concept develop employer forum describe company create culture inclusion remove barrier access adjustment enable individual disability contribute employee customer partner hold tick symbol jobcentreplus demonstrate gsk commitment employ disabled people read information approach diversity inclusion positively manage hiv workplace discriminate prospective current employee base hiv status require testing prerequisite employment maintain medical confidentiality time provide information training staff hivaid prevention addressing problem stigma relate disease provide hivaid test voluntary counselling treatment programme employee family country easily available government healthcare programme offer preferentially price antiretroviral equivalent notforprofit arrangement employers subsahara africa workplace clinics home responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plan gender diversity please percentage woman management increase incrementally year lot room improvement gender diversity management cent position hold woman worldwide corporate executive team senior vice president vice president director grade manager grade management position gender equality workplace affect factor external gsk include requirement family life flexible working policy help employee balance demand work home life particularly beneficial care family responsibility example offer parttime working job share remote work read programme encourage woman science woman science event scientific women scholarship programme ethnic diversity minority define black hispanics asians pacific islander american indians alaskan native cent workforce compare cent cent cent uk ethnic minority account cent employee compare cent cent cent ethnic minority account cent uk population england wale uk census use uk commission racial equality definition ethnic minority include identify white british mean people identify white irish north american european include minority measure diversity uk count number employee define non white cent employee define nonwhite compare cent cent cent ethnic minority ethnic minority uk multicultural marketing diversity award annual multicultural marketing diversity award aim inspire employee find creative way reach broad range potential employee customer community award give category employee attraction development retention multicultural marketing sale community outreach diversity ambassador awards recognise project team individual awardwinne project include initiative year increase representation diverse subject clinical trial cent cent slightly high overall minority population literacy programme teach indian manufacturing employee sign name official document instead thumb print read case study literacy programme plan plan simplify approach diversity inclusion ensure maximise employee empowermenthome responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plan gender diversity please percentage woman management increase incrementally year lot room improvement gender diversity management cent position hold woman worldwide corporate executive team senior vice president vice president director grade manager grade management position gender equality workplace affect factor external gsk include requirement family life flexible working policy help employee balance demand work home life particularly beneficial care family responsibility example offer parttime working job share remote work read programme encourage woman science woman science event scientific women scholarship programme ethnic diversity minority define black hispanics asians pacific islander american indians alaskan native cent workforce compare cent cent cent uk ethnic minority account cent employee compare cent cent cent ethnic minority account cent uk population england wale uk census use uk commission racial equality definition ethnic minority include identify white british mean people identify white irish north american european include minority measure diversity uk count number employee define non white cent employee define nonwhite compare cent cent cent ethnic minority ethnic minority uk multicultural marketing diversity award annual multicultural marketing diversity award aim inspire employee find creative way reach broad range potential employee customer community award give category employee attraction development retention multicultural marketing sale community outreach diversity ambassador awards recognise project team individual awardwinne project include initiative year increase representation diverse subject clinical trial cent cent slightly high overall minority population literacy programme teach indian manufacturing employee sign name official document instead thumb print read case study literacy programme plan plan simplify approach diversity inclusion ensure maximise employee empowerment home responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plan gender diversity please percentage woman management increase incrementally year lot room improvement gender diversity management cent position hold woman worldwide corporate executive team senior vice president vice president director grade manager grade management position gender equality workplace affect factor external gsk include requirement family life flexible working policy help employee balance demand work home life particularly beneficial care family responsibility example offer parttime working job share remote work read programme encourage woman science woman science event scientific women scholarship programme ethnic diversity minority define black hispanics asians pacific islander american indians alaskan native cent workforce compare cent cent cent uk ethnic minority account cent employee compare cent cent cent ethnic minority account cent uk population england wale uk census use uk commission racial equality definition ethnic minority include identify white british mean people identify white irish north american european include minority measure diversity uk count number employee define non white cent employee define nonwhite compare cent cent cent ethnic minority ethnic minority uk multicultural marketing diversity award annual multicultural marketing diversity award aim inspire employee find creative way reach broad range potential employee customer community award give category employee attraction development retention multicultural marketing sale community outreach diversity ambassador awards recognise project team individual awardwinne project include initiative year increase representation diverse subject clinical trial cent cent slightly high overall minority population literacy programme teach indian manufacturing employee sign name official document instead thumb print read case study literacy programme plan plan simplify approach diversity inclusion ensure maximise employee empowerment home responsibility people train development corporate responsibility report train development approach performance plan train development opportunity help employee feel value engaged work gsk provide workrelate training course employee leadership training manager focus provide people right behaviour expertise job skill need apply knowledge effectively goal individual achieve potential contribute fully company performance conduct regular appraisal identify training need help employee set achieve development objective operate degree assessment manager ensure receive objective feedback performance employee manage colleague work manager training carry business function online example mylearning intranet site uk offer project secondment help employee learn new skill leadership development identify highperforme employee potential leader business function annual talent management cycle manager accountable develop talent successor priority leader process ensure diverse highperforming talent require deliver business strategy reflect global growth gsk talented people participate leadership programme connect senior management programme chief executive forum leadership framework help employee fulfil potential leader field contribute fully business performance specifically help develop behaviour distinguish highperforming leader include innovative thinking engage develop lead people achieve excellence work understand behaviour personal responsibility action continue perform integrity enhance expertise include technical functional skill broad knowledge contribute directly gsk overall performance likely unique position role function employee effectively use apply process practice gsk provide extensive health safety environment train employee home responsibility people train development corporate responsibility report train development approach performance plan train development opportunity help employee feel value engaged work gsk provide workrelate training course employee leadership training manager focus provide people right behaviour expertise job skill need apply knowledge effectively goal individual achieve potential contribute fully company performance conduct regular appraisal identify training need help employee set achieve development objective operate degree assessment manager ensure receive objective feedback performance employee manage colleague work manager training carry business function online example mylearning intranet site uk offer project secondment help employee learn new skill leadership development identify highperforme employee potential leader business function annual talent management cycle manager accountable develop talent successor priority leader process ensure diverse highperforming talent require deliver business strategy reflect global growth gsk talented people participate leadership programme connect senior management programme chief executive forum leadership framework help employee fulfil potential leader field contribute fully business performance specifically help develop behaviour distinguish highperforming leader include innovative thinking engage develop lead people achieve excellence work understand behaviour personal responsibility action continue perform integrity enhance expertise include technical functional skill broad knowledge contribute directly gsk overall performance likely unique position role function employee effectively use apply process practice gsk provide extensive health safety environment train employee home responsibility people train development corporate responsibility report train development approach performance plan majority employee receive annual performance appraisal performance development planning pdp programme compliance requirement measure local level know twothird employee receive appraisal pdp programme assess employee implement gsk business principle work appraisal impact bonus payment future career development focus embed leadership framework include follow training initiative hot topic training focus lead times transformational change nearly manager senior leader attend workshop teach gsk leader importance coach staff technique effectively manager take workshop online development resource available englishspeake employee provide variety step build leadership skill offer learn programme gsk employee online learn management system plan leadership organisation development function work support gsk strategic priority plan include forecasting deliver capability need future growth success gsk addition leadership development continue area focus include refining behaviour necessary successful leadership support prescribe learn development opportunity experience home responsibility people train development corporate responsibility report train development approach performance plan majority employee receive annual performance appraisal performance development planning pdp programme compliance requirement measure local level know twothird employee receive appraisal pdp programme assess employee implement gsk business principle work appraisal impact bonus payment future career development focus embed leadership framework include follow training initiative hot topic training focus lead times transformational change nearly manager senior leader attend workshop teach gsk leader importance coach staff technique effectively manager take workshop online development resource available englishspeake employee provide variety step build leadership skill offer learn programme gsk employee online learn management system plan leadership organisation development function work support gsk strategic priority plan include forecasting deliver capability need future growth success gsk addition leadership development continue area focus include refining behaviour necessary successful leadership support prescribe learn development opportunity experience home responsibility people reward recognition corporate responsibility report reward recognition offer employee competitive salary base industry benchmark performancerelate incentive benefit help attract retain good people particularly reward employee innovation good performance reward leader empower staff pay strategy manager base programme call totalreward help recognise good performance enable manager share gsk success use feedback manager identify type reward prefer component totalreward include cash include salary bonus incentive include longterm incentive eligible employee recognition award salary allocate define band different employment level saving choice pension provision share scheme lifestyle benefit example healthcare childcare support employee car ownership programme totalreward apply gsk manager world component part employee package differ country accordance local legislation good practice share ownership share ownership scheme help create culture ownership employee country share ownership opportunity exist open employee high level participation example uk cent employee participate sharesave scheme cent sharereward scheme home responsibility people reward recognition corporate responsibility report reward recognition offer employee competitive salary base industry benchmark performancerelate incentive benefit help attract retain good people particularly reward employee innovation good performance reward leader empower staff pay strategy manager base programme call totalreward help recognise good performance enable manager share gsk success use feedback manager identify type reward prefer component totalreward include cash include salary bonus incentive include longterm incentive eligible employee recognition award salary allocate define band different employment level saving choice pension provision share scheme lifestyle benefit example healthcare childcare support employee car ownership programme totalreward apply gsk manager world component part employee package differ country accordance local legislation good practice share ownership share ownership scheme help create culture ownership employee country share ownership opportunity exist open employee high level participation example uk cent employee participate sharesave scheme cent sharereward scheme home responsibility people health safety wellbee corporate responsibility report health safety wellbee keep employee contractor healthy safe priority rigorous management system reduce risk harm employee help stay healthy broad environment health safety sustainability ehss programme right thing improve business performance increase attendance improve productivity reduce healthcare insurance cost home responsibility people health safety wellbee corporate responsibility report health safety wellbee keep employee contractor healthy safe priority rigorous management system reduce risk harm employee help stay healthy broad environment health safety sustainability ehss programme right thing improve business performance increase attendance improve productivity reduce healthcare insurance cost home responsibility people health safety wellbee health safety management corporate responsibility report health safety management manage health safety integrate environment health safety sustainability ehss management system incorporate ehs sustainability vision policy associate standard ehss plan excellence include strategy improve ehss performance employ health safety professional site business unit global level manage health safety risk gsk read ehss management system occupational health safety datum independently assure assurance include personal health wellbeing programme datum audits performance overall environment health safety sustainability audit programme conduct occupational health safety audits site year frequency depend current risk past performance carry frequent visit site base degree risk site health safety performance issue raise previous audits audit result present audit committee board directors occupational health safety target link environmental sustainabilityplan excellencetarget reduce reportable injury illnesse cent year place quartile comparable industry rating systematically assess manage occupational health safety risk performance incident happen identify root cause action prevent reoccurrence believe address cause incident help eliminate risk hazard prevent future occupational injury illness audit gsk site implementation occupational health safety standard overall environment health safety sustainability audits average audit score cent compare target cent good performance see fire prevention site management commitment occupational health safety investigation report injury illnesse emergency planning response site generally weak resilience mental wellbeing control chemical agent use work equipment risk assessment permit work system noise control ergonomic auditor find critical finding indicate high probability incident potentially consequence relate deficiency control risk fall construction project second relate risk fire inadequate management highly flammable liquid issue monitor ensure appropriate action take mitigate risk ensure ongoing compliance active pharmaceutical ingredient manufacturing site fine uk regulator hse process safety incident occur explosion occur irvine uk site involve placebo batch test plant condition control operator injure event thoroughly investigate learning share improvement report corporate responsibility report site receive fine south carolina state occupational safety health administration osha violation forklift regulation concern address site ohsa certification twentysix pharmaceutical consumer healthcare manufacturing site consumer healthcare rd site certify international health safety standard ohsa set goal manufacturing site jointly certify ohsa environmental standard iso end new site certify certify site argentina australia brazil china egypt france germany india japan kenya mexico panama philippine poland saudi arabia spain turkey ukhome responsibility people health safety wellbee health safety management corporate responsibility report health safety management manage health safety integrate environment health safety sustainability ehss management system incorporate ehs sustainability vision policy associate standard ehss plan excellence include strategy improve ehss performance employ health safety professional site business unit global level manage health safety risk gsk read ehss management system occupational health safety datum independently assure assurance include personal health wellbeing programme datum audits performance overall environment health safety sustainability audit programme conduct occupational health safety audits site year frequency depend current risk past performance carry frequent visit site base degree risk site health safety performance issue raise previous audits audit result present audit committee board directors occupational health safety target link environmental sustainabilityplan excellencetarget reduce reportable injury illnesse cent year place quartile comparable industry rating systematically assess manage occupational health safety risk performance incident happen identify root cause action prevent reoccurrence believe address cause incident help eliminate risk hazard prevent future occupational injury illness audit gsk site implementation occupational health safety standard overall environment health safety sustainability audits average audit score cent compare target cent good performance see fire prevention site management commitment occupational health safety investigation report injury illnesse emergency planning response site generally weak resilience mental wellbeing control chemical agent use work equipment risk assessment permit work system noise control ergonomic auditor find critical finding indicate high probability incident potentially consequence relate deficiency control risk fall construction project second relate risk fire inadequate management highly flammable liquid issue monitor ensure appropriate action take mitigate risk ensure ongoing compliance active pharmaceutical ingredient manufacturing site fine uk regulator hse process safety incident occur explosion occur irvine uk site involve placebo batch test plant condition control operator injure event thoroughly investigate learning share improvement report corporate responsibility report site receive fine south carolina state occupational safety health administration osha violation forklift regulation concern address site ohsa certification twentysix pharmaceutical consumer healthcare manufacturing site consumer healthcare rd site certify international health safety standard ohsa set goal manufacturing site jointly certify ohsa environmental standard iso end new site certify certify site argentina australia brazil china egypt france germany india japan kenya mexico panama philippine poland saudi arabia spain turkey uk home responsibility people health safety wellbee health safety management corporate responsibility report health safety management manage health safety integrate environment health safety sustainability ehss management system incorporate ehs sustainability vision policy associate standard ehss plan excellence include strategy improve ehss performance employ health safety professional site business unit global level manage health safety risk gsk read ehss management system occupational health safety datum independently assure assurance include personal health wellbeing programme datum audits performance overall environment health safety sustainability audit programme conduct occupational health safety audits site year frequency depend current risk past performance carry frequent visit site base degree risk site health safety performance issue raise previous audits audit result present audit committee board directors occupational health safety target link environmental sustainabilityplan excellencetarget reduce reportable injury illnesse cent year place quartile comparable industry rating systematically assess manage occupational health safety risk performance incident happen identify root cause action prevent reoccurrence believe address cause incident help eliminate risk hazard prevent future occupational injury illness audit gsk site implementation occupational health safety standard overall environment health safety sustainability audits average audit score cent compare target cent good performance see fire prevention site management commitment occupational health safety investigation report injury illnesse emergency planning response site generally weak resilience mental wellbeing control chemical agent use work equipment risk assessment permit work system noise control ergonomic auditor find critical finding indicate high probability incident potentially consequence relate deficiency control risk fall construction project second relate risk fire inadequate management highly flammable liquid issue monitor ensure appropriate action take mitigate risk ensure ongoing compliance active pharmaceutical ingredient manufacturing site fine uk regulator hse process safety incident occur explosion occur irvine uk site involve placebo batch test plant condition control operator injure event thoroughly investigate learning share improvement report corporate responsibility report site receive fine south carolina state occupational safety health administration osha violation forklift regulation concern address site ohsa certification twentysix pharmaceutical consumer healthcare manufacturing site consumer healthcare rd site certify international health safety standard ohsa set goal manufacturing site jointly certify ohsa environmental standard iso end new site certify certify site argentina australia brazil china egypt france germany india japan kenya mexico panama philippine poland saudi arabia spain turkey uk home responsibility people health safety wellbee hazard assessment communication corporate responsibility report hazard assessment communication assessment understand intrinsic hazard material produce use research development manufacture important step enable effectively manage health safety risk prevent damage environment occupational toxicologist environmental scientist assess material hazard product development increasingly use computerbase modelling vitro method instead animal test use hazard information assign occupational environmental exposure limit help guide design system protect employee health protect environment chemical contamination hazard assessment help meet regulatory requirement new eu registration evaluation authorisation chemical reach legislation communication provide hazard information enable employee contract manufacture partner customer handle dispose material product safely develop safety data sheet new material product progress development process ensure health safety information readily available staff handle chemical customer product launch distribute safety datum sheet webbase system provide safety information nearly gsk material key manufacturing process chemical include safety datum sheet pharmaceutical biological consumer healthcare product information regularly update available english french german italian portuguese spanish safety datum sheet product available website communicate directly customer fax demand customer response centre safe transport material normal business operation transport material require special handling chemical biological radioactive material finish product network highly train employee oversee transportationrelated activity ensure material transport safe effective manner complie national international law convention ensure employee public environment keep safe use system support track classification emergency information transportation chemical biological radioactive material hazclass system available use rd site manufacture site use sap system manage transport material product understand fire explosion risk inhouse fire explosion laboratory conduct test determine fire explosion property material handle research development manufacturing work primarily drive requirement eu regulations explosive atmosphere directive ec atex manufacturing site receive hazard datum laboratory undertake risk assessment design work practice eliminate reduce risk fire dust explosion home responsibility people health safety wellbee hazard assessment communication corporate responsibility report hazard assessment communication assessment understand intrinsic hazard material produce use research development manufacture important step enable effectively manage health safety risk prevent damage environment occupational toxicologist environmental scientist assess material hazard product development increasingly use computerbase modelling vitro method instead animal test use hazard information assign occupational environmental exposure limit help guide design system protect employee health protect environment chemical contamination hazard assessment help meet regulatory requirement new eu registration evaluation authorisation chemical reach legislation communication provide hazard information enable employee contract manufacture partner customer handle dispose material product safely develop safety data sheet new material product progress development process ensure health safety information readily available staff handle chemical customer product launch distribute safety datum sheet webbase system provide safety information nearly gsk material key manufacturing process chemical include safety datum sheet pharmaceutical biological consumer healthcare product information regularly update available english french german italian portuguese spanish safety datum sheet product available website communicate directly customer fax demand customer response centre safe transport material normal business operation transport material require special handling chemical biological radioactive material finish product network highly train employee oversee transportationrelated activity ensure material transport safe effective manner complie national international law convention ensure employee public environment keep safe use system support track classification emergency information transportation chemical biological radioactive material hazclass system available use rd site manufacture site use sap system manage transport material product understand fire explosion risk inhouse fire explosion laboratory conduct test determine fire explosion property material handle research development manufacturing work primarily drive requirement eu regulations explosive atmosphere directive ec atex manufacturing site receive hazard datum laboratory undertake risk assessment design work practice eliminate reduce risk fire dust explosion home responsibility people health safety wellbee hazard assessment communication corporate responsibility report hazard assessment communication assessment understand intrinsic hazard material produce use research development manufacture important step enable effectively manage health safety risk prevent damage environment occupational toxicologist environmental scientist assess material hazard product development increasingly use computerbase modelling vitro method instead animal test use hazard information assign occupational environmental exposure limit help guide design system protect employee health protect environment chemical contamination hazard assessment help meet regulatory requirement new eu registration evaluation authorisation chemical reach legislation communication provide hazard information enable employee contract manufacture partner customer handle dispose material product safely develop safety data sheet new material product progress development process ensure health safety information readily available staff handle chemical customer product launch distribute safety datum sheet webbase system provide safety information nearly gsk material key manufacturing process chemical include safety datum sheet pharmaceutical biological consumer healthcare product information regularly update available english french german italian portuguese spanish safety datum sheet product available website communicate directly customer fax demand customer response centre safe transport material normal business operation transport material require special handling chemical biological radioactive material finish product network highly train employee oversee transportationrelated activity ensure material transport safe effective manner complie national international law convention ensure employee public environment keep safe use system support track classification emergency information transportation chemical biological radioactive material hazclass system available use rd site manufacture site use sap system manage transport material product understand fire explosion risk inhouse fire explosion laboratory conduct test determine fire explosion property material handle research development manufacturing work primarily drive requirement eu regulations explosive atmosphere directive ec atex manufacturing site receive hazard datum laboratory undertake risk assessment design work practice eliminate reduce risk fire dust explosion home responsibility people health safety wellbee safety programme corporate responsibility report safety programme operate number programme employee contractor safe chemical exposure rigorous procedure control place ensure employee involve develop manufacturing product protect exposure chemical goal cent operation involve handle hazardous compound respirator free mean employee need wear respiratory protective equipment routine production task instead site install technology prevent release hazardous compound work environment example instal contain powder transfer system glovebox technology pilot plant facility cork ireland special containment system new penicillin facility pakistan develop proprietary manufacturing technology greatly reduce operator exposure medicine manufacture gsk site monitor air quality assess exposure hazardous compound implement control protect employee achieve respirator free goal occupational hygienist employee health staff engineer work site regional global level reduce employee exposure chemical end cent operation achieve respirator free level engineering control base occupational hygiene monitoring result continue upgrade engineering control achieve respirator free level control situation engineering control possible employee remain protect appropriate respiratory protective equipment process safety product begin formulation process hazardous material flammable solvent combustible powder scientist look opportunity eliminate use hazardous material green chemistry green technology programme substitution elimination option process safety programme aim ensure safety build manufacturing research development process employee receive training understand risk implement appropriate control engineer use online assessment system develop safe process plant maintenance strategy share hazard information control strategy gsk review update process safety strategy employee injure explosion factory irvine uk result review continue update integrate process safety management system psm ehss management system gsk site include design code contain new engineering standard process safety assessment new engineering standard gap analysis upgrade risk assessment remediation process process safety indicator step embe process safety overall safety culture new training competence programme process safety tool appoint new director process safety safety engineering safety engineering programme focus improve construction plant safety ensure effective emergency response system develop safety engineering guide manage risk fire explosion provide guidance machine guard electrical hazard webbase guide provide standardised approach manage safety risk gsk ensure safety build maintain site worldwide follow programme risk assessment control process construction contractor safety programme capital project ehs review process emergency response programme ergonomics musculoskeletal illness repetitive strain injury lead cause time away work corporate executive team set target reduce number illness injury cent year good workplace job design know ergonomic help employee job effectively reduce risk musculoskeletal illness injury ergonomic improvement team work gsk business assess manage ergonomic risk exist operation plan project team include member area manufacture quality safety health medical service perform work team work identify risk develop solution share good practice globally dedicated ergonomic community intranet addition train facilitator business help manage computerbased ergonomic risk assessment employee assessment identify step reduce discomfort injury relate computer use information ergonomic good practice available employee intranet site effort contribute cent improvement ergonomicsrelate injury illness short target annual percent improvement equivalent cent improvement order meet exceed target increase effort resource area cost productivity gain manufacturing operation example nabha site india manual handling task improve result simplify work process reduce risk injury reduction number employee need perform task people person allow worker focus task reduce risk injury worker improve audit score implementation ergonomic improvement process example kuala lumpur improve ergonomic management risk score cent cent result implement ergonomic improvement process improve overall audit score significant impact introduction new ergonomic improvement team example tianjin facility china major ergonomic improvement initiate new team month result cent reduction report discomfortinjury improve morale gsk ergonomic improvement team give special recognition european safety health council europe widefocus improve manual handle internal recognition global ergonomic community team process example new way work gsk share global resource span function business culture team award cross sector multicultural marketing diversity award driver safety sale representative spend significant amount time drive risk involve road traffic incident aim reduce risk possible worldwide driver safety programme include instruction guideline driver training vehicle selection risk assessment accident report motorbike rider safety manual employee country provide motorbike scooter threequarter gsk commercial business extensive driver safety programme place include drive licence check guidance use mobile phone safety training tracking report incident plan extend site common cause fatality injury remain drive accident cent injury lose time motor vehicle accident cent injury lose time road traffic accident cause death employee fatality injury defibrillator programme people resuscitate automated external defibrillator aeds ae safe easy use portable medical device analyse heart rhythm deliver electric shock victim ventricular fibrillation order restore victim heart rhythm normal begin expand number site aed save life uk key personnel train use aed emergency situation equipment instal estimate gsk site belgium brazil canada egypt france germany india italy japan mexico puerto rico singapore south africa spain risk assessment decide site aed base factor include heart disease risk employee hazard site chemical energise circuit cause cardiac arrest ambulance response timeshome responsibility people health safety wellbee safety programme corporate responsibility report safety programme operate number programme employee contractor safe chemical exposure rigorous procedure control place ensure employee involve develop manufacturing product protect exposure chemical goal cent operation involve handle hazardous compound respirator free mean employee need wear respiratory protective equipment routine production task instead site install technology prevent release hazardous compound work environment example instal contain powder transfer system glovebox technology pilot plant facility cork ireland special containment system new penicillin facility pakistan develop proprietary manufacturing technology greatly reduce operator exposure medicine manufacture gsk site monitor air quality assess exposure hazardous compound implement control protect employee achieve respirator free goal occupational hygienist employee health staff engineer work site regional global level reduce employee exposure chemical end cent operation achieve respirator free level engineering control base occupational hygiene monitoring result continue upgrade engineering control achieve respirator free level control situation engineering control possible employee remain protect appropriate respiratory protective equipment process safety product begin formulation process hazardous material flammable solvent combustible powder scientist look opportunity eliminate use hazardous material green chemistry green technology programme substitution elimination option process safety programme aim ensure safety build manufacturing research development process employee receive training understand risk implement appropriate control engineer use online assessment system develop safe process plant maintenance strategy share hazard information control strategy gsk review update process safety strategy employee injure explosion factory irvine uk result review continue update integrate process safety management system psm ehss management system gsk site include design code contain new engineering standard process safety assessment new engineering standard gap analysis upgrade risk assessment remediation process process safety indicator step embe process safety overall safety culture new training competence programme process safety tool appoint new director process safety safety engineering safety engineering programme focus improve construction plant safety ensure effective emergency response system develop safety engineering guide manage risk fire explosion provide guidance machine guard electrical hazard webbase guide provide standardised approach manage safety risk gsk ensure safety build maintain site worldwide follow programme risk assessment control process construction contractor safety programme capital project ehs review process emergency response programme ergonomics musculoskeletal illness repetitive strain injury lead cause time away work corporate executive team set target reduce number illness injury cent year good workplace job design know ergonomic help employee job effectively reduce risk musculoskeletal illness injury ergonomic improvement team work gsk business assess manage ergonomic risk exist operation plan project team include member area manufacture quality safety health medical service perform work team work identify risk develop solution share good practice globally dedicated ergonomic community intranet addition train facilitator business help manage computerbased ergonomic risk assessment employee assessment identify step reduce discomfort injury relate computer use information ergonomic good practice available employee intranet site effort contribute cent improvement ergonomicsrelate injury illness short target annual percent improvement equivalent cent improvement order meet exceed target increase effort resource area cost productivity gain manufacturing operation example nabha site india manual handling task improve result simplify work process reduce risk injury reduction number employee need perform task people person allow worker focus task reduce risk injury worker improve audit score implementation ergonomic improvement process example kuala lumpur improve ergonomic management risk score cent cent result implement ergonomic improvement process improve overall audit score significant impact introduction new ergonomic improvement team example tianjin facility china major ergonomic improvement initiate new team month result cent reduction report discomfortinjury improve morale gsk ergonomic improvement team give special recognition european safety health council europe widefocus improve manual handle internal recognition global ergonomic community team process example new way work gsk share global resource span function business culture team award cross sector multicultural marketing diversity award driver safety sale representative spend significant amount time drive risk involve road traffic incident aim reduce risk possible worldwide driver safety programme include instruction guideline driver training vehicle selection risk assessment accident report motorbike rider safety manual employee country provide motorbike scooter threequarter gsk commercial business extensive driver safety programme place include drive licence check guidance use mobile phone safety training tracking report incident plan extend site common cause fatality injury remain drive accident cent injury lose time motor vehicle accident cent injury lose time road traffic accident cause death employee fatality injury defibrillator programme people resuscitate automated external defibrillator aeds ae safe easy use portable medical device analyse heart rhythm deliver electric shock victim ventricular fibrillation order restore victim heart rhythm normal begin expand number site aed save life uk key personnel train use aed emergency situation equipment instal estimate gsk site belgium brazil canada egypt france germany india italy japan mexico puerto rico singapore south africa spain risk assessment decide site aed base factor include heart disease risk employee hazard site chemical energise circuit cause cardiac arrest ambulance response timeshome responsibility people health safety wellbee safety programme corporate responsibility report safety programme operate number programme employee contractor safe chemical exposure rigorous procedure control place ensure employee involve develop manufacturing product protect exposure chemical goal cent operation involve handle hazardous compound respirator free mean employee need wear respiratory protective equipment routine production task instead site install technology prevent release hazardous compound work environment example instal contain powder transfer system glovebox technology pilot plant facility cork ireland special containment system new penicillin facility pakistan develop proprietary manufacturing technology greatly reduce operator exposure medicine manufacture gsk site monitor air quality assess exposure hazardous compound implement control protect employee achieve respirator free goal occupational hygienist employee health staff engineer work site regional global level reduce employee exposure chemical end cent operation achieve respirator free level engineering control base occupational hygiene monitoring result continue upgrade engineering control achieve respirator free level control situation engineering control possible employee remain protect appropriate respiratory protective equipment process safety product begin formulation process hazardous material flammable solvent combustible powder scientist look opportunity eliminate use hazardous material green chemistry green technology programme substitution elimination option process safety programme aim ensure safety build manufacturing research development process employee receive training understand risk implement appropriate control engineer use online assessment system develop safe process plant maintenance strategy share hazard information control strategy gsk review update process safety strategy employee injure explosion factory irvine uk result review continue update integrate process safety management system psm ehss management system gsk site include design code contain new engineering standard process safety assessment new engineering standard gap analysis upgrade risk assessment remediation process process safety indicator step embe process safety overall safety culture new training competence programme process safety tool appoint new director process safety safety engineering safety engineering programme focus improve construction plant safety ensure effective emergency response system develop safety engineering guide manage risk fire explosion provide guidance machine guard electrical hazard webbase guide provide standardised approach manage safety risk gsk ensure safety build maintain site worldwide follow programme risk assessment control process construction contractor safety programme capital project ehs review process emergency response programme ergonomics musculoskeletal illness repetitive strain injury lead cause time away work corporate executive team set target reduce number illness injury cent year good workplace job design know ergonomic help employee job effectively reduce risk musculoskeletal illness injury ergonomic improvement team work gsk business assess manage ergonomic risk exist operation plan project team include member area manufacture quality safety health medical service perform work team work identify risk develop solution share good practice globally dedicated ergonomic community intranet addition train facilitator business help manage computerbased ergonomic risk assessment employee assessment identify step reduce discomfort injury relate computer use information ergonomic good practice available employee intranet site effort contribute cent improvement ergonomicsrelate injury illness short target annual percent improvement equivalent cent improvement order meet exceed target increase effort resource area cost productivity gain manufacturing operation example nabha site india manual handling task improve result simplify work process reduce risk injury reduction number employee need perform task people person allow worker focus task reduce risk injury worker improve audit score implementation ergonomic improvement process example kuala lumpur improve ergonomic management risk score cent cent result implement ergonomic improvement process improve overall audit score significant impact introduction new ergonomic improvement team example tianjin facility china major ergonomic improvement initiate new team month result cent reduction report discomfortinjury improve morale gsk ergonomic improvement team give special recognition european safety health council europe widefocus improve manual handle internal recognition global ergonomic community team process example new way work gsk share global resource span function business culture team award cross sector multicultural marketing diversity award driver safety sale representative spend significant amount time drive risk involve road traffic incident aim reduce risk possible worldwide driver safety programme include instruction guideline driver training vehicle selection risk assessment accident report motorbike rider safety manual employee country provide motorbike scooter threequarter gsk commercial business extensive driver safety programme place include drive licence check guidance use mobile phone safety training tracking report incident plan extend site common cause fatality injury remain drive accident cent injury lose time motor vehicle accident cent injury lose time road traffic accident cause death employee fatality injury defibrillator programme people resuscitate automated external defibrillator aeds ae safe easy use portable medical device analyse heart rhythm deliver electric shock victim ventricular fibrillation order restore victim heart rhythm normal begin expand number site aed save life uk key personnel train use aed emergency situation equipment instal estimate gsk site belgium brazil canada egypt france germany india italy japan mexico puerto rico singapore south africa spain risk assessment decide site aed base factor include heart disease risk employee hazard site chemical energise circuit cause cardiac arrest ambulance response time home responsibility people health safety wellbee safety programme corporate responsibility report safety programme operate number programme employee contractor safe chemical exposure rigorous procedure control place ensure employee involve develop manufacturing product protect exposure chemical goal cent operation involve handle hazardous compound respirator free mean employee need wear respiratory protective equipment routine production task instead site install technology prevent release hazardous compound work environment example instal contain powder transfer system glovebox technology pilot plant facility cork ireland special containment system new penicillin facility pakistan develop proprietary manufacturing technology greatly reduce operator exposure medicine manufacture gsk site monitor air quality assess exposure hazardous compound implement control protect employee achieve respirator free goal occupational hygienist employee health staff engineer work site regional global level reduce employee exposure chemical end cent operation achieve respirator free level engineering control base occupational hygiene monitoring result continue upgrade engineering control achieve respirator free level control situation engineering control possible employee remain protect appropriate respiratory protective equipment process safety product begin formulation process hazardous material flammable solvent combustible powder scientist look opportunity eliminate use hazardous material green chemistry green technology programme substitution elimination option process safety programme aim ensure safety build manufacturing research development process employee receive training understand risk implement appropriate control engineer use online assessment system develop safe process plant maintenance strategy share hazard information control strategy gsk review update process safety strategy employee injure explosion factory irvine uk result review continue update integrate process safety management system psm ehss management system gsk site include design code contain new engineering standard process safety assessment new engineering standard gap analysis upgrade risk assessment remediation process process safety indicator step embe process safety overall safety culture new training competence programme process safety tool appoint new director process safety safety engineering safety engineering programme focus improve construction plant safety ensure effective emergency response system develop safety engineering guide manage risk fire explosion provide guidance machine guard electrical hazard webbase guide provide standardised approach manage safety risk gsk ensure safety build maintain site worldwide follow programme risk assessment control process construction contractor safety programme capital project ehs review process emergency response programme ergonomics musculoskeletal illness repetitive strain injury lead cause time away work corporate executive team set target reduce number illness injury cent year good workplace job design know ergonomic help employee job effectively reduce risk musculoskeletal illness injury ergonomic improvement team work gsk business assess manage ergonomic risk exist operation plan project team include member area manufacture quality safety health medical service perform work team work identify risk develop solution share good practice globally dedicated ergonomic community intranet addition train facilitator business help manage computerbased ergonomic risk assessment employee assessment identify step reduce discomfort injury relate computer use information ergonomic good practice available employee intranet site effort contribute cent improvement ergonomicsrelate injury illness short target annual percent improvement equivalent cent improvement order meet exceed target increase effort resource area cost productivity gain manufacturing operation example nabha site india manual handling task improve result simplify work process reduce risk injury reduction number employee need perform task people person allow worker focus task reduce risk injury worker improve audit score implementation ergonomic improvement process example kuala lumpur improve ergonomic management risk score cent cent result implement ergonomic improvement process improve overall audit score significant impact introduction new ergonomic improvement team example tianjin facility china major ergonomic improvement initiate new team month result cent reduction report discomfortinjury improve morale gsk ergonomic improvement team give special recognition european safety health council europe widefocus improve manual handle internal recognition global ergonomic community team process example new way work gsk share global resource span function business culture team award cross sector multicultural marketing diversity award driver safety sale representative spend significant amount time drive risk involve road traffic incident aim reduce risk possible worldwide driver safety programme include instruction guideline driver training vehicle selection risk assessment accident report motorbike rider safety manual employee country provide motorbike scooter threequarter gsk commercial business extensive driver safety programme place include drive licence check guidance use mobile phone safety training tracking report incident plan extend site common cause fatality injury remain drive accident cent injury lose time motor vehicle accident cent injury lose time road traffic accident cause death employee fatality injury defibrillator programme people resuscitate automated external defibrillator aeds ae safe easy use portable medical device analyse heart rhythm deliver electric shock victim ventricular fibrillation order restore victim heart rhythm normal begin expand number site aed save life uk key personnel train use aed emergency situation equipment instal estimate gsk site belgium brazil canada egypt france germany india italy japan mexico puerto rico singapore south africa spain risk assessment decide site aed base factor include heart disease risk employee hazard site chemical energise circuit cause cardiac arrest ambulance response time home responsibility people health safety wellbee health wellbeing programme corporate responsibility report health wellbeing programme gsk offer programme boost employee health wellbeing create sustain energy engagement work turn help improve business performance gsk help improve employee wellbeing offer flexible working option health wellbeing initiative include health risk appraisal screening diabete hypertension smoking control support fitness nutritional advice immunisation prevention screening initiative focus lead cause illness disability employee include depression nonwork relate injury heart disease stroke respiratory infection increasingly focus way encourage team personal energy resilience time high pressure employee health wellbeing programme national awards excellence platinum awards national business group health nbgh health promotion board singapore team resilience programme receive award nbgh innovation commitment provide lifestyle improvement programme design improve healthy lifestyle employee energy resilience define resilience describe skill trait necessary success highpressure work environment skill behaviour help prevent mental illness stress leading cause ill health disability work energy performance employee energy focus well perform task efficiently energy performance ep programme design boost energy level help employee invest energy right way work home uptake good employee participate ep workshops employee country attend ep workshop end cent report significant improvement physical mental performance emotional energy participant find performance improvement persist month workshop personal resilience run workshop employee want enhance build personal resilience focus improve work home life programme aim help employee increase focus energy confidence help reduce tension anxiety fatigue programme start employee participate programme team resilience healthy collaborative motivated team critical business success team resilience programme help employee manager identify source pressure team process complexity lack workplace flexibility accountability team work agree action plan address concern programme help team control work eliminate manage source pressure lead ill health inefficiency programme begin complete team country comprise employee end participant report cent reduction workplace pressure cent drop worklife conflict cent increase satisfaction gsk employer wellbee worklife balance gsk offer programme improve health employee family find increase employee commitment productivity reduce absenteeism cost ill health support vary country accord local need site use public health gsk datum identify high risk area investment lead significant health cost improvement programme include benefit onsite health fitness centre flexible working arrangement immunisation regular medical checkup assistance stop smoke disease screen management family support service health education assist employee suffer chronic disease ensure access correct longterm treatment support programme help local healthcare service focus health education prevention awareness management current condition create network gsk employee health professional share health wellbee good practice gsk support key public health effort world aids day world health organization health day tobacco free day global handwash day tophome responsibility people health safety wellbee health wellbeing programme corporate responsibility report health wellbeing programme gsk offer programme boost employee health wellbeing create sustain energy engagement work turn help improve business performance gsk help improve employee wellbeing offer flexible working option health wellbeing initiative include health risk appraisal screening diabete hypertension smoking control support fitness nutritional advice immunisation prevention screening initiative focus lead cause illness disability employee include depression nonwork relate injury heart disease stroke respiratory infection increasingly focus way encourage team personal energy resilience time high pressure employee health wellbeing programme national awards excellence platinum awards national business group health nbgh health promotion board singapore team resilience programme receive award nbgh innovation commitment provide lifestyle improvement programme design improve healthy lifestyle employee energy resilience define resilience describe skill trait necessary success highpressure work environment skill behaviour help prevent mental illness stress leading cause ill health disability work energy performance employee energy focus well perform task efficiently energy performance ep programme design boost energy level help employee invest energy right way work home uptake good employee participate ep workshops employee country attend ep workshop end cent report significant improvement physical mental performance emotional energy participant find performance improvement persist month workshop personal resilience run workshop employee want enhance build personal resilience focus improve work home life programme aim help employee increase focus energy confidence help reduce tension anxiety fatigue programme start employee participate programme team resilience healthy collaborative motivated team critical business success team resilience programme help employee manager identify source pressure team process complexity lack workplace flexibility accountability team work agree action plan address concern programme help team control work eliminate manage source pressure lead ill health inefficiency programme begin complete team country comprise employee end participant report cent reduction workplace pressure cent drop worklife conflict cent increase satisfaction gsk employer wellbee worklife balance gsk offer programme improve health employee family find increase employee commitment productivity reduce absenteeism cost ill health support vary country accord local need site use public health gsk datum identify high risk area investment lead significant health cost improvement programme include benefit onsite health fitness centre flexible working arrangement immunisation regular medical checkup assistance stop smoke disease screen management family support service health education assist employee suffer chronic disease ensure access correct longterm treatment support programme help local healthcare service focus health education prevention awareness management current condition create network gsk employee health professional share health wellbee good practice gsk support key public health effort world aids day world health organization health day tobacco free day global handwash day home responsibility people health safety wellbee health wellbeing programme corporate responsibility report health wellbeing programme gsk offer programme boost employee health wellbeing create sustain energy engagement work turn help improve business performance gsk help improve employee wellbeing offer flexible working option health wellbeing initiative include health risk appraisal screening diabete hypertension smoking control support fitness nutritional advice immunisation prevention screening initiative focus lead cause illness disability employee include depression nonwork relate injury heart disease stroke respiratory infection increasingly focus way encourage team personal energy resilience time high pressure employee health wellbeing programme national awards excellence platinum awards national business group health nbgh health promotion board singapore team resilience programme receive award nbgh innovation commitment provide lifestyle improvement programme design improve healthy lifestyle employee energy resilience define resilience describe skill trait necessary success highpressure work environment skill behaviour help prevent mental illness stress leading cause ill health disability work energy performance employee energy focus well perform task efficiently energy performance ep programme design boost energy level help employee invest energy right way work home uptake good employee participate ep workshops employee country attend ep workshop end cent report significant improvement physical mental performance emotional energy participant find performance improvement persist month workshop personal resilience run workshop employee want enhance build personal resilience focus improve work home life programme aim help employee increase focus energy confidence help reduce tension anxiety fatigue programme start employee participate programme team resilience healthy collaborative motivated team critical business success team resilience programme help employee manager identify source pressure team process complexity lack workplace flexibility accountability team work agree action plan address concern programme help team control work eliminate manage source pressure lead ill health inefficiency programme begin complete team country comprise employee end participant report cent reduction workplace pressure cent drop worklife conflict cent increase satisfaction gsk employer wellbee worklife balance gsk offer programme improve health employee family find increase employee commitment productivity reduce absenteeism cost ill health support vary country accord local need site use public health gsk datum identify high risk area investment lead significant health cost improvement programme include benefit onsite health fitness centre flexible working arrangement immunisation regular medical checkup assistance stop smoke disease screen management family support service health education assist employee suffer chronic disease ensure access correct longterm treatment support programme help local healthcare service focus health education prevention awareness management current condition create network gsk employee health professional share health wellbee good practice gsk support key public health effort world aids day world health organization health day tobacco free day global handwash day home responsibility people health safety wellbee health business continuity corporate responsibility report health business continuity develop contingency plan protect employee business event natural disaster manmade emergencies flu pandemic plan aim ensure business continue function continue supply critical medicine patient develop implement programme protect staff dependant key complementary worker country event pandemic offer employee annual seasonal flu vaccination cent market travel health programme stockpile multiple antiviral medicine prevent treat pandemic flu include prepandemic vaccine administer pandemic start pandemic flu vaccine available month exact pandemic flu strain identify event outbreak implement special rule prevent disease spread workforce example nonessential service close facetoface meeting hold special cleaning personal protective programme implement restrict business travel access gsk site employee encourage work home develop special website accessible intranet externally act single source global local flu information gsk home responsibility people health safety wellbee health business continuity corporate responsibility report health business continuity develop contingency plan protect employee business event natural disaster manmade emergencies flu pandemic plan aim ensure business continue function continue supply critical medicine patient develop implement programme protect staff dependant key complementary worker country event pandemic offer employee annual seasonal flu vaccination cent market travel health programme stockpile multiple antiviral medicine prevent treat pandemic flu include prepandemic vaccine administer pandemic start pandemic flu vaccine available month exact pandemic flu strain identify event outbreak implement special rule prevent disease spread workforce example nonessential service close facetoface meeting hold special cleaning personal protective programme implement restrict business travel access gsk site employee encourage work home develop special website accessible intranet externally act single source global local flu information gsk home responsibility people health safety wellbee training awareness corporate responsibility report training awareness training help create workplace culture occupational health safety take seriously employee responsible manage occupational health safety issue site business unit receive regular training turn instruct employee safe work training environment health safety sustainability ehss standard programme process safety chemical exposure protection identify risk auditing ergonomic site develop conduct training base local need capability use internal learning tool commercially available training programme locally available government university sponsor training programme develop training framework identifie gap employee knowledge health safety provide inhouse external training course health safety professional share knowledge good practice teleconference intranet community training programme discussion forum raise awareness employee health safety issue employee bulletin announcement myehs community intranet site ceo ehs excellence awards programme health safety week hold october coincide european health safety week event encourage employee address potential risk work home employee site country take health safety week activity read training environment health safety issue health safety worthe ehs challenge competition gsk penicillin manufacturing facility worthe uk run competition improve employee knowledge ehs issue month ehs team send question staff topic fire evacuation aid respond penicillin exposure site eh target follow month question pose employee work unit point award correct response team publish league table month quarter win team award charity choice total competition winner give charity follow success worthe competition introduce site uk france china india project second place ceo ehs excellence awards safety initiative category home responsibility people health safety wellbee training awareness corporate responsibility report training awareness training help create workplace culture occupational health safety take seriously employee responsible manage occupational health safety issue site business unit receive regular training turn instruct employee safe work training environment health safety sustainability ehss standard programme process safety chemical exposure protection identify risk auditing ergonomic site develop conduct training base local need capability use internal learning tool commercially available training programme locally available government university sponsor training programme develop training framework identifie gap employee knowledge health safety provide inhouse external training course health safety professional share knowledge good practice teleconference intranet community training programme discussion forum raise awareness employee health safety issue employee bulletin announcement myehs community intranet site ceo ehs excellence awards programme health safety week hold october coincide european health safety week event encourage employee address potential risk work home employee site country take health safety week activity read training environment health safety issue health safety worthe ehs challenge competition gsk penicillin manufacturing facility worthe uk run competition improve employee knowledge ehs issue month ehs team send question staff topic fire evacuation aid respond penicillin exposure site eh target follow month question pose employee work unit point award correct response team publish league table month quarter win team award charity choice total competition winner give charity follow success worthe competition introduce site uk france china india project second place ceo ehs excellence awards safety initiative category home responsibility people health safety wellbeing performance corporate responsibility report performance performance datum table injury illness rate main health safety measure reportable injury illness rate measure number injury illness result lose day number day lose injury illness provide indication severity incident rough guide set target improve injury illness rate injury illness target injury illness target progress reduce reportable injury illness improve cent rate cent year end reduce reportable musculoskeletal improve cent illness injury rate cent year end rank quartile industry improve rank place remain benchmark group quartile datum cover gsk employee contract worker directly supervise report separately datum contractor work gsk site supervise staff datum table contractor datum externally verify injury illness datum collect pharmaceutical consumer healthcare nutritional manufacturing site vaccine site site operation pharmaceutical consumer healthcare research development site site consider new start report uk headquarters site eighteen office sale group million hour work small office distribution centre sale office site report injury illness datum estimate approximately cent datum miss large sale group report injury illness injury illness rate reportable injury illness rate continue improve average rate cent year gsk injury illnesse total reportable injury illness rate reportable injury illnesse hour work improvement cent baseline exceeding target reportable ergonomicsrelated injury illness rate improve percent short target annual percent improvement equivalent cent improvement order meet exceed target increase effort resource area pharmaceutical consumer healthcare manufacturing organisation injury illness rate include manager objective rate improve cent machinery safety project manufacturing site project encourage employee safety awareness example initiative contribute improvement rate losttime injury illness improve cent losttime injury illnesse hour work day lose hour improve cent indicate low number day lose incident possibly indicator severe injury illnesse injury illness performance place quartile benchmark industry group mean need improve target quartile comparable industry rating read case study site improve safety shutdown sgs verify injury illness cause frequent type incident overall ergonomic mainly musculoskeletal illness repetitive strain injury account cent injury illness continue expand ergonomic programme address cause injury illness frequent reportable injury slip trip fall account cent injury illnesse team assign look way address type injury injury machinery account cent injury illnesse manufacture site renew focus machine safety continue improvement area road traffic accident account cent injury illnesse fatality detail belowdriver safety continue area focus especially sale force mental ill health account cent injury illnesse case result high number day lose day case average cent total number day lose injury illness address resilience programme sgs verify fatality injury employee fatality year trend employee fatality sale employee kill fatal road traffic accident philippine passenger kill accident sale employee india kill fall bicycle path oncome motorize threewheeler tire bicycle puncture gsk employee seriously injure road traffic accident india vehicle transport contract driver strike vehicle kill people amputation finger injury accident move machinery employee amputation finger finger tip employee sustain amputation foot contract worker amputation forearm employee injure foot catch power roller reconstructive surgery prove unsuccessful foot amputate contract worker india reach clothe dryer rotate remove article clothing result amputation forearm employee south africa slip wet floor grab piece equipment fall weight cause valve close hand amputate finger joint badly crush finger sever finger reattache crushed finger save amputated engineering mechanic pakistan place hand operating piece machinery tube holder strike finger inflict severe damage result amputation employee clearing jam assemblypacke machine place hand machine close finger amputate finger tip fitter australia suffer laceration finger instal cutter blister pack machine hospital treatment require amputation avoid amputation result renew emphasis machine guard programme site sgs verify injury illness milestone gsk operation strive work experience losttime injury illnesse issue certificate sign business head site reach million hour work losttime injury illness site reach million hour work losttime injury illness award certificate sign chief executive officer small site attain level million hour work year period obtain certificate year work losttime injury illness milestone achieve hour work lose time injury illness million hour site million hour site million hour site million hour site million hour site year site year site tophome responsibility people health safety wellbeing performance corporate responsibility report performance performance datum table injury illness rate main health safety measure reportable injury illness rate measure number injury illness result lose day number day lose injury illness provide indication severity incident rough guide set target improve injury illness rate injury illness target injury illness target progress reduce reportable injury illness improve cent rate cent year end reduce reportable musculoskeletal improve cent illness injury rate cent year end rank quartile industry improve rank place remain benchmark group quartile datum cover gsk employee contract worker directly supervise report separately datum contractor work gsk site supervise staff datum table contractor datum externally verify injury illness datum collect pharmaceutical consumer healthcare nutritional manufacturing site vaccine site site operation pharmaceutical consumer healthcare research development site site consider new start report uk headquarters site eighteen office sale group million hour work small office distribution centre sale office site report injury illness datum estimate approximately cent datum miss large sale group report injury illness injury illness rate reportable injury illness rate continue improve average rate cent year gsk injury illnesse total reportable injury illness rate reportable injury illnesse hour work improvement cent baseline exceeding target reportable ergonomicsrelated injury illness rate improve percent short target annual percent improvement equivalent cent improvement order meet exceed target increase effort resource area pharmaceutical consumer healthcare manufacturing organisation injury illness rate include manager objective rate improve cent machinery safety project manufacturing site project encourage employee safety awareness example initiative contribute improvement rate losttime injury illness improve cent losttime injury illnesse hour work day lose hour improve cent indicate low number day lose incident possibly indicator severe injury illnesse injury illness performance place quartile benchmark industry group mean need improve target quartile comparable industry rating read case study site improve safety shutdown sgs verify injury illness cause frequent type incident overall ergonomic mainly musculoskeletal illness repetitive strain injury account cent injury illness continue expand ergonomic programme address cause injury illness frequent reportable injury slip trip fall account cent injury illnesse team assign look way address type injury injury machinery account cent injury illnesse manufacture site renew focus machine safety continue improvement area road traffic accident account cent injury illnesse fatality detail belowdriver safety continue area focus especially sale force mental ill health account cent injury illnesse case result high number day lose day case average cent total number day lose injury illness address resilience programme sgs verify fatality injury employee fatality year trend employee fatality sale employee kill fatal road traffic accident philippine passenger kill accident sale employee india kill fall bicycle path oncome motorize threewheeler tire bicycle puncture gsk employee seriously injure road traffic accident india vehicle transport contract driver strike vehicle kill people amputation finger injury accident move machinery employee amputation finger finger tip employee sustain amputation foot contract worker amputation forearm employee injure foot catch power roller reconstructive surgery prove unsuccessful foot amputate contract worker india reach clothe dryer rotate remove article clothing result amputation forearm employee south africa slip wet floor grab piece equipment fall weight cause valve close hand amputate finger joint badly crush finger sever finger reattache crushed finger save amputated engineering mechanic pakistan place hand operating piece machinery tube holder strike finger inflict severe damage result amputation employee clearing jam assemblypacke machine place hand machine close finger amputate finger tip fitter australia suffer laceration finger instal cutter blister pack machine hospital treatment require amputation avoid amputation result renew emphasis machine guard programme site sgs verify injury illness milestone gsk operation strive work experience losttime injury illnesse issue certificate sign business head site reach million hour work losttime injury illness site reach million hour work losttime injury illness award certificate sign chief executive officer small site attain level million hour work year period obtain certificate year work losttime injury illness milestone achieve hour work lose time injury illness million hour site million hour site million hour site million hour site million hour site year site year site tophome responsibility people health safety wellbeing performance corporate responsibility report performance performance datum table injury illness rate main health safety measure reportable injury illness rate measure number injury illness result lose day number day lose injury illness provide indication severity incident rough guide set target improve injury illness rate injury illness target injury illness target progress reduce reportable injury illness improve cent rate cent year end reduce reportable musculoskeletal improve cent illness injury rate cent year end rank quartile industry improve rank place remain benchmark group quartile datum cover gsk employee contract worker directly supervise report separately datum contractor work gsk site supervise staff datum table contractor datum externally verify injury illness datum collect pharmaceutical consumer healthcare nutritional manufacturing site vaccine site site operation pharmaceutical consumer healthcare research development site site consider new start report uk headquarters site eighteen office sale group million hour work small office distribution centre sale office site report injury illness datum estimate approximately cent datum miss large sale group report injury illness injury illness rate reportable injury illness rate continue improve average rate cent year gsk injury illnesse total reportable injury illness rate reportable injury illnesse hour work improvement cent baseline exceeding target reportable ergonomicsrelated injury illness rate improve percent short target annual percent improvement equivalent cent improvement order meet exceed target increase effort resource area pharmaceutical consumer healthcare manufacturing organisation injury illness rate include manager objective rate improve cent machinery safety project manufacturing site project encourage employee safety awareness example initiative contribute improvement rate losttime injury illness improve cent losttime injury illnesse hour work day lose hour improve cent indicate low number day lose incident possibly indicator severe injury illnesse injury illness performance place quartile benchmark industry group mean need improve target quartile comparable industry rating read case study site improve safety shutdown sgs verify injury illness cause frequent type incident overall ergonomic mainly musculoskeletal illness repetitive strain injury account cent injury illness continue expand ergonomic programme address cause injury illness frequent reportable injury slip trip fall account cent injury illnesse team assign look way address type injury injury machinery account cent injury illnesse manufacture site renew focus machine safety continue improvement area road traffic accident account cent injury illnesse fatality detail belowdriver safety continue area focus especially sale force mental ill health account cent injury illnesse case result high number day lose day case average cent total number day lose injury illness address resilience programme sgs verify fatality injury employee fatality year trend employee fatality sale employee kill fatal road traffic accident philippine passenger kill accident sale employee india kill fall bicycle path oncome motorize threewheeler tire bicycle puncture gsk employee seriously injure road traffic accident india vehicle transport contract driver strike vehicle kill people amputation finger injury accident move machinery employee amputation finger finger tip employee sustain amputation foot contract worker amputation forearm employee injure foot catch power roller reconstructive surgery prove unsuccessful foot amputate contract worker india reach clothe dryer rotate remove article clothing result amputation forearm employee south africa slip wet floor grab piece equipment fall weight cause valve close hand amputate finger joint badly crush finger sever finger reattache crushed finger save amputated engineering mechanic pakistan place hand operating piece machinery tube holder strike finger inflict severe damage result amputation employee clearing jam assemblypacke machine place hand machine close finger amputate finger tip fitter australia suffer laceration finger instal cutter blister pack machine hospital treatment require amputation avoid amputation result renew emphasis machine guard programme site sgs verify injury illness milestone gsk operation strive work experience losttime injury illnesse issue certificate sign business head site reach million hour work losttime injury illness site reach million hour work losttime injury illness arpea agew ard oef certificate sign chief executive officer small site attain level million hour work year period obtain certificate year work losttime injury illness milestone achieve hour work lose time injury illness million hour site million hour site million hour site million hour site million hour site year site year site tophome responsibility people health safety wellbeing performance corporate responsibility report performance performance datum table injury illness rate main health safety measure reportable injury illness rate measure number injury illness result lose day number day lose injury illness provide indication severity incident rough guide set target improve injury illness rate injury illness target injury illness target progress reduce reportable injury illness improve cent rate cent year end reduce reportable musculoskeletal improve cent illness injury rate cent year end rank quartile industry improve rank place remain benchmark group quartile datum cover gsk employee contract worker directly supervise report separately datum contractor work gsk site supervise staff datum table contractor datum externally verify injury illness datum collect pharmaceutical consumer healthcare nutritional manufacturing site vaccine site site operation pharmaceutical consumer healthcare research development site site consider new start report uk headquarters site eighteen office sale group million hour work small office distribution centre sale office site report injury illness datum estimate approximately cent datum miss large sale group report injury illness injury illness rate reportable injury illness rate continue improve average rate cent year gsk injury illnesse total reportable injury illness rate reportable injury illnesse hour work improvement cent baseline exceeding target reportable ergonomicsrelated injury illness rate improve percent short target annual percent improvement equivalent cent improvement order meet exceed target increase effort resource area pharmaceutical consumer healthcare manufacturing organisation injury illness rate include manager objective rate improve cent machinery safety project manufacturing site project encourage employee safety awareness example initiative contribute improvement rate losttime injury illness improve cent losttime injury illnesse hour work day lose hour improve cent indicate low number day lose incident possibly indicator severe injury illnesse injury illness performance place quartile benchmark industry group mean need improve target quartile comparable industry rating read case study site improve safety shutdown sgs verify injury illness cause frequent type incident overall ergonomic mainly musculoskeletal illness repetitive strain injury account cent injury illness continue expand ergonomic programme address cause injury illness frequent reportable injury slip trip fall account cent injury illnesse team assign look way address type injury injury machinery account cent injury illnesse manufacture site renew focus machine safety continue improvement area road traffic accident account cent injury illnesse fatality detail belowdriver safety continue area focus especially sale force mental ill health account cent injury illnesse case result high number day lose day case average cent total number day lose injury illness address resilience programme sgs verify fatality injury employee fatality year trend employee fatality sale employee kill fatal road traffic accident philippine passenger kill accident sale employee india kill fall bicycle path oncome motorize threewheeler tire bicycle puncture gsk employee seriously injure road traffic accident india vehicle transport contract driver strike vehicle kill people amputation finger injury accident move machinery employee amputation finger finger tip employee sustain amputation foot contract worker amputation forearm employee injure foot catch power roller reconstructive surgery prove unsuccessful foot amputate contract worker india reach clothe dryer rotate remove article clothing result amputation forearm employee south africa slip wet floor grab piece equipment fall weight cause valve close hand amputate finger joint badly crush finger sever finger reattache crushed finger save amputated engineering mechanic pakistan place hand operating piece machinery tube holder strike finger inflict severe damage result amputation employee clearing jam assemblypacke machine place hand machine close finger amputate finger tip fitter australia suffer laceration finger instal cutter blister pack machine hospital treatment require amputation avoid amputation result renew emphasis machine guard programme site sgs verify injury illness milestone gsk operation strive work experience losttime injury illnesse issue certificate sign business head site reach million hour work losttime injury illness site reach million hour work losttime injury illness award certificate sign chief executive officer small site attain level million hour work year period obtain certificate year work losttime injury illness milestone achieve hour work lose time injury illness million hour site million hour site million hour site million hour site million hour site year site year site home responsibility people health safety wellbeing performance corporate responsibility report performance performance datum table injury illness rate main health safety measure reportable injury illness rate measure number injury illness result lose day number day lose injury illness provide indication severity incident rough guide set target improve injury illness rate injury illness target injury illness target progress reduce reportable injury illness improve cent rate cent year end reduce reportable musculoskeletal improve cent illness injury rate cent year end rank quartile industry improve rank place remain benchmark group quartile datum cover gsk employee contract worker directly supervise report separately datum contractor work gsk site supervise staff datum table contractor datum externally verify injury illness datum collect pharmaceutical consumer healthcare nutritional manufacturing site vaccine site site operation pharmaceutical consumer healthcare research development site site consider new start report uk headquarters site eighteen office sale group million hour work small office distribution centre sale office site report injury illness datum estimate approximately cent datum miss large sale group report injury illness injury illness rate reportable injury illness rate continue improve average rate cent year gsk injury illnesse total reportable injury illness rate reportable injury illnesse hour work improvement cent baseline exceeding target reportable ergonomicsrelated injury illness rate improve percent short target annual percent improvement equivalent cent improvement order meet exceed target increase effort resource area pharmaceutical consumer healthcare manufacturing organisation injury illness rate include manager objective rate improve cent machinery safety project manufacturing site project encourage employee safety awareness example initiative contribute improvement rate losttime injury illness improve cent losttime injury illnesse hour work day lose hour improve cent indicate low number day lose incident possibly indicator severe injury illnesse injury illness performance place quartile benchmark industry group mean need improve target quartile comparable industry rating read case study site improve safety shutdown sgs verify injury illness cause frequent type incident overall ergonomic mainly musculoskeletal illness repetitive strain injury account cent injury illness continue expand ergonomic programme address cause injury illness frequent reportable injury slip trip fall account cent injury illnesse team assign look way address type injury injury machinery account cent injury illnesse manufacture site renew focus machine safety continue improvement area road traffic accident account cent injury illnesse fatality detail belowdriver safety continue area focus especially sale force mental ill health account cent injury illnesse case result high number day lose day case average cent total number day lose injury illness address resilience programme sgs verify fatality injury employee fatality year trend employee fatality sale employee kill fatal road traffic accident philippine passenger kill accident sale employee india kill fall bicycle path oncome motorize threewheeler tire bicycle puncture gsk employee seriously injure road traffic accident india vehicle transport contract driver strike vehicle kill people amputation finger injury accident move machinery employee amputation finger finger tip employee sustain amputation foot contract worker amputation forearm employee injure foot catch power roller reconstructive surgery prove unsuccessful foot amputate contract worker india reach clothe dryer rotate remove article clothing result amputation forearm employee south africa slip wet floor grab piece equipment fall weight cause valve close hand amputate finger joint badly crush finger sever finger reattache crushed finger save amputated engineering mechanic pakistan place hand operating piece machinery tube holder strike finger inflict severe damage result amputation employee clearing jam assemblypacke machine place hand machine close finger amputate finger tip fitter australia suffer laceration finger instal cutter blister pack machine hospital treatment require amputation avoid amputation result renew emphasis machine guard programme site sgs verify injury illness milestone gsk operation strive work experience losttime injury illnesse issue certificate sign business head site reach million hour work losttime injury illness site reach million hour work losttime injury illness award certificate sign chief executive officer small site attain level million hour work year period obtain certificate year work losttime injury illness milestone achieve hour work lose time injury illness million hour site million hour site million hour site million hour site million hour site year site year site home responsibility people health safety wellbeing performance corporate responsibility report performance performance datum table metric injury illness gsk employee hour work million fatality number injury lose time calendar day lose injury number illness lose time calendar day lose illness number injury lose time number illness lose time reportable injury illness rate reportable ergonomic injury illness rate losttime injury illness rate injury illness nongsk employee hour work million fatality number injury illness lose time calendar day lose number injury illnesse lose time occupational health safety datum cover employee contract worker directly supervise gsk employee report snapshot injury illness performance year case add end year prior year change losttime injury illnesse workrelate injury illnesse result day away work lose calendar day calendar day include weekend employee work workrelate injury illness help provide measure severity injury illnesse reportable injury illnesse lose time incident result time away work lose time aid result lose time sgs verify tophome responsibility people health safety wellbeing performance corporate responsibility report performance performance datum table metric injury illness gsk employee hour work million fatality number injury lose time calendar day lose injury number illness lose time calendar day lose illness number injury lose time number illness lose time reportable injury illness rate reportable ergonomic injury illness rate losttime injury illness rate injury illness nongsk employee hour work million fatality number injury illness lose time calendar day lose number injury illnesse lose time occupational health safety datum cover employee contract worker directly supervise gsk employee report snapshot injury illness performance year case add end year prior year change losttime injury illnesse workrelate injury illnesse result day away work lose calendar day calendar day include weekend employee work workrelate injury illness help provide measure severity injury illnesse reportable injury illnesse lose time incident result time away work lose time aid result lose time sgs verify home responsibility people health safety wellbeing performance corporate responsibility report performance performance datum table metric injury illness gsk employee hour work million fatality number injury lose time calendar day lose injury number illness lose time calendar day lose illness number injury lose time number illness lose time reportable injury illness rate reportable ergonomic injury illness rate losttime injury illness rate injury illness nongsk employee hour work million fatality number injury illness lose time calendar day lose number injury illnesse lose time occupational health safety datum cover employee contract worker directly supervise gsk employee report snapshot injury illness performance year case add end year prior year change losttime injury illnesse workrelate injury illnesse result day away work lose calendar day calendar day include weekend employee work workrelate injury illness help provide measure severity injury illnesse reportable injury illnesse lose time incident result time away work lose time aid result lose time sgs verify home responsibility people case study corporate responsibility report case study diversity inclusion woman science event create global programme gsk rd encourage celebrate woman science woman science event wise programme start uk bring woman scientist daylong event network education knowledgesharing opportunity develop scope attendance annual event hold simultaneously site stevenage north carolina series speaker workshops simultaneous broadcast keynote speaker internationally renowned female scientist site hold event uk site north carolina delaware keynote speaker network opportunity plan hold event late additional speak network event arrange year uk feature lead female scientist gsk scientific women scholarship programme scientific women scholarship programme place programme offer unique combination scholarship mentor relationship professional woman scientist support endowment fund programme open college university woman scholar select participate programme gsk research triangle park north carolina fiftyfive gsk mentor work scholar pass dedication energy passion science new generation student scholar pair professional woman scientist gsk serve mentor woman scholar wing provide expert advice share experience lesson learn year gsk volunteer mentor work secure internship funding opportunity scholar internship offer insight career scholar handson experience pharmaceutical industry support adult literacy manufacturing site nabha rajamundy india take action improve literacy rate employee begin cent worker read write use thumb print instead sign site set goal employee able sign employee nabha factory take nearly hour training total include session read write punjabi english result initiative people learn read write employee able sign session include area family relation aid awareness good health practice domestic safety budgeting project receive honourable mention employee attraction development retention category multicultural marketing diversity awards occupational health safety contractor competition improve safety shutdown gsk slough site make lucozade horlick powder hold annual shutdown clean maintain manufacturing equipment site ehs team develop programme reduce number accident occur shutdown time increase risk employee contractor undertake nonroutine engineering activity short period time team review log accident nearmisse previous shutdown hold briefing meeting supervisor contractor raise awareness risk run competition identify reward contractor good safety performance initiative contribute reduction minor accident shutdown reportable incident competition begin project place ceo ehs excellence awards safety initiative categoryhome responsibility people case study corporate responsibility report case study diversity inclusion woman science event create global programme gsk rd encourage celebrate woman science woman science event wise programme start uk bring woman scientist daylong event network education knowledgesharing opportunity develop scope attendance annual event hold simultaneously site stevenage north carolina series speaker workshops simultaneous broadcast keynote speaker internationally renowned female scientist site hold event uk site north carolina delaware keynote speaker network opportunity plan hold event late additional speak network event arrange year uk feature lead female scientist gsk scientific women scholarship programme scientific women scholarship programme place programme offer unique combination scholarship mentor relationship professional woman scientist support endowment fund programme open college university woman scholar select participate programme gsk research triangle park north carolina fiftyfive gsk mentor work scholar pass dedication energy passion science new generation student scholar pair professional woman scientist gsk serve mentor woman scholar wing provide expert advice share experience lesson learn year gsk volunteer mentor work secure internship funding opportunity scholar internship offer insight career scholar handson experience pharmaceutical industry support adult literacy manufacturing site nabha rajamundy india take action improve literacy rate employee begin cent worker read write use thumb print instead sign site set goal employee able sign employee nabha factory take nearly hour training total include session read write punjabi english result initiative people learn read write employee able sign session include area family relation aid awareness good health practice domestic safety budgeting project receive honourable mention employee attraction development retention category multicultural marketing diversity awards occupational health safety contractor competition improve safety shutdown gsk slough site make lucozade horlick powder hold annual shutdown clean maintain manufacturing equipment site ehs team develop programme reduce number accident occur shutdown time increase risk employee contractor undertake nonroutine engineering activity short period time team review log accident nearmisse previous shutdown hold briefing meeting supervisor contractor raise awareness risk run competition identify reward contractor good safety performance initiative contribute reduction minor accident shutdown reportable incident competition begin project place ceo ehs excellence awards safety initiative category home responsibility people case study corporate responsibility report case study diversity inclusion woman science event create global programme gsk rd encourage celebrate woman science woman science event wise programme start uk bring woman scientist daylong event network education knowledgesharing opportunity develop scope attendance annual event hold simultaneously site stevenage north carolina series speaker workshops simultaneous broadcast keynote speaker internationally renowned female scientist site hold event uk site north carolina delaware keynote speaker network opportunity plan hold event late additional speak network event arrange year uk feature lead female scientist gsk scientific women scholarship programme scientific women scholarship programme place programme offer unique combination scholarship mentor relationship professional woman scientist support endowment fund programme open college university woman scholar select participate programme gsk research triangle park north carolina fiftyfive gsk mentor work scholar pass dedication energy passion science new generation student scholar pair professional woman scientist gsk serve mentor woman scholar wing provide expert advice share experience lesson learn year gsk volunteer mentor work secure internship funding opportunity scholar internship offer insight career scholar handson experience pharmaceutical industry support adult literacy manufacturing site nabha rajamundy india take action improve literacy rate employee begin cent worker read write use thumb print instead sign site set goal employee able sign employee nabha factory take nearly hour training total include session read write punjabi english result initiative people learn read write employee able sign session include area family relation aid awareness good health practice domestic safety budgeting project receive honourable mention employee attraction development retention category multicultural marketing diversity awards occupational health safety contractor competition improve safety shutdown gsk slough site make lucozade horlick powder hold annual shutdown clean maintain manufacturing equipment site ehs team develop programme reduce number accident occur shutdown time increase risk employee contractor undertake nonroutine engineering activity short period time team review log accident nearmisse previous shutdown hold briefing meeting supervisor contractor raise awareness risk run competition identify reward contractor good safety performance initiative contribute reduction minor accident shutdown reportable incident competition begin project place ceo ehs excellence awards safety initiative category home responsibility people qas corporate responsibility report qas respond question raise stakeholder reduce workforce ensure remain employee face additional stress job recognise stress work important issue establish programme help individual team deal stress offer support onsite health fitness centre flexible working arrangement family support service health education gsk aim simplify operating model create culture individual empowerment employee take responsibility work simplify work remove process structure reduce work area result few people require empower individual decision carry work layer bureaucracy support operational excellence programme affect employee regrettably operational excellence programme result job loss support affect employee include provide competitive severance package provide outplacement support assistance identify alternative employment career counselling retraining work hard ensure programme negative impact morale staff produce guide manager information support employee uncertainty anxiety stress encounter major organisational change relatively woman senior management gsk please percentage woman management increase incrementally year recognise room improvement especially senior management position role historically maledominate discipline science engineering aim attract woman gsk support career development exist employee flexible working programme help employee balance demand personal professional life diversity champion business unit employee network support career development woman minority group gsk health safety performance industry average need improve know need improve performance area assessment project identify ergonomic attitudes health safety workplace main cause injury illnesse target awareness training programme base result year launch toolkit help site assess risk identify intervention adopt pharmaceutical manufacturing business behaviourbased safety programme plan site progress respiratorfree target result baseline monitor level exposure chemical workplace define new upgrade engineering control need meet target employee operation able work need wear respiratory protection reach operation achieve level engineering control pende completion verification monitoring continue upgrade engineering control achieve respirator free level control situation engineering control possible sure appropriate respiratory protective equipment home responsibility people qas corporate responsibility report qas respond question raise stakeholder reduce workforce ensure remain employee face additional stress job recognise stress work important issue establish programme help individual team deal stress offer support onsite health fitness centre flexible working arrangement family support service health education gsk aim simplify operating model create culture individual empowerment employee take responsibility work simplify work remove process structure reduce work area result few people require empower individual decision carry work layer bureaucracy support operational excellence programme affect employee regrettably operational excellence programme result job loss support affect employee include provide competitive severance package provide outplacement support assistance identify alternative employment career counselling retraining work hard ensure programme negative impact morale staff produce guide manager information support employee uncertainty anxiety stress encounter major organisational change relatively woman senior management gsk please percentage woman management increase incrementally year recognise room improvement especially senior management position role historically maledominate discipline science engineering aim attract woman gsk support career development exist employee flexible working programme help employee balance demand personal professional life diversity champion business unit employee network support career development woman minority group gsk health safety performance industry average need improve know need improve performance area assessment project identify ergonomic attitudes health safety workplace main cause injury illnesse target awareness training programme base result year launch toolkit help site assess risk identify intervention adopt pharmaceutical manufacturing business behaviourbased safety programme plan site progress respiratorfree target result baseline monitor level exposure chemical workplace define new upgrade engineering control need meet target employee operation able work need wear respiratory protection reach operation achieve level engineering control pende completion verification monitoring continue upgrade engineering control achieve respirator free level control situation engineering control possible sure appropriate respiratory protective equipment home responsibility people qas corporate responsibility report qas respond question raise stakeholder reduce workforce ensure remain employee face additional stress job recognise stress work important issue establish programme help individual team deal stress offer support onsite health fitness centre flexible working arrangement family support service health education gsk aim simplify operating model create culture individual empowerment employee take responsibility work simplify work remove process structure reduce work area result few people require empower individual decision carry work layer bureaucracy support operational excellence programme affect employee regrettably operational excellence programme result job loss support affect employee include provide competitive severance package provide outplacement support assistance identify alternative employment career counselling retraining work hard ensure programme negative impact morale staff produce guide manager information support employee uncertainty anxiety stress encounter major organisational change relatively woman senior management gsk please percentage woman management increase incrementally year recognise room improvement especially senior management position role historically maledominate discipline science engineering aim attract woman gsk support career development exist employee flexible working programme help employee balance demand personal professional life diversity champion business unit employee network support career development woman minority group gsk health safety performance industry average need improve know need improve performance area assessment project identify ergonomic attitudes health safety workplace main cause injury illnesse target awareness training programme base result year launch toolkit help site assess risk identify intervention adopt pharmaceutical manufacturing business behaviourbased safety programme plan site progress respiratorfree target result baseline monitor level exposure chemical workplace define new upgrade engineering control need meet target employee operation able work need wear respiratory protection reach operation achieve level engineering control pende completion verification monitoring continue upgrade engineering control achieve respirator free level control situation engineering control possible sure appropriate respiratory protective equipment home responsibility human right corporate responsibility report human right commit uphold un universal declaration human right oecd guideline multinational enterprise core labour standard set international labour organization signatory un global compact voluntary global standard human right labour environment anticorruption believe government responsibility define enforce legal framework human right accordance international law agreement universal declaration human right business responsibilitie work hard uphold human right sphere influence include employee supplier community society direct control human right operation influence supply chain wide society marketer medicine strive widely available possible running business sustainable way high standard human right important gsk help good employee support relationship community near site ensure supplier contract run smoothly provide reliable supply highquality product protect reputation human right relevant issue cover report section give overview approach information gsk human right human right clause include contract supplier read supply chain read effort improve access medicine read investment local community read employment practice read position statement convention biological diversity home responsibility human right corporate responsibility report human right commit uphold un universal declaration human right oecd guideline multinational enterprise core labour standard set international labour organization signatory un global compact voluntary global standard human right labour environment anticorruption believe government responsibility define enforce legal framework human right accordance international law agreement universal declaration human right business responsibilitie work hard uphold human right sphere influence include employee supplier community society direct control human right operation influence supply chain wide society marketer medicine strive widely available possible running business sustainable way high standard human right important gsk help good employee support relationship community near site ensure supplier contract run smoothly provide reliable supply highquality product protect reputation human right relevant issue cover report section give overview approach information gsk human right human right clause include contract supplier read supply chain read effort improve access medicine read investment local community read employment practice read position statement convention biological diversity home responsibility human right employee corporate responsibility report employee employment standard issue diversity equal opportunity health safety protect employee human right employer commit provide fair salary good employment condition commit provide healthy safe secure workplace employee contractor oppose discrimination work commit promote respect diversitys commit promote personal development dignity employee respectful employee right join independent trade union freedom association oppose form slavery exploitative child labour work appropriate partner address problem responsibly encounter employee report concern supervisor line manager human resource ethic compliance office use global confidential reporting line read employment practice home responsibility human right employee corporate responsibility report employee employment standard issue diversity equal opportunity health safety protect employee human right employer commit provide fair salary good employment condition commit provide healthy safe secure workplace employee contractor oppose discrimination work commit promote respect diversitys commit promote personal development dignity employee respectful employee right join independent trade union freedom association oppose form slavery exploitative child labour work appropriate partner address problem responsibly encounter employee report concern supervisor line manager human resource ethic compliance office use global confidential reporting line read employment practice home responsibility human right supplier corporate responsibility report supplier buyer raw material manufacture good service world require supplier contractor business partner meet standard human right gsk knowingly use supplier responsible human right infringement conduct regular audits exist supplier engage new supplier meet expectation human right clause include contract consider human right issue routine interaction critical supplier contract manufacturer supplier present great risk gsk key risk area eh audits potential new exist critical supplier include question help identify potential breach human right clause include supplier contract supplier ask information policy practice relate age limit employee discrimination employee local population prevention abuse individual wage benefit work hour meet legal minimum right worker organise recognition worker organisation question contribute ehs audit score reason progress business supplier read supply chain home responsibility human right supplier corporate responsibility report supplier buyer raw material manufacture good service world require supplier contractor business partner meet standard human right gsk knowingly use supplier responsible human right infringement conduct regular audits exist supplier engage new supplier meet expectation human right clause include contract consider human right issue routine interaction critical supplier contract manufacturer supplier present great risk gsk key risk area eh audits potential new exist critical supplier include question help identify potential breach human right clause include supplier contract supplier ask information policy practice relate age limit employee discrimination employee local population prevention abuse individual wage benefit work hour meet legal minimum right worker organise recognition worker organisation question contribute ehs audit score reason progress business supplier read supply chain home responsibility human right community corporate responsibility report community respect promote right community near operation example local community gsk aim good relationship community site operate way infringe human right seek minimise impact local environment operate site safely aim bring social economic benefit area presence read investment local community un convention biological diversity cbd convention biological diversity provide framework conservation sustainable use biodiversity promote fair equitable share benefit arise use genetic resource gsk support cbds role currently involve bioprospecte activity result access benefit sharing agreement place possible future undertake development work natural genetic resource indigenous particular country instance access resource obtain accordance cbd reflect local law ensure relevant party receive agree benefit use resource example monetary payment read position statement convention biological diversity read position protect biodiversity home responsibility human right community corporate responsibility report community respect promote right community near operation example local community gsk aim good relationship community site operate way infringe human right seek minimise impact local environment operate site safely aim bring social economic benefit area presence read investment local community un convention biological diversity cbd convention biological diversity provide framework conservation sustainable use biodiversity promote fair equitable share benefit arise use genetic resource gsk support cbds role currently involve bioprospecte activity result access benefit sharing agreement place possible future undertake development work natural genetic resource indigenous particular country instance access resource obtain accordance cbd reflect local law ensure relevant party receive agree benefit use resource example monetary payment read position statement convention biological diversity read position protect biodiversity home responsibility human right society corporate responsibility report society un declaration human right state right standard live adequate health wellbeing family include medical care improve healthcare great challenge face particularly develop world gsk contribute healthcare develop world discover new treatment vaccine wide range product affordable develop country preferential pricing voluntary licence agreement generic manufacturer engage government multilateral agency ngo pharmaceutical company help improve access medicine read effort improve access medicine community investment initiative home responsibility human right society corporate responsibility report society un declaration human right state right standard live adequate health wellbeing family include medical care improve healthcare great challenge face particularly develop world gsk contribute healthcare develop world discover new treatment vaccine wide range product affordable develop country preferential pricing voluntary licence agreement generic manufacturer engage government multilateral agency ngo pharmaceutical company help improve access medicine read effort improve access medicine community investment initiative home responsibility human right activity sensitive country corporate responsibility report activity sensitive country stakeholder concern gsk business activity country poor human right records burma myanmar north korea sudan share un belief box people deny access medicine regime operate country aim provide medicine vaccine country need wish purchase observe trading control require law country operate nation longstanding commitment presence predate oppressive regime subsequent introduction measure trade embargo period governmentimpose trade embargo continue operation subject specific legal restriction need product sensitive country country operate support commit uphold universal declaration human right core standard set international labour organization observe local law regulation un statement right highest attainable standard health paragraph relate access medicine sensitive country paragraph health facility good service accessible discrimination jurisdiction state party paragraph party refrain time impose embargo similar measure restrict supply state adequate medicine medical equipment restriction good instrument political economic pressure paragraph state party covenant ultimately accountable compliance member society individual include health professional family local community intergovernmental nongovernmental organization civil society organization private business sector responsibility realization right health state party provide environment facilitate discharge responsibility read un statement right highest attainable standard health home responsibility human right activity sensitive country corporate responsibility report activity sensitive country stakeholder concern gsk business activity country poor human right records burma myanmar north korea sudan share un belief box people deny access medicine regime operate country aim provide medicine vaccine country need wish purchase observe trading control require law country operate nation longstanding commitment presence predate oppressive regime subsequent introduction measure trade embargo period governmentimpose trade embargo continue operation subject specific legal restriction need product sensitive country country operate support commit uphold universal declaration human right core standard set international labour organization observe local law regulation un statement right highest attainable standard health paragraph relate access medicine sensitive country paragraph health facility good service accessible discrimination jurisdiction state party paragraph party refrain time impose embargo similar measure restrict supply state adequate medicine medical equipment restriction good instrument political economic pressure paragraph state party covenant ultimately accountable compliance member society individual include health professional family local community intergovernmental nongovernmental organization civil society organization private business sector responsibility realization right health state party provide environment facilitate discharge responsibility read un statement right highest attainable standard health home responsibility public policy patient advocacy corporate responsibility report public policy patient advocacy pharmaceutical industry highly regulate government policy legislation significant impact business important engage government stakeholder legislative policy process public policy activity work legislation policy encourage scientific innovation balance interest business stakeholder work patient group help member voice healthcare debate believe conduct advocacy work responsibly valuable contribution debate public policy issue impact business particularly relate research development use pharmaceutical healthcare aim increase stakeholder trust gsk transparent lobby public policy work address concern stakeholder pharmaceutical industry strong influence government publish annual public policy activity website report membership trade association political contribution lobby expenditure publish information work patient group include detail funding provide provide information approach work doctor healthcare professional research practice ethical conduct section website home responsibility public policy patient advocacy corporate responsibility report public policy patient advocacy pharmaceutical industry highly regulate government policy legislation significant impact business important engage government stakeholder legislative policy process public policy activity work legislation policy encourage scientific innovation balance interest business stakeholder work patient group help member voice healthcare debate believe conduct advocacy work responsibly valuable contribution debate public policy issue impact business particularly relate research development use pharmaceutical healthcare aim increase stakeholder trust gsk transparent lobby public policy work address concern stakeholder pharmaceutical industry strong influence government publish annual public policy activity website report membership trade association political contribution lobby expenditure publish information work patient group include detail funding provide provide information approach work doctor healthcare professional research practice ethical conduct section website home responsibility public policy patient advocacy approach external affair corporate responsibility report approach external affair employee involve public policy work abide employee guide business conduct base principle partnership commit working government regulatory authority constructive way communication give view board concern external audience enable assess improve business practice integrity base public policy work research analysis fact respect opinion look constructive solution external affair work line code conduct relevant policy include related competition law prevent corrupt practice political contribution external affair team major region monitor propose legislative reform policy development meet regularly government official stakeholder example multilateral organisation ngo explain view range public policy issue tailor approach suit different culture political tradition country engage public policy process ensure position discussion fully consistent public policy statement ensure standard set guide business conduct apply globally lobby issue affect pharmaceutical industry conduct trade association hire professional lobbyist support public policy work political contribution policy govern contribution political candidate party trade association gsk member trade industry organisation include association british pharmaceutical industry abpi bioindustry association bia biotechnology industry organization bio british pharma group bpg confederation british industry cbi european federation pharmaceutical industry efpia international chamber commerce icc intellectual property owner association ipo international federation pharmaceutical manufacturer association ifpma japan pharmaceutical manufacturers association jpma organisation pharmaceutical producers india oppi organization international investment ofii pharmaceutical research manufacturers america phrma important lobbying conduct trade association reflect policy value work member help set policy attend lobby meeting government stakeholder share view particular issue member trade association trade association adopt public policy position agree participate advocacy activity relate subject senior gsk manager sit board majority industry trade association member raise concern particular advocacy position tophome responsibility public policy patient advocacy approach external affair corporate responsibility report approach external affair employee involve public policy work abide employee guide business conduct base principle partnership commit working government regulatory authority constructive way communication give view board concern external audience enable assess improve business practice integrity base public policy work research analysis fact respect opinion look constructive solution external affair work line code conduct relevant policy include related competition law prevent corrupt practice political contribution external affair team major region monitor propose legislative reform policy development meet regularly government official stakeholder example multilateral organisation ngo explain view range public policy issue tailor approach suit different culture political tradition country engage public policy process ensure position discussion fully consistent public policy statement ensure standard set guide business conduct apply globally lobby issue affect pharmaceutical industry conduct trade association hire professional lobbyist support public policy work political contribution policy govern contribution political candidate party trade association gsk member trade industry organisation include association british pharmaceutical industry abpi bioindustry association bia biotechnology industry organization bio british pharma group bpg confederation british industry cbi european federation pharmaceutical industry efpia international chamber commerce icc intellectual property owner association ipo international federation pharmaceutical manufacturer association ifpma japan pharmaceutical manufacturers association jpma organisation pharmaceutical producers india oppi organization international investment ofii pharmaceutical research manufacturers america phrma important lobbying conduct trade association reflect policy value work member help set policy attend lobby meeting government stakeholder share view particular issue member trade association trade association adopt public policy position agree participate advocacy activity relate subject senior gsk manager sit board majority industry trade association member raise concern particular advocacy position home responsibility public policy patient advocacy approach external affair corporate responsibility report approach external affair employee involve public policy work abide employee guide business conduct base principle partnership commit working government regulatory authority constructive way communication give view board concern external audience enable assess improve business practice integrity base public policy work research analysis fact respect opinion look constructive solution external affair work line code conduct relevant policy include related competition law prevent corrupt practice political contribution external affair team major region monitor propose legislative reform policy development meet regularly government official stakeholder example multilateral organisation ngo explain view range public policy issue tailor approach suit different culture political tradition country engage public policy process ensure position discussion fully consistent public policy statement ensure standard set guide business conduct apply globally lobby issue affect pharmaceutical industry conduct trade association hire professional lobbyist support public policy work political contribution policy govern contribution political candidate party trade association gsk member trade industry organisation include association british pharmaceutical industry abpi bioindustry association bia biotechnology industry organization bio british pharma group bpg confederation british industry cbi european federation pharmaceutical industry efpia international chamber commerce icc intellectual property owner association ipo international federation pharmaceutical manufacturer association ifpma japan pharmaceutical manufacturers association jpma organisation pharmaceutical producers india oppi organization international investment ofii pharmaceutical research manufacturers america phrma important lobbying conduct trade association reflect policy value work member help set policy attend lobby meeting government stakeholder share view particular issue member trade association trade association adopt public policy position agree participate advocacy activity relate subject senior gsk manager sit board majority industry trade association member raise concern particular advocacy position home responsibility public policy patient advocacy public policy activity corporate responsibility report public policy activity engage government stakeholder wide range issue affect industry key issue engage access healthcare disease prevention research practice patient safety intellectual property pricing competitiveness publish position key issue relate corporate responsibility include access medicine develop country research development intellectual property environment public health competitiveness pricing reimbursement market access happy discuss position issue legitimate party contact corporate responsibility team csrcontactgskcom home responsibility public policy patient advocacy public policy activity corporate responsibility report public policy activity engage government stakeholder wide range issue affect industry key issue engage access healthcare disease prevention research practice patient safety intellectual property pricing competitiveness publish position key issue relate corporate responsibility include access medicine develop country research development intellectual property environment public health competitiveness pricing reimbursement market access happy discuss position issue legitimate party contact corporate responsibility team csrcontactgskcom home responsibility public policy patient advocacy public policy activity advocacy healthcare disease prevention corporate responsibility report advocacy healthcare disease prevention global activity safeguard timely unrestricted access influenza virus organisation engage world health organization key developed develop country government include country affect hn strain eu institutions industry association involve efpia evm ifpma ivs phrma gsk position influenza virus unstable mutate quickly government remain vigilant emergence new strain virus share virus strain freely government free sharing virus good interest global public health enable government develop vaccine prevent influenza pandemic s global influenza surveillance network recommend content influenza vaccine twice year act global alert mechanism event pandemic international community unconditionally support network relie receive information virus strain government despite importance timely unrestricted access virus indonesia stop share influenza virus insist access benefit exchange viruse international community include vaccine industry spend finding way help develop country prepare pandemic progress agree effective solution intergovernmental meeting geneva december gsk hopeful solution ensure speedy access pandemic virus assure develop country support require secure access prepandemic pandemic vaccine agree igm activity investment chronic disease prevention treatment organisation engage department health human service office lady congress white house state legislator governor office state health agency industry association involve phrma gsk position chronic disease diabete heart disease lung disease account quarter healthcare spend relatively little invest prevention chronic disease costly complication preventable increasingly manageable advocate threepart approach achieve lowercost higherquality healthcare increase prevention improve treatment accelerate research well treatment chronic disease healthcare provider need incentive promote preventative service address major cause chronic disease obesity smoking healthcare policy need reform well encourage reward medical research improve treatment costly unmet medical need alzheimer disease prevent well manage chronic disease reduce overall healthcare cost long term support petition protect americans fraudulent weight loss claim organisation engage food drug administration industry association involve healthcare association involve gsk position twothird adult overweight obese increase risk illnesse cancer heart disease type diabete dozen dietary supplement market manufacturer claim help people lose weight claim review food drug administrationp afge oaf nd support credible scientific evidence ineffective weight loss product prevent people get support need lose weight federal trade commission consumer fraud survey recently highlight victim fraudulent weightloss product million american consumer fraud cover survey gsk manufacture alli overthecounter weight loss product gain fda approval safety efficacy april gsk research advocacy organisation american dietetic association obesity society shaping americas health submit citizen petition fda asking provide great protection americans fraudulent weight loss claim petition request fda treat weight loss claim way unsubstantiated claim efficacy disease permit dietary supplement health education act petition call fda require rigorous scientific evidence claim aim raise awareness educate public issue fraudulent weight loss product separate development january fda demand recall large number weightloss supplement product warn number company liable criminal charge fda complaint supplement product illegal inclusion regulate unapproved withdraw prescription pharmaceutical include sibutramine rimonabant weight loss phenytoin antiseizure phenolphthalein laxative previously withdraw fda carcinogenicity gsk support continue work fda help protect public false unsubstantiated weight loss claim possibly unsafe product tophome responsibility public policy patient advocacy public policy activity advocacy healthcare disease prevention corporate responsibility report advocacy healthcare disease prevention global activity safeguard timely unrestricted access influenza virus organisation engage world health organization key developed develop country government include country affect hn strain eu institutions industry association involve efpia evm ifpma ivs phrma gsk position influenza virus unstable mutate quickly government remain vigilant emergence new strain virus share virus strain freely government free sharing virus good interest global public health enable government develop vaccine prevent influenza pandemic s global influenza surveillance network recommend content influenza vaccine twice year act global alert mechanism event pandemic international community unconditionally support network relie receive information virus strain government despite importance timely unrestricted access virus indonesia stop share influenza virus insist access benefit exchange viruse international community include vaccine industry spend finding way help develop country prepare pandemic progress agree effective solution intergovernmental meeting geneva december gsk hopeful solution ensure speedy access pandemic virus assure develop country support require secure access prepandemic pandemic vaccine agree igm activity investment chronic disease prevention treatment organisation engage department health human service office lady congress white house state legislator governor office state health agency industry association involve phrma gsk position chronic disease diabete heart disease lung disease account quarter healthcare spend relatively little invest prevention chronic disease costly complication preventable increasingly manageable advocate threepart approach achieve lowercost higherquality healthcare increase prevention improve treatment accelerate research well treatment chronic disease healthcare provider need incentive promote preventative service address major cause chronic disease obesity smoking healthcare policy needs reform well encourage reward medical research improve treatment costly unmet medical need alzheimer disease prevent well manage chronic disease reduce overall healthcare cost long term support petition protect americans fraudulent weight loss claim organisation engage food drug administration industry association involve healthcare association involve gsk position twothird adult overweight obese increase risk illnesse cancer heart disease type diabete dozen dietary supplement market manufacturer claim help people lose weight claim review food drug administration fda support credible scientific evidence ineffective weight loss product prevent people get support need lose weight federal trade commission consumer fraud survey recently highlight victim fraudulent weightloss product million american consumer fraud cover survey gsk manufacture alli overthecounter weight loss product gain fda approval safety efficacy april gsk research advocacy organisation american dietetic association obesity society shaping americas health submit citizen petition fda asking provide great protection americans fraudulent weight loss claim petition request fda treat weight loss claim way unsubstantiated claim efficacy disease permit dietary supplement health education act petition call fda require rigorous scientific evidence claim aim raise awareness educate public issue fraudulent weight loss product separate development january fda demand recall large number weightloss supplement product warn number company liable criminal charge fda complaint supplement product illegal inclusion regulate unapproved withdraw prescription pharmaceutical include sibutramine rimonabant weight loss phenytoin antiseizure phenolphthalein laxative previously withdraw fda carcinogenicity gsk support continue work fda help protect public false unsubstantiated weight loss claim possibly unsafe product home responsibility public policy patient advocacy public policy activity advocacy healthcare disease prevention corporate responsibility report advocacy healthcare disease prevention global activity safeguard timely unrestricted access influenza virus organisation engage world health organization key developed develop country government include country affect hn strain eu institutions industry association involve efpia evm ifpma ivs phrma gsk position influenza virus unstable mutate quickly government remain vigilant emergence new strain virus share virus strain freely government free sharing virus good interest global public health enable government develop vaccine prevent influenza pandemic s global influenza surveillance network recommend content influenza vaccine twice year act global alert mechanism event pandemic international community unconditionally support network relie receive information virus strain government despite importance timely unrestricted access virus indonesia stop share influenza virus insist access benefit exchange viruse international community include vaccine industry spend finding way help develop country prepare pandemic progress agree effective solution intergovernmental meeting geneva december gsk hopeful solution ensure speedy access pandemic virus assure develop country support require secure access prepandemic pandemic vaccine agree igm activity investment chronic disease prevention treatment organisation engage department health human service office lady congress white house state legislator governor office state health agency industry association involve phrma gsk position chronic disease diabete heart disease lung disease account quarter healthcare spend relatively little invest prevention chronic disease costly complication preventable increasingly manageable advocate threepart approach achieve lowercost higherquality healthcare increase prevention improve treatment accelerate research well treatment chronic disease healthcare provider need incentive promote preventative service address major cause chronic disease obesity smoking healthcare policy needs reform well encourage reward medical research improve treatment costly unmet medical need alzheimer disease prevent well manage chronic disease reduce overall healthcare cost long term support petition protect americans fraudulent weight loss claim organisation engage food drug administration industry association involve healthcare association involve gsk position twothird adult overweight obese increase risk illnesse cancer heart disease type diabete dozen dietary supplement market manufacturer claim help people lose weight claim review food drug administration fda support credible scientific evidence ineffective weight loss product prevent people get support need lose weight federal trade commission consumer fraud survey recently highlight victim fraudulent weightloss product million american consumer fraud cover survey gsk manufacture alli overthecounter weight loss product gain fda approval safety efficacy april gsk research advocacy organisation american dietetic association obesity society shaping americas health submit citizen petition fda asking provide great protection americans fraudulent weight loss claim petition request fda treat weight loss claim way unsubstantiated claim efficacy disease permit dietary supplement health education act petition call fda require rigorous scientific evidence claim aim raise awareness educate public issue fraudulent weight loss product separate development january fda demand recall large number weightloss supplement product warn number company liable criminal charge fda complaint supplement product illegal inclusion regulate unapproved withdraw prescription pharmaceutical include sibutramine rimonabant weight loss phenytoin antiseizure phenolphthalein laxative previously withdraw fda carcinogenicity gsk support continue work fda help protect public false unsubstantiated weight loss claim possibly unsafe product home responsibility public policy patient advocacy public policy activity advocacy research practice corporate responsibility report advocacy research practice regularly engage policy maker stakeholder issue relate research practice research environment read research practice global activity advocacy revision declaration helsinki organisation engage world medical association american medical association industry association involve bio ifpma phrma gsk position declaration helsinki set ethical principle conduct research human subject declaration revise world medical association urge world medical association resist change document detailed prescriptive believe create confusion conflict detailed guidance ich guidance good clinical practice shape scope international regime access benefit sharing organisation engage secretariat convention biological diversity cbd ad hoc work group access benefit share uk defra dg trade european commission national european government government industry association involve bio bpg efpia icc ifpma phrma gsk position convention biological diversity cbd sign main goal include fair equitable share benefit arise use genetic resource gsk believe good way achieve cbds access benefitshare objective country introduce national law govern access genetic resource mutually agree contract define benefit arise use share approach allow national government flexibility develop guideline well serve national interest enable user guideline reach agreement appropriate individual case notwithstanding gsk support national legislation recognise cbds mandate elaborate negotiate international regime access benefitsharing believe result regime currently discussion cbd consistent cbds treaty objective create new obligation cbd signatory apply retrospectively provide guidance government cbd member achieve access benefitshare objective prescribing rule adopt sectoral approach seek enforce size fit solution industry apply genetic resource define cbd broad class material extend human genetic resource derivative pathogen read position statement convention biological diversity european activity advocacy european animal directive organisation engage european commission industry association involve abpi efpia gsk position european animal directive originally introduce govern use animal experimental scientific purpose aim establish framework animal research activity eu european commission publish draft revision directive control use laboratory animal set minimum standard housing care gsk welcome review directive recognise need revise reflect advance animal welfare science welcome recommendation draft revision integrate current practice example welcome rule relate replacement reduction refinement use animal research know rs need permanent standing ethic review body establishment use animal research essential legislative change achieve high animal welfare standard support environment allow research lead new medicine vaccine meet patient need regard number concern relate restriction use nonhuman primate disease consider lifethreatene seriously debilitate reuse surgically instrument animal likely result increase number animal procedure mild moderate read position statement use nonhuman primate research support new approach pharmacovigilance eu organisation engage european commission european medicines agency uk government industry association involve abpi efpia gsk position gsk seek new approach pharmacovigilance regulation eu allow pharmaceutical company regulator focus resource safety evaluation activity instead compliance unclear complex regulatory demand new pharmacovigilance legislation contain clear concise provision simplify strengthen provide legal certainty eu legislative framework pharmacovigilance specifically contain single set simplified rule single reporting point adverse drug reaction eu require report case electronic reporting system implement contain clear flexible provision allow individual company appoint number qualified person pharmacovigilance qppvs require provide consistent standard inspection company pharmacovigilance department emea eu member state authority tophome responsibility public policy patient advocacy public policy activity advocacy research practice corporate responsibility report advocacy research practice regularly engage policy maker stakeholder issue relate research practice research environment read research practice global activity advocacy revision declaration helsinki organisation engage world medical association american medical association industry association involve bio ifpma phrma gsk position declaration helsinki set ethical principle conduct research human subject declaration revise world medical association urge world medical association resist change document detailed prescriptive believe create confusion conflict detailed guidance ich guidance good clinical practice shape scope international regime access benefit sharing organisation engage secretariat convention biological diversity cbd ad hoc work group access benefit share uk defra dg trade european commission national european government government industry association involve bio bpg efpia icc ifpma phrma gsk position convention biological diversity cbd sign main goal include fair equitable share benefit arise use genetic resource gsk believe good way achieve cbds access benefitshare objective country introduce national law govern access genetic resource mutually agree contract define benefit arise use share approach allow national government flexibility develop guideline well serve national interest enable user guideline reach agreement appropriate individual case notwithstanding gsk support national legislation recognise cbds mandate elaborate negotiate international regime access benefitsharing believe result regime currently discussion cbd consistent cbds treaty objective create new obligation cbd signatory apply retrospectively provide guidance government cbd member achieve access benefitshare objective prescribing rule adopt sectoral approach seek enforce size fit solution industry apply genetic resource define cbd broad class material extend human genetic resource derivative pathogen read position statement convention biological diversity european activity advocacy european animal directive organisation engage european commission industry association involve abpi efpia gsk position european animal directive originally introduce govern use animal experimental scientific purpose aim establish framework animal research activity eu european commission publish draft revision directive control use laboratory animal set minimum standard housing care gsk welcome review directive recognise need revise reflect advance animal welfare science welcome recommendation draft revision integrate current practice example welcome rule relate replacement reduction refinement use animal research know rs need permanent standing ethic review body establishment use animal research essential legislative change achieve high animal welfare standard support environment allow research lead new medicine vaccine meet patient need regard number concern relate restriction use nonhuman primate disease consider lifethreatene seriously debilitate reuse surgically instrument animal likely result increase number animal procedure mild moderate read position statement use nonhuman primate research support new approach pharmacovigilance eu organisation engage european commission european medicines agency uk government industry association involve abpi efpia gsk position gsk seek new approach pharmacovigilance regulation eu allow pharmaceutical company regulator focus resource safety evaluation activity instead compliance unclear complex regulatory demand new pharmacovigilance legislation contain clear concise provision simplify strengthen provide legal certainty eu legislative framework pharmacovigilance specifically contain single set simplified rule single reporting point adverse drug reaction eu require report case electronic reporting system implement contain clear flexible provision allow individual company appoint number qualified person pharmacovigilance qppvs require provide consistent standard inspection company pharmacovigilance department emea eu member state authority home responsibility public policy patient advocacy public policy activity advocacy research practice corporate responsibility report advocacy research practice regularly engage policy maker stakeholder issue relate research practice research environment read research practice global activity advocacy revision declaration helsinki organisation engage world medical association american medical association industry association involve bio ifpma phrma gsk position declaration helsinki set ethical principle conduct research human subject declaration revise world medical association urge world medical association resist change document detailed prescriptive believe create confusion conflict detailed guidance ich guidance good clinical practice shape scope international regime access benefit sharing organisation engage secretariat convention biological diversity cbd ad hoc work group access benefit share uk defra dg trade european commission national european government government industry association involve bio bpg efpia icc ifpma phrma gsk position convention biological diversity cbd sign main goal include fair equitable share benefit arise use genetic resource gsk believe good way achieve cbds access benefitshare objective country introduce national law govern access genetic resource mutually agree contract define benefit arise use share approach allow national government flexibility develop guideline well serve national interest enable user guideline reach agreement appropriate individual case notwithstanding gsk support national legislation recognise cbds mandate elaborate negotiate international regime access benefitsharing believe result regime currently discussion cbd consistent cbds treaty objective create new obligation cbd signatory apply retrospectively provide guidance government cbd member achieve access benefitshare objective prescribing rule adopt sectoral approach seek enforce size fit solution industry apply genetic resource define cbd broad class material extend human genetic resource derivative pathogen read position statement convention biological diversity european activity advocacy european animal directive organisation engage european commission industry association involve abpi efpia gsk position european animal directive originally introduce govern use animal experimental scientific purpose aim establish framework animal research activity eu european commission publish draft revision directive control use laboratory animal set minimum standard housing care gsk welcome review directive recognise need revise reflect advance animal welfare science welcome recommendation draft revision integrate current practice example welcome rule relate replacement reduction refinement use animal research know rs need permanent standing ethic review body establishment use animal research essential legislative change achieve high animal welfare standard support environment allow research lead new medicine vaccine meet patient need regard number concern relate restriction use nonhuman primate disease consider lifethreatene seriously debilitate reuse surgically instrument animal likely result increase number animal procedure mild moderate read position statement use nonhuman primate research support new approach pharmacovigilance eu organisation engage european commission european medicines agency uk government industry association involve abpi efpia gsk position gsk seek new approach pharmacovigilance regulation eu allow pharmaceutical company regulator focus resource safety evaluation activity instead compliance unclear complex regulatory demand new pharmacovigilance legislation contain clear concise provision simplify strengthen provide legal certainty eu legislative framework pharmacovigilance specifically contain single set simplified rule single reporting point adverse drug reaction eu require report case electronic reporting system implement contain clear flexible provision allow individual company appoint number qualified person pharmacovigilance qppvs require provide consistent standard inspection company pharmacovigilance department emea eu member state authority home responsibility public policy patient advocacy public policy activity advocacy patient safety corporate responsibility report advocacy patient safety activity legislation prescription medicine import organisation engage department health human service food drug administration fda congress state board pharmacy state legislator governor office industry association involve bio phrma gsk position current law prevent prescription medicine import safety cost saving certification secretary health human service pende legislation remove safety saving certification requirement make easy legally import medicine undermine fdas ability protect distribution system counterfeit unsafe medicine harm patient guarantee consumer save money department health human service find thirdparty payer insurance company likely benefit gsk support safe alternative help patient afford medicine partnership prescription assistance ppa example give access public private patient assistance programme patient lack prescription drug coverage read gsk patient assistance program home responsibility public policy patient advocacy public policy activity advocacy patient safety corporate responsibility report advocacy patient safety activity legislation prescription medicine import organisation engage department health human service food drug administration fda congress state board pharmacy state legislator governor office industry association involve bio phrma gsk position current law prevent prescription medicine import safety cost saving certification secretary health human service pende legislation remove safety saving certification requirement make easy legally import medicine undermine fdas ability protect distribution system counterfeit unsafe medicine harm patient guarantee consumer save money department health human service find thirdparty payer insurance company likely benefit gsk support safe alternative help patient afford medicine partnership prescription assistance ppa example give access public private patient assistance programme patient lack prescription drug coverage read gsk patient assistance program home responsibility public policy patient advocacy public policy activity advocacy intellectual property corporate responsibility report advocacy intellectual property activity patent system reform federal legislation organisation engage patent trademark office pto congress industry association involve bio coalition st century patent reform phrma gsk position patent law framework provide business certainty long period promote investment essential researchbase pharmaceutical industry wide range manufacturer long lead time research market congress consider patent reform legislation negative effect current framework specifically proposal fail strike appropriate balance area restrict abuse inequitable conduct doctrine encourage infringer try prove litigation patent improperly obtain completely valid patent hold unenforceable allocation damage infringement addition give pto substantive rulemaking authority remove responsibility establish substantive patent law congress innovation policy public debate gsk work coalition researchbase company manufacturer university small inventor promote patent reform stimulate investment research strengthen patent system support patent reform clear provide business certainty improve quality patent remove subjectivity litigation issue asian activity compulsory licensing thailand organisation engage thai government include thai ministry public health academic ngos member business community thailand world health organization international ngo eu member state industry association involve bpg efpia ifpma phrma prema gsk position late thai government issue compulsory licence pharmaceutical product compulsory license oncology product announce prior previously elect government leave office early implement support thai government public health goal want help improve health outcome people thailand compulsory licence legitimate policy option thai government routine policy tool commercial purpose unilaterally compulsory licence increase access medicine believe effective engage dialogue industry stakeholder find sustainable way address healthcare issue include access medicine hope reinforce dialogue government stakeholder future healthcare intellectual property india organisation engage relevant agency indian government member pharmaceutical industry wide business community india indian academics civil society representative eu member state government european commission industry association involve bpg efpia oppi phrma gsk position believe india tremendous strength science pharmaceutical couple rapid economic growth offer government opportunity tackle fundamental characteristic healthcare system policy base improvement indias intellectual property ip regime level provide eu encourage investment collaborative rd issue poafg iep rig ohf ts fundamental barrier access healthcare believe reform increase investment indian healthcare system priority want active partner address challenge tophome responsibility public policy patient advocacy public policy activity advocacy intellectual property corporate responsibility report advocacy intellectual property activity patent system reform federal legislation organisation engage patent trademark office pto congress industry association involve bio coalition st century patent reform phrma gsk position patent law framework provide business certainty long period promote investment essential researchbase pharmaceutical industry wide range manufacturer long lead time research market congress consider patent reform legislation negative effect current framework specifically proposal fail strike appropriate balance area restrict abuse inequitable conduct doctrine encourage infringer try prove litigation patent improperly obtain completely valid patent hold unenforceable allocation damage infringement addition give pto substantive rulemaking authority remove responsibility establish substantive patent law congress innovation policy public debate gsk work coalition researchbase company manufacturer university small inventor promote patent reform stimulate investment research strengthen patent system support patent reform clear provide business certainty improve quality patent remove subjectivity litigation issue asian activity compulsory licensing thailand organisation engage thai government include thai ministry public health academic ngos member business community thailand world health organization international ngo eu member state industry association involve bpg efpia ifpma phrma prema gsk position late thai government issue compulsory licence pharmaceutical product compulsory license oncology product announce prior previously elect government leave office early implement support thai government public health goal want help improve health outcome people thailand compulsory licence legitimate policy option thai government routine policy tool commercial purpose unilaterally compulsory licence increase access medicine believe effective engage dialogue industry stakeholder find sustainable way address healthcare issue include access medicine hope reinforce dialogue government stakeholder future healthcare intellectual property india organisation engage relevant agency indian government member pharmaceutical industry wide business community india indian academics civil society representative eu member state government european commission industry association involve bpg efpia oppi phrma gsk position believe india tremendous strength science pharmaceutical couple rapid economic growth offer government opportunity tackle fundamental characteristic healthcare system policy base improvement indias intellectual property ip regime level provide eu encourage investment collaborative rd issue ip right fundamental barrier access healthcare believe reform increase investment indian healthcare system priority want active partner address challenge home responsibility public policy patient advocacy public policy activity advocacy intellectual property corporate responsibility report advocacy intellectual property activity patent system reform federal legislation organisation engage patent trademark office pto congress industry association involve bio coalition st century patent reform phrma gsk position patent law framework provide business certainty long period promote investment essential researchbase pharmaceutical industry wide range manufacturer long lead time research market congress consider patent reform legislation negative effect current framework specifically proposal fail strike appropriate balance area restrict abuse inequitable conduct doctrine encourage infringer try prove litigation patent improperly obtain completely valid patent hold unenforceable allocation damage infringement addition give pto substantive rulemaking authority remove responsibility establish substantive patent law congress innovation policy public debate gsk work coalition researchbase company manufacturer university small inventor promote patent reform stimulate investment research strengthen patent system support patent reform clear provide business certainty improve quality patent remove subjectivity litigation issue asian activity compulsory licensing thailand organisation engage thai government include thai ministry public health academic ngos member business community thailand world health organization international ngo eu member state industry association involve bpg efpia ifpma phrma prema gsk position late thai government issue compulsory licence pharmaceutical product compulsory license oncology product announce prior previously elect government leave office early implement support thai government public health goal want help improve health outcome people thailand compulsory licence legitimate policy option thai government routine policy tool commercial purpose unilaterally compulsory licence increase access medicine believe effective engage dialogue industry stakeholder find sustainable way address healthcare issue include access medicine hope reinforce dialogue government stakeholder future healthcare intellectual property india organisation engage relevant agency indian government member pharmaceutical industry wide business community india indian academics civil society representative eu member state government european commission industry association involve bpg efpia oppi phrma gsk position believe india tremendous strength science pharmaceutical couple rapid economic growth offer government opportunity tackle fundamental characteristic healthcare system policy base improvement indias intellectual property ip regime level provide eu encourage investment collaborative rd issue ip right fundamental barrier access healthcare believe reform increase investment indian healthcare system priority want active partner address challenge home responsibility public policy patient advocacy public policy activity advocacy pricing competitiveness corporate responsibility report advocacy pricing competitiveness european activity guide principle relative effectiveness assessment pricing organisation engage eu member states european commission stakeholder representative participate eus high level pharmaceutical forum industry association involve efpia europabio gsk position government funding decision base assessment medicine clinical cost effectiveness believe value assessment conduct transparently timely manner key stakeholder able submit evidence assessment government allow great pricing flexibility longterm value medicine certain launch gsk represent efpia strongly support good practice principle relative effectiveness assessment develop framework eus high level pharmaceutical forum hlpf adopt guide principle good practice implement pricing reimbursement policy efpia health technology assessment principle industry previous adopt gsk help develop align principle adopt hlpf improve regulation impact pharmaceutical industry competitiveness uk organisation engage uk government european commission industry association involve abpi cbi institute directors gsk position pharmaceutical industry highly regulate industry europe gsk support strong regulation work uk government european commission propose way simplify regulation achieve policy goal align aim uk government european commission reduce regulatory burden place industry gsk submit series proposal uk government simplification exist regulation similar submission commission focus regulation originate european level home responsibility public policy patient advocacy public policy activity advocacy pricing competitiveness corporate responsibility report advocacy pricing competitiveness european activity guide principle relative effectiveness assessment pricing organisation engage eu member states european commission stakeholder representative participate eus high level pharmaceutical forum industry association involve efpia europabio gsk position government funding decision base assessment medicine clinical cost effectiveness believe value assessment conduct transparently timely manner key stakeholder able submit evidence assessment government allow great pricing flexibility longterm value medicine certain launch gsk represent efpia strongly support good practice principle relative effectiveness assessment develop framework eus high level pharmaceutical forum hlpf adopt guide principle good practice implement pricing reimbursement policy efpia health technology assessment principle industry previous adopt gsk help develop align principle adopt hlpf improve regulation impact pharmaceutical industry competitiveness uk organisation engage uk government european commission industry association involve abpi cbi institute directors gsk position pharmaceutical industry highly regulate industry europe gsk support strong regulation work uk government european commission propose way simplify regulation achieve policy goal align aim uk government european commission reduce regulatory burden place industry gsk submit series proposal uk government simplification exist regulation similar submission commission focus regulation originate european level home responsibility public policy patient advocacy political contribution lobbying expenditure corporate responsibility report political contribution lobbying expenditure late december gsk announce new global policy voluntarily stop corporate political contribution prior gsk political contribution corporate fund country authorise law culturally appropriate canada new policy ensure contribution future contribution political party political organisation european union prohibit gsk policy prior change corporate governance section annual report information prior policy change contribute political organisation canada rest world contribution rare low monetary value contribution agree local management approve gsk international legal operation corporate government affair department contribution compliance local law custom contribution corporate contribution party affiliate committee candidate run federal office prohibit law state local political campaign finance variety source include contribution company individual ngos local campaign committee support pro business candidate corporate contribution accept legal mean corporation voice political debate ensure implication whatsoever contribution provide gsk special privilege company change policy late december prohibit corporate contribution political candidate contribution state candidate prior change policy gsk donate candidate stateheld office contribution permit law basis political party contribution candidate support environment appropriately reward highrisk highinvestment industry work preserve free market principle intellectual property right approximately cent contribution republican candidate cent democratic candidate state publish information disclose name contributor contribution establish threshold political action committee contribution accordance federal election campaign act gsk establish political action committee pac facilitate voluntary political contribution eligible employee pac control gsk decision recipient contribution participate employee exercise legal right pool resource political contribution pac contribution voluntary contribution subject strict limitation example gsk pac contribute election individual candidate federal office pac run govern board participate gsk employee company require law pac contribution report federal election commission fec gsk employee pac contribute cent republican cent democrat cent unaffiliated party candidate run state federal office contribution canada gsk donate canada political candidate province legal lobbying expenditure europe december gsk sign european commission new code conduct voluntary register organisation work influence european union institution transparency register interest declare cost associate lobby eu institution range include run brussels advocacy office salary external event educational material figure take account proportion employee time spend interest representation report lobby expenditure congress accordance lobby disclosure act spend million federal lobbying activity include cost salary benefit employee register lobby government use lobbying consultant support lobbying contact planning activity research run gsk washington dc government affair office support staff portion trade association fee associate federal lobbying report state lobbying expense line applicable state law contribution policy group gsk contribute group provide forum policy analysis debate include think tank number country organisation ushome responsibility public policy patient advocacy political contribution lobbying expenditure corporate responsibility report political contribution lobbying expenditure late december gsk announce new global policy voluntarily stop corporate political contribution prior gsk political contribution corporate fund country authorise law culturally appropriate canada new policy ensure contribution future contribution political party political organisation european union prohibit gsk policy prior change corporate governance section annual report information prior policy change contribute political organisation canada rest world contribution rare low monetary value contribution agree local management approve gsk international legal operation corporate government affair department contribution compliance local law custom contribution corporate contribution party affiliate committee candidate run federal office prohibit law state local political campaign finance variety source include contribution company individual ngos local campaign committee support pro business candidate corporate contribution accept legal mean corporation voice political debate ensure implication whatsoever contribution provide gsk special privilege company change policy late december prohibit corporate contribution political candidate contribution state candidate prior change policy gsk donate candidate stateheld office contribution permit law basis political party contribution candidate support environment appropriately reward highrisk highinvestment industry work preserve free market principle intellectual property right approximately cent contribution republican candidate cent democratic candidate state publish information disclose name contributor contribution establish threshold political action committee contribution accordance federal election campaign act gsk establish political action committee pac facilitate voluntary political contribution eligible employee pac control gsk decision recipient contribution participate employee exercise legal right pool resource political contribution pac contribution voluntary contribution subject strict limitation example gsk pac contribute election individual candidate federal office pac run govern board participate gsk employee company require law pac contribution report federal election commission fec gsk employee pac contribute cent republican cent democrat cent unaffiliated party candidate run state federal office contribution canada gsk donate canada political candidate province legal lobbying expenditure europe december gsk sign european commission new code conduct voluntary register organisation work influence european union institution transparency register interest declare cost associate lobby eu institution range include run brussels advocacy office salary external event educational material figure take account proportion employee time spend interest representation report lobby expenditure congress accordance lobby disclosure act spend million federal lobbying activity include cost salary benefit employee register lobby government use lobbying consultant support lobbying contact planning activity research run gsk washington dc government affair office support staff portion trade association fee associate federal lobbying report state lobbying expense line applicable state law contribution policy group gsk contribute group provide forum policy analysis debate include think tank number country organisation home responsibility public policy patient advocacy political contribution lobbying expenditure corporate responsibility report political contribution lobbying expenditure late december gsk announce new global policy voluntarily stop corporate political contribution prior gsk political contribution corporate fund country authorise law culturally appropriate canada new policy ensure contribution future contribution political party political organisation european union prohibit gsk policy prior change corporate governance section annual report information prior policy change contribute political organisation canada rest world contribution rare low monetary value contribution agree local management approve gsk international legal operation corporate government affair department contribution compliance local law custom contribution corporate contribution party affiliate committee candidate run federal office prohibit law state local political campaign finance variety source include contribution company individual ngos local campaign committee support pro business candidate corporate contribution accept legal mean corporation voice political debate ensure implication whatsoever contribution provide gsk special privilege company change policy late december prohibit corporate contribution political candidate contribution state candidate prior change policy gsk donate candidate stateheld office contribution permit law basis political party contribution candidate support environment appropriately reward highrisk highinvestment industry work preserve free market principle intellectual property right approximately cent contribution republican candidate cent democratic candidate state publish information disclose name contributor contribution establish threshold political action committee contribution accordance federal election campaign act gsk establish political action committee pac facilitate voluntary political contribution eligible employee pac control gsk decision recipient contribution participate employee exercise legal right pool resource political contribution pac contribution voluntary contribution subject strict limitation example gsk pac contribute election individual candidate federal office pac run govern board participate gsk employee company require law pac contribution report federal election commission fec gsk employee pac contribute cent republican cent democrat cent unaffiliated party candidate run state federal office contribution canada gsk donate canada political candidate province legal lobbying expenditure europe december gsk sign european commission new code conduct voluntary register organisation work influence european union institution transparency register interest declare cost associate lobby eu institution range include run brussels advocacy office salary external event educational material figure take account proportion employee time spend interest representation report lobby expenditure congress accordance lobby disclosure act spend million federal lobbying activity include cost salary benefit employee register lobby government use lobbying consultant support lobbying contact planning activity research run gsk washington dc government affair office support staff portion trade association fee associate federal lobbying report state lobbying expense line applicable state law contribution policy group gsk contribute group provide forum policy analysis debate include think tank number country organisation home responsibility public policy patient advocacy patient advocacy corporate responsibility report patient advocacy patient group nonprofit organisation found patient caregiver family member health professional provide member information condition guidance live disease engage healthcare provider government medium promote improve treatment service patient campaign change issue affect patient carer life carry vital research cause potential treatment specific condition gsk work wide range patient group disease area cancer asthma diabete alzheimer disease multiple sclerosis hivaid gsk patient group share common concern healthcare system focus prevent treat manage disease party believe patient access quality medicine service information disease patient group important stakeholder gsk engage commitment patient focus company relationship patient group mutually beneficial help well understand patient need illness work patient group strengthen support patient illness diagnosis chronic treatment endoflife care help group patient ability voice hear healthcare debate alongside stakeholder approach support patient group world number different way include provide core funding support daytoday running group oneoff donation help patient group conduct specific event activity example breast cancer awareness day educational support training staff management skill disease education work disease awarenessprevention project relationship patient group define write agreement specify group use funding benefit member stakeholder concern pharmaceutical company use patient group way marketing product support patient group big agenda dictate new medicine available patient patient access kind treatment need commit maintain high ethical standard transparency area develop detailed guidance standard operating procedure sop employee major region policy conjunction gsk patient advocacy manual ensure gsk employee work patient group comply applicable law regulation standard read summary sop employee outside agency work gsk likely interact patient group abide guideline sop provide training employee understand requirement example marketing employee attend webinar guideline sops patient advocacy team europe asia pacific japan emerge market region coordinate interaction patient group adherence policy global principle patient advocacy decentralise number function include state government affair rd communication marketing coordinate state government affair group employee region access patient advocacy resource intranet site europe publish newsletter raise employee awareness internal external development relate patient group conduct review department relationship patient group lead development interactive patient group database track relationship patient advocacy group project support enable employee learn past interaction patient group type project support help allocate resource patient group efficiently database launch encourage independence believe patient group independent encourage seek financial support wide range organisation possible ensure funding patient group appropriate size guideline state gsk funding cent group overall income vast majority instance actual percentage lower allow exemption cent cap group support limited income small donation example exceed limit group difficulty attract funding nature activity example provide needle exchange drug user case approve general manager local operating company encourage patient group seek fund multiple source hold workshop fund applicationshome responsibility public policy patient advocacy patient advocacy corporate responsibility report patient advocacy patient group nonprofit organisation found patient caregiver family member health professional provide member information condition guidance live disease engage healthcare provider government medium promote improve treatment service patient campaign change issue affect patient carer life carry vital research cause potential treatment specific condition gsk work wide range patient group disease area cancer asthma diabete alzheimer disease multiple sclerosis hivaid gsk patient group share common concern healthcare system focus prevent treat manage disease party believe patient access quality medicine service information disease patient group important stakeholder gsk engage commitment patient focus company relationship patient group mutually beneficial help well understand patient need illness work patient group strengthen support patient illness diagnosis chronic treatment endoflife care help group patient ability voice hear healthcare debate alongside stakeholder approach support patient group world number different way include provide core funding support daytoday running group oneoff donation help patient group conduct specific event activity example breast cancer awareness day educational support training staff management skill disease education work disease awarenessprevention project relationship patient group define write agreement specify group use funding benefit member stakeholder concern pharmaceutical company use patient group way marketing product support patient group big agenda dictate new medicine available patient patient access kind treatment need commit maintain high ethical standard transparency area develop detailed guidance standard operating procedure sop employee major region policy conjunction gsk patient advocacy manual ensure gsk employee work patient group comply applicable law regulation standard read summary sop employee outside agency work gsk likely interact patient group abide guideline sop provide training employee understand requirement example marketing employee attend webinar guideline sops patient advocacy team europe asia pacific japan emerge market region coordinate interaction patient group adherence policy global principle patient advocacy decentralise number function include state government affair rd communication marketing coordinate state government affair group employee region access patient advocacy resource intranet site europe publish newsletter raise employee awareness internal external development relate patient group conduct review department relationship patient group lead development interactive patient group database track relationship patient advocacy group project support enable employee learn past interaction patient group type project support help allocate resource patient group efficiently database launch encourage independence believe patient group independent encourage seek financial support wide range organisation possible ensure funding patient group appropriate size guideline state gsk funding cent group overall income vast majority instance actual percentage lower allow exemption cent cap group support limited income small donation example exceed limit group difficulty attract funding nature activity example provide needle exchange drug user case approve general manager local operating company encourage patient group seek fund multiple source hold workshop funding application home responsibility public policy patient advocacy patient advocacy corporate responsibility report patient advocacy patient group nonprofit organisation found patient caregiver family member health professional provide member information condition guidance live disease engage healthcare provider government medium promote improve treatment service patient campaign change issue affect patient carer life carry vital research cause potential treatment specific condition gsk work wide range patient group disease area cancer asthma diabete alzheimer disease multiple sclerosis hivaid gsk patient group share common concern healthcare system focus prevent treat manage disease party believe patient access quality medicine service information disease patient group important stakeholder gsk engage commitment patient focus company relationship patient group mutually beneficial help well understand patient need illness work patient group strengthen support patient illness diagnosis chronic treatment endoflife care help group patient ability voice hear healthcare debate alongside stakeholder approach support patient group world number different way include provide core funding support daytoday running group oneoff donation help patient group conduct specific event activity example breast cancer awareness day educational support training staff management skill disease education work disease awarenessprevention project relationship patient group define write agreement specify group use funding benefit member stakeholder concern pharmaceutical company use patient group way marketing product support patient group big agenda dictate new medicine available patient patient access kind treatment need commit maintain high ethical standard transparency area develop detailed guidance standard operating procedure sop employee major region policy conjunction gsk patient advocacy manual ensure gsk employee work patient group comply applicable law regulation standard read summary sop employee outside agency work gsk likely interact patient group abide guideline sop provide training employee understand requirement example marketing employee attend webinar guideline sops patient advocacy team europe asia pacific japan emerge market region coordinate interaction patient group adherence policy global principle patient advocacy decentralise number function include state government affair rd communication marketing coordinate state government affair group employee region access patient advocacy resource intranet site europe publish newsletter raise employee awareness internal external development relate patient group conduct review department relationship patient group lead development interactive patient group database track relationship patient advocacy group project support enable employee learn past interaction patient group type project support help allocate resource patient group efficiently database launch encourage independence believe patient group independent encourage seek financial support wide range organisation possible ensure funding patient group appropriate size guideline state gsk funding cent group overall income vast majority instance actual percentage lower allow exemption cent cap group support limited income small donation example exceed limit group difficulty attract funding nature activity example provide needle exchange drug user case approve general manager local operating company encourage patient group seek fund multiple source hold workshop funding application home responsibility public policy patient advocacy patient advocacy transparency corporate responsibility report transparency believe transparent support patient group help build trust stakeholder include group publish information work patient group europe asia pacific japan emerge market region information support patient group work globally include detail funding receive detail fund patient organisation pharmaceutical company publish level information go industry code practice require list group fund detailed information gsk australia canada find website february report educational charitable grant provide healthrelate organisation include hospital teach institution patient advocacy group report update quarterly detail fund patient organisation work patient group standard operating procedure state involvement patient organisation declare transparent gsk seek patient organisation endorsement medicine pay patient group endorse gsk service medicine promote patient organisation gsk create patient organisation sole funding sponsor patient organisation provide cent funding patient organisation exception allow case rare disease focus startup funding cent agree directly local country region general manager head regional government affair gsk seek direct return investment funding patient organisation information gsk pipeline compound factual nonpromotional provide patient organisation scientific dialogue acceptable gsk clinical trial medical personnel work patient organisation ensure optimal clinical trial recruitment consult clinical trial design protocol gsk directly sponsor patient organisation representative attend medical congress conference healthcare professional event exception include representative invite speak conference medical congress specific workstream design patient gsk sponsor representative attend nonmedical congress gsk pay modest honorarium speaker fee patient organisation advisory board member speaker represent party working gsk give project fully transparent relationship interact patient group project home responsibility public policy patient advocacy patient advocacy transparency corporate responsibility report transparency believe transparent support patient group help build trust stakeholder include group publish information work patient group europe asia pacific japan emerge market region information support patient group work globally include detail funding receive detail fund patient organisation pharmaceutical company publish level information go industry code practice require list group fund detailed information gsk australia canada find website february report educational charitable grant provide healthrelate organisation include hospital teach institution patient advocacy group report update quarterly detail fund patient organisation work patient group standard operating procedure state involvement patient organisation declare transparent gsk seek patient organisation endorsement medicine pay patient group endorse gsk service medicine promote patient organisation gsk create patient organisation sole funding sponsor patient organisation provide cent funding patient organisation exception allow case rare disease focus startup funding cent agree directly local country region general manager head regional government affair gsk seek direct return investment funding patient organisation information gsk pipeline compound factual nonpromotional provide patient organisation scientific dialogue acceptable gsk clinical trial medical personnel work patient organisation ensure optimal clinical trial recruitment consult clinical trial design protocol gsk directly sponsor patient organisation representative attend medical congress conference healthcare professional event exception include representative invite speak conference medical congress specific workstream design patient gsk sponsor representative attend nonmedical congress gsk pay modest honorarium speaker fee patient organisation advisory board member speaker represent party working gsk give project fully transparent relationship interact patient group project home responsibility public policy patient advocacy patient advocacy understand patient corporate responsibility report understand patient help well understand patient need set advisory board europe include representative wide range patient group advisory board independent chair meet regularly attend senior gsk manager board enable voice patient hear high level gsk allow access view patient group seek feedback subject clinical trial pharmacogenetic information provide patient ethical issue region invite speaker patient group meet gsk employee include scientist researcher marketer discuss issue affect member improve understand patient need show gsk employee difference work people life read focus patient initiative help well understand patient need develop well medicine engage patient group patient advocacy leader summit pal bring group discuss health policy concern develop new skill andor way expand influence pal patient group opportunity learn gsk tell company well support work involve run total summit european country japan discussion pal focus broad range issue include effort establish patientcentred healthcare japan availability medicine role patient patient organisation netherlands clinical trial germany healthcare political priority healthcare funding impact patient estonia healthcare system reform patient rights czech republic healthcare finance patient access healthcare economic downturn latvia patient input national strategy cancer bulgaria communication strategy patient association france importance innovation intervention prevention health care reform gsk cosponsor european patient forum annual conference brussels pharmaceutical company pfizer bring approximately patient group stakeholder exchange idea improve healthcare role patient organisation intend hold pal summit europe support similar number pal plan regional pal meeting asia pacific emerge market region home responsibility public policy patient advocacy patient advocacy understand patient corporate responsibility report understand patient help well understand patient need set advisory board europe include representative wide range patient group advisory board independent chair meet regularly attend senior gsk manager board enable voice patient hear high level gsk allow access view patient group seek feedback subject clinical trial pharmacogenetic information provide patient ethical issue region invite speaker patient group meet gsk employee include scientist researcher marketer discuss issue affect member improve understand patient need show gsk employee difference work people life read focus patient initiative help well understand patient need develop well medicine engage patient group patient advocacy leader summit pal bring group discuss health policy concern develop new skill andor way expand influence pal patient group opportunity learn gsk tell company well support work involve run total summit european country japan discussion pal focus broad range issue include effort establish patientcentred healthcare japan availability medicine role patient patient organisation netherlands clinical trial germany healthcare political priority healthcare funding impact patient estonia healthcare system reform patient rights czech republic healthcare finance patient access healthcare economic downturn latvia patient input national strategy cancer bulgaria communication strategy patient association france importance innovation intervention prevention health care reform gsk cosponsor european patient forum annual conference brussels pharmaceutical company pfizer bring approximately patient group stakeholder exchange idea improve healthcare role patient organisation intend hold pal summit europe support similar number pal plan regional pal meeting asia pacific emerge market region home responsibility public policy patient advocacy patient advocacy develop industry standard corporate responsibility report develop industry standard take leadership approach develop industry standard engage patient group work industry trade group phrma develop guideline member work patient group launch help national health council develop guideline patient group follow work company patient group member council require follow guideline launch update august publication report work phrma develop guideline work patient group stop company agree need develop industry wide guideline phrma support national health council guideline patient group work company gsk remain committed develop industry standard engage patient group europe closely involve development efpia code practice relationship patient organisation come effect july code bear close resemblance gsk policy work patient group senior gsk manager chair efpia patient relation network originally develop code efpia code contain requirement gsk policy states company promote medicine patient group write agreement place interaction patient group company list patient group work describe nature support involve training company prepare implement code european level locally country include finland germany home responsibility public policy patient advocacy patient advocacy develop industry standard corporate responsibility report develop industry standard take leadership approach develop industry standard engage patient group work industry trade group phrma develop guideline member work patient group launch help national health council develop guideline patient group follow work company patient group member council require follow guideline launch update august publication report work phrma develop guideline work patient group stop company agree need develop industry wide guideline phrma support national health council guideline patient group work company gsk remain committed develop industry standard engage patient group europe closely involve development efpia code practice relationship patient organisation come effect july code bear close resemblance gsk policy work patient group senior gsk manager chair efpia patient relation network originally develop code efpia code contain requirement gsk policy states company promote medicine patient group write agreement place interaction patient group company list patient group work describe nature support involve training company prepare implement code european level locally country include finland germany home responsibility public policy patient advocacy patient advocacy advocacy corporate responsibility report advocacy activity describe advocacy activity undertake partnership patient group global recruitment lung cancer vaccine clinical trial partner global lung cancer coalition glcc body comprise notforprofit group world promote understand lung cancer advocate patient right early detection well treatment supportive care glcc member commit campaign lung cancer research increase enrolment patient clinical trial new therapy trial glcc network help recruitment patient phase lll clinical trial therapeutic lung cancer vaccine raise awareness trial glcc member disseminate information lung cancer patient call recently undergone surgery ask doctor enter study hope vaccine give lung cancer patient surgery help stop tumour return reduce effect disease chronic hepatitis b asia pacific continue campaign asia pacific raise awareness chronic hepatitis b increase number people test diagnose improve compliance antiviral medication million people region live disease gsk patient consortium develop patient engagement programme create resource support healthcare professional encourage patient adhere treatment regime include sms service remind patient manage condition pilot programme resource korea roll country world hepatitis day raise awareness breast cancer treatment times canada partnership canadian breast cancer network cbcn gsk help raise awareness unacceptable treatment waiting time difference access breast cancer care canadas province cbcn publish report reveal wait time year initial application manufacturer patient access new breast cancer drug report provoke extensive national medium coverage strong action policy maker politician concerned organisation individual work address issue home responsibility public policy patient advocacy patient advocacy advocacy corporate responsibility report advocacy activity describe advocacy activity undertake partnership patient group global recruitment lung cancer vaccine clinical trial partner global lung cancer coalition glcc body comprise notforprofit group world promote understand lung cancer advocate patient right early detection well treatment supportive care glcc member commit campaign lung cancer research increase enrolment patient clinical trial new therapy trial glcc network help recruitment patient phase lll clinical trial therapeutic lung cancer vaccine raise awareness trial glcc member disseminate information lung cancer patient call recently undergone surgery ask doctor enter study hope vaccine give lung cancer patient surgery help stop tumour return reduce effect disease chronic hepatitis b asia pacific continue campaign asia pacific raise awareness chronic hepatitis b increase number people test diagnose improve compliance antiviral medication million people region live disease gsk patient consortium develop patient engagement programme create resource support healthcare professional encourage patient adhere treatment regime include sms service remind patient manage condition pilot programme resource korea roll country world hepatitis day raise awareness breast cancer treatment times canada partnership canadian breast cancer network cbcn gsk help raise awareness unacceptable treatment waiting time difference access breast cancer care canadas province cbcn publish report reveal wait time year initial application manufacturer patient access new breast cancer drug report provoke extensive national medium coverage strong action policy maker politician concerned organisation individual work address issue home responsibility public policy patient advocacy qas corporate responsibility report qas sure lobbying activity not contradict undermine corporate responsibility work corporate responsibility central business aim ensure lobbying activity reflect value set report sensitive view stakeholder employee involve public policy abide employee guide business conduct commit acting honesty integrity wellestablishe public policy position develop wide consultation approve corporate executive team employee lobby gsk closely involved develop position believe transparency key building trust stakeholder disclose public policy position website gsk political contribution socalle organisation yes support number organisation new democratic network gsk influence organisation use gsk contribution support enable organisation develop advocate policy position participate function debate discuss important issue gsk organisation public policy maker contribution organisation define political contribution subject policy stop corporate political contribution not support patient group marketing tool gsk promote medicine patient group ask patient group endorse gsk medicine work patient group number area include improve clinical trial run disease awareness initiative big agenda ensure new medicine available patient gsk provide funding try buy favour patient organisation ask endorsement medicine return investment support careful support organisation compromise independence base trust mutual respect complie high standard code conduct group maintain independence receive significant funding company gsk encourage patient group diversify funding source public private sector patient group dependent funder sector guideline state provide cent group overall income exceptional home responsibility public policy patient advocacy qas corporate responsibility report qas sure lobbying activity not contradict undermine corporate responsibility work corporate responsibility central business aim ensure lobbying activity reflect value set report sensitive view stakeholder employee involve public policy abide employee guide business conduct commit acting honesty integrity wellestablishe public policy position develop wide consultation approve corporate executive team employee lobby gsk closely involved develop position believe transparency key building trust stakeholder disclose public policy position website gsk political contribution socalle organisation yes support number organisation new democratic network gsk influence organisation use gsk contribution support enable organisation develop advocate policy position participate function debate discuss important issue gsk organisation public policy maker contribution organisation define political contribution subject policy stop corporate political contribution not support patient group marketing tool gsk promote medicine patient group ask patient group endorse gsk medicine work patient group number area include improve clinical trial run disease awareness initiative big agenda ensure new medicine available patient gsk provide funding try buy favour patient organisation ask endorsement medicine return investment support careful support organisation compromise independence base trust mutual respect complie high standard code conduct group maintain independence receive significant funding company gsk encourage patient group diversify funding source public private sector patient group dependent funder sector guideline state provide cent group overall income exceptional home responsibility work community corporate responsibility report work community donate money time medicine equipment support community world programme long term focus address healthcare challenge increase access medicine invest improve education especially science education provide support art environment initiative believe contribute profit benefit community responsible company community investment bring longterm business benefit improve reputation boost employee morale help build good relation government use community investment way generate sale invest innovative project prevent disease build capacity community organisation promote education particularly science focus community investment area relevant business skill people bring benefit community gsk investment nonprofit organisation expert healthcare education organisation well place understand local community need target resource effectively donation company level individual site healthcare support major public health initiative develop world example found member global alliance eliminate lymphatic filariasis gaelf commit donate albendazole tablet need eliminate lymphatic filariasis elephantiasis disable parasitic disease threaten billion people onefifth world population country positive action programme work community reduce stigma improve capacity hiv prevention treatment african malaria partnership support mobilise malaria advocacy initiative generate political commitment funding combat malaria phase personal hygiene sanitation education handwash programme child prevent diarrhoearelate disease improve school attendance donate essential antibiotic medicine disaster relief underserved community world specific programme support lowincome uninsured patient education support education programme link support science education uk inspire young people science improve understand science encourage pursue sciencerelate career programme enable young people informed decision sciencerelate issue meet everyday life healthy eat vaccination value medicine measure impact ask partner organisation large programme report annually progress project support gsk ensure money great possible impact review result partner identify change require achieve programme objectiveshome responsibility work community corporate responsibility report work community donate money time medicine equipment support community world programme long term focus address healthcare challenge increase access medicine invest improve education especially science education provide support art environment initiative believe contribute profit benefit community responsible company community investment bring longterm business benefit improve reputation boost employee morale help build good relation government use community investment way generate sale invest innovative project prevent disease build capacity community organisation promote education particularly science focus community investment area relevant business skill people bring benefit community gsk investment nonprofit organisation expert healthcare education organisation well place understand local community need target resource effectively donation company level individual site healthcare support major public health initiative develop world example found member global alliance eliminate lymphatic filariasis gaelf commit donate albendazole tablet need eliminate lymphatic filariasis elephantiasis disable parasitic disease threaten billion people onefifth world population country positive action programme work community reduce stigma improve capacity hiv prevention treatment african malaria partnership support mobilise malaria advocacy initiative generate political commitment funding combat malaria phase personal hygiene sanitation education handwash programme child prevent diarrhoearelate disease improve school attendance donate essential antibiotic medicine disaster relief underserved community world specific programme support lowincome uninsured patient education support education programme link support science education uk inspire young people science improve understand science encourage pursue sciencerelate career programme enable young people informed decision sciencerelate issue meet everyday life healthy eat vaccination value medicine measure impact ask partner organisation large programme report annually progress project support gsk ensure money great possible impact review result partner identify change require achieve programme objective home responsibility work community corporate responsibility report work community donate money time medicine equipment support community world programme long term focus address healthcare challenge increase access medicine invest improve education especially science education provide support art environment initiative believe contribute profit benefit community responsible company community investment bring longterm business benefit improve reputation boost employee morale help build good relation government use community investment way generate sale invest innovative project prevent disease build capacity community organisation promote education particularly science focus community investment area relevant business skill people bring benefit community gsk investment nonprofit organisation expert healthcare education organisation well place understand local community need target resource effectively donation company level individual site healthcare support major public health initiative develop world example found member global alliance eliminate lymphatic filariasis gaelf commit donate albendazole tablet need eliminate lymphatic filariasis elephantiasis disable parasitic disease threaten billion people onefifth world population country positive action programme work community reduce stigma improve capacity hiv prevention treatment african malaria partnership support mobilise malaria advocacy initiative generate political commitment funding combat malaria phase personal hygiene sanitation education handwash programme child prevent diarrhoearelate disease improve school attendance donate essential antibiotic medicine disaster relief underserved community world specific programme support lowincome uninsured patient education support education programme link support science education uk inspire young people science improve understand science encourage pursue sciencerelate career programme enable young people informed decision sciencerelate issue meet everyday life healthy eat vaccination value medicine measure impact ask partner organisation large programme report annually progress project support gsk ensure money great possible impact review result partner identify change require achieve programme objective home responsibility work community community investment corporate responsibility report community investment global community investment million million compare restate million increase cent half comprise product donation year value donation cost average cost good wholesale acquisition price wac new approach value donation accurate reflection true cost gsk transparent believe pharmaceutical company adopt practice continue report wac value donation benchmarke purpose belong uks london benchmarking group lbg committee encourage corporate philanthropy cecp lbg guideline report product donation cost cecp guideline report product donation market value comparative purpose total value give wac product million million compare million million giving figure build follow way method give million breakdown cash give product donation main programme patient assistance programme support lowincome patient total million cost humanitarian product donation underserve community country include people affect natural disaster burma china totalling cost donation million albendazole tablet lymphatic filariasis lf elimination programme announce double manufacturing capacity albendazole tablet million tablet year current million meet growth lf programme especially india result donation albendazole tablet increase significantly onwards publish datum charitable grant patient group european emerge market asia pacific region increase transparency publishing detail charitable grant find grant gsk company manufacture company award new communitymark follow independent assessment outstanding community investment mark create business community endorse uk government voluntary sector leader give work local national level uk large international programmeshome responsibility work community community investment corporate responsibility report community investment global community investment million million compare restate million increase cent half comprise product donation year value donation cost average cost good wholesale acquisition price wac new approach value donation accurate reflection true cost gsk transparent believe pharmaceutical company adopt practice continue report wac value donation benchmarke purpose belong uks london benchmarking group lbg committee encourage corporate philanthropy cecp lbg guideline report product donation cost cecp guideline report product donation market value comparative purpose total value give wac product million million compare million million giving figure build follow way method give million breakdown cash give product donation main programme patient assistance programme support lowincome patient total million cost humanitarian product donation underserve community country include people affect natural disaster burma china totalling cost donation million albendazole tablet lymphatic filariasis lf elimination programme announce double manufacturing capacity albendazole tablet million tablet year current million meet growth lf programme especially india result donation albendazole tablet increase significantly onwards publish datum charitable grant patient group european emerge market asia pacific region increase transparency publishing detail charitable grant find grant gsk company manufacture company award new communitymark follow independent assessment outstanding community investment mark create business community endorse uk government voluntary sector leader give work local national level uk large international programme home responsibility work community community investment corporate responsibility report community investment global community investment million million compare restate million increase cent half comprise product donation year value donation cost average cost good wholesale acquisition price wac new approach value donation accurate reflection true cost gsk transparent believe pharmaceutical company adopt practice continue report wac value donation benchmarke purpose belong uks london benchmarking group lbg committee encourage corporate philanthropy cecp lbg guideline report product donation cost cecp guideline report product donation market value comparative purpose total value give wac product million million compare million million giving figure build follow way method give million breakdown cash give product donation main programme patient assistance programme support lowincome patient total million cost humanitarian product donation underserve community country include people affect natural disaster burma china totalling cost donation million albendazole tablet lymphatic filariasis lf elimination programme announce double manufacturing capacity albendazole tablet million tablet year current million meet growth lf programme especially india result donation albendazole tablet increase significantly onwards publish datum charitable grant patient group european emerge market asia pacific region increase transparency publishing detail charitable grant find grant gsk company manufacture company award new communitymark follow independent assessment outstanding community investment mark create business community endorse uk government voluntary sector leader give work local national level uk large international programme home responsibility work community prevent disease corporate responsibility report prevent disease infectious disease kill million people develop world year cause misery cost billion dollar slow economic growth prevent infection effective treatment significant social economic benefit vaccine play significant role prevent disease gsk support innovative community approach disease prevention tailor local setting need mark significant milestone support community disease prevention year commitment eliminate lymphatic filariasis lf worldwide launch handwash programme phase prevent diarrhoearelate disease support wide range local programme help prevent disease community operate home responsibility work community prevent disease corporate responsibility report prevent disease infectious disease kill million people develop world year cause misery cost billion dollar slow economic growth prevent infection effective treatment significant social economic benefit vaccine play significant role prevent disease gsk support innovative community approach disease prevention tailor local setting need mark significant milestone support community disease prevention year commitment eliminate lymphatic filariasis lf worldwide launch handwash programme phase prevent diarrhoearelate disease support wide range local programme help prevent disease community operate home responsibility work community prevent disease eliminate lymphatic filariasis corporate responsibility report eliminate lymphatic filariasis lf commit donate tablet albendazole antiparasitic drug need eliminate lf lf disfigure disease prevalent tropical subtropical country transmit mosquito lead severe swell arm leg breast genital thicken skin lf world lead cause permanent disability billion people country approximately onefifth world population risk infection gsk donate million albendazole treatment country include million tablet india country large lf burden economic cost lf india estimate exceed million treatment cost reduce working time programme began donate billion tablet million people treat albendazole estimate end million baby bear treat region spare risk contracting lf study publish journal public library science neglect tropical disease confirm progress eliminate lf year decide double annual manufacturing capacity albendazole tablet million tablet year open new production line nashik western india additional benefit albendazole tablet give lf programme treat intestinal worm parasite particularly affect child cause anaemia malnutrition stunt growth estimate begin lf programme million albendazole treatment administer child million woman childbeare age positive impact overall health infect intestinal worms country aim eliminate lf treat atrisk people year year far egypt pacific island country sri lanka zanzibar complete annual mass drug administration mda country monitor population evaluate impact programme disease assessment conduct egypt vanuatu pacific island nation show lf eliminate area country programme tanzania madagascar burkina faso report unexpected benefit mda reduce infection rate country patient infect lf describe alleviation symptom mda include reduce leg swell reduction frequency length acute attack spell feverishness loss energy acute attack incapacitate symptom lf read approach lf patient live disease home responsibility work community prevent disease eliminate lymphatic filariasis corporate responsibility report eliminate lymphatic filariasis lf commit donate tablet albendazole antiparasitic drug need eliminate lf lf disfigure disease prevalent tropical subtropical country transmit mosquito lead severe swell arm leg breast genital thicken skin lf world lead cause permanent disability billion people country approximately onefifth world population risk infection gsk donate million albendazole treatment country include million tablet india country large lf burden economic cost lf india estimate exceed million treatment cost reduce working time programme began donate billion tablet million people treat albendazole estimate end million baby bear treat region spare risk contracting lf study publish journal public library science neglect tropical disease confirm progress eliminate lf year decide double annual manufacturing capacity albendazole tablet million tablet year open new production line nashik western india additional benefit albendazole tablet give lf programme treat intestinal worm parasite particularly affect child cause anaemia malnutrition stunt growth estimate begin lf programme million albendazole treatment administer child million woman childbeare age positive impact overall health infect intestinal worms country aim eliminate lf treat atrisk people year year far egypt pacific island country sri lanka zanzibar complete annual mass drug administration mda country monitor population evaluate impact programme disease assessment conduct egypt vanuatu pacific island nation show lf eliminate area country programme tanzania madagascar burkina faso report unexpected benefit mda reduce infection rate country patient infect lf describe alleviation symptom mda include reduce leg swell reduction frequency length acute attack spell feverishness loss energy acute attack incapacitate symptom lf read approach lf patient live disease home responsibility work community prevent disease personal hygiene sanitation education corporate responsibility report personal hygiene sanitation education phase year million people die diarrhoearelate disease children develop country death easily prevent well handwash sanitation phase schoolbase programme help reduce diarrhoearelate disease encourage school child wash hand establish phase invest million million programme phase run partnership amref save children earth institute columbia university ministries health education country programme operates programme impressive result bangladesh example partnership save child introduce phase school country poor area help improve live young child family threeyear period programme fund school handwash facility increase cent cent lead increase hand washing soap schoolchildren cent cent latrine available school latrine construct children home result mark decrease open defecation cent population cent healthy child school attendance rate increase cent cent period july success phase nasirnagar bangladesh lead decision expand programme include school brahmanbaria district save child work health education minister prepare scaleup committed funding year extend programme slum area mumbai india partner pratham phase operate country reach child aim programme reach million child year support millennium development goal world leader agree millennium development goal mdgs meet need world poor people mdgs include target halve extreme poverty hunger improve education health gender equality environmental sustainability introduce phase millennium village malawi senegal millennium village research project african community design find practical way meet mdgs global handwash day global handwashing day hold marked week activity encourage million child adult world wash hand aim improve hygiene health phase partner arrange range activity promote handwash reach people read phase global handwash day home responsibility work community prevent disease personal hygiene sanitation education corporate responsibility report personal hygiene sanitation education phase year million people die diarrhoearelate disease children develop country death easily prevent well handwash sanitation phase schoolbase programme help reduce diarrhoearelate disease encourage school child wash hand establish phase invest million million programme phase run partnership amref save children earth institute columbia university ministries health education country programme operate programme impressive result bangladesh example partnership save child introduce phase school country poor area help improve live young child family threeyear period programme fund school handwash facility increase cent cent lead increase hand washing soap schoolchildren cent cent latrine available school latrine construct children home result mark decrease open defecation cent population cent healthy child school attendance rate increase cent cent period july success phase nasirnagar bangladesh lead decision expand programme include school brahmanbaria district save child work health education minister prepare scaleup committed funding year extend programme slum area mumbai india partner pratham phase operate country reach child aim programme reach million child year support millennium development goal world leader agree millennium development goal mdgs meet need world poor people mdgs include target halve extreme poverty hunger improve education health gender equality environmental sustainability introduce phase millennium village malawi senegal millennium village research project african community design find practical way meet mdgs global handwash day global handwashing day hold marked week activity encourage million child adult world wash hand aim improve hygiene health phase partner arrange range activity promote handwash reach people read phase global handwash day home responsibility work community prevent disease local programme corporate responsibility report local programme support wide range programme help prevent disease community operate fund programme corporate local level local programme example australia help aborigine tackle diabete indigenous australian poor heath life expectancy year rest australian population rapid increase socalle lifestyle disease include type diabete wipe indigenous population year gsk work unity people australia far north western australia diabete management care program programme aim arrest rise incidence diabete aboriginal community encourage local people responsibility communitys health health provider active support uk improve sexual health service disabled people donate year leonard cheshire disability fund project young disabled people well access sexual health service project address knowledge understanding gap relate disabled people sexual health issue threeyear period organisation run focus group workshop identify key issue develop range material support sexual health worker deal disabled people uk promote sport child consumer healthcare business support access sport organisation encourage young people uk fit participate sport access sport hold sport jam event bristol bath london child take sporting activity provide fund employee volunteer time hold fundraising event example employee raise money cycling land end john ogroats future gsk staff support access sport volunteer local sport club annual employee volunteer day prevent childhood obesity support zone health initiative help school strengthen policy programme nutrition physical activity aim improve health child follow successful pilot zone health expand gsk announce support fitu programme washington dc area benefit young people year home responsibility work community prevent disease local programme corporate responsibility report local programme support wide range programme help prevent disease community operate fund programme corporate local level local programme example australia help aborigine tackle diabete indigenous australian poor heath life expectancy year rest australian population rapid increase socalle lifestyle disease include type diabete wipe indigenous population year gsk work unity people australia far north western australia diabete management care program programme aim arrest rise incidence diabete aboriginal community encourage local people responsibility communitys health health provider active support uk improve sexual health service disabled people donate year leonard cheshire disability fund project young disabled people well access sexual health service project address knowledge understanding gap relate disabled people sexual health issue threeyear period organisation run focus group workshop identify key issue develop range material support sexual health worker deal disabled people uk promote sport child consumer healthcare business support access sport organisation encourage young people uk fit participate sport access sport hold sport jam event bristol bath london child take sporting activity provide fund employee volunteer time hold fundraising event example employee raise money cycling land end john ogroats future gsk staff support access sport volunteer local sport club annual employee volunteer day prevent childhood obesity support zone health initiative help school strengthen policy programme nutrition physical activity aim improve health child follow successful pilot zone health expand gsk announce support fitu programme washington dc area benefit young people year home responsibility work community build community capacity corporate responsibility report build community capacity lack healthcare infrastructure include clinic train healthcare professional cultural attitude significant barrier treatment develop country global programme positive action work community affect hiv aids african malaria partnership improve prevention access malaria treatment support local initiative help overcome stigma build capacity community provide healthcare combat disease provide humanitarian relief time emergency natural disaster home responsibility work community build community capacity corporate responsibility report build community capacity lack healthcare infrastructure include clinic train healthcare professional cultural attitude significant barrier treatment develop country global programme positive action work community affect hiv aids african malaria partnership improve prevention access malaria treatment support local initiative help overcome stigma build capacity community provide healthcare combat disease provide humanitarian relief time emergency natural disaster home responsibility work community build community capacity combat hivaids positive action corporate responsibility report combat hivaids positive action positive action work community organisation build capacity counter ignorance stigma surround hiv outreach education advocacy establish provide million funding project country africa asia latin america eastern europe positive action gsk pioneer support vulnerable community include man sex man intravenous drug user sex worker migrant young people orphan vulnerable child marginilise poor rural woman group limit human right public voice exclude play role develop mainstream programming essential work group expect difference epidemic support positive action programme country key project include fight stigma discrimination mexico vulnerable sector population bring hiv education vulnerable woman india selfhelp group help community asia understand prepare treatment programme improve access treatment kenya promote great understanding involvement community update august july announce creation new positive action child fund fund million million available year help prevent mothertochild transmission hiv support orphan vulnerable child positive action programme involve grass root organisation able continue support community project come end year principal sponsor global village community space international aids conference hold mexico city host community forum allow delegate share experience fight hivaid read positive action home responsibility work community build community capacity combat hivaids positive action corporate responsibility report combat hivaids positive action positive action work community organisation build capacity counter ignorance stigma surround hiv outreach education advocacy establish provide million funding project country africa asia latin america eastern europe positive action gsk pioneer support vulnerable community include man sex man intravenous drug user sex worker migrant young people orphan vulnerable child marginilise poor rural woman group limit human right public voice exclude play role develop mainstream programming essential work group expect difference epidemic support positive action programme country key project include fight stigma discrimination mexico vulnerable sector population bring hiv education vulnerable woman india selfhelp group help community asia understand prepare treatment programme improve access treatment kenya promote great understanding involvement community update august july announce creation new positive action child fund fund million million available year help prevent mothertochild transmission hiv support orphan vulnerable child positive action programme involve grass root organisation able continue support community project come end year principal sponsor global village community space international aids conference hold mexico city host community forum allow delegate share experience fight hivaid read positive action home responsibility work community build community capacity combat malaria africa malaria partnership corporate responsibility report combat malaria africa malaria partnership year million people affect malaria million die young child africa disease prevent control breeding mosquito low cost measure insecticidetreate net malaria cure treat promptly effective medicine establish african malaria partnership improve prevention access treatment malaria subsaharan africa invest million initiative combat disease final year threeyear grant support mobilise malaria advocacy initiative generate great awareness political commitment sustain funding malaria europe africa national coalitions malaria launch uk belgium france ethiopia cameroon bring advocate activist public sector ngo medium private sector political academic scientific community initiative award innovation grant civil society organisation africa boost advocacy effort inspire african civil society organisation medium leader fight malaria country grant award civil organisation nigeria tanzania ghana mozambique democratic republic congo burkina faso support journalist competition run guardian british newspaper raise awareness issue face people malaria lf global web site attract unique visitor win story publish dedicated supplement read malaria programme home responsibility work community build community capacity combat malaria africa malaria partnership corporate responsibility report combat malaria africa malaria partnership year million people affect malaria million die young child africa disease prevent control breeding mosquito low cost measure insecticidetreate net malaria cure treat promptly effective medicine establish african malaria partnership improve prevention access treatment malaria subsaharan africa invest million initiative combat disease final year threeyear grant support mobilise malaria advocacy initiative generate great awareness political commitment sustain funding malaria europe africa national coalitions malaria launch uk belgium france ethiopia cameroon bring advocate activist public sector ngo medium private sector political academic scientific community initiative award innovation grant civil society organisation africa boost advocacy effort inspire african civil society organisation medium leader fight malaria country grant award civil organisation nigeria tanzania ghana mozambique democratic republic congo burkina faso support journalist competition run guardian british newspaper raise awareness issue face people malaria lf global web site attract unique visitor win story publish dedicated supplement read malaria programme home responsibility work community build community capacity local programme corporate responsibility report local programme support wide range programme build healthcare capacity community operate fund programme corporate local level local programme example training midwive vietnam support project train birth attendant bring maternal healthcare service rural village vietnam project aim reduce childbirth complication decrease newborn fatality unacceptably high level cent trainee house residential training centre build gsk tu du hospital ho chi minh city support hospital staff spend month gain practical knowledge maternal child healthcare phase project midwive represent vietnam ethnic group graduate governmentrecognised qualification midwife return village equip medical pack provide motor scooter assist access remote area phase project launch involve hospital staff visit village provide additional training midwife provide basic pregnancy reproductive health education community member palliative care child romania year work partnership hospice casa sperentei romania beacon hope project improve level care available terminally ill child balkans huge progress achieve help change attitude die patient region project receive acclaim romanian government begin partnership hospice view create national plan palliative care key achievement include establishment children palliative care unit brasov mobile nursing team network care provider region project develop regional centre excellence southeastern europe provide palliative care training health worker volunteer result children palliative care service set neighbouring moldova new fund childrens hospital philadelphia october announce million donation children hospital philadelphia help young people cancer hospital run world large paediatric cancer programme contribution match donation hospital form glaxosmithkline hope family fund fund permanent endowment enable child young adult suffer relapse hardtocure cancer access innovative therapy help cover travel accommodation cost patient family stay near hospital extend period healthcare homeless pittsburgh gsk support pittsburgh mercy foundation operation safety net street medicine outreach programme enable pittsburgh homeless access free healthcare programme include mobile medical unit dropin clinic team clinician care worker walk street offer medical examination treatment homeless people reward community healthcare organisation uk year gsk impact award recognise voluntary organisation significantly improve health local community win charity receive overall winner award extra uk impact award programme introduce initiative manager win organisation train leadership network fundraising skill help strengthen small charity unable afford vital skill training gsk impact award run philadelphia read gsk impact award win organisationshome responsibility work community build community capacity local programme corporate responsibility report local programme support wide range programme build healthcare capacity community operate fund programme corporate local level local programme example training midwive vietnam support project train birth attendant bring maternal healthcare service rural village vietnam project aim reduce childbirth complication decrease newborn fatality unacceptably high level cent trainee house residential training centre build gsk tu du hospital ho chi minh city support hospital staff spend month gain practical knowledge maternal child healthcare phase project midwive represent vietnam ethnic group graduate governmentrecognised qualification midwife return village equip medical pack provide motor scooter assist access remote area phase project launch involve hospital staff visit village provide additional training midwife provide basic pregnancy reproductive health education community member palliative care child romania year work partnership hospice casa sperentei romania beacon hope project improve level care available terminally ill child balkans huge progress achieve help change attitude die patient region project receive acclaim romanian government begin partnership hospice view create national plan palliative care key achievement include establishment children palliative care unit brasov mobile nursing team network care provider region project develop regional centre excellence southeastern europe provide palliative care training health worker volunteer result children palliative care service set neighbouring moldova new fund childrens hospital philadelphia october announce million donation children hospital philadelphia help young people cancer hospital run world large paediatric cancer programme contribution match donation hospital form glaxosmithkline hope family fund fund permanent endowment enable child young adult suffer relapse hardtocure cancer access innovative therapy help cover travel accommodation cost patient family stay near hospital extend period healthcare homeless pittsburgh gsk support pittsburgh mercy foundation operation safety net street medicine outreach programme enable pittsburgh homeless access free healthcare programme include mobile medical unit dropin clinic team clinician care worker walk street offer medical examination treatment homeless people reward community healthcare organisation uk year gsk impact award recognise voluntary organisation significantly improve health local community win charity receive overall winner award extra uk impact award programme introduce initiative manager win organisation train leadership network fundraising skill help strengthen small charity unable afford vital skill training gsk impact award run philadelphia read gsk impact award win organisation home responsibility work community build community capacity local programme corporate responsibility report local programme support wide range programme build healthcare capacity community operate fund programme corporate local level local programme example training midwive vietnam support project train birth attendant bring maternal healthcare service rural village vietnam project aim reduce childbirth complication decrease newborn fatality unacceptably high level cent trainee house residential training centre build gsk tu du hospital ho chi minh city support hospital staff spend month gain practical knowledge maternal child healthcare phase project midwive represent vietnam ethnic group graduate governmentrecognised qualification midwife return village equip medical pack provide motor scooter assist access remote area phase project launch involve hospital staff visit village provide additional training midwife provide basic pregnancy reproductive health education community member palliative care child romania year work partnership hospice casa sperentei romania beacon hope project improve level care available terminally ill child balkans huge progress achieve help change attitude die patient region project receive acclaim romanian government begin partnership hospice view create national plan palliative care key achievement include establishment children palliative care unit brasov mobile nursing team network care provider region project develop regional centre excellence southeastern europe provide palliative care training health worker volunteer result children palliative care service set neighbouring moldova new fund childrens hospital philadelphia october announce million donation children hospital philadelphia help young people cancer hospital run world large paediatric cancer programme contribution match donation hospital form glaxosmithkline hope family fund fund permanent endowment enable child young adult suffer relapse hardtocure cancer access innovative therapy help cover travel accommodation cost patient family stay near hospital extend period healthcare homeless pittsburgh gsk support pittsburgh mercy foundation operation safety net street medicine outreach programme enable pittsburgh homeless access free healthcare programme include mobile medical unit dropin clinic team clinician care worker walk street offer medical examination treatment homeless people reward community healthcare organisation uk year gsk impact award recognise voluntary organisation significantly improve health local community win charity receive overall winner award extra uk impact award programme introduce initiative manager win organisation train leadership network fundraising skill help strengthen small charity unable afford vital skill training gsk impact award run philadelphia read gsk impact award win organisation home responsibility work community build community capacity respond disaster world corporate responsibility report respond disaster world gsk provide humanitarian assistance form cash product donation times emergency natural disaster ongoing programme provide humanitarian relief area include china burma zimbabwe follow cyclone burma work americare partner specialise rapid response delivery supply gskdonate medicine donation save child charity establish presence burma contribution support recovery effort include provision shelter child protection food nutrition emergency health service child family earthquake hit sichuan province china leave dead million people displace homeless gsk hong kongchina give cash donation million yuan approximately million china red cross donate supply basic medicine provide fund british red cross mass sanitation module provide emergency sanitation facility hygiene education people time crisis help avoid outbreak disease deploy december zimbabwe help stem cholera outbreak continued support community affect indian ocean tsunami cause huge damage coastal area south asia sri lanka help establish mobile clinic increase access quality healthcare isolate community affect tsunami conflict country mobile clinic set different location provide reliable healthcare service area clinic treat nearly patient total give healthcare education message patient people accompany work leonard cheshire disability create inclusive barrierfree rightsbase society people disability affect tsunami galle sri lanka new resource centre establish support people disability provide rehabilitation service mainstream education livelihood opportunity support longterm relief effort affect area chennai india provide nursing train young woman poor village boost healthcare service area training enable woman support financially nursing assistant woman train thailand help boost economy coastal village local fishing industry destroy tsunami rak thai foundation support initiative provide business loan organise youth activity effort improve local environment give funding help ngo francois xavier bagnoud fxb introduce concept model village lowcost sustainable communitybased programme successful help family achieve self sufficiency home responsibility work community build community capacity respond disaster world corporate responsibility report respond disaster world gsk provide humanitarian assistance form cash product donation times emergency natural disaster ongoing programme provide humanitarian relief area include china burma zimbabwe follow cyclone burma work americare partner specialise rapid response delivery supply gskdonate medicine donation save child charity establish presence burma contribution support recovery effort include provision shelter child protection food nutrition emergency health service child family earthquake hit sichuan province china leave dead million people displace homeless gsk hong kongchina give cash donation million yuan approximately million china red cross donate supply basic medicine provide fund british red cross mass sanitation module provide emergency sanitation facility hygiene education people time crisis help avoid outbreak disease deploy december zimbabwe help stem cholera outbreak continued support community affect indian ocean tsunami cause huge damage coastal area south asia sri lanka help establish mobile clinic increase access quality healthcare isolate community affect tsunami conflict country mobile clinic set different location provide reliable healthcare service area clinic treat nearly patient total give healthcare education message patient people accompany work leonard cheshire disability create inclusive barrierfree rightsbase society people disability affect tsunami galle sri lanka new resource centre establish support people disability provide rehabilitation service mainstream education livelihood opportunity support longterm relief effort affect area chennai india provide nursing train young woman poor village boost healthcare service area training enable woman support financially nursing assistant woman train thailand help boost economy coastal village local fishing industry destroy tsunami rak thai foundation support initiative provide business loan organise youth activity effort improve local environment give funding help ngo francois xavier bagnoud fxb introduce concept model village lowcost sustainable communitybased programme successful help family achieve self sufficiency home responsibility work community support science education corporate responsibility report support science education uk number young people choose science subject fall student lack proficiency read mathematic result country face significant skill shortage success business rely able recruit talented individual particularly science qualification want young people sound decision sciencerelate issue meet everyday life education programme help science relevant young people uk stimulate interest science support training development science teacher uk project enthuse half secondary school science teacher uk subject training past year project enthuse launch improve continue professional development science teacher provide late technique rekindle interest science teacher assistant technician apply enthuse award help study national science learning centre university york award cover course fee cost cover teacher role course travel accommodation teacher year school receive small money help implement idea classroom commit million initiative help create million fund support uk government wellcome trust industry partner crest star investigators afterschool club help broaden interest experience young people focus sport art science crest star investigator develop british association advancement science fund gsk aim redress balance engage year old sciencebase activity ukwide programme offer activity pack school organisation brownie cub use afterschool club activity encourage child solve scientific problem exciting practical investigation pack contain activity different difficulty level child award certificate complete stage far pack distribute nearly school aim school child take institute competitive workforce icw building gsk leadership state local level relate reform improvement public school gsk lead effort create icw national level result national movement businesseducation partnership focus improve academic achievement public school system order help ensure qualified workforce american business future science summer support science summer free education programme design young people pittsburgh pennsylvania great philadelphia north carolina interested science class hold local library child chance handson experiment course range genetic oceanography programme begin gsk invest site child participate programme north carolina new school project gsk partner north carolina new school project initiative aim transform teaching learn high school student graduate ready college workplace gsk help fund development science technology programme north carolinas lowperforme high school initiative aim improve school test result graduation rate gsk fund review state curricula benefit share widelyhome responsibility work community support science education corporate responsibility report support science education uk number young people choose science subject fall student lack proficiency read mathematic result country face significant skill shortage success business rely able recruit talented individual particularly science qualification want young people sound decision sciencerelate issue meet everyday life education programme help science relevant young people uk stimulate interest science support training development science teacher uk project enthuse half secondary school science teacher uk subject training past year project enthuse launch improve continue professional development science teacher provide late technique rekindle interest science teacher assistant technician apply enthuse award help study national science learning centre university york award cover course fee cost cover teacher role course travel accommodation teacher year school receive small money help implement idea classroom commit million initiative help create million fund support uk government wellcome trust industry partner crest star investigators afterschool club help broaden interest experience young people focus sport art science crest star investigator develop british association advancement science fund gsk aim redress balance engage year old sciencebase activity ukwide programme offer activity pack school organisation brownie cub use afterschool club activity encourage child solve scientific problem exciting practical investigation pack contain activity different difficulty level child award certificate complete stage far pack distribute nearly school aim school child take institute competitive workforce icw building gsk leadership state local level relate reform improvement public school gsk lead effort create icw national level result national movement businesseducation partnership focus improve academic achievement public school system order help ensure qualified workforce american business future science summer support science summer free education programme design young people pittsburgh pennsylvania great philadelphia north carolina interested science class hold local library child chance handson experiment course range genetic oceanography programme begin gsk invest site child participate programme north carolina new school project gsk partner north carolina new school project initiative aim transform teaching learn high school student graduate ready college workplace gsk help fund development science technology programme north carolinas lowperforme high school initiative aim improve school test result graduation rate gsk fund review state curricula benefit share widely home responsibility work community support science education corporate responsibility report support science education uk number young people choose science subject fall student lack proficiency read mathematic result country face significant skill shortage success business rely able recruit talented individual particularly science qualification want young people sound decision sciencerelate issue meet everyday life education programme help science relevant young people uk stimulate interest science support training development science teacher uk project enthuse half secondary school science teacher uk subject training past year project enthuse launch improve continue professional development science teacher provide late technique rekindle interest science teacher assistant technician apply enthuse award help study national science learning centre university york award cover course fee cost cover teacher role course travel accommodation teacher year school receive small money help implement idea classroom commit million initiative help create million fund support uk government wellcome trust industry partner crest star investigators afterschool club help broaden interest experience young people focus sport art science crest star investigator develop british association advancement science fund gsk aim redress balance engage year old sciencebase activity ukwide programme offer activity pack school organisation brownie cub use afterschool club activity encourage child solve scientific problem exciting practical investigation pack contain activity different difficulty level child award certificate complete stage far pack distribute nearly school aim school child take institute competitive workforce icw building gsk leadership state local level relate reform improvement public school gsk lead effort create icw national level result national movement businesseducation partnership focus improve academic achievement public school system order help ensure qualified workforce american business future science summer support science summer free education programme design young people pittsburgh pennsylvania great philadelphia north carolina interested science class hold local library child chance handson experiment course range genetic oceanography programme begin gsk invest site child participate programme north carolina new school project gsk partner north carolina new school project initiative aim transform teaching learn high school student graduate ready college workplace gsk help fund development science technology programme north carolinas lowperforme high school initiative aim improve school test result graduation rate gsk fund review state curricula benefit share widely home responsibility work community plan corporate responsibility report plan volunteer expand volunteering programme gsk employee spend day year help community employee select local organisation support undertake variety work range manual job fundraising include support employee wish visit school encourage science education launch international assignment programme enable select number employee use professional skill support nonprofit partner extend period positive action agree extend large hiv programme zingatia maisha kenya vida digna mexico reach india additional year ensure sustainability work ubuntu education fund south africa expand programme call live positively programme work man old boy port elizabeth township challenge gender role exacerbate hiv infection exclude man hiv service working aids action europe provide network hivaid ngo eastern europe central asia improve hiv policy advocacy programming support face hiv crisis work american foundation aids research amfar expand initiative provide prevention care support service man sex man asia pacific work aids patient group philippine increase member understand health issue phase partner pratham implement phase programme slum area mumbai india extend phase new district uganda advocate incorporation phase national policy enable sustainability replication project nationwide lf increase manufacturing capacity albendazole tablet million tablet year enable increase fourfold number tablet donate continue provide leadership support children health fund chf referral management initiative increase access specialist healthcare homeless uninsured american family support pilot telemedicine project help patient access specialist care chfs new memphis regional children health project serve pilot site link approximately rural patient specialist memphis hospital stateoftheart videoconferencing technology europe emerge market asia pacific region new programme implement example greece help introduce concept homebase nursing service child live cancer netherlands support national programme promote healthy behaviour young people helping informed decision eat encourage regular physical activity seek new partnership improve community healthcare social venture anpda ge enterprise project prepare funding stop programme run number year recognise take time build change start plan happen end funding work hard community organisation bring result life project usually year help organisation win funding source continue work start require partner work budget sure funding spend effectively produce right result ask partner demonstrate achievement produce annual progress report report evidence success crucial attract new donorshome responsibility work community plan corporate responsibility report plan volunteer expand volunteering programme gsk employee spend day year help community employee select local organisation support undertake variety work range manual job fundraising include support employee wish visit school encourage science education launch international assignment programme enable select number employee use professional skill support nonprofit partner extend period positive action agree extend large hiv programme zingatia maisha kenya vida digna mexico reach india additional year ensure sustainability work ubuntu education fund south africa expand programme call live positively programme work man old boy port elizabeth township challenge gender role exacerbate hiv infection exclude man hiv service working aids action europe provide network hivaid ngo eastern europe central asia improve hiv policy advocacy programming support face hiv crisis work american foundation aids research amfar expand initiative provide prevention care support service man sex man asia pacific work aids patient group philippine increase member understand health issue phase partner pratham implement phase programme slum area mumbai india extend phase new district uganda advocate incorporation phase national policy enable sustainability replication project nationwide lf increase manufacturing capacity albendazole tablet million tablet year enable increase fourfold number tablet donate continue provide leadership support children health fund chf referral management initiative increase access specialist healthcare homeless uninsured american family support pilot telemedicine project help patient access specialist care chfs new memphis regional children health project serve pilot site link approximately rural patient specialist memphis hospital stateoftheart videoconferencing technology europe emerge market asia pacific region new programme implement example greece help introduce concept homebase nursing service child live cancer netherlands support national programme promote healthy behaviour young people helping informed decision eat encourage regular physical activity seek new partnership improve community healthcare social venture enterprise project prepare funding stop programme run number year recognise take time build change start plan happen end funding work hard community organisation bring result life project usually year help organisation win funding source continue work start require partner work budget sure funding spend effectively produce right result ask partner demonstrate achievement produce annual progress report report evidence success crucial attract new donor